<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />
<meta name="author" content="Tim Woelfle" />

<meta name="date" content="2023-07-26" />


<title>PRECIS-2 Scores in PragMeta: Human Consensus vs LMM (Claude 2)</title>

<meta property="og:title" content="PRECIS-2 Scores in PragMeta: Human Consensus vs LMM (Claude 2)" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script id="flexdashboard-navbar" type="application/json">
[{"title":"Source Code","icon":"fa-code","href":"","align":"right"}]
</script>
<script src="lib/header-attrs-2.21/header-attrs.js"></script>
<script src="lib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="lib/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="lib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="lib/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<link href="lib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="lib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<link href="lib/value-box-accent-static-0.6.1/theme-cosmo-value-box.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/flexdashboard.min.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/theme-cosmo.css" rel="stylesheet" />
<script src="lib/htmlwidgets-1.6.2/htmlwidgets.js"></script>
<link href="lib/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="lib/datatables-binding-0.28/datatables.js"></script>
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="lib/dt-core-1.13.4/js/jquery.dataTables.min.js"></script>
<link href="lib/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet" />
<script src="lib/crosstalk-1.2.0/js/crosstalk.min.js"></script>
<style type="text/css">
/*
  CSS for flexdashboard.js' use of Sly(). The sizing/position of this CSS needs to be
  applied _before_ flexdashboard.js initializes, which is why this CSS has been pulled
  out from flexdashboard.scss and inlined in the document's head.
*/

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  text-align: left;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.sbframe-commentary {
  width: 300px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}
@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  PRECIS-2 Scores in PragMeta: Human Consensus vs LMM (Claude 2)
  <span class="navbar-author">
    Tim Woelfle &mdash; 2023-07-26
    </span>
</span>

<button id="navbar-button" type="button" class="navbar-toggle collapsed pull-right" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false,
      resize_reload: true
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.append(h1.contents());
        h3.insertBefore(h1);
        h1.detach();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if resize_reload is set to true and it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    if (_options.resize_reload) {
      $(window).on('resize', function() {
        if (_options.isMobile !== isMobilePhone() ||
            _options.isPortrait !== isPortrait()) {
          window.location.reload();
        }
      });
    } else {
      // if in desktop mode and resizing to mobile, make sure the heights are 100%
      // This enforces what `fillpage.css` does for "wider" pages.
      // Since we are not reloading once the page becomes small, we need to force the height to 100%
      // This is a new situation introduced when `_options.resize_reload` is `false`
      if (! _options.isMobile) {
        // only add if `fillpage.css` was added in the first place
        if (_options.fillPage) {
          // fillpage.css
          $("html,body,#dashboard").css("height", "100%");
        }
      }
    }
    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          var a = navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target);
          a.removeClass("nav-link").addClass("dropdown-item");
          li.append(a);
          menu.append(li);
        }
      } else {
        var li = $('<li class="nav-item"></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li class="nav-item"></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('data-bs-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover its inner contens, then detach it
    var h1 = wrapper.find('h1').first();
    var title = h1.contents();
    h1.detach();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      li.find("> a").removeClass("nav-link").addClass("dropdown-item");
      menu.append(li);
    } else {
      li.addClass("nav-item")
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a class="nav-link"></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = null;
      var iconSplit = icon.split(" ");
      if (iconSplit.length > 1) {
        iconSet = iconSplit[0];
        icon = iconSplit.slice(1).join(" ");
      } else {
        iconSet = icon.substring(0, dashPos);
      }
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.append(h2.contents());
      h3.insertBefore(h2);
      h2.detach();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.append(h3.contents());
      h3.detach();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.append(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingDom = heading.contents();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab" class="nav-link"></a>');
      a.append(headingDom);
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation" class="nav-item"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children()[activeTab]).tab("show");
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.contents();
    h3.detach();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.empty().append(blockquote.children('p:first-child').contents());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.empty().append(caption.contents());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.decodeURIComponent(window.location.hash);
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.decodeURIComponent(window.location.hash);
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from currently active tabs
    $('.navbar ul.nav .active').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").tab("show");
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.append(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var iconSplit = chartIcon.split(" ");
      if (iconSplit.length > 1) {
        iconLib = iconSplit[0];
        chartIcon = iconSplit.slice(1).join(" ");
      } else {
        var components = chartIcon.split("-");
        if (components.length > 1)
          iconLib = components[0];
      }
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // If valueBox(color=) was an accent color, this attr should
      // be populated with the accent color and the relevant CSS comes
      // in through HTML dependencies
      var dataColorAccent = valueOutput.attr('data-color-accent');
      var valueBoxClasses = "value-box-" + (["primary", "info", "danger", "warning", "success"].join(" value-box-"));
      if (dataColorAccent) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.addClass('value-box-' + dataColorAccent);
      }

      // If valueBox(color=) was a CSS color, these other data-color-*
      // attrs will be populated
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.css('background-color', dataColor);
      }
      var dataColorText = valueOutput.attr('data-color-text');
      if (dataColorText) {
        valueBox.find(".inner").css('color', dataColorText);
      }
      var dataColorIcon = valueOutput.attr('data-color-icon');
      if (dataColorIcon) {
        valueBox.find(".icon").css('color', dataColorIcon);
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});
</script>

<div id="dashboard-container">

<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<style type="text/css">
table {
  margin: auto;
  border-top: 1px solid #666;
  border-bottom: 1px solid #666;
}
table thead th { border-bottom: 1px solid #ddd; }
th, td { padding: 5px; }

pre {
  white-space: pre-wrap;
  word-break: keep-all;
}

/* Hack to make prompt-tab scrollable again */
div.level3.tab-pane .chart-stage {
  overflow: scroll;
}
</style>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="column" class="section level2" data-width="55">
<h2>Column</h2>
<div id="score-comparisons-of-56-publications" class="section level3">
<h3>Score comparisons of 56 publications</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-c0a31a71f27734208fc2" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-c0a31a71f27734208fc2">{"x":{"filter":"none","vertical":false,"fillContainer":true,"data":[["648","650","651","655","657","662","663","664","665","666","668","669","670","671","673","674","675","677","678","679","680","681","682","684","685","686","687","688","689","690","691","692","693","694","695","696","697","705","712","713","714","715","722","725","733","1528","1529","1567","1568","1569","1570","1769","1770","1771","1772","1773"],["<a href='#648' title='Jump to individual results on the right'>CORONIS Collaborative Group (2013)<\/a>","<a href='#650' title='Jump to individual results on the right'>van Dijk-de Vries. A, (2015)<\/a>","<a href='#651' title='Jump to individual results on the right'>Price. D, (2011)<\/a>","<a href='#655' title='Jump to individual results on the right'>Galdiz, J. B.  (2020)<\/a>","<a href='#657' title='Jump to individual results on the right'>Arntzen E. (2019)<\/a>","<a href='#662' title='Jump to individual results on the right'>Bogosian A. (2015)<\/a>","<a href='#663' title='Jump to individual results on the right'>Callesen J. (2020)<\/a>","<a href='#664' title='Jump to individual results on the right'>Carter A. (2014)<\/a>","<a href='#665' title='Jump to individual results on the right'>Cooper C. (2011)<\/a>","<a href='#666' title='Jump to individual results on the right'>Cutter G. (2019)<\/a>","<a href='#668' title='Jump to individual results on the right'>Dodd K. J. (2011)<\/a>","<a href='#669' title='Jump to individual results on the right'>Feys P. (2019)<\/a>","<a href='#670' title='Jump to individual results on the right'>Finch P. (2014)<\/a>","<a href='#671' title='Jump to individual results on the right'>Freeman J. (2019)<\/a>","<a href='#673' title='Jump to individual results on the right'>Garrett M. (2013)<\/a>","<a href='#674' title='Jump to individual results on the right'>Giovannoni G. (2016)<\/a>","<a href='#675' title='Jump to individual results on the right'>Grossman P. (2010)<\/a>","<a href='#677' title='Jump to individual results on the right'>Hermens H. (2008)<\/a>","<a href='#678' title='Jump to individual results on the right'>Higginson I. J. (2009)<\/a>","<a href='#679' title='Jump to individual results on the right'>Jongen P. J. (2019)<\/a>","<a href='#680' title='Jump to individual results on the right'>Kiropoulos L. A. (2016)<\/a>","<a href='#681' title='Jump to individual results on the right'>Learmonth Y. C. (2012)<\/a>","<a href='#682' title='Jump to individual results on the right'>Mayo N. E. (2020)<\/a>","<a href='#684' title='Jump to individual results on the right'>Miller L. (2011)<\/a>","<a href='#685' title='Jump to individual results on the right'>O'Hara L. (2002)<\/a>","<a href='#686' title='Jump to individual results on the right'>Papeix C. (2015)<\/a>","<a href='#687' title='Jump to individual results on the right'>Paul L. (2014)<\/a>","<a href='#688' title='Jump to individual results on the right'>Pozzilli C. (2002)<\/a>","<a href='#689' title='Jump to individual results on the right'>Renfrew L. M. (2019)<\/a>","<a href='#690' title='Jump to individual results on the right'>Solari A. (2018)<\/a>","<a href='#691' title='Jump to individual results on the right'>Thomas S. (2013)<\/a>","<a href='#692' title='Jump to individual results on the right'>Torkhani E. (2021)<\/a>","<a href='#693' title='Jump to individual results on the right'>Velikonja O. (2010)<\/a>","<a href='#694' title='Jump to individual results on the right'>Vermöhlen V. (2018)<\/a>","<a href='#695' title='Jump to individual results on the right'>Ward C. D. (2004)<\/a>","<a href='#696' title='Jump to individual results on the right'>Weinstock-Guttman B. (2016)<\/a>","<a href='#697' title='Jump to individual results on the right'>Williams K. L. (2021)<\/a>","<a href='#705' title='Jump to individual results on the right'>Petrella, R. J.  (2017)<\/a>","<a href='#712' title='Jump to individual results on the right'>Mafetoni, R. R.  (2016)<\/a>","<a href='#713' title='Jump to individual results on the right'>Jonsdottir, H. (2015)<\/a>","<a href='#714' title='Jump to individual results on the right'>Pinnock, H. (2003)<\/a>","<a href='#715' title='Jump to individual results on the right'>Ndosi, M. (2014)<\/a>","<a href='#722' title='Jump to individual results on the right'>Patel. A. (2015)<\/a>","<a href='#725' title='Jump to individual results on the right'>Rangan, A. (2015)<\/a>","<a href='#733' title='Jump to individual results on the right'>Iliffe, S. (2015)<\/a>","<a href='#1528' title='Jump to individual results on the right'>Humphreys I. (2013)<\/a>","<a href='#1529' title='Jump to individual results on the right'>Khayeri F. (2016)<\/a>","<a href='#1567' title='Jump to individual results on the right'>Stuifbergen A.K. (2018)<\/a>","<a href='#1568' title='Jump to individual results on the right'>Riemenschneider M. (2022)<\/a>","<a href='#1569' title='Jump to individual results on the right'>Straudi S. (2022)<\/a>","<a href='#1570' title='Jump to individual results on the right'>Mazdeh M. (2010)<\/a>","<a href='#1769' title='Jump to individual results on the right'>Millar J.H. (1967)<\/a>","<a href='#1770' title='Jump to individual results on the right'>Hoogstraten M.C. (1990)<\/a>","<a href='#1771' title='Jump to individual results on the right'>Langeskov-Christensen M. (2021)<\/a>","<a href='#1772' title='Jump to individual results on the right'>Calkwood J. (2014)<\/a>","<a href='#1773' title='Jump to individual results on the right'>Medina-Perez C. (2014)<\/a>"],[0.333333333333333,0.375,-2.22044604925031e-16,0.0904255319148934,0.341463414634146,0.0604395604395603,-0.182481751824818,-0.444444444444444,0.0869565217391304,0.329787234042553,0.34375,-0.240469208211144,0,0.0727272727272726,-0.220338983050848,0.578125,-0.0815450643776823,0.460829493087558,-0.12,-0.238095238095238,0.3671875,-0.285714285714286,-0.148936170212766,0.228571428571429,0.445497630331754,0.31390134529148,-0.0752212389380531,0.322175732217573,0.318918918918919,0.238970588235294,0.756756756756757,0,-0.125,0.568493150684932,0.0284090909090908,0.326771653543307,0.275862068965517,0.421052631578947,0.533864541832669,0.291666666666667,0.487341772151899,0.145569620253165,0.147368421052631,0.0869565217391306,-0.064516129032258,0.4375,0.322175732217573,0.113636363636364,-0.0975609756097562,-0.216216216216216,-0.0227272727272727,0.133891213389121,0.168067226890756,-0.322274881516588,0.28,0.0377358490566038],[0.444444444444444,0.333333333333333,0.444444444444444,0.222222222222222,0.333333333333333,0.222222222222222,0.333333333333333,0.222222222222222,0.111111111111111,0.444444444444444,0.555555555555556,0.222222222222222,0.555555555555556,0.333333333333333,0.222222222222222,0.666666666666667,0.222222222222222,0.555555555555556,0.111111111111111,0.333333333333333,0.333333333333333,0.333333333333333,0.444444444444444,0.666666666666667,0.555555555555556,0.444444444444444,0,0.333333333333333,0.444444444444444,0.333333333333333,0.777777777777778,0.444444444444444,0.222222222222222,0.555555555555556,0.222222222222222,0.222222222222222,0.555555555555556,0.111111111111111,0.222222222222222,0.444444444444444,0.333333333333333,0.333333333333333,0.666666666666667,0.444444444444444,0.444444444444444,0.444444444444444,0.333333333333333,0.222222222222222,0.111111111111111,0.555555555555556,0.222222222222222,0.333333333333333,0.444444444444444,0.111111111111111,0.333333333333333,0.111111111111111],[0.294117647058823,0.25,0,-0.166666666666667,0.181818181818182,-0.102040816326531,-0.18421052631579,-0.285714285714286,0,0.307692307692308,0,-0.142857142857143,0,0,-0.142857142857143,0.46,-0.05,0.1,-0.115702479338843,-0.2375,0.0999999999999999,0,-0.0934579439252339,0,0.169230769230769,0.0869565217391306,-0.151162790697674,0.26027397260274,0.294117647058823,0.234042553191489,1,0,-0.216216216216216,0.571428571428571,-0.125,0.257731958762887,0.181818181818182,0.470588235294118,0.756756756756757,0.4,0.341463414634146,0.307692307692308,0,-0.125,0,0.2,0.027027027027027,-0.2,-0.0285714285714285,-0.0975609756097562,-0.258064516129032,-0.0588235294117647,-0.18421052631579,-0.421052631578947,0.0526315789473685,0.357142857142857],[0.555555555555556,0.444444444444444,0.888888888888889,0.222222222222222,0.555555555555556,0.333333333333333,0.444444444444444,0.555555555555556,0.444444444444444,0.555555555555556,0.777777777777778,0.222222222222222,0.666666666666667,0.555555555555556,0.444444444444444,0.666666666666667,0.222222222222222,0.555555555555556,0.333333333333333,0.444444444444444,0.555555555555556,0.666666666666667,0.555555555555556,0.777777777777778,0.666666666666667,0.555555555555556,0.111111111111111,0.333333333333333,0.555555555555556,0.444444444444444,1,0.888888888888889,0.222222222222222,0.777777777777778,0.444444444444444,0.444444444444444,0.666666666666667,0.666666666666667,0.777777777777778,0.444444444444444,0.666666666666667,0.666666666666667,0.777777777777778,0.555555555555556,0.555555555555556,0.444444444444444,0.444444444444444,0.333333333333333,0.333333333333333,0.777777777777778,0.222222222222222,0.444444444444444,0.555555555555556,0.333333333333333,0.333333333333333,0.555555555555556]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th>Ref.<\/th>\n      <th>Author & Year<\/th>\n      <th>weighted κ<\/th>\n      <th>agreement<\/th>\n      <th>pooled weighted κ<\/th>\n      <th>pooled agreement<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"t","order":[[0,"asc"]],"columnDefs":[{"targets":2,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":4,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":5,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"className":"dt-right","targets":[2,3,4,5]}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render","options.columnDefs.1.render","options.columnDefs.2.render","options.columnDefs.3.render"],"jsHooks":[]}</script>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
<div id="score-heatmaps-unpooled-pooled" class="section level3"
data-height="720">
<h3>Score heatmaps
(<a onclick="data = 'data:image/png;base64,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'; $('#score-heatmaps-unpooled-pooled p.image-container')[0].style = 'background: url(&quot;' + data + '&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = data;" style="cursor: pointer">unpooled</a>
/
<a onclick="data = 'data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAB4AAAAQ4CAIAAABnsVYUAAAACXBIWXMAABMRAAATEQE5YH/wAAAgAElEQVR4nOzdd3wT5R8H8Oe5y2iS7p3uNuy991ZQ9hJkCQIqCDgAwQE/xI2KDMENiOJA9hJQFARBRFCWDFml6d47TZPc3e+PMjrS9tomvbT5vP/g9SJN7r43nu89903ueaggCAQAAAAAAAAAAAAAwNYYqQMAAAAAAAAAAAAAgPoJBWgAAAAAAAAAAAAAsAsUoAEAAAAAAAAAAADALlCABgAAAAAAAAAAAAC7QAEaAAAAAAAAAAAAAOwCBWgAAAAAAAAAAAAAsAsUoAEAAAAAAAAAAADALlCABgAAAAAAAAAAAAC7QAEaAAAAAAAAAAAAAOwCBWgAAAAAAAAAAAAAsAsUoAEAAAAAAAAAAADALlCABgAAAAAAAAAAAAC7QAEaAAAAAAAAAAAAAOwCBWgAAAAAAAAAAAAAsAsUoAEAAAAAAAAAAADALlCABgAAAAAAAAAAAAC7QAEaAAAAAAAAAAAAAOwCBWgAAAAAAAAAAAAAsAunK0DzN5Z3U1CqGrut0OrfuctvdVBQxuOxPdb/XndZkk99tfSJoZ0bh/i6uig1ntpGnQc/8cbms+m81JHVK0LS9knhIRO2pQqEEP7Wyh5Kquy56nbFO5m79m5nBVV2/+Cm7Q+G8fSi1r69PrhksvmSxbH8s7i5nLIhsw5XGIGYtxXue9yboZQyym7Lb3DlvIn7793OCkopZbwf31d5Iy5xvOyicM9jHgwbOueImRDpDwcA1DGFeyd7MbQi8hb/O2shpMylhLvwWhs5dRnwWVJV8lvJT4m+ipVcl00iqQL7Z3KwLz7p2IaVq7aey7v/Ei6X9mA+MU8nK5tEGEau8ghs1HnYnFWHYhzu/sfuCUQSjp21hNST36z9+niSU94jWklHIjlf1hLy/tu34tnRvVqE+bqrXFx9Qxq07jlyzvu7r+TY6byWLBs4doOF6kP3o/Y5XQHaOZljdszp1Ljb1NfW7zt9M51z9fFWmlJv/LV//ZIJnVsNXvF3rtQB1hdC2u6Fz+0Km/faSD8qdSx3uHSY/+rD11+f/cm18kq2dY5g/nvH7mjrnWLu1p5d5yyil1Trx6seHg4AsD+q9AqOKE+wp8JRrjgimeLPHvn1yOkYg02WZudMbrix+60pfZtqPdQan4j2w57/7GSquPwt6oNCzuVtbzz+YMtQb43K1S+y/dA5a35LFH0Rs6tqbbj56LPhVgqclCo6vnOl3G+Oozc8MfrJeS9+ciLr/qUdl0v7oXIPbYkcEhbiqzKl3vhr70fzHu4wZPW/DleDLsm2CcSGxAfmqFnrDl6/+eUn5765J6ZUX7uyL0Qraua1oqYbTspJR/cU3v7pg6cHto3wdXP1jWrbb+KS7Vfz7//VybKW6fpXk9q2HTZ/zc4T13MUAY2aNwqQZ/73x+6PFo5s22bsF5eNVVyctebjII1doht8+3Y/iCnu8IfPjuzSMMhL7aL2DG7eZ9KSzReyHaHCXv2GXHELLQvdD0kIToa7/n5XOSEuY7Yarf7dcunN9nJC3Sfttv73OohP/2l2YwWlrG+Xpz89fCPbIgiCIJizbx7b8HyvABmlbNjUPam8xFHWC8aTC5sqAifvzrqzN7mbK7oriKLHymiuws9Z/lvWSU4U3ZbfqPh91WQ6u6SVwv/RH1KkOMjmvxc1kxEm+OlfC2v6NuPeKV6UUJZlqaLb8uvW9hV3Y3k3BWVZlhLqNWVvJY249PGyC+PuSe6UCZl92HTnBUkPBwDUMcY9j3lSIm/7xr+Wyt5a6lLCZ/yzc8O6Lw9cNVRlfSU/JfYqVmpdlUTCJ3zygJLIO7x9udJtEsGemZzPOvFqV0+GUEYT2KRViwgvBSVUHjXh+9uVRC7ug1zcjiebaSihVOEZ1rxV40ANSwmVaYd8ekXiPmh1N5xP2zDIhVLKyEpTdX7nivXPmq6u7ufJEEIUfdfGljjPcLm0OdPxuVEsYXXzT5hK/6kw+Y/VI8JklFD3Qevi7NIdrSb7JhAbEh+YQ2at+0vI+PXZpnLKNlzwp7nkX4x7H/eRl2ncMplMJmMZSqiyx4qbkp06Nd9woaJ0JAh8xtHFXbwYShlXbZNWzSO8lZQQxqvnO3/nF1uA02Qt0/k3OqgolYUMfOPAzdy7m8vn3vzp3eERCkoVzRf+kV/hEkqy2nzKvFi9jk1N1coNYyl27n4IhrPL+/mylFBGo23StnWjQI2MEkLVTZ7cGS9p/q9+QxbVQktA90MaKECXUu8K0HzmvmkhLGF8+6+8UDZXG/55o7OaUnnb1y+arXwYqoJP+makt6zBvOP3Th0HKUALXPSHfVTK9m/+K8FBtnkBWtGxdzd1ORVo7ubKHkqq7tq7o6LyAnTZ42UXZQrQkh4OAKhjql+AtgWxV7GqRWLL+pFdM3n+8Reayinj2/etE2kWQRAEw7VvJzdUUMZ3+FcVVuhEfZCL/mSAB6Xy8GHLf08q2hOGGzvnd/NhqKrz2xfLFAhrUbU33Hz65SYyqhq2KVPsqozn3+nmWvSTsrIVH1wuba2CArQgCHza5jHeDKGuo7/PrvXQxKvzBWjHzFoCl3njj4ObP35txoNRakoIsVKALg+ffmCGTqZsNve3bMnKNdXf8PsqSkd80g/jAhmqaDB+3fksThAEoSB656xWKkpVXd4r9u2as2Qt07HnIljChkzfXzZZFJxZ1EpOqcfo79PFnw/iCtBSqKUbxpLs2/0QCk693EJBqbLRxPV3Tmch/9qO+d28GcL4jtyUIF3ZtdobLraF3ofuh1QwBIcdWIyGQrv+Yt9iKrSIfD6Cu/Hlsu/jedc+Sz99pqWqzJ9VbWY8/YCGmC9u3Xqp+o98ViEeW6jl1YnF39782YEc3ehHOymlDqU0JmzUuB7MuQ3rTjr4U5ViMP6DR/VSm89YGYWD1+/dedqk7jV6kH/lmU3U8eJyc/Jtfq7Vq8MBACAhe155hcy9q9Zdtah6/m/dS918WEIIUTWcsPbDKSE0bf/KDZfL7eiJ+6Dln88/PJzNhE3/4pv5PQJYQgghKt2I97etGOpVeHr1Bz9VfQBSG6n2hhNivHU9lmOCGzXQiFuV4a+3pr5+SvXQ5CFBrJU/43JZu6hX527NZEQwpSRl2HXwX7t0ru5ypLswqxwyaxFCDAcW9Ht43KxXP/vllqFK2yek/bjg6fXxLRd8+WZvd4nGg6rJht9VYToyn1m1dFsy02jOl19Mb+XBEEKIS8SID1ZNC2MK/v5uy/0VOEnWErKv/ZfIEVnTjm3dyvzRpfXIIQ1ZIf/aldjaHcLALiUCKW7w7dz9IIW/r9942cToZn7x+bQ7pzNRNxz53ua3H3QV0vev3x4r0fDv1W/IolvoXeh+SAcF6IpZTr/cVE5VI74tOUqy6eenAlnWd9qBO4OT83Ef9VMymke33P71jeGNfd1cVQqlR3CrQfO/u2IgQt7lzS+N7BDhrXFReYW1H/HKjhslB0UqjD289rlR3ZsEeamVSrVncNOeYxasO5VarOXfWf64bVk3ts17INJbrVLIlG7apv2mfXAkoaLCMXdz5w+nCqjX4JkTIq01LkJ9Ry3fu3vX9reH3B/TSMi5tOW1yQ+0DPHWuKi9gpv1HvfyV2fSirdb8fEIuZe3vT7lgZahXmqFUuMT0W7QzFWH480ld3LKn+sWjOneWOuh1viENes+5qUNfySa7bA6kUdTZNhldvW2zafMIQOHtJWX/SOffW7j/GHtI3w0KlffyPZDn/noWGL5SxMfp5i9RwghjPbhIR3ZmG2bT5SbRA0/PRXMUnnzRX+XOqEKDs0MKfqDmVRrz9ga4z94dE9rFWg+bt+uv0yqHqMGBVSe2KweLz5mdS8l4z5pd6Hp5vYXHmri4xrx7JGi3S1qPxPD9T1vP96vebCnWuWhbdpnyjv7bxvL9oREHA4AgBoqmlS55Fw9fPrpdc8PaRvmpVZ7hrYZ8sL3V3IuvtFWUWwCWGufIpVexcr5lJW/5n0/SsUEPf1rITGfeaWZjCr7rNHzQvKXQ9wYNuDxvSWLrkLqphEeDOM1ZnOG9XtKa5lcSP9ykAuVN3npr3tXMy5hz8zmaob16PzSkXTRd6eG33b/kk2UPSaMjSx2TXHrN2FYEGu+tO/HcifDFfVBIfXMX7csjGefIT1L3L5T7bDRPRRC6sG9J6s4/03lnUmRqr3hhNNfjzYJMl3jKJmYFeUeWzLtvfOeI1d9PCXCah8Vl8vaxnE8IYTx8Pa8f+jF9X/4zHPfvDKuZxOth0rloW3Sc9wrm85m3jn5yutciezuVppAanYXZpvbEKuBWd/HDpm1CCGq3ot27tu3b9++fXs+n9ZEVBMmhBAhY/9Lc75KbD7vk1c6qcV+6C4HyFp3VZyOzGd+2HbNIms/bUbX4t+uufR+9/St2zf2zG5w/yPOkbWoQq2WUWL+9/cTaWVPT1m71/7Ozss+tahlsfOogoZmtflYfbFUZ6MqFZLK+z9W2bXBlse+3Q/Cx56/mMYz/g8M6VKizTJBvfs2lQmWG1dvVe2bA+kbchVaKCEE3Q+JSf0T7NpWxSE4zH+91ERGXIZ/k1PiXYU/PRnAMD5T998ZLoCLXdtXQeVN2rd2YxQ+jbr2H9C9obeMEsKGPrJ4bncvRhXQvOeABzqEuTKEUEXTBScK7i7KeGF1f3+WEir3CG3WrmO75uFeCkoIVbV88fe8e1HHru2roC59pz7WQE6VPg06PfhQ3zbBakoIdWmx8P77SuNTNwxWUap84BPRj1JwiXtntdRQQqjSR9emQ7vGASqGEqqIGrfpxr1nEMTGk3N8UXs3Siij9m/YukO7pkGuLCVUHjlt970RdQr+/WRYiIwSymoCGrZq1cBPzVJCZSFDVv+Ta+vViTyaYsIuu9/0a/sqGa+JO4sfjKKHl+WtHpnQzpVSRh3QsGmEl4JSQqg8dMS6/+4+AFnqaWWxcYrbe0XMfy9qLmN18/8o96Hegl+eDmWJrPniv0s8a5J/4AktQxUd375iqdaesfkQHC5Dv85I+OJhNVV0+6DE092c/qN+LlQ94LO49K+HulQyBIfV4yVwt1f1VFC38Z9unhqpUPo17f7w+NVnzCL3M591/NVuXgwhhMrcghs3DnZlKWUD+w/toi45BIcg5nAAAAhCTYbgKOrPKPt/mnh3WoKE3U82caGEMir/Rm3aNPBVUsa704h+YWyx3FvyU6KvYiXXVUEkhWc3vvzCzP7hLGEDe06b/8JLHx/P5AU+acMgDWUCpu4rnpP5pPWDXCnjN3FnOeMBWM3kfNqGgUoia/ziKfOdzd47q4WaMh6dXjqSVoXHSs3nXm0lI7KmL58u+QAmn7FxiAulHhN2lDOqoLgPctEreyoI4zttf+krVf6WMRpKFD1XVWXcE1GdSXGqveGCYNw3xZuyobN3n93x3typYwY+OGDYhDlvbDweZ+VqzKcfnNlAzoZM3JbIm47MCWWtDbqKy6WNVTIER+LGoR6UKtq9eS/diOtnWvTbpjZ2oYSy7qEt2rdtonVlKaHKxtOLBhMtr3MlsrtbaQKpwV2YzW5DrGc2Kxwza5WK8fr7XeXihuDgsw7NaiCTNXr+aBXzjOAoWavofZWkI+7Wih4KwurmWW04ZaJxhqzFxW8Y4kkJoeoGgxd8uv98YkGFJ2rFDc1q87H6YqnOhugKiaj+j9XttGeDLY+dux8CF/vjsnnPz1/+U2KpS27h0WcjWCJr9sqZKgw84QgNuWotFN0PiTlrAZpx1eoaWBXmo6TVK0ATQtngYavPFHU4LIk7poSzhBAq103YeLmo/RVcXfuQF0PYyLnH75zKeTsnelOqaPzE1lt3R2guTDi0oL2KMt5T9t7tIN1ZPqHKJtN/uHHnjYZrX4wMZAjjM2Xf/Y5USebzr7aSESbwqZ8rLP7dxyd+P8afIUzAgLeOJhaFyKWfXjMyTEape781d+t94uLhYtb0daGMd793/kwv6slyWafe6OlO6b27UuPpJW1cKOPT/YXt1+5kFEP03oVdvRgqb/T8b3m2XZ24oykibCtyt4/zoIquJd9QdOtOCGH8+7/1W0KhIAgCn39r34vdvRlC3fqsvl60gmoWoMXtvTvyto9zL1OzLcF45Jlwlsha/u9ssaSf9+O0QIaq+qy5zVVvz9ijAJ3JJXz+kJoqu39QbK4TLu6TB1VU1f/TOC6z8gK01eN15x5J7q8NbTt7V/TdZiVuP+f+Okcno9Sl8WPrz2ZYBEEQzKl/rRkZJqOEkNIF6PuHo6KdAgBQVICmSp8w652WBk0Gr75i9VJS6j6NT94yLpChyiZTv7uWzwuCIJjiDi7o7E4JIZUUoEVcxUQXoAXB6qiOdyrQgdP337+74OI/G6CmjHb6/vJuYaxm8hJ3hlzij3Naqinj0fnlqt4WFv441Ychygc+ji/1ucJDM7VMBQVikR80HHgikCGyxgtPlrxUZe2bFswSImu+6G/xd4DiOpPiVHvDBS56VU8FoUqNWlbiOXzq1urJLbdKbA2fvHNyGMtGFE2CXcEdoIjeC4hXXgGaM2bePvXdgl5+DFU1f+7Q3YFbRfbSoz8f6MVQlyZTNl0pmouMyzy7dkQwS9nQJw9kl9e5qlYBWhCsJJDq34XZ8jZE5Hi1jpm1ShJfgDaeXtxawWonbKvGVF2OkbUEQUw6KvxlZhBDFP0+unX75/enPdA8yEPl4urXoMsjC788k+asWcsSs/3pNneGbyCUUQW27Dfu2Tc/3/XHjczSBTsxDU3cGNDWCtCVt02R/R9r7Npgy2Pv7kc5LLFfj/RnCKt7/lgV2p9DNOSqtFB0PyTnrENw8HmJN29YpU8vrO5zE9T14Tc+e6a9JyWEEDZwyNRhwSxhfEYvWzu5adHTAC6Np0x7UE359JS0oocS+EyLf6/Bw2e9sWRU5N0RmhXaPpOGNGT5/JTUUiOksZFPffLhWN2dN6oaTpk/IYLl85ISc8sJWcjKzBYI1bhpxA3Jxd345sM9qcTvkdWbXu4VWPSkCePdYfaXnz4ewuQc+3j9PyWeZqkkHu7m1etmQdZ69GMdvYsebmA8Os5+94Mli14c3ogKhJDs/as+vmDyHr5q23ujGt55BkQVMeSd79/qp7Hc2LT+13ybrk6cai2Hi/73qoGoohoEW2lSjN/o1d+83FurIIQQqo4c/PYPK4Z409zjn315rvojb1dx7ykjG4ax5qsXrpY7XIay29hR4azlyu5d98cDzzu8ZV+K4PrAlDFhjM32cM0xgYNH9VCZzuzYffvu0z1C0o87/zC6dBs5WCsiq1V0vARzhtvYtR8Mj3Ap+r+o/Syk7Vrz9S1O3ubF77+Y1saLJYQQmW/HORu/mB5m7cmee4ej6hsPAM5HKEzXW++03LgRmyGm28Lf+vbDnck0fPraD8c3VFNCCJEHP/T2Fy+0kVfeQbDTVawY6j9odG+1kHJg5+8FdyOO27n59wImZNSEvuUMKFzhlZcQwiUfeP6hsR9dknd+aff+t/r4VG1wUktersFqD4pqNBpKhPy8csZJFflBVe+pkxrKuGtrZ8zdftNw56Mpf6yc/PTXCRwhgtEovjtatc5kJaq94cQSfe2WhQhmWZMnNpy8nWk0GVKu/vLRtLbu+RfWPf7osnP3HnPm4zfPmfVtQuSTn34wxLeSw1J57wWqirv5QXcFLY518YroPGH5n67Dlh86suJB76KDIq6faTn7xapDmUyj2es+mdSkaEYnxrPN02sX93XhEw7++M+dA1e6c2Vz1bgLs+ltiDgOmrWqh49e/9Lqi2zneUtG+FUtUOIwWUtcOhJysrMFIqTufKLbwIVf/h7HaHVhbgW3T217b1qPzlN+0JcaF8A5shYbNurjv/47tXXFgskPtQtWm5IvHt784eKnRnRrGBDUasTLP1zKu7vPq9bQqhNKxW2zBv0f+zbY8ti7+2GFkH1u3bSHn96VyoRPeO/FHuLTtGM0ZPEtFN0PB+CsBehKhuCoHja8XdtiZzLj5eNFiax5t84e919U+Pi4UXKv7TAhj6zYuXfnyjGh946EJfvGrz/8Em1liBvGv/+wbsWH6mE8PN0ZQggpr21TN3c3SoT8PHGtX8j64+g5E/UaOGmof/EWST0emDgsiLXcPH48rthoPpXFw0Y1aaik5t/ffnzRpt9vZJoJIYR6dX1i6RuvLxwaxRJiOnPoSIag7vPosMASCYAJfXhQazmffepE8ZkRa7w6kaq1HC4+Jo5j/LT+Vv7OeA+aPKzEDmWCH5k+2Iux3DjxR0K1B/mv2t4jbIDWnxHy4/TlD0yl6Dx2dBRrubJ795U7p1/OL1t+TCPeg6YM96e228M2QLVDRvdQmc5sv1uBFpL37zxeoOw6akiQmKRW0fEijH+/gR3uTTQhbj+bTh85nifIuzw+tXWJKSrc+04ZY2349XuHQ0SwAOD0KhiCw3x+aevKR+sUMo798reJBjw8qodrsZdlzYYPb1Zp9rbTVawE6j94dG+1kLR/5/GiCjQfs+OHP4xM5CMTyr0TqjCTc8k/zX94zNoL+UTTccpTPb3vh285tbCRjFZA0WnZVY4Q4c7Vspw7FJ4rbyxCkR9UdVvy1dIe3saLn4xp7B/QsE3bZiE+IT3mH/bq1yOYJdRFpRR9KyuuM2n3DadBA19esfqTHcePfvx4l3BPpVzl1/iBWesObhgfzBj+Xv3B/qKhfrnoDTOe3Z7WcPbnywZ4VbqNInovUEVU7qGNKCE8xFcjo4JZf/SbTUdi7txsi+v/cNGHD1+3yBqOGte5+FznTPDjm6/e+O/o4g5301PJzpXtVf0uzLa3IeI4ataqjtxf33vvt/zAR19+slE17gEcJGuJS0dmo5ETiPnir6f8nth0MSUj9srF/xIy4469+3Cg+ea3M5/eWHLONufJWvKADo/Mfe+rg3/Hpqdc/X37J6/NHt01QmNJv7h72YTuD752Mo+QKt+xVl0lbbMm/R87N9jy2Lv7UXIz0s5seLZ3s85PfX1ZaDTh8wOfjQqsQh3dMRqy2BaK7odDED3FAIjAskyZU5kqFJV8u8Zn/bvv262HTp2/cv1WdPTt2JQ8syAQQsp00hjfAL+qfWPABgYHsPRS5s1b6QLRWg9DSD357ea/0hndw08N5OISLAIb0bhB6XXLdE10LElIiE3gSMTdGCqLhwmfvubDU2Pnfffrssm/vMtqApu079Kt5wODx4wd3NpPRoiQq49J54XC7eM86Dgrn6epyanc/XO0pqsTq1rL4fPzDALVqlRWdjIb2aTMDnVp0lzHkn+SE5J5Elatr4GquPcIUalVlPB5uXk8IeVcbuUdxoxuuHLZpV27ryxq2YIl2b9sOZBBAqdOGehFie32sC3QwMEju7kc+n3H7tvPzY1ihJQDu34vUHYdOaScb6hLqeh4ETYwOPDeHhK3n4WchIRcnvFu2qz076/lzVo1k5NbZT5393CIiRYAoIa4uNuxZoENiwormazZcF24jFys+MP2uYqVUvQb6AM//bjzD2P/B1y4m9t/OGViG4+d0ElR3kcqyuTcza9e/Zi6R0T6xkQffm3hlhGbx929pWICuo6fMTOl/MI5G97WixLW1dWFEIMh3yAQ9+JrEAz5+QKhGtdyHi4T/0G3zot++qvdmndWfnPgr+tX/lNpmw9Z8NzSF0LWdfj1d8bd06NK+7XyzqS9N5zIGw+Z3bjMq9R/6KxHIzavuH3i6HnziB702sdPLDiQ2/yFXW/29RBzlyui9wJVw4Q9se3K8m4lf29jSTv9yRMj5+7+/Kl5PfvtmOhLRfYzaeztWI6wusa6Uh1BF5+wKB9CCCFFp1yJzpU9VPUuzMa3IeI4aNaqzpbov3lvk542fWXOQ6IastVlSJ21LCLTkUypZCmhis7/27x24t0JGmUBPRZsfOdE46l7flm/JXrqfN3908MJs5bCu1GPUY16jJq55MOsC9+9NGXW5+f+Wjb34/EnFjYS19BqsJ8qaZs16f/Yt8EW7p0cOHxT1r3qpqLb8su/z9cxtdD9uLMJqX9+/vKzS746k8ZpGg5Z/M77L45q7Fr15ix5QxbZQnl0PxwDCtDVZZtvQoTsk2+PGLH0aKrgFt6hR7duIx96TNeweRvvY7OGv3ulzLsZhlYtJ1C/bj0as79e/PuXo5lPjfO2+uHcIytnPbfVEDmv41MDPYo+ZeV9DMMQQjieL/liJfGomk/fdH7kK4d37zp4+PcTJ0+d2rXu2M517yxqPfOrfWuGB3EcRwjj3m7sE/1CrFw3qLJtePHGXsPVVVSZLHk0q7EcKlfICTGbRT+iwbAMIUQmr9rP7YvHWcW9R8xmCyFUoVBU1MFqO/aRJsvf/HfX7v9ebtE09+ctBzNp+DOT+919/Ln6e9jmGO3Q0d3n/fr7jj0xzz0fkX5wx1GDsvPIodZ2hRUVH68Sh0Xcfi5qINYo1aqyd0T3D4eocAEAaoizWAixcoGvar/i/gerdRWrAA0YNLqX+sDP+3aeXPlAr1vbfvjbLGsxbnyb8juqFWVyQaBePZbs3TX91pPtHt+5/cVXfuy/fkjR07FMxMjXPhpZaTyW4LAQllxJjEvgSGDxIAoSEzIFqgwO9bee99mqfFAVNXDhFwMXFo8846voFJ6qdQ3FX1TFdSbtveHlkkU0iJCRW5kZmTwhhpM/n8giCo9DL/Q/di/+nNvJPLH888Hw7t8oZE1mblo/5d6PHUT1XqDmZL4dZy1//rv9C04d/flP08QhSpH9H56zcIRQlq309rwK2aJ2fm5m69sQMRw0a1Wd5cL6T44aFF2mT2tbvYuAQ2StXJHpiPXy8aKksNGAhxuUuCJRv979Wsn3nLh26T8L0d3v09f7rMVd2TBr8d6Mpk988sbg0uMYMJ6tJq3dFP1XuyXnzh05nrGgkVDFO9aqq6Rt1qD/Y+cGG9J97CTh/qgSsobN3CipYi+iuKp8UMg4sSiByW0AACAASURBVGz8o68eShD8Oj2x9r1Xn+wVXJ27UodoyERcC81H98MxoABdLYUZGfkCqfkoZtzltc+8fjTdf/hHB7+a2fLeNz3cv//Y6DyXNRsxstnbFy/uX/vltUfmNy57uIWsX3b/li8wPt17tZQzhcFaGT0Xc+2WiTQt/iAd4aKv3+IIq63Gjxdk3k0HTG06YOrLhAiGhL/3ffjCnPePfjr7zZEPfdIzSOvKCKaGj7zx/mh15Uuq6eoeLOdst3o0K1qOlQPP+Ab4MnxWRpaVr/a46Ks3CkmTElto+u/yTY7KQyOCxe/QknFSj6rtPT4rI4unMl9/74r6nrJWY8c0f/fVC7t2X3sx8PwPP2UxTWZN7lbil29V3DN2w2iHjOo279fjO3bHzJl0fOfRfEWnUUNDRXasKzpeJYncz24hIV4Mn3H1ShL/YIkfA/Jx0XpL2Tupe4dDXLwAADXCBAQFMuS/2Gg9RxoUu+5wcTFxlT6TbaurWCWKKtAHf9638+S7vse2nLfI2094tGkFi68okzNBk77cvaS7N+2y/PVvjsw+tGne0km91vRzFx+OTNeqmYb+G332QpbQrtgdtvnfs/+aBVnzVs1VNfsgZ8hMzzWzGi8f1+IFnIJTx06biLJb13ai7wVt25ms7oYLWf/+fOhSjluzBx9qWfLRVj47M4snjN/9H6nxuTFn/4wpvYTs6H/+jCZyy7CCYldNcb0XsAU2tHFDDf3TkJaWLxClyP4Ppw0JZEl6zK0YjrQs1lyFnH/37/47w7vdsEHNqxaGrW6yKlPVjrRNOGjWqjLTqa+/vWxR9np0dET1GqZjZC1CiKh0JGvcvLGcJlnK1iF5nieEKJQlbpWcIGsxKWf37vrnTPCsxYP7WmmrbFBoEEPOEkopoe6iGpr9vnWqSf/Hzg227YzPvp5h5XV7dz8IMfz99pBB//uzMGL48m8+f66bX3V7cg7SkKvQQtH9kB52pxhCXm5esbNRyDq8/0SBLfJkwcV/LpuJe/8nprUs/pxBQWxMso0G6ZK1fvrFoT7UcPKN6W+fyikTc97Jd1/fkcazoaMnP+hGqFfXXq3kQvqBb39MK/HW3N++3RXLySJ69qxCN4P794MBDSMbPPDu+bsDO1F1UIexr/9vdCDDp0XfzhUUHfp005D8YzsPllwdH//1uIZBwa1f+K1Q/JZWvro7L1dyNEUvpwRZVKMomZAZG1t2HxM+48CmvSnFXxcSt6/fky4o2j3Yq/zZCio766q497i4mDiODW3UoOI+NtvskTGt5ObzO3ed2rfll2x520mT7o4uWr09Yz9M0JBRXZWmv3bsPndg55E8RaeRQ0U/B17R8SpF3H6Wt+vT3Z2aT27ceNFU/F2mi999/7eVr83vHQ6RAQMA1ASj7dWnmVxIOrjrD0Oxl7nru3dfrHTwxWpexaqMBgwe3UvNx+3dum7T1n8tyq7jxzSo6KaookzOuGm17pQQwkZNX7moq5q78fnz7/xpIET8WISufQb1diUFv2/bm1Rs+YV/7dgbw8kaPjyw3GFPRX7QcGBWI21g6PAvio8eKiRu+2xXquDa+9FhomY0IISI7kzaecOp7PqmmRMeHfHEZ1dLnlKW/3bv+dfC+PXs20pOiNeUvWUmYSkxDb3p9MtNS9cIKu+9gC1QF5ULJUJudo5AxPZ/2Ea9egaxlkvbt14o3v8R0nYvnjBl6uwNl4RKUoTdbrIqZdPbEJEcNWtVkenkDztu84rOI4eJfPKwDMfIWmLTEQ18aHAHBXdj365zJc4JXn/wx3NmqmrXuWXxrxHrf9Zio/r0iWC5uO+Xrb9mKvtnPmH39j/MRN60aycvKklDK64m/R87N9jy2Lv7wV1dO+etP/N8h3z869Z51a8+E0dpyCJbKLofDgK/gK4Y4xfox5D/Tny28tjYZb29GUJI/pWNM+d+n8yXNzx6VSj8A72pkPzngd8zBt2Zc7rg1v4Pnnn6q0SeKCwmG8y5SQPGrflk/5nx35147aGeN/73zktT+zfzlhMiGPTHv3v3hRc/vWCkgaPefKWfhhDCNpw0Z/D7U3ZteXZKu+CNc7v6sYTwWWc/f+qp9TG8W+85T3aowgnDhkX5Z+oPRX/01ldDN0xr5koJIXz2xU1fHEjmZbrWLT0plY96ZuLS/Z99P3Oszu2rV/qHKgkhhQm/Lps0f+vN7EbzR3WuwmQlla9O3NEUsRxru9m3fUcde/jKhSsW0rP0s2h86vbnp7wf8tW87v4yQoz6g29Men53Ogkc//wknbV+m7izjvpXZe/xyZcvpwquvTo1q+QQso0fGdP29X/ObpzzfnyOS/cp4++l+urtGTtigoeO6jb/yPENzxbczlV0HDksXHQvuMLjVeqtovYz9Rk2+7Go3WvPLpswM+KHVZNauDNEyLu6ee6kd8+ayz70df9wVH2zAQCqjm3+xPyhH03ZuW7OvD77Vo+KUBJiSTqy9In3zpgJoZX0aKp6FRNFKDQWlrqjK6pAH/xp4+KPjJzqwQmjK/5WUWQmlzd75sMF33d/7ezqZ1eMO764tUzcWISE+o56bvLSHz86uPT5b3ptekynIERI/33p3M9u8O4Dnnvq/tgg5ttHt5+I42XhPcf0CGVEf9D1wQkjArd89dsbs9Z02fRMO0+GWJKPvjNx/t5MebMFSx67X9cpWj7HhnZ/pFeEtWu4yM6kyEEYq73hrg9OmxD1w0en35w4t9GWZaMaaAghfM7lzQvHv/mXSd35+bn9q3ETJ7r3ArbAsgwhfE5WDk8II7Kfqegxc3anDS/++cHjz7XaseIRnYoQIffS+tmL9+VSv3Hj+3sQkm19bTW6ybKSQKqqah1psSoOzFGzVtVY/j30azwna9W/X3kDBdWVrCUWEznlpQkrR2xcPmFy4KaPZ3X2YQgxXN/+yqRFRwxMxIxnRxWfptcZspa807NLR34zefuhuQ8OS3z/zVlD2wWpGUII4fP1f3z/1nPz92cS/9EvTG/GEkKq0NCsNp+aNvYa9H/s3GDLX61dux+W899+faaAbf7C65MjKz5H60xDrlILFckZGrJErE+qXn9x19/vKifEZczWMt+ACIIgCJZLb7aXE+o+aXfR37nYTaMCGEKo3LdJr0FD+nfUeSso49miVbiM8Zm6v/DOUmPX9lUQWeul54vNUm85v7S1jCj7f5rI33+x8JeZWoa6TdxVtPjCc8u6uVNCZT5Neg4aPqRfhwa+Ssaj7eTxnVSUKsJ6TX7jx3iunOULguXi623kRPnQF8m8UKH8SxsmNlZTQgihrMpLGxrsq5FTSgih8uCH3j2Zdf/zXPyup5qpKaGMKrBZp86tIzwVlBCqjBq36Yb53pvExVN4YXlvL4YQyroGN+/UvWv7JoEahhKqajbrxztv4bN+f7WbF0MIlXtFtu3SpW0DXxdKCOPT860/c2y+OnFHU0TYVhgPzw5l5V3eu1YsRu7miu4K6tqwRZSKEipzC27WsqGfiqGEUE2rZ/Yn3V2Y5b9lneRE0W35DU4QH6fIvVckZ/t4T0YzaENlp4ogCNz15d0UlBBC3YZuTCr+/ursGfPfi5rJCJV5BDewpum4L2M5kW8z7p3iRYnL0K8z74Uas6avCyWEUEW3D+7sPEEQMr8e6kKota8577N2vATu9qqeCiLvtOy/EmeauP3MZx5b3NmDIYRQuWd4i5Y6HyWljF//+U91UjAhsw+bii2xCocDAJyacc9jnpRQpU+Y1eTYoEGDBo26L/nDJJS5lBT1Z4p1QvikH2e3UFNCWdeg5u1ahnnIGU37ec8NUBI2at7xOymq5KdEX8VKrquySHJ+GONGKePT8uHRjy7aWzwR8onrHtZQQgh1H/ZV5RnSWibn0zYMVBJZ4xdPme+/mPf7C83klLr2WnHVXHYx5eIzDs9vraGU0UR0GTRiaO8m3jJKZSGjvrxZfCnZm4a5EELVj24zVu2DXNzWx6LklFCZe0jz9u2aBKgoofLgoR//WyCUWT5xGf5NqSv7PSI7k3bfcD77z7d6+zCUULl7SNN2ndo3CVQzlFBVo8e+vVnBji/xE6SScLm0KdPxuVEsYXXzT5is/dl8bklLGaFuQzdWpZcuCIVX140Mk9M77+rUMtxTTglVRE7cHGMRyu1cie3uVppAqn0XZtvbkIoyWzEOm7XuK7pZZhsu+NP6ii3X3usiJ2zYM79ZPY3uL78uZK0yyktHfPqv89toKKFU6RXRonXjQA1LCWX9+rx9MqfkoXaWrJX796ohYcqi8oLc1S84IjIixFcto4QQyvr2WHwk7d4OENPQrDaf0i+Wygai26ao/o9V9m6w5bFj94NP/LS/khAqc3G1yrPr2/9aii+/bjRk8S20OHQ/JIACdCmlC9CCIORd/uHlUR0jvFxYSgmhyrCH3zx8bm0/hS0K0ILAZ5z+/JlBrUM8lAoXj+BWA558/8AtA5d5ZEnfMFeF0nfAmuuWmhegBUEQDNGH1s4f17dlmK+7i1yh8dI26jL0qbe2nEu3lH4nn3nh+yUT+zQL8lQpXNwDG/cY++LG06kl6nSi033u5a1LH+vXMtRLLZfJ1T7hbfo//toPF7JKxGu4uf/9GQPbhvtoFAqVd3jbQTNX/Hy7+OGx5epEHE2RYZfZwb88Hcqq+n8aX6yaf3NFdwUT/PSh5PPfLhrXo3GAu4vS1b9h90cXfXchu9jCShegxcYpau8VvevnGcGs68B1CWJSKHdrVS8lJYzPuK2Zpd5f9T1TVFkul6LHymhO5NvKFqAFLmZNHxdKqKLr8uv3rxtiCtDWjlf590hi93PefzvemNynmdbDRanx1XUdt3TXjbzoVT1LF6CrdDgAwJkVFaArxAQ//WuhUHnZVxAELu2vL+Y90rt5oJvGt1Gfpz4+lZ765SAlkbV69dydnr2VArSYq1jVCtBC/tmPx7cLclPIVP4jvyxxb3KnAk29xmzOENO1KZvJrd4ZCnzWz09HySjj9fBn0VW7F8o+9/XC0Z2jfDVKlWdwywFPrTwcX+rm0npFQ8QHBUEwJx798OkhnZsEuavdAhp0HjX/i5MppS9Ald8BiuxMVkl1N9wUf/TjeY90b6z1VClUXiEtH5jy2g8XK+4/VXAHiMulbVVSgBYM+6cHMISyIY/vudf+xPV/zEknPn1+RKcoX41CofaJ6jj8+c/+SL5z0lXQuRLT3a00gdTgLkzUBoq/Cys/sxVfn+NmrbsbXHEBmk/4tL8LpeqhX6WX2y7rVtYqoYKCFJ/z7+bF43s0CnB3UWp8IjoMfWbNYX3N7rnqOD736p4Vc8f1aREe4KmWy13cfMNa9Bgx863vTqeUOXcqbWhWm0+pF6tbgBbE9H+ss3+DLY+9uh/mM69U+JveYvuzjjVkcS20BHQ/JEAFoZYHbq3DuPwUfTLnF651tdmUOyAZ2x9N86mXWvZYE7b22sEZ4qeur5RN4jQcmtl40Lbu3137fow35nG9wz7HSwwcDgCodZa81JRss9wjwK/41cRy9n9tOr11c+DGhD2TvaQL7j4h7ZtRDSbvUUzccWPTcBFz+UiXyWtX/ubRYTvGxW4Z41xDEeJy6Tyc6CYLWateQ9ZyPDXr/zhLgy0PGjIaso05YzOqNlbjHxnlBB0j52D7oynv+PRzfZhjG7+7YaMZJAkhNolTyDzw5fbkBtPnDkMCLcY+x6tyOBwAUPuEzK2PNwgNbfX8z8Un4TFf3rPvGidv26tbFeZttyc+fvvXh3Jo4IhJ/cVFJFUmr2VcQmxycINIhdRx1C5cLp2JE91kIWvVY8haDqiG/R8nabDlQUOWOpb6BwVoAFthwqcsnRl19tM1x/KlDqU47ubGVXuYEUvmdqrOZCr1mDTHC4cDACRAfQdOHORDkr+dP/OLE7ezjJbCzFvHPntywnvnOd8hsyZEOUTZR8g49Ob7RwxMxJjH+oj9qY2DXnltqfDvT6dM+sr3ueltnWsiHFwuoZ5C1qq3kLUcUU37P07QYMuDhoyGbAcYggPAhoSMg093Gn/t+TOH5ugc4naeCJn7preZmvjKqX0zHKPA4FBq/XjhcACAVPikgy+OnLTyVDp3r+NH5QG9Fn6z5fUH/SX+PQIfvXZIn/fPZiYk5/IeAz7658DMSPEROd6V17Yscf+czAnr2szXqW4AcbmE+gxZqz5C1nJYNe3/1PcGWx40ZGc62rUGBWgAmxJyLuzZej101Kh2Xg7xyIbp+k/f/qV5aHyPIDzuYE0tHy8cDgCQkiXj0qGd+05cTsglGr/I1r0GDeoZ5eYAFys+4ZvxnWfszfVtNeT5D1Y/392najE52pUXag6XS6jfkLXqH2Qth1az/g8arPNAQ7YzFKABAAAAAAAAAAAAwC5Q1wcAAAAAAAAAAAAAu0ABGgAAAAAAAAAAAADsAgVoAAAAAAAAAAAAALALFKABAAAAAAAAAAAAwC5QgAYAAAAAAAAAAAAAu0ABGgAAAAAAAAAAAADsAgVoAAAAAAAAAAAAALALFKABAAAAAAAAAAAAwC5kUgdQq1599dX8/Hypo6hLeJ6nlFJKpQ4EpCEIgiAIOAecFk4AJ4cToHoGDhz4wAMP1Hw5S5cuNRqNNV+OrXAcJwiCTOZcXUeLxUIIwVY7A0fbao7jCgsLV65cybJsDRd1+vTp7du32yQqmxAEgeM4SmnNN60Occ6t5nme53mGYRjGiX735oBbXVhY2KlTp/Hjx9d8UStWrEhJSan5cmylqHPCsqxTdVadc6sd7TJdOxxtq3meLywsXLx4sZ+fXzU+7iibUTtOnjy5fPlyp2qlNSEIQn5+PsuyKpVK6lhAGgaDged5jUaDVuOcTCaTyWRycXFxnGse1Cae5w0Gg1wuVyqVUsdSZ/z00096vd4mizp+/PiaNWtssiibyM/PN5vN7u7ujnNHXQtycnJ4nvf09JQ6kFqVnZ1NKXV3d5c6kNojCEJ2djbLsm5ublLHQggh+fn5ycnJK1asEASh5kuLj49XqVRjx46t+aJsguf5nJwchUKhVquljqX2WCyWvLw8pVLpVDdWJpPJYDCoVCqn6kgYjUaj0ahWqxUKhdSxEJ7nU1JSTp8+bavOyZ9//vnCCy84SKokhBgMBpPJ5Obm5lRf7Thnlyw3N5fjOHTJJGQ0GpOSkr744guTyVS9JThdTaFly5YopYkkCEJ6erpcLvfw8JA6FpBGVlaWxWLx8fFBq3FOBoPBYDC4ubk51W0D3GOxWLKyslxcXFxdXaWOpc44d+4cz/M2WRSltGnTpjZZlE3k5OSYTCZvb2+nutvJzMzkOM7X11fqQGpVeno6pdTb21vqQGpPUadXJpM5wp1tamqqIAg9e/Zcu3atrZbp6+vrOPmE47jMzEylUuk4NaxaYDabs7OzVSqVRqOROpbaYzQa8/LyNBqNU5XdHaf/bDab9Xp9ZGSk0Wi8dOmSrRbbsGFDLy8vWy2thvLy8oxGo6enp1P9XMY5u2RFpQl0yaSSmZmZmJjYpUuX77//vtrVISc6XwEAAAAAAByTIAhxcXGZmZk6nc5Bfu4EAHWUwWC4efOmSqUKDw93qjIlANiWIAjJyclJSUnh4eE1/PLJib4mAgAAAAAAcEAWiyUmJoZSGhUV5VQ/5QMAm8vKykpISAgICPDx8ZE6FgCowziOi42NtVgsOp2u5sMKoXMDAAAAAAAgGYPBoNfr3d3dtVotxj0DgGoTBCElJSUjIyM8PNypxnsBAJszmUwxMTEKhSIqKsomD1KgAA0AAAAAACCN7Ozs+Ph4Pz+/6s0pDwBQhOf52NhYs9lsk98qAoAzy8vLi42N9fb2DggIsNUyUYAGAAAAgEo454i0jjPPUm1ywke2KaVSzWuUkpKSnp4eFhbmPNO9sizrbLNIEULkcrnEWx17tfbX6UKICyGkIK32V00IIdnpkqxWTYiaEJJU2+s1ESaGqBVunpGRkSzL1vbqJeLq6ipl8jQXSrJad5WSqJSEMxNOitVnpUixVnJnjuDUWEnWTvxCJVmtVF2yjIyMpKSkoKAg207OjAI0AAAAAABAreJ5Pi4uzmg0RkVFKZVKqcMBgDosn7CxRONBzNrwcKljAYA6TBCEhISE3NzcyMhIlUpl24WjAA0AAAAAAFB7zGZzTEyMTCbT6XTO81tFALCHDKJIIi5BxOhJTFLHAgB1GMdxer2e4zidTieXy22+fBSgAQAAAAAAagmmHAQAmxAISSKqbCIPJ/kaaYZjAIB6wmg06vV6lUoVHh5ukykHy0IBGgAAAAAAoDZkZmYmJiZqtVrnHGEcAGyFI1RP1ByhOpInJ7zU4QBAHZabmxsXF+fj4+Pv72+/taAADQBQHU1ei5M6hNpwfLaL1CEAAADUB4IgpKSkZGRkhIeHazQaqcMBgDqskDB6olESLpzk2+WXigDgNNLT05OTk0NCQuw95TgK0AAAAAAAAHbE83xsbKzZbNbpdAqFQupwAKAOyyPyWKLyJqYAYpQ6FgCowwRBiI+Pz8/Pt8eUg2WhAA0AAAAAAGAvJpMpJiZGoVBERUXZaVxFAHAS6USZTJRBpMCTmKWOBQDqMIvFEhMTQynV6XQyWW0Uh1GABgAAAAAAsIu8vLzY2Fhvb++AgACpYwGAOkwgNIGo8ogskuSrMOUgANSA0WiMiYlxdXUNCgqqtfmQUYAGAAAAAACwvYyMjKSkpKCgIE9PT6ljAYA6jCOMnqgEQnUkT4YpBwGgBrKzs+Pj4/38/Pz8/GpzvShAAwAAAAAA2JIgCImJiTk5ObUzriIA1GNGwsYQtZpYgkkBBvEBgJpITU1NS0sLDQ11c3Or5VWjAA0AAAAAAGAzHMfp9XqO43Q6nVwulzocAKjDcog8jqh8ickfUw4CQA3wPB8XF2c0GqOiopRKZe0HgAI0AAAAAACAbRiNRr1er1KpwsPDMeUgANREKlGmEmUIMbgTi9SxAEAdZjab9Xo9y7I6nY5lWUliQAEaAAAAAADABnJzc+Pi4jDlIADUkEBoPFEZCKsj+UpMOQgANWAwGPR6vbu7u1arrbUpB8tCARoAAAAAAKCm0tPTk5OTQ0JC3N3dpY4FAOowC2FiiJoSIYrkyYggdTgAUIdlZWUlJCQEBAT4+PhIGwkK0AAAAAAAANUnCEJ8fHx+fj6mHASAGiqactCVWIJIgWS/VASAuk8QhJSUlIyMjPDwcI1GI3U4KEADAAAAAABUl8ViiYmJoZTqdDqZDLdXAFB92UQeT1R+pNCPFEodCwDUYTzPx8bGmkwmqaYcLAs9JAAAAAAAgOowGo0xMTEajSY4OFjCcRUBoB5IIS7pRBFGDK6YchAAasBkMsXExCgUiqioKKmmHCwLBWgAAAAAAIAqy87Ojo+P9/Pz8/PzkzoWAKjDeELjiMpImCiSpyS81OEAQB2Wn58fGxvr4eGh1WqljqUEFKABAAAAAACqJjU1NS0tLTQ01M3NTepYAKAOMxNGT9QsEXQkn8WUgwBQAxkZGUlJSVqt1svLS+pYSkMBGgAAAAAAQKyiKQcNBoPjjKsIAHWUgcj0RO1OzFpMOQgANSAIQlJSUlZWloNMOVgWCtAAAAAAAACimM1mvV7PMExUVBSmHASAmsgkikTioiVGL2KSOhYAqMM4jouNjbVYLA0aNJDL5VKHYx36TAAAAAAAAJUzGAx6vd7d3V2r1WLKQQCoNoGQFOKSQRThxKDBlIMAUAOFhYV6vV6pVEZFRTEMI3U45UIBGgAAAAAAoBJFUw4GBAT4+PhIHQsA1GE8obFEZSasjuQpMOUgANRAXl5ebGyst7d3QECA1LFUwuEK0FzK6c3rv/31fGwWrw5s3G3E1Cn9o9SUEMJnnN++cfNv52JyXcPb9Bs3dXRrL0oqeB0AAAAAAMAWUlJS0tPTHXZcRQCoK0yEiSEaBeGjSB6DKQcBoAbS09OTk5ODgoI8PT2ljqVyDlaA5m5vf/e9/Uz/qS/NCpMln9m6/pPXCz3WPNfZjY/Z8fZb27jeU58d55N67Jsv31rGfvD2yFCWK+d1qTcEAKBe8N37sdQh1IqpS6SOAAAAHBTP83FxcYWFhZhyEABqKI/IYonak5i1pEDqWACgDhMEISEhIS8vLzIyUqVSSR2OKI5VgOZiTvweox3y/vQHI1lCGjX0TT8/e+uf/3GdW13cty86ZPSqmQ+HsoS08M268cLeHy8NntnkkvXXWymk3hQAAAAAAKjbTCZTTEyMXC6PiopiWfzIBQCqL4MokohLEDF6YspBAKgBjuP0er0gCDqdrg7Nh+xYo1NT12aDpozvHny3b8ewDJXJ5YSLvXQlL7Bd+6CiP7Bh7dv651y5nGgu53WMogQAAAAAADVhMBhu3brl6uoaHh6O6jNAdQjpO18aHjbyk3+cYZo9Puf0jg+Hjh3l1ekh7dCnJ35x6nbhnb8IhCQSVQpRRpJ8VJ+hxox/vDd+3JpzztCqShDSds4fEDZ4tVPkk/IZjcabN2/KZLKIiIg6VH0mjvYLaMa/7cChhBAh/b8/LkTHX/xlX2KLsTOby/i/U9IEHz/vu+VyxtvPW0hLSbWkWX+dJ+FFL2VkZBQUlHi2heM4zFgtkiAIRf9yHCd1LCCNonMArQbqPWQ5q3ieJ7gKVBHP80WZEwDquoyMjKSkJK1W6+XlJXUsAHUUH7fr9Vmbr6WG9zRLHYrdCVkH35kzcktSYJtuE8YFGK8c3bxmwbHrS08t6xfAUD1Rc4TqSL4cUw5CjQmp+9eu3Xts2FNOdjLxcdsXz/r2ampEn/qfT8qXm5sbFxfn4+Pj7+8vdSxV5lgF6Lv4pH8O7PsjMT5J3nikVkMJZyq0UJVKdbcERlUqF2oqNFnKef3end/q1at//PHHe8t1d3fPzMxEKa1KLBZLZmam1FGAlLKysqQOAcC+kOUqUFhYWFhYWPn7gBBCSEFBQd36JQIAlCUIQkpKTyzdiwAAIABJREFUSkZGBqYcBKgJTr99xmu/JAvUsR67tgsh+8TnM7YkNHl81W/Pt/KghAgThi6e/siP61dO7vtkCzcV4cJJvhPsB7ArriAt5tKZI9+8++oPSXyA1NHUMi5m84zFB50jn5QrNTU1NTU1JCTE3d1d6liqwzHvkdjm49/8YLxguLn9zUXvrvZc+z8fJStkFxgF4kIJIUQoKDAKcjcFq7D++r0FNW/evPht85kzZ5RKJQrQ4hUWFjIMI5fLpQ4EpGEymQRBwHw75TBKHQDYDE5yqwRBMJlMLMuioiqeTCZjGGfuGAPUeRzHxcbGWiyWBg0aoA8MUH2WW2sXvn8sdNi4wH1b6v18e0LO7i2/xLn3+uCJlh5FxQbqNXTWSx80i2dclB7EHIAbB6gxIeXrkbqnf7pT33Ky3qb55tq5bx8LHzVOu6v+5xNrBEGIj483GAw6na7u3ro61C2lkHv992Px/j16N/GghBCqjurbQ/f9t9f1QiM/XxqdnskTT5YQQvis9Czq09xH5mP99XttcezYsWPHjr23ggEDBri5uaEALZIgCIWFhSzLurm5SR0LSCMrK8tisbi6uqLVWJMtdQBgM8hyVlksFpPJJJfLXV1dpY6lzlAqlUVDlwBAXVQ05aBSqYyKisKXSQA1YDr/2aL/XWy8dPt07kUnKECbLx05a1S07NTX9f5NU1Zwz/4TlSGkwB3VZ7AF6j109ZEWWTwR0nY9O2ZlnNTx1CLT+Y9f+N+Fpkv3zuTmOmMB2mKxxMTEUEqjoqLq9A+DHKxfFXfsq093nM27O4SGJTU5g7h5uMvCmjfVJJ47n1r0Bz7p/IUkt2bNgxXlvI4pQgAAAAAAQLy8vLybN2+6u7uHhYWh+gxQE4Zzn0778FbnhW8+11DuDD9j4dPib+UT/xC3m7tWDxw13L3jw0Ejn5208hdDfp47cebhasGmZL6NO3Ts3Klj57YR7s50jTL8s2baihudX3nvuUZOkU9KKZpy0MXFJTIysk5Xn4mD/QKaunbo323Tu1+v2MyOah/IZFz+6ZsDmQ3H99OxCmHQoLCXtq75LmhaL++UI+t3xOpGPdNCQdhW1l8HAAAAqMsEQUhPTy/7uo+PT+0HA1DvFU05GBQU5OnpWftrt9rYbfU4hcViKSgoQD6B2pN3ZskLG/RdF2+bFC4jMVJHUxsEQ36uQLKPrBywzazr1fvRni6p53776ctF/c/P/O2zCa1r8XF5qy09Ly/PbLZNHZzjuMzMzLLZCckE7CXv1JLnPtV3f33blEgZiZY6mtqWnZ0dHx/v5+fn5+dX+2u3mk8sFku1+ycOVYAm1K3TU/+btenLneve3JYrqAMbdZmy9LFBYSwhJOqRlxeaP/tq7Us7jOrgNkNenDEynCWEyMp5HQAAAKBuw28wAWqBIAgJCQm5ubmRkZEqlUqSGOzd2CmlyCdQS4Scn95ZtCaj57qvR0WyhHBSx1MrBAtnEficNJfpqzfM7RXqTrhgfvLPbz01ZOtXiw8+vGe4d639bNNqS6eU2mpAxaJFIZ9ALRGyf3p9wZqMvus2P+o8+eSelJSU9PT0sLAwqYZDtHlLd6wCNCFUHfngjNcfnFH2L6xfh0mLO0wS/ToAAABAnUUp9fLykjoKgHqO4zi9Xs9xnE6nk3DKQauN3VY3fjKZzMXFBfkEaoWQ9dvyGd8bR364ZGKQE9UoqYuLilJF+0cn9AjzI4V+pJAw7v2nj+q6c82xExcMw/toaisSqy1do9HY6sl9hmE8PT2RT6BWCFmH35nxbcHIj9+cGOxE+YQQwvN8XFyc0WiMioqScMpBqy29JjOuO9dRBAAAAAAAIHfHVZTJZFFRURJWnwHqET7l6n8JlpQfZvViw5rSsKY08uGFZy1c9PouUU1lvZefskgdoH2wvn4+LFUGhrdkCvxIYdGLjG9gsIwU5uYZhIo/DQBW8SmXLyeYk394sgPrH0b9w6i298J/LNytT7sEhcm6vF1f84nZbI6OjuZ5XqfTSVh9tgdH+wU0AAAAAACAfeXm5sbFxfn4+Pj7+0sdC0C9wXi3H/XKs93vPygvZJ3cuuWIseWUSV1DfdrVy18xCoTGq1s2jmJ+vX01i2/je3cbucS422bqEeDn7oTzpgHYAOPd8dFX5vUqkU82f3vE2GbKlO6hPh3rZT4xGAx6vd7d3V2r1dpq5BzHgQI0AAAAAAA4kdTU1NTU1JCQEHd3d6ljAahPqG+nR5d2KvYCF/P+8a2/ZbWfMe/ZzvWx9mAmVE80DKN7YmDjT1dte/WnPhsHBsoJIVzq7i92nuZ9Hn+gRb36BSNA7aG+XSYu7VLsBS76/aPf/ZbVccbCF+plPsnMzExMTAwMDPT29pY6FruojwcNAAAAAACgDEEQ4uPj8/PzJZxyEADqBwNh9UTtTixaUkDHzpl7YO6yl564eqjfgHA2+tSvO/7NDRuy5LXutTb+MwDUVYIgpKSkZGRkhIeHazT1NmmgAA0AAAAAAPWfxWKJiYmhlOp0OltNyQUAzimbKOKJSwAx+hATIYRoWr7x2crgtes/OXxw5VHBK6z51IWPLx3fRlsfRwkAABvieT42NtZsNut0OoVCIXU4doSOFwAAAAAA1HNGozEmJsbV1TUoKKj+jasI4KDY8AW7Ly6QOgqbSyEu6UQRRvJdyf3xaVmvlrP/t2r2/ySMC5wC1T75S+6TUkchBTZywcFb9SyfmEymmJgYhUIRFRXFMPX8CysUoAEAAAAAoD7Lzs6Oj4/38/Pz8/OTOhYAqMN4QuOIupAwUSRPSXipwwGAOiwvLy82NtbT01Or1UodS21AARoAAAAAAOqt1NTUtLS00NBQNzc3qWMBgDrMRJgYopYTPorksUSQOhwAqMMyMjKSkpKCgoI8PT2ljqWWoAANAAAAAAD1EM/zcXFxRqMxKipKqVRKHQ4A1GEGItMTtQcxB5ICDOIDANUmCEJSUlJ2drazzYeMAjQAAAAAANQ3ZrNZr9ezLKvT6ViWlTocAKjDMokikbhoSYEXMUsdCwDUYRzH6fV6juN0Op1cLpc6nFqFAjQAAAAAANQrBoNBr9e7u7trtVpMOQgA1SYQkkJcMog8nBg0xCJ1OABQhxmNRr1er1KpwsPD6/2Ug2WhAA0AAAAAAPVHVlZWQkJCQECAj4+P1LEAQB3GERpL1BZCdSRPgUGfAaAGcnNz4+LivL29AwICpI5FGihAAwAAAABAfSAIQkpKSkZGRnh4uEajkTocAKjDTISNIWoF4aNIPoPqMwDUQHp6enJyckhIiLu7u9SxSAYFaAAAAAAAqPN4no+NjTWbzTqdTqFQSB0OANRheUQWS9TexBRAjFLHAgB1mCAI8fHx+fn5zjblYFkoQAMAAAAAQN1mMpliYmIUCkVkZCSmHASAmsggiiTiEkQKPDHlIADUgMViiY2NFQRBp9PJZM5egHX27QcAAAAAgDotPz8/NjbWw8NDq9VKHQsA1GECIQlElUtkkSRfRTipwwGAOsxoNMbExGg0mqCgICeccvD/7N15fFNV3gbw383N0jRpmi5pSLfQBARkxw3cUJRFXEYEFQRUQHQQBV9HRUdwwXUYEVlcBncFRUUWF9ARFBEXFB1cABkBydI2bZq0adPs9573D4RBKYpJ2tubPt/P/DHelvRJmnt68+TknCOhgAYAAAAAALny+/0ej6e4uNhoNEqdBQBkTCDOSdkCcXZqVpEodRwAkLHGxka3220ymUwmk9RZ2gsU0AAAAAAAID+MMY/HEwgEsK4iAKQoQgon6bWUsFIzZioCQCq8Xm9dXV1ZWVlOTo7UWdoRFNAAAAAAACAzgiA4nU5BEOx2u0qlkjoOAMhYEyndpCugaBG2HASAFBzYcjAUCtlsNo1GI3Wc9gUFNAAAAAAAyEk0GnU6nVlZWVarFesqAkAqvKTxkqaUQgZsOQgAKYjH406nU6FQ2Gw2bDl4JDwiAAAAAAAgG8Fg0OVy5efnm81mqbMAgIwx4iopq5lU2HIQAFIUCoWcTqfBYLBYLBzHSR2nPUIBDQAAAAAA8uDz+WpqarDlIACkKEEKB2VzxOzUpCQmdRwAkLFAIFBZWWk2mwsKCqTO0n6hgAYAAAAAgPaOMVZVVRUMBrHlIACkKEK8g7L1lCimMGYqAkAqamtrfT5feXm5Xq+XOku7hgIaAAAAAADatQNbDjLG7HY71lUEgFQESFVJWhNFTRSVOgsAyJgoim63OxqNYsvBY4GrNwAAAAAAaL8ikYjD4cjOzi4pKcGWgwCQCi9p6iirjEI52HIQAFIQi8UcDodKpbLZbDzPSx1HBlBAAwAAAABAO9XY2Oh2uwsLC4uKiqTOAgAyJhLnJm2EeBs1aUiUOg4AyBi2HEwCCmgAAAAAAGiPvF6v1+stLS01GAxSZwEAGYsT5yQdT8xOQR5bDgJACurr66urqy0WS15entRZ5AQFNAAAAAAAtC+MscrKylAoZLfbsa4iAKQiRLyTdAaKW7DlIACkgDFWW1vr9/utVqtOp5M6jsyggAYAAAAAgHYkkUg4HA6O42w2G7YcBIBUNJCqirRmihRQTOosACBjgiC4XK5EImG329VqtdRx5KdjXc8xxgKBANZn+VMEQQgEAlKnAGkIgkBEjY2NUgcBaF0Y5VrEGCOiWCyGx+fYRSIR7JAGkKIDWw7m5ORgXUUASAUjqqUsP6mtFNJRQuo4ACBjB7YcVKvVNpsNV/vJ6VgFNMdxer0eF7LHiDHW0NCgUCj0er3UWUAajY2NgiDodDqcNS1pkjoApA1GuRYJgtDY2KhSqbKzs6XOIhtqtfpAcQ8AyQkEApWVlSaTyWQySZ0FAGRMJM5F2jjxdgqqseUgAKQgGAy6XK78/Hyz2Sx1FhnrWAU0EfE8jyrtGB14Cc1xHM/zUmcBaRw4WXDWQMbDKNci/BVIgkKhEEW8ygVIUm1trc/nKy8vx/uCAJCKmMgcpFMTq6AmXMQAQCr8oZjH6ywuLjYajVJnkbcOV0ADAAAAgMxs+0DqBFI4aZjUCdqOmJ3tfuihiN1uO/dcbDkIrStQJ3UCKcy7ReoEbae5U2fX8Im5ioQl7CPCx5IA0qqoXOoEbYepVFVz5jSddlrFoEFarVbqOLKHhUsAAAAAAEAy8U6d9r3wgpiVZR83Du0zAKTC3+Nkx8jJnb5YZwnXoX0GgKQJRuP+f/0r3L27ffx4tM9pgQIaAAAAAACkEerff+9rr2Xv2GG9/nq+CfsrAECSGKeoPu3C2pOHW9c/b9z9tdRxAEDGIl277l2xQunz2a68UuXxSB0nQ2AJDgAAAAAAkED96NHVt91mefjhvNWrpc4CADImaLKdQ68QsnT2VUtUTfVSxwEAGWs64wz3vHkFL79c9OSThN3F0wcFNAAAAAAAtCmmUNTOnOkfNcp6ww26r76SOg4AyFg0t9B53lUan8f63ouKRFzqOAAgY74JE2qmTy+dPduwcaPUWTINCmgAAAAAAGg7ol7vevjheHGxfexYdVWV1HEAQMaC5d1cQ8bm7/rS/OV7mKsIAEljanXl3Xc3n3JKxeTJ2l27pI6TgVBAAwAAAABAG4mVlzsWL1ZXVtquvFIRDEodBwBkzNf7tJqThxd/vMq4Z7vUWQBAxhImk2PhQi6RsF9+udLnkzpOZsImhAAAAAAA0BaCgwbtffVVw6ZN1htuQPsMAEljvLLyrEvr+g6ueGsp2mcASEWke/e9y5dn/fRTxZQpaJ9bD2ZAAwAAAABAq/OPGeO59dbiBx4wvvWW1FkAQMYErc45dALjefuqxcpQk9RxAEDGAsOGVc6da1q61PTcc1JnyXAooAEAAAAAoBUxnvfMmhU499yKa67Rfv+91HEAQMYiBZ2cI67Sepwlm95QCAmp4wCAbHGcd9KkuqlTy2bNyvn4Y6nTZD4U0AAAAAAA0FoEo9E5f75gMNjHj1dVV0sdBwBkrKm8u/ucsQXfbynatkHqLAAgY6JW637wwchxx9nGj9fs2yd1nA4BBTQAAAAAALSKSJcuziVLtD/8YJ0+XRGJSB0HAGSL47x9z/T2P7v0o9cN+3dKnQYAZCxuNjsXLeIDAfu4cXxjo9RxOgpsQggAAAAAAOnXdPrpP7/0Uu7775fdeivaZwBIGlOq3GdfVt/jFPvaJ9E+A0AqQn377n3tNe3Ondbrr0f73JYwAxoAAAAAANLMN2FCzfTppbNnGzZulDoLAMhYQmdwDLuSExK2NU8ow0Gp4wCAjDWMHFl1993mxx4rePVVqbN0OCigAQAAAAAgbZhaXXnXXc0DB1ZMmaLdibmKAJC8SGGJY/iVetfu4i1rOVGQOg4AyBVTKGpnzvRfcol1xgzd1q1Sx+mIUEADAAAAAEB6JEwmx2OPcaJov/xypc8ndRwAkLGAvU/l4NGmbz40bf9Y6iwAIGOiTud66KGYzWabMEHjcEgdp4PCGtAAAAAAAJAGkW7d9i5frnG7K665Bu0zACSP42pPPLfqjIvL338Z7TMApCJWVrZ3+XJSqWxjx6J9lhBmQAMAAAAAQKoCw4ZVzp1rWrrU9NxzUmcBABkTVWr3kLGRvCLbmic1DV6p4wCAjDUPGOB67LHcdess8+aRKEodp0NDAQ0AAAAAACngOO+kSXVTp5bdfnvOpk1SpwEAGYvrcp0jruIjzfZVS/hYROo4ACBj/jFjPLfeannwwby1a6XOAiigAQAAAAAgWUyjqZw7N9S7t23CBM3evVLHAQAZC3Xq7Bw2wbB/p+WTNRzDXEUASBLjec+ttzaMHGm9/nrd119LHQeIUEADAAAAAEBy4kVFzkWLFNGobfx4ZX291HEAQMbqe5xcPegCy6dv5e3eJnUWAJAxITfXNX9+wmjsMnasqqpK6jjwC2xCCAAAAAAAf1qob9+9r72m3bWr85QpaJ8BIGmM42pOOc9z8gjrey+gfQaAVESt1n3LlikCAduECWif2xXMgAYAAAAAgD8nMHJk5d13mxctKli+XOosACBjokrjOmdsPCfPvmqxuglvZQFA8oKnneaaNy9/5UrzwoXYcrC9QQENAAAAAADHjONqp03zjRtnnTFDt3Wr1GkAQMZiuQWO4Vepm+pta59SYMtBAEiBb8KEmhkziu+91/juu1JngRaggAYAAAAAgGMiZme7H344arPZJk7U7N8vdRwAkLFgaVfXuVcYf/rG8tk7xJjUcQBArphaXTVnTvDUUysmTdLu2CF1HGgZCmgAAAAAAPhjsdJSx+LFKo/HNnYsHwxKHQcAZMzf42TPoAuKt6wx/vcbqbMAgIwJeXnORx9larX98suVdXVSx4GjwiaEAAAAAADwB0IDBuxbvly/dat1+nS0zwCQNMYpqk//S+2J51a88zTaZwBIReS44/auWKH0ejtPnoz2uZ1DAQ0AAAAA8Ath/4qTBw3jTmrhf8pLnt4qSJ0vfUJEc4l6EGmJColGE/1wxPd8RXQhUR6ROafgslOujD7yqOXhhzns6gNwzEJ718299qIe3e1ac1lh3+Gj71n1Q3MGrzUhfvb112O/bUwc8YVGX9Ud6z+1PfOe9l8bbB81PrJfW7r6CW2tS4KMrYUF939659139r10Ys6IKcdf9+CMt/5bh8ESWkXks3njxi7efuSJlgHcRJOIiok0RFaiG4l8R3zPoYuTTlrDpUOmNa1aW3bbbYpoVIK48Ge0uyU4WHj/h8teWLNlV3VYXdC579BxV1/cv1BJRKL/2zdfWLFpu6NJb+03ZOyk0X3zOPqd4wAAAAAAfxKnsw4bepb9N0Wz6Pty8w81RSZTplxmxolGE71PdCrRGKK9RG8SfUi0iajvwe95j2gUUSfiLj5xQCNVv/fk/11AbCtRsYS5AWQl/tPzo8+7/f2mTqdePGFMaXzvJ++8uXDah19Ublp7Y1+N1OFaAQvXLPm2ZrPN+pveNej5adhbP31FuuG9jh/a1fLthx8t+PuX1cNOXdYlK2MmxMX2vXXh9Bc2C8XDhgw5Pzf641efPvnP2Ztcd2+Z3tMgdTbIMMy7bsmStzdfdG3mvcHhIzqbyEk0mqgr0ddETxB9SrSFKPvg9xy8OKFRvXsHsvzrn7p5Oy5OZKKdFdAs8Nnjdy/5ofziibeeaGH7P1z+8v13N86dP7mnyrHqwQdWCoMnzRhb4N287PkHHubnPziqjBeOclzqOwIAAAAAMqQwDbp/7qBfH2P718w+8bMes2+5wJYpZclaon8TTSJ6+uAnIjcQjSSaTfQWEUcUILqOqJtG9/Lix7QF+dYbp79LbAzRYqKHJM4OIBMssPbhh//dUDZp2fqnR5gURCTesuGOi0YuXTD7zcvfuqIoU97PIiIWjoR31NQt27b7tRCZf/vF4OLNe75SFD50/bgLx0/M37nVZGi6bfXWxz7dM9na61yVJIHTLrxu+ZubQ2W3PD7vH72yiIimXrjgpr/9bdVryy+9d1om/apBSkK4zrFj20fL/nH3ax7xtydaRniBaB/RC0QTDx65lWg+0RqiK4jo4MVJd171yn1z+f79rDdevx4XJ/LRvgpoVv/5+1sTA2fcduUZORxRz+6dQj/PXPPB9xO6Kt955+fS0Y/9dUQZT9SrsGHPLW+/u+P8v3bf0fLxPmqp7woAAAAAZAKxdsNNj39vu+qxm7u0ryvnVGwm4on+dth6fEOITiX6hChKlEW0lsit0N3ywiu51XtLZ85QhMMXEj1OVCRlagBZSezYvDXA95r2t6GmX040Rf6QGVef+vzfP/n4m+gVI7KkjZc+LOwe9cJ37//ywZHflq1CQ83qOlY8+C/Dxk8s2bTS8PMPpMm/8wTzM//2vFLV41xrRswdE+t3u5op79Rh3Q7+VpWWEaeUzvqueleVSEUZcR9Baqz2pVH2ae//ss5Eprwf/mufEOUQjT7syMVEC4h2HPzPtURuRdZtS5/TKOPl48cr/X5cnMhI+7qMZk1xjfXEk7rrf/mrxZssZmUsHIq6XLuCnQaeUHxg5ObLT+hf9OZ/dlbHdTtaPC72sWbm6QgAAAAAbYkF1i55/r28Cz+6wpZhExx6E9kP+0+OSEuUIDrwkd5/K0l10k1Dv9xUvnAhiSIR8UTXSRIUQKYSIcqz9z6tr/2w+pHL0mo5SkTjmfTZeU5jXjj6tAZGLOyZsW6f+9dfTYQjTsaX9R3e9e2ndXWVBw7mGPVlnOeb2pBgzcmEdlZh7FqSTT/t+cyZOMeuJCIS67f+UCOorMd1QjMB6cHlX7jwo14NIrG6NTMuXeD+438hP9cSjSU6/M25JiJGZDr4nxt4Up1w42Dn7ooHH+TiccLFiay0rwJaYb3wzkf+959C7eYPv6Mul3fT1H1dxwpM+QfHbkW+KZ/V1XoTdbUtHhfplwJ63759dYftg8kYi8fjHIePwBwTxhgdfNCkzgLSOPAcwFkDGQ+jXIsEQSAiURTx+Bw7QRAOjJxpkUi0sLuMUtm+Lt4yXujbFXdsEEfff9nAjJmsSEREi4444ib6nKgfURZR3ch+uz/4zlT9fuOCbecRfUqUSzSIaA5RbwnCZr4WT/Z0YYyJoojxRALacxd9cu6vD4nud97+PK7qd1LvjBpRFOpuRWoiYs0Bw69fNCSydK5zTspZ6/RveUp12DAaaw7XMhKbIgJlRAFN2Rdde92Vuxff/3937jl/YD9DdPfWD1/+Vn3e9Gsmd2rTl1Etnulpvzg58qdgMGkLysJuJxYSEavebsjQ9zVGHvw/ESI/0fdEtxAVE11GRET1g3vs+my3Kfif0L0bRuLipPW1OJ6kMpi022Ei6vnyzaf+tWqvbcLc4Z3EL6MJTqvVHhy7Oa02i4tFY4lYy8cPPR4vvvjiu+++e+hGDQZDIBBAlfanJBKJQCAgdQqQUmNjo9QRAFoXRrnfEYvFYrGY1ClkIxKJpOs1mCiKDQ0NRx4vLCxMy+3DMRGrnn1qnaPruFVn5Wb25eN+osuImonuVKmq58xpKN4XX7+9af+2YURdiK4jqiZ6k+iDX+9SCOnS4skuiumZI5tIJKLRKMaTdiC2f/3cy2Z/1Fw+cfb4DvGB3UiBxTH8Sp17/XAde3LHjld6Drg6hyMiijcu+o/Hy1h2XEhbLSo1pbnPtSN7rFu6/aWXd79ERMTlHH/RDWeWZv/RP0yvFs/0UCiUrne5BEFobGw8slHBYALptYDo70RElEe0jqiY42qnTasdGItv3tW0cwMuTtpGi+OJIAgHZikloT0W0PGar15/aumaH6j3xbPmX3ZSkYriag3PAuEIoyyOiIiFwxGmylHzRzl+6KZOP/30w4fCtWvXarVaFNDHLhwOKxQKjSYTN2mGYxCNRkVR1Gq1UgdpnyJSB4C0wZO8RaIoRqNRpVKpUmXIDkFtQKVSpesyg+O4rKyMmiEnR81fr1qwXXXRfSN7ZG5XFCNaSHQ/UYzoiZzc7gsXhPV627R5IqNGomuJHic6MD9xItEFh+1SCGnU4smersFEoVDwPI/xRFqxqs0L59x5/+rdsc5/eeqV+0cYM/8carT1dp81xvTNh6bt394+0LJ2Q9XUNz5b36WwqyLyxc+er0hj5hIhRaY8Diy05el7Riz39hk9c+1lJ/XKif709b9vX7jyohuaVjx54yUFbXc3WzzTVSqVQpGeP2Mcx2k0Gown0NouIepMtJfoGaILFKrnHn6k+/H2iusm4OKkLbV4pisUiqTHk/ZWQLPQj6/fd/9K73GjZy255ETzL1WyosBUyP3sqxfJyBMRiQ2+Bq6gZ4HyKMcPPRhDhw4dOnTooVt/++23dTodCuhjxBgLh8M8z+t0OqmzgDTi8bgoitnZ2ThrWlIvdQBIG4xyLTowaU6pVOLxOXZqtTpdkxY5jtPr9Wm5KUgSa1j9+ocu09lPn2nI1L+CXxFdQ/Q90TlED9u75jyxRPndd9Zp01g0qiVSE805+AKPiIZpb/f1AAAgAElEQVQSDSLaTBQiwqCQXi2e7Om6+uJ5Xq1WYzyRDGv46rk7r7l35fexknOmP7ngtkt65WTqiHII5+03uLH/2WUbV+Q4dhFxpcf1/USTM3ub672d+95WZg2w9fiwT2LGGz861MrMeCxE7+a5b/ysPm3m6hlnmTki0vcfPG5ldqD33z6Y8+b5F11rb7PapcUzPSsri+fTs9KJQqHQ6XQYT6C1dSPqRkREl+Wo+we5R76LbLxvnKKpCRcnbanFM12hUCR9fdLOpnNEvn/50TcaT7vjkTljD7XPRMSX9+yhq97+rffAJ3REz7ffeXKO71miPsrxjFhGCgAAAAAkI3o+fvbzcOdzzzkzQz8JtpJoMFED0RqiVWeckb3sJePatWW33aaIRnmiYqJsosM/U60gKiGKEoUkiwwgN4J75Y0jB9+ypuHk/1vz2acf3De6A7TPJJSc1dDjZNuaJ3Mcuw4eU3S2dlk2+uy6v54XuubsLUPKe0dCTpGrMGrb24S45CSc+3+I8b0G9DQd9uvN6d37ZLW4d4+jMWPWGQFoTTGiZUSfHHYk1L9//Kkp3bmYY/kd1NSEixO5a18Dfnznx1vqLAO7Cnu+3nbooCLf3t/WZ+TI8tvfWPxK8eQz82s/enaVy37Jjb3UxB/lOAAAAABA8tj+TR9/Hjdff9ZxGbkGzS6iyUQ9id7lOG7SJNfUqaV33mn48MND33Ai0ToiF1GXg0cEov1EuUQGKQIDyFBi15N/nfxKdc8bX3n3nsFF7WzqV2uIZ2vDCiKVvmL1E5pI8y9HWXjTbu+erPwrOusPLojMvnf7PFz2lRZtZjwqnFarJ1YfaBLJdOgeseameoHUWq0m8990AEiPm4m6E20iUhDVjx5dffvtpjlXR0WmJXbgNMLFiay1qwKaNVRWNScc7y+67/3/HeSyzrh9+a2DbGPuuC3+rxeX3L4qkl3S74JZ142y8kSkPMpxAAAAAIBksfqNn/0UN549rEe7ulpOm0VEUaIX1erYPfc0n3RSxeTJ2l27Dv+G0UT3E91N9ALRgQp+LdFXRFcTZeiMcIB0i3y66Ilt0f63v3RXh2ifQ0XljhOOVyzdxjvWKTvnHf6lnT/uvNGbn7j8pL8aOCKKB9z37GjWdOpxtSlDqllVlwHDitY+tW71ygtvGms+sDpo06ZX1n8i6Eac2qON9yEEkCkV0WCit4i2KhS2mTP9l1xinTb1w207fiS65mB3iYsTWUvHJbXo3PL6J45j2QWRLzttzJmdj/ozOdOFD6268Gj/1nTihNknTjjm4wAAAAAAyQnt2LgjltWv98mZOP9ZIPqCSK1Uzx44ULF+ve7eexXR6IEvGYjmEymJuhP9H9HDRD8SDSP6mWgVUTnRvdJGB5APYd9XX3hFteGLh2fc+Ov+mTOcNm3++Ix6dyvQpV/lmaOKPrhPIxKxX1cDnHbCSdYn3tp305tffH5cvjna9O+fa3+gwsfOsnbNkP6ZSNPrzplD3r9r44RJrhVD+vfJif33m89X72zIG3TtP87pADtOAqQDR3Q30QdEI4qOP9/p6TpyxM6m5jVEpUR3HvweXJzIWjr+6sW/XDRpwhuRY/hh3W//bMyZndPwIwEAAAAAWkt05/YtzYou3e0Zuf9ggshBFEzEVm/e/JsvFRH98+D/v4+ohOhJogVEeUSTiO4hsrRtVAD5SrgczgQL/rjxpR9/8xVFkXLUP8f3kCRV+nFc7Qnn+HqeWv7+S7r/7m3xWwwl3T+8OHvOVse6nT83KLL6lx+35hTbBYZMmhbOWc64/tNFXR54+YM1G99dF1GaSrtMnDZjzqX9rJn0PgNAKzuuvGz5pSc/uXrzxlU/vMmoE9G1RLN/fe2BixP5SsdwqLnkpW8ebzpzxsf6IVNvvHrECZ1zEt79321avmTpx8pRjz5500m5v1y5K3I798b4CwAAAADtm+akG91bb5Q6RWuJDB++5d57TUuXmp577ne+jSeaTjS9zWIBZBbN8MW++sVSp2hdokrtHjI2mldkW/OkJuAlnXXDNGtL38gVWaz/urjFL2UMRVHvEQvnjVgodQ7IeJxl6oamqVKnSL/goEGuRx4Z8Pbb7+xfTUffuhMXJ/KVlj64ecO8+zbqJrzxxXN/Mf/yNubp5/zlivFDpg4cM2/1lB8Wn41ljwAAAAAAJMZx3kmT6qZOLZs1K+fjj6VOAwAyFjPkO4ZfpQo22FYt4WPH8IFoAICj8I8Z47n11uIHHjC+9ZbUWaC1pKOAjm1b/4GvfOx1I82/+hCNoui86y6rWPbKqi8fPfusTFw+DwAAAABALsTsbPeDD0a6drWNH6/Zt0/qOAAgYyFLZ+fQCbl7v+302TscO/pkRQCA38V43jNrVuDccyuuuUb7/fdSx4FWlI4CmjUHmxkTxSO/IIqi2BhoPPIrAAAAAADQVuJms3PRIj4QsI8bxzc2Sh0HAGSsvsfJ1YMusHy6Nm/311JnAQAZE4xG5/z5gsFgHz9eVV0tdRxoXelY+F/Vo+/xCseqZ9Z7f/XOJ6v79zMr93FdunXBus8AAAAAABIJ9eu397XXtDt3Wq+/Hu0zACSNcVzNKed5ThpuXf882mcASEWkS5e9K1YoGxpsEyeife4I0tENK2xX3nbFwjEvXnFG4ObbJg/tby8k375vNzw/b/4qh/H82RO782n4IQAAAAAA8Gc1jBxZdffd5sceK3j1VamzAICMCRqta+j4RJbevmqJOlgvdRwAkLGm0093z5uX/8Yb5sceIyzj0zGkZXIyV/iXx9c/q5z4fy/cP2X1fYeOZnUe+cDLL0wqT8csawAAAAAA+BOYQlE7c6b/kkusN96o+/JLqeMAgIzFcgsdI65SN/psbz2lwJaDAJAC34QJNdOnl86ZY9iwQeos0HbStTpG9vFXPr1t9OwvPtj45Y+VgYSmoHOf04cO6WtWp+n2AQAAAADgWIk6nevhh+OlpfaxY9WVlVLHAQAZC5Z2dZ17Rf6uL81fvoe5igCQNKZWV951V/PAgRVTpmh37pQ6DrSpdC7PzOmsgy6ePCiNtwgAAAAAAH9SrKzMsXixurq6YuJEPhiUOg4AyJi/x8meQRcUf7La+NN/pM4CADKWyMtzLVjAlEr75ZcrfT6p40BbS9/yGCz449sL/379VWPHTFj4VTyxZ/P6b73xtN06AAAAAAD8seYBA/YtX67/4gvr9OlonwEgaUzBV541pvaEcyveWYr2GQBSEenWbe+KFcqams5TpqB97pjSNAM68fPyq4dNfWVPmBFxeVlXi7F9iy4Z917nif96++nxXbAOBwAAAABA6/OPGeO59dbiBx80rl0rdRYAkDEhK9s5dIKg1tjXPK4KBqSOAwAy1jhsmHvuXNPSpabnnpM6C0gmLTOgxX1PTfnrivr+N7/2n33PX5JFRKQdPufp64+vXnbd1Yt3C+n4GQAAAAAAcDSM56vvuKP2+usrpk5F+wwAqYjkd9o7+kZlOGhb8yTaZwBIHsd5J09233tv2R13oH3u4NIxA1rYsezZLWzwguXzLuscX8kTERFn7Dth0ZuhPT1veOnVH2be0zeda00DAAAAAMD/CLm5zvnzBaPRPmGCqqpK6jgAIGNN5d3c54wr+H5L0dcbseUgACSNaTSV994b6tPHPnGiZs8eqeOAxNIxAzqxd/de6nrW4LLf3Jii+NTTutD+PfsxBRoAAAAAoHVErdZ9y5bxgYAN7TMApMbX+zTXOeNKPnq9aNsGtM8AkLR4UdG+F1+MWyy28ePRPgOlp4Dmco0G8tfWHdEzx2uqvUyfo+fS8EMAAAAAAOA3gqefvu/VVw0fflh+662KSETqOAAgV4xXus++rK7vmRVvLzXs3yl1HACQsVCfPntfe027a1fnKVOU9fVSx4F2IR0FtHrA0LONla/845mfoocfDv/w5MMrqg2nDxmgSsMPAQAAAACAw/kmTHA++qjl/vvNCxaQKEodBwDkKqEz7Lvoupgh3/7mYm0dPkgBAMkLnHfe/qVLTc88U3zvvVwiIXUcaC/SsjZz7gVz5g59f/qMQQM/vLxidyKas27J/e9vWv7Suv8qB8+/6+I8zIAGAAAAAEgfplZX3XVXcNCgikmTtDt2SB0HAGQsUljsGH6l3vXf4i1rORELaAJAsjiudto03xVXlM+cqd+6Veo00L6kZ3NA5XF/XflRzuyZc55+ak2zyOjJW77gc2xDZjw/f+7Enpj/DAAAAACQNkJenvPRR5labb/8cmVdndRxAEDGAvY+lYNHm7750LT9Y6mzAICMidnZ7ocfjthstgkTNPv3Sx0H2p10FNBCqCEQ4btcsWDDFQ959/64rzbMGyz2bp3zUD0DAAAAAKRT5LjjHIsXZ2/fXnLXXYpo9I//AQBAizjO2/fMuv5nl21ckePYJXUaAJCxWGmpY/FiVU2Nfdw4vqlJ6jjQHqVjDejwO9daLRf8yykSl2Xq0u+UUwed2AvtMwAAAABAejUOHbrv5Zfz1q4tmzUL7TMAJE1Uqp1Dx9d3P9m25gm0zwCQitCAAfuWL9dt326dPh3tMxxNOmZAZ59yzqna2Z9/FbjRiuWeAQAAAADSj+O8kyZ5p04tvf12w0cfSZ0GAGQsrst1jriSj4Tsq5fw0bDUcQBAxurHjKm+9VbLQw/lrVkjdRZo19JRQCus1zz38q7Rd141z7Bg2jl2A5+G2wQAAAAAACIiYhpN5T33hPr1s0+cqNmzR+o4ACBjIbPVOXyiYf9OC7YcBIAUMIWiduZM/6hR1unTddu2SR0H2rt0FNDxj++f/Oi3isj2v4/oemdWbmGeXnXYyh5ZFzz1w5Pna9LwcwAAAAAAOppEUZFj4UIuFrONH6/0+6WOAwAy1tClX9WZl5i3ri/Y8bnUWQBAxgSDwTV/fiI/3z52rLqqSuo4IAPpKKBJmaXX69XdTh/ZrYUvqjsb07HQNAAAAABARxPp0cOxaJF+y5biBx7gEgmp4wCAXDGOqz15hL/7Sdb3XtRV7ZU6DgDIWMxqdSxerHa5bFddpQgGpY4D8pCOAlp12qw3356VhhsCAAAAAIBfBEaMqLznHtPSpabnnpM6CwDImKjSuM4ZGzfk21ctVjfVSx0HAGQseOqprn/+M3/lSvPChSSKUscB2Uh+cvKVJmOv2z+P/++AEA2FwjE8+QAAAAAAUlV7/fVVs2eX33QT2mcASEUsIewddT0pFBVrnkT7DACp8I8Z41ywwPLQQ+YFC9A+w5+SfAEdCQZD0cO2LIiunlhg6Dnrs/jR/wkAAAAAAPw+kTinOq9h5EjbxIn6L76QOg4AyFhzNLav1qev3GNd/wIfi0gdBwDkijFWVVNbO21axZQpxnfekToOyE9a1oAGAAAAgDYRDUmdQArmMqkTtJ24SM6QwHNk3/cxf+NFUseBjNYxx5OsbKkTtB1/oNFT11BcVGgs60SXXyN1nLbVtb/UCSDTqTRSJ2g7giA4nU5BEOyleapVL0odB2SpYxXQjLH6+nqO46QOIieJRKK+Hh/U6qAEQSCihoYGqYMAtC6Mcr8jGo3G4/h007EKh8M8z0udAmQsJDBns2hQcZYsBZeISR0HAOSKMeap8weagtZis06rlToOAMhYJBJxOp1ardZqtSr2bpc6DshVxyqgOY4zGo0ooI8RY8zv9yuVSoPBIHUWkEYgEEgkErm5uThrWtIsdQBIG6PRKHWE9iiRSAQCAY1Go9PppM4iG1lZWSKWw4Nk1cdYdUSwZCny1MmvkgcAIAiiy1OTEAR7eYlK2bFe8gNAejU1Nbnd7oKCgqKiIqmzgLx1uL9GHMehSvuz8Ih1cDhrIOPhGd6iQw8LHp9jhwETksMYq40yf0y0ZvM6JZ5CAJC8aCzmrK7RqNU2i1mhwLtZAJA8n89XU1NTWlqKWYmQug5XQAMAAAAAtB8ikSskxhnZ9bxagfYZAJIXDIVdnpr8XIO5IF/qLAAgY4yxysrK5ubmiooKLZbxgXRIpYBmga9XLJi/9ZeVDhPf/Vf49ZFffkK3C2+44DgshwgAAAAA8GsxkRzNgponm47HTEUASIWvIVDjqy82FRoNeqmzAICMJRIJh8PBcZzdbldiGR9Ik1SeSaL/k8dnffLrY0ceybrU+lcU0AAAAAAAvxJMMFdIyFcrzFkonwEgeYyxqtq6YChcUWLRZmmkjgMAMhaJRBwOh16vLy4uxspykEbJF9C3r37nKuEYvo+3nKBK+ocAAAAAAGQgf0z0RMRiLW9U4dUdACRPEEVnVQ1jzF5eouQx8wsAkhcIBCorK00mk8lkkjoLZJrkC+gBI85PYw4AAAAAgI6AMfJExUBMrNDxWh7tMwAkLxKNOatrtFmakqJCbDkIAKnwer11dXVlZWU5OTlSZ4EMhMVcAAAAAADaiMDIGRIExux6pQplEQCkoKk55K6pLTDmFuXnSZ0FAGRMFEW32x2JRGw2m0aDZXygVaCABgAAAABoCxGBOUOilues2bwCU58BIAVef4O3vr7UXGTQ66TOAgAyFo/HnU4nz/N2u53HMj7QalBAAwAAAAC0uqa46A6L2HIQAFLEGKus8YYiUXtZqUaNDZcAIHmhUMjpdBoMBovFgi0HoVWhgAYAAAAAaF2+mFgTFkuzeQO2HASAFCQEwVHl4YizlRVjy0EASEVDQ0NVVZXZbC4oKJA6C2Q+FNAAAAAAAK2FEVWGhGaBKvTYchAAUhKJxhxVHn22trioEHMVASBpjLHa2lq/32+1WnU6LOMDbQEFNAAAAABAq0gwcjQnOOLsel6JsggAUhBoClbWek15eaZ8o9RZAEDGRFF0uVyxWAxbDkJbQgENAAAAAJB+EYE5QoJOqSjRYsdBAEhJrb/e1xAot3TSZ2ulzgIAMhaLxRwOh1qtttls2HIQ2hIKaAAAAACANAvExcqwaNIoTBpsOQgAyRNF0V3jjURjttISbDkIAKlobm52uVy5ubkWi0XqLNDhoIAGAAAAAEgnb1Ssi7KybD4H624AQAriiYSzuoZXKOxlJTyPd7MAIHl+v9/j8Vgslry8PKmzQEeEAhoAAAAAID0YUWVYDCWYTc9j6jMApCIUiTiragx6ncVUgC0HASBpjDGPx9PQ0IAtB0FCKKABAAAAANIgLjJnSFRwZNMplGifASAF9Y1N1V6fxVSQZ8iROgsAyJggCC6XK5FIdOnSRaXCMj4gGRTQAAAAAACpCiWYMyQYVAoLthwEgBQwxmr99f6GRmtxJ502S+o4ACBj0WjU6XRqNBqbzaZQ4L1xkBIKaAAAAACAlATirDIsmLMUBWq8ugOA5Ikic3lq4omEvbxEjbmKAJCCYDDocrny8/PNZrPUWQBQQAMAAAAApKA2KvqiolXH63hMfQaA5MXicUeVR61S2UpLFPgoBQCk4MCWg8XFxUajUeosAEQooAEAAAAAkiMycofFqMhsOl6D9hkAUhAMhV2eGmNOjsVUIHUWAJAxxlhVVVUwGKyoqNBqtVLHAfgFCmgAAAAAgD8tJjJHs6BScDadgufQPgNA8vyBRk+dv7io0JijlzoLAMiYIAhOp5MxZrfblUo0ftCO4OkIAAAAAPDnhATmbBZzVYpOWRyH9hkAksUY89T5A03BihKLNksjdRwAkLFIJOJ0OrVabUlJCbYchPYGBTQAAAAA/KHIZ/+cskh727Ib+nasy0fmW33H5Jm7R6x5Y9qAg/fcHxM9EdGSpcjLhC0Hhc82vrdIdfKyM02/+s3G9oy7+90V0V9/r7Li+Xsuujq7LeNB5umYg0nL91oQRWeVRxBFe3mJKnPmKrLg/s8een7dOzud+5rUZVb7ueePueuC4wozYLz8PQn3x8/MWfjG+9+5fPGsTl1PuOjKGfdM6F+Q4fca2pGmpia3211QUFBUVCR1lvQQ9r0w6ILFXyVa+BLf+cpP1888hW/zTJCCjPkjBwAAAACthdWtX7Lknc0XTRWlTtK2RPeaudev+K/XekaciIgYY7VR5o+J1mxep8yEic8suG/J5n2be/f5zW9WCAT2JzhzWcXZhYe9XuCLKvBiD1LTMQeTFu91JBpzVtdoszTWosJMmqsY2/fWhdNf2CwUDxsy5Pzc6I9fffrkP2dvct29ZXpPg9TZWg3zbbzr7Kteceb3Gz3uuq4a39fvrXnitnGfVr265fb+eM8O2oDX6/V6vaWlpQZD5pxnnL5i2PnD7b8poEXvlxu315jNpky4CutYUEADAAAAwNEIYZ9jx7ZNy/5x72s1olnqNG1McL553b0bahh3oBkSGLlCYoJRlxylSvYve1i4uXGH07Vsw2evNbEjf7NCfWA/U59z7nnLe+P1AqRFxxxMjnqvm5pD7pra/FyDuSBfsnStIrxu+ZubQ2W3PD7vH72yiIimXrjgpr/9bdVryy+9d1qR7IfOlgmOFxa8sc84/IX3nphYzBMR3Tz61uGXzX/mqTV/feoKY4bea2gfGGOVlZWhUMhut2s0GbWMj6Jo8P3/HPzrY+L+1286cXPv2XNG2zLnbbuOAheUAAAAANAy5n15VJfp7/+yDkMHu9JP7Fty2z83l100ttM7r4cpLtK+sKDhyZbNK+RfJrDgjlFzN77/y6yiFu5PvS9QTzld8elxSJOOOZgc7V77GgI1Pn+pucig10kUrdWI9btdzZR36rBuWb8cUVpGnFI667vqXVUiFWXoZyiat3/yfTxn5CWjiw/ewey+F59dvODZvTscAhnRukBrSSQSDoeD4zibzdYRthwUPetumv+N7drnbj5OJXUW+NMy/wkKAAAAAMnh8i5YuLFnAyNWt3bGZQvdUudpQ7Fv/3XnnO+73fPmFGHWO6+HWGVzoqtWYc7KkOKMy7YvvKGwgRFr3jPj+W+O+M2K+31NAp9nz278+NuqHxrj2caiId0sVrUUWSEjdMzB5Mh7zRhz13ibw5GKkuLM3HJQYexakk0/7fnMmTjHriQiEuu3/lAjqKzHdcqQ8bMFyp7X/mPe2C79s/53KNEUDDPObMrL3HsNUotEIg6HQ6/XFxcXd4j9kFnD2vmPv1dw6UdXH4frETlCAQ0AAAAAR6Es7HZiIRExz7eGjvQiOrT9qcmL9p3y99dndqUHRCLGCrIyp30mIlJou5VriYg1eg0tvGgV9tcFBRa9ff7L1c0iIyIitaHs9vEj7uma3QFe40Ir6JiDyW/uNRMclR4lY/byEiWfoXOBKfuia6+7cvfi+//vzj3nD+xniO7e+uHL36rPm37N5E6ZO3hkdx05tisREYmRpga/r/r7D5+9ZVV98QX3XFbacZ7u0KYCgUBlZaXJZDKZTFJnaSOhb56/Y50w+tGrBmqljgJJaa8FNPO8fdf93rELJ/c8+IdZ9H/75gsrNm13NOmt/YaMnTS6bx73e8cBAAAAZIsxFg6HjzyuxSvZNhDcdtctzzkHzX5jgrUm/HOQEXFcjqojPfRi016/wAS+4pSRH5xt7UzBr7//esZbO+5/aYP15gsn42I73Vo82RljablxURQTiQTGE8mJRImgT6XiraaM2nLwSEpzn2tH9li3dPtLL+9+iYiIyzn+ohvOLO0Qe/EJ+xaMGf737QkiRd4pN6975Pzitv1Vt3imx2IxUUzPrp+MsUgkcuRP0WrRCLap2tpan89XXl6u1+ulztJWRPezj61ydJ+y6lysqt5GWhxPRFFM+vqkXRbQLFL50ctrfgid/L9BUnCsevCBlcLgSTPGFng3L3v+gYf5+Q+OKuOPdlzC9AAAAACpYow1NzcfeVyb0yFewkuJNb7/0J2L/WcsffESLiKEE2KBgqgjfLL1cFz2xRde2F+VP7izIZuIyHjGwCFvc8FerzsWfem7anghrrXTq8WTPV0FtCAI8Xgc44m0GptjYUYKdXaJuSiTu2ciYqEtT98zYrm3z+iZay87qVdO9Kev/337wpUX3dC04skbLynI9LFUYblkzuOdXTV7t7//zKsLLpioWLds+sltuNB3i2d6NBoVBCEtty+KYigUUql+u/wuCug2I4qi2+2ORCI2my3Dthz8fc1fLl+wTXXR/FE9cAnSVlocT0RRTPoNrfZWQDPvh4/e/fznlY0xRoX/Oxz77p13fi4d/dhfR5TxRL0KG/bc8va7O87/a/cdLR/vgwVhAAAAQMYUCkVOTk5LX0nPa0g4Ctaw6ZHrXo1c9NicUwxMyZFVz/OZXpi0gMs6vmvn4399qKRnl0H8/k3uuiAV5kqUK1O1eLKna0FPnufVajXGEwl5/Q3euqYsjhSazJ+rKHo3z33jZ/VpM1fPOMvMEZG+/+BxK7MDvf/2wZw3z7/oWnt7KyDSjNN1O31ENyIaN+GKbhP73rlkzqrR6ye23erXLZ7pWVlZfJqWfFEoFHq9/ijjCbS6eDzudDp5nrfb7en6ncoD869+ab3LPPzpIbkd8KJMKi2e6TzPJ/0hnvY2/nPGAZf/rfwvrPGzpx7YdOio4NqxK9hp4Am/7CnLl5/Qv+jN/+ysjutaPi72sWb4G8sAAACQ6Vqe2BINtXmQDkWs/XF3VaJ25Q2DV/7q+LMDbc/yFVM+3XjLKe3t8rmtcFkao4KYKAqMCK//0qrFkz1dBbRCoeB5HuOJJBhjlbXeUDhqsxg7SFeUcO7/Icb3GtDTdNjzN6d375PV77+1x9HI7PmZOHrE9n/6+pd11tMuPKPkUA/BW88+qxf/xY8/7heo7QroFs90lUqVrlVfOI5Tq9UdauJt+xEKhZxOp8FgsFgsHWLLwcOIVR88uyXUefz5Z2b98TdDuhzt4iTpp1+7u4JWGUvtRmL1P2kPu0diXW0dKzDlHxw0FfmmfFZX600c5bhIvxTQ27Ztczqdh27nwIpFHe1cTdqBz/2JohiJRKTOAtI48NkKnDWQ8TDKtejACCAIAh6fY5dIJKSOAClSsD6jpl43SKfkNAdmPrOGz994/VfUY/cAACAASURBVKNI76smDCorGFDSMeY4JNzfjFr5U96p571w8v+2ixN89XsEzmLKzcFFAcAxiCcSzuoaBaewlRXz3g7SPxOn1eqJ1QeaRDIdGj1Yc1O9QGqtVpOpo8fPb908883uc0/YNPV/ew6ypsYmxmm1WZl6p6Et1dfXV1dXd+rUKT8/X+osbU/c/8G/P49brh/a47eLv4CstLsCukVCLJrgtNpDnTSn1WZxsWgscZTjh9ZLe/vtt999991Dt2MwGILBIKq0P0UQhGAwKHUKkFKLS/8AZBKMcr8jHo/H43GpU8hGNBpVKuVxcQVHYkSVIZH6XPrIQIX20LobguOfW97Y1HDCdTfP6Dhzn5WFxjx/zSsffHnZ8edecGDNAKHpjQ3f/4cZb+7XCS//AP5QKBJxVtUY9DqLqYDjuPSs5y0Hqi4DhhWtfWrd6pUX3jTWzBMRiU2bXln/iaAbcWqPTF10XNXvtMGG199avvzL8bMGHriTQt3659f+yEzXnNGtw/zpgFbBGKutrfX7/VarVadrwwXF2w9Wv3HzrnjeecN64gJE3uQxGPJqDc8C4QijA28fsnA4wlQ56qMdP/QPhw4darPZDv3nyy+/rNPpUEAfu+bmZp7ns7LwOYcOKhwOi6KYnZ2Ns6YlmBOaOTroxdwfEUUxHA6rVCq1GjsrHCu1Wo0BU6YSjBzNAkdk1/NK/A6zOs8e2fmDlTvGzK+/tF9phSL03e4971QLvc+66O/WjjKREyBpgaZgZa3XXJBfYOx466Vret05c8j7d22cMMm1Ykj/Pjmx/37z+eqdDXmDrv3HOcZMHVy5vBF3zzzpg/ueOm/47rHn9bMw7/eb313zbaD04gV3noHd+SB5oii6XK54PG632zvuBXnzfzZ+F886sf/JHfUByBjyKKAVBaZC7mdfvUgH1s4SG3wNXEHPAuVRjh/62Mvpp59++umnH7qd5cuXa7VavDI8Royx5uZmhUKBPW07rGg0KooizhrIeBjlWpRIJMLhMM/zeHyOnUqlSnpjaJBQRCBHKKFXcsXajrjjYEsUxw08/3Pj9gc2/bj+y29eTyhLLKW3jDvl9hMKM7ZAAkiTWn+9ryFQbumkz+6Yfz05yxnXf7qoywMvf7Bm47vrIkpTaZeJ02bMubSfVR7dQ3LUvaY9v8WyZO4z61Y9t6UhntWp64BrH5g2+6pTLB1j4SZoDbFYzOFwqNVqm82WrlW85Sj6/VdbglyXnt0MuAKROXn8EeDLe/bQrd3+rXdcRSeOSPR8+50n5/ieJeqjHMfEDAAAAIA04jpdsyFwjdQpWkUgLlaGRZNGYdK09OqOt9669vtb2zxVm+EMvTfM693SV/jO3U94uvsJbR0IMl0GDyaiKLprvNFY3FZaolH/6qPiGXyvW6Io6j1i4bwRC6XO0aY4Xa9Rs14fNUvqHJAhgsGgy+UyGo0Wi0XqLBLTDLrD/eMdUqeANJDJuyjqPiNHlu9/Y/ErX+517fl82ZJVLvsFI3upj3ocAAAAAOCPeKNiVZiVZfMtt88AAMcmFo/vdVWKomgrLf5N+wwA8Kf4/X6n02mxWNA+QyaRxwxoIqVtzB23xf/14pLbV0WyS/pdMOu6UVb+d44DAAAAAByVyMgdFiICs+l5jQKf6gSA5B3YcjA3R9+pMB8r1wFA0hhjHo8nEAhUVFRgETzIMO20gObyzrtv5Xm/OsSbTpww+8QJR3zr0Y4DAAAAALQkLjJnSOQ5suuVWPUZAFJR39hU7fVZTAV5hhypswCAjAmC4HQ6BUGw2+0qFT5IAZmmnRbQAAAAAACtISQwZ7NgUCksWsx8BoDkMcZq/fX+hkZrsVmHuYoAkIJoNOp0OrOysqxWa0fechAyGApoAAAAAOgoGmJiVUQ0axQFWPQZAFIgCKLLU5MQBHt5iRpzFQEgBU1NTW63Oz8/32w2S50FoLWggAYAAACAzMcYq40yf0y0ZvM6JaY+A0DyYvG4o8qjVqlspSUKfJQCAFLg8/lqampKS0sNBoPUWQBaEQpoAAAAAMhwIiNXSIwzsut5NdoiAEhBMBR2eWrycw3mgnypswCAjDHGqqqqgsEgthyEjgAFNAAAAABkspjIHM2CmldUZHM8h/YZAJLnDzR66vzFRYXGHL3UWQBAxg5sOcgYs9vtSiWqOch8eJYDAAAAQMZqTjBXWMxVKixaLPoMAMljjFXV1jU1hypKLNosjdRxAEDGIpGIw+HIzs4uKSnBloPQQaCABgAAAIDM5I+JnohYrOWNKkx8BoDkCaLorPIIomgvL1FhriIApKCxsdHtdptMJpPJJHUWgLaDv50AAADJ6H6vW+oIbWHb37KkjgCQDMbIExEDCYYtBwEgRZFozFldo83SWIsKMVcRAFLh9Xq9Xm9ZWVlOTo7UWQDaFApoAAAAAMgoAiNnsyAQ2fU8pj4DQCqamkPumtoCY25Rfp7UWQBAxhhjlZWVoVDIbrdrNFjGBzocFNAA8HsK335C6ghtYtJdUicAaKf0bzwqdYQ2gUEgg0QF5gyLGo6s2bwC7TMApMDXEKjx+UvNRQa9TuosACBj8Xjc6XQqFAqbzYYtB6FjwvMeIEkd5NP3P5ZLnQAAAOCYBRPMFRLy1QpzFj4mDwDJY4xV1nibw5GKkmJsOQgAqQiFQk6n02AwWCwWjsN749BBoYAGAAAAgEzgi4k1EbE4S2FUo30GgOQlBMFR5eGIs5eXKHle6jgAIGOBQKCystJsNhcUFEidBUBKKKABAAAAQN4YUVVYDCZYhY7X8phbBADJi0RjjiqPPltbXFSIuYoAkIra2lqfz1deXq7X66XOAiAxFNAAAAAAIGMCI2dIYER2Pa9EWQQAKQg0BStrvaa8PFO+UeosACBjoii63e5IJGKz2bDlIAChgAYAAAAA+YoIzNEsZCu5Eq0CWw4CQCq8/oa6hoayTuYcXbbUWQBAxmKxmMPhUKlUdrudxzI+AESEAhoAAAAAZKoxztxhoVCjKNJg0WcASJ4oiu4abyQas5WWaNQqqeMAgIxhy0GAFqGABgAAAAD58UZFb0QszVYYVGifASB58UTCWV3DKxT2shKex3gCAMmrr6+vrq62WCx5eXlSZwFoX1BAAwAAAICcMKLKsBhKMHuOElOfASAVoUjEWVVj0OsspgLMVQSApDHGamtr/X6/1WrV6XRSxwFod1BAAwAAAIBsJBg5mgWOyKZTKNE+A0AKGhqDVd46c0FegTFX6iwAIGOCILhcrkQiYbfb1Wq11HEA2iMU0AAAAAAgDxGRHM0JvZIr1vKYqQgASWOM1frr/Q2N1uJOOm2W1HEAQMYObDmoVqttNptCgffGAVqGAhoAAAAAZCAQZ5VhwaRRmLDuBgCkQBSZy1MTTyTs5SVqFbYcBIDkBYNBl8uVn59vNpulzgLQrqGABgAAAID2rjYq+qJieTavV2LqMwAkLxaPO6o8apWqoqQYWw4CQCr8fr/H4ykuLjYajVJnAWjvUEADAAAAQPsliqI7JEQEZtPzGgXaZwBIXnM47Kquzc3RW0wFUmcBABljjFVXVzc2NlZUVGi1WqnjAMgACmgAAAAA+dBkS52gTcXjcafbyauy7GXmDjdXcfJsqRNAputg44nf7/d4aoqLCo05eqmztLlep0mdoM1ldaynN7QlQRCcTqcgCHa7XYVlfACODQpoAAAAAGiPQqGQ0+k0GAyW/FyOw9xnAEgSY8zj8QQCAavVqsMyPgCQgkgk4nQ6tVqt1WrFloMAxw4FNAAAAAC0O/X19dXV1RaLJS8vj6IhqeMAgFwJguByuRKJxC9zFTGeAECympqa3G53QUFBUVGR1FkAZAYFNAAAAAC0I4yx2tpav99vtVp1Op3UcQBAxqLRqNPp1Gg0NpsNcxUBIBU+n6+mpqa0tNRgMEidBUB+UEADAAAAQHshiqLL5YrH43a7Xa1WSx0HAGQsGAy6XK78/Hyz2Sx1FgCQMcZYZWVlc3MzthwESBoKaAAAAABoF2KxmMPhUKvVmKsIACk6MFexuLjYaDRKnQUAZCyRSDgcDo7j7Ha7UokODSBJHevkYYz5fD5sYvOnJBIJn88ndQqA1oUneQeHJwCk6zkQCoV4nk/LTXVAB+YqGo1Gi8UidRYAkDHGWFVVVTAYxFxFAEhRJBJxOBx6vb64uBhVEkAqOlYBzXFcQUEBRo1jdKCvVyqVubm5Umdpn9xSB4C0KSgo+PP/CE+AzJHUE4DwHMgkyT4Hfis7O1sUxbTcVEfj9/s9Hg/mKgJAigRBcDqdjDHMVQSAFAUCgcrKSpPJZDKZpM4CIHv4kwwAAAAAkmGMeTyeQCCAuYoAkKJIJOJ0OrVabUlJCZbxAYBUeL3eurq6srKynJwcqbMAZAIU0AAAAAAgjQNzFQVBsNvtKpVK6jgAIGNNTU1ut7ugoKCoqEjqLAAgY6Iout3uSCRis9k0Go3UcQAyBApoAAAAAJDAobmKVqsVcxUBIBVer9fr9ZaWlhoMBqmzAICMxeNxp9PJ87zdbsfGHgBphAIaAAAAANragbmK+fn5ZrNZ6iwAIGOMscrKylAoZLfbMVcRAFIRCoWcTqfBYLBYLNg8DCC9UEADAAAAQJvy+Xw1NTWYqwgAKUokEg6Hg+M4m82GLQcBIBUNDQ1VVVVmszlde1MDwOHwRxoAAAAA2siBuYrNzc3YchAAUhSJRBwOh16vLy4uxlxFAEgaY6y2ttbv91utVp1OJ3UcgMyEAhr+QO6qhf/P3n3HN1H+cQB/nruMpnvvAQmjUPbeU6YIArKXoAKCiAMHKoKKggL+VHAjooCylwwFAYGyRfaGQtO9d5omuXt+f7S0aWlLOtI0zef98h9D7u57vbvvPfd9njxn6RBqxNT3LR0BAABAHVc4VlGlUmGsIgBURUZGRkxMjJeXl5eXl6VjAQArJopiVFSUTqfDKwcBzApNfwAAAAAwu/yxig4ODgEBARirCABVkZiYmJKSEhwc7OjoaOlYAMCK6XS6yMhIqVSqVCrxykEAs0IBGgAAAADMC2MVAaBaiKIYHR2t1WoxVhEAqignJycqKsrFxcXX1xdd4wDmhgI0AAAAAJhRUlJSUlJSUFCQk5OTpWMBACum1+vVajXP8yqVCmMVAaAqUlNT4+Pj/fz83NzcLB0LgE1AARoAAAAAzCL/lYMajUalUmGsIgBUhUajUavVzs7Ofn5+GKsIAJXGGIuPj09PT8crBwFqEgrQAAAAAFD98scqchynVCrxykEAqIq0tLS4uDiMVQSAKhIEISoqymAwNGjQQCqVWjocABuChwEAAAAAqGYYqwgA1YIxlpiYmJqairGKAFBF+a8clMvlSqWS4zhLhwNgW1CABgAAAIDqlP/KQR8fHw8PD0vHAgBWTBTFqKgovV6vUqlkMpmlwwEAK5adnR0VFeXu7u7j42PpWABsEQrQAAAAAFBtEhMTU1JSgoODHR0dLR0LAFix/LGKMpkMYxUBoIryXzno7+/v6upq6VgAbBQK0AAAAABQDURRjI6OzsvLUyqVeOUgAFRF/lhFV1dXPz8/S8cCAFaMMRYbG5udnV2/fn2FQmHpcABsFwrQAAAAAFBV+WMVpVKpUqnked7S4QCAFcNYRQCoFoIgqNVqxphKpcL7kAEsC1cgAAAAAFRJ/isHXVxcfH198cpBAKg0xlh8fHxGRgbGKgJAFWm1WrVarVAoAgICMI0PgMWhAA0AAAAAlZeWlhYXF+fn5+fm5mbpWADAiuWPVRQEQaVSSaVSS4cDAFYsKysrOjraw8PD29vb0rEAACGEoBcIAAAAACqDMZaQkBAfHx8SElJHq8/ak8smjF11yWDpOGqA5t6+D6cPbRKqUvgEebYcMHLR9qs5zNJBgQ3RarX37t2TSCRKpbIuVp9tKJkQW88ntnWsa6ekpKSoqKiAgABUn62aELG2Q9O2tFEp/0n6f3lGsHR8UEEYAQ0AAAAAFSYIQlRUlMFgUKlUMpnM0uGYBUvev2rVnmNDXxAtHYm56e/8PHLQ239l+XZ5euIzgfp7x/ds+/LFw6dj/tk1pyVeJwnmlz9W0d3d3cfHx9KxmIXtJBNi8/nEpo51LcQYi4mJ0Wg0SqXSzs7O0uFAlVDH+v2fHKAq0ZkjJp09dDHBx8cLU75ZGxSgAQAAAKBi8l85KJPJlEplXZxXUchNibz27z/rP/1gU4JYN+thxljGrqVLD6QHTV2//8eBXhwhRJz39/yhg3/433vbxuwe741HPDCrlJSUhISEwMBAZ2dnS8dS7WwsmRBbzie2d6xrH4PBEBkZSSlVKpV45WAdwHn3XLysZ/HPxAebX2l3rPl7C0Yq617zs67DNQkAAAAAFZCdnR0VFVWXxyomrRveYPZfefn/ZwPPN4Zrx85k8M1efL2fV8Hecu59Xn62y8/vHD/6X974gRhCBmaSP1YxJyenrr5y0OaSCbHdfGKLx7qW0Wq1kZGRjo6O/v7+eB9yXSXG73tlxX/K6Wtea1T3Zmqq+1CABgAAAABTpaamxsfH+/v7u7q6WjoWc6FuQ748FJbOCEve9fLoL6MtHY/ZGTTETdW8a0sVX/QZtVMoKDHk6fErcjATg8EQFRXFGFOpVHV1rKLNJRNiu/nEFo91bZKRkRETE+Pl5eXl5WXpWMBsWPquFV//6THqyLON6ubUb3Vd3bzTAwAAAED1YozFxsZmZWXV1bGKRSSejdt5EkJY/CVnWxjHpnjiq+NPFP9IjN7zxym9tFX75nV1uCJYVv5YRQcHB39//7o4jc9DtpZMiA3nExs81rVGYmJiSkpKcHCwo6OjpWMBM9L89/P8fcLIz6d0qtON0DoMBWgAAACAWocxlpGR8ejnLi4uNR8MIUQQBLVaLQiCSqWSSvGzx7pN92D/h6PfO5ITPOm9CSEopNSAUi92Uaye0aIGgyEvL69W5ZPMzMzo6GiMVbQNyCc1qtQrXaPRCIJQLesXRTEzM/PRTiNLJRNRFKOjo7VarVKplMtt4B2XtkyM/umL7ZGhz21/whUTrNSMUvOJIAiVbp+gAF15oR/YxA9rbgZbOgIAAADbwxjT6/WWjqKAVqtVq9UKhSIkJKQuj1UEQnSxx75c8O7iHbd09YZ999vigXjKqxFmvdgZY6Io1p58kpSUlJycHBQU5OTkZOlYwLyQT2peqVd6VQpGJTDGDAZDLckner1erVbzPK9SqXief/wCYM1yzm7437/SoSuGN8GhrimlXumMMcZY5VaIAjQAAABArcNxnIeHh6WjIISQrKys6OhoDw8Pb29vS8cC5sTSz6159/kPtl7RBfSd/e3/3hzRzAnVohpS6sVeXZ09EolEoVDUhnyS/8pBjUaDsYp1H/KJhZR6pTs6OlbXT5d4nndzc3Nzc6uWtVWFRqNRq9XOzs5+fn545WDdx1J3/Lo/ymfAj31ccLBrTKn5RCKRVLq/BwVoAAAAgNqoNjxQJSUlJSUlBQYGOjs7WzoWMCcheuvc0ZM3RHr1fXXnZ3OHKjG9Yo0y68Wev3KL55P8sYocxymVyrr6ykEogHxiOaVe6dV7+VNKLZ5P0tLS4uLifH193d3dLRsJ1Awx9uBP4Zp6E57sUZcnkq91qv1Kt/57v5h6advajf9cjMxyDGnVZ+zUkS3dLP+0BgAAAGDV8scq5uTk1P1XDgIx3Ph25rTf4sLm/LZ3UU9vTLIC1Q1jFW0J8gmYEWMsMTExNTU1JCTEwcHB0uFAzRAfHDxwSu83q18TvITEqln7DUGI3P7Jx1ujAp96+a05T/lHbv546c6o6pleHwAAAMBGGQyGiIgInU6nUqlQfa77tCe++ubfvNZzf30f1SKofhkZGQ8ePPDy8vL390f1ue5DPgGzEUVRrVZnZWWpVCpUn20ISzt07IberV3/MNSfrZuVj4DWXd6z537gyC9mDgziCWnmmX533h97rz05s4XM0pEBAAAAWCWtVhsZGeno6IhqkY0QIs6dThJlzqeXvjyneL2IOnd9ccWEJlb+wACWlJiYmJKSEhwc7OjoaOlYoCYgn4CZ6HS6yMhImUymVCrxPmTbknPh0GW9XbvWHVDns3LWnf+FqGs3sn07tfXPnwGbD27b2nvbhetxYosQJCQAAACAisrIyIiJifHy8vLy8rJ0LFBDDFGRagPLvnno15sl/oXzlgxfNqGJRaICayeKYnR0dF5eHl45aFOQT8AcsrOzo6KiXF1d/fz8LB0L1LS8K+fCs2mDsMbOGBRh5ay7AC0mJyYzDy/3h9Vmzt3LnSUnJomkoAB98ODBmzeLbn2iKObk5GAsDzwqJyfH0iGAJeEEsHE4AaC6zgGdTmfVzYykpKTk5OSgoCAnJydLx1IrUN/n/8543tJRmJ18wMqUtJWWjgLqlPyxilKpVKlU8jxv6XAsz0aSCUE+saVjXWNSU1Pj4+P9/f1dXV0tHQtYgLzz/Oib8y0dBVQD6y5AC7o8A1UoFA+f9KhCYUd1eTr28Avh4eF79+4t/L6zs3Nubm51PRmGz7aJF3Amk1mWDqFG5OZWdAmcAHUKToAy4AQoB86BOqVS58Cj9Hq9RGKVjav8sYparRZjFQGgivDKQQCoFoyx+Pj4jIwMvA8ZoA6wymekQrxMzrOMXC0jdpQQQlhurpZJnYomhhk9enT37t0L/3fp0qVOTk5oBpmIMZadnc3zvL29vaVjAcvIyckRRdHR0RFXjW3S6XR5eXl2dnZSKV74YIvyfzYklUrt7Gyi1F4trLR0q9fr1Wo1z/MqlQpjFQGgKtLS0uLi4vz8/Nzc3CwdCwBYMUEQ1Gq1IAgqlQoPIwB1gHUXoDkPL096PyVNJK48IYSI6Snp1CPMo3AC6LCwsLCwsMLvf/bZZ3K5HKU0E+UXoDmOs9LHaai63NxcURRx1dgsQRAIIVKpFEnANhkMBkIIz/M4AUwnkUhEUbR0FBWDsYoAUC0YY4mJiampqSEhIQ4ODpYOBwCsWF5enlqttrOzCwkJwSsHAeoG676S+eCwJg5xFy8l5c+5IcZfuhzv1DQsAEN3AAAAAB4rPT39wYMHXl5e/v7+qD4DQKUJghAZGZmVlaVSqVB9BoCqyMrKioiIcHZ2DgoKQvUZoM6w8otZ1mLw4OAHW1b+dvZe1N1T61dtj1INGdxM9vgFAQAAAGwYYywhISEuLi4kJMTDw8PS4QCAFdPpdBEREZRSpVIpk+FZDAAqLyUlJSoqKiAgwMfHx9KxAEB1su4pOAiRKJ+Z/6b++19Wvb1dax/QashbM4aHYPwzAAAAQNlEUYyKitLr9SqVCtUiAKiK7OzsqKgod3d3VIsAoCoYY7GxsdnZ2XjlIECdZO0FaEJ4r3YT32s30dJhAAAAAFgDnU4XGRkpk8nq16+PVw4CQFWkpqbGx8f7+/u7urpaOhYAsGL5rxxkjKlUKonE+utUAPAIXNgAAAAAtiInJycqKsrFxcXPz8/SsQCAFcsfq5iVlYWxigBQRVqtNjIy0t7ePiAgAJM+A9RVKEADAAAA2ASMVQSAapE/VlEQBJVKJZVKLR0OAFixzMzM6OhoLy8vLy8vS8cCAGaEAjQAAABAHccYi4+Pz8jICAkJcXBwsHQ4AGDFtFqtWq1WKBQhISEYqwgAVZGUlJSUlBQUFOTk5GTpWADAvFCABgAAAKjLMFYRAKpLVlZWdHS0h4eHt7e3pWMBACvGGIuJidFoNCqVSi6XWzocADA7mytAr1q1ytIhWJPc3FyO43A/sFl5eXmiKGJeP5ul1+sNBoNMJsNrymyTKIp5eXk8z8tkMkvHYjWuXbvWuXNnS0dRTF5enlqtlsvlGKsIAFWUkpKSkJAQGBjo7Oxs6VgAwIrp9Xq1Ws1xnFKpxCsHAWyEbV3qr7zyilartXQUVkOv1x84cMDNza1Lly6WjgUsIzw8PCMjY+DAgag/2qZbt27dvXu3devW/v7+lo4FLCAtLe3y5cuBgYEtW7a0dCxWIyAgoFmzZpaOokh2dnZUVJS7u7uPj4+lYwEAK5Y/VjEnJwevHASAKtJoNGq12tnZ2c/Pj1Jq6XAAoIbYVgF68ODBlg7BmmRlZS1btqxFixYjRoywdCxgGbt377569erKlSvt7e0tHQtYwA8//LBt27Zx48Y98cQTlo4FLODy5cvffvttvXr1cBewUvljFfHKQQCoIoPBEBkZSSlVqVQYqwgAVZGRkRETE+Pj4+Ph4WHpWACgRqEBAQAAAFCnMMZiY2Ozs7MxVhEAqkir1UZGRjo6Ovr7+2OsIgBURWJiYkpKSnBwsKOjo6VjAYCahgI0AAAAQN2R/8pBxhjGKgJAFeWPVfTy8vLy8rJ0LABgxURRjI6O1mq1SqUSr5gCsE14LAEAAACoI/LHKtrb2wcEBOCVgwBQFUlJScnJyUFBQU5OTpaOBQCsmE6ni4yMlEqlKpUK7xYCsFkoQEOZHBwcdu3aJZPJLB0IWMxnn32m1+vt7OwsHQhYxtixY5988kl3d3dLBwKWERoaumvXLkwBb0UyMzOjo6M9PT29vb0tHQsAWDGMVQSA6oJXDgJAPhSgoUwcxwUEBFg6CrAklDBsnLOzs7Ozs6WjAIuRyWS4C1iRpKSkpKSkwMBAXLYAUBV6vV6tVvM8j7GKAFBFaWlpcXFxfn5+bm5ulo4FACwMBWgAAAAAK8YYi4mJ0Wg0KpUKYxUBoCowVhEAqgVjLDExMTU1NSQkxMHBwdLhAIDloQANAACFmC4nyyB3tsfNAcBKGAyGyMhISqlSqcQrBwGgKtLT02NjY318fDw8PCwdCwBYMUEQoqKiDAaDSqXClJ4AkA9vpwEjLP6PBS+tuSYU/zDrn08XbI8RWe6DQz8umjNlzDOjJ814c/nWC8kGC4UJNUBIPLdhySvTxo4cMXrSrAXfHojQMEuHBDXAELlz4XOzf7psdHEXZAAhbf+CkUONDH/xl9tCqi1oyQAAIABJREFU2WsC6yHc/XX28GHPLj+RbnyVC7d+nvHMW7vijT/TnFw+YdjQ4XN+i8Chry20Wu29e/fs7Ozq16+P6jMAVBpjLCEhIS4uLiQkBNVnAKgKnU4XERGR3zWO6jMAFMKzCjzEtDFH1u28qukgFv84+7+zWS3H+2ad/N/CVVeDn570Rjs/9uDwhnWLF2Z+uGJaGF5PVxcJD7Z9+tk+rt/Ut2cFSxL+3fLTtx/muayc29EJv8Ss03R3t3712/Vcub/RZwUZwI8kHkikjZ56bURYQSuSKgL80YVZd7DU8J/W9mg+t4NzmVc5y/r32HmNwl4WHR4eMUbZENOCWlxGRkZMTIyXl5eXl5elYwEAKyaKYlRUlE6nwysHAaCKsrOzo6Ki3N3dfXx8LB0LANQuKEADIYQkHV6x8OdTMZk6RjyL/wvLvnA2s9VYv4xTP5wxdHr5zcndnSghYaG+mvtzdx68Mi2svWUiBnMSIk8cj/Qbsuy5J+rzhDRq6JlyafaW07eEju2QMeow7Y3fV/7JNwjio4w+LMgA/pz+REKac8NO3bs0R9mxLuJ8m4eKx39c173prLaOpZegWea5Yxf0TUdN89r944nwOxMahuJUsKjExMSUlJTg4GBHR0dLxwIAVkyn00VGRspkMqVSiVcOAkBVpKamxsfH+/v7u7q6WjoWAKh1MH4NCCHEtc2Y1xcuXbHwmUYlCows5+LZ9BYdAmiWXh7Srn3ow8IE7+XnI9Hlamo+VKgB1LHp4CnjugY8fAjheI5KpFKLxgTmxXIu/brqqO/kF/t6c8U+zs8AnJiUkMi8/bzF3LTE5Cw9JmSpa6hjiwnTe7HDP2y4XMZ0Oyzt9LHLQpNuvXp1aeOYePL4TX0NhwiFRFFUq9Xp6elKpRLVZwCoipycnIiICEdHx5CQEFSfAaDSGGOxsbGJiYn169dH9RkASoXxjEAIIVLXQJUrYWl3FCVGvmkunk1r8Uwgx3FPvbu86GMh8djhy6TBmMY1GybUEM679aCnCCEs5dbJy/djrvy9J67Z6JlhSBd1Fsv8d83XZ+o/t7yX53/hxv/wMAMQMSkuyZB0eMm0n+9nCETiVK/r+DkvDm5gj0lZ6gzq1Hby891eXfb9790+f+7RyZVY8qljV1nT5zt42Nt3bu1w9NSx61PCWmJWv5qn1+vVajXP8yqVCtUiAKiK/LGKfn5+bm5ulo4FAKyYIAhqtVoQBJVKJcWoJQAoAypKUB7NxbOpzUcEFRsonxd/dtt332+/p5z44QBfSwUGNUKM/2//npNxMfHSxsP9HFBqrKtY2skfvrvSbMayLm40u9i/FGYAlpGcplc4qp6a+0H3AJJwac93K1d/strrq5c7YPRl3UFdOj47tdMrX363qevyKaHFmwcs4cSxm1zYzI7ulNDmnVvbHzt9/Oq0lm0wU2jN0mg0arXa2dnZz8+P0ppOypmZmTqdzt3dneMs8fs5ub0FNkpIWlqaIAienp6P/6o5WGivU1JSKKXu7u4W2bpFMMZSUlIkEomNDNxjjMXHx6enp4eEhDg4ONTw1gVBSEtLk8vlTk5ONbzpApa4svR6fUZGhkKhqPk/eAFL7LVWq83OznZwcFAoFDW/dUvRaDQajcbJyclGZlTXarVqtVqhUISEhNR8CyE7O1ur1bq6utrUq5gt3CRr2MYCGyUkPT3dYDBYrElmIXWsSYYpOKAcmktnk5t1LKo/6xPObfjgpTnLjnB93lrx/tP1beKWasv4sHGLV6xcvWbpIP3uT7/8KxHzLtRJKUe/X32v3YvT2ruULGcVZQDq1v/9jb99Oaev0kUmdwnqMO6lEQ3STx69ZJGAwWyoW7epz7ZN3/Pd1ru6Yv8gxoQfv0PqNfLNjFKr1clu9ZWy9DPHLmktFKeNSktLe/DggY+Pj7+/f81XnwGgzhAEITIyMicnp0GDBhYrhgJAnZCVlXX//n1XV9egoCDLFEMBwHrYUDcRVJjm0pmkZkOD83/hyzQ3N3+0eGtSo5FvrRrRzgc/vK7DWNad48divLv1DHWhhBBqr+zdTfX7hjtqgXgjZdQ9sbdup8UkLxy/v+ijRSMO+Y/4bFljowxQHOcZ4C/Xp2XVWJBQQ6hnr+cmHX919bc7Ojxb9KkYFR4eYdALG9+ds7Hoq+eOX9B06GyZ8Zk2hjGWmJiYmppqkbGKAFCX5OXlqdVquVyuVCpRLQKAqkhJSUlISAgMDHR2drZ0LABgBVBNgjLlXjmbEDYkJL/6pL2y7vMtmV3fWT6zjSvGXdV50cd++Z5zaDu/lxMlhBBDUkIqcWrojCNfJzUYuXBF34evFdScW/3Bbqepi8a28HS/tr4wA2hOrXp9nWHCkrnd8odJCzH3InVuYUGWixrMhXo/MX1C+Ktrv9vd1FDwkRBx7HiktM1LPy3s716QBTRn/jdjyblj57M7dXdEYjAvURSjoqL0er1KpZLJ0PsLAJWXnZ0dFRXl7u7u4+Nj6VgAwIoxxmJiYnJycurXr29T86sAQFWgAA1l0V45Ex82uF5+/Vl//Wh4sl+nhsLd8/8WfoNzV7VR4qUldQ91bNevy7pPf/18Iz+irS+Xev2v9fvTGo7ro8LrruokhWeI6uFUWiwr0p7yzv4qVbDh7M6iDKBo3qmZfsmPy9wNozsF8CnX/tqwMylsypNNLBc1mA/nO2D6uPDXf/ovl29CCCHC3fATsfbtxnV2Kyo127fu08X96NHj/2Z164WuKTPS6XSRkZEymQxjFQGgivLHKvr7+9vIPNcAYCYGgyEiIoJSqlKpbGrmZQCoIuQLKIP2ypm4JgPqF8y/kR4Tm2OI/Ourj/4q+ga16/725jc6Wyg+MCPq1GH6glnrft6xevHWLGbv26jTlEWTBpc6FQPUVcUyAKGO7aZ/9KbrL5vXL9mdybsHNmr3wkcT+/qjHFZH8YFPzhgd/savdwkhRH/zWHiCS+fp7ZyMC82ysD49/A7sO3Y2o+cT+FmMmTDGLl++7OLi4ubmlp2d/fgFzCwrK0un00kkEpsqhWdlZQmCYGtjz7OysiilNlVWYIxlZWXVttNbFMVqWU/+KxYjIyMDAwM5jsvMzKyW1VaaIAj5+YQxG3q9iF6vz8rKMhgMgiBYOpaak5eXl52dLYqiXq+3dCw1Jzc3V6PRMMZqz0sIc3Nzq2tVjLHr16/7+vr6+vpqNJrqWm2l5eTkaLVajuNs6p5ls00yg8GAJpnFVeUuRm3qxg8AAABgFSZPnmwwGHi+tnT+iaLIGKs98dSM/EY29toW1M69Xrt2bdVD2r9//9q1a6VSaS15fyljTBRFSqlNlU5sea85jqsl517NyL9d1ra97t+//6RJk6q+njlz5iQnJ9eecljt/GubG5pktqN27vXnn3/u5eVViQVRgAYAAAAAAAAAAAAAs7ChDlgAAAAAAAAAAAAAqEkoQAMAAAAAAAAAAACAWaAADQAAAAAAAAAAAABmgQI0AAAAAAAAAAAAAJgFCtAAAAAAAAAAAAAAYBYoQAMAAAAAAAAAAACAWaAADQAAAAAAAAAAAABmgQI0AAAAAAAAAAAAAJgFCtAAAAAAAAAAAAAAYBYoQAMAAAAAAAAAAACAWaAADQAAAAAAAAAAAABmgQI0AAAAAAAAAAAAAJgFCtAAAAAAAAAAAAAAYBYoQAMAAAAAAAAAAACAWaAADQAAAAAAAAAAAABmgQI0AAAAAAAAAAAAAJgFCtAAAAAAAAAAAAAAYBYoQAMAAAAAAAAAAACAWaAADQAAAAAAAAAAAABmgQI0AAAAAAAAAAAAAJgFCtAAAAAAAAAAAAAAYBa2XYDWn36zsZRSSqVh7/1neOSfhdufdpRRedcV98RS/td0ebsnuXB80EtH9NUSdTURLn/QSkrt+n8fz2pqkyx+28SQwPFbk2psi2B22nPvtvTsseKaztKBAAAAAAAAAABALWTTBWjd2c3b7xkIIcRwe9uWC49WoKE6seRdb87dGfzaB8O9qBlWr7m76+MpvZv4udg7eNRrO/SV708lCdW6YN6Dv1a8OKh1PU8nR09l6z4T3t92M6da96CSKrXj+qMvh0hoKWTtl9wwXlwXfeSrl4Z2UHk7K+T2rgFNe46b/8u/KUZdMHbtXl848M6Hs7+9bdqfGwAAKoFl3tj9xbwJfVup/D0c7Bzc/ZQteo155bMtF1NrcfKtma5uC3So5yvsVq/ZzULlifHH1vzviy0Xsyu8ZF3pbp/sxpXW+itsBbZZfE2owpgbM6ncUJ6SA4kslSgqoXbnFpZ0av2qX8Pja8fJUcOQQwpZZzIxUYmcI0Z/3UdOZR0/xeNuMbU7U9m02pypbLkAnXdq044HAh8Q2tiFM9zdvvV8rRqgbHZc0NBFP6z+7rVeLuYoBz8q78yydzYJI994rgFf7etmGScXPdF+xHvrjkUR/4ZK58yre758sWenyRsjH3OXMHVBlnZsQa82g9/4/sBdnZeynlPGjX9++2h0l0FL/9NU+85URGV3nGVG3EsUKeUkj+Bp0fmgv/X9yPb9X/l6z/kESUCTZio37f3jm5ZO7dZx6taYwlYEdX9q3vR6pz55fxtGtgMAmINevXtej8Ytn351xW+HL0emCo7uTixdffXo5i/fGtOuUceZv93WWjrEmqSLuXDk0JFzkZa9ARt3q9fkZs3b3f7YXmfLqfSOFxHur3l+5AuvvfXtifRHdklzd++n0we2CnF3kNs5+zbuOvrNNWeMN1CXutup3C2gXulC/F2llg4PzJxbqnopieqN8194dfHuyNITgy768FcvD+/U0N/N3s7eNSCs18T3N17OqA2PCGbOIY8bq1SXckghJBNbVlszlWkLPu6mbzl1v7XDbFbuoVlBPJE0euPApgkeHOEbzjupK/4Nw62lHaRE1mX5XaGU/zWddtdEZ8oFzj6se/x36yoxfv1wd0mD18K1Zlh5Tvi8JlLKefb++ESygTHGNLc3TG4oo5znsF+iyztYJi4oxm8a68tRWYNxqy+lC4wxlnt/x6wWCkoVnT67YTDDHpmo0juuPzc/VEIVQ9ellfMlIXr1IGdKZY0n/3otU2SMMZYXc2hhLw+OcP7T9mQaffP+V70U8raLr+qrYacAAMCI4f660cFSSqhDw6HvrQ+/n5l/1xGy1ac3fjiqqTNHKO8z6JvreRaOszRi6n871qz+ef9NTXWuNPbbvnIibffJdYMZt/JY2lNvNpH5Tt6VLtbcNsX0Ews7u3KEcg6+oS2a1XOTUUKlyvG/P3hMU8S0BXU3vxviK6GEcg5+oa3bNKvnbkcpoXLV5C3ltinMr9I7bkx388s+rhwhRNZ7VVSx/RFT/5nf3pkjhMpcAkObhym97HlKqDR45JrbRk133YX3W8i8x2xKrMFDXu0muVIibf3R1fL/cJV+5DGTyj1JldgLyySKSjBnbqn6pSSmHnq5iZTyDd84XUqrX3NheR9P/mESadnI10FCCaH2oS/siLHouWTmHMKYmHr0vU5uHKWco19oi7B67nJKCOfWfcn5HKMV1IUcUsg6k4mJSuQcIWpVbxmRdlh6y4LP/bVNrcxUpi1o4k3fAmyitWO7BWjNX9P9OSIJe/e8LmP7eA+O8KpXw4s/vtWmArQ+N0dbkxlPn6fVV+MpJ0R80d1O0vitM2a4psXUjc+4Umrf88t7Rgcmc/8LQTyRtvrwSpl/NlMX1J19u4mEShq/djzbaOncw7NDeCJt9cFlS92JKr3jjGVtesaB8g3mnSrneIhxP/S3o5z35F2Zxh/rz78XJiFcwIuHjK4WIfq7fgpe+coxc/QvAADYLv31z3s4U8J59Fp8Kq2U23LWhS8G+XKE2rf78L/aWII2g0cK0BYJwpzd6mUxb3e76b3ONa7SO25Ee2lJF8f8n3iVfCTThr/WQEI5j17vH1TnMsYYE1Iv/jShgZRSl8GrjTZQF7rbrbNmVC0FaCtRO4fsMCHt7sk/N37zwYwnlPaUEFJqATr3zPxmMkrljSb8VDBih+Xc3v56F3eOcJ7D18Varuxq5hxi8lilupBDCllnMjERCtCPUzszlWkLmnzTr3G20dqx2QJ09t5pvhyRtvzgsoGxjG3jPTjC1597rNjTW6UK0Dm3d308pXdTfxeFnbNvaM/Jn+y9n77z0WaTmHF106JJfZoFuNnLFa7+TXqMeXvtuSTjnCZEreoto/ajN93/+8OhjVwklHIyZ//mg17bcD2HiVnXfn/r6bYhbvZyO9egNsPmb7uTWywMrfrQypeHd2ns56qQyRQu/qHdnpn34+lEo8gN1xa3lRJ5v+/iRKPNjdmSdmfLq33qOfGUcjJH39DeU5cfjil27omZ17Z8MLlPs0BXhVRm7x7SetCM/x2KLrdJaLj9WScZX++V48Z/geQ1g+RE0vitM4VrN8TsmtFUQTnnDm8dTja5kZK9fZwrpXb9v48rtkjekdlBPJF2WHqzrDuFiQvqTr7egCfSjp+WuOUI2YmRDyLVyRUdSPH4Q2OiSu/4w2M/4MeEcv7KuvBXlTyRdf/ifvEmVuLqgXJCncbvML7fCA++7CHjA2cdQgUaAKDaiGm7pvhxhPMesa7MlqeYsG1iIE84j1G/lzVWwZCZkW3WJ/9q7rQun3kK0BXbBXN2q5fFzN3tFel1rllV6G4vlHNmQRsF7zVw8hB/vuQjmf7s26ESwjcs3ikvJv40SEGp/dPr04s+rAPd7dZZM7KqAnTV8m2tHLLDGMv6bbid8U+oSytAaw9M9+MI32Du0RzjjwX1d/0dKZX3WhlpodPJ3DmkAmOV6kAOKWSdycRENVuArnzSqNHWl7FamalMXLACN/2aZSutHVudAzrr0KY9iUzacsyopjwhzk+M7O/KCeqdW07mVWWtLOPEon4dh7/7y5EbiaJ7iB8fHb7u3aGdR/10t/gLDsX4PS916zh20bojd7TujZo38REehG9eOrVrx4nr75V4FaL+8mdPD1/0Z4pP+yf6dQ6RJF7d//nkAVMWvD6w24SvTmmD23du7m2I+W/X0nFD3z9ZOAVk3pWvnmrX/+Wvdp6Ll/g3adlM6ZobcWLr8um9+74TXv5788TEfS8PGv/FiSyftn3792zqknnryM9vDB7wbtFiWScW9O40euG6fyJ0Xo1aNguxS7n85/evDew+c3fZMwCLsQf2XzA4d+3Zupy5oMS4PS8PGPfDTVn7N3ftW9Lbw9SZqQ13L13LZnz9tm08iy0ibdm+pZQabl2+XsYxNXFBMfr0GbXAB3ftVr/45NWcg1dwSHCQh8LEQAkhVTk0lY2/1EXv37lv4L0beMfuXPbatNGD+w0YNmHO4l9OxBgvIe209EpmdtrB2fWKZYnMf09fM1BpkxahEqNPuYBu3RvSuL/2/WdbM6kDAJhTxv5fd8SLkiYvvDMmoKwGG/UeNv/FVlKWuufX3YmMEELEyC97yDnnibvydPe2zRsQ6uFY7+UjD98mIqacW/3KkNbBbvb2rkGthsz7/UbmlY9ay/jAWYcLXziSF3V41dwRXUP93ezlcnvXgCbdR72x+kyS0URyYvTXfeScw9it6Xe3vta3vru9QiaRO/k16TNtxZHYooaMcP3jdrLCt34JVz9qLSv9bUV2A1cnMhO2nv37CAXn/+KhPKL/952mEirvtVItFt9KPpZ5bfMHk/s2D3R3sLN3C2jac+z8X/5NNp7PzsRdKJVwb+vGM/rAQUOMmjUs5efBdlQa+vbZwoWF2N0zw+w53qXj20dSqjwFquafXX9nEHm38aPrG50LTn3GD/Xn9df27L1b1mx9pi1ouHfjrp5JGrdp4WC8MB9UL4gnLDMjs6I78PizyESV3vFCWcfen/bZJdfhX3wzpV4p7yERRZEQKpVJjVtTVGZnxxEiGgSjiDm/gUPa85FbN56o0uOClTIknl79xqiujf1c7B08gpt2HfX2mpNxBa0+8cFPQzx5zrXvyjtGF4/2wocd7Dmp8oV9FTn/NXd2f/Jsn7AAV3uFi1+TXlOW7HugLW3x8uIpjXGi0Pw1PYCn0rB3z5e41nMPzgzM/we9iVspNd/mJfw8xInjfZ79o/gboFjSuqddOM5t1MbU0v8iZs0tVbmUFD3f3bFnz549e/bs/mFasUeAQmLUpSvJIufdd0gne+PPOf+evZtImOHuzYiKTSlqNTlE/++mrbcNkrbTZnQ2Tp92PT89F/Hg7u7ZRq8/su0cUqimkomJp5CpOYcQwnLv7lw0tksDLyc7Oye/Jr2nrTj8SIOhcklDZ+KyFWi6iGkX178ztnuon4tC4eIX2n3sO+supJXc+Yom0ny1M1OZuqDpN32TWE2mqjWtHTMUta1AxvbxnhyVdV52u6AnIX3rOHeO8EGzDhkNJK7oCOisQy+pJJTaNZ7004VUA2OM6ZPOrhweLKGEkKI+NDHu91HeHOF8+n98NK6gWy3l3MrhwRJKnfusfLj2/K42QvmAoV/+m/+7W0Pc9ikhPCGESlXj117P72TNvblqgBtH+Pqvhhd0ZmTvmOBOqazx81siHo7OzYs9+EZbBeXcp/zxcAdLGwFNCKHy0Oc23S1YTnP7x+G+HOE8puwpGKYfubK3HeXc+yw5nVIwC2X6mY+6O1NaXs9m1raxLlTWufgXio2AFuL2vtTcnnIuHecfMX3sc/6u7Z3qwRF5329iSiyXd3CmH/foCN6KLpj390x/jsj6fB3x4MCyaX3D/F0Udo5eDTo98+bP/yZXtC/XtENjmkrvOBPuf9FdRqjcwV5SrHRNnVq8sDmitJ9aiOn3/zt9/OCONYufbefBUYdWrx9KKbHV7G1jnamsywrr6t8GAKjF8g5M9+UI3+CRd1SUoL+woLmEcO6TduUwxpjw4IvuMuo07ruNU+vL5F5Nug4c9+W/esYYE2J3vRBqRwnlFN6NWrVq4CmnnHuHp/sE80VDXLWXv+znzVNCpS5BTdu0bxMW4iajhFBF87eKBnfl/2rKrvfUSQ2kVO7RoMMTA3q3CrCnhFC7Zm8Wfq94S0OI3DJvzDPFPd05SEYJdRq+IVU0Yet5F9bOnzezXwhPeN/u016f9/Y34WliifYMY0LcH7OaO1BCqNxD1apdm8Y+Co4SKlOOXXdXX8FdKI2gXtVbzrlN2GH8pZK/6xJi/5jVzJ5yLh3ermjDplT6iwtbSIikyfxzxW/TYuraIXaUuozfnlO1BQ15OTnZOdoSjYD0fc8H8VTWYWnF3nhh0llkmkrv+MPvpfw5s4GUD5ywNU7UHXkp6NHRi7kn3mgipXzAiO+vFMw9wvJi/nq9rT3lPIauLf7bA/35d8MkvOr1x1yStVdlBy3mXv12aKCEEso7+DRs0aJB/sSRksAhX/6XxRhjTHjw0xBPjnPt9/WdgnVrL3zU3p5KG846kGryBSCmhy/s4sYRQqjEKaBx4wBHnlLet99TneyLj4B+bDyP7kWxRJH794tBPJGEvXe+2GmVs/95P47K2n+Sf76bspXS860Yv2awA+V8pu4pliXifxrsSDmvCTsySt9/s+aWql5KD2O8s6yztLQR0ELU3qWvvfL68r/iSjwK5B19uR5PJE3f+bcCP+e2ohwiRHzeTUZ41WsnTEkLVp9DCtXyZGLiKWRazikYAd1s3Mzenrzco0GHJwb2bumvoIRQu+ZvnTA6gSqfNExc1tSmi0G9dWpjO0oo7xzUrG3rUD9HnhIqb/yc8XTspmyxNLUzU5m8YEVu+o9jRZmq1rR2bLIALaZtHuPOUXn3LyIK/87pW8e6c4QPnHmwaEaFihWgxaR1TztTKmu98L9iY9Uz/poRwhsVoA23l3WWU85r9MZi8x+I6fueD+KNzrn8TEednlxjNMOC7p85wTzhPMduMcq/WZtGOVLqPGGntmDBLa8+PeTpVzarjePUX1rYQkLkg9Y8TAClF6B55Zwjxue2Lvw1JU/kA37M/2Gv7vDsQJ7Ien9t/Iq+1JM/Lnxvwae775VxAzJc/qCVlLpM2FmswFqUpLTx++a0cKCcS6d3/ilZ1ny8nE3PKCixG7qu5M8lCqbOaLP4Wulxmbigdvs4B0qkzZ/o489TKnMJDG3WyM9RQgmhdqqJGyMr8kRm4qExTaV3nOUdnhXAEcK5tJn586kHaVqdJvHm319Pa+3CEWrf/qMLj/7MVrt9XMFcQoQqQqduing0Fen/W9BMQt2n7KkDvykDAKgN8qc8IvIn1z7ukUuzZZQ9JbIeXz4Q2MNnG6m3X1Dr2TvvF916xYTNY305Kg+d+tvtnPybevSfb3R0poQUzbFgWkepaZ3WJVsaj+xg+vG3W9tTznvwd7fybyumbP2RKThKbKVi3fyP24XSmLVbvSzm7m43ZkKvc/lqR3c7Y4yJCTsmB/N8vam7k0TGSn8kY0x7+/eZbdw4KvVo1Lnfk4N6tQp0oFShHLb85CP7be3d7ZNcKaFyj+AGpWg6dVPB2VrykUd77v1WdpTz6Dpv2+2CpwTN/T/e7OzGUWmjV/7Jf8oWItcM9eI4twHf3jMwpr34cUd7Kgt95UiG6eeOiUN5TIun3AI00x6ZE8ITSfMFF4we9bP3TvPlqKLXygeCyVspI98WVKB9n9tX9FglxHzf355yfs/tK6suUTuH7BRXZgG6DIaoX4d7c4RXvXKsApe+NeWQCo5VsvYcUqh2JxMTTyETc05hg8GuyfNb7hUsrL23flwwTziv5/Y/fPqtStIwcVnTmi7C/R8GuXHULnTKuhtZ+aWetAurng7gKR/0wv6MimyxNLUzU1VgwQrc9MtnTZmKsVrS2rHFKThY2v5Nf6Uxu65jR4QU7r9L/iwcsbs3H9dUbrW6c0fCs5m007NTW8qNP3fuPWWU0eQNLP3k0Ys66jZo4lPexUa/u/SdMNSfN9wLD482Gv/Oh7RpbTTDAufm4UaJJKxLR5eiD2UeHk6UFP6sgQt85vMdf+z436iC5A2cAAAgAElEQVSgwr0zZNw9tOnv+4//4RPn3W9oF+PfTXEurs4cIaRg9bwytKGc6o9/8uy7647fTdMTQgh16/z8oo8+fPMpZSkj/QkhRIiJjBY4Lz/v0v5dSPjr9YGjVl3OIQ7tp0zv7l60W4YzbzaSlP5b3XyyDktvCoSwgj0vY84OUShrt01bUK/VCozorxw64/X8uiuJqVE3rtyKTYs+9ulAX/29DTNfXBtl+g8sTDs0Zt9x6j9o/udffrs9/Og3z3YKcZVLFV6N+85a/eeacQGc5vyXK/ZllVxC2nbm9z//9P0Xi+eObOlwd+349r0W/FPix4O8j583x3Ki1VX/mTEAABBCWGZ6BiNU4uxs/5hZqXhnVydKxLSU9MI7EtOnOo1etWJYvcJ5O8WIDV/tSKAhz636alzD/DVKAwZ88uO8VkY/xhPTDN49nhw266P3R9R/OMOUzK/XxCENeTEnMSmnROavP/3br0arCr6oaDjl9fH1eDE7Pi7LhDuB4cH658YuuyiEzlr36/RG0opvvXTC3fVf7U4iXs98uW5+D9/8H4dy7u1m//zds4Fc5rFvfvqv2I9UK7ELwv2rNzVEoWxQxrQoQsL+VwaM/vqatOPbu/Z93MvkKcXKZ8jO0jBCHZwcSqyPOjg4UMJysjWlR1yJBXWH3+nRuXu/4dPeW3te0+jZNduX9HGvyF5Ux3GsSvxFgcRsfGnWhtj6L3y3YohnOXsgdQ1soPRWEH3K7VMH9+7/52J0DpG4hYQqvR659OT1Gwbz+puXb1rxjGMsL0V9txT3YjNLbzlm7Pvim8s692FfbP1sRMOCpwRFvSFLfv+4j4Ph7rqfDuUQQggXPGXV8qc8Mw6+O2fNrYv/m/nJWSFs7o8f9XI29dxhyTtX/hohSFu99fuP01q58YQQIvFs/9LaH58LLvYIYVo85ZN3GT0ihDfc2LXzWmFGyD68eU8ic+w7ZVQwV7GtPJpvqffgkT3tWeL+HcdzCz4So3dsPJ7LBY4Y37vYPDdFzJtbqnIpVRLLuLh62sAXdyZxIeM/e6ub3eOXKGBVOYRlZmQwwpJ2PN9l0Js/H4/m/FTBTrkPzmz9bFq3jlM2qUtcVXUhhxSqrcnExFPI5JxTgK//wjdfPqMsOJHlytGzRgTzYmZ8fMEZWZWkUbG09pimi+HCj18cTOMazV797cTQ/EFknGurF1e919tOjP1zb/6MmZVPpLU0U1VgwQrc9MtlVZmKkFrS2rHBAjRL2bf5YAZjuYdnB/NFRT3XURtTRSLG79l8rFIVaJYZG5slcu5NmvqV+KNKm7ZoWjQ9jpgQHWtgfL3GDeQl1iBRhap4IsRGxRpnbJ7nHjmJqKz41C2PEtOv7v564ZzJTz/RuYXK19nerdHAT06Y8DzIefp4lXdOcCHPrfxqQhP7uENLJ/do5OXm36zniOnvfb3rUlI58yWKOdkaRhUKRSkxC/d+WfjNZUm9+p406/AHb242msCR8+k8bsbMckwf0dqNEt7R0Y4QpskpeUkyTU4OI9TBseRFXMDEBSVyOU8JlXdcsHHVhDCX/L+OxKfbG2uXPOlC0v/+afP9Ck3x8/hDY+4dJ9LGQ2bPfXnmsGaOxl+g3k/NGlOPF9NOHL1UMtFwwT3GT5k2fe67X2w9d/bbJ93STi6d8enZ4t9S2CsoEbOzsis+4xEAADyKOrs4U8IMmZmPKwuI2Vk5jFA7hdyox9q7z6B2Ri0Nlnrs7/M66jNwRDdHo0UlTYcNa2o0QWVF+rAf12ldDpZ16oNRs7bHufT5dMvy/g+fTqrSg/5wxRXr5q/MLpi5W73MPTNvd7sxE3qdy1VLutuF+2tmvLwtueHsH5b2dyu72cxSD77au/8b2xMaP/f1nxcfpGZnxt0K/21+Lxr+2ajuo368U7yBWxe628v61bz2z+e9S/s76f49eCSV2fcaM9S32D9zQQMHt5SKGWdOFNRwuaCJq1YM80r/c16P/h+cFVrOW72oWLZ5DBOH8pgeT7lkHUePVPKGG7t23Sg4gzL/3rw3mbgPnjLMm1Z0KyXzLSHU+8mRPe1Z/L4d4fkVaDFy+6aTWq7+M+PLLMTW1iE7lSEk/7vm5Z5NO07/9TprNP6H/d+P8K1AYceqckgFxyrVhRxSqLYmExNPIVNzzsN1+g54uliDgTo6GT9MVyVpVHTZcpsuwv3Dh+8YJA1HjO1o/K4qLuDZjTfv3jr6XjtJhbdYTG3NVCYuWLGbfrmsKlPVmtZOqS8RqNNY0p5Nh7II59GoXUP3YrVWlqO+fDU2Yc/mIzkDnyyja7ocHFdW5VZurzAqIucfQlrKuZG/BkGsYgGPZZz65OmnFx1NYk4h7bp16TJ8wCRVw7BW7sdmDfv0xuMW5rjSIjOiCHtu3aXh7xzetfPPw8dPnDpzZufqYztWL3m35cxf9qwcVmo/GJXKpITo9aV1nzBG3bq9/8fO5yJeaPPsjm1vvbO3309D8p9EuXrDP/h6+GN31xAQHMiTG3HRsQLxNT6fc+Ni0xiVBwR5l35geNMW5N083CjJa9R/YINiVwv16tmnhXT3idvXbhmISvbYOAkx9dCYe8fLJKnXoJ6ERKSlpomEENGgMwiEk8okxVYjqT9hxpNv7/vlwdl/E8SOgUX/ptcbCKEymax6xnoBANg66hwc7MqR5FtXbxpI53Le4ivcu347j1G7+qrAoqcB3jfA1/jZQIh+EKVnfLAyuHjTjw9RhUjIFaNPxPSrezZsOXjm0o07EffvP4hKzNYzRggp2W/+2E7rsgNWb3xhzJLzeappv214Oaz4ek3eeuke180fGxsVK5DCt+tWZhfyu9X9yu5Wp8716ntG3j/8wZubn9449uGjXX7vcmLZbTw+pLUbJXl/TPYdti69sL0v67L8+vHXVVx+r7NGk6NhpNgoMNO62yu0IBfcY/yUHoQQMvetuauHd5ixZ+mMT4dc/bRjOSdhSY8/jib+QSq744bb3zz/xv6ssHk7F/d2Kadloj+/4pVvruf5jv11/w/PFJRMGnUd9/GuRpKuXT/a9/Y7W0dsHms0gMu4u72MX/7VMSxLHZkisrxtY13o2FL+nSYlJAkFj5Rc4PiVy7afeHZHEt9i/g/vdrQv5ftlbucxQ3kiKhFPeaTtRo1s+L+l13buuvFu82Y8yfh78/5U4jt1yiA3WuGtlMy35OEY6P1/7d1xUtuvr51wb9umMzq+8ejxHcp8aDBvbql0DqkoIen0D/Nffv+Xf5MFh4ZD3luy7K0RjR0rvmqrySEFY5VkHRdsXDXh4Qsa88cqnWg8dfffP22+P/V1VdFJbXs5pFBNJZMCjzuFTM05D/G+gX7lHLGqJI0KLvuYposQ9SBKILyqsapEHrTzCFZ6VGqLxdTSTGXighW96T+O1WSqWtPasbkCNIvfvelINpG2f2P3ybcaF/9bpm8ZoxyzOWnv5sPZTz5VoU42Qgh1Cgx048TUmzfixSeCjVOCGH1fbSiaIMMnwE9CL0bejtCRJsadUkS4fydCILzfIy2YihGur5rz4dEU72Ff//nLzOaFZ69w9b9qKwxK3Jv0n9qk/9T5hDBN7Pk9X817adnR72YvHj7g2ydK6dTnPH08OTE9Nb2Uy47zn/jzrve7utNOyz9cf2T2wXWvLZrYY2Uf5woEo2rR1IFevX/hcjprY/STA/3VC1f1TBLWIkxRpQUljcMaS2m84dH6uSiKhBCZ3MSH4uo+NJXdcZZ+9cDBa5lOTZ8Y0Lx4H5mYkZYuEs7Lx4sjxHD+vRZdPr3ffvn1cONGEyFE4uCooCQzV5Nr3B8mpqemi1Ti6e1ugz+rAAAwB1n7np3tV+988OfeK590blNm8U+4t2/vVQO169Crs/ETmkRafAnBYCCklA7wYh3PFevDfmyndamyzy4ePWNzjGPXjzd/9ZRPsUZ2VXrQH66DEFKBbv5K7IKZu9UDu46eyIrGvEsaNnWixORe80eZuGBFe53LUyu627NOHTiRTmQuB+f1O1YYWOaDBJEY/lsxrOt6mSR05rqfpgSrjx65a6AeAycOKT5gT9FqwpiWSy78e/zwef3Y/kUlQxvsbhcEgRDOuc3o5/uUdgZQeeuQoieXvLh76ixGmBB55ky0oX3DCjxpmjqUp0LxlEPSevQzocsXX92569b8Zk2yDmz+M42GzJncx6EyWymZbwkh1GfwyB72+w/s2XHqf317RGzddF4vaTZ2XKuy/yS1dMhORbDUE0vHjVl4MJZ5dXh+1WcLX+gRYNognRKrsaIcUq+iY5VsMIcUqqlkYuIpZGrOeYjny00tVUkaFVz2MU0XwSAQQssPtwqJtJZmKtNaO2JFb/rlsaZMVXtaO7ZWgBZjd28+piHSDiOHN3jkmnJ5YkRfly1bk/dt/jvrqaedKrhqaZteXZ1/3H5q7dorM95vWXTsdFd++/180fVJ3Tr3aCHdd27/hr3Jg58xqhtm/bNhZ5QgUXXvXq9Kt//cK/9d1xPnfs9Pa27cd5IbFZlQ5V9WCVdXDBq+KiJ45ra/3mopIYQQau/fbvSHC46sO/5d8v0HWYzYPXqKSpSNlBJ2LCoqk5GSk9JwTn5+zpQQwiuf+9+76zu8efKHV5ZMOL2kkz0xnHmzaddld8oOWtp+yeVTb4c69hrc03HzH8e3/hE/Zarfw/Xnnd3+R6QgaTxwUKOykqdpC1LfAU+2kx0+u2fnxYXtjH5dJ6r/3HtRTxVtOjY3dUSQiYfGzDtOJXfWzRz/W067Ty6ceLuJUQYw3Nq1+6qB8+reu4WUENagZZg9vX3l0D/xr6n8qfHXwk8mCJxraBP/4mPrIqMFPqhRg0p0UAMAQCmo66BJw7x3b7i+esmWWZvG+5faOmDJe5esOqej7iOmjShjOj5CCCGcj78vR25F3VcLxLgFJERHRhfecMzfhy3GbJk5evHZ3ODxv298s3XxO0Z1bN3s3fxm71ZvPeP7X2eU8rl5u9sr2utcntrR3U4IIUTMirxwOrLkpxn3/zt9n0gNQ3MZYaIoMkLk9oqSpwWVK+zow9EGRWu0ve526uLv58gxXcNnPlo28jGNvJzTHz3/6X8ktHPbhDNHFrz43YA/XzK5amTqUJ6KxFM+SYvRo8I+XXh5567bb/le2vRXOhc6a3IXebVtJb8C/eeBPTtOfep5bPMlg7Tt+DFNysk/tXTIjuk05z8ZMnjB6bx6w5av/2FuF6/K5lqryiEVHatkgzmkUE0lExNPIVNzjomqkjSqL60RQgjvF+jLk5TIiEiBNDe6Clnm1X27zqe6txk6uLlLFbZYSzOVaQtW9KZfHqvKVLWntWNjmU+M3rkpPJdIW494WvXoPZG69h/Z15mKqfu3HMys8Lqpx9DZk5S8/sLS8TN/vZopEkIIy775++yJn17QG83lwjec+NKTHiRx88tTVpxKyn/oE9MvfPfc9J8iRaduL73Qrmq9AjJvX3fKsk7vP144X19uxL7FY2b+EicSYtBVZR5xPljpnaa+d/Trj3+5nl2wdjHjyrof9yeIkpCWzV1LvdioZ9v2Kt5w4/KNcqfUkTad89UbreX6q1++/PklnclTIRPqOWLu5Hpc5p+LXll/T0cIIYSlHF/06vd3Ree+c6cXDTTQPzi6ccOG3zaFF0zFZeKCXP0pb48PFK8uHz951ZmU/EU1d7a9NubdIxqu3qSXRzzsRMpf/4aNxx6UsZ8mHhpz77jjE9PGK3nducUTXt1+t+D1AmLm9d9eGrf4rM6+wyuv9rMnhFC3wc+O8KM5Bxa88Pnph1N8s5x7O+ZNXXbRIGkw8bk+xvPUiAnXrycxxzYdmtpapxYAgNlQ96Fvv97JkSVsnztp2bmMUp6Gsi+tnDLjV7Wo6PDmR6N9ymvxcn49ejWVsvg/d540ftWFcGfXriuFdy1z9mETQkjO+aVjnv9Nbdf+3U3fPfNIubw6tp7fzc9S9m/Ym1zs71XQzV+vqt38D7vV06KiMh89IMW71TvbC3d/eGXJaQ0hVZ8D2rHX4J6OJPf41j+MXpfxsNe54eO62x+3IN+gZZg91V859E988b0qo9e5PKZ3t5v0B6nkjrtN+UNbcl7SYu+F152b34QnfGDzZh6cGH/krwt5xZZn8YcPXNJTaVirYg0bW+xul7Xr1cWB5Bzb8Wfxa0qM+XVsQ/+AlvP+KfjTZYcveuHzy7T1G78e2LJ0gGvmkQUvfleB6TSlbXp1dab6U2vXXtEZf15iKI/p8TwW3/SZUS2k+ks7dp7Zs/nvDGnriRNbPjza1bEV6vPkyB72YvQfW1av23LVIO88btSj45+MmDm3VDqHmEi4ueqlj09new755tCW1ypffSZWlkMKxioJd/fsvFjsnChjrJIt5pBCNZVMTDyFTM051b131bzsI/hGPbr784Zr27ZcNt4vlrzrvfFTps5ec43RKm2xtmYq01o7Fbzpl8eqMlUtau2UMm183SVEfNFDTqms42e3SpsvnzExef1wZ0o49zFb0hgz3FraQUpkXZbfFRh75H9LWzzt2HsdXThCCJW6hjRrrvKQU8p59Xt9egcZFzj7sO5hHDE7pze1p4RyCt+mHTq2rOcqo4RQuXLsurv6wmCjVvWWEUnLRZeMYjVcWtRSQuT9vosTiz7M+3umH0edJuzMP/fyLi7t4kwJlXiEdh88bEifdg085ZxL68njOigolQX3mPzR3hiBMcO1xW2lRasqdXOMGa582EpK5AN+TMjfYN7l5T3dOEIo7xgQ1qFr57ahvg4cJVTRdNbeBJGVQXt4dhAv7fTZbaN1i8lrBsmJpPFbZ/RFH2Yfn9dUSqljj89v6h9dTZnE1MOvt3SglHOo12nw00/1DHWXUCoJHPHzPeO1ZKwbakcItR+zVVuxBZmYcuj1Vg6UUCp3q9esZWNfB54Synv1+uRUplhi/cRu2PrMMuI08dCYfcfFjNMf9/TgKKFS58AmbTq0DfW15yihikaTNhgtKSbsebGJPSWU2nk2aNWxU/uwQCcJJZT36fvZuazikWRuG+fKOQxeU/ZJAAAAlaC/u2Z4gIQS6hQ6YtHGM+rs/NuEqIk9v/Xjsc1cOEIlQSPX3M4rXEJ48EV3GZF2WFqirSPErBvhzVFF2Ixt9/NvB/q4w+92deMoJVzArEN5jOUdmhXAEUnj2QdTHmZzzb29Hw0OllJi3Pgwsc1QvKUhxG6fopRSPuCZdQ9KbYWZtnUx9tu+ciJp/v6FgvtVyfZMzLrhnhzl/QYvO5mYvx0h7b9vR9WTUurU66s7hgrtQqmH5N93mkr4enOP6Yw+LKVVoz2/qI0dpYr2H13MY0y4v/39WeX1Ls9e8md8uW2ArEOz6/OEDx796928gm0ee7u9A6XOA76PLFpSd/+f39ev37DxuFqoyILpu5/15yjvN3j5qcSCXRCz726f286JUkmjV4/lFF//+t+P3i+jpWbiWWT6H6TSO15SsUeywsN09t0WMkrtGk/66WJawee5D/a/19OTI5zP2M3FzgRBvbKXjLqO21aiFWQ1JrnSMt8bVqTkI0/mgZn1eMp59X7/gLqgKamN+XtRL0+OSkPnndAwxpiYfnhuqJTatX7vrIYxZrj7TT9XjnN9YtXth+fJ4w9Q9uE5KgmliqZTf7mSITDGmJh147fnm9lTSqnRk5Qp8Tz6HFc8URR85+bSDjIqbdSqmQNV9F71wDgy07ZSVr7NJ8atHuRAOXtHe47a9/8++jGtfHPnluq4lIQ7yzpLCd/wjdMlEoD+/HthEiJpvuDC457h6loOYWLKH1ODeCpvOHrl6eT8f8i5vXVuB1eO8vVn/pVR7O9n7TmkUK1OJqY2ZkzMOfkNhkcuc/2FBc0lRP7kzw83UpWkYeKypra+PuvsQKl9i5lb7uYvKWZe/XFUME8573FbksUKbLE0tTZTmbSgyTf9upapaktrx6YK0MLd5V1klMqKF0KLEZPWDXOihLqN2pgqVrgAzRhj2be2fzS5V1M/Fzu5g6eq89hFO+9m3/+ie7ECNGNMTLv8+/sTejX1d1XI7Jx9G3cb/dbac0nGYVW6AM2YmHruhzmDWwa6yGV2LgEt+r+wbH+ERkg78n7vYEeZ3LP/yjuGyhagGROzrm9ZNKlP8yA3e6lEau8R0qrfsx9supxebuFR8/eLQbyi33cxRd8qtQDNxPQDLyollHMb+P39ipViMy7++ubIjkpPB7nCNaB5/+n/OxxTIleUUoA2bUHGGBMzr258b1y3Rj7OdnIHj3rtnpqz8rC6eG/T4wvQJh6aCqnsjutijn7z2jNdG/u5KmQKt8Dmfad8sOnKI0dRzLi8cdGzT7QI8Xa2kylc/Jp0Hz3v+/BYXYmvMc2BGQG846DVsag/AwBUt7x7W17u5CWhhBBKpQ6eAcGBXk4yjhJCKOfWdsaGG8WeE8ouiIjxe2c3s6eE8o7+YW2aB7tIOYe2r83tLye88rVwHTO5o7QyBei8gzP9OEI4j5ZPjhlb0qTPjmabuvXMTaOcKOU8mg8cOebdPxLER+pKle/mN60AbfZu9bKYt7vd1F5n6+luf0TpxSOWe+WboUEySigndwsOa91C5W3PU0I41w5v/Z1c/Dyw+u72ytWMmJh+fGEXN44QKnWr37pTp9YNPO0oIZxH949PZzLGmJh6YFZDKbX7P3t3GthEtfYB/Mxka5am6ZLuC01YZd9lFVFQUVAWBQRkUREEL1wVd3FfrwooKq6gIqIiIqIi8CIUFAGRfVGg0HShTZu0aZZmmZnzfqhUlCI1TTJZ/r8P98p0MvNMJnPmzHPOnNP54Z1nSyPfb68OTmDOyRpd/AQ1uSvPReNp5CgaTUBT/vhLfeUMIYSJH76s/K+ntUl7+ecENBXOvHu1miGEMNoRH1z8ZxO2XXb+dKEEtHBmyRAFIYw0TtMoXZ9nz/7soq8MaWJfJUqjoAxpEN6FSVN/Qk0rc5qagG5WodG0zza16uI59u7IXBnzx8Z6dczTyRjCyPMnrCzi/tUeGxW2JVXTPtjEm370lVThUduJqQQ0iMf78/1tpKohSy7W9B/pHJ+MSrrxM+fFV4wuzg13ZEuTx35mifjKFABAeOKrD65+6b9jL+vQIk2nlCk0ydnt+o+c+dxnv1aeV6f/x4QIX7XrnbvHXNY+PV6d0nrQ9Dd2WiqXDlMQaafH9tVvqEkNpf4koN1fT/7rzLfnUly3zNrkvTv3vjG+W2a8XKpMHbm0lG8sr+RnM38TE9AhaFa/kOA2tzep1Tmymtv/4kLJI0q5yt0fPHTzoPZZOqVcodEbe42YtXDDqbq/byDym9v9zBlRSqnr5Lf/u+OarnnJarlcmZTXddiMVzacrv+qhapvbjdIGUWnB3ecWwX2Hnl5YDzD6q58/ThHm5SAprTJXXn+KZ5Gj6LxBPQfr8cSNnnc59WNnNaL7uUiCeizGej6vk3/dNx/7C98u+z84UIJaN8vD/3ji+vnFLZRWYY0pa8SjYYypEG4FyZN/wldvMxpcgL6IkdX7x8KjYt/9l9UXXzlPy6Ze0MvQ4paLlclG3peP/etnyr+vsuL7rFxYVxSNa1zYVNu+lFZUoVBbYeh9N8OsA7gB6Hozas6/Ncx/8D2ec0dYiyM8cf/d9no6oW/PtvMgbwjC63+YkLr8Xunbdv3Qm/FxVcHAAAxcI5Ks80nS0jTa865D3N7H+3S65mT1ywrW3tLonjBRRjfzgc69n8td/Hv6+/4p5kfo5Zz5ejc1eOKP7sxtkYxdW2c0WbYqn4rfv/kxqRATwsPUYpWLR/V8pa18gmrT3x0fRMm4oqVsgVlCMoQiGQoqaJaUEuqaP69QDhh8yY/PsOwd8lrBU6xQwkWz54lkyd+kDLn1q6xlH0mhD+5bOFa9ob5/+2F7DMAQNii1Z9PaZmT02nuhnMnIfQdWbvud17WdWDffzFHOch6zpwziC1YtuJEQCZnjDR8WXFFVst8udhxhBat/m7pFxUtb/3vCGSOoKmE0i8+3FjLpN8wcUjTitgYKVtQhogdC0CzoKSKYkEuqZCAhlBR9X3wlSnM8qeWnozSckqS1uuOpVtW3WqM3h7ejaDV3z278NiAJ5+/KR11KQCA8MWkXDNhWDKp+PieGe/8eLrGzXmqCwveuv3mF/fzKdfdebMhpu5dzRYDzeoXguZ2NLdDE1Hrxqf/94OLbXHjpEFN7T8XA2ULyhCUIRDxUFJFrWCXVBiCA0KI1h5Y+/nxnFGjul14HEiILN7j33+8S33V+P6ZaM0CAAhvQvn6+0dOXLDTwjfU/RhZ2sD7ln/25JWpKMT/JWpdP7PX+N/n/rJxdky1PHMlv+6oze1zSUpMPZHR6nW3dpl65qGd6+5AWw1cnHBq8XWD/re3uqzCLiQMff3X72bkN72IjfayBWVINJ5ViD0oqaJR8EsqJKABAAAAYgRnPbzxy3U/HimzE7U+v/PAYcMGGOLRKOyXs83qo7th9Oxoh+Z2+FeEsuXje9/xtT2l03VzX140t1/yvytkUbZEH5QhEH1QUkWf4JdUSEADAAAAAAAAAAAAQFCgCQ4AAAAAAAAAAAAAggIJaAAAAAAAAAAAAAAICiSgAQAAAAAAAAAAACAokIAGAAAAAAAAAAAAgKBAAhoAAAAAAAAAAAAAggIJaAAAAAAAAAAAAAAICiSgAQAAAAAAAAAAACAopGIHEFKzZs2qra0VOwrC8zzDMCwbzdl/nucJIRKJROxAgkgQBEopy7IMw4gdS7BQSgVBEP0YKaVer3f+/PkdOnQQMYxQWrRo0e7duwVBCFJZQSmt//UGfMtBvS7qv5BgbDmoRRbP88HYcv3lGaRfSPC+6qD+QoL0VZN/+QsZO3bsddddF4wwAAAAAAAAIlFsJaCPHz/+/vvvi5tKEwTBZrNJpdL4+HgRwwg2m81GKdXpdGIHEkROp9Pr9Wq12ijOs3s8HpfLpVKpFAqFWCDdO/YAACAASURBVDG4XK6ysrLly5dzHCdWDKFXUlIyceLE7OxsuVyuVqsDvn2PxyMIglKpDPiWXS6Xx+PRaDQymSzgG7fb7SqVKhhXXE1NDSEkGEUWz/NOp1Or1QZ8yxzH2e12hUKhUqkCvvG6ujqWZYNx4Qe15LTZbFqtNhh3+erqapZlExISLrrmmjVrLBZLQHZaVlZGKQ3IpgKivvEgim95jYrNo46FrhLnC8Oj9vl8eXl5zS/TXC5XdXV1QEIKlDD8toMtTHp1hBiOWuxY/iAIglqtTkpKav6mzGazz+dr/nYCJRb6hJ0vNisnsXnUYXi75DguKytLKvUnmRxbCWhCSFZWlugJaKVSKZPJmvIcG7lUKpUgCMnJyWIHEkR2u93j8eh0Ov+uvYjgdrsdDodGo4mLixMlAKvVarPZOnfuvG7dOlECEJFer09PT1coFMForHK73YIgBCNx6XQ66+rqtFqtXC4P+MZtNptGowlGtUOpVFJKg1Fk8Txvt9uDkdr2+Xw2m02pVAajicLlcrEsG4wLP6glp0ql0ul0wbjLKxQKiUSSmJh40TW1Wq0gCAHZ6YQJE7KzswOyqYDgeZ5SGsW3vEbF5lHXt/jG4FEzDBM+T7Y+n+/UqVPbt29vfoPuhg0b3nzzzdTU1IAE1nyU0von6vD5tkOg/qhZlg2rPEKwCYJQn4qNwaOWSCRhkhIVBMFqtfbt2/fRRx9t/tZmz54tlUrD5+INt287NGKzchKbRx1uVTKfz1dcXLxy5cqcnBw/Ph4uhwEAcC5KaXl5uc1my8/PD0ZHXQCAMCeVSj/66COxo/hTbW2t1+tNSkqKqTxCdXU1z/MpKSliBxJSFouFYZiA9JWLFJRSi8UilUrD4e09nudNJhPP87Nnzw5USmXEiBGzZs0KyKaaj+f56urqIDWxh62gNhuHrfq+LGq1OqYq8y6Xy+VyxcfHi/gKaQO73V5SUnLo0KGioqJAbfP1119vSpN8aDgcDrfbHd19ws4Xm1WympoajuNQJROLIAglJSVut/upp57yuwkqhq5SAIgUDY9eRqMxGCM5AAAAAIQht9ttMpmUSmVABt8AgFhWWVlZWVmZnZ1tMpnEjgUAIpjP5zOZTBKJxGg0NqdyggQ0AISXcx+9YqpRFwAAAGJZfV/FpKSktLQ0sWMBgAhGKS0tLXW5XEajMRw6YgNA5HK5XCaTSavVZmRkNLNpHAloQgghIZzkh2WYlPphRkM8sxDnDeXeEjUqQgjxeUK5U1J+KpR7iycknhBSVxXKnRJfSM9jHCFxhJDa0O3RzpMSL5usTw2fkQoBAAAAgs1isVRUVGRnZwdj3loAiB0cxxUVFTEMYzAYYmpgCgAIuJqamrKysrS0tIDMloTyCADCRaWPVPqYbAXVhnn2mZZ/Pf/pynGLprVvbPAjwbr/i2Urt+wrsmvyugweN3V050Tmn5YDAABADKvvq+h0OjHvBQA0k9vtLioq0mg0mZmZGMYHAPxGKTWbzVarNS8vL1CzF+D1dgAQHyWkxMtYOTY/jmoloX054N+i7tIfPlpzyOUTGv0zX7T62WdWFWcP/8/9dw3PLPrsmefXFPP/sBwAAABiF8dxhYWFXq/XaDQi+wwAzWGz2QoLC5OSkrKyspB9BgC/CYJgMplqa2sNBkMA585FD2gAEBlHmSIPYQgxxgnSsK4p0crNrzy2dEdprZeSC0y/6z2wbt2p7NELZ1ydIyGkQ0rNiXu//ubwtTPaHm58eSd5aA8BAMBPIg8LEOJBvc4SZ0ixBod3iLLbP96xFGvOqlZdQ79PhpAUpYwQQpy2UO7X7fUVVVSq4+Ky8lrETrZIIpGkpFygHhW9ZDKZyEddWRz6ff4xmp+jjjhCv3NCZOKMfawiRCUlpM5G6kK6X3Ot0+Jw5ebmaTSakO5YVBqNRszjDe0to4FWQohSRursouyduEI4QOc5dPX/J0ZRRgghq98SZbcBGPbi3/PGaYraDZB7XYY+gyWSxt759hd6QAOAmNyUOelm4liSH0fDO/tMCGF03cbe89jzLz82pvUFGu/44sNHHendumfWl9OS3O5dU2uPHjnju8DyxntRAwAAQLSzOV2FZRVJ8ZpsfVLsZJ8BIOAESk0WW43LbUhNjKnsMwAEnFOrL+w8RGOryDtSENjsM0EPaAAQkY1nSj2MXiboZWKH0jQyXbZRR2j1ceUFnhOFKnMVTdYnnW3bY5P0SbTKXMldYLlA8uoXbd++fcWKFQ3b8Xq9dXV1hBCfz2ezBb5pXRAESqnP5wv4lnmeJ4Q4nc76+AOL4zi73R6Mp3RKKaU0GF81pZTn+SBtmRDi8Xg4jgv4xnmeZxjG4wl8r8/6X4jD4QjGeeR5vrY2WJ0ymnge3W43y6J1HwAuorKmtspmz0lNiVfFiR0LAEQwH8+bLLUSljGmJkpQAwGAZrCmGcvzu2YU7kk0nwrG9pGABgBxmH2MhWNyFYImwO1qYuK9Ho5RKhvy04xSGcd4PV7uAssbhrs2m827du1q2E67du3q83SCIAhCsPpJB2/LPM/Xxx9wwUi2NghGRj7YWw7qLyRIJ5EE8zwG76tu4sbrc/fBiwEAIh2ltLSq2uX2GDJTFbIIaYEHgLDk8vpMFptWqchI0KD6AQB+owxTnt+1JiUv78hWdW1lkPaCBDQAhJpASImHdQvUoBAU0dVOL5ErJNRW56YkjiGEEFpX56ayePmFljd88Kqrrurdu3fDP1966SWVSkUIkcvlARz1v4HH4xEEIRiTHdXV1bndbo1GIwvCQ7XdblepVAF/FYgQYrPZKKU6nS7gW+Z53ul0BmPw3Pr+4HFxcUE6jyzLKhSBHzzR6XR6vV6tVhuk86jVaoPxAFZdXc2ybEJCwkXXVCqV9Z3TAQDO5+N4k7mKZRhDZqo0CMUgAMSOaqf7TI09Q6dJVGP+UgDwHy+VF7ftx0kVLQ9skLmdwdsREtAAEFJeSkweVspQYxyVRF07PZusT2FOWaoFopMQQohQY6lhktsnSy+wvCH9rlarz000S6XS+rf4GYYJRp6ufuPB2HJ97o9l2SBtXCKRBGPL9YK05SCdxPqOz8H7hQTvJJIg/0KC1AOoiV81y7LB65MOABHN5faYzBatWpmRpENfRQDwG6XUbHdZHa68FJ1agRcpAMB/nrh40yUDFc4aw5ECVgjW+6/1oqvzIQCEN5fAFLpZFUvyFFGYfSaESHLbt1Of2be/sr4DpFC+/0B5/CXts+QXWI6+TwAAALHA5nSdLq/U6+IzkxORfQYAv9VPOWiv8xhTk5B9BoDmcCRmFHYeorWW5P7+U7CzzwQJaAAIGStHTruZNJmQKRei68GLO7lp2fuf7qwQCJF3GjYs9/Tnr63YdbL4xI7li1cXG68b1kF+weUAAAAQ7cw1tWVV1Xnp+mRtvNixAEAE83L8yQorIYwhNVEuRVcWAPCfNc1oatMvo3BP2un9JCRDCGIIDgAIOkqI2cdafTRPIaijsKbEle5et/YU32dM7zQiNYx58D7fWx8sfmC1W5XV5br77xiZJyHkgssBAAAgagmUllRaPF4OUw4CQDM53N5ia61OFZeh04gdCwBEMMpKyow9HLr0/EOblQ5ryPaLBDQABBdPSbGX5ShpqSSyqOj5zCRe89Sqa85ZEDfwwVUDG/4l0feY+EiPied97ELLAQAAIBp5fVxRRaVMKjVkpkpYvHgKAP6zOurKbY7MxHidKk7sWAAggvEyhaltP8pIjPu/l3rdodw1EtAAEEQegZi8rIKhBgVloyL7DAAAAHBRLo/XVFGVoFalJyVg0GcA8BultNzmtLnc+fpEpRwJHADwn1utM7UboKytyjqxKwSDPv8Nyi8ACBaHwBR7mCQpSZOFYkQhAAAAgHBgrXWUW2sykhMT49VixwIAEYwXqMlSwwvUmJYkk+BFCgDwnz0xs6RNn+Sy31JNh0QJAAloAAgKC8dU+JhMmaBDMQMAAACxgVJqrqm11jry0vXqOIXY4QBABHP7OJPFppTL8lLiWbxIAQD+Yyqz2lZmX5L9+89aa6lYQSAzBAABRgkp87IOnuQrBCXa6QEAACA28IJQbLZwPN8yK10mxVzDAOA/u9tTYrUnaZRpWrxIAQD+o6yktGVPV3yK8eAmhcsmYiRIQANAIPGEMXkYSokxTpCinR4AAABig5fjisqrFDKpISONxcQXANAMFkddhc2RnaTVKvEiBQD4j5Mri9oNYATecGCj1OcRNxgkoAEgYNwCKfIQFUuzMOUgAAAAxAxHnbvYbEnSatISE8SOBQAiGKWktLrW6fHl63VKuUzscAAggrk1iUVtB2iqz2QW7mGoIHY4SEADQIDYOFLqZfUyQY+aEgAAAMSM+ikHM1MSdRq8KQ8A/uN4odhaSyk1piZKMeUgADSDLSW3tGVPffERfelRsWP5AxLQABAAlT5SxbE5ChqPAQ8BAAAgNlBKyyzVdlddfkaqUiEXOxwAiGBuH1dUVaNWyLMStZhxEACagTHntrdktM49ul1jqxA7mD8hAQ0AzSJQUuJl3AJjiKMKhoodDgAAAEAo8IJgqqjiBcGYiSkHAaBZaus8JdZafbxKjykHAaAZBIm0pHUft1JrOLBJUVcrdjh/gQQ0APjPR4nJw7IMMWDKQQAAAIgZbq/PZK5SyuV5aXpMOQgAzVFZ66xy1OUkJ8TH4UUKAPCfT640XTJQ4vMY92+Q8D6xw/k7JKABwE8ugZg8rFZCMuQCHrwAAAAgRthddSWV1uSE+FSdVuxYACCC1U856PL6DKmJCrxIAQDN4NLqTW37aa2lGSd/YWg4vpuOBDQA+KOGI2VeNk0mJGPKQQAAAIgZlTW1lTW12fpkrVopdiwAEMF8PG+y1LIMY9BjykEAaJbqNOMZQ7f00/uSzhwXO5YLQjEXeu6fnr9x3KK9nNhxBItg3b103vBeLRMTUzM6XD7h+Q2n3WKH1Cxcybb3po67LvOSLorWvfOumXHXxwcswr9aIfxxJduXTp0wMrNzL0X7AXnDZ9/1ycG/HgJ1nNjw8H+mdb7ssvguQy4ZPee2jw8dcbN5cRTZZwAAAIgRlNKSSqvV7sjPSEX2GQCaw+X1nayoVsqlLVISkH0GAL9RwlS06Fye1ynvyNZwzj6T8E1A8yc+nDXy+ikv/Vhzbr9x/reld4y5/6vyc5e5fnppwvUjRt61opAPdZB+oZXrFr/6VcFv1ghLUTYRrVo/94qBM98/pL705hm3DsspX/PYyAG3rSqL1KOllh+evnzyyytOaAaNnfbA1Gs6un9546HJQ1454GrqCuGPWrY+d/mti1YUagbdOPmByUM7en5949Hbhiw82HAI3t+XD7/p/ue3WDL7jpg9flCuZ9+yx6bd8dpung3H1zoAAAAAAo7jhcIzZq+PM2amKRUYpxUA/Ger85yurNFrVZm6eIbBWIYA4CdBIjO1G2BPzDTu36C2mcUO5yLCeggOat3+3rKBHef00l6wTKb2Xwr2uJQqecn27YVjDa3CeNgkvq7q9OHd/7f8uUc/LRfSxI4mOKhtw/w73jnV9u5vtzzTN4EhhN49/NY+Y1Y+9drcG57rEdY/tsbxxcte/bJQd+WyrxdMypAQQsic6+cNv+Xl999dc9uim3XMxVcIf3zxssVrC3WDl3350qR0lhBCZg+fN/LWlz9YumbayzfrGEKc3771boEj/95PP36qi7LIw8pnT1p169h5y9/6eOqSmenh2ogFAAAAECBur6+oolKjjMtMTkS2CACaw1zrtDhcuckJGkw5CADN4FXGF7UdIPc4DQc3sVzYTTl4vnBOHrHpHduz29756FfHBbtZ0trdBXt9l4y5pU/8mR+3Hw/jPtDUvHRkTque185YtL0yUnsDXxS1fvXW5yW6EQ/f1yehvmbO6IfPX/L6izN6Kb0ix+Yf1/5th33x/a8fnXG2aUPV8YbLMlh34eFioUkrhD/XwW1HfPF9rxvdkEpWdbhhYDpbd+pwiUAIIXzVb6ccJKX7gHbKk25Ww9I8dfawy/KlPtPRogg5RgAAAAB/2ZyuwrKKpHhNVkoSss8A4DeBUpPFZqvzGPSJyD4DQHM4dOknOw3R2MrzjhZERPaZhHcCmtF0mjB9EN389scHXI2noGn1zwUH+Hb9Bw3q201j/mnbsfD90pmk6xcV7Ph5x44dX9/XM1qHzfXu+mGHU95ryOUJf1bNJS2uvGP2zJHtVSLG5T/JJdOfeWrJ5E5xfy7i7M46yuj09b2bL7pC+JO0m/7k40tuOfcQeLvTTdkEff15lCS3ytMQ6+ENv/EZcpohp0So3Lm3lJdltc4O5wIEAAAAoLkqa2rLqqpzUpP1Oq3YsQBABPNy/MkKq0CpQa9TyCLw5WAACBvWNKOpbf+MU3szCn8lNGJGRg3v/BET3/2W2/r7Nrz1yZHG5rGjVTsKDtFL+vVKVnXs01VdtaPgSPj2s5Xq2/Ts3bt3797dWmjD+1v3m1BRWGhnUvN1Jz+455puLbS6tJyuV9700CcH7RFzPfydyjjsxtHjuutZIrgd1WVFR7//4PF711RnDptwUxbbpBXCn8owbPQN47qmsERwO2rKTMe+/+ipe9dWZ159c/0hUKLp8Z+Hrs86+dYdU+cseH/BO2/OmDJlVoH8mvvvmxYpxwgAAOAn908vjh/32r6onTv6T7T2+P89eO9Mw6Crlf1Gtp72zLPbKzxixxQCrpPfPHnrsHYtc5XJ6Skdrhg9f9Uh5x8VV0GgJnNVtd1pyEyNV2HKQQC/0Kov7xmae+2iX6O/GPWV/LB46oj+mbm5iow2eZdNvGvprw3zuru8vsLKak2cIi85QcLiGQr89A/3rJgQ/eUJ99P6L8ZtLj//+GpLDz/41lLDPS8q5ywwLN72VHFy5uEfdOZTIsTYDOHe8sYk9J4y9dK5i5Z82u+lyW3/Gi2t+LHgGNt+Ru8khjAd+3RVFfy87dC0zt0Uf67y2GOPffPNNw3/1Gq1VVVV5786l5KcHMRjiBnUbrNTals7d+i73pbXXH/H1fIzP3/9xcu3btx5Zss3d3eOu/gWwhd/asG4Gx46wBHCJvac/e1zV2ey/3KF8MefXjDxxocOcoSwiT1mfvvMkEyW8ISY3Ayfeul/x3T98ZUdH765/0NCCGHiO0+aPcQQvG7tVVVVf1vi9Xo5LmrvMwAAEJ5o5beLF39dMGJ61I855Tj44dA7P9hNcq8ZOnKs0vLT5q2PzD1w6NnFy4fqI65G03S+4++NHjLve3t635G3jMnhThZ89cWC6Zt3lG5ZN+cSCW8yV0lY1piVhmwRgL+Eki8eufPjY5UtBoXvq8qBQS2bHrr85o9MSd1GT5zVSlG155vVb9wz6sey1dsf7uZxus/U2DN0mkQ1mrLAf/9wz+qsuPjHI1/0lyfUfnzx5t8LunT/W7XTcWrb0Fe37SbJV/fsfVV63J6CgkVzJ1fcOml59wjr3RruCWhCmMT+U6ds/+8bS1b1e3HcuX8QSrdvO05ajEmvLTbZCUnMN8gLdhbsv61brz8znYmJiVlZWQ3/dDqdEokEY7cFCeV4jgq1Ferpn//0+rA0CSFEeGTSfwZe987zj3w2Ye0taRH8vbPpox56pUWJ+eT+Te9+9vp10yTfLp3eS/1vVgh/bNqo+19sUWo+eeCHd1e9ed3tkjVv35oqZZXEXvzG9GHvlHea9PRX0wZ2SHAf/+mLB558d8T4mpWfPTEqNSglnkTy9/lEGYbBlQsAAKHC11UVHf7lh+UvPBa9c0efQyh67fmPd0u6v/Le03OMCkKIcPuw++64f+HCj6cNmHtltCZMqO2rZ57ZUJM7dcWGd4alsoQQYd6m+64d9tZLD64Y9fIVkgS1MiNJh+oHgN/4opV3PLK+gjKRlSLxB3962f9WFiYOW7b5nUmZEkIImXfTvMEjX35r8QeTXh0krctLSVArMOgzNMOF71mPfD5u7cRITrY0TVSXJ7TOUXP49Onl67d8Wkv/Xu0Uql5b+eNuNv/Fh6aOGHpFnLMmo0/mA6+sWPjFT9M6XH1lRLU9RMK5Y1IG3TqpY+VXb35ZeM4IG0Lx9u2FnO/Yyofvmj179uzZ9y3b76a1u7ftdZ3z0blz5351DpZlExsT8kOKToxSqWQYef9Zj16d9kf6kE0aMu+OPjJ7wYafXP/84TDHqNv0HTL+pgmPPPPu5kd6enYtefSrCuFfrRD+GHWbPleMHzP+kSeXbH6wp3v3Ow+srtJKaFbNt09/8Lv88nlfPjr80uwETXxa16vuXPXCqMyybx796FiQ+iSff5HKZLLzs9IAAADBQM0fjsy/pOeIWYt+rIqwu7lfeNOPX/7OZ18zYYbxj+cYNqHzw1P7aCoKVuyJ3nE4uEMFO22SjpPuuepsczqbPHju1F5Sx/bvtyTo4jOTE5F9BvCf7+Ti/z5bkDdq3CUxUId3/rrtgC9+4I2jMxumpu8yYnAm6/rt4Ik6Y2oSss/QXBe4Z/WVObZt+TV6b9VnRXV5Qu37Rz7wRs/F3y464Tq/2smbf/+yRMjsP/zKa6/VWkpyjv0kVeY8fFUrTc2xFccjrC94JCSgCWFSr5w+oW3ZF0vWFp3Nd/GFBduKZN1mL/tq7VkrH75c69xTsMcRS4PghBNJWlamlFFl56Sc87Ni03OzZMRjs11gIsmw5i36efkX67aVnlsISPIuG9CB9R77zcQ3YYXw5zXtXP7lt9vKzj0EVtW3X0vWU1R4OllGuZO/HfJIOvTprj/nESy+e69ecuHk0eO1EXhaAQAA/hmTNHzRD9t+3r5tx5p7onbu6HPw5opSgc3LTj/nWJn4vLwcxv7rkdKIqM/4w+ckiS079u9qPPswSyk1exiGIYJEqdPGixocQKTz7n/j3kcPtHt84YwuEdVBz0/SjtNffmXJ9G4N72J7Oe/vlU7KJrQyJMmlUZgyg1A7755FCGGUKiVDOI832hvLo7w8YdStF9075ef7p+yY1afneaUFX2MrFiRpHYfkHd+Zdno/IZQQEp+WnEPqfi2qjqxKWvgPwVGPTb9q+vjt97z3a52kHSGE8Ce2/1im6jG+T+KfSTFV18F9k7Zu3faLvf8gLboriEDTuUdbybfHfysWhrU8m4Pmi0+e9jIJWVkReUpOf3P3PV+1nd91yznT7VGHw06IMk7BEEIvtkIEOL3+7vu+bvtwly1TMllCKCGlXqa2xumjjFoVxxBCVGoNI1RX2wSS8ecx2m3VPJGr1BFykJGHUsrzPCFEEASfL/ANmzzPU0qDsWVBEAghHMcFo9cYpZTjuPpdBEOQvpAgfdX1o6IH6RcSvLAbfiE0CPM118ccpB6LTfxC6i+uQO3R7W5kDua4uIieVCFCSFPa9EghhNAz+yJsdD2/sJr4BEYoq7BwJL2hk5630mymvHCmiieG6MydqIa++tPQhn8JlBabzaa16w5ysi6Xdg/xZdboxR6owkQQBI7jUJ5AKLl+fW3aKyd6P7Z2TmuyQOxgQkHVetjNrQkhhAhue01x6ekt3yx5+ZvqzBHPjs0NaQna6JXu8/kCVX+mlHo8nvP3gsIk6P56zyKEECKUrF27wyfv0qtTdH/70V+esKo2LVSEEGqr+FvejLKSM60NanZf9eH1qpYJDcu9NbVmSgWLnSepwStiGi1P6p8T/dtgpCSgCZFkX3vHTdvnfXiCEEJ8xwq2VyT0md4j/tyzI28/eGDGhm8Ldtkuu1KHvFjoSdqMvqnr04+8+diq0ctuypURQriyr557e7eQPuX63pHYUiXr1Oey+NVrV366a9zdl9bPuMdbvvtg3TGqv61/aykh9GIrhD9Zp96Xxa9Z+9nnu26a00PJFHkIw1t+//yb30jKbX1bSgkh7foPTf9wyRfLVo19elymlBBChJot73y6jYu/+vKuwZuHMMY1ZBUFQWi03G+m+ux2MDKA9VlRn89Xv4vAEgTB4/EEKbV9oWRf87ccpJNYf/oulFNoJp7nGYYJRq6//ofh9XqDdB49nmC9g9jEXwjHcWyA5iujlDocjvOX4xkPAk7asvvg1E/eXLdyxfjHp2RICCHEdfzVDwoqBaKq88TCy05ejisqLzNvXXD3i9udeZMfmdQixO0OjV7sgbpN8zzv8/lQnkDoOHbOn7PE1O/JVZPzpeSU2NGEFn/y2esGPVU/Nf2l9327cESIp6Zv9Ep3u92BqpkLguB0OqXSvz/pojAJOc/pbx6/6aH/E+WeFVIxXJ7wMoWpbX/q0w3VrX5r+8YVA0ZNSWIJIcRT/urG3yopVXl9Qa2kNVqeCILg90NiuKbIJC1veX3VLX9bljf6xc9G1/93+u3vfnn7eZ+Stpny5pdTgh8dXICk7fQX/vvptc9P7nvsizFDW0tObV61+pfq3JuXPXGVVuzY/MEkXvnY7G4bn3vvmuHHxw3tlEErD27fsOagLXvECw/3i2vKCuGP0Q1+bGbXjS8uu3rkyWsu75hFKot+3rjmUG32dc883DeOEELiuj/86Ijv//PVxOGFK4f17ZTg/v3nTV/usyQOeuiF4clo6AkSiURSX42TSqXx8YF/C9jtdguCoFIFvgXB6XTW1dUplUq5PPBD3dlsNrVaHYzRwK1WKyEkGF81z/N2uz0YW/b5fF6vVy6Xq9WBn/DU5XKxLBuMZwm73e7xeFQq1fmPLs1XXV2t0WiCkdr2eDwsyzblPCoUikAl7hmG0Wg0AdkUwEXIuzzwn8u+emTL7ZNmfzekeyuZ5ecftu4mSWlsnSsG3hx3uj2FB7/5bMHzr6477m0xcslnz10d8p4sjV7sgSrNJBKJTCZDeQIhQm3fPznvNevl764cmy8hJLLeD28eSkmZLb7P3JeX1dqLD3z/7sf/u24c++2nc0I5NX2jV3pcXFyg6s8sy6rVapQn4vKWbl308P1Pr/5NrHtW6MRweeJW64rav9MutwAAIABJREFUDlDZq7JOVD90Q9uvlx65/fkPvuveopXE8fP+Y7uJOo31uCTBbXpo9EpnWdbv3jbhmoCGCBXf56lvvs164sk313684FuaaOw19aUHH585ICNSm+TkHaa/tT19yZPLvl/9wY4aTpFu7DL9idsfmdjj7BFddIXwJ+9w2+L1qe8+/sHGTZ/8XMsp0g2dp8+f+siE7mcPgc0Y8tiPH3d45s0v1nyz4ts6qT6vw6T7n3p0Sp88lB8AAEHDMAz6E0GoMNlXP7RNk//Ie+vXf/np13H6bpffuXmc6z+TlhSpldH7XEsIIVZb6aYlDzy56Jsj3qwr7np7wQNjOsSLcMSNXuyBSkCzLCuVSlGeQEjQms3P3fFx3cg3np6QFTGPQwHBC9RkqeEF+ZUjbpRJJIRMu7nd2M73L3z085u+mxK6R8NGr3SZTBao17MYhlEoFChPRENrdr/3wG3zPzso6j0rVGK3PKlNyTG37KUvPqIvPUoIye45YptS/8h3B9Zv3/m1PL5blys3D/L+54X/K4qTB/X0N3qlsyzrd/0ECaRQYzJmbKqbIXYUQSTRXzpr8bezFosdR6Awqg7X3/3Z9Xf7v0LYM3PqhKFzV133H80F28XZ1G43LnrnxkWhDAsAAABCR9qi/6Tl/Sc1/Nu7e6GJl+Tnpkfr0wKltLzy6Gf3TnzwyxL9lfeuefm/IwxKsYMCiHSC+ciRMl/Fp7f3+PQv7ysvuTRzicQw48ftD/WOxjKl9viWtzcX5fcbMbJ9IvtHakaSN3hwB8lPx46e4knk9E2CcMaXrLpr1C0fFcXMPStGyxNBnVtq7GU4/nO8pfTsMkmLDv2Xd+jfsI73t/Umns1P1UXWFxBZ0QJAIAmElHhYt0ANCkGBahEAAEBsEsxbvtl1IqHjzQPzzo7NxB3cua+cybqlW2pUVhB4QTBVVPz+7l2PrjG3n/PZN08Ois7jBAg1Nqnn2IfuHvjni/K0ZsfKj39wd5k8uV9Ocs+o7MVod3tO7/v8+Ye+uuSZwSM7JDYsp/ZaO2WUqih/jwRChTv6+m3Tlpe1n/NpzNyzYq48oSzrYYigyjQc3BTvsp1dWrvl55MnNDk3d0w5W0kTDh4rKmcSb2kVYVNlIwENEKO8lBS5GRlLjXFUgmoRAABADDuybvFdRztxnzw/I4slhPhKvn98dbGi851T2kThGNAen89UYVEIu75cvs/T7eEPH4+RJ3mAEGBSLp3w+KXnLOBP/W/rii01Pe+4796o7KtocdRV2Bx5/QZdrl299qMPd93y8Nmp6Su/e3f1MZp628C20XjcEHLu7a++vjvG7lmxVZ745Mqitm0E8q3Uskfhyjr3T0d+3nBXcS730LgZKQwhxFd54PHtFoXxyinZEfZTiLqTBgBN4BIYk4fRSkiGXEDyGQAAIKaxqROnj3jjzlVzp83dcXXnNHvhhi07D5HuCx8e0SrCHm0uzlHnLjZbkrSalLJjO82CPH7H87Pv/OtRMtp+s1+e1A6PSQDwDyglpdW1To8vX69Tyq9/7O6PNz6++JrBR8cN65ZBzQe3fr1mny171OKHL4v6cRIgFPiTO3/GPSt6ueKTTW0HxJ98T0kJEXx/+RujnXht9zde2zn3pY929MxNqzNv2H/yEMlfeHP3iKuk4VcKEHOsHCn3MhlyIREFAAAAABCi7T5j89tZj77x1bdffl4j1XftM3nNnWOvy5KJHVeAWWodFdU1mcmJOo3as7PIxFHHsY0fHvvbWmyqdNT/JrUTJUIAiAicIBRV1TCEMaYmSiUsIaTD7I+3Zy588q2vV79bUONTprfuMf2F2Y9M7YPhnyEguGLcs6KWTZ9XauyRVnQw6VRRoytoW1+xeW7io1/v+fbHXTWS+K7tBqwZcel1KZH3jhryTwAxhBJi9rFWH81TCOrIK68AAABCism4fZP99ouvFw3Y1M7Xv/XW9WKHESyU0jJLtaPOnZ+eqlTICSGKq9+w2N8QOy6AaCfJn7e+cJ7YUQSW28cVVdVo4uSZOi3T8DIpo+4w+uHPRj8sZmQQvXDPIiQqyxPGnNvektE69+h2ja2CJHTbtLhbo6ulGru/Nbd7qKMLNCSgAWIFT0mxl+UoaakkMoy7AQAAALGBFwRTRRUlxJiZJpWgBR4A/GdzuUur7fp4lV6rFjsWAIhggkRa0rqPW6k1HNioqLOLHU4oIAENEBM8AjF5WQVDDQrKIvsMAAAAscHt9RVVVKoUiqyUJBZ1IABohspaZ5WjLic5IT5OLnYsABDBvHGaonYDZB6Xcf8GCe+7+AeiAhLQANHPITDFHiZJStJkVOxYAAAAAEKk1lVXYrak6LSpOq3YsQBABBMoLbHWun2cITVRIcWLFADgP5dWb2rbX2styTj5C0NjKEWDBDRAlLNwTIWPyZQJOlzuAAAAEDMqa2ora2qz9clatVLsWAAggvl43mSplbCMMTVRwmJWQQDwX3W68UyLrhmFexLNp8SOJdSQkQKIWpSQMi/r4Em+QlCipgQAAACxgVJaWlXt8niMWekKGZ53AMB/Lq/PZLFplYqMBA3DYBgfAPATJYy5RSdrqiHvSIG61ix2OCJAhQwgOnGUFHtZSokxTpCipgQAAACxgeOFoopKhhBDRiqmHASA5qhxucuq7WkJ6mSNSuxYACCC8VJ5cdt+nFRh3L9B7nGKHY44kIAGiEJugSnyELWEZMoFTLcDAAAAMaJ+ykGNMi4zORF9FQHAb5RSs91ldbjyUnRqhUzscAAggnmV8UXtBsjdDsOh/2O5WJly8HxIQANEGxtHSr2MXiboMeUgAAAAxAyb01VaadXrtHpMOQgAzSBQWmyx+XjBmJokx5SDANAMDl16cZu+SRUn04oOkFiacvB8SEADRJVKH6ni2BwFjUdNCQAAAGKGuabWYrPnpqVolHFixwIAEczL8UVVNXKpNF+vw5SDANAc1jRjeX7XzJO/6CpPix2L+JCABogSAiUlXsYtMIY4qmBiumENAAAAYodAaUmlxe3xGTJTFTK8KQ8A/nN6vMXW2gRlXIZOI3YsABDBKMOcye9Wm5Sdf2iz0mEVO5ywgAQ0QDTwUWLysBKGGOMECQY8BAAAgNjg43iTuUrCssasNPRVBIDmsDrqym2OzMR4nQovUgCA/3iZwtSmHy+RGQ9ulHlcYocTLpCABoh4LoGYPKxWQjLkApLPAAAAECNcHo+pwqJVKzOSdJhyEAD8Rikttzltde68lAS1Qi52OAAQwdyqBNMlA5V2S96RrazAix1OGEECGiCy1XCkzMumyYRkvHIKAAAAMaPa7jxjqc5ITkyMV4sdCwBEMF6gxVYbxwvG1CSZBC9SAID/7IkZJW36Jpf9lmo6TAhGRv0LJKABIhWlxMyxVh/Ji6Nq1JQAAAAgNlBKzTW11lpHXrpeHacQOxwAiGAeH2ey1iqkEkNqIosXKQCgGSyZrStyOmYf36m1lIgdSzhCAhogIgmEFHsZHyXGOEGO7DMAAADEBoHSYrPFx3HGzDS5DM8yAOA/h8dbbKlN0ijTtHiRAgD8R1lJqbGHU5eef2iz0lktdjhhCpU2gMjjpaTIw8oZYoijSD4DAABAjPByXFF5lVwmNWSmoa8iADSHxVFXgSkHAaDZOLmyqG1/hgrGfd9LfW6xwwlfSEADRBgHzxR7mSQpSZMJYscSewTr/i+Wrdyyr8iuyesyeNzU0Z0T//L069v5ysRnt9T9dawnNnPUi69P1m+Yf9ub+30NSyVZo19YPLm1JDSBAwAARDpHnbvYbNFp1BnJOrFjAYAIRikpq7E73N58vU4px0Q6AOA/tzqxqF1/TU1F5slfGIoUzT9BAhogklg5Uu5lMuVUJ8V49qHHF61+9plV/GVT/zMuubJg+dJnnpe8/OzInHNyyNJWw+954FKu4eRQ+/5V7+9t2TGDFcrKzUzr4XePav/HvNqMMisT/dcBAACaxFrrKLfWZKYk6TQqsWMBgAjGC9RksVFKjWmJUha1cQDwny05p7RVL33xEX3pUbFjiQBIQBNCCPHWiR1B8P22W+wIgq/zILEjCCIqkZy5//7am8fnayRKCd45FYP3wLp1p7JHL5xxdY6EkA4pNSfu/fqbw9fO6CRvWIVJatWrT6uz/6KOX9/4oG7QzCnd4hmPuaJa2+rSAX07os8zAABA01FKy602m9OVn5GqVMgv/gEAgAtw+ziTxaaUSbOSEjCMDwA0A1OZ1bYq55Kc33fEW8vEDiYyoMUPIALwOt3pd95xdeli1EiRfRYLX3z4qCO9W/fM+gyyJLd719Tao0fOXPA1G/fhle/tbTdlQhc1Q4TKCjNNzUgV6qrNVXYf+q8DAAA0AS8Ip8srnW63MTMN2WcAaA6723OqskanistJRvYZAPwnsFJT237VaQbDgY3IPjcdekADhDt3q1amxYuVBw7kzZzJHt8ndjixS6gyV9FkfdLZdjs2SZ9Eq8yVAslrrCmPL1q7dGvy6Jd7axlCiFB5ppKr3PzctKWnbDyRxrfod/NdM4e1VJ2t+u7atWv16tUNH66pqXG73YQQjuPsdnvAj4Xn+Yb/DSyO4wghdXV1Ho8n4Bvned7pdDJBeGCglFJKg/FVU0oFQQjSlgkhXq9XEAI/1lj9b8Pn8110zX+rfpsulysY51EQBIfDEfDNNmy8KefR4/GweJ8XIEDcXp/JXKWUy/PS9CyLbBEA+K+y1llpd2UnabVKhdixAEAE88mVpnYDJZzHeGCjhPOKHU4kQQIaIKzZBw4seeGF5I8+Sn3zTULRb1ZMvNfDMUql8uwDMKNUxjFej7fRs0JtP37ytWPgA1ekMoQQQu1V1T6lxjh8zhMDskjF/nVLXnv32Xf1r97VS1O/uZKSkk2bNjV8vF27dvWZXJ7ng5Emrle/i2AIRuKyntcbxHt8MJLmwd5yhP5Cgnceg/dVU0qbsnGO46RSVK4AAsDuqiuptCZpNWmJCWLHAgARjFJSWl3r8vqMaUkKKQbDAwD/ueJTTO36a62lGSf3YMrBfwvPSADhimEqp06tvP327Icf1m7eLHY0QCRyhYTa6tyUxNUnlevq3FQW3+jrwELJxq9+1V/5cruzMw4mDp2/cujZv+b0Gj971L5Zn27df3uvfkpCCCFXXXVV7969Gz7/0ksvqVQqQohcLler1QE/Fo/HIwiCUqkM+Jbr6urcbrdGo5HJAj+luN1uV6lUEkngnxxsNhulVKfTBXzL9b22tVptwLdc3zs+Li4uSOeRZVmFIvBdhJxOp9fr1Wq1QTqPWq02GH2rq6urWZZNSLh4FkypVFI0FgI0m6XWUWGtyU5N1qoCX8QBQOzgBKGoqoYhjEGfKJXgFSUA8F9NSl5Zy55pRfuTzxwXO5aIhAQ0QDiiCkXp44+7unQxTJoUd+KE2OEAIYSwyfoU5pSlWiA6CSGECDWWGia5fXIjNVn+5A8/FBuumpd9oVoum5KVqfBV292U1PeoVqvV5yaapVJp/Vv8DMMEI09Xv/GAb/nrr79etmzZgQMHHA5Hdnb2kCFDZs6cmZOTE6jt138bwfhC6gVpy0E6ifUjbwTvF8KybDC2XJ8dDt7GJRJJMBLQpMlfNcuywRgUBSB2UEpLq6xOtwdTDgJAM7l9XFFVjSZOnqnTYsxnAPAbJYy5RSdrqiHv2DZ1TYXY4UQqtAEChB0uNbVw2TJvZqZhwgRkn8OHJLd9O/WZffsr6zs3CuX7D5THX9I+6/yMFHdsS0FFqwF90xoquq4di2feuXC77Wy/SL70ZJE3MScnPlqqwhaLZciQISNGjFi9evWJEyfKy8t/+eWX5557rk2bNm+99ZbY0QEAQGTgGLbwjNnr4zHlIAA0k83lKTRXJ6mVWYnIPgOA/wRKTW371yZnGw5uQva5OdADGiC8uDp1Mi1cqN26NePZZ5mgDaQL/pB3GjYs94HPX1uROW1gkvmH91YXG0fd1UFOCHdy0/KtlnbX3tg7jSWE8EV799Vk9G2X+GdVV9nx0g6+5975XxJ306VZEsvh7z9eU9l+8rXtoqMIdjqdV1555b59jcyQWVdXN2PGDI7jZs2aFfrAAKKTL1jjXIc1r1vsCMSw6h2xIwgpty61aMAYdYIsKyUxSK8yABBCSI1Z7AjEsDqmOgQw5tz2ltwOuRq5RsoTV63Y8YSQLlWc/cbmZXV8r9gRiEEd+KEFw5mXsEWCUpaoNwh2SafeF/8AXFh0ZD8AooTtmmtKH3tM//bb+vffFzsWOJ/UMObB+3xvfbD4gdVuVVaX6+6/Y2SehBDCle5et/YU32dM7zRCCK08eKBc2bpd9jldoxlNj+lP3af74LPlz62tlSRlt+5x+1MTr8iMkndQ5s+f32j2ucHdd9991VVXtWzZMmQhAQBAZKnNaVvS61r9kR/1HTqIHQsARDBBIi1p3cet1Bq0CoUETVkA4D8nlRQTZQLjSxdqUZo0HxLQAOGBYcwzZ1puvjl3zhzNzp1iRwMXINH3mPhIj4l/Wxo38MFVAxv+xaTf8OIXN5z3UVl67wn3954Q5ABDz263v/nmm/+8jtfrXbBgweuvvx6akAAAIJIwTGXb3lWX9M35eW186XFywy1iBwQAkconV5ouGSjxeYz7N0iyoq/eDQChY6WycqrIYNyJDCd2LFECCWgA8QkqVcnzz3sMBsOkSYpTp8QOB+Bf2LJlS11d3UVXW79+fQiCAQCAyEIl0tJe17qSMwybPlTYqsQOBwAimEurN7Xtp7WWZpz8haH04h8AAGgMJaScKmqoLI+pUzO82OFEDySgAUTmzc4ueu01WXm5Yfx4id0udjgA/05JSUlTVisuLqaUYkxPAABo4FNqTAPGsDxv2Pih1OMSOxwAiGDVacYzhm7pp/clnTkudiwAEMF4whRTJUdJS9YlI4LY4UQVJKABxOTs1q14wYKE775Lf/FFRkDpBpEnLi6uiash+wwAAA1cyZmmAaO1pScy9nyPKhAA+I0SxtyikzXVkHdkq9oWk1PhAUCAeAlbRJUKyhtYd5TM1xROkIAGEI11zJjyefMynn028auvxI4FwE8dmjZbVBNXAwCAWGDLa1/a4+q0g1uTf/9F7FgAIIIJEllx6z6+OLVx/wa5xyl2OAAQwRxEWizEJTG+NNYjdizRCQloABFQiaR83ryaYcPy7rxTvWeP2OEA+K9Hjx6tWrU6fvwibzuOHz8+NPEAAEBYYxhz+/6WVt1zt6/SVBSJHQ0ARDCvMr6o7QC5x2k4uInlfGKHAwARrH7KwUzGrcOUg0GDBDRAqPEJCcUvv8zpdC3HjZOVlYkdDkCzMAzzwgsvjBo16h/WadOmzfTp00MWEgAAhCdBKi/pM8KjTTZs+lBht4odDgBEMIcuvbhNX13l6YxTewmmHAQAf1HClFGFg0jz2TolwZSDQYRRTQBCypOXV7h8ucRmM0yciOwzRIeRI0c+8cQTF/prRkbGmjVrFApFKEMCAIBw49XoTg65RWBZw4ZlyD4DQHNY04ymtv0zTu3NKPwV2WcA8BtPmNNU6SGskXEi+xxsSEADhI6jf//CTz7Rbt6cM28e63aLHU7s8f7fgwMGP779/Bf0aNUXd/a/9sU9eNvGX/Pnz1+5cmVOTs7flo8cOXL37t1t27YVJSoAAAgTLn1O4ZDJmoqivILPJT4MrQgAfqIMc8bQ3ZzbIf/wDzrzKbHDAYAI5ibsSaqWEqEFcUkJmrKCDkNwAISIZeLEilmzsufP127cKHYssYavMf1eaheI98DeX/bEHTh8OFH2l79Tz28/FOz60V7Kk+4oFP01duzYUaNGrV+/fs+ePT6fLzc3d8iQIQaDQey4AABAZNXGLme6XpGxZ2PiqQNixwIAEYyXKUxt+vJSufHAJhmmHASAZrBTaQlRJhNvKoN28RBBrgUg6KhcXjp/vvPSS/NvvVV55IjY4cQeWvPljK7Tvjt7X5nV9atGVmKU/ae1Q4nYPDKZbPDgwX369NFqtXK5XOxwAABAZJRhzJ0GWQ2d8go+V5tNYocDABHMrUowXTJQ6bDmHSlgBbwpDwD+q6TySirPZuq0mHIwhJBuAQguTq8vWriQEQTj2LFSi0XscGISo+k/d8m7o3nC7Vnynw/kM16Z1ulvRR/DxqV2u+qaVhJxAgQAAIg+vDyuuN9ITqEyblgmd9rEDgcAIphdl1HStm9S+Ym00wcI3pQHAH9RwpRShYtKDIwrjhHEDie2IAENEETutm2LXn1VvXdv1vz5jAdvdohF0WrolFaEEF/Lki9LFOOm3dpHdtHPAAAAgN+88UlFA8bIHdWG/1vOYtBnAGgGS2bripyO2cd3ai0lYscCABGMI2yREMcQYmAx6LMIkIAGCBbb0KGlTz6pf/tt/fvvix0LEEIIkV322PrLxA4iqhw9evSTTz7Zu3evw+HIzMy84oorhg8fzjCM2HEBAICYHOn5xX1vSDq5L+3AFkLxgAcAfqKspNTYw6lLzz+8WemoFjscAIhgbiIpEpQa4stkPXheFQUS0ABBwDCVU6dW3X57zgMPxG/ZInY08FecvfT330vt3N8fiNnkVj1aJuFe1DRer/fuu+9esmQJz/85Bt+KFSsyMjIWLVp0/fXXixgbAACIyGrsUt71isxfvtedPiR2LAAQwTiporhdf8owxn3fS31uscMBgAhmo9JSGqdnvHrGK3YssQsJaIAAE1SqkmeecbdubZgwQVFYKHY48BfuQ29PumHOFyfdjXTHirvx85rPxihCH1Tk4Xl+9OjR69atO/9PZ86cmTBhwieffDJ69OjQBwYAACKirKSsx9X2jPz8zSuU1jNihwMAEcyt1hW1HaB2VGUe34UpBwGgOcxUYaGyXKZOw6AwEVOkJKCp12nnFFpVpMTbCOo4uvq5Z99et+tIYU1cTpuuV06eN39qzxRW7Liaw10wfvBjK51/TeXJL1266bkpCX/0I3WZtr+05PNPdp44Xcup9YbLrhrzxO2DO6jCupepi5CXCPmEkNOEqAm5jJAnCOnQ2Jo/EfIqIcvPuZB8aWmmV1+V2GzG8eMltbWEkC8JmUPIGkK6hSr+f48r2fbBo69/+f2BEgunSDd2HTHxzsfHd0pmm75ChBBKPrj77i+KUwbfNWdszwzV3+KX5PXC0NBN88orrzSafa7n8/mmTp3av3//tLS0UEYFAAAi4hVKU79RvExu3PihzFUrdjgAEMFqU3JKWvbSFx/Rlx4VOxYAiGACYUponJuyBtalIJhyUGSRkdDlitY8dv/qzPuW3tXtbMDUvuXFF60TH7/8wOO3vbnf17CqJGv0C4snt5aIE+iFeQ+/NvzKhws449DRE69Nrjv2f1+8OfuaLSfWbH+uv1bs2PzGm8tOe5i09n0vzzmn16i0Vb7sj/yy7/RXo6cs+t6Z3HfIdWMyuJO7t36x9JnNe81b3h7fWS5OzBflI2Q0Id8T0peQMYScJOQLQjYTsoWQzn9dkxKymJAC8mcx5urSxbRwofaHHzKeeYbhOEJICSF3ElJJiI+ELWr54enLb/3MlNRp9NhpreTWPRvWvfHQ5B/PfLD93k6qJq0QOXz7ftrtyZn63ppXh2rEjiVyeb3e559//p/Xsdvtr7zyygsvvBCakAAAQFzuBL1p4I1KS1ne1k9ZnhM7HACIXExlVtuqnEtyjv8cbykVOxgAiGA+wpioSkIFI+uSYMrBMBAJCWjviVWvrjhSp8g8Zxl1/LrL3vnmDGLeYGZaD797VPs/8pmMMiszDLtlOr596aUCe5t7/2/rC73VhBDy+KwF1/S/Z8lzH8/+emZWGAbcJHxp2WlBecVt8z8e3NiwBdTx1ZvvbahNn7rg9XcuS2QJIcItm16cM2zl8ke+u2rt9WE61u5XhGwgZCoh7xBSf2I2ETKMkEcIWUtIfcx1hBwmZDkhnxLS0MOzevToMw88kP7KK0mffFK/hCfkDkIqzm4nTPHFy179slB35bKvF0zKkBBCyJzr5w2/5eX3311z26KbdczFV4ggHpvNzRo7XhJhefMws23bNqvVetHV1q5diwQ0AEAssGcYS/pen/zb7tTD2zHlIAD4jbKS0pa9XPHJhgObFC6b2OEAQARzEYlJUGoZLoN1R1TOIpqFdWaMEEKI++gnr62XtMz5S59m6ti7q7ZL70zWZ66o1ra6dEDfs/p0zdOE36+LP/PbiVqi7z+0q/qPJTLD1UNbS70njxZG7hg0tLr0TDWT3irrAs0Y/MmC/Q5Jm2H3DEj843fGJgyeMqKv1LVt51FP6OL8dwoIkRByzznXxmBC+hKyjZD6mCkhIwnpSciis32fKctW/Pe/5XPn5s2a1ZB9Jmf7R48L8QH8W6792w774vtfPzrj7DWm6njDZRmsu/BwsdCkFSKIsmWbXHpkx24bno6bobBpI5sXFhZSpCEAAKIbw1S2u7S47/VZP69LPbQN2WcA8JtPrizseIVPoTLs34jsMwA0RzWVnRZUqaw3k0H2OYyEeQKaOvd/uHhr+i0zr0hl/7J4366aTr2yWKGywkxTM1KFumpzld0XtpVeSVorYzyx7Pnp97MTbgrlO3ee5uUtWueF3WghTSacLinnpenGhDNbN373+oovl24+XFR3zjng6og2p2P3NsZzzh0Tp1AyhPNx4Zy57EiI8Zx/MoQoCeHOppsZQhYR8jMhOwjpSQiRKYtffdU+YIBx3Dj1rl0Nn9pPyKOEPE5Il5DG/u9JLpn+zFNLJneK+3MRZ3fWUUanr+/dfNEVIois1/1L7s1bP3vMQ6sOWrxhW2CEOYmkSaUWy4b5/QUAAJqFSqQlva61tu6Rv/ljbenvYocDABHMFZ98svNVSmd1i0M/SLmw7aoEAOGOUlJBFeVUkce6koj34h+AEArrITho7S/vv74z/9aXBqX8uv3cP7j27aruNCabJULlmUqucvNz05aesvHht8B0AAAgAElEQVREGt+i3813zRzWsmGKO6vVWldXd+5HeZ5nmL9nzYKfA9aOeGLBLb/OfPraq09MHt4l0fXbxo8/2h53zfP/m5YbuTka7+niSp46Hhg75UwNRwkhhJGndH3guUcf75XIEELiLn31s0v/+hGh5P8KdnDSLp1axTWywbDw6nlLSgjZQUgXQhpibkMIIYQSomEId8WDhGUNt9zCOhwNH3ERMo2Q3oTMIWRBCIJuDpVx2I31+XbB7bBZLeUHt3xw75rqzGEP3VQ/OMxFVwgCnv/7mwGU0gB0p/X+8MoTP3jVtT88f2OnF6SapGSN7JzSIG74O8fevq6x4WTgXK1atWriaucXtgAAEB04ZXxR/1GMIBi/Xyp1O8UOBwAimE2fV2rskVZ0MPkMmrIAwH8CYYppnI9hjYxTjkGfw08YJ6Bp9U9vLznY4Y7/9U1kHH/5i2vfLmvHUTksobaqap9SYxw+54kBWaRi/7olr7377P+zd99xTZxvAMDfuywCSSBA2BAgLoYo4kBFraJUrVLFUfeqrVtbR/WnOIu7VkFbV90T97YqKqIVR23duFAIO0AgEELW3f3+wFpEFBoSQsLz/cOPXO4uT3Ijd8+97/P+JoiZ2vrtAGPR0dFnz559tyCPxysoKPgwJ2LPNXhJWLp752+HB59beGX3qtu7EUII47aaMjm8sQnXoiUlyZlaSkt4RSy6NLKVJ8q7d+XA1DXnomatEh5cOsb5w9SkJiV+88A1d0tcekV+WcnLdVMKQgMRKkEo8oP+AvKW3qUPUvDMBx6Tj+Pke026FyAkRuhInT7APkC8WTuoz9yHWoRwfqvJ55Z3r1hNvcoZ9KegoKDCFI1G82FW+j/DLGwcnTz5Tp4tKnuV2cjWVPZLo2rXrp2zs3NWVtanZ+vXr1/txAMAAKCWKfmOqSH9OdmvXe5dxEjTrSYHADA6TOLhl+/cyCPpBkeWY+xgAAAmTI3wVJLNxEhvTIFD9rlOqrv5sfxrm39Lbjl1dStrrMK+o3hwJ8+/jzuOEOKHLTgY9s9099aDJ0fcnxR77cHU1u3LJolEotatW79b8sWLFwwGwwiN8qjiG4t6d1+TFjBh68mpPfxtFC+v7pgzY3V4t/yDVzdFOJlm0gvj9/k+KpAl7NTM2RIhhFw7REw/jeX5L74Tc/LNyPGi8u3K1Tl/Rf8cE3UxVe3WeVP0pO48E2gXqUYoGqEohNQIbUKo+/uvSvv3zxotYvVehT88WmHBCwitR+g3hLxqLVa9wJ0i5v7smS5JfhD326Ffeo2hndvxbWur/zKD/jAYjApTMAzTQ0kHRruZscdn1nQttYGiKJIky/6j1Wr1vn6SJEmS1HnNCxYsmDBhwidmEAgEkyZN0nvkFEURBGG40tIG+qoNtBHLHsnUZDt+QtnuZ4g1l20+PTxP+sjKtVqtgX7lq7kdy7a4IQIAoI6QefhktOopePqHIOmWsWMBAJgwkkZPb9RWZcnzfniJVVps7HAAACZMTtHSKLYNpnHGoIZP3VV3E9CZz18UZOQtHHL+30mLIi67RKxa3fh2rn+4R2VlM3B7VxeWpuDfX68RI0aMGDHi3Z9hYWHW1taV3JqqFHqNvSIyM3bJhkfMnluO/zTYEUMI8QP7RB7h5jYN3zl/44TwxYF1dzN8AsbzbR3s+94k3PWzDm2X3Y5Pei1HIuuyaVTx3cPrx0bHPdIIQofPWzsu1N/KBLLPdxEai9AjhEIRWouQf7mXKAYjc/784vbtvSYNp5MVswyFCI1DqC9CQ2szXL3ArBq369YYITRw0JBGY5st3DT/5Jfnhzji1Z9Bf6ytrStMYTAY9aqmMEmSKpUKIaTVaktK9N+1uSy9qHMScPDgwdevX9+/f3+lr1pYWGzfvp3BYOg9coIgFAqFIdKLZTVeDPFVlz1LMNCaEUIajYYk9V9Uv2ydGo1G72su2+tKS0sNtB0VCkP9oFdzO6rV6np1sgL1C4blNmmT59vOPfEkN/OVsaMBAJgwtQUn1acDQ6Xwvn+RRuj/egMAUH9IKUY2xXLBVDYYnEzqtLqb+WzQb+Ga0H+GFVTc/W3xKe7oRYMC7G2f7M3x61U2dJ8iccOMPdqhy6eFWGMIIURkJKeq+X7uxou6ctrnjx4r6f6d2gvK3W5z23Zqzdp26uGTIirQ1gRSstWCWXFtaIgiCIJCCEOIzDmyeNaIk1mCdsNOzBkS7lFnKz+/5whCIxASIHQCofD3XyL4fPGaNQSHIxo6lJ6d/eGyEoQyEYpFKPb96cEI0RD6A6E2hotbJ+rUW4f+zBMG9+zwb0FnmrBTB3/87rPnYgI5aquawfQSLZT82Zltu8//9VpCtJ29YxI/8VKJT9dmgoqNro2KRqOx2WyEEIPB4HK5el+/UqkkSdLSUvciQHv37vX19V22bFmFfJ+vr29MTEyHDh2YTGaNw6xIJpNxOJxqjoL4n0ilUlTZk4+aIwiiuLjYEGvWaDQymYzFYllZ6b8ngkKhwHHcwkL/J+3i4mKVSsXhcOh0/V+BFBQU8Hg8Q6S28/LyaDRadbajhYWFIR4J1A3Km6tGx7Bn753SvO5ePuqPIvnsT8t+OXDtcUqB2srZr1PEhMWz+5nEQ/TqU0jTf7r+7EBKQUopacW16eTTZHGI0L/yk7fy2PmrU5Sfb9jcvOel3ayivFoO1XDqw4YGRqVJv7p5/tqDF+6L8zVsp0atwkdNXzSyhZ3pXUBXk/bm7ydjmO33dnGq8EtRlPFk+Zk7sS9ys7QMN0+fXpMWTSvOEyb/iZlNt6HSi4ObTz4of//jMD/b8feWUSY3crsJqFdHlvrmrlUxrMF7B4kqHFZU8csd2w/tufXkXhbh1Kj1N9+M+q6VXZ26q9UHSp58ZfnGo2cevnldxHT3btK174gF/fzscYQQohDKpixkFM0LL2Ujs6kJRhW9vLJ885HYP99kadjujVuOGjN2RoijGQxWVXfvINj2QpH92/9TxamWGI3nIhJ5aO+cyPbr6VmWfmA3DfbXLN+62lY7MNiVlv/kwr4TuX4jv/AxXtSVwzgcDkYWSAtI9O+Yg1SRtIBATA6HZZq/R9qk2L5R1/gD5u/s829BZyI97ZUGc/Zw4WIIISJpb9SYU3l+I1ecnRbkYCI/BkkIjUHID6GzCDm8/5KyUSPx+vXsBw+EEybgKlWl10q2CM1F7535EhG6itBIhNwRcjVg4LpKOTt9xskmCwLjx/ybYKbk8mKE2BYsDCGqqhlMjPbNvlFh3+x/VUohhPEtRpHq1zERg3/3HL759NahDfSfMjVbGIbNmzdv7Nixx44du3fvXklJiYuLS9euXdu3b69Ww3DDAJghKvfchg2nE8K/Ndf8enmal9v6dZt1odipXd8R/d21yQknj6799kpiRvyZac3M4PIfIYSQJv9lv91/XlCx2/k06G9NJqekHU28eSW9JH6ob7OKj/molBf3x98vkDqrneJ2srRKowRsCPVhQwOjovLj5nYeskds26LfsEkNWXn3zh77dUbEH5nHbsxrYcJDAX0cVfxyw5UXCc2DKvxSyN9cD4u5fhfZ9QgK+pKP3fjzXvT3I3PGDN0bZAqVGauHyBanKHHHZp07e5Z7fs/w9WKYzUesO+rXkUUV3N5wMDGhU6+KF2CqF1FTZy96ZtG6W+cp7UpuX7465/unb1at/aWd+RxWCCH1y4O9R/ySQLiFde/5hY3q2c3LGxdPjk9de2NmcyuEiUkLAmEivJSBzOf6VP5od9jEXXeRR4+wvl+x829euRb53cPHyzbsDROYSFLto+puArpyyke3s3w+93p7XYxxWn774w82uw7tXX6qiGbr1qjlNz8OCzXcyGi6YjT9PMx1/abd646M3jLInYEQQqQ0/uct1zXW3Xu0M9FTJN3DjZ/5bP/WvQM7zuxV1oRbk3P4t1N/U67TP/dhIIRU92P2PlH5fr17qslknxFCMQipENr9Qfa5uGPH9JUr7fbscdi4EX38Qb09Qoven7IaoXiExtW9ts9lGAFtO3GPnToYe2fQ9OCyfZHIP7/rzDNKMDakER0hqqoZTAr5etPX4w8WBE6P/WWS4ke/6Qgh9ufzt04UT944blRAy2szGuu/ba1Zc3R0rFAM2hC1JgAARkWU5qU++fPq3pULY7NJR2NHUxso2cmlSy8Weozef3FrTwccIUTOivvhi56bf4o8POjUMEezuK9Tn0x4eFFpNbp/2NaGFjhCiPKPuxTX8+6TyCfepwIsyn/GYkw68lJKHoXhpc9wdfOKgzKbrnqxoYFRESk7Vx98ze+588rW4S40hBCaNXBWl75rNm84MXHbEL457WJUqbzwSUrK3t/jY4uoir8UZN76g3/cxb3WzBgwuF2Q1MF7yZ+7Fv+4cd3Rm2P8u3c1l4c9RFpqCmUZOnXtvu6m0evXhNWXI4ssLcx58vTvvTt3xeZ/eAFGpZ7ZsSoJ6zRt1e+D3ZkIkUNaDh+x/LeY41+3HhlkanfpH6c4t21PQolw5u7fVjZnI4TQ1IFrvx4948D2XcOiuztyLDBCiCnM5sIEIYTI1PUr9t2lBf28LWqaiIUQIr/p+cO42evW7RvT4buubGOHVzOmsWNi3NAFR0IRQgi1mrK8VfmXGE5ths5uU9fr7bJD5v009MLwPcPaJB3s1zWAX/oi/uTxuxJ+959XDnAw1ROkVXDk5NaXos71/0o84PPmXrTCh4nXzrzQNB25bG4AAyFEiB/fyqeYVg9XLE57/4yA8VoMXNPHqw7ufARCtxBiIrQCvXd7pWzYkN5hXPS8ebZXrhgtOMPA+F0XTm5xafm2Hr1fDgoLcKZyH924eOKRzC185bz2FtWZwZQQT/Zuu0F1Wrtv1UBPzZGyXDNm02xYzFHFK7/Juw88nraoWR3cLwEAwHgoye6+ogkX3g7oYlZX+B+lfZxwW0ZrOmnG5/88QMftunw3ut32Odfj/1IN62FqP36VIQsT0tU0xyYzGli8/YwYq0tww3Z//Xn9TZ4qwO3dZyx0E6zcfvoeP2gQ694hjbn0lC9THzY0MK6Sv64/1HB7Dejn8k8LB8vmfUJd1m55+SSVQHzzueikih/0/d/ZC29H6q14d0tIXhxPJ906deoZ1q2YzhI9uMgkefM+b/jb9mf7X4Z29TePggFUgTi9AHNt6GEeH6duqx9HFlVwsW/vdRfe9iz9IGlESk5efKyw6TzjS/eyTry4XbuZvd0P7UyIfTY0yN9MvgRE5D1PkSO7LmF+/2Re6W7dQ4Sz/0q/LWYPdNQ4mt2Qg4T4j+MvCLf+Q8eL3j6dw62bzRvd9re5CfvvTegaYtqP7Mxlv6zrcOfwDX9cCFq6aseJIxvPKRgCUdDwpZvnTw4VmvAvFK1RvyWJTseW7rl4/sShQ2qWa8PmM6NGzvlCVFbkSpudJSYo+evbu19XWBB3oHVZ3cfLCCFXRYuQGCE5QrsrvPDylWD9LE5RplGiMjCm/7ebbzhtWrLzwrFdiYValpOo+beLv4kc1vKf0ipVzmA6tMnPk1HDiE7uFSLHXdq1b4B+epVCIEhAAwBAeZht7+ir/oUkovJOTB2wNt3Y8dQGTQniN2gaEigq1ykGY1uyMaRVqc2khyehRWxuUw9bUblbWoxOYyOkJd5WMacwTBIQknjt1w2PbRYPcyDOoUNmNrRPfdjQwLjoTb9d8/Oghi3KPcwgiuWlFO4k4JvcZfSnYFaNomcKCilEyZ9P3XSrwi8FUShLJ3HXZl8wSEL4+DKu1SCEuI527uj5X6kFhL+DWXRAJFNSMwi6SGSTdu3svcfZpZaufl06NhdammpjszqtfhxZGK9t9BbPQhJRsj+mzjpS8QJMk3znpZbZrGnwv01iab6BvnY7L917JiP9zaUaNs22oYcVevb05htNaKOyWgJ5l+9nEYxGzd3UjpgZ/lYTkpwMEhe5OZXLFGJcodAd++OvpxlEiLdJnzAh11JraA7BY6OPjY02dhx6xfRsP2hr+0GVvsbqMCf//pxaDqiGWAjll/tT4+Agjo7G1GqP77+nSytmnzGE4qqxzlkIzdJjiIaAWfp/Of3Ql9N1n8FUYNY2PCSV5BEIvX/i1uRk5VIcLgcuEQEAoAK6feOW9gghKus+z0zuZqpiGRZzM+z9SWT6qVOJGmbz1gFm0iqW4RIz1uX9SVT687REEm/uamuBEMlgpgWHF4lPLNnyIrhL2DQBWmucQA2pPmxoYFyWjXoOaYQQQohUFhdK8zIeXd4y87DUpXfUwIqtIUwcbtnY0xIhRMlyPqw+q3CwZ+NUXmqSa5IK/6eSobqwSEJRZH4xgcwjAa1KSc0myKI5n/fIkmophBDCmA7BczasXdTeDu4w9KyeHFk068a+1gghKi/5wwswMj87RYXsnAXccrsX3dHJHSfFGRICmUsCGnHCp80Y8XRZ1DeTXvXt2Mxa9fcf54/8yQqbOXWiixlmnxFCOIdrjZGZOfla5PRugCp1rkRCEWRWHoEgAQ2AOVIEBIijo3nx8c5Ll2JarbHDAfrAbNGts83m/St/m9p2ose/k0sfb1xxMIvXrUsLE+6RAAAwNxRFFRcXfzidawHjpdYyVcrZRQPnXi4Rjowc7mkud3QVkCkv7g+8nFViLYpsxtFy+Kkd+jPzE3dG7ksTtjwaxKWjSnZFs2PMDV3pwU59fNCR/4QgCLVaXfn5hMvVy1uAKhDJa7/sPPdvDUI4P/iHc+vC696gRYYidRRlBwq7rI3bfmnv/pYRo2xxhBBSZcdcep5LUZZqc6nsQ2Qlp2koLeE1OObS+A6eKOfe71unLjkcNe5/wgubyg3lbnCVHulKpZIgCL2snyRJuVxOp1fMIxnnVFKPjyxKUVpC4Rwry/KfGGOzORiVXqo0k8MKIYQQ3bnlt30CzkXf2b31MUIIIYzbdPC0rh4mOpRalegNgro4HNh45uD+wYtGOdMQQkjxMmZXQi6JLEtVtbxlKz2fEARBkjpm/yEBDUAlZD16ZCxcKNiyRbB9u7FjAXpk3Wv+km4XJk1tG3zlK6/nWhX33IaoC/H7dp97Qe+0ZkEf8xmyAgBg+iiKUqkqKWwHCejapM64Fj1vdtSx52rPvpsOLe9uY4a/E+qi7OjL96KSZGob4aaBQR3c3V6H9LNOuftw+fINJS6/feXthSFkTveylTH6hq70YNdXApokSYIgKj+fQAK6duDOEYs2e6ZlJ/91/rd9q3sNws/FTmttZeyoDIzC8ExRy2IbZ69nCQvDm/y+4+k3K3adD/JsSJPfevDsLrJyxFUKmrnkC3H7PpEbAy0adApys0QIIWGHIUtOYzn+sxJiYl+MnN6k1hotVnqkazQanRNGFVAUpVarP3wXrlESS/XyyPoHRVEfVoZGCCF9bes6gSq5EfNd9+05/kMWrh8eGsArKbl9eO7yXeEjCw/unRshMJcTSHnM5nOmdjoZGf/N8MnnuwU1ZOTfunrtLrJ1xEsV9Npu/fyxixOdr08gAQ3A+zBMMmFC/pAhHtOmcW7fNnY0QM/ojcYfucqNnDZ/66YTJSSFNs68ReN6d5m6Y82S4X7Q/hkAUIfgOM7n8yt5gYROObWCKry7bc7YBYceqV1Dp2xZO6e/P9f8ss/qu/fujb2a8oiwDG3Tbm2Ip4tv89TAUJd7F1Dc9nF/a/v2aTn0w+70ZqZubOhKD3Yc18+tNZ1Ot7CwqPx8AmoHxmnc8YvGCKGho4b4fNVs9rr5hweeH2V6w6lUH8FgZTRuT9AYokeXGCqFW6vw62xB5PmHv9+4fZrJbdG865XP1FNXXk61YJrJKQaz9m3/me97k3DXsLC2c6/FP3ouR02sayuQSo90KysrBkM/dzo0Gs3a2rqSdynOr2x2A6t/R9Y7GNuSg1PS9xs7U6WlcgrjWFqYyWGFECm5uGTPK0anhat/6NsEVwswOuo29ohVQdPxp+bv7x8+rYk5JjQxt+5zr3O8Irf9/vvx2NMWghadJ14ZpJg6fFOqFbuWt2yl5xMajUaj6ZgKN8ftBYCuSCur9OXLVd7e3sOGsVJSjB0OMAgrv6Fr44Ysz01+9lpSSuM5ixp78iH1DACoiyq/vIMEdC0g0o9MiRixJ1XQdeaJNd+He7OrXsTkUCVHzl4d8UAuEPmd+Ny3ty0zOzBUIvQVXou1yk17ISnIJEtjjx2PfW+ZpODlSTRbnz/GBbYxj/v7OrOhdb6Xqw4MwzAMM+hbgEqp31w/dDtXGNKng9u7A4Ym7NLFn3bzWdIbApltmoyiW71uFsYrzhc+vYaTZZUfaJ7+IXv9Q97No37+u5jAvRxszDgfgXGtbeiI0hIEhSpvqmoAlR7p+nqa9e4tjHs+qbdHVnm4nZMHk7qXkVNEoXdVxolcSQaJN3Yxj7rqCCGkff3qoZomatUmgKa0Rm8vgLktglozTpx6nlxENbE1m1z7e+ieIcP3hgx/97f67joxQfPycKrlE2alRzqG6f6lm/EJH4D/Ru3unhoTw8jO9h40iCaXGzscYFCYhaBBc0EDY4cBAACgDtIm/TJ2zN5Mv2mxZ5d85mCeN7JU0p2bYx6W+gV/draLkx2LndK+D8GyFF3cySiRIYTZuonmhjj/WzGUUiU+fHVVazeyhZO7pcDVTO736sOGBkb1+vj0SYeaLG0VP/7fkdGo4qJiCmNb1nZDtlpDYIiwa2EjeeMqfvK2fA9VFH8r+RXHfUhT+3/KtpKPnqVmY/wRDc1kdFvto9/6zrnAH7F251f/5kSJ1Nev1Lizt4cZ9p8xrnp5ZFXEbBDciB77+O/rpd36vD2uyJePn+chh6G+fPM4rCiEZbJ5FohUyiRWiPfv9GJZAYmYllYss9zYpCT+7J1X1k2HdBT+c8LUPrp9PxtzHdHC5C9VIAENAEIIlbRokbZunfW5c06rVmHmVDUJVEQWvki4kvg8W66tWLiI3qD72M9FZvO8GAAAgG6UN2J+uatqMW/3IvNNSmpzYu7kqZwDdnd2subZvu44gFUoESYcxom3zYvs3Rssci83P1W8OiU5vlQwrmOAmbR9RvVjQwOjYgR27MQ7cGrP7jsj5gWXJRKI3PO/HXtGOYztaJY9x1G+k4MSw2iFSQIxp/z0p7cuTknz0M4dNN4eQwhpch8uupHPEnUd5WYmxx7d05Of/nB/9K8DQ5f2sscQQkiTcTjm4N/IY3p4APS11K96eGRVAheEd/Wbu+bOr2czvhjgykCIKnm48cxr5DnwK7P4DjQUJqbYeJOQnk57tpzYc6T//EHOdIQQImXx249d13K6dwww13EIn57ZMCUpQHtgxXhXHCGkSb+w6Fgaq9nEUY1NPlWh665JvI7beSm5On1A6aJuo7p6m/wXBcyZtH//7FmznJct4588aexYgEERr7b37zzhZLq6sqr5FgMOj4IENAAA1HdE8u1bEpLJTVwxeeL7qRGM137ymuE+ZnBjR0jzbskpJjM36uqTUgcP5u//YxdklzVV5Hk0WdPMnDvFv1MfNjQwLsy258LpbS4t2tCjS9Kgni2cKcmja6dP3Je5RWyY18ncCvtQOC1D1FKuJdgkhanyECqXgMZ4w74I+nX97e9+2pPYysOxVHLxQfJj5LVuSFBDM8k/I8TtHPlDx0v/O9L/8zcDwlt70aQPr50/k6RpOn7z3BYwdLCe1asj6+Mwz16jZ56d/WN0ZK+UsC88iHtnT+7Ncv7mp4gg0//1UlA0McXmYVpnC5/5c3pemnl2WL83B7sHB/CUL+7EH38o5XecsbKnmZbfwB2GfRv+68Qj3435LrF7M8fi1xfjbz9GQevmhZvBCVPXfVP715bJ4w8rqzGnxYDDwyABDeooikbLnjVL1rOncOJEq3v3jB0OMDDN3S0rTmfadJqzZkG/Zg7sCmdw3Nodrg+NrWxkbRaLZexAAAD1lzYtVayl5M8u7X5W4RXcgR6xeriPUaLSL22RXEwieV7m/rxMhB6UewVzwIWrm9kYLbJaVB82NDA2pv/kfTdc1i3ZfPrYbwmFGrZTo5bfrpwcObqtmRWp1TLZqU1CMIoU3X5a6SfjNQq98h1//ul75/64U0jjBvp0OBEe3MvenHIEtEZDNyS67Fm65cT5g9sPqVmuTYJnrps8p18TG/NMkhlXfTmyqsBuvCB6ueCXnevjYn9QMFwbtYz6+euZwSY/drCMYmRQLAGmFmBqhHDn0Dl/7PBZuuXUifOHzikZAg+f4dMj5w9vLTT9PPvH8ILGX9niOv/Xk+eOHy6kCwLbjjwx8aterubQlaKGGw2zcGrerW//iO6t3K0+cqzTHJuawxcFzBBhbS1es4awsRENGsTIzDR2OMDwyOyMbLz5DxuihvmZ0wWvGSguLo6Ojo6NjX327JlWq3V2du7Zs+fMmTObNGli7NAAAG9hzt/EFX9j7ChqA6v7r/nFvxo7CsNiNg55eCpK7uTlcf0IW5pV9QIYd9aoQbMMH1htqg8bGhgfZuXfb96hfvOMHYcBKa34qT4hnMIcl+Q/McumcRuaVjYX5iAK2vxdUG0HV6tYnp3Hbu081thh1A/14Mh6B7P/Iu7GF5W+hFv7TJq7ctLcWo7IgCQUK59ieGClHOzdOBS4Q/O+0b/2jTZmXLUMd2j25ebNXxo7DP3TNQHN+mJdwrEOR44cPXr2/KbIc3uEbXpGDBgwIKJHa4+PZaIBqEtUQqF4wwaLFy+Ekyfjyuo05gemj+bu6U57AaPA1zH37t378ssvMzIy3k3Jysratm3brl271qxZM3XqVCPGBgAA5odgWYrb96VodNGFHXQljLoMANCdzN4jo0ErQdpTQUaSsWMBAJgwEmHplIWSwr1xBQvBoFzmSedkMdulVd8pK/fFv8pOu3dy/dSOFg92/DCwnZejZ9sB36+J/SNFDnsMqLuKQ0JeHzjAu3LFfdYsyD7XI/TmX0/9LGXD/35LKjF2KOCtF9XQ81IAACAASURBVC9edOvWrXz2+R2tVjtt2rTNmzfXflQAAGCulDYOr8JG0Uvlnlf2QfYZAFADWK6rT2aDVu4vEiH7DACoCTXCk0k2SSERZJ/NWs3rplg4BfaeENh7wlJ17qPLJ44cOXJ079zB0T+wXVt+HtF/QP9+X7Tz5kF7Q1CH5A8bljNpktv8+by4OGPHAmoZzXvMz7P3tprYosEvwS0b2lu89wiO2XbGzunBUDKodo0fP76goOATM0yfPr1Xr16urq61FhIAAJirIvcm6W2+sH92x+HxdWPHAgAwYSROT28UrLS09n54iaUoMnY4AAATpkA0McnmYVpnTGnqBazBp+mxcDdT0LTHN017fLNYI02KP3nkyNGjsQuGrp/NG3YiZ3c4DCgF6gCKycxYsKAkONjr66/ZT58aOxxQ+0pvzh8Y+UcJhdRvHt7KqtADxMJ6ODxtrV0PHz68evXqp+dRKBRbtmxZvHhx7YQEAADmCcNym7TJ9W3nlniKl/HS2NEAAEyYhskW+3SkaVWih5doWrWxwwEAmLACxMwimc6Yio9pjB0LMDhDjBzJ4Dl5uLu7ubrYWz2VKFVK+FECdYFWIEhdtw4jSdFXX9Hz840dDjAGdeK+vUl4s2lnT63s4Q6PxYzv8uXL1ZwNEtAAAKAzikbPaNVDYe8mitvDkuUaOxwAgAlTcO3FPiE8aYZz8j2MgrYbAAAdURSSIJaUYgixUqt/hxwE5kyfCWht4YuEk4cPHT58PO6hRM2w8/msz9zvBwzo0wXyPMDYlE2apMbEWP31l+vChZhKZexwgJGosjPzaUEzv/scss91Q1ZWVnVmy8zMNHQkAABgrrRsbmqHfhih9b60i65SGDscAIAJK7QXZjZo5Zj6wC4LOlIAAHRHICwNsbUUJsJKmBhl7HBALdFDApqQvbp+6tChQ4ePxT3IUdHtfDp/OWfLwAF9uvjZQzFVUBfIPv88Y/FiwZYtgu3bjR0LMCo6386aepqWoUaeFsaOBSCEeDyeHmcDAABQgZLvlNqhHyfrtcu9ixgJzYsAADqiECbxDJA6eAufXbcqzDF2OAAAE6ZGeCrJZmKkN16KI8g+1yO6J6CJouQbpw8fOnTo2MX72Sq6XZPPwn/YMnBAn1B/yDuDOgPDckePzvvmG/fZs7nXrhk7GmBs7G5zln1x4buJ37WJXd2/CReveglgUC1atKjObEFBQRWmEASRmJj44MEDlUrl5uYWGhpqZ2dngAABAMCEyTx8Mlr1FDz9Q5B0y9ixAABMGEljpDUMVlvxvB/GsZTFxg4HAGDC5IieRlrYYhpHDDqm1zu6JqBVp0Z79NkrQyynZt1GLx0woE/XAAcmQgihogrVdTEW15bDrGGYAPx3pKVl+rJlyoYNvYcOZb1+bexwQB2gTti5K41Je7zlK9/tHDs7zvsnQIveW59t6QXFOWpRaGioq6trRkbGp2cbMWJE+T8PHDgwZ84csVj8bgqDwRg7duyKFSugrTQAACCEEIZJ/ELyGwV53DjKyUkxdjQAABOmtuCk+nRgqhXe9y/SCBglDACgOynFyKZYLpjKBoYcrJd0bgGtVqooCiFl9v3TG++f3jj3ozNaDDhceKg/5HRA7dI4OorXr6cVFIgGD6YVFRk7HFA3YBY2Tu4Btu4Blb7KbGRbZZtoUvrg6M6D8fdTiznC5l0Gje7XjI+9PwdVcH7B2I0P/v1Fpbn2W7lhZCNaNZatd1gs1urVq4cMGfKJeQYMGNCpU6d3f86fP3/58uUV5tFoNBs3brx27dqVK1ccHR0NEisAAJgIks5Mb9tbybP3jtvDKoJRlwEAuivhCdJ8QqxzU53f/I0o6CkPANARhVAWySpCdC+8lI2gJlg9pWsCmuYd9s14u+o8tGAEedN0fBMAdKMIDBSvXcu7etV56VJMqzV2OKDOYLSbGXt8pu7LE6nHli09QnQaPXWQXW7C3h1LV9DWLOvr/t4pjpRkS7BGvadH+L3t+YGxXV3w6i1bHw0ePDg5OXn+/PmVvtqxY8ft5Uq3x8bGfph9fufp06cDBw6Mj4/HsPqe2QcA1FsaNlfccQBNpRBd3EnTQOdWAIDupI6ibK9A59f3+JI3xo4FAGDCCISJSTaBkAhXMKDocz2mawKa3mJszMaxVc2lVRQWKekcPYx0CEB1FfTrlzVnjtPPP9seOGDsWIB5UT88c+aNW79147u70xDyty98NfP02SdfjA8oX2RII8kp4DUM7tCuKe0/L2ti8vPzs7Ozra2tXVxccFz3itqRkZG+vr6zZ89+9erVu4k2NjYzZsz44YcfmMy3X5FarV60aNGnV5WQkHD8+PGIiAidgwEAANOlELiJ20fwMl46/3kBo0hjhwMAMFUUhmV7BRbaC4VPr1kV5Ro7HACACVNSuBhZsjFCiJXCGEz1nEF3AM2fC1s5uI45Bc0vQK2gcDzn+++zp00TTpwI2WfwUZT82enouRNHDuo/LPquRvsq4fyD3Op05yDSniTJnVoEuZRllmkeQYEORUlPs967xSdzcySUg7MDWVogySvWUP9lWRNBEMSOHTsCAwPt7e39/f3d3d3d3Nxmz54tlUp1WFt8fHxYWNhXX31Vln1msVht27bdvXt3Tk5OZGTku+xz2ZxZWVlVrnDfvn06hAEAAKauQNQ8pdNXjg/jXe6eh+wzAEBnBJ2Z6vdZCc+hwcOLkH0GANREMUV/Q1naII07ZJ9BDWpAA1C3kBiWFhOjcXERDRrEzMw0djigrtK+2Tcq7Jv9r0ophDC+xShS/TomYvDvnsM3n946tMEnmyOTeZI8yk7wrlA0biuwpfIkuSQS/vtrSuZm5Wpzrywfs+ONjEB0rmf7IVMm9GzAqGrZO3fuHDt27N1qCgsLlUolQkir1RYX63+0cYIg3v37n5SUlIwYMeLSpUvlJ2ZlZa1atWr//v2xsbE+Pj4IodLSUpWq6mePS5Ys+emnn8pPUalUiYmJf//9t1ar7d+/f/mX7t69W50I//77bx2+MYqiKIoyxFdNURRJkgZaM0JIrVaTpP4zTWX7hkaj/+FBytapUCgMUSmFJEm5XK731b5beXW2o0qlqkmHAAB0QGGYJOAzqXczYcJhK4m46gUAAOAjVBZcsW9HVkmh99MEnIQ6rQAA3eVTzByK6YYpeRiURQUIQQL6LYaFsSMwPFFzY0dgQGqtNjU7j9nBylsrw0/tMnY4huTgYewITBr5etPX4w8WBE6P/WWS4ke/6Qgh9ufzt04UT944blRAy2szGn+iJjOhVmkxNpv9T9YMY7MtMLVKXb6KFVWcV6Bhc0S9py3u4IpyHpzZtP63Zb8JYr6patn09PS4uLh36/Hx8dFqtQghgiB0SBNXk/Y/VkinKGrUqFEVss/vpKenR0RExMXFOTk5VSdx+csvv1TIPr+jVCrHjRvH4/HKDz9YVL3RREtKSqqT+66Uzgsacc11ag+pPrVabaA1G+6rpiiqOivXarV0OlxcgdpDMphpbb/UWFmLLu5glsiMHQ4AwITJ+c5pjdra5iQ7pj6EIQcBADqjEJZBsUoouhemYGPQKwu8BfdIwOTJS5VpknxbHsdRno6gpD34BOLJ3m03qE5r960a6Kk5UpZrxmyaDYs5qnjlN3n3gcfTFjX7+EmRxmTRKFmpkkIWGEIIUaWlSorBfa/VNMYPW3Aw7J+/3FsPnhxxf1LstQejOlaxbOfOncvaDpfZvHmzpaUlQojJZJb9R7/Kms1aWPy3Z2/Hjh27cOHCJ2bIyclZunTp+vXrraysGAzGJ+ZMS0tbsWLFJ2bQaDSzZ89+9OjRu/WIRKLqBOnu7m5jY1OdOcsrKiqiKMra2vq/LlglkiRLSkq4XK7e16zVauVyOYvFYrPZel+5UqnEcbx8CRR9USgUarWay+XSaPofgrOoqIjL5RqibXVhYSGO4zwer8o52Ww2BTftoLaoufzUDv2ZJTLvuD04DDkIAKiBfJdGOcIAl1d3bXJTjR0LAMCEaRGeSlpgCInwEjrkZ0A5kIAGpk1aJM+WFrrY8204VigHzm7gk7TJz5NRw4hO7hX6x+Mu7do3QD+9SiHQJxLQuJ3AHnuTX0AiGxpCCJGF+YWYnZ/dpzrb4/auLixNQbHatopl+Xw+n89/txyDwSjrxY9hmCFaU5a1bP2va966dWuV8xw9ejQqKorH43165fv27SurMfIJycnJW7duTUpKSkxMlMlkHA6nOkFmZmZGRkaOGzfOy8urOvOXZ4ivmiAIA23EsiwnjuOGWDmO4wZac1l2mEajGWjldDrdEAloVO2DEcdxQxRFAeBDcievtHZ9bFIeO/8dB20VAQA6o3Bapqil3MbJ69EVtlyXIT0AAKCMEtFSSQsORrhgSoNckQNTBmUKgamiKCojTyoplHk5O9hwrIwdDjAFmLUND0kleR8ULNDkZOVSHC7nkz+SNA8/H6us+w9yy+7yyewHD7O5vn6u5ZtxKhI3TJi47obs3eCDGcmpar67u42w6mXrOIqibty4UeVsGo3m3r17Vc52/fr16rzptGnTNm3a9ODBg5SUlMePH1dnkaysrJUrV/r4+Pz888/VmR8AAEyRVNRcHBLh/Hec81+XIPsMANAZwWCl+HVSsXmiBxcg+wwAqAkZRX9Nsm0xjStkn0FldG1/REoeJzzKqaLsJPE0tVTH9QPwSQRJinPyKIQauDrRDdCPG5gnZotunW0271/529S2E8sV0y59vHHFwSxety4tPlU0AiFmQM+eHnMOr9/vMqajreTqtmNpoogp/kyEtMlxe6/l+3wxoI1D02B/zfKtq221A4NdaflPLuw7kes38gsfOpP8yLImQy6XV9lmuUxeXp5e5qkJlUo1Y8YMpVI5d+5cg74RAADUMgrDs1t0lbk19rp6gJ0Poy4DAHSntLIR+3RgF+W5vroDQw4CAGoil2LmIZY7XspFMOQgqJyuCWhNwpIeAw5XJxdRD4b3A7VMqdaIJXlsJtPV3hbH4dEaqD7rXvOXdLswaWrb4CtfeT3XqrjnNkRdiN+3+9wLeqc1C/rwq9ib6N79//eDZvOuDXOOKS1dm/eaPa6vkIYQ0mbcPXPqDdG2fxtHTstvf/zBZtehvctPFdFs3Rq1/ObHYaEuOEL4R5Y1GRwOh8lkVmfsuPK1RD7G1tZWH0FVYcGCBT169AgMDKyF9wIAgFpAsNjidn0JpoUobhejpFpDswIAQKWK+S7pjdvaZT53EFerkxkAAFSKRCidZCsR7o2XsBBUogMfpWsCmu47MHKRX3UebND9fKHQNNCfYkVpeq7UzprrYFP1YFAAVEBvNP7IVW7ktPlbN50oISm0ceYtGte7y9Qda5YM9/t0+2eEEEI0QcthkS2HVZhq0fF/Rzr+8wfDqc3Q2W2GVndZk4FhWHBwcEJCwqdno9FoQUFBVa6tbdu2cXFxNYnHxsamqKjo08V2CYJYtWrVgQMHavJGAABQRyit7cUdB7LzM4UJh3ACmhcBAHSG5bo2yXXzdXtxiyfNMHYwAAATpqEwMbLEMcobKWDIQfBpuuaGab795y3sr9dQAKhSbmFRbmGRm8COZ8U2dizAVFn5DV0bN2R5bvKz15JSGs9Z1NiTX43Uc7137ty5pKSkKmfr3bt3dVo3jxw5csWKFRqNRud4qsw+lzl//rzObwEAAHVHsbN3ers+tq/+dnwYD0WfAQA6o3BaRoNWCq696FEcSyEzdjgAABOmoGhiis3DtM5Q9BlUg2EHIdQqCqVSedUdtgGoCkVR6bnSAnmJyNUJss+gxjALQYPmbdq1bekP2efq2LlzZ58+fXJzcz89m62tbVRUVHVWKBKJ5syZU5OQqpN9RgjJZLLCwsKavBEAABhdfqNWae36uN4+6/jgKmSfAQA60zLZr5uGqllW3g8vQfYZAFATMsRIodgCTOUC2WdQPQZNQGv+XNjKwXXMKZUh3wTUAxot8TpLotZovJ0dWAwo6QJqhpI/Ox09d+LIQf2HRd/VaF8lnH+Qq3tD3HrgwYMH48aNq7K1sr29/alTpzw9Pau52kWLFo0fP76mwVUFwzALCxiLAABgqigaPb1NrzyfNl5X9vPSnxs7HACACVNy+MkB3SzkBV6Pr9I1cIsOANARRaEcipVJsoS40g6DO2lQXYZtAQ1AzSmUquTMHDaL6eXsQKeZ1KhtoA7Svtk3PLDFl98t37g79ti5v3NI9b2YiECvgJH7XkFnjY9YuHBhlWMPenl53b9/v3379tVfLY7jGzduPHbsWPma0TQaLTQ0lE6v+jkTj1etKvAikQgS0AAAE6VlWaZ8NljN5Ysu7GAXZBs7HACACZPZe7z272Kb9dI1+S5GwShhAAAdkQgTU+wixPDGFFYIRqQA/wEkoEGdJitRpGTnCmy4LnZ8DIOOHaCGyNebvh5/sCBweuzfr3dEWCCEEPvz+Vsn+mbtHTdq/XPC2PHVQcXFxdUpo5yVlcXn83VYf9++ff/888+MjIwbN27cunUrLy8vLi6uR48eVS44cODAVq1aVTnboEGDdIgKAACMTqnWJIeNYiiKvK4eoCtLjB0OAMCESYpKMkUtPZJuCDKqHs8DAAA+Ro3Rk0lLCiFvJGdh8CgL/DdQzQDUXZLConxZsYejPYcNDRiBPhBP9m67QXVau2/VQE/NkbLm9JhNs2ExRxWv/CbvPvB42qJmcFJ835s3b6ps/owQUiqVKSkpvr6+ur2Li4uLi4vLuz+joqIuXryoUn20cyiPx5s/f35ycnKXLl0+sVpnZ+cZM2boFhIAdReDZewIgMEVyeXpWRKBo6PA2wO1bmvscAAApoqkqHRpkVKj9WZqWAEtjR1O7bIWGDuC+sTGwdgRGEOrz40dQa0qKSlJS0uz5nKcBPb1rnUgXH7rA7SABnURSVGpObkyucLbxQGyz0BvtMnPk1HDzzq5Vzjz4S7t2jdAKa9SoAn0B6os/fxOdfLU1RQQELB9+3YGo/LxIdlsdmxsrIeHR+fOndetW/exldjY2Bw/ftzGxkZfUQEAQO3IzZdmZEvcXZwEVnC3AwDQnYYg3uQWkhQlcuCzELRVBADoTiqVpqamOjo6OjsI6l32GegJJKBBnaPWapMzcigKebs4sD6SgQJAF5i1DQ9JJXkf5Jk1OVm5FIfLgV/SDwiFwupcYeA4LhQK9fi+Q4YMuXjx4odNqlu2bHn9+vXu3buX/Tlt2rSTJ096eXlVmK1z5863bt1q06aNHkMCAABDoygqPSunQFbk7eHGtbIydjgAABOmUGuSJQVsJl1oZ03D4a4fAKAjiqKysrJycnKEQqFuRRcBKKNrb3NS8jjhUU4VrQWJp6mlOq4f1FclSlWaJN/aytLJ1hoerAE9Y7bo1tlm8/6Vv01tO9Hj38mljzeuOJjF69alBTzv+IC9vX1wcHBiYuKnZwsJCdH75chnn3326NGjmzdv3rx5UyqVCgSCFi1adOjQocIQheHh4T169EhISLhz505RUZGTk1Pnzp0DAgL0GwwAABiaRqsVZ2ThOObt4U6nw6jLAADdFZQoswqLnWw4tlZsY8cCADBhBEGkpaVptdoGDRp8rH8qANWkawJak7Ckx4DDymrMCeUTQLVJi+TZ0kJnOz6fC61+gCFY95q/pNuFSVPbBl/5yuu5VsU9tyHqQvy+3ede0DutWdCHD488KjN37tzevXt/ep558+YZ4q1xHA8JCQkJCSn7UyaTVfpcisFghIaGhoaGGiIGAACoBYpSpTgzk8fhQM9WAEBNUBQlKVZI5QqhvY0VC7JFAADdqdXq1NRUFovl7e2NQ0cKUGO6JqDpvgMjF/lpqzOnny8M6gWqQlFUtlQmK1F4OTuwWUxjhwPMFr3R+CNXuZHT5m/ddKKEpNDGmbdoXO8uU3esWTLcD67RK9erV68pU6asX7/+YzNMnz49LCysNkMCAABzIisuzsiWONrb2fGhbD0AQHckRaXlyzQEKXKwZUJHCgBADcjl8rS0NFtbW0dHR2PHAsyErrlhmm//eQv76zUUUG8RJCnOySNIUuTiyIBLJWA4hKJQpqQ1GLI2bsjy3ORnryWlNJ6zqLEnH1LPVYiOjrazs1u2bFmFkQaZTObChQv/97//GSswAAAwdZJ8aX5BgYeLM8fK0tixAABMmFpLpOYVMul0bwc+Dh0pAAA1IJVKs7OzXVxcYER3oEfQOBkYmVKtEUvy2Eym0FGA43CpBAyp9My3wuE5S19cnSq0EDRoLmhg7IBMBoZhCxcuHD58+I4dO27cuCGVSu3s7EJCQkaPHv3hAIAAAACqgyTJ9KwclVrt7eHOYkL3LwCA7uRKdZq0yMbSwtmGY+xYAAAmjKKozMxMuVzu5eXFZkMReaBPkIAGxlSsKE3PldryOI58a2PHAuoByzah7diRiXdlU4RQ7lkH3t7eP/74o7GjAAAAc6DWaFLTMxkMureHG40G3b8AALqTykuzZXIXPtfGEsZfAgDojiAIsVhMUZRIJKow8DsANQd1xIHR5BfJ0yT5rgJbyD6DWoILx27fM/TNkpGrLiYXEcaOBgAAQD2lKFW+FqdxrCyFri6QfQYA6IyiqKxCuaSoxEvAh+wzAKAmlEplcnIynU739PSE7DMwBNirgBFQFJWRJy1RqmDIQVCrNNeixvz8AFfen9u94TwLa3s+h1HuIZxFr02PN37BMl54AAAA6oECWVGWJNfZQcC35hk7FgCACSNISpxfSJCUyNGWQYOGZQAA3RUXF6enp9vZ2Tk4OBg7FmC2IAENapuWIFJz8jCEiVwc6dDqB9QqugWHw2E2DunZuJIXmZ42cOkOAADAYCiKkuRLpYWFQlcXK0uoqwgA0J1SoxXny9hMhtCeC0MOAgBqIjc3Nzc3183NjceDR+PAgCABDWqVUq1JzcnlsC1c7PgYXCqBWsZoP/vo6dnGjgIAAEA9RBBEWla2VkuIhB5MBsPY4QAATFixUpUuLbblsB15VsaOBQBgwiiKysjIUCgU3t7eFhZQxgcYFiSga4/i5cmflqw7cPVBilRt5dK004Bpi+d95c8xjySs8uaab2PYM/dODKiwSymSz/607JcD1x6nFKgtHX1adBu84IevGtubTtFn5Y3BYUsOKqj3JjLb7Pj9x1E8jEg52HbQtrvaSpajeQz84/A3bUy1hTclTzq2fNmWM3eevi60cG8c2HXkrAWjW9mbfANhlUxSqKQ+mIxhNAaLbcmxYpnqBgMAAFCXlQ05yGQyvD3ccNzkf00BAEaULy/NkcndbHk8NlSOAwDoTqvVpqamYhjm7e0NRZ9BLTD5nYyQ3D24bd/lB2mFpKVT43Z9Ro/s5m1ZB3O6mueb+nWacqHIpV3/r/t7aJLjjx1dPfzKzbT4i7Oamf6VA5V3YcOv5xJ6f02+P13zclu/brMuFDu16zuih6DkecLZuO1zwp+Wxp+ZZiqfmpBkpqgxR9+2nd3KRUwXedExhBBmJQwL6yyqkIAm8+4kPM4RCAR1cEesHvWT9b27zkvQisL6DfvCrvTZ5aMbJ/eIf3XixvIQ0+6Tozr9jXDAYWXlL2IYg+PUsMVnfcbMnD60hR2kogEAAOiFvESRlpVta2PtaG9n7FgAACaMolBGQVGJSuMlsGEzoSMFAEB3SqUyNTWVw+G4uLhA33RQO0w8AU2kHF256hzebfSciR70nD8Pb9u4RGW9flobbh07fqjCk4sXXCzwHH30xtZejjhCiIyM+75zz1+WRR4cfmqkUx0Lt/qI0nzxk3vX9q6Ois0hHSu8SMlOLl16sdBj1P4LC1rS1CqNcNGc6/O+7Ln5p8jDg04NczSJT01kZaWQ7NAxc/d9VknKHBe0jVrS9v1pVMrxyJY3fSNn9fI21RZO8nM//ZRQ3Hjm5Wsr21ghhNCiSWt7hMzYtHzf5NMTXE31UyGEEKP1lE2LlPOjzuTYNu3crb2fGw+XZyclXoh7oA0cMrydtSz10Y3fV406cebppZsr2kOXRgAAADUlLZRl5+a5ODrY8LjGjgUAYMK0BJkmLaIoSuTIp0NHCgBADchksoyMDIFAIBAIjB0LqEdMOwFNpP5xPdW51+qvu3rREGrU0D7/waTDt54TbVrWsc+lfZCQWEhr9v2MHo5vLxZw+y4zx7Xb8t31y3dVI3ubaK0dKndf3yZTL6jK/vrgMkj7OOG2jOY/8aumCJGUyNWRhuNdvhvdbvuc6/F/qYb1MIVPTRVkZBVgjg1dqrtHkZJL3/3y0HtU9PQGdWwnrD4i6/mrIiSICAv8JwPL8O4e1mh2YnLSawKZdAIad+KknLxc2nlV4pEZLXjvHoHIH0YP6B4tmX599xpXlBc/O6znLysOrzg9yoiRAgAAMHUURWXmSIrlJV7urmyoqwgAqAGlRpuaV2jJZLjaWsOQgwCAmpBIJHl5ee7u7lwuPBoHtcpkc2QIIYQwjm/Pkd5+rv/0lcdpOEavi8O6aBTItlHTji1F5Xr1Y2xLNoa0KjX58eXqOIzfM/qibyGJqPzTUwevT6/wsqZEa+PdsLmwsSVTaGtT1q3D1D41mZKeQ9A9RNbZ1y4/fpyrsnRq0KWNj5D9kcs+SnZyw47fbcOvDvFm1m6g+kRzbCjiogf3br5Qh/ozEUKIzL59O4Vg+jUSmnhdCs2dPbueOAyNm1ou+4wQ4gRMXDBkfeclm2b0/THQvtPM8R02LExEaJSxwkQIURRFkmTZf7TayqqM1wxJkiRJGmjNCCGCIAyxcoqiCIKgqA/LeOuHgb4QA21EgiDK1m+47WigjYj+Cd4QK9dqtQbqRVjN7Vi2xQ0RADAtBEGKMzMJghR5ejCgriIAoAaKSlXp0iIB11IAQw4CAGqAJMn09HSlUikSiVgsEymKCsyIaV8Q4w6BPXojhKj85zcfvsl4FHcmy3/geL9/P1RmZqZMJiu/SKW3pgbvxGTZI+Zex+VMigAAIABJREFUj/cnkeknjiZqmM2Dm5twkxi6feMge4QQlf2Q98FXWEC0n3zg+FI7Pp/77lKJTD91KlHDbN46wEQ+tTolPY+g5HOGjs0q1FIIIYQx7ZvN+XHeolY2H2Y4FA8O/u8S2W/pwGAT+XgfwQtfvHbEXxOivuj+amTv5nzF80v79tyw6LFi9RiPWmr+/GGWh6IoPeR0yIL8AsqSY/XBx8AsOVZkWmo6gQLpmCXHEispqel71QxJkiqVCiGk1WpLDBDMuzSx3tdctk6lUqlWqw2xcoVCYYj0YtkOZoivuuxZgoHWjBDSaDRlW1O/ytap0Wj0vuayPaS0tNRA21GhUOh9tWWquR3VajUMMQeUKpU4I4ttYSF0dYD9AQBQE7lFJbnFCnc7a66FCbdvAQAYnUajEYvFNBpNJBLRaCbesAyYJtNOQP+DzP7r/JmbWRnZjMZ9na3K3dJu3rz57Nmz7/7k8XiFhYUf3vTa29rWTqD/UKWc/t/AWRdLPMdGjjLZQsEfR1GUpLBIWiQXOgmsLN49WFOlnF00cO7lEuHIyOGepvGpydzkLC2lJb2+jLw0vKUnyr8XHzt13fmoOWuE+5aMqVC7m8zctvFsasMhxz6zNvV+cXT3zt8ODz638MruVbd3I4QQxm01ZXJ4Y8vaCqCwsLDCFI1Go4dsKcO/RQBt/+FtV78P7Gb371aiChK2HUqiNR3ly0CIlPx+5jbhPa6m71UzNBqNzWYjhBgMhiH6RimVSpIkLS31v0lLSkpKS0utrKyYTP3fJslkMg6HY4gLJqlUihCytrbW+5oJgiguLjbEmjUajUwmY7FYVlb6bw+lUChwHLcwQNGA4uJilUrF4XAMMdZ2QUEBj8czRGo7Ly+PRqNVZztaWFgY4pEAMCHF8pL07Bw7vo2DXS1fXgIAzErZkIMKtUbkaMuiQ7YIAKA7hUIhFot5PJ6zszMMOQiMxTwS0DS/wVFrBlOK5KNR81ZG22xY0tOh7JAKCgoq37Pg6tWrFhYWxj3e1OlXon/4LurwU7X3gE3Hf+7ON7eDnyDJNEm+liBELo5MxtsdTJ1xLXre7Khjz9WefTcdWt69ktbDdRLG7zN1cSDLo1OAkyVCCLl06PPdaSzPP+puzKk3I7/1Ln8lWHLv6Nr7jPAfe/qYRnL946jiG4t6d1+TFjBh68mpPfxtFC+v7pgzY3V4t/yDVzdFONXGx/sw7YXjuB4akeGeo5dM3tbj5y9bPhsxpn8HXxcOkmcl3Ti6ffcVif8PW8Z6puz7dvCs3X8qOq4fVtP3AgAAUP/kFxTm5OW7OTvyOBxjxwIAMGEaghDnF+EY5i3g02mmfncBADCmgoKCrKwsJycn29pueQnAe0w6AU0Vv7yekOEQ0qmJNYYQwiy9O4eIDux7KSaQQ9kHCw8PDw8Pf7dAfHw8h8OpJAFdO42VqIK7m78bO3f/I5V76Pd71kYO8ueZSB622tRabVZ2HpNB93ZxfDs+BlV4d9ucsQsOPVK7hk7ZsnZOf3+u6XxqjOvbqrXv+5NcO4a0ZdyNf/ZGjrz/bQtHFR6PvZIm6Ly1k8lvVDIzdsmGR8yeW47/NNgRQwjxA/tEHuHmNg3fOX/jhPDFgbVw1uB8cN9Op9P10YsZ43VaGXfBafq0lTsWXtlcVtIDo1n7RKz8/dfpIVzyTtJfucKBq1f/PF5U4/cCAABQj1AUlZGdU6IohSEHAQA1pFBrxHkyniXL2bqyW1cAAKgeiqIkEolUKhUKhYboNAnAf2LSCWiE0hN2bcatgv73WVlOU5ubI0XchnUyA0iIj4zrMWLnG0HY3BMxs8Mb1Foxg9pDadWvM3IceRxH/j+JWSL9yJSIEXtSBV1nnljzfbg326gB6gdmxbWhIYogCAqhf3Y1MvvatsRSz4FdO5p+KX/t80ePlXT/Tu0F5Q4kbttOrVnbTj18UkQF2tbFA6z6cIcOM/b+NSXm1f2/n2XICAt7z4Cgpq5WuDr3yXOiZdSfr6OMHSEAAAAToyWI1PRMDEMioQcdesoDAGpAVqrKkBY5WlvZcczwhhEAUGtIkkxLS9NoNCKRyBDVEQH4r0w6AY1xWnZrt2fl7p8P0iKCnHDp0wt7zxc0HNxFVPcu/LVJ0cPH7Mrwm3H67PJQB3PsRKWhEKGQOdnZOHDePVjTJv0ydszeTL9psWeXfGaKn1r77HDf5df5/ebuDP+38ASRkfZKgzl7OJdryU2lXI1P1DhO/KwRwyiB6hXG4XAwskBaQKJ/xxykiqQFBGJyOCzTzj6/w7Rt0Dq0AUKIKHx57cjSxQcOHrvypsv+gkP9Tf8RAgAAgNqkVKlS0zM5VpYujg7QVhEAUBOSopJ8ucLDzpoDQw4CAGpArVanpqYymUwvLy8YchDUESaYFCwH47b+dv7ENsSN36L+N3vxLxekPiMXze3jUfeOLuW1mOhEVcs5u5eaYfaZoqgMaYkaIZoV34ZTrluH8kbML3dVLabvXmSS2WeEEN3dlZ/1bP+2/eek1NtJmpzD28/+TbkO6Nbk31wzVXD55kuNTbMwH5N+ovMWo+nnYa5U0u51R9I0byeR0vift1zXWHfp0c5cWmJQirRbh9ZMi2jp7tw4dNSCrRefKRxaNHU1zR0VAACAsciKi1+L021trF2dHCH7DADQGUlR4nxZoULpLeBD9hkAUBNyuTw5OZnD4QiFQsg+g7rD1PNlmKVX13FLuo4zdhyfRry8eSuHZPKur/j2xfsJLozX8fs1o/xNdzMQJCnOySO1pCWGMNp7n4NIvn1LQjK5iSsmT6z4qdtPXjPcFJK1Vm0iJ7S+tPz3/sPSBnRr5kUrfHgr4cxLbdPhS+Y2LdfWWfH48hO1RWDT1mbQ/hkhxA6Z99PQC8P3DGuTdLBf1wB+6Yv4k8fvSvjdf145wMHU763VkgcXjx48eCD21M2UYoJCGN2mUdchg4cMHRLRqaE1/DgDAACovtx8aV5BobuzE5cDdRUBALpTa4nUvEIGnSZy4NP0MOoJAKD+kkql2dnZLi4uNjY2xo4FgPeYQA7QDGjT3oi1lPzp77ufVngFd6B/tXqUv1GiqjmlWiOW5LGZTBf7SgYW1KalirWU/Nml3c8qvII70CNWD/epnSBrhtao74JExxNL98WdP3XkkJrp2qD5zMXD5vTwtin3gVVP7t8owRs0EdXJ6uM6wJ3DN/xxIWjpqh0njmw8p2AIREHDl26ePzlUaLIZdqLwxbUTsQcOHjx+JSlfQyGMbi0KCbN+cflJxy33Dw2AwaIAAAD8FyRJpmflKFUqbw83FtRVBADUgEKtEefLeGwYchAAUCMURWVnZ8tkMi8vLzbbHMbfAmYGEtC1gdVze752u7Gj0LMiRWm6JN/ehudgw0NoTFz+mAozsLr/ml/8q1Fi0yumZ7uBW9sN/MQcrNZT0+9MrbWAagXNIXhs9LGx0caOQy82DGi57MxfWUoKYSyBX9jXEf0iIsJDm9mnrmzn/wTBdT4AAICPU95cNTqGPXvvlObvLpo1Wq04I4tGw0VCd/Ps2UrlHZ85ZNqzL06cnNbC3O8VFMlnf1r2y4Frj1MK1FbOfp0iJiye3c/fCi4OgL5o0q9unr/24IX74nwN26lRq/BR0xeNbGH3TyvnghJlVmGxsw2Hb2VO2SJKnnxl+cajZx6+eV3EdPdu0rXviAX9/OzNvW03nE+AEREEIRaLCYIQiUQMhsk2HPuUSi7JgGmBDQd08X/27jvOiTL/A/gzabvJZrPZZLPZZEvYBBGkiAiIYsMuij8URVCxi56eep7Y69kbVvSwVzxE5BArFlREPLHRbKeUtN1sssmm7yRTnt8fAaTsHsvuJpPyeb/udS/Jzky+057MfOeZ5xsIRwPhaIPJqCuqSyUoTsvf/b41XTnszDtm33rOEYOqt7Z6gqRBAQBAAaCB9+fMeWf5STPFrZ8kO1lXS4tOq7XUmoq0r6LoeevmS+f9GhhwOLf7iQsb9/vzU46+Zmms7qCTzz61kd+w/O23Hpm57Gvv5+9euS+KEkM/oMFPbpxwxqsuw6gpZ122V1n79+8teurqU75qWbTiplFqSv2xZCietNVUVZQV1YsU6d/nTzr7yeVCwzHHTTxBn/p15af//MdfP3c+smLWSJ3UsWUP2hOQUCqVcrlc5eXlNptNVqTD+Ox6SQYFBwlo2DOUUm97R5JNOerrypQ4fqAAGA0qpiW2/vXrzlr7yZTp06dPO+ng5sri/FkGAID+IXS2O3/67rPX7r/tDZ9o3vppOBptaQuYa4zG6qIdV1Fwzr/45g/bKFP8P5Q08vbdd38Ubjrv9Y+enVgrI4SI13xy7QkTn37o5jenLTnLXJSPFyCnhM0vPTh/Y/XEl5Y9O8MqJ4SQa6Zec8TJs5+es+iSZw+mMV4QHbUGlaLIXqRIvv/8q8sTtlmvPHf/SDUhhFwx9ZELzrv6Xy/Mm/HoX8xF2rSgPQHpxONxt9ttMBjMZvPupy48XV+SQSEq0h8AyA6OFza2+jmet1trkX2GQvHPzd417z51/fQDKjZ98PSNZx0+sG7AgafPenzxD20pqUMDAIB8RP2vnNy8z5iTLnvsq/ZMRxtKaVt7sNUfsNVbizj7TLgNc666Z7ntlGn7FFlGrCv8+uXfROTDZ1x9bO2WOyKZ8Yi/nXeQMv7l5z/gEgH6QeKHL9dylYeeNsW69YTSjJx8pFXW+ftXq0MMYey11UWXfSZEaP9tc5wY9ztm6NY3ZRUNxx1sU3DuX1zF23MR7QlIJBgMulyu+vr6Is0+d3FJBoULCWjoqSSb2tDSpi5TDagzKYpyxEMoVsqa4Sf85d55yzf6Nn75+n1/mbhX6sc3Z1956vRH1nD86jcee3NVC0uljhEAAPIHY5j02Gdf/mfFl18vvnqMkhAqur2tsXjCYWuq0BTx4GPpNU/NumXtkNsfvWRkKbwwziVI9cDhB+/n2O6qllFr1AzhU2nc5UI/UAyfOfvhuTNHbVfuWvBHkpTRWuvKbTVVsqIcxkdu2KupgnT8vHLT1lF8xPZvVrcKyvpB9cWbfEB7AjlHKfV6ve3t7c3NzTpd0Q5vs/MlGRQydGKFHokkkt5AyGyoMuoqpY4FoJeYCtv46deNn37do8GfPln4+uv/mr9kxR8Lr5v61k3Vex8x5cwZF1985mhTMd4IAADAnlHU7D26hhBCW1drZYSPBwgzpLmxvjhLDm6V/OGJ8x/+44Dbllw5iDwidTC5oDnm8ZXH7PiR6Fmy5GtONXLsiPKu5wHYE5pBE88YRAghRGRj4VC7d+X7/7zhrVDdCbdfMKSIb6m0J1159dk/33PXRZf9cfKhI6tSv331/qvfqY6/5m/nW4s3AY32BHIrU3KQUupwOBSKok7rbXdJpiveJqREFPWRCv2BUuoPR0PRuK3OVFFeCv1hoPgpjUOPv/ju4y++K+n+zzvzX3/9X28u/fi5W5ZHBp+24FQc4wCQHyilwWBw18+NRmPugylZiU6ukxKZoqyp3lrMuWdCSPybW6+c6xp/x8JzmhVkk9TRSCK1+b3bp974acJ2zs0zBuT4JrfLk10U+6ffJM/znZ2daE+kJGx4+P8m3PQjR4hMf8CsD56YUsSZWEKIwjJ65uQR7z+26pVn179CCCFM5fBpfz3SppE6sBySrD3p8kyPx+Mc1z9lZQVB6Ojo2LV1QmOSSyzLOp1OjUZTX19frCUHIR902Z7wPN/r6xMcrPC/iJS6/O3RRKfdWovsMxQdRtN44OnXPPH2D56Wnz585saJub7dBACAPBYKR5y+cBkhMnXxDvqcQSNL77jmidCEhx88vbnIE+1dS3u/ePDcw/adPnedafLcN+89To/3oaA/CaTugKsefuSem28/76Cq1bNPnPb4qoTUMWUPTax4/G9HP/6b44xbvv7ow9h/Fv/w2HkH+hecdM79iwIlMRYF2hPIqmg0unHjRoPB0NjYiOwzFBb0gIZupXne6WtXKRV2a60cTRsUM4VhyLEX3SJ1FAAA22EYBv2JpEIp9QXaI7GYrU6vKP7UAQ0vu/fieZ0nP3XXmUU8Qmt3aPjb56+/8NYF69L1R17+zCPXnzqsUoJd3uXJ3l+ZBYVCoVar0Z5IheV4VzA9aPyxE6p1MubSGfucvu91j97y5tQPzrUU5fkm+j+649U/VIfd/O/rjzMzhBDdfkdduFDTMfySJbe8fupJVw4u5gREHrQnXZ7pWq1Wqeyf0XPlcnl1dXV1dXW/LA32VCAQCAQCjY2NlZVFPIwP5Isu2xOFQtHr65Nibv+hLxJsyu0PVlVoLMZi7/UDAAAAsJUgCO5WH88LDluTIlAK9W5E/88/t3Btb1w0+o2Ltv987jjrXLn9kq9W3HhAsd4xCJ6Fl59y9qtO01GzFs++6iR7EVeYBAmkN335yoqW8n0mHLNXRa2ughBCiNx2xBHD5Ct//WWTQIozAc1v/GN9Wj5s7MjtC6tUjtp/rHLxkt82ROlgQ7E+1UN7AtmUKTmYTCYdDkdZGd5Nh4JUrJeT0CehaNwXCltrDHptKQ3VBQAAAKUtlU67vK1lKpW9ySKTyajU8eSEzDDm9Bv/fqiw7QMa/nr+vM/YkeecM77ROKZ4e0Xzvzx54fmvtQy98o337ji8tmhXEyQT/HnhdX97a/DtX5yxf+22D2ksGqOMWqMu1jQso9FoGbEjHBVJ3bazisYiHSJRaSrKinW10Z5ANnEc53K5ZDKZ3W4v8pKDUNRw7MIOKKW+UCSSSDZbatVlKqnDAQAAAMiReCLpbvUZ9FXmmpIarICpGXfm7eO2+0DY9OAXr38eHnPxtbOKtu8zIYRd8fiT36ZG3fTK7cgWQT+jlHg7onH76MN0C96bP3/VBTeNy/TqEQIfPLfoV1p74aFFOxKFcu8DjzH/a+7ieQtPvWWaRUEIIWLk8xcWfclrjzt0RNF2bkJ7AlmTTCZdLpdOp7NYLAxTtM9woBQU6w8f9IYgiq62dkEUHVazUlGSNWgAAACgJAU7wm3tQavZpNfppI4FckHY8M1//KKq8uv7/nrpjvkiRjf+r7NnDMFtEvQOL4rO9jBDmIGDTrvj728tu33O8Uf8Mm3iKAv1r/vincWrIw2nzLnpsOIdn6F85E3XT1w6672zpmyaf9y4ETr2v6s+//faUPWhV98/sXiH30B7AtkRiUS8Xq/JZDKZTFLHAtBXaAlhCzbNufztapXKZjbJZMV6bQAAAACwA0ppS5s/nkg2N9ary8ulDgdyhHc7XTyN//rxK7/u9BdZreKUB2cMkSQqKHQsxzvbw9pylVWvYxgy7K/zVlgfvePpdxY9tzzMqesGjZ55/19vPu/A4hz+eQuZ5cjrv3pxyN3PLFn8wYL3WaWpaciMv998y4yxtuLNPaA9gWzw+/3BYLCpqUmr1UodC0A/KN4fAdgTsWSnJxAy6LTm6iqpYwEAAADIEUEQXS0tlFKHrUmxy+tfjOWiT2IXdTljMZM3X/PhxmukjiLbyo57Khh7SuoooKhEkqy3I2aq1Ji2lBwkhKkYNuWmBVNukjSu3JPVjjz5sadOfkzqOHIG7Qn0L1EUPR4Py7J2ux0lBzNK9JKsuCABDSQYjbeFwg0mo66ieN8FAwAAANgRm0q5vK3q8vL6ulqZrJh7JAJAtgWiifZ4Z6OxqrIcdXQAoPfS6bTL5VIoFA6HQy7HyKhQPJCALmmUUm97KMGmUHIQoEfE0Jq3Xpr/+WpnTGsbecS086bsW73zeDW0c/Oy115avOKX1k6VccC+R08/d/J+NQpCOz649cJ/ruG2TSevn3L/nHMG4ZICAEAasXjC42szVutrjQapYwGAAiZS6glFWY6311aXoY4OAPQBSg5CEUMCunTxguhsCzCEcVjNCjxYA9g9wbnonrsXCoedd8U0Y2D5ay/efZ989j0nN25/9tDIyidvm7O+afKMa0Zb6OZl816967boHbPPH6r0+/zMoEl/P2Xolkc9jLreit52AADSCARDgVBHg8Wsw7iKANAHnCC4glG5jHHUVsvxIgUA9EFHR0dra6vFYqmurpY6FoD+hwR0iWLTnLMtoFWXW43VeLAG0CPpte++u6lhyqOXHNcoJ2RYTfiPWe+899MJl4z48+0B2vH10m/4cVdce/YhlQwhQwfXJTddufjjdWcNHe5v69DtNe6Qg4bjaQ8AgIQopV5fW7KTddgay1R4/QsAei+Z5lzBiE5dZqnS4pYKAHqNUur3+0OhkM1mq6io2P0MAAUID2lLUSSR3NjSZqjU1tcYcKkE0EOC+6df4nWj9rdmMsjypv33q43+8nOruN00NMaV2UaPGazdcl7JTRazIt2Z5MVAm5/WWmrFzg5/e4yjuQ8fAAAILwgbXZ40x9mbkH0GgD4JJ9nNgbCpUmPVV+KWCgB6TRAEp9MZi8UcDgeyz1DE0AO65PjD0fZwtLHWWKlByUGAPSC2+9up0WTY+txOZjAZaLs/IBLbtkd5Mtukmx76cxbBv3zZWjLw9L3VYktrgA8su/f8FzdFBKKoHDD+jMv/MnGgZuvdyqpVqxYtWrRtxnA4zLIsIYTn+Vgs1u/rIgjCtv/vXzzPE0I6OztTqVS/L1wQhEQikY17PEoppTQbm5pSKopilpZMCEmn06Io7nbiPZU5NjiO2+2UeyqzzGQymY39KIpiPB7v98VuW3hP9mMqlUItu7zFplJOT4u2QmM11yJbBAC9Rin1x5KheNJWo68oU0odDgAUsHQ67XQ6VSqV3W7HNSQUNySgS4hIqScQZFOco95cpsSlEsCeEdIpnlGr1VtzFoxaXc6kU+luejOnfKvemvv0og32s+44to7E1nZwaq1j0pX/OKSetK15d+4Tz93znOnxy8du6Svt8Xg++eSTbTMPGTIkk8kVBCEbaeKMzFdkQzYSlxnpdDpLSyaEZCNpnu0lF+gRkr39mL1NTSntycJ5nlcocHGVjyKxmNfnNxmqTSg5CAB9IFLqDkbSgmg3VZcp0eADQO/F43G3220wGMxms9SxAGQdfjJLBccLLn+7XCZz1JtRHwOgF+SqMjmNdLKUlDOEEEI7O1mqrOziDW6u7dsFc59ZvJ4Mn3zd7KljapWElB1z6/xjtv69cez0v56y+rI3vlhz0djxmTcRJkyYMGTIkG1LePrppzUaDSFEpVJl/qN/ZbrNlpeX9/uSM32fKyoqlFl4yhWPxzUaTTa6BkSjUUppVVVVvy9ZFMVEIlFZWdnvS+Z5Ph6Pl5WVqdX9/zoLy7IymUyVhQEKkslkOp2urKyUZ6H4bTQarazMynvQ4XBYJpPpdLrdTqlWqzOd0yGv+IOhYEe4yWrRVvR/iwoApSPNC872sEqhsJv0uKUCgL4IhUI+n89qter1eqljAcgFJKBLQjKZdLW06SrUFoMe75wC9I7MaKphNgU7RKKXE0KIGA6GGeNQ4443HzT564I771oYGDTlujmnjDZ3k7+T1dRby7iOGEtJpkd1dXX19sWOlUplJs3KMEw2elNmerZmY8mZsOVyeTYWzjCMXC7PRuIyIxsxC4KQpZ2YyXLKZLIs7ccsLTnzG5S9I0ShUGTpZ66H+1Emk2VjUBToNVEUPa1tbCplb2rAoM8A0BeJVNodilapyy16rdSxAEABo5S2trZGo9Hm5uZsdCUByE9IQBNCCCnqnGxHR0erz2cxGaurdt91q7DVDZA6guxT9n+XVeghedPQIRVvr14TmN5cxxAi+tas9VXuM7R+h2wou+7Vh9+Mjr/xoUtG6bdrV5Jfz7n6Vf7Me688uIohhBDBu8GZrh7aWFnMbQ8AgMQ4nnd5W+VymcPWmL1nVwBQCkLxTl8kbtFrqyuQLQKA3hMEweVyCYLgcDiy8c4oQN5CArqYUUr9gUAoFLI1NVWocN8F0DeqERMnNl3/5hOvW88/1OD/7PlFbscplw9TEcJv+OS1L4JDTjjtAMPPX6xot4zbS/jj+++2zSczOEYOHzeMu/fZBw381HH18uBPS+ctDgw954QhaIIBALIk2cm6Wlp0Wq2l1oTXvwCg1yilvkginOy01VRVlOFFCgDoPZZlXS6XWq222WwoOQilBtmPoiUIgtvj4XneYberVCrCsVJHBFDoFPZTb7iWe/rlOdcvYjX1I0+87uKTbXJCCO/99t0lm4QDTx0r87YkeOfSx+9c+udcTPkh18+75sCZd16rf3nBa/cuicoNDYNGX3TnWUdacc0BAJAVHZFoqz9gqTUV/+tfAJBNgkjdoQgviAPNRqUcV24A0HuxWMzj8RiNxtraWqljAZAAEtDFKZ1OO10ulUplb27GgzWAfiM3jT7r5tFn7fRp+aE3LDw085+T7l00qZt56w4487oDzsxmdAAAQCn1B0OhcNhWb63Q4E15AOi9FMe7QtEyhdxeWy3DixQA0AfBYLCtra2hoaEnRa0BihIS0EUoHo+7PR6DwWDGgzUAAAAoGaIoult9HMc7bE0qjKsIAH0QZ9PuUNSgVZt1FVLHAgAFjFLq9XoTiQRKDkKJQwK62IRCIV9bm9Vi0ev1UscCAAAAkCNpjnN6WlQqpb2pAa9/AUBfZEoOWqsr9RoUAAeA3uN53ul0MgzjcDgUCuTfoKThBCgelNKW1tZ4PN48YAAerAEAAEDpiCeS7lafXldpqTVJHQsAFDBKSUs4FmfTzSa9WoUXKQCg91iWdTqdWq3WarWiHjIAEtBFQhAEl9tNKXXY7XiwBgAAAKUjFI74Au1Wc61eVyl1LABQwASRuoIRSqnDXK3AixQA0AeRSMTr9ZpMJpMJj8YBCEECujiwLOt0uTQaTb3VindOAQAAoERQSn2B9kgs1txYry7Hm/IA0Hssx7uCEbVSUW+oQslBAOiLQCDQ3t7e2NhYWYlH4wBbIAFd8KLRqMfrrTEaa1FyEAAAAEqGIIiulhZBEB22JiVe/wKAPoixKU98Uhj8AAAgAElEQVQoZtSqa1FyEAD6QBRFj8fDsqzdbi8rK5M6HIA8gov1whYIBALt7Y0NDXiwBgAAAKWDTaVc3lZ1ebmtvhavfwFAXwSiiUAs2WDQ6dTIFgFA73Ec53K5ZDKZHSOjAuwCp0ShopR6W1qSyaQDD9YAAACglMTiCY+vzaCvMtcYpY4FAAoYpcTbEU2mOXttdbkSt8YA0HvJZNLlcul0OovFgpKDALvCr2xB4jjO5XbLZDJ7czMerAEAAEDpCHaE29qDDRazTquVOhYAKGC8KDrbwwxh7KZqhRwvUgBA72VKDprNZqMRj8YBuobcZeFJJpMut1un01nq6vBgDQAAAEoEpdTra0skO1FyEAD6iOV4Z3tYW66y6nW4owKAXqOU+v3+UChks9kqKjCIPEC3kIAuMOFwuKW11VxbiwdrAAAAUDp4XnC3tlJKHbYmhUIudTgAUMAiyZS3I2qq1JhQchAA+kAURbfbnU6nUXIQYLeQgC4YlFJ/IBAKhWxNTXiwBgAAAKWDTaWcnpYKjcZqNqHkIAD0hT+aCMaTTcYqbblK6lgAoICl02mn06lUKu12u1yOR+MAu4EEdGEQRdHt8aTTaXtzMx6sAQAAQOmIRqMej8dkqDYZDVLHAgAFTBRFj8fDJll7bXUZ6ugAQB8kEgm3211VVVWHkVEBega/uwUgnU47XS6VSmVvbsaDNQAAACgdgUCgvb290VpXWYKvf4UDUkcgBVOj1BGUEi4ldQS5w/G8y9sql8scA2yleEul0UkdQc6pUCoAsiUUCvl8PovFUl1dLXUsOadEh0joJSSg810ikXB7PFVVVZa6OqljAQAAAMgRSqnX600mk3a7vQyjbgBAHyQ7WVdLi06rtdSa0FcRAHoNJQcBeg0J6LwWCoV8bW1Wi0Wv10sdCwAAAECOcBzncrlkMpndblcoFCXVTxMA+ldHJNrqD9SZagz6KqljAYACJgiC2+3meX7gwIFKpVLqcAAKDBLQeYpS6mtri0QizQMGqNVqqcMBAAAAyJFkMulyuXQ6ncViQV9FAOg1Sqk/GAqFw7Z6a4UGt1QA0HuZkoNlZWV2ux31kAF6AQnofCQIgsvtFgTBYbfjwRoAAACUjkgk4vV6zWaz0WiUOhYAKGCiKLpbfRzHO2xNKtxSAUAfxONxt9ttMBjMZrPUsQAUKiSg8w7Lsi63W61W25qa8GANAAAASoff7w8Gg01NTVqtVupYAKCApTnO6WlRqZT2pgbcUgFAX2RKDlqtVoyMCtAXSEDnl1gs5vF6jQZDbW2t1LEAAAAA5Igoih6PJ5VK2e32sjIUWAeA3osnku5Wn15Xaak1SR0LABQwSmlLS0s8Hm9ubsbIqAB9hAR0HgkGg21+f0N9vU6nkzoWAAAAgBzJjKuoVCrtdrtcLpc6HAAoYKFwxBdot5pr9bpKqWMBgAImCILL5aKUOhwOhQKpM4C+wutIuceuvO+0aY/9yG/3EaXU4/W2B4PNAwYUbvZZ+O2hsVoNU9bF/xRDb/qG3/0S8hLvWf7seVOPsw4ZVjZwtO24iy5/bU1Q3GEKGln/wp1XTDjyIN3eBwyact2DK9o4iWLtR8nf375jxoQhDQa1Rlsz8MApN8xfH6dSBwUAAEUomUxu3LhRq9XabDZknwGg1yilrf6APxhsbmxA9hkA+oJl2Q0bNigUigEDBiD7DNAvCuFEor53br0rMO2x84dud09CY58/8EDorH+cbHAte+2lxSt+ae1UGQfse/T0cyfvV5PPa0UD7855/O3lky/ZlsPked7pcjEM47DbC7ppY3RDjjntNMdOiWahddW7K9usDaaCfNhBg5/9Y8J5b7gM+045/cK9VMHvP3rnqRtmfNX66opr9tVkJmHX3XXmjNvXa8ZOmnT5kbFv3n3n+rN/2PT8m09O0DPSxt4H3G9zpxx2+dKo9aBTLzi1idvw+aK3HpyxbKX784+u2RdvRecEpVQUxcx/8Hz/P70RRVEUxSwtmRAiCEI2Fk4pFQSB0mw9C8nSBsnSThQEIbP87O3HLO1EsjX4bCyc53mGyUrr28P9mNnj2QigWHV0dLS2tloslurqaqljAYACJgiiq6VFEESHrUlZyLdUACC5WCzm8XiMRiNGRgXoR3n/20xZ72evLl6fHLtTn9P4D6ti+55RF1v5yG1z1jdNnnHNaAvdvGzeq3fdFr1j9vlDyyUK938QOts3//Ttp6/de8sbPnFb5VSWZZ0ul1artVosWbpnzhmZ5YS7Xjxhx8/Ezc+fMvqjsTc/coG9EBPQguulxxZtrD76pfcen2GRE0LI306+5sQzZ7/wzOKL5pyhZwgRnQseemAtc9itr314oV1FiHjRITOOv+q5O1+84JCr9s/706trNPz2P279qGPAeW+tePZEs4wQIt78yVUTJj55z83zZyw5p66wD9MCIYpiKpUihPA8n0gksrF8kp0kYGaZLMum0+lsLDyZTGajqaSUUkqzsakzzxKytGRCCMdxmb3ZvzLL5Lj+f50jc4R0dnZmaT8mk8l+X2xGD/djOp1GtaseopT6/f5QKGSz2SoqKqQOBwAKWCqddnlby8vKbPW1aIQBoC8CgUAgEGhoaCjcd9MB8lNeZ8gCy2bf9uLX3miakpod/0LjP66KjpxmiXz9zDf8uCuuPfuQSoaQoYPrkpuuXPzxuvOHjpEm4u5R/4sn22YuTWX+teWqKBKJeFtaTDU1JlNx1scQva//7dav7LOW/X2YSupYeiW55sv1XOVxk6dYtva+14yYfJjlkRc3/uQSiV5OxNa33/4uaZx09XR7Zg1lpmNmnW5fMOf9N9Zevv+ovD6/usWvWf51WL7vVVcfb95ypMpqjph18UHP/O3LT79NnTMpDx/vFB+5XJ4pc6FUKisr+/8dUpZlRVHUaDT9vuREItHZ2VlRUaFS9f9ZH4lEtFptNt7QD4VChJCqqqp+X7IgCLFYLBtL5jguEomUlZVlI3OXTCZlMll5ef+f7rFYLJVKabXabLzx09HRodPpspHabm9vl8vlPdmP5eXl2XgkUHwEQXC73TzPOxyObDQXAFA6YvGEx9dm0FeZa4xSxwIABYxS6vV6k8mk3W7PxmUwQInL6wSZftTpVzf9H42unHv35zv8gSZWrwqPmFrPxFaX2UaPGazdcq8pN1nMinRntno/9QVj+L/Hlg8Pi4S2//uKUx7yEBLw+6OhUFNjo1arlTq67KDBt2++/UPTzM+uGF6od5byfWbec880x8jtfnz4WJyljNmUGWAj/fOqnznVmLHjNNvNM3aUkS76fl1QHGUuyA4YXJIYBg0/dLRjuywfo9aoGcKn0kirAABAH2VKDqpUKrvdjr6KANAXwY5wW3uwwWLWFestFQDkBM/zTqeTYRh7gY+MCpC38vq8UuobHHpCO35X79SZKbl6VceIUxtkMtmkmx7682PBv3zZWjLw9L23ffLTTz+1trZu+2fmrfZd+0aV5aDrjcK09xgTIYS2/lgpI0I8EI5EBjY3l5UV7ZC6yZUP3rBQmPLK38f1fyfLXNEMnDh1ICGEEJGNRUKh1nWfvTRrcch6ws1TG2SEENHv2cwyxkZL5XbHlMLa0CgTXa4WgRRmAlpz/OPfH7/jR6Jn8Vtfc6qR40bm5kFwZvSJHSIQRXQqBAAoAvF43O12GwwGs9m8+6kBALpBKW1p88cTyebGejX6KgJAH7As63Q6tVqt1Wot9JFRAfJWXiegu5NcvSo0/JTGHXJ7Kd+qt+Y+vWiD/aw7jq3b9umCBQvee++9bf/U6XSxWKyLBLQxd69rcbzAUkKoaLfby4q41Lu48fnbX3COuHbRScZiaL+FTY+cfuKNa3lCZNVjr3z/vuOtMkIIoclEgjJabcX2ByNTUaFlqCfRWSxVqFKb37lh6jUfJQZcePO5ORrKOxaL7fQJz/NIQAMAFLpQKOTz+axWq16vlzoWAChgmZKDlFKHrUmhKN5bKgDIvkgk4vV6TSZTsY6MCpAnCjEBnVyzqn3Y5D/zz1zbtwvmPrN4PRk++brZU8fUKv+c9Oijj7bb7dv++eqrr1ZUVEj4RCuZTDqd7TJC5FpzNoYxzR+J5U88slJ10kvnDymOtZTVnXLTYwM8bRvWfPLcG4+feK7s/ZcvGVuxpQpYl8dTcWRL055lj137t7ve/DltP23uvx8+rjpH586uY9rK5XK8pg0AULgopS0tLbFYrLm5OTPGPQBA77CplNPTolGr6+tQchAA+sTv97e3tzc2Nmaj7g4AbK8AE9DJNd8Ehp3UlMlr0uSvC+68a2Fg0JTr5pwy2rzzSBoHH3zwwQcfvO2f8+bNU6vVXSSgaS76qnZ0dLT6fHU1lWVMNznLokED/35yvtsy9dkTDUWyokzF3uOP2ZsQcvoZZww6f99bn7pl8ckfnGlmKiq0DAkld+jsTBOJOGW0FTuPHFNgaMe3T//twhtfX5dqPPKqVx+5edowXe5WaNfcBBLQAACFSxAEl8slCILD4VAqlbufAQCgG9F43NPaZjJUm4wGqWMBgAImiqLH42FZ1uFwFPHIqAD5o/AS0J3rVrUNPdGWyT+z6159+M3o+BsfumSUPo+zfZRSfyAQCoVsTU2aaOGOiNxTovut5z9ODLjkjEMLvIdT2rlywbdB24EnHFK/LfUptx1+yDDZN7/+6hSIWWlqaCoXv3d5o5RsG2pEaGvxirK9m6wF3PlbcC28+PizX9pkOubGxY9fd9LA4j9oAQAgS1iWdblcarXaZrPhUSIA9EUgGAqEOhqtdZW7vC0HANBzHMe5XC65XO5wOIr73XSA/FFwCWh23Te+oRMHZFoI7ucvVrRbxu0l/PH9d9umkBkco+zVUsW3K0EQ3B4Pz/MOu12lUtGo1AFlnbj57YVfp5suPWm/gu/jtPm9v//934NvG/X5BX9moGksFiNErS5nCCFlQ8fto3zjh6++TJ4yectlsPD7D2vbGeuZ+5oK9iab/+WxGee/7B169Tvv3XtkbcGuBgAASC4Wi3k8HqPRWFtbK3UsAFDAKKVeX1uyk3XYGnNRQB4AilcymXS5XDqdzmKxoOQgQM4UWgKaXfdN65Bjm7eMvxH2tiR459LH71z65xRM+SHXL7jmQIni21k6nXa6XGVlZfbm5lLp9UMDn374I2c8/ZhRBX9pqBxx4GGVC5f861+rps8al+kELLR/8PI7v1LThQfvpSCEyCwnTdr/xlu/eOrNTSec26wkhMa++eeCX4lj5ukjCu3k2ob94vHHvk6NvuOVu5F9BgCA3gsGg21tbQ0NDTqdTupYAKCAcTzv8rbKZIy9qRElBwGgLzo6OlpbW+vq6gwGDOMDkFMFkCNjqo+/c+HxW/5RPubye8ds+4tp0r2LJkkUVg/E43G3x2MwGMwl1esntvLT71Ll48ePLfxhlJjqY267fP+P73n2+BP/O+2YfS00sO7LDxevizT834M3HZwZXkQ2YOqsWW+edeedF5z4x6kn2PnvF77ymqfxohfP278Azq2uCb+v/E+bqNJ9ed/M/+6Yf2Z0h141+9xhBbtmAACQI5RSr9ebSCRQchAA+ijZybpaWnRaraXWhL6KANBrlFK/3x8KhWw2265F7wEg25BKypZgMNjm91stFr1eL3UsOZX6/vMVUdnA/fbNYcm67FENu/i5FXVP3fHih4teXhnmyusG7jfzjpk3zxhj2Zaa1Yy49bWXTfc+/MS7c6+Nq+qHHnrXy9fOOqy6cNeed29y8TT+84ev/LzTX2S1itMfPHeYJFEBAECh4Hne6XQyDONwOBQKXGoCQO9FYjGvz2+uMRqrS+uWCgD6lyiKbreb4ziHw6HCMD4AUsBdQf+jlLa0tsbj8eYBA3bt9cNYLvmk8xJJAsuNsgmPeTofkzqK/sNohk2etWDyrP8xiax6v8seePWyB3IWU3aVTXwhyL8gdRQAAFCQWJZ1Op1ardZqtaKvIgD0hT8YCnaEm6wWbQUKYgNA76XTaafTqVKpmpubUXIQQCpIQPczQRBcbjel1GG3o9cPAAAAlI5IJOL1ek0mk8lkkjoWAChgoih6WtvYVMre1ICSgwDQF4lEwu12V1VVWSwWqWMBKGnIkPYnlmWdLpdGo6m3Wkul5CAAAAAAIYFAoL29vbGxsbKyUupYAKCApTnO6WlRKhUOWyP6KgJAX4RCIZ/PZ7VaS21kVIA8hAR0v4lGox6v11RTg14/AAAAUDpEUfR4PCzL2u32srLCr0EMANJByUEA6BeUUp/PF4lEUA8ZIE8gAd0/AoFAezDY2NCAXj8AAABQOjiOc7lccrnc4XCgryIA9EVHJNrqD1hqTdVVOqljAYACJgiCy+USBMHhcCiVSqnDAQBCCMEwEX0liqLL7e4Ih+3Nzcg+AwAAQOlIJpMbNmxQq9U2m61Is8/sygemT3tiNS91HFklbHxp7D77M4O6+J/imMe+EaSOD4pNF6cVpbStPegLBGz11iLNPpdEY/InMfLtG/dPOvGo6qHjLEfOOPPJFZtTUoeUOyW2r/NPKpXauHGjQqGw2+3IPgPkD/SA7hOO41xut0wmszc3o+QgAAAAlI5wONzS0mI2m41Go9SxZAsNvD9nzjvLT5opSh1JVjHa5mNOONaxU7JEDKz6dHWb2WzCKAjQr3Y9rQRBcLf6eF5w2JpURZotKpHGZAva8eHt5548r6Vu1KFnnGVhf/pk/uxLl//24DePHmstgf5vpbWv8088Hne73QaDwWw2Sx0LAOwAOdPeSyaTLrdbp9NZ6uowQhkAAACUCEqp3+8PhUI2m62iokLqcLJB6Gx3/vTdZ6/df9sbPrHob2FltYfd9eBhO34mbl7wt9HLh998yxR7CSSMICe6Pq0yJQdVKqW9qaEYq7iXVmNCCCGERpY/dvHrnsEXPfv5daOqGELo+ZNmTT317TlPXHjUvSOK8l2ZjBLc13knGAy2tbU1NDTodEX5IgVAYUMCupfC4XBLa6u5traIe/0AAAAA7EQURbfbnU6ni7jkIPW/crLjL0u3vDBefBmx3RN97/9t9g/2mS/8fVBxdkeF3OvytIonku5Wn0FfZa4pzluqUmxMaPjt1z7w6I6Yfel+VZk+Woxh0t/ueHL45tpyjpCiTUCX4r7OJ5TSlpaWeDyOkoMAeQsJ6D1GKfUHAqFQyNbUVKS9fgAAAAC6kE6nnU6nSqWy2+1FOugzIYQwhkmPfTYsLBLavviK0x7xSB1PrtHw27Of/NB42mfnDlJJHQsUjV1Pq1A4Egq0W821el3R1tEpxcaEW/fZ952qkeMnVP75irC88aCLzz1IwqByoBT3dd7IlByklDocDoyMCpC3cHLuGVEU3R4Px3EOu12lwjU5AAAAZAvPd1HBSMI7q0Qi4Xa7q6qqLBaLVDHkiKJm79E1hBDaulpXev3Ykj+8eMP7wpSHzxmHPmS50uXJ3l8opaIodt2eZO9bu/iyHU4roTMcaA8ObKxXl5fnMopcK73GRAy4N8ZJbaNuw5v3nvXCR1+5OqsaBx844dRbLj9heEVRj1qZH/u6yzNdEARKaT9+xa7fIuHFCcuyTqdTo9HU19cX4zA+AJLpsj3pS2OCBPQeSKfTTpdLpVI1DxhQxL1+AAAAQHKiKIbD4V0/r6mpyX0whJBQKOTz+axWq16vlyQAyBHR8/yji5yDL1h0lL6oc0X5pcuTXRT7p4YZz/OpVKrr9qRKgq7Hgkg7KaF82j6gSY2+ikWHJmIxSiIf333Mv7iBRxx18eHK1h+WvfXMjR//GPj8lfP2Lc5xm/JIl2d6Mpnsr6dcgiBEo9FdK2BJdXESjUY9Ho/JZDKZTJIEAFDEumxPBEEQBKF3C8RPfk/F43G3x6PX6y11dVLHAgAAAEWOYZg8GWGZUurz+cLhcPGWHIQ/JVbNe+Q75UmzTx6CvhY51OXJ3l9FzmUymVwuz5P2hE2lnJ4QQ4hCW6NE9rkYUV7gqRgNqGc+/caTR9TICSHiX2bceuaJrz998zuTlpxagydbWdXlma5UKvurazDDMCqVKk/ak0AgEAgEGhsbKyuLdhgfAAl1d3HS6+sT/Or3SCgU8rW1WS0W9PoBKGliaM1bL83/fLUzprWNPGLaeVP2rd6l8e1ump7MCwCwFcMw+XBDJQiC2+3meX7gwIFKJerRFTsa+vcrH7jNxz57RBV+onKpy5O9vxLQcrlcpVJ13Z5wqX75ih6KxRMeX5uhsrycIYTBm/LFiSkvVzOMauxZtxxes+Uxlkx/9CXTDlzwwPLlPyZPPRqPMbOqyzO9vLy8v17glslkWq1W8usTSqnX600mkw6HI0+y4QDFp8szXS6X9/qBFn74d4NS2urz+QOB5gEDkH0GKG2Cc9E9dy90N0y64rrLJ1mdC+6+b7F757dPupumJ/MCAOSXVCq1ceNGmUxmt9uRfS4FYsvHz69IDjj+hEOLelRekESwI+xu9dXX1dZWIwNZzOQms1XBaCyWmu0yDbJaa72SpKKxZL8NRAyli+O4jRs3ptNpu92O7DNAAUEP6P9FEASX2y0IggP3XQCQXvvuu5sapjx6yXGNckKG1YT/mPXOez+dcMkI1e6nGfzT7ucFAMgn8Xjc7XYbDAaz2Sx1LJAb4uaPP/qas1x69BBc9UI/opR6fW2JZGdzY726vJzGpA4IskozePRA2fubNrnFwwZuzUELLa7NaaaqzqzDuxXQN8lk0uVy6XQ6i8XSX6+JAEBuoAd0t1iW3bBxo0KhsDc3I/sMAIL7p1/idaP2t2ZeYJM37b9fbfSXn1vFHkzD9WBeAID8EQwGXS6XxWJB9rmE0I5Pl//CVY8+Ziiue6Hf8Lyw0eVJc5zD1qQuR9f6EiC3T5k0VLbm9dvea+Eynwj+t+fM/5bWTDoWNQihTyKRyObNm41Go9VqRfYZoOCgB3TXYrGYx+s1Ggy1tbVSxwIAeUFs97dTo8mw9bmdzGAy0HZ/QCQ22e6m4Xc37w8//PDhhx9u+65oNMqyLCGE5/l4PN7v6yIIAqVUFPs/Ac5xHCGEZdl0Ot3vCxcEIZlMZuNyk1JKKc3Gps5s52wsObP7OI7LxsJ5nmcYpr8Kpu+0ZEJIMpnsr2I42xNFMZFI9Ptity28J5s6lUplY9VyiVLa0tISj8ebm5vVarXU4UAOJX78dC1XPnq/sXg5B/oJm0o5PS3aCo3VXItsUcmQDT5z1lVLLrrvqtN//eC4Y5plm75aumhtpGny/f84TCt1bFDA/H5/MBhsamrSanEgARQkJKC7EAgEAu3tDfX1Op1O6lgAIF8I6RTPqNXqrbdPjFpdzqRTadqDafjdzbt58+ZFixZtW86QIUMyeTpBEAQhW2NFZyO9mJGN7HNGKpXFckmZpH9hLZnn+eztx8zjhGzI3hGSvU1NKe3JwnmeVygK+OJKEASXy0UpdTgcBb0i0Aupdd+uiDMDh+6Nd+ShX0RiMa/PbzJUm4wGqWOB3KrY785Xnqt/+Ml/frTkkU9p9YB9z7vl4tvPHm0p7OezIBlRFD0eD8uyGPQZoKDh1mIHlFJvS0sikWgeMAC9fgBge3JVmZxGOllKyhlCCKGdnSxVVqp6Ms1u550wYcKQIUO2/fPpp5/WaDSEEJVKlfmP/pVOp0VRLM/Cm7CdnZ2pVKqioiIbIxfF43GNRpON7qXRaJRSWlVV1e9LzvTJzUat8Ezv+LKysmz8WrEsK5PJVKr+7waZTCbT6XRlZWV/VWPfXjQarayszEYnu3A4LJPJevJYWq1WU1qoJZZYlnW5XGq1ur6+vtD7cfcXxnLRJ7GLpI4iR8oOvMHz6w1SRwFFIhAMtXeEG611lRU7lxwsqdNqm1Jba7lh5GV3PXvZXVLHIYVS29fZlk6nXS6XQqFwOBzZuHoEgJxBAvpPPM87XS6GYRx2O3r9AMBOZEZTDbMp2CESvZwQQsRwMMwYhxplPZhGsbt5q6urq6urty1HqVRmsj8Mw2SjOcr0mc3GkjNhy+XybCycYRi5XJ69S89sxCwIQpZ2YibLKZPJsrQfs7TkTHY4e0eIQqHI0lvePdyPMpksG4Pb5EAsFvN4PEajEYOPAUBfiKLoaW1jUyl7U0NZFh5kAkDpQMlBgGKC7i1bZEoOlpeXNw8YgOwzAOxK3jR0SEXr6jWBTOdG0bdmra9yn6H18h5Mo+rBvAAAUgkEAm63u76+HtlnAOgLjuc3ub0iFR22RmSfAaAvOjo6Nm/ebDabUXIQoDggAU0IIZFIZOOmTYbq6no0bQDQHdWIiRObNr/5xOurNrj/+Pq1OYvcjhMnDlMRwm/45KUX3vimTex+mm7nBQCQEqXU4/F0dHQ4HA6UvgCAvkh2shucLnV5ma3eijflAaDXKKVtbW0+n89ms23/kigAFDR09d1aTbWxEdVUAeB/UthPveFa7umX51y/iNXUjzzxuotPtskJIbz323eXbBIOPPUAc7fTdPc5AIBkeJ53Op0Mw9gx+BgA9E2m5KC5xmis1ksdCwAUMFEU3W43x3EOhyMb9UgAQColfbMhSTVVURRDoZBSqcxGtav/RZXTmoodHR2iKBqNxlx+KakfmMtvi8ViqVRKr9cX8U07y7LxeFyr1WajWl1BkptGn3Xz6LN2+rT80BsWHrqbabr/HABACizLOp1OrVaLN1sBoC8opf5gKBQO2+qtFRpUcQeA3kun006nU6VS2e121EMGKDJFmzjbLVRTBQAAgNIUiUS8Xq/JZDKZTFLHAgAFTBRFd4svzXH2Jgz6DAB9Eo/H3W63wWAwm81SxwIA/a9EE9CopgoAAAClacvgY01NGHwMAPoizXFOT4tSqbA3NaBDDwD0RSgU8vl8VqtVr8cwPgDFqRQT0JmmzWKxYDx7AAAAKB2SDD4GAEUpkex0t7ZWVVbWmWrQoQcAeo1S2traGo1Gm5ub1WoM4wNQtEouAd3W1tbR0cBv0u8AACAASURBVGGz2SoqKqSOBQAAACBHOI5zuVxyuRyDjwFAH4XCEV+g3VJrqq7SSR0LABQwQRBcLpcgCA6HQ6lUSh0OAGRRaSWgBUF49NFHtVqthOPZU0pTqZRMJivuiq6pVIpSWtyV6ziOEwRBpVIVcXkEQRA4jlMqlZKnKn777TdpA8i91157rbKyUi6XZ+NSTBAESmk26mfyPM/zfJbOi3Q6rVQqs9HNKntNFqWU47hsNPiiKKbTaYVCkaX9yDBMNk78rLacqVQqS716WZZlGKYnC//9998PP/zwbMTQRxh8DAD6BaXUF2gPR6MoOQgAfcSyrMvlUqvVNputiO+pASCjtBLQ1157rUwmk/a+K5lMLlq0yGw2H3zwwRKGkW2LFy/u7OycPn261IFk0YoVK1wu18SJEw0Gg9SxZMuvv/763XffjRkzZu+995Y2krFjxw4YMEDaGHJpxowZv/3223vvvdfU1DR+/Ph+X74oioSQbFznff/99xs3bpwwYUJ9fX2/L1wQhCy14QsXLqSUnnbaaf2+ZEqpKIrZyOS2tLQsW7Zs7733HjNmTL8vPHtHSFZbTp7ns5GOp5TOmzevqqpq0qRJu5147NixAwcO7PcY+qijo6O1tbWurq6If7AAIAcEQXC3+nheGDjApsxCewsApSMWi3k8HqPRWFtbK3UsAJALpXXdcOyxx0odAmlvb7/jjjs0Gs1RRx0ldSxZ9PjjjweDweJexy+++GL9+vU33HCD5MnZ7AmFQuvXrz/hhBOKe1fmoREjRmg0mvvvv99qtRbWxv/555/Xr19/4YUXFtYztgcffJDjuMLa1P/5z38ef/zxESNGFFbYy5cvX79+/fXXXz948GCpY+kpSukNN9xgt9sLa1NnUEr9fn8oFMLgYwDQR5mSg2Uqlb3Jgr6KANAXwWCwra2toaFBp8MwPgClorQS0AAAAAAlQhRFt9vNcZzD4Sjugb8AINviiaS71WfQV5lrjFLHAgAFjFLq9XoTiQRKDgKUGiSgAQAAAIpNOp12Op0qlcput6OvIgD0RabkoNVs0qOvIgD0Ac/zTqeTYRiHw5GNYdMAIJ/hnAcAAAAoKvF43O126/V6i8UidSwAUMAopS1t/ngi2dxYry7q6uIAkG0syzqdTq1Wa7VaUQ8ZoAQxlFKpYwAAAACAHRx99NEff/xxL2YMhUI+n89qter1+n6PSjJcSuoIpLD5J6kjkMJeo6SOIF8cf/zx77zzTt87CS5evNjr9V522WVd/O1/nlmCILpaWiilTVarQtH/1XQhp7x/SB1BztXnXU3gXFCW7frZ0qVL161bN2vWrL4vfurUqU8//XR1dfWezhiJRLxer8lkMplMfQ8DAKRy9tln33fffVartRfzogc0AAAAQDGglPp8vkgkgnEVAaCP2FTK5W1Vl5fX19ViGB8A6ItAINDe3t7Y2FhZWSl1LAAgGSSgAQAAAAqeIAgul0sQBIfDoVQqpQ4HAApYLJ7w+NqM1fpao0HqWACggImi6PF4WJa12+1lZV30zgaA0oEENEDP0XQixpfpNDhvAAAgn7As63K51Gq1zWZDX0UA6ItAMBQIdTRYzDqtVupYAKCAcRzncrlkMpndbkfJQQBAK5B91PfOrXcFpj12/tDthk6jsc8feCB01j9ONriWvfbS4hW/tHaqjAP2PXr6uZP3qynovSL4v53//LxP17jDoqZu74Mmn3fO0XZNcZQY4J2Lb7tukfXaFy8ftXUXbdmPt09Ye/uF/1zDbZtUXj/l/jnnDCqQwfKEP1654pq3EuOvffTq8fpt+0r47cVLb/p14pz7/q9u22fJlQ9ddP/yZNO02Y+eYS+QtctzYmjNWy/N/3y1M6a1jTxi2nlT9q3e+XShnZu7aiVoxwe35vqo60G03U7Tk3mlCzuPNvIehN19eFJt7d19L/fNw2fd83nnjrUnZNZTHnjyHNNH0m3qjC5/rLfJwwN7O7FYzOPxGAwGs9mc+28HgKJBKfX62pKdrL2poRx9FQGgD5LJpMvl0ul0FosFJQcBgCABnXWU9X726uL1ybHijh/Hf1gV2/eMutjKR26bs75p8oxrRlvo5mXzXr3rtugds88fWrA1poXNb93/wPuyo8+7/tImRdt3bz7/zztSVU9ceUBl4f/kpP9Y+PjrP3eWbT/W+pb9aCH+j/zMoEl/P2WoKvMHRl1vLbAOaDS04vmXDh1+5Vhdt/uKxr5b/n1SrVF5VqzYeLp9L2Sg+0xwLrrn7oXCYeddMc0YWP7ai3ffJ599z8mN229ZGln5ZJethNLvy/FR14Nou52mJ/NKF3YebeQ9CZuI3YQn1dbe/fcq9pp09fXj+G0JaBpbs/CFHwcOt8jEFsk2dSaSrn+st8rDA/tPwWCwra2toaFBp9Pl9IsBoLjwguD0tDAMsTc1ouQgAPRFpuSg2Ww2Go1SxwIA+QIJ6CwKLJt924tfe6NpSmp2/AuN/7gqOnKaJfL1M9/w46649uxDKhlChg6uS266cvHH684fOkaaiPtMcH71pdNy4oMXHNUsJ2TQXjXBNZe9+Z/fhANGF/qRxv7yryc+lA9slLu3+3DLfrTKuK/aOnR7jTvkoOEFe7Uuqxs+WPzy2VcP2efS/bVdp6Bp9NvlP3L7nHa+acmzX634/cy9Bhfs2uaL9Np3393UMOXRS45rlBMyrCb8x6x33vvphEtGqLZNQju+XtpVK3HW0OH+HB91PYi222kG/7T7eaULO4828p6ETQjXdXg9mleamBnDXmMP3Gvrv2j8h6de7jz8L+eOqmRSkm1qQgPLHu7mx3qrPDywM6FT6vV6E4kESg4CQB+xqZTT06Kt0FjNteirCAC9Rin1+/2hUMhms1VUVEgdDgDkkQLrpFlY9KNOv/q2+2bfduqgnbKvNLF6VXjE2HomxpXZRo8ZvDXfJzdZzIp0ZzL3ofYXRrvPxHOmj6/fmkCQyWWMovArIdHEmlfmfFF39l+OrJXt8HFmP8rEQJuf1lpqxc4Of3uMo90uKI8x2hFnzjycLntm3tpk1ytAO/6zfK0w5ODDDz9olNa/8stfuS4ng54T3D/9Eq8btb81c8LIm/bfrzb6y8+t23fBpN20EnzOj7qeRNvdNFwP5pUw7PzZyHsUNukmvB7NK1XM22N/mv/8j0POPXNkBdPduuQE0+2P9VZ5eGATQnie37x5czqddjgcyD4DQF9EYrGNLo9BX1VfZ0b2GQB6TRRFl8sVjUbtdjuyzwCwk0Lvl5rXlPoGh57Qjt/VO13IJVev6hhxaoNMJpt000N/fiz4ly9bSwaevnduw+xPstr9jp9ECKHB31au3eRd98m7rcOmXjK0sA8zGv3uhSe/ab7gocNrflix/R+27kciBloDfGDZvee/uCkiEEXlgPFnXP6XiQMLbOhrpnL/sy88+KoHn/7XwQ9fsOsoMLT96+Xr6T4XjjVqNAfuV/HF18t/Pmfovjnq5lekxHZ/OzWaDFsfa8gMJgNt9wdEYtv2pENm67qVUIstOT7qehJtd9PwPZhXwrDzZyPvUdjdtTxKibZ2j2L+k+Bc8uIXximzD9Ax3a9LblrRbn+st8rDA5tlWafTWVFRYbVaUXIQAPrCHwy1hzoaLXWVWmSLAKD30um00+lUKpV2u10ux6uyALAz3LRIILl6VWj4AY07bPuUb9Xrd97wzO/2M2YeWydVYP1H9P3wwbvvLV3pVNoGWSoKKw+7E9qx8pm564ZdfNFBOxeW2rYfaay9g1NrHZP+8dKbb7465/qJ2tXP3fPct3FpAu4DpuqAc88bl/hg7hu/pnb+G237avmvsqGHHGBgiHr4gftpQv/5cv0uU8EeEdIpnlGrtyW9GLW6nEmn0t30/tyxlejmqMtez9GeRNvdNPyerWmuw96OxBt5j8LuruWRamvv0aamka/+9U780NOPrGX+17rkyfsk+XZgR6PRjRs3GgyGhoYGZJ8BoNdEUXR5W8ORqMPWiOwzAPRFIpHYuHGjVqu12WzIPgNAlwq7a2phSq5Z1T5s8p/5Z67t2wVzn1m8ngyffN3sqWNqC37ACkKIfOj0u2ZPp8kNb9110/2P6efcMbG2QLPQwS+efm7D6CseHFPFkB1zCtvtx+pjbp1/zNbPG8dO/+spqy9744s1V4wdn+tw+4qpPvi8c1dc9dTcheMfmLb9H0Tvii9/JwNOrYu6XTFCqpvtquXfLF9z4aixBVswUwrcNw+fdc/nnZQQRnvEzS9fpiqT00gnS0l5JgnX2clSZWUX3cq7aCXKuj7qLho7Pkuv4st7EG130/Rk3izp+Vfnw0beo7CZblqecw+VZmvvyV4WPR+//YPpqNlDtlYc7GZdcrCpeyKvDuxAINDe3t7Y2FhZWZnVLwKA4sZxnMvlkssYh60R2SIA6ItQKOTz+SwWS3V1tdSxAED+QgI655JrvgkMO6kpc51Hk78uuPOuhYFBU66bc8poc6GPZ0Bjv3+53Ft78GGDqxhCCKOxTzjY8a95v7sEUlugh1rLb//t8LbfdsYHf350+ymfWk954MG9t9uPO5LV1FvLuI5YzoLsT0zN4RfM+PKq5/7577Hn/vmp6F6xYiPPCfNvunz+n5N+++WPybEHanIfZMFSjrrkmVfOp5QQhlFplDKnqYbZFOwQiV5OCCFiOBhmjEONO3Zo7FkrsfWoYynpbhiBPpIZdx9td9MoejBvlvQk7PzZyHsYdtfhpQ3SbO09iFnY8Nlnbvux1zR0F1MON3VP5MmBnSk5mEwm7XZ7WVlZdr7kf4lGo+l02mAwSNPtWinBKhNCOjo6BEGoqemmQGW27TVKkq8NBoMMwxgMBkm+XRKU0mAwqFAo9Hq91LHkQjKZdLlcOp3OYrHkftBnQRA6OjrKyspK6kEax3GRSEStVks2MO6Aobn/TpZl4/F4RUVFSdUqSCaTyWSysrJSkh/rHJO85GA8HmdZVq/XKxQFmm/oDYkvySQSDod5npfskkwiRXZJVkLHa57oXLeqbegBtkzekl336sNvRsff8NAt0wo/+0wIIcSz/OW5i37c9to0H2gLkcoqXR4kEHpp4JTbZj+81V3T91FWHDDzwdk3TjL99Od+TH495y+XProisq0EmHeDM13d2Chh2H3B1B4188zBLW/NXeLkt3wkbFz+pVM56q8vvb1kq/k3TdAlvl/+fb68Il8glJqqKr1er9dXVWmURN40dEhF6+o1gcxGFH1r1voq9xlav8NjjW5aie6OusqsnWw9iba7aVQ9WVPpws6fjbxHYXcXnt4mzdbu0aYmhBDC//r58ra9DjnIvG1DSripeyIfDmyO4zZu3MhxnFTZZwAoGh0dHZs3b66trbVarSg5CAC9JgiC0+mMxWIDBw5EyUEA2K0SekyUH9h13/iGThyQuTvlfv5iRbtl3F7CH99/t20KmcExyl6gr64w2tFHH/Tq/a88PF9+yv51stDPS1/7oGOv6Uc4Cve9PnWNzbH1GRuNOTWMXGd1OJr4VYv/3I/q4eOGcfc++6CBnzquXh78aem8xYGh55wwRLqo+0hWd+zM6Suufv6HTvkQQggR/ljxVYtm9PQDtxsGW7PfEQcZvvjiy+9iBx9ewA8YJKYaMXFi0/VvPvG69fxDDf7Pnl/kdpxy+TAVIfyGT177IjjkhNMOMHTTSozs5qjLYpveg2jN3U0j727e7CusjbwnYdd2F55KlGZr9+QIkRFCBOePq8OWg4Zs16B014pKeo2SRwe2tH0VAaBoSN5XEQCKRqbkYFlZmd1uL6l+uADQa0hA5xa77pvWIcc2bxl/I+xtSfDOpY/fufTPKZjyQ65fcM2BEsXXV0zl2Jm3XPrqi/9+7q6FMaqpGzTunNtnTOxynIqCtsN+JIx29Mw7r9W/vOC1e5dE5YaGQaMvuvOsI62F/DMsbzjh4qkrrnnlD0II4X5dvqKt6sCZo3fojKgaesShlo/eX74qcthReuRDeklhP/WGa7mnX55z/SJWUz/yxOsuPtkmJ4Tw3m/fXbJJOPDUsbJuWol51xyY86Nut9EeYO52mu4+z4HC2sg9D/sAc7ctj0yird2TI4QQGli31qceNKRhu5DyshXNlwM7Eol4vV6z2Ww0Gvt50QBQSkRRdLvdHMc5HA6VqijevAQAicTjcbfbbTAYzGaz1LEAQMFgKMUb9AAAAAD55eijj543b14wGGxsbNRqtVKHU6IDDko8BrREimzAwZ7IzzGgjz/++HfeeafvA5suXrzY5XIdf/zxKpWqsbFR8lMYY0BLHUvuYAxoqWPZYunSpevWrZs1a1bfFzV16tT77ruPZVmr1ZoPDSbGgJY6ltzBGNB54uyzz77vvvusVmsv5i2hsxQAAACgUHAcN3fuXJ1OJ5fnxYtEqVRKFMXy8vKSGgaEZVlKaUmlTgghnZ2dDMOUl5dLHUhOdXZ2ymSy/EkYEUISiUS/LIfjuJUrVyaTyTxJfVJKWZaVy+Ul1RFbFMVUKqVQKJRKpdSx5A7P8xzHKZXKkkoOchzH87xKpcqTn29CyKZNm3qXLdoVz/PPPfecyWTKk32aTqcFQSgrKyupVGxpXpJl1hqXZJLz+/29nhc9oAEAAADyzhtvvKFQKPLn1oLneUppXoWUA5m1LqmEESGE53lCSJ4kF3KG4ziGYfJtrSdPntz3rMp///vf77//Pn9y65RSnudlMln+pOdyILPWcrm8pNJkoigKgoC1zgcDBw4cMWJE35ezZMmSdDqdP6smCIIoiqV5cVKaa41Lsnxw3HHHaTSaXsyIBDQAAAAAAAAAAAAAZEW+PLn6f/buMiyKrQ8A+Dkz23SnNBImYqGAiYGBYqAY2NdrXLt9vdZVr93dmFjY3cm1CxVpEEW6Y3dm3g8LssCyu5Ss8v998HlcZk7MzDkz858zZwAAAAAAAAAAAAAAAAD8ZiAADQAAAAAAAAAAAAAAAKBaQAAaAAAAAAAAAAAAAAAAQLWAADQAAAAAAAAAAAAAAACAagEBaAAAAAAAAAAAAAAAAADVAgLQvys6aoM7l1AZcCqv1J+Edyaasdj15r8Q1UC5KiMn4tqGv7xb2RlrCbg8NT0rZ88xqy6F5dR0sQAAv7mX/6vPJutMuC0s/nN+6EEfCw6h1mTqte90zZQMAAAAAAAAAABQehCABr8G+uvlKW6Nu07Zfi/V1NV76LD+Hk5aCXf3zOrRtOOix+lMTRcPAFDLiCKPjewy+kSiw8QTl1d30oeTKQAAAAAAAAAAIB2rpgsAgAKEH7cMGbTxjU6frad3/tFYE4t/FcVdmd6tz8Z/RvzT6eW/LryaLSIAoPagYk+P7TLsyNe6fwZcXdfFAKLPAAAAAAAAAABAmeC2GZQHlZ8nqtrRxpRQKPfVdSbp7KIlt7PqTT96YOyP6DNCiGXcZcWG0ZZ0yP5dt7KrJ+sKq9bEAQA1iP56cWKXwfuirUcfvbqxm2H5T6NyuwfoPwAAAAAAAAAA/EYgAF3r0eHrXLmclqs+U0U/ha1pzeW0Wh0qDoFkHvXmc1svu7BneBMDVT6Ho2JQv9vc89HC3NCAKR3t9VX56kb2bcfseZNVlGhexKXlwzvUN9Hkc7iqelbNvKYdeF00T0bmUW8+13XNk5tLethq87lsnrZZo84TD7zNlF5CJunCgXOJ/PZ/TWzOL/k3XqvJu/fuWuFlkl+YOp30dNfkns4W2io8FW0L556Tdz1NKgrlKJB19qdTCwa0tjVQ5XJVdK1d+i8IDMv98cecsPNLh7ZxMFTnq+pZNun+19YH36iqSFz+XpBTMADAT0F/vzbN02dHmPmII1e39DQmJf4ks9/LO+Orxm3xz/XAmR6Wmnwum6dp5uw149BbxReQmwUAAAAAAAAAAKCUYAoOoBDR+zVDJ2k0G/b3Gsvs//y3BKwY0PVBg9RQovPoWd3I4BObD+z+c4iR8/NFjVkIMfEnR7oPOJpq5eEzpo8ZPzvqcWDAuhH/fVN7d8hbp3D8MhW1b0S/WMJ9xMJxdajgwJ0HtozsSZu+29JBpVTewmf3g3JZ9dq66eNSf0Msi3ZDR/z4H5N2Z1b7bmvecRw9+47z1Ux5fenUpj/a3g65eG9lWw1Fsqbjjvi1HXo6z7HngL8G6Yli7p84urT/64wbL9e5C1B+8OZebSfdyLfr0u+PvvrCyAdndk3oePHxwbsH+psSlUtc7vwhMgsGAPgp6KQ7/+ved8MbQc89V7b1MpWMPivS71GhW4cOjBfaeg6fYseJfXju7Bq/+8++3706tQFHkQUU6loBAAAAAAAAAAClw4DfExW53o0jY8ezHOc9FzIMw1Bha1tz2C1WhoiK1g1d3YrDdln1mWIYhmEyjvTmIcLI51ic+P9UxHo3DsYqrVe+y2MYhmHohEO9NTC3085vNMMwTNpRbxVCq7d/PF2YXuzW9jzSZNxN8eLiBDG/2f+CMgqWyLozyYZk2c95KixdEzpxrycX8XodTpdbaeHrhY3ZhJ7nluDswoTfb+yiQ3CcFr8RKpI1/XWHB5fQ9T2VWvDX/NfL3QwNnOc/ETJU9PZOaqRet+0heYUlS3s015lPGg47n17pxOXsBVnrAgCq2Yv59ViEse/i2a00CQ6Xg8k6Q07/6ODE5PV7uacHqmJEGPbaHZJTsED8tUkNuYR6971xtCILyO9aAQAAAAAAAAAAZQQjoH9rmFW325+eNmTxX+nY2/tOvS9fSoRut+G9jMTDfAnjeo7a+L/Gw4c5ikPcWNOxXh3yojBfyCCEkWqvfdEJDF+jaMhxXh6NGJFQJFk0fvtxfzVTLfifoLGzA5sJzs+X9i45TYsnoZA7wo/6dO7ce9rqr3mjHArn6hA4/jF3yLrrW85d+Dy3gQMpN2sWl0symcF374Z37mGlghG74ex7X2cjhBATd/Hk3Ryrv/430rYwsI/VW04c47pm3M2rz4Xd27IrkTiSO9+rjHUBAD8B8/XY3yvVXf53favZao/RRyZO6t7ycH+jH9NYKdTvsRxH/+1nW/DCA6Hf8e85PQ4MunTmesqwodpyF8AKZQEAAAAAAAAAACgbCED/3jhOw1at68Mt/qPwzsQzZ8oZgMY8Pq9ownCCIBFWVVf7ERImSInZxAmeunr6ywu7Lj168yk8Mjry8/t3YYl52KBYgoS2hbkGlkixzOnIsbqBgQBTcbFxFKpLlvqz6MuzG68SNBzbuFiSkWGRIrZb4/qSQ785DZzqsaknoVEUKghAy8ga6/ZduPTk27mbetnuMnBs7tLSxbWdp7eXq4UKFkV+jhCJwla1ZK8qWUBBQhKFELsSiZdV9ypZFwBQBRis1nLuuQt/u2kxlqvPNx0eMOmvHq2P+5oUNHGF+j1BI2d7ibMuVndubk8Ghn+OpJC23AVYCmUBAAAAAAAAAAAoG/gIIZCCYZiKf9aKSbkzt3Xdpj5/nwjO0a3ffsDkNacf7+ynXjJQKiPkXAKnaatmXNG7m3e+SRknLHqzbViPHj7rn9PigqNSI6UJgkAMTVPFfymLivOU858in5/bPn+Ak+DLre2zB7exd+i17X0eIkgCser/se/8hRLOn5rhwqpk4tIU3wvlWxcAUMUIQ99//uemhREi6gzevLa3/vfTU8b7Rxf0Sgr2eyX6J0yQBEY0RSuygMJZAAAAAAAAAAAASgVGQAOEEEIMLREBEX2N/Uojo4qlREcfWrjuGa/vkVdHfQwLYrE5p7fSFY9oY4MegzrNvnF5w7pHvqtdVYv9Le/FiTOfKEFHj9YqCNHm1hYsYfCr98JBLuzCJYTvXwcLWeZW5qUHT0spfPLn56FpWrbO3Uc7dR+NEMr/cnGyR68dSzY/GLGwrhWb+cSz7tStaHJtJvXd1esf2KrqijQkGYmP3GKJkKy9IGvdbR1kTfYNAKgaBIELg72EycCN6849GnRy+rh9bc6OtCAV7Pey3778JPJq+KO/yHj17KOI1cyqDokQJWeBqu9aAQAAAAAAAACAnwJGQAM2m42oiNfv0griGFTsiU0B0ZTslcpGJ39PFBHa1tY6hQdXfuSZEw9yKlFCbOSzcHpz7ocNAwaufZJYVLL8mAvTx2z8wNQZ+Fc/Q4wQad+jhz0RdnD53pDcgkVyP+1ZdiCccOjRw16RALTo5bpeLi7ea14UjivmGNrb6pBIJBRivc693fnR/ou3vS9MnEm+vaB/z4GzLyawy0pQwcTl7gWZ6wIAfjbC2GfDBh+jlMszx+4KoxTt90Tvdy05HJ4v/g+deOefZYEp/NZenfSw/AWqoWsFAAAAAAAAAAB+BhgBXesRRq5tHdl3A8Z25b4d1Ewj6cWZ3f4vs1VZFX2vm+XQpYvVv+s2DR1Aj/Iwx/HBt48fe8loqqHvj4/vu2ExqENdVfmJlMR1mnVsb7jn8L3TXW22uXq0aWDMzYp5devak+gc9WazD67sIp52mdVoyrrxp3tsGOfS8qqPZwON1DeXjp97m1tv6vopjRQ61DkugwbZ7139r6frp34eDY04qZ9uBpx4RDacM9KdQwiGrVp4rN3Mqa0bX+jR1cWG//Xh8aM3Y0wHH53Riis/aTmJc2TvBVnrln9zAgAqDRv2Xb/p/IN+h+f8sa39lVHy+j02QgjxjLmPxrq4nOvrYceOfXDm1INYrsuSlcPMfjwKlrEAIb9rhdk4AAAAAAAAAAAoJQb8nqjI9W4cLPA5mVvqT/m3J9QhWY7zngsLfsgLOz3by9lST8DCCLP0W886u2uwFsdl1WeKYRiGyTjSm0eaTbyTX5hA3s0/TQhe34Ccwh+Er/5uyOK02xwjXiHnU8CMHs6WeqpqBnYtuk/Y8TQp/dFidyM+R7PT1khKSoIMk37Ii0daT3so8VMpdNr7U0tHdHYy11HlsrlqelZNu41ddTE0u0TFvz/eNtGzsakGj8PTrOPUfdLOoETqx1/lZ50fdXnZEHc7A1UOfISIZQAAIABJREFUiy3QsWjac/KOJwmFCdAZ74/P7dfCUlvAVdW3auwxcvWN2PwqSlzOXpBdMABANXoxvx6LMB1/q2QHRX8/O8yMxOpt1gbny+n3ck8PVCX0R10Iu7TAq6GxGperZtzQc/LeFyl0QVpyF5DftQIAAAAAAAAAAMoIM5X42hz4zTB5KV+TCT0jDYVmlADVA/YCAL+hvDO+un1vDrgUs6uz9LcW5C4AAAAAAAAAAAD8mmAKDlAEc7WMK/jpQVBlYC8AAAAAAAAAAAAAgN8GfIQQAAAAAAAAAAAAAAAAQLWAADQAAABQzQjDJl26ezTUK/OkK3cBUFsN1SKwDJwmS99TiqVEhfzbgoO5rdeE0VL++3tivp0abG7qezKhpgtSXehv9/auW3/iVWZNF6TKVLxGuU/nNdJ1X/M+vxpK9bth0j+cWz99UIfG1sY6KjwVbSOrhm19Jq888SpZwd6k9vjRh8CcldWASXh8aPPBB99KnISgLf9ahE9m2rExxphdb/4LUTVnVuWXLtSbRY3ZmNdpx7fKt3Hl7i7KaG61FvQzNQRudQEAAIBqxnaZfuLsoYlNypz3Su4CoDbDXC0TC+nMjTXhiwFlYRLPzpwUaDZ1UW+9n5ltdujZf/zaORhpCFR0LJx7Tt7xOEGxqF65V6Qi9o7qM3rqrG0PU5XhjrLCFS9SZo2Ed/8yZ0l9BNNs+QdxLrym0/7u8nnx+G0hEESVRRh9brq7XaNeU9YcufUmKplS1VZjUqPf3Q3YMMunad0WY4+E5FYo3fwvL2/fvP00KruKy1ujJPoQXA3JV0GTqR7lLljeednPSovaqSQ6+tic0VOWnosq0X9BW/6l5P8XcDpMhBBCopBTJ15WdwRaeSl5d1FWc0NIoTNszalQxeGaQYnV9FcQAQAAAACAdEM0MWI7LXknqnRKok8rmrMRp9XqUErKf39DuY9nOnAMh55NpX9ennTqw79dNAmECRVD+4b1LbQ4GGG2le/RSDk7sAIr5n/c0F6TQAhx2m2OqemdWOGKSyq7RnTiXk8exphglcRvsfzDjyzyXy5oyNH3Of79J+7yX4sowr+/GRsjrGLbc/6hBxHp4m1HZUY/Oba4n6M6gTBp0HVrcF65U6bjtnXgInbTZcGV76uURnX2IVXSZKpDhQqWe36YDrtU62SxWCwWSWCEua5rw0p2UnTyzb8c2Ji0nfFEWCpBaMu/jNw7Ey1IRJrY22kQiFV35pP8as2uyi9d6OQXZ/bu3nf5Y3YlE1Lu7kJmc1PwDFsDKlpxuGZQYhCABgAAAABQUhCAriD626He2iybqQ9yf2KmWQ+mO7Axodvun4eJIoZhmOyQw0NtOZjQ9ToQK2s7l3/F3NfLW6mKR1kpQQC6whWXIKtGwqdz7FmY39M/RXYaVMTGtnyu89J3pe+wAcMIg9e6q2NE6LRd+jhFyg13xsv1XQ0JhAVNF78obwj6NwxAV2sfUhVNplpUbcHopMt/WLO4jlPupBUecFRK6KMrx7Yu+qOjlQAjhKRHxKAt/ypybo6rQyJW3RnXjg/SIRBpO/1RtUaglfXSRUm7C8Wam6Jn2J+uwhWHawYlBgFoAAAAAAAlBQFoMVqYl1+eglLh6914LLtZQdU7GKsYOvlYX02MBW02SI71S788ug6J2I0Xvy1zH5Z/xayg/zXhk3pdhnY3Jms+AF3hikuQXaOM431VMGkz/bG83UnFbvfgk1aT7/3M5w6/CDrlrJ8RgQh9b/8y79zp+FODTUlE6PQ7Ws4hYT8vAC3Mycr9GUHu6uxDqqLJVIuqLRidcH6EBYvnND8oq+jHjCO9eZJvY5cRgIa2/GvIvjrGmECsevOe56ed9tUhEGk95YHMx1fCvFxhJcabKumli7J2F4o1N4XPsD9XJSoO1wxKDOaABgAAAAD4xTHp7wMWDe3QwFRbhSfQMnFsM2DOgWeJ5ZzYTkYizNddnQUEod7naOqPxUVPZ9uzMSZUehxI/PHJHdHrvxuyMWk46nJOWdmIns5xYGN+r8MZxX7OvzbGkCR1R1wWfxGGDl/nyiW0hp6Ne7x+SFNjdR6XxVHVs27hPWPvsyR5FaPCTh4LEpp27e5UNEU2k7TPk4fZ9rP/+zFHJRV3bmw9AUFqtJh9O6nSXw3KvnP2Rhriuvr2t5S4vlZr79vTmBS+v3AxtKxSl3fFjHsLRqx8rdl7/VY/C7Li5c2LubV5kndre2MtAZcr0DRxcOs3Y3dQQvmnk65wxX+QUyMq+nNEPsOytrOSN00+YdSlezMy6uSxh3nlrMTvL+3ywTPfaJbD6Lk+JmXdAGJ9rzl/NmYzyRcOnvvOIKRYa8086s0njP+8mYeEz+Y6sjC37aZo8WFEp7w6NHeAm72RBp+vYWTvNmCu/8uUEkeY/L6Ljt3Snkuo+ARE3lziZaerpsrncDVMGnpOO/IhGzGZwcdm925qoa3C42uZOfeaezq0xCTWou9Pds/o19rOSEOgomPm2Lrf7L2Pvgrlba5q7UMq32SKU6K2XIRJvjR7woGv9aZum9tcUPQzv828MxcuXLhw4cK5nSPsy27R0JZ/BVm3j5/7RrPr9fdpxFbv0KezFkFFBp4IKvZZt4L2O+BkaujJqR0stQV8DourZuTQfsSa23ElZowu35HMxO/rrkaQBsPOF/9qLZPg30uDILT6HUtmEEJMRvDJxX4dGtTREnC4KjoWTTzHrr/1pbALoIL/acop9hFC2ctLpbTdhULNTfEzrEKUoDuCawalVtMRcAAAAAAAIJ1CI6Cpr+fHNVDBCGGujnXjpk3sDPgERphjNcA/9MdYF3kjoOUkQoWvdeVgwnD0lZzCXCPWuXIQQojQG3ahcPZEKnpTWy7GWgNPpZdZXOF/s+1ZiOd1qPgieVdHGxCEzvBL4tFTVNja1hwsaNKupSaBMMHXt7G31OZijBDm2vqdiJY1+omK3tyOS2gNOpMp8SOduLcrF7HsZgWJtwkVd35cfQEmNJrPvp1YBRMACl/93ZCFWA5znhYfX0Qn7+/Ow1jD93RWVaxIJ10Za8MmTQed/Ern355Qp4IjoHPfbPDQJzHCbI06jk2aNalnrsXBCGF+g1n3M+WvXvHylya/RrkX/LQxWWf82ZenV04Z3q9rx049fScs2f8gVsqYJeHzefVYpPW06n0N/BeUd22MIYFIG3kvyAtf/q8BCxHaQ85mMYxirTXv5f4508d6mJOINHQbMW367K0PUmiGEUWfHG7HwwiT6nXqOzvZG6mSGGGu3cgzX37sXYX6LipmczsOZts7N1IjODp1XTw6tbbVZmGEyDp9509prUXwDeq5derQ1EyVQAhzHGY8zPlR0Jx323qasjDCpIqBbcOGNnoCEiPMMu2+4UWGrM1QrX1IZZtMcUrUliVXSb0+zobFqjv5bplloD6vcmGXOQIa2vIvIP3sUH0C/3jxIe3UQG0CkeYTb0t2zeL2y2s3fIgNG3N1bJp37NyusYkAI4R59WdKHKMKHcnFLl3ob3s9VTBhMPxCsXb6bY+nKib0Bp1JYxgm/cE8ZzWMMCHQt23UtImDsSqJEWZbjjgrfstD9H6pMxtxPbZ/FTdhectL8yt0FzKaW3nOsPIoR3cE1wzKDALQAAAAAABKaogmRpirY2YjhePw44k0w9Bfj/bTJxBh0Omfu1/FV9BU0tNNvc1YGKu331QYYJYdgJafiOjtEie2xM0Uk3LEWw2zBCpcTNrOKHzPMfVoH3WMVb0Oyri/KkcAWhzfbr/ohvi2gc6OuDjHVZtAciYAzDg1QANzXIq/o1vsbpD6enFCAwEmNFrMqZLoM8MweReH6xCI22HrlxLp5V0fa0Qgjtv6COklLs+KdPyZoWYkaTH8XALNMBUPQGeeGaSNMcdu1InwwmcHeXHXZzjzMaHtdz5H5rqVKX9pCtSIiljvxkGYqyJgYclRNFit4eiA8JI305mnBqhjTqs1yvWCdo2jv+/uwkWI221/spzjPftEPwFGHPcNkRSjaGuVMgUHFbGzqxaBefZ+/h8yaIZhGCrl5eZeJiQm64y+nCZeSbG+i4rZ3I6DECZNem54Jp68WvT1tJ85iRDCbGvf/cHiwEbOx82dtQhEWk55UNAf5T5d0JiHCZ3W00+FFMQqsiPOz3TRIjC77uQ7MuIh1dqHVK7JlKA8bVlS7tP5jTikke9JGVO5yAtAQ1tWdmmnfXUJzHFZFVLQ6lNPDtQmEFln3E2JA6+g/SLMtR95PLTgIM0O2dXbkECEjt+FwkUVO5KLX7oURKANR14qikVSX3Z0EmDCaOSlTIahoja142FCu/3yJ0kFn1xNDVripo5xYRLFA9Dyl5fmV+guym5u5TvDyqYc3RFcMyg1mIIDAAAAAECJMXlJ0aFShMWlUwhRoYc2nktAen03+M9xNxS//kloNx2/b/swUyL93tY9L0Ry0kcKJULad+pkxRKF37kbQSGEUP7ze0+yWE1GjWrBoSPvP4iiEEIo7+mdx5mI59K1gzaWkV05EDo91xz6XwcTLkIIYb6F59Lja7tro6TLm/1Dynr9kop49zEb8a1syphpgIq/PLlz/y3v2S1mn730T1udqimqKDMjm0FYRU2lRHpYRUUFIyYrM1v6K7eKr0h/OTZh3OE4y9Hb13TXrUyp6RSRvns3r3FLFnhb8gt+4xi1HdzdlqSzvidklWs6kgpXHClYI1FESLgIMUKW/ai9jyNTcvOzv3+8sWWEk3rWm93DfFa8Kva6N+Ja2pqRwo9vPsqdZKFWYdJT0xiEWerqAjlHDqmuqYYRnZKUWv5XpouIXu5afz2FqDt+97bB9uKPSxKajf/cPL8dj467cvGFEJW378KqXZbsmOisiRFCiDTsPrynCYkInT4rNg91UEEIIcSz8xvRUYDppO+J4qKnXVq/9U2+ttf6kyu9bQtmgeBbdF9+9J/2KqJQ/z03s8oqfvX2IZVpMiUpTVsuVqiIPbM3vCVbTF3QS68SHRW0ZaXGpF49fiWZ4bTw6WNdMHOSRsc+nTQJKu7ciQel5uAiLcds29jfuuAg5dv6TfO1IOnMb18zxMdUhY5krO/Zp42A+X75zP3CDOnYM8fu5xCm3r7tVBCiwj5+FjKsRn2GNNMWF5LQaDb+3zUL5s3yqotLp1ne5cUr/TLdhfQMynWGlUlJuiO4ZlBqEIAGAAAAAFBiZU3BkXtllD5mUh/dfZWPtboO7qEveZGONToM6mlMisIePIiVG0dSKBFW4y4djUjRm1v3EhmERB8fPP6Ozdz6Du3gwBK9ufsghUFIFHz3wXeG3aSLh2EVxZ+xRueh3kaSiRHGfUd208LCt3ceJJZ1N/glKpYi9Iz0pU2QTMVfndal3+Y3WUilmd8YN4lAuShoZl0WloHTfMVHGZMtMgXFKaPqNFXWugquSEXs/eOvU4m243eu6KRVue1LmPZde+b8mXX96vy4ExClhd48fiNCsoyKbpAKV1zBGmHjrnPWbth2+sHdrcNammty2Xw9uw7jdl/ZO9CEyH6+Yc2lYtMTkwZG+gSTFRtd+Vm9fydYXUMdI0aUni4vWEFnZmQxCPP43EocZFTErVufRSxb7wEt+BI/EybDjn0M/XR3flOWgt1O0c+keRMniYcUhJaOFkaseq1aaBT9yNHRUcOosIL5z67fTmYEbX16Fu+PiDpdPBux6bSgh+/LejpXzX1IhZtMaUrSlovJuLly5Z0sQ585o+tWYpJ6aMvKjUm5fPxqCsNrPcDb/Mex9yMCHXA/u/jihL5Hz1YCyR80NNUJhFBhe1XsSC4J63fr00bAfLt0piDkTUedPv4ol7Ds6+vKQwiRVva2XCy8v2zYPP/7oSlChBDCWi6jFi5ZPLOHVenDs7zLI4R+pe5CqvKdYWVSku4IrhmUWpXMNA4AAAAAAGoAHR8bJ2JICzsbbom/sKztrUkUFxcTRyEL2SMOFEykedcOOtsOBN16lDWyV/qjBx9pzf7uTepruBkRb57cfZI7zPP7/XufKVb9Lp3NCYTyzg819PJP/XFFz2m1Ovj+NOvyjX1gWdjb8kr8xrOvZ00yL75ExVHIQNqVLJ2Vmc1gIz5fym0LFXbg761Y3cJSNyri1qKZAb2ODSgMThEGLgP/GPu97HA9ae6khcusF6mqykMoOzsrm0Hqkjkz2VlZDMIqqiWH8RQmq9CKopCto2Zczqg3PXBpO42qCO/Tqe8uHD5xPej1h8/hERGRMd8zhQyDECo6BBTcIBWtuMI1Ytt1H29X6les32Ocj8WxtZEP774W9nIt+vQTX8DHiM7MyKQRqlT467eC1c3MNAmU+OndRxFyYZe9IBUWHJLHYJ6ltWklth4VExlDIdLazrpEC+XpmFnpFCxTzr6LJIlShwnmcNhlHTtMRnRUEs3knRqggQdI+TtOiE+gyrgZrt4+pMJ9RRlqvC0XL030oZX+0dhh7oTOle2poC0rLybpUsD1NIZhbo03I8eX/Ou3CwH3sjt1kQg4E7oGenLP/vKP5FLEY6AvX7145lGuRwceFXbqeFA+adfft7l4Ci/zkZs2BvWfeuTmiqE3/iVVDO2dW7Zy69CtX/9ujfSktP3yLi8u9i/VXZRSzjOsPErQHcE1g1KDADQAAAAAwC9LHAjFUq7DCYJACFG0Ai/SK5aIwLVrG7UDp+/fepbvkXL/uZDT3L2FgKPS1lV98/GH917ntw6/81JIWnfqbEcihEjT1v0HM0XDLVm2jmpybpOkDT+RViaSQAhRZY9+YXPYCAmF0t6nZBis5brgfODI8NFNhp05NWvuRY893cVvxBIWvRdt6S27hAghURn1Ik3MTEn04WtsHIUMJS+wc77GpTCYa1JHX/rtt2Irpj2+9jAVcTSuT/e496My6ZHxNBK9WOPV+hCHZT/Wf4+fnEcNhSumPV7Wq9fCuwmMmnlT11atenceYm1br7H2vXFe/374sZSiG6SCFc+obI1YFjYWLBSekpxS7BAXCkUIYQ6HU0Wj8H8TnGZtXAS7AyOvXHy7zKVJmdEEKuzSxXcizGve1kVQ1jJisgeLUSIKIUySsm7nq6TvklUGikKIUG/Sf1R7UylHEeY6mZdVvGruQyraV0grjTK05WJpvNmz7W42p+XIEU6Kx6zKAG1ZaTEJF47fzECETt2mttrFDgomK/rNu7j4CwG3s7p0Uyn6nSCkNXWJ9RQ6kkvDBp593AWXr10483hdB/fwk8efC1n1BwxsXHj88uuN9H/de+6ts4FXbt1/+DgoKHD3vTO7l89rNPbAhU1epSfNKO/y6FfqLsqljDOsLErXHRUH1wxKAQLQAAAAAAC/KsLAxIiFX0WFhOcjB8mX3REV8TmcQqSRiaHcIR2KJqLetktr/slr9+68eZb2OJ2s59ZKFyOiVdvmvKO37t//1C70SRZh4tGlEQshhFhOf+w4+IfiNclLTs5iUInhzqKoj6G5qL6K5G/5IcHhFCIMTQzLuPkgdA10CTo1WdoctoTx4H1nF7TWxi1XLz50e/x1/6kLB7tvaq+ueDnLqhfLuqGjCn4X8fJNKtNEYqoA4buX74QMq17DevzSK5VzRToj6uWTqJIJpEW8eBKB2KKeOQq+QEoFb564+G6SvteWKwfGNvgxtIh696Ii918VrjhCitSISX137fr7dDXHjp0bFJ+ng05LSaURoVd8YB2dmpxKY5auvnb13JT/qrBm1yFe+ucOB+9efmLccV9jqVuHSby4fPPTfKztPcK7jOlMxaS2VgmkkakhiZKiwqMo1ECiA2LS3106+zxZu0lPzwbqVdF3yYA1jI1UCSbftu+SVX3kRNNLquY+pDJNpjglasti+UEHDweLuO4+fRR7GCYLtGWlxXw7d/x2JmI3m3Hu0Sy74s009YSPlU9AwsWAW5ndeqgqmmLFj2RxBPrKtQtnHv+rey/gtYjt7OvjUKxMLG2HTsMdOg2fgxCTHff8wsbpE1bd3T5+ae/O2zpKe0wia3kpvd4v011IU94zrCzK0R3BNYOSg80MAAAAAPCrwlou7g3ZTNLlwxeLT4mccedwYAzFsnBzkx8HUDQRrNuhSzMO9fHGvoD7sciolasNiRDWc2tbnyV6c2PHmXsJSLdjV/Gbr/IwmRmZEnkxqbcuPSwdQGVSr/gHfpP8mfl2es/5RJpl7+5aVgCaZVXXisWkxMSklw7IEmpGRuoYIURajVw3z0VAhe6cvPxJNkKVnwNata1nG1WUc//keckC5/13+nwUxbLt0rXM6VAVWlHL73xuyVnA829PqEMiTrvNMRTD5D+d46BguC7n7YtgIVL3GDWigeSLrTkxUfEVmaixghVXsEaY9dl/rK9Pr1E7PhafsFf06ey5dyJCz61dQ8kQAhUbFUuRderalDPk+NvD2j1nT2upysSfnjRk1dM0KQ8rMl9v8vvjYDTNbz5zSX+DYq88K9RaJZB13d2MSdH7UyfeSH7viUk8O9/Xb/j4ve8ZXDV9lyycpm1bqaCse2euFE+f/nJwgK2xSaPpd/LKWrWa+5AK9xWlKEdbLpL/+PjpSJrTondPaYPOywnasrKi484F3MtGbKc+vW1KHRIaHb07aGA68VLADcUnD1b0SJYGG3Tr4y6gY8+f2O1/4p2I6zKwX2GpqHdrOtla2nT493Xh2QMLjJv2X/y/PoYEnRgRmVGifZd3ebFfpruQuvXKeYaVRTm6I7hmUHIwAhoAAAAA4JdF2g6e0G2VX2DAX35NTPZPcdEjEaJTX+4cM2ZPFK3WZsLopgpc7CmaCGHq0bkB695/e/cxlGof9yYchBAird3dzYhn9/b651EaAzxd5Y3GIfQM9Qj06eGOdff6r2ijTSCEsj7sHzvlaDxdesINOilw6pDldfxnuBuyEcqLufbPkMmBiUizy4ThDcqqGNZ1bmZN3vrw5oMIuZV958R2nLhxxtHWi15u+GvtgAfzG7EUm5ewTFjXe9LQhRe3XFk4+ZC7/xBrDkJM0v2FU3aE0uqdJo358UYwEkbePfUwlmaZu/VzrUOUY0UFidOnyDqt+7pbSFuZo2+ojZn4J5fvJ3t2FH8TKSf80pqJfx74SiOOKL/gRWIFJ2qseMUVo9pxhK/V8S1Plw6aUjdghbeNCkKITg8+NnPg0v/yBS0mT/GQvG2k44ODExhV9+aOcJNTEqv+lIMbH7cZE3hrToeW/01bOGtE96Z1VAiEmJyvLy/tW7VwZcC7dKKO95aDk39svXK1VsTk5eaJIwUc17Hjm++d9WTNsEkNT6/ta81HiMl4v2f8/AsZWG/AQA8NVEV9lwxY33vioIWXdhwd299a7cBcjzpchFBe3M0Vg6edCEurO827RZlTy1ZzH1LOJvPrtGXRu+s3v1Cshh7tZQ6gVwy0ZWVFxwYef5CD2M29e1mXjgFizU59OqifOpV8+cT19F7eCo71VfBIlkocgb5ydf/8LbkUv6NvH7PCo480s9JPib4eseWfAz32jnBUxQghOu2t/67L8TTLulEDzRKdWHmXL8hfqbqL6jvD/irdEVwzKDkpH1UHAAAAAABKYIgmRmynJe9EshaivgSOcRRghAm+oWPzFo0sNDkYIcy1GuAfKixcSPRpRXM24rRaHUpJ+a+CiTCM8NlcRxZCCHPbb4kpWJXJOu+nSyCEsKrXwURabqWoGH9vAwIhzNa1d/fs7tHMWpuDCc36Dc1ZhM7wS3nihcLWtuYglnU7j7o8jElVY4eGdfX5BEYIc6x8j0TI3CK5t8bXIdktV4ZILEUn7u3KRSy7WUES1cm8P92RjbGq+9qPwtLJlBudfGtaIxWMCRWLlp69erSx12ZhzDL13hcmmXqaf08eQljgczK3fCuWVGy8cMn0Ec/rUHoZK+a9WtFKHSPM0rF38/Tq3r6pjS6X0HAaOrA5H2OOmfvQJRe/UGWsW7UVV6hGdNqTf9roEBhhtrqpQ5PmzvaGAgIjzK875HDJDZR+aqAmoeK5N17+cVg75YWd+KulHgsjhDBmq+iamJnqqXEIjBDChJbzH4c/ZBdbXqHWyjBM+vF+ahgTOg269PGZdz6eZpi8j7t7m7ExwmwtS6eWzRuYa7IxwhzLQceifrRLhbodKmZzOw5iNVr4WqI9i14vbMRCXI/tXyX2dN6NsUYEVhsUWHiA0an3/26lRaCCQrR0stHlYYQIHbd/npTVOsSquw8pT5P5ZdqyKGRlSzYizSbeyVcgJ+rzKhc2Im1nPJG+4aAtKykqfL07F2NOi5WfpJ+H6cRDvdUxIrR9TqSU0X4ZRvR2cWM24nbeVbB/FTySS126iHP8uruLCkYIYfWeB4odMHlvVrfRIhDCpKpJveatXZztDVUIjDDfcdzFeJphGNH7pc7sop5E7vJSKVN3UcYZVkZzU/QM++t0R3DNoMwgAA0AAAAAoKQUCkAzDEOnvDm6YFBbR2NNPoenbmjn2n/W/qcJkmvJC0ArlAjDMHn3JlmQCLEaLHj14zKeTtjfXYAR5nls/6LYNXxm8PE53s0stHgkxghhrlmXpbdebW7PKRmAZrus+vjtyfYJXRuZavK5Ah2Lpl6Tdz7+Lm9zMNk3/qxD8osVR+rdIEOnXvvTioUJrS47Isp1X1QWOu3VwZl9WljpqnD5miYNOo1Zd+tLifsd6XeJCqxYUoUD0AxDJz/dOdGzkakGl8PTMGnYafSqy+HZVMrtBe3MVDlc3U6bPsvdxlVVcQVqxDBM/pe7W6f2bW1npMnn8LVMG3TwW3T8bWqpoy372h8mpGrX3XFwLykDlfL29OopPm3qWxho8tlcVR1TB9fefy4PeJEg9YiT31oZhmGyXm4d2MRYjcPi6/feVxBkEH57uH1yr+ZWuiocjkDHqpnX5B2P4kscWfK7nUoEoBmGYbLDLq36o6uTuY4Kh8PXNnfyHLv2WmRZR6DEatXehyjcZH6VtkzHbffgYSzocSBJkfYnJwBsjxQ/AAAgAElEQVQNbVlJUaGrW3Ew5hQPtxZDJ/h7qWGEtfodS6YVDEAreCRLD0AXRqDFOZYoTEbwiYVD2jeooyVgs9gCHfPGHsMWHX9TePYoEYCWu7x0StRdlD8AzTCKnWF/re4IrhmUFWYYBb9XAgAAAAAAQFWisr5Hx1N65kaqJd7kpcPXuTtM/c95VfCD6Tblf5tbGDS7gesms80hV/6ognfBfz1Zx/qYnR4QE9Cvds1qmH19rJ3nydZHQo7204YP2le5Mlvrb0lZ+hBoy9CWgTxM4iFvm6HnOINOh/p7leMLf1VGWbqL6va7dUfQz/x8v3P7AAAAAAAAyoxU0be0qoZ4FrvZn5PaEvf2HwmV9wGj3xIVFxNvYmOp0Ocgfx9MyuV9p+JtRk7pCXeS1aK6WqtyUpI+BNpyTZcFKD/6y6mD19OxYa/BHjURfUZK011Ut9+sO4J+piZAABoAAAAAAPxmCHO/hWOtXm7fdC+rpovys+U93+43+IDupJFOteubOlTY/vXniF4LpjQv89tyAChOCfoQaMvQloFcTPL1patuZxMW/Ya0rbGBuUrQXVS33647gn6mRtTGAPSuzjyMeZ12fKuKyUfyzg3RIMg6E26Lv+pJvVnUmF2OxBVcvkQuVYsK+bcFB3Nbrwkr+1ukVYcOX+fKxVy39ZGycytRqvJu2Ar7aRlJlZf6Le5LXHxafnVnVLPVlIX5dmqwuanvyQRlK1hJuU/nNdJ1X/O+2vcVAACAihG0mrN2GD60ZF/Ybz0iqTTSoPkf++6cHGldS0aqijEpl5et/+i2eEV/QxjKBKpGjfch0JZruixAqdERmz3NzY0tuu8MozU6zJjUuiYDiTXeXVS336w7gn6mhtTGADQARfK/vLx98/bTqOyaLghCCOU/nNu0jqlZ6yXPqvpJg1JVUwYm8ezMSYFmUxf11queM4Hw7l/mLCwFp9nyDyWuFvIir675s6uTha6aqq6VU/tBC059lHikzWs67e8unxeP3xbym15kAABAzcK6bSetWb92cvuKnxCwdueVp/cPMkpLr8qCKT+WaRM3R93fZIiSwoSJbLdlZ/aMtvo97o2BUijqQ2pmYAS0ZQBk4Wqq0YlphHHzQasvHPnDsmZDWzXdXVS336w7gn6mhvw2R5CSIOr0XLjTNNXIVUOxu6XyLl9rVdeGYpLOz+j6570Gy14/meNAVmNGNetXqWZe0Kq5x6k+J0baVNOZgEkPD/tOY0yQZIkrFBaJJTcFk3JvgWevZUGpSMWwrpVFbuyHO0de3b18558bV2Y3Eb/chbV7TB9j0WLZglO+R/tXU7wcAABqL6zu1G+CU6UTaeg1smGVlAcoOY5t5+G2NV0I8NuBPuTng7YMFEQYDz4eM7imS1EEuotfCPQzNQQC0FULazn1Gl6Ou6XyLl9r/bQNVaN7BPP4PFzwbzXnpIwHHhN/cuXuz2bDdnWutrA4FfE5XIR4PQ7EnR2sKaskJ8b5LAvKshqw69S24Q01CJQbGTjNy3fbg8Xjt/R6MMNeHB9nNxw+qtWqGSt3BnvPqwd9KQAAAAAAAAAAAIAUMAVHCaL8PNHv+dJEFWFE+cKfMVf0L62iRxHLoXE9LhbUa2irWDSTykjPqo6jtWZaAR15bMfldOs+PmV/B6DSBcsN/xxDESZ1bVRkLSV8tn7hyXii7oR9u0Y21CAQQohn0WvN+hFmRM7zIwHBP+bcIMy8B7gSr/bufpxXmVIBAAAAAAAAAAAA/L4gAE3HbmnPJVQGnEwNPTm1g6W2gM9hcdWMHNqPWHM7TlR82ezP55YNa1/PRFPA1zByaOu3/FJkbvFwGBX8T1NOwbfdsq+OMSExu9685yWSybk+1lT8B6Hk8ornIno6x4GN+b0OZxT7Of/aGEOS1B1xWfKzaHkxtzZP8m5tb6wl4HIFmiYObv1m7A5KKEcMmQ5f58oltIaejXu8fkhTY3Uel8VR1bNu4T1j77Mkielvy1MqhBCd9mr/tJ7OFjoqfFVdS+ceE7fc+1r2zMfSNhSd8urQ3AFu9kYafL6Gkb3bgLn+L1NKVExW9TOPevMJ4z9v5iHhs7mOLMxtuymalpYRk/4+YNHQDg1MtVV4Ai0TxzYD5hx4lig586/iRxGTEXxysV+HBnW0BByuio5FE8+x6299Kag4VndqWpfn4NxI+gd86agN7lxCffDZvPywU9M72+uoWvx1O78qqlmeVkAnPd09ubuTmZZAoFmncffpRz+kv13ixCFNx90q2sUyq1nGLg47eSxIaNq1uxO7IhtWIVT054h8hmVtZyUrwi98dvxkiIjlPOIPF8k4Na/Nv0/DI0PPjZeYH4Qw6tK9GRl18thDiEADAAAAAAAAAAAASAOvjYvR3y/91fXQoRh1a+cOrVQS3wW9vr1vxuOn368/+ddVHINi0h4u8uyx5FEKjVlqxtbGKPaB/7wH1257WpQVBhO08fEy2bst5Gzgm0XOTYq2dPbdgHNfGY7z4CGN2ehT8XXKn4tMeW839ug49cZ3mqVhauvQiJf3PeLzw5OrH168Gnrt8QpXmaNAS8h/v6GP590naYivZ22nkhwR8fTM6qeXzt47dHNv3zrlfo7BpD/8X8f/HX2Zzde3NjdMDIt6eWHzxKtnb2y7ETCyLlv++ghRMadGewze/ymPUDd1qOcgivv8OGD5w8DTd4/d2tnLmFCk+hwHrynTDZ6d2HU9Vs/Nb1ALfesm6hhllsiI/nZhYqcB295mIa6OlUMDjZyYDw8CVtw/E3BlzzX/wdaSLUj+UZTx8H/tui57nokFetZ1G6nlx4W8ubJj6o1rb08G7e6phxFp13/xmib2sufCp78Fjp0y9EimddO2nZsYkVVTTcXKj+iv58a299n9MQ/z9WzsjOnYG2sHu97v2Ti5WOBfXjWl1iru2uWXIvW+bZxK738FCqYYUcTnCBGpb6MfF7hqxfmnH2PS2Pp1m3UaMHxAa5Mfw67p2CdB0RRp1trVsvh+IFT0zEpmR5i4utnih1cvvRC2d1HoyAUAAAAAAAAAAACoXZjaZ2cnLkJcj+1faYZhGCpmczsOQghz7UceD80WL5Idsqu3IYEIHb8LOeJfMm5OsGZhzLMbsudlsohhGEaY8N+m3mYsjBAiTMffymcYhmFE75c6s38knnt7ojmJWA3+91JYlH3mxRGGBOa33RRJlVxe0VyE/822ZyGe16H0YhXLuzragCB0hl/KK8zqzCBtjDl2o06EZxcuE3d9hjMfE9p+5wtqxog+rWjORpxWq0MpqduLClvbmoMQQoRe+0U3YnMZhmHo7IiLc1y1CUToeh2IpcpRqqLU9D3+uROXxzAMQ2eFX5jVWptAWK3ths8iaaUqsaGoiJ1dtQjMs/fz/5Ah/iXl5eZeJiQm64y+nKZ49em4bR24iN10WbCIkbIHGfrr0X76BCIMOv1z96t461NJTzf1NmNhrN5+U+EmU+wooqI2teNhQrv98idJ4uyo1KAlbuoYl731i+2JyPVuHMzWN6rjND4wonD/VUU1FWwFdHzAAEMCc+2HHwnJohmGYfJjr8xooY4RQoTJnzfzKlHNjFMDNDDHpcQCChZMQVTEejcOwlwVAatYFByrNRwdEF7YSPNujDUmEKf9lvDIa6tGdKhnrMHnqerZtOw7c9+zxNLFzzw1QB1zWq0JLVdRAAAAAAAAAAAAAGoJmIKjAGk5ZtvG/tZ88f/4tn7TfC1IOvPb1wwGIcQkBm46GE6xG886umtEYy0SIYRYus0m7N810kzGYFVuq/7e5qTow9nA9z8GMGfeCrjwnVHt4NfPrOTGr2AuZaJTRPru3bzGLVngbVlQMcQxaju4uy1JZ31PKOfswYROzzWH/tdBPFAU8y08lx5f210bJV3e7B9CyVu5dGp6fTYcmtPGiIMQQlhg2W3Z8bXdtXHGgx37Xskf7C16uWv99RSi7vjd2wbbq2KEECI0G/+5eX47Hh135eILIUJVU30q9NDGcwlIr+8G/znuhuIBroR20/H7tg8zJdLvbd3zolhhZR9FiAr7+FnIsBr1GdJMW7xDCY1m4/9ds2DeLK+6WMHdwQiT1fpvXuNlwRP/vyr3spzy0+GHN56Jx+YjN28caCvACCHENum8bNf0xmzJeG6FqklFvPuYjfhWNibS+iQ5BVOUKCIkXIQYIct+1N7HkSm5+dnfP97YMsJJPevN7mE+K16JpxBh0tPSGMQknBnVquvMffdjCSNrM7WcyKCTK0e4tvA7Hl3iaOda2pqRwo9vPpanJAAAAAAAAAAAAAC1BQSgxQh9j56tJCfeJTQ01QmEEGIQQij/6e0HmQy75bDhjYp9H029nV8/SxmxYU6L/n2sSNGHs2c/FESt0m8EXExE2p5+XvqlZiKoaC5lVsq079oz58+s61c0RYYoLfTm8RsR5Q8YI6zReai3kWSZCeO+I7tpYeHbOw8Sy/thOELbc2jPYluAMOk7spsWIQp9+ChO3gTVVMStW59FLFvvAS34Ej8TJsOOfQz9dHd+UxZCVVJ9JvXR3Vf5WKvr4B7FCos1OgzqaUyKwh48iJUorJyjCJFW9rZcLLy/bNg8//uhKUKEEMJaLqMWLlk8s4fsaTckE9Vv37Vp0QFShXtZTvmZ5Hs3nudjgy7erqoSC7EcvbwcJQtfoWpSX6JiKULPSF/a3+VtWFHQzLosLAOn+YqPFELYuOuctRu2nX5wd+uwluaaXDZfz67DuN1X9g40IbKfb1hzKQMhhIS5uRSDhG9vBumN8n/7PTnmw9tPcSmx9/7tYigMOzz2z/0xxQ5Q0sBIn2CyYqPlb2AAAAAAAAAAAACA2gfmgBYjdA30yg7GM+lxcRk0oe3gaFRiIbZjQ0c2Ci9zTXbTfn1s1614H3j2w7wG9UmUdiPgcjIyHO7XVatU/LniuchAp767cPjE9aDXHz6HR0RExnzPFDIMQogrd80SWBb2trwSv/Hs61mTzIsvUXEUMijXoURa2tuULALPvp41iV7Ex8XTqNTo8GKomMgYCpHWdtYlMuXpmFnpSP5QyerT8bFxIoa0sCtVWJa1vTWJ4uJi4ihkUVhY2UcRQoT5yE0bg/pPPXJzxdAb/5IqhvbOLVu5dejWr3+3RnoKbz/S0MSwRJS2ivaynPJTsZExQoY0szIrXlbS3Nqchd4WJVORatJZmdkMNuLzpc0QLXfDGrgM/GPs97IfXJDmTloYIbZd9/F2pf6I9XuM87E4tjby4d3Xwl6ubBaXS2KEOS3+d2zzIPuCArMMXGfsX/7Qbvi5G3sCIoZPsy4qD1/Ax4jOzCiVMAAAAAAAAAAAAACAAHQhgsDSv41W8Neywl9cAZ+QsSJiOfXva7966bvAs5/m1HfIuBZwJQWbTxzaXtqn0yqeyw/FRiIzaY+X9eq18G4Co2be1LVVq96dh1jb1musfW+c178fFEmtOCkFIEgCIURRcsbaKjg+Wpwaiy3/U26UiEIIk6TMQcNVUX1xyaUdGuKdRdF08R9lHUUIIX69kf6ve8+9dTbwyq37Dx8HBQXuvndm9/J5jcYeuLDJS+rsE6UV30JVuZfllJ8SiRCSsjlKrVWBamI2h42QUCisSMEIi96LtvSWsYAcLAsbCxYKT0lOoRFCpJaOFkZ5dTt1sSnWP2K9Nu0bss89DHn/SYSsOT9+FwpFCGEOp2SqAABQOWvWrMnLy6vpUhQRiUQMw7AVOEv/TmptrRFCLFbtuk0QCoUYY+WpNU3Tubm5ixYtknPBq4BXr15dunSpSkpVJRiGEYlEBEFUvmq/kNpZa5qmKYoiSbLs+9zfkBLWOi8vz8nJqVevXpVPaufOnYmJiZVPp6pQFEXTNIvFwnJuxH8rtfbipHbWGinTJZn44mTq1Kna2toVWF1ZqqHcsJqpqRZBJ3/88I3uWGxwLh0bES2SGV9lNezfr96/f78JPBsyy/D18auphP24oa2kDU2tTC4IIYTykpOzGPRjmDIVvHni4rtJ+l5brhwY20C9sEOm3r2oSN8sivoYmovqFwuc54cEh1OIMDQxlHFuLVGqgkJEfAzNQ/aSsyqg/E/BYRRm17EwkXdVRhqZGpIoKSo8ikINJBZm0t9dOvs8WbtJT88GGnQVVJ8wMDFi4VdRIeH5yEFytg9ERXwOpxBpVGowsnwsbYdOwx06DZ+DEJMd9/zCxukTVt3dPn5p787bOpYcYy5f1e5lmQgDY0MCfYqJiKaQjUS1qdio2NKPIMpZTULXQJegU5NT5c2/UnFM6rtr19+nqzl27Nyg+AsIdFpKKo0IPfE4a5ZdPTs2/iYqHQynaRohxOEWa750anIqjVm6+tVWcABALXXp0qU5c+bUdCmK5OTkiEQiVVXVWnWPl5WVRdO0mppaTRfkp8rIyMAYq6qqyl/0d8EwTGZmJkEQKirSBon8dHl5eYmJifv27WOY8s5zJ0VkZGRycnKXLl0qn1SVoGk6KyuLxWLx+Xz5S/8uKIrKzs7mcDhcbrnfRP11CYXC3NxcLpfLqU1jNfLy8vLz83k8njJEyhiGSUlJefPmzcePVfPFmhs3bgwaNEhJukqEUG5urlAoFAgEterRDlyS1R5KdUkmFAoTEhICAgJycnIqlgIEoBXCbtK2tfqu04/373/7x4JGRafP/LdHjj6XPmbzB9Kxb7+GS+e/PhMYZPL0RhrbadbgRtI3ezlzYTIzMhmkVtjlMKm3Lj3MkQj15rx9ESxE6h6jRhTFJRFCOTFR8RWYA5pJveIf+M1rkOGPpJhvp/ecT6RZ9d1dJQLQ8kolRidf9j//vZtP0czKzNdTe84lMRyXju468npRsq67mzH5+v2pE29mN3D6saGYxLPzff3OMb2P9OjWoEqqj7Vc3BuyLz29fPhiomdf3aJkMu4cDoyhWNZubhaKP9em3q3p2ntzuNnYU1dniQ8BLDBu2n/x/27739+eGBGZwSBeuU8gVbuXZSKM3Ns6su+8vRL4KLt92x8PD6jPZ8++lfgWY8WqybKqa8Vi7sXEpDNIt7xbQRQ007H1qs9lV5jdbPmbx7NNP/uP9T2S1XTZy4ezHSTaoOjT2XPvRISeW7uGbIQQNuzcrSnn1n8XAl/93VRitm06+srFV0LMb9KigeS1JBUbFUuRderalLPQAAAgB0EQHTt2rOlSFElPT8/Pz9fW1laeIV0/QUpKCkVRurq6NV2QnyopKQljXLGxLb8ohmGSkpJYLJampmZNlwUlJyd/+/atVatWx44dq6o0LS0tlac/oSgqJSWFy+XWqjiCUChMS0vj8/nKE7n7CXJzczMzM1VUVGrVw4bs7Ozs7Gw1NbUaf9hAUVR0dDRFUaqqqsHBwVWVrLu7u5aWVlWlVkmZmZm5ubmamprKM0T0J6idl2SpqakikQguyWpKRkZGbGyss7PzjRs3KvzkoxYdr5WBdXqOH2JFCl+u8B178F06jRBCTObHo+MH//tSKG1uCkmkXd9+ThzRq/0TVl1L57X2G1i3jIdzCudC6BnqESj/4Y5195ILBoxmfdg/dsrReMnhoxx9Q23MZDy5fD+5cOxETvilpT5jD3ylERLlywmcl0QnBU4dsvzeN/FqeTHX/h4wOTARaXacMLwBS/FSFaaWcGqy36qH38WBy9zoK/N9Jp9NQobekwdbyz8oOa5jxzcXiN6uGTbpZJj42QuT8X7P+PkXMrBe94EeGuWsPpOXmyd1fAlpO3hCNx30PeAvvzWPE8QBTjr15faRY/ZE0WquE0Y3Lcd5jjSz0k+JDru75Z8DwZkF2dFpb/13XY6nWeaNGmhWpBFXSTUVrUC9UdN66DERuydMPR0pfitc9O3236NWPhN/aLBgqQpVE+s6N7MmRR/efBBJ+7Ns4jmgZRjj7aSFkWrHEb5WZP7TpYOmnA7NKihZevCRCQOX/pcvaD55ioc4qk5Y+s32NaXfrfYdujkoSXz0Zn8+NdVn3u1swmLIX96SX6Sk44ODExjVJs0dy19uAAAAAIAiDMPEx8fHx8ebm5srT3wHAPArys3NDQsLY7FYVlZWtWp0MACgyiUkJMTExJiYmOjrV+rN71r0mKhyVNou3jf7vx7Lgvb5NTw0ycyuDutrSHiyULfj1NFpm3bHyVyXtO3Tv+mCp49evcNqPfz6yvjAnoK5EGZ9xnRf/vD0q9UeduddmttwEz48fx2eKqjXwPzju8zCpTiuYya2PDTn0daudW+6tLDTyP3y8c3bcKHj4L7NThx7eneZz7CEWcvnehortgFY1u3akQ/mtzVdblTXSjXpc2hCDo04VgO3bhthTpSjVAghhLCqbT392Kuz3EyWGte1ECSEhiXm0Eil4YQ96/roKxKGJR0n7dvwuNOfgdv7Oxy3qG+nJ/oa8jE6VcS29N24orcOVrz6atraHEy93zK0x3tH52Ebl3QtnhFh7Lt59/1PvrsuzXQ1X2PfwJz9/dOHqNR8xLXy2br7T5tyncrVu82a43Zp5t0Toxte/tve0UKdSor4GBKfxfAc/1w3rXmFXtGqmmoqiDAetHXfk5B+W3f0tTlsZF9XJyPsY6yo4eSJHls23OTyuLgS1WTV79jO6N+dQU8iKTfbcl4hKToHtFq7fw4tetvtf/c293U8aGJjYyzIjv4QEp/N8OoO3n14Wv3C7hBrd1u9f/LLnmsD/nI5u8Dc1oybGBoan0UTem2WHFnpoS6ZZtbTR69EglYerrVoMAsAAAAAqhxFUTExMSKRyMbGRhne3AcA/LrEYxW1tbUNDAxquiwAgF8YwzBfvnzJzs62trau/FsdMAJaUVjTbcnN/04uGdrWQZeJ/xyeptnE5+/Tj89McJS/Dwgr7/4tORgR2t2GeskMsCqYC2E6+ODto3O8m5pQkQ8vX7z+NDzLsPPi04fGFBs9zGk088LNHRO71uN//e/G1fuf8q16L7348uG+rf/OaFuH8y3o0v3wbIUHxGJ9z0337mwb38ma+Po5KlNg5uw1ecfdJwcHWvwIFipWKoQQwhod1z1+cmieT0tjUezn6Bw161Y+8w4/vr+hq4Gio4A5diMD/ruzbbKXk1ZGyItXYZnajXtO3n7nyQEfM7I81VfrPvffAU6G+Z9uXLodnChlpm3C2Gv7wydHFvi6WxJxb19+SuZZtu4/a9+DoEODrcv7/IbTYOqFh8cXDmnnqJUd8TLo2YcErm0Hv0XHgh5t9lQo8C4tzaqppoKwgefGO3d2Tu3jak5Hf/rKcxq++da1OY1ZCGFVNVVcmWpyW/bubky/vn4rvgomOyyr+Oot5l5/c3vL1D7NjaivH14Fx7Os2w1ddOy//w74WknuTazdftW9oKPzB7Q25ySHfowV6jl1n7jx+vMrc1qqFatBzpNr9zIE7t5d9GrR9FsAAAAAqFr5+fnh4eEEQVhZWUH0GQBQGUlJSeKxihB9BgBUhkgkCg8Pz8/Pt7KyqpI5hXCVfNoC1CAq63t0PKVnbqRaTS/W0OHr3B2m/ue8KvjBdBtFn1hUe6lADRBlJnxPE7I1DPQkd6vo5f8aN/8nrOv+uHNDK/WyqDBodgPXTWabQ678YfKLPBrLvj7WzvNk6yMhR/tpQwQaAFC1PDw8rl+/XtOlKFI7JxyEOaBriZqdAzozMzMmJqb0WMWuXbueP3++8hObBgYGfvnyZfz48ZVMp6rAHNA1XZafB+aA/slZi8cqZmVlmZmZSW7zq1evvn37dvr06ZXPon///jt27FCeOYJgDuiaLsvPA3NA/2S5ublRUVGqqqrGxsaSkz4PHTp0xYoVxsYKzqVQTC1qpb8rUkXf0qqmC1GKcpYKVAqTcmKYzcgrGiMuhO3u+uMjhMLgcxdCKHZT91bqslZWALvZn5Pabpmy/0joqBllTZSuVJiUy/tOxduMnNITos8AgN+funplu/lfkfLcY/9MOjo6NV2Enw1jXFP3tOJPDhobGyvD9w9/DpIka1sEASHEZrNrYa15PB6Px5O/3O9FIBAIBAL5y1U1kUgUExPDMIy1tXUNRGOFeT87R4QQQqpctiqXjRgKCcv+In31EebXQKYIqbMwYnFRblaN5I5iP9VItgXnyOTIGsm9phRckCWG/+R802jyi4ilZ2Cop6dXhcnWogcmAIBKwbpdB3nqoPjD08buehiZmivKSwm/t2O078rXlG73cb5WlY4ZE+Z+C8davdy+6V4NnUvLhwrbv/4c0WvBlOY1/IFrAAAAAPx6xGMVv3//bmlpWXuizwCA6iD+5CCbzba0tKxVY4EBAFXuO8WKE7HMWMKqjT4jCEADABSGDQds9p/aQiXk0BhXSy0+m6dt3WbswRA19zlHtvkaV0VnImg1Z+0wfGjJvrCaeIJdLkzK5WXrP7otXtHfEIY/AwAAAKBcKIqKjIzMycmxtrauVbMTAACqXHp6enh4uLa2tqmpqeSb8gAAUC40QtEiTipFWLHzVQm6ytOHh2NAHqzbdtKa9fH6bvCZNUAYdll1P2TY9TMXHgbHZSAVPctG7p6eblZqVXVsYO3OK//P3n3HN1X1fwA/d6VNR7pId5s2YcimgExFZFSWKIIDQUAciCI4GQ+ggoiiP2Q7EdkiDwgiQwRlb1D2bkuSLpom6W7GHb8/orVAGU9HbpN+3i//sLch93NPbk5vvjn3nJ+W/vdKfoFEQmr1CefM5R6cueGRwVUf+A0AAAB1is1mMxgMSqVSo9HUqRk8AaDamUym3NzcuLi4OjWpOgBUO6dEGQQFQyQd52BqphaDAjTcDaVKenJMktwpoNZgQ5v2fqFp75p6ekrV4rEXWtTUs1cfRYNHnm8gdwgAAADwMIWFhenp6WFhYeHh4XJnAQAP5prGp6SkRKvVun/BQwDwJiUSbeA5FS1GMc6aGwiIAjQAAAAAAECNM5lMJpMpNja2bq7qCQDVxel0GgwGmqa1Wi0mfQaAqrCKTJbARTJ8KM3X6I7QVUslKD4AACAASURBVAEAAAAAANQg11jF4uLixMRETPoMAFVRUlJiMBhUKlVUVBQmfQaASpMkkiNyFoHWcA5/qvonfb4JCtAAAAAAAAA1hed5vV5PUZROp8NYRQCoivz8/IyMjIiIiLCwMLmzAIAHEwllFFinROs4h4KS3LBHXAABAAAAAADUCJvNptfrAwICoqOjMVYRAKoiJyfHbDbHx8cHBATInQUAPJhDovS8QkFJWs5BE3dUnwkK0AAAAAAAADXBNVZRrVar1Wq5swCABxNFMT093W63Y8lBAKiiIpE28opgRohinO7cLwrQAAAAAAAA1cxkMuXm5sbFxQUGBsqdBQA8mMPh0Ov1HMdptVqGYeSOAwAezCIw2QIXzTqDacHNu0YBGgAAAAAAoNq4xirabDaMVQSAKnItORgUFBQZGYlpfACg0iRCsgUuX6ATOYey5pccvBUK0AAAAAAAANXD6XQaDAaGYXQ6HcYqAkBVWK3WrKysqKiokJAQubMAgAcTCGVwcgIhOs7BuWXJwVvVrQL05cuXBcHdg8zvnSAIFEXRNC13EI8kiiKarnJw4lWaJEmSJKHpKgcnXqXhxKs0SZJEUazpEy88PBwL0wPUWa6xiiqVKioqCmMVAaDSJEnKycmxWCwajcbf31/uOADgwewSZeAVvpSkYRy0fNcmdasAPWbMmPr168ud4racTidFUSxbt16UaiFJkiAIaLrKwYlXaTjxKk2SJJ7nceJVDk68SnPDiZednf3YY48NHz68hp4fAGqzvLy8zMzMiIgIfAsFAFUhCILRaOR5XqfTKRQKueMAgAcrFOl0QRFKCxHuXXLwVnXu4+uiRYtq52AESZLMZjPLssHBwXJn8TyiKBYUFKDpKsF14nEcFxQUJHcWzyMIQmFhIU68ShBF0WKxKBQKlUoldxbPw/N8cXEx3rOVIAiC1Wqt0RNvxYoVoijDlGoAIC+MVQSA6uJaclChUGi1WtzxBgBVYRbZ6zwTyzpVbl9y8FZ1rgANAAAAAABQXURRNBqNTqcTYxUBoIqKioqMRmNoaGhERITcWQDAg0mEZPBcseRaclCeSZ9vggI0AAAAAABAZZSNVUxMTMSSgwBQFRaLJTs7Ozo6GndYAkBV8BIxCgqJEB3nYEmtqD4TFKABAAAAAAAqobi42Gg0BgUFRUVFyZ0FADyYJEmZmZmFhYWJiYlKpVLuOADgwWwSrXdyfrQYwzhr1SQ+KEADAACAl7NYLOvXrz98+HBGRoZSqWzcuHGvXr26dOkidy4A8GAYqwgA1UIQBIPBIAiCTqfjOE7uOADgwQokJt3Jqhlezcg/6fNNalMBWsr+5b0ZpmfmjWxa0c1rouXU+qVrdp/UFwZoWnV75vmBLUOoO20HAAAAIGTbtm0ff/zxuXPnAgMDGYaRJOno0aMLFiwYMmTIxx9/HBISIndAAPAwkiRlZ2fn5+djrCIAVJHNZjMYDEqlUqPRYMlBAKgKk8CYBDaO4wOpWld9JoTUmg5OsmXsWrHxbImz4qXjBf1PMz9aZ4x9dOyE1x+N1q/96JONRuEO2wEAAADI1q1bn3zyyYyMjMTExLCwsMDAQNfN8jqdbv369aNGjSouLpY7IwB4EkEQrl27VlxcrNPpUH0GgKooLCxMS0sLDg6Oi4tD9RkAKk0iVDrPWUVWxzlrZ/WZ1I4R0JLpj8/f//5QRoFDIvUqfojj9ObNabED577SK44hpFm9vKvv/LLlXN9X7jtX8fYWWH4aAACgrjOZTDNnzoyMjLz1BnmWZePi4nbu3LlgwYKJEyfKEg8API7dbjcYDD4+PhirCABVZDabr1+/Hhsbq1Kp5M4CAB7MKVEGnqMpSsva2Vo8JURtuGyigls//fb7n8x+f1DD29TDBeO5C0WRrdtEu+bmYOLbJIUXXDif5bzN9opHUQMAAEBd8uOPP168ePF207PSNB0REbFx48b8/Hw3BwMAT1RUVJSamqpSqeLj41F9BoBKkyQpPT09Nzc3MTER1WcAqIoSkUpxKpS0lFC7q8+kdoyAJlxwrC6YSNYryts0lpibkyuFqUP/uc6jQ9WhUm6Oib/NdpFoXJtKS0udTmf5p5IkqYaOoorKgtXahLWZq9HQdJWAE68qcOJVGk68qsCJd+8OHjx45891/v7+Fy5cOHz4cHJycrXsUZIkvDQAXsk1VhFLDgJAFfE8r9frKYrS6XQsWysKMgDgofJFJoNnIxg+rPYtOXgrz+jvBIedp5TKsvo0pVT6Ug67g7/N9rJPfp988smWLVvKnkelUpnNZoqqvV8K8DxvNpvlTuGp0HSV5nQ60XqVhqarNIfDgdarNDTdvTAajQzD8DxffqMkSeW3cBx39erVNm3aVMseS0pK8GESwMtIkpSZmVlUVIQlBwGgimw2m16vDwgIiI6Ors11CQCo/XIE1iww8awzgPaMaSA84zMSo/BhpPxSm0R8KUIIkUpLbRIXqLjd9rJ/qNPp2rVrV/bj5cuXOY6rtR290+mkKAofXCtBkiRBENB0lYMTr9Jw4lWF0+mkaZphGLmDeB6cePfOx8eHEFL+775rePJNW5RKJcdx1bJHhmFq7WUGAFSCIAgGg0GSJIxVBIAqys/Pz8jIUKvVarVa7iwA4MFEQtJ5hU0kWs7hQ3nMzZeecRVFh6nrUWlmq0iCGUIIEfPMeVRY0zD2NtvLpmQbNmzYsGHDyp4nOTk5KCiodn4ylCTJbDYzDBMUFCR3Fs8jimJBQQGarhJcJx7Lsmi9ShAEobCwEE1XCaIoWiwWlmUx7V0l8DxfXFyME+9eNGrU6PLly2Vt5ardUxRV9s2HKIoOh6N58+bV1Z6+vr6i6BljEADgrlxjFf38/GJiYjDpMwBUhclkys3NjYuLCwwMlDuLN7Ed/PT5+coJK19v5Rm1raopubr5/2Yu+mHPmWtWp39Uk4eeeG3ahIHNAmpjgav6SEVXf/940drNp1JTCxRxusY9nnj+vSeb1fPmv8l3OWSHROl5jiNExzkYj3rxPeNFY+KbNvbPOnnK5Crsi9mnTmcHNmkao7jNdgyoAwAAgOTk5Pz8/DtUhPPy8h544IGkpCR3pgIAj1BQUJCamhoSEhIXF4fqMwBUmiiKBoPBarVqtVpUn6uXZNq6cOEvey9Z68KX/84riwd2H/rBxmthXYe/M3Z4ckTW5jkvPjhg3im73MlqkuPK6kcHT/5kjyW646OvP/3QfY5TX77/Srf/+6tA7mA1586HXCLRqbyPPy1pPK36TGr3CGg+ZefKPebGfZ9sH6Fo0adP/MT/LlgdPbJLaM6u734y6p54vZmCMLfZDgAAAHVe3759e/XqtWfPnpiYmFvvf7LZbCaTacGCBbitHgBuYjKZTCZTbGws7tQBgKpwOp0Gg4FhGJ1Oh6nnqo9Qmqs/d3zXylnv/5gtRsidxh2k/J8/mvFbXvzzP+z8tk84TQgRJ+wc37vPV59N+e/gTUMjPK0UeY9Ktn6zdG9xwjurls5KUhJCCP/MnBHD3l717aphC0dHeuV3w3c65GfCFVk8G8U4QzxhycFb1eYXjM84tnnT72ctEiGE1Q6aNL638vDCiW/856vjgf0mTBigYe6wHQAAAOo6lmVnz57dunVrg8Fgt/87PkSSJKvVqtfrp02b1rdvXxkTAkBtI0lSenq61WrV6XSoPgNAVZSUlKSkpCiVSo1Gg+pzNZJylg9IbHJ//9fmHcitC2OfCSGEP7P3cD7TfNjbj4T/XcWjw7q98UInrmjfrhNeOwZayL10rYiEtU5u9s8KwGxcrwc1rNN4weClr/ztD/nENSabZzSsw0Orz6RWjYCmQnp/uK53uQ2+XSat61L2E6NuO3RK26G3/LPbbQcAAIA6LzY2dtmyZZ999tmiRYt8fHxYlpUkyWazdezY8fPPP3/sscfkDggAtQjP83q9nqIorVaLeyMAoCry8vIyMzMjIiLCwsLkzuJtqNBH5+1qlicSKXfj2CfnpMudxx2cJSSkfvMHW+vKfZFBKZVKivAOh5fWYglhQhto/MmFcwfTnN0bcoQQIuYeOZkpcPUbxtbm0bRVUNEhHzqZKXANYqJYHedQeM6Sg7fCdRUAAAB4M7Va/emnn44dO/bAgQN6vV6pVLZq1apdu3Y+Pj5yRwOAWsS15GBAQEB0dHTtXLQcADyCJEk5OTkWi0Wj0fj7+8sdxxux9Rq1rUcIkbJOqry0Dnkzv+T5h5Jv3CSmb/r5kFPR6v6WvvJkcoOA/m9OGHZ2+oznR10d2LVVkO3S/s0rjil6T3h7ZLS3vvA3H/KF/VtWHvPp+u74dzW8gnhw9ZmgAA0AAAB1QWxs7KBBg6xWq0Kh8Ijb6l3zhNy6PSQkxP1hALxefn5+RkaGWq1Wq9Xu33uFb/Y7LKD6P+F53mazoT8BcA9RFI1Go9Pp1Ol0CoW7l6eq8J1eXFzM83y1PL8oinl5ebduDwnwq5bnh3tmv7bl/acm/V6sGTFlWIK31mIJIWzU/S8/0XLrnCPLvz6znBBCqMAWQ8b0SPDiE+7WQw5o/ty7ybEBbq8+V9if8Dxf6esTLz5RAQAAADyYWBG5QwF4oZycnMzMzPj4eFmqz6Tm3+ySJKE/AXADh8ORkpJCCElMTHR/9ZncpjORJEmSqqd05XoqdCbycmTs/mxEl5bPfHkmfMBX6z7uFey9t+xIxfvnjuk596Ju6AeH/vi98PiWPxe80DHnh/7PzfzJ5KVnXblD3r5j17FDO/fMf6mTaZUsh1ztVw4YAQ0AAABQ61AUhVkjAWqaKIrp6ek2m02r1co4LU+Fb3aarp6hQizLKpVK9CcANa24uNhoNAYFBUVFRcmVocJ3ekBAAMdx1fL8DMOEhIRUcPOE02uXwatdpLxji8e/+N7aM46Y7q8vnjNpULNA760+EyJe/3X68iuKru9v+E+fCIoQokpKHrXO39r8pY1TVz7V/83G3lfQLDvkL8f395EYDedUPvJSUoBZlkOusD9hWbbS1ycYAQ0AAAAAAHWO0+lMS0sTRVGn02FSeACoCovFotfrIyMjZaw+g5cT0te92uOhNzfktX9349HjO2Y+6d3VZ0IIn3rlrJ1p1iFJXe5AA1u3bacQUy6mFHj2fMgVcx1y/fvbKwmt4xxKSiRedMje94UBAAAAAADAnZSUlBgMBpVKFRUVhSUHAaDSJEnKzs7Oz8/HkoNQk/gLi14YuTKz6bi1Wz58OLxuDCWl/PwCKNFqLRBJVNkRS0X5VoEo/Px8vPFPt93PX0HEgry8BDaM++cAveaQ68ZpCwAAAAAAQAghxGq1Xrt2LSIiIjo6GtVnAKg0QRD0en1xcbFOp0P1GWqQbd/8hUftrd9ePq2uVJ8JIdx9nZIjpAsbVqzL/GcVTTF/9+J1+/jAbl1bed86hIUinV7/oe6R0tWfv/8pywsPGSOgAQAAAACgTpAkKScnx2KxYKwiAFSR3W43GAw+Pj5arba6Jm0HqJCQcuRwjqgIPPjJa1dvPNUo1QNjZj/XxDtLe76tJ0/ut/3NX4Y+nrqmT8cWKtvlI7s2nDKHPDR+Vt9QL/v22Cyy13km1q/ljMn99nrpIXvnWQoAAAAAAFCeKIpGo9HpdOp0OoVCIXccAPBgRUVFRqMxNDQ0IiJC7izg/Xij3sBLRRd3LL9402/ocHbgZ881kSVVzaOjekw+sLzJR19v3LhlzVYbp9Y0ee6d96YO76DxolqmREgGzxVLdCLrUNKSynsP2fOPAAAAAAAA4I4cDoder1coFBirCABVZDabr1+/Hh0dHRwcLHeWOo2Kemln4Utyp3AHn15fmou+lDuFLOjwpIHzvho4T+4cNYQnlN7JUYToWAdLuRYZ9NpDRgEaAAAAAAC8GcYqAkC1kCQpMzOzqKgoMTFRqVTKHQcAPJhNovU8F0CJ0azT06fXuBcoQAMAAAAAgNeyWCzZ2dkYqwgAVSQIgsFgkCRJp9OxLGopAFB5+SKdwXNqhlczgtxZ3ASdJgAAAAAAeCFJkrKzs/Pz8zFWEQCqyGazGQwGpVIZExODaXwAoCpMApMrcnGsI5AW5c7iPihAA9RpaWlpJ06c8PPz69ixY2hoqNxxAAAAAKqHa6yiIAg6nY7jOLnjAIAHKywsTE9PDwsLCw8PlzsLAHgwkZB0nrNJtJa1+/w96XNdgQI0QB01Z86cRYsWZWdnFxcXE0ICAwObNm06e/bsTp06yR0NAAAAoErKxipqNBqMVQSAqjCZTCaTKTY2VqVSyZ0FADyYU6IMvIKhJB1nZ+QO4364GgOoc3ie79Gjx1tvvXXt2jVBEJRKpVKptNvtR48e7dWr1//93//JHRAAAACg8goLC9PS0oKCguLi4lB9BoBKkyQpPT3darXqdDpUnwGgKkpEOoVXKGlRwzrqYPWZYAQ0QB309NNP//HHH76+vq6PZJIkURTFsizLsjabbdq0aTExMYMHD5Y7JgAAAMD/zGw2X79+HWMVAaCKeJ7X6/UURWm1Wiw5CABVkSfQmYIignGG1ZklB2+FEQEAdcuuXbu2b9/OcVyFA4I4jistLZ0wYQLP8+7PBgAAAFBprrGKubm5iYmJqD4DQFXYbLaUlBRfX9/ExERUnwGg0iSJXBe4LIHTcI66XH0mKEAD1DVz584tLS29w1WUQqEwGo3r1693ZyoAAACAquB5PjU11eFw6HQ6pVIpdxwA8GD5+fmpqamhoaExMTEURckdBwA8lUgoA88ViLSWc/hTotxxZIYCNEDdcvbsWYa504xDFEXRNL1jxw63RQIAAACoCtdYRR8fH4xVBIAqysnJyczMjI+PV6vVcmcBAA/mkKgUJ0coSsvafShJ7jjyw/UZQN1SUlJyLw8zm801nQQAAACg6vLz8zMyMtRqNapFAFAVoiimp6fbbDatVuvj4yN3HADwYMUiZRR8gmghinHKnaW2QAEaoG7x8/O7l+JyWFiYG8IAAAAAVIXJZMrNzY2LiwsMDJQ7CwB4MKfTaTAYGIbR6XR3vmEUAODOLAKTLXBRjDOkbk/6fBNMwQFQtzRr1kwQ7tQJSpIkimL37t3dFgkAAADgf+VactBqtWq1WlSfAaAqSkpKUlJSlEqlRqNB9RkAKk0iJEvgrgushnWg+nyTujUCWpKkoqKi2rmMgCRJhBBRFIuKiuTO4nlcNVM03b0YNWrU77//7nQ6y8+QKElS2fvC4XDExsb27t0b7XlXkiQJgoCGqgRXj4fWqxxRFNF0leM68Xier7nWs9vtNI1v9wFqnGusIk3TWq0Wkz4DQFVYrdasrKyoqKiQkBC5swCABxMIZeQ5XiL1FQ6OYNLnm9WtyzWKonx8fGptAdput7sSyp3F84iiyPM8mu5e9OzZMzk5eePGjTRNl1VJyt4UTqdTqVTOmjXL399fvoweAydepbl6PJqm0XqVIAiCKIpoukoQRbGmTzyWZV1lbgCoOSUlJQaDQaVSRUVF1c4LewDwCJIk5eTkWCwWjUaDjz8AUBV2iTLwCh8ialknRqNUqG4VoAkhHMfVzutU1+dViqI4jpM7i+cRRRFNd+/Wrl3bu3fvnTt3Mgzjeke4RvLyPB8QEDB16tRnn31W7oyeQRAEnHiVI4oiQY9XWRRFoekqxzUBEU3TNdd6DMO4Tm8AqCGuJQcjIiKwXgUAVIUoikaj0el06nQ6hUIhdxwA8GBFEm10KkIZIQJLDt4e6vIAdQ7Lsjt27JgzZ05CQgLDMKWlpaWlpT4+Pu3bt9++ffs777wjd0AAAACACuTk5GRmZmo0GlSfAaAqHA5HSkoKIUSr1aL6DABVYREYg1MRxTpRfb6zOjcCGgBc3njjjTfeeCM1NfX48eP+/v6dO3cODg6WOxQAAABABURRTE9Pt9vtWq0WcxABQFUUFRUZjcbg4OCoqCi5swCAB5MIyRS4IpFO5BxKCjdB3gUK0AB1WmJiokql4jguKChI7iwAAAAAFXA4HHq9nuM4rVbLMIzccQDAg1ksluzs7OjoaAy+AYCqEAhl4DmJUDrOwWLJwXuAAjQAAAAAANRSriUHg4KCIiMja+dSLgDgESRJys7Ozs/PT0xMVCqVcscBAA9mkygDr1BSYgzjwNTG9wgFaAAAAAAAqI2sVmtWVlZUVFRISIjcWQDAgwmCYDAYBEHQ6XRYyRkAqqJQpNMFRRjNhzO83Fk8CQrQAAAAAABQu0iSlJOTY7FYNBqNv7+/3HEAwIPZbDaDwaBUKjUaDU1jtCIAVJ5JYEwCG8s6VDQmff7foAANAAAAAAC1iCAIRqOR53mdTqdQKOSOAwAerLCwMD09PTQ0NCIiQu4sAODBJEJl8GyJRGs5hy+FSZ//ZyhAAwAAAABAbeFaclChUGi1WoxVBICqMJvN169fj42NValUcmcBAA/GE0rv5ChCtKydxYIUlYICNAAAAAAA1ApFRUVGoxFjFQGgiiRJysjIKC4uxpKDAFBFNonW81wAJUSzPIrPlYYCNAAAAAAAyM9isWRnZ0dHRwcHB8udBQA8GM/zRqNRkiSdTseyKHoAQOXli0wGz6oZXs0IcmfxbOiLAQAAADyH0y53Ajlc+VPuBHJY943cCdxHopnMpB6F4QmJ9zVW+vrWufOc85Fnv3WtnV3SzsidQA6N7pc7gfvYGjXSz5/vr42P9lfQuUa547hXZKI8+3U65NmvvM4dlDuBHC79JXcCt8qJbGhWJ8ZHhQb4yvSX2otgVjUAAAAAAJCNoFBe6zywNEit271a6esrdxwA8GAFycmpy5aF/vhjbIAPTeFeeQCoJJFmDYlt80JitJcPoPpcLVCABgAAAAAAedhU9VK6DWXtJdrda7jSQrnjAIDHoijTyJEZ06bFTZqkXrJE7jQA4MGcnG9ag44izegu7/exF8kdx0tgCg4AAAAAAJBBYWRiert+YVdOhF84RIgkdxwA8FSSj0/GtGklLVpohw71SUmROw4AeLAS/1BDYhtV/vUo4xkKFyfVBwVoAJmlpqYePXrUbDYrlcrGjRu3bduW4zj37Hrnzp0LFy7U6/UcxyUlJU2ZMiUuLs49uwaoCWaz+cCBA5mZmTRNx8fHd+rUSaVSyR2qRpSUlBw7diwtLY3n+YiIiM6dO0dERMgdCgDgf0KZGrY1NWofe3ybKvOq3GEAwIM5w8MN8+fTdrt2yBDWapU7DgB4MGtYfFZM08isC6Gma3Jn8TYoQAPIxmg0fvzxx8uWLfP19eU4ThTF0tLSLl26vPnmmz169KjRXZ8/f75Xr14ZGRmiKLq2HDt2bMmSJQ8//PC2bdsYhqnRvQNUu9LS0nnz5m3cuPHixYs+Pj6EEJvN1rx58+eee+7FF1/0plNaFMXly5d/9913Z86cUSqVFEXZ7fYGDRr07dv3rbfeCgwMlDsgAMDdSTST0bpnsVqTuG+tMi9H7jgA4MFKWrQwzJun2r076qOPKJ6XOw4AeCqJkJzoxpbQOE3qUf8is9xxvBAK0ADyuHTp0ujRo8+fP6/T6RQKhWujKIrnz59//PHHFy5cOGLEiBra9ZEjR7p27Wqz2Wiapul/J4IXBGHHjh06nS4lJcWbCnbg9YqLi0eNGrV169aIiIj69euXbTeZTOPHjz937tznn3/Ost7w904UxSlTpixcuFCtVjds2LBse3Fx8fz588+cOfPNN9+EhobKmBAA4K54ZYC+fX9KEnV/rGDtJXLHAQAPlt+7d8b770csWBC2apXcWQDAg4kMa9QkORV+usv7FQ5cnNQILEIIIIOSkpK33nrr8uXLsbGxZdVnQghN02FhYXFxcWPGjDl48GBN7FoQhEceecRVfb7pVxRF0TSt1+t79epVE7sGqCHTpk3btm1bQkKCv79/+e2BgYGJiYnLly9ftGiRXNmq19KlSxctWqTRaG6aWkSpVGo0mj179kyZMkWubAAA98IWHJ7y0GDfgtzEff9F9RkAKo+icl59NXPy5Phx41B9BoCqcPj4pzR4gBBKe+Ugqs81BwVoABmsWbPm4MGDt5uz1d/fPzQ0dN68eTWx63HjxuXn599afS5DUdTu3buNRmNN7B2g2p09e/aLL76IiYmp8KxmWTYqKmrNmjU5OR5/i3dBQcHSpUsjIiLKf2tVhqbp6OjoFStW1NB3VwAAVZcf0yi1y9OhqSdj/vyNEgW54wCApxL9/Azz5uX36aMdOjTgyBG54wCABysKrJfS8IGAQpMm7RgtOOWO481QgAaQwW+//RYSEkJR1O0eEBoaunnz5pQaWMF548aNd9gvIYSiKJ7np0+fXu27BqgJv/32m7+/f4U1WRd/f/9Lly798ccf7kxVE/bv33/q1Kk7LKvIcVxgYOBvv/3mzlQAAPeGMjW8P7NNctyxLerLx+QOAwAezBEbm7JqlahQaAcP9rl2Te44AODBLGHxhsS2URnnojLOEUmSO46XQwEawN1EUUxLS1MqlXd4DMuyHMfVRAHaem8LQ58+fbradw1QE1JTU+/8biKEKJXKmng3uVlKSkodOVIA8DIiwxk6PGpNaKHdtTowK1XuOADgwUpat05dtSrgyBHNq68yhYVyxwEATyURKiu2WU5kw8SUI8GWdLnj1AnesCgTgGcRBEEUxTsPQyaE0DRtt9urfe+iKN7Lw2pi1wA1weFw3PXdRFGUF5zSdedIAcCbOJUBho6PMw6bbtcqxmmTOw4AeDDroEFZ774b9fHHIRs3yp0FADyYwCoMmtYCy+muHOAcpXLHqStqRwFatJxav3TN7pP6wgBNq27PPD+wZcgNn7GdRz4fOnN36Y3D4enoJz5dNFz923svfnnq32lamJiBsxYOb8i4JzhAJXAcFxoampaW5uvre7vHSJLkdDqjoqKqfe9KpfJe6lMxMTHVvmuAmhAZGelwOO78GIfDERkZ6Z48Necej7Qm+g0AgMopCYs2dHhMlXU16q/fKemevgIHALiVRNM5HC0A+AAAIABJREFU48ZZBgzQvPaa//HjcscBAA9m9/E3aNv5lhZo0o7RWJHCjWpDAVrQ/zTzo3XCQ8+PfSbMtHfl9x99wsyeOSCuXA2ZbfDo2xM78GUFaKnw1Lolf9VvHkWLmdk5VMNH33qi6d/Tf1LKmGjMKwK1XefOnU+ePHmHuVwLCgratGnTokWLat91q1atdu3adedxlDRNv/rqq9W+a4Ca0KlTp7lz50ZERNxuaU2n01lSUtK5c2c3B6t2HTt2tNlsdrv9dhNeS5JUUFDgBUcKAN4hL/a+zNbJEWf3hqWelDsLAHgwQaUyzp7Nh4bqnnlGkZkpdxwA8GCFger0hNahZkNE5gW5s9Q5taAA7Ti9eXNa7MC5r/SKYwhpVi/v6ju/bDnX95UW/37ApkIbtOvY4J+fpKI/v1hW2nX0iNaBlD3nulXVoMODnZpjzDN4kKFDh27ZsiUvLy8wMPDW3wqCYDKZxo8ff4d11Srt66+/btKkiSAIt6tBi6IYExPTt2/fat81QE3o3r17t27djh8/frsxztevX3/22Wdbtmzp5mDVTqvVvvLKK8uXL4+Li6vwAbm5ue3bt+/Xr5+bgwEA3EQiVE6zBy0JzTSHNvqbDHLHAQAP5tBo9AsWKIxG7fDhdFGR3HEAwIOZ1YnXIxvGGk+r8rLkzlIXyT9YWDCeu1AU2bpNtKuCzMS3SQovuHA+67Y36dnOrfnur8YjhrTyp4houp4jhUeFi6XWnNxCJ5asBA+h1WrHjRuXmZmZn59/068cDofBYBg0aNCIESNqYtcNGjR44403aJqWKlrjVRRFHx+fzZs318SuAWoCx3EzZszQaDQ5OTk3ndWiKGZkZDRr1uyDDz6QKV01mzRpUrt27TIyMgThhpvFJEnKzc2Njo7+8MMP/fz85IoHAEAIEVmFoeNjhZFa3R+rUH0GgKoo6tQpZfVq1a5dmtdfR/UZACpNoumM+Fa54brEq4dRfZaL/COgxdycXClMHfpPKZwOVYdKuTkmkWgqqo4L+k3f7wkbOLu9iiKEiKYsE2/64+OR36flC4QNTOj87Ouj+9T3+2dkZ2lpqdPpLP/vKyy61QZlwWptwtrM1Wie1XSDBw9mWXbevHmXLl0KDAzkOE4UxeLi4sLCwldfffX9999nWbaGjujTTz+VJGnevHk8z5cfBy1JUmBg4JYtW1q2bOlZjSkXTzzxaonq7fGaNm36xRdfTJo06eDBg0FBQa5bB2w2W0FBwSOPPDJr1qyoqCjveJnCwsK+/fbbd999d9OmTUFBQUql0rXqYEFBwf333z99+vT777/fO460hrjhT60kSXgJoC5z+AfrOz6uKC1I3L2a4e8ybT0AwB1YBg3Kfvfd6A8/DMbgGACoAoFVGBLbSoTSXd7HOrFgu2zkL0ALDjtPKZXKf6pglFLpSznsjgo/vUn5B374pajLxO7hFCGESIW5VqcyQPfouGkPxpDrpzZ/tWDxzMXq+a+3C3A93SeffLJly5ayf65Sqcxm851nv5UXz/Nms1nuFJ7K45quW7duzZs3/+WXX/766y+LxeLr69uoUaOePXsmJSWVlpaWltbgYqwTJ0586qmn3nrrrbNnz5aWltI0HRQU1LNnz1mzZikUCo9rSXmhuSrN4XBUV+vFxMR8++23v/7664EDB7KyshiGiY2N7dKlS/fu3RmG8abXSKFQzJkz5/HHH9+9e7fBYHA6nZGRke3bt+/bt6+fn583HWnNqcYT71YlJSUsK//FFYAsisNijB0fCzJeiDq9m+CbGACoLInjMqdOLezcOfGFF5Rnz8odBwA8mE2p0ie29Su2xhhO0VgPWVbyf0ZiFD6MlF9qk4ivq6hcWmqTuMAKp74V03f8/Ke6x+zG/6w4GJL83prkf34b127wmCdOvvbjnlMvteusJIQQotPp2rVrV/bvL1++zHFcrS1AO51OiqLwwbUSJEkSBMETmy46OnrUqFGy7LpRo0aur2dw4lWa5554tYHT6aRpmmGqbQJ/juMGDRo0aNCg6nrCWkuSpG7duiUnJ9/9oXAjSZJcd37U3NuWYZhae5kBUKMsCS2yW3SNPvV7sP6c3FkAwIMJwcGGzz8XAgJ0Q4Zw2dlyxwEAD1YQHJ0e10J9/Yo6J0XuLFALCtB0mLoelWa2iiSYIYQQMc+cR4U1Datg/g0hZdcuo/aRd2NvN3M1XS8m2sdpLbRJxDWietiwYcOGDSv7fXJyclBQUO38ZChJktlsZhgmKChI7iyeRxTFgoICNF0luE48lmXRepUgCEJhYSGarhJEUbRYLCzLqlQqubN4Hp7ni4uLceJVgiAIVquV47iaO/F8fX1FEWMroG6RKCq7Rdf8uMaaA+v9zRlyxwEAD2Zr0MCwYIHyzBnN6NG0HXfKA0DlmcJ1poj6cYaTgfn4KqtWkH8RQia+aWP/rJOnTK779MTsU6ezA5s0jbl1UBx/cffe6w0e7BRRVj8uObRw9Ktz9+f/c4ufkJGid4TExQXWxgozAAAAAIBXERS+1zoPKq4Xp/tjJarPAFAVhQ8+mLZ8efCmTXHjx6P6DACVJtFMuibJGqbRXT2I6nPtIf8IaKJo0adP/MT/LlgdPbJLaM6u734y6p54vZmCED5l58o95sZ9n2wfQRNCBP1fJ/OiOjUO+be6rGzeoZnz428/C+Wf6hDDmM9tX7XR1HR438a14KgAAAAAALyZPSDE0GmAT55Jc2gDLfByxwEAD2YeOvT6a6/FTp6s+uMPubMAgAdzcr6GxPtpSdBe2c9iPeTapDaUalntoEnjnV8vWzjxJ5tfTKt+E0YN0DCEED7j2OZNaULHQe0jCCGS6czpbGXDxrHlhkZTAW1f/nB88LK1Kz/eVMCExjZs+9KHQ7tHyz+sGwAAAADAixVFJhrv7xuadjri3D4sOQgAlSYpFBnvv1/cvn3iyJHKCxfkjgMAHqzEL9iQeL+q4HpU+hkKFye1TG0oQBPCqNsOndJ26E1bfbtMWtel7Ccq8vFP1z9+yz/lItsPmdB+SA0HBAAAAAAAF3P91tebPhB94rfg9ItyZwEAD8aHh+vnzqV4Xvf006zZLHccAPBg+SHRGbEtIrIvhZnS5M4CFagdBWgAAAAAAKj1JJrJbN2zKFyTuPdHpfW63HEAwIPZ7rtPP39+wMGD0R99RDmdcscBAA+WE9nQrE6MTzseUJQrdxaoGArQAAAAAABwd4KP0tC+v0Qzuj9WsrZiueMAgAfLf+SRjGnT1N98o16yRO4sAODBRJpN1yTZfAO0l/f72HFxUnuhAA0AAAAAAHdhC1LrOz7uZ86MObGdFrHkIABUFkWZnn8+96WX4iZMCNyzR+40AODBHAo/feL9nNOmu7yfEXAjRa2G9foAAAAA4K5sBz8d/MyCk3Wj7igVpfw++Z1XWyb3DuzwWJNnJ4z977lcUe5Q1a3EbJi+flvj/1ut/HBFvbmbB+5IPXvDWvFiesrZ55duiJ65wmfG6rjvDr1gak6unYs7tsUbq8916vSWXZ1qbano6s7Jb77csluPwLZ9mjz99tgfz3pfZ3KTDYTEE/LnjRslQpYQ8jAhKkJpE9t+pusaN2SIV1WfS7cPbqCjorQ3/Kd5YWkelkGrESVXN08f2buxLlYZGlGv6cMDp647W+StTe04uGzGM2tSbt9n3vUBnog/+MuqZ7Zn3nJQUoHx5KT5i7Sj31O+NKPBzI0TcnRciVWTetSLqs/O9F0Lnu/XOTo21ieygebBZ1///oTZK/5wYAQ0AAAAANyFZNq6cOEve/u/7BUXwHfhuLLm0WGL9gqxyb369A22Xzz4+5fTxuzWz9n/TiuV3NmqizP34sAlR7bb/To1bTAoSExJ068/sO8PQ8nu4c1asoQQYr5y5OEfLhn81ANbN49RBxw7/eeamS9c6JK8v5vaT+7w1a5Ond6yq1Ot7biy+tFn5+8V4pJ7P9o32Hbx4I4v339lt37B/vFJXtOZ3CSdkFcJMRFyUyloBiEfEHK/r9/Q5A6nD+6bPXlEEREXEULJkrIGCFn6a3Y6omW3hxN9/93KNknkvOYQaxHnlcUDe7yzvTCq04Dhg+KcKXs3rZ/z4h+H03dvfqOlj9zhqptkPbJwzaG9D/W7XZ951wd4Iqnw4sLt5/e26XDTQRVd/SP5s9+PEXXv9h0fCxL3Hzk6743h10e/tLJ9kLe80yTzjkkPD15uCGsz8LkxDRS5J7au/+LNAQcyNuyf0sbTL8BQgAYAAACA2xFKc/Xnju9aOev9H7PFCLnTuEXJ1u9W7C3WvLN88axWSkIIGfvUnBeef/uHJauemzs6wituH5QcP+/+67fSgOef6fNtIyVNCJFa7tz2a5+jp6ac0W1KUlJiwdI9V1OVmu9H9+jW9ZGS0OgZe76Y8n9rZh8+u7Hjw88q5c5fberg6S2jOtjaJVu/Wbq3OOGdVUtnJSkJIYR/Zs6IYW+v+nbVsIWjI72iM7mRQMgoQq7fcp+1npBPCXkg5r6Fq74K27UrYuueYURcTMgLhLSRJ2n1E4yGa6Jf9zfmrerle/dHQ1VI+T9/NOO3vPjnf9j5bZ9wmhAiTtg5vnefrz6b8t/Bm4ZGeEshUizNu37u/F8rly770Vxhn3nXB3gisbTQei41ZeWm337Ml24+KDFnwfLdx+j6s6c8N/j+FpbQuOlnVk+bOm/umt0jWz3Wwzu+exCuLf3sh9SQvkt3LX4umiGEkAlPv/vwY7O/WrjxtSXPhnj22Y0CNAAAAABUTMpZPkA3ervd9ZMXlksqIOReulZEwrolN/2nzsrG9npAM+Ev4wWDSLyjAC1a9hocTGTTtxso/z4eyrdb50adjh/Zl5ZrT4rzdeTuyxYCmzVt3e8ZhyBod69m7ezj9f3nHMk/ZxWJ0isaoW6e3vKpi639d2fSI7lZWWcS1+tBzYQ/jRcMIvHGAvRCQvYS8gwha2/c/jMhJT6xz6xaFv313LAffiCEvEPIWkJ+9J4CtGQ1Gq1UTIM4Tu4kdQB/Zu/hfKb5mLcfCf/7XUSHdXvjhU7fjd+364R9aB/v+AZAsv424NG52/+eGquCsuNdH+CJpIITA8b9tP3veTduPigh+/wGgxjbvUefLg8Wsgrd5X0KKmxyv/sWf3l29cU+PVp6xbuv+MS+087Afk8OdFWfCSF+rR7vHj3n6yvn9AIJ8ewSbnWkd/w+qftHPh9v/+CBm15vKXf9a48vSZj38/g2nt1KAF4oNzf3gw8+2Lt3b25uLsMw8fHxTz/99JgxY2jas6+GDx8+vH379kuXLtntdrVa3ahRI6fTefHiRYvFEhwc3Lx580cffbRhw4Zyx/ybyWTasGHD8ePHc3Nz/f39Gzdu3K9fvxYtWtz6SLvd/ssvv+zduzcrK4um6cTExG7duvXo0UPe18tut2/evNmViqKowMBA18aioqKwsLDWrVsPGDAgKipKxoQAUEVU6KPzdjXLE4mUu3Hsk3PS5c7jDkxog3h/cvH8wTRn94YcIYSIuUdOZgmcrmGMZ/+J/JfIE6WqeUI9XbkDojhWSRGeF0RCCB064sneXbqPDsrLiT35OyWJhEiFDl6i/NRKL/mUS+rm6S2futjaTGgDjT+5cO7GziRT4Oo3jPWWzqScU4RMJeQDQoQbC9ASTe3lJK71sH7jXw87etS1sQkhYYScIET0kq8jxGvX0gW2vi7EuGfz8bPZpX6xTbt1SdL4eU+HWYs4S0hI/eYPttYx/26jlEolRXiHw2umoaBUHed9k5AnEin/wNh3193aZ971AZ6I8m8yb2pknkSkwrNj5+676aAEa166SMU068lJoubqIVpwEkIFRoXHURf+TDULLSOZip/Vo7DNX54995kGbcp9jyIUFpVKdKQ6xOM7y6oUhoU8w+WMQpE4Tv91/ITv6XPnQm4sQEv2S7v2Hj1QmCEQFKABapUlS5aMHz/eYrHQNO2qYGZlZR08eHDRokW//PJL7anP/k8KCgqmTJmyZMkSlUqlVCppmrZarfn5+RRFhYWFBQQECIKwbdu2H3/88amnnnrzzTcZRua/UOvXr58zZ86FCxcCAwM5jhNFcceOHTNnznzjjTemTJni6/vvH53Tp09PnDjx4MGDKpXKx8dHkqQDBw588cUX/fv3//TTT6Ojo2XJf+bMmYkTJx44cEClUikUCqvVarVaCSH+/v716tUjhGzcuHHlypVjxox59tlnZUkI4OkEQbh1o7t7LrZeo7b1CCFS1kmVx1/33qOA/uPeHnZ+5oyXXrs6oEurIPulA1tXHFf0fveNkdHe0gRc7PzRsTduktIvXDskMK1iw3wJyde2bzgoufPFw+q/jtrsdktxyZmr5945bY9u0vipYC+qp9Sa07vCN3t1kSRJkiT5+5Na09puFND/zQnDzk6f8fyoqwO7tgqyXdq/ecUxRe8Jb3tPZ/KPEkJGEtKekHGEzCm3XfT317/7SNqMDWFnv4sovF62nSUkjhADIYKXFKDt165dF8SCiT2Tsyy8RAghlCKiw8SF8z94IMydnWaF73RRrM6qrCAIt+7FrZ2JX/L8Q8k3bhLTN/18yKlodX9L7xj+TAghTFCjJkGEECk3peI+864P8ESMfyOtPyFEystU3fLOKakXpqSlXMPlmDRCS3+vOemw5ueIomguEIhXFKD9GvUZ0ogQQohoK8yz5Gac2fn1O2st0f1nPhXn7pe5wv5Ekiq/2mcVCsNS3oZXkkZu+/s2KvJa0s8VPIhSPjCyMarPALXJ4sWL33zzTZvNplQqCSGSJFEURQgRRfHq1atdu3Y9cuRIXFyc3DH/N6WlpaNHj96+fbtOp+M4jhCSk5OTl5fHcZwkSTk5OYGBgaGhoaGhocXFxTNmzMjLy/vwww9dBy6LH3744eWXX46MjExMTCzbGBISYrfbv/jiC7PZvGDBApZlCSFnzpx55ZVXjEajTqcrH1itVu/cufOFF15YtmxZeHi4m/OfO3fulVdeMRgMrlTp6en5+fk+Pj40TdvtdovFkpCQEBYWlpubO2rUqNLS0hdeeMHNCQE8nSiKri91blIvKND9YeoaNqrty4+32Drv6PJvzy4nhBAqsPkzY7prPH3tl9sTrl068dT2zOLghlOSVLmNO5p1SfGHfw7IMRCxYM7Sn/+TKRJChcS32vpoQrQX1Z9rjwrf7NVVM+J53mazoT+RBRt1/8tPtNw658jyr8/83Zm0GDKmR4L3dSbvEWIgZN2N9QVHXJx+wQLm+GKBlwILr5evnVCEBBCSTkjlKxm1ipCZYnRIvE/iswt3jO6SQK6f2Pb12OlrZ7w8QbPjm5FuvHumwnd6cXGx0+m8dXslCIKQn59/6/Z6fjLOv2u/tuX9pyb9XqwZMWVYgtdUYuEmlrD47EaPdwv7dcn25as7DxlRjyaEEFvm/C1nTRLxszu9pDMpI1yd82jX//zlJIQO6Thh67z+7v/issL+pMKvoO5RFWrDVMADb3y1eKBA+BNfjV2meOXzkS1uejaK9g1v/UjvBt7wNQSAl8jJyZkwYYLNZlMoFDf9iqZpX1/f7OzswYMH79+/X5Z4lbZo0aJt27YlJCS4BnQXFxdnZGQoFIqyGSqysrL8/PxYllUqlfHx8fPmzevUqVOfPn1kSZuWljZ37tzo6GjXnBXl+fj4xMfHr169un379iNGjHA4HJMnTzYajRERN6/BwDBMTEzMiRMnZsyYMX/+fHdlJ4QQp9M5efJkvV4fGRlJCLFarbm5uQqFwlUf5ziupKQkKysrPj5epVIxDPP111937NixSZMm7gwJ4OkoinJ9nQbuJhXvn/9GryXXWzw79edhnZupbFeObJo4c1n/4flrVv7nCbW3fbZ1FGTN++3IjLN5jpDEL5/r1OTh/nmqMO2eH3wKLYQQQvk9kfxQQl5JSoZh8V8n+62mtg5p0e7mKwioqhp9s1MURdM0+hMZSMX7547ptTi7xdAPfh7xYDOV7cqhDRM/+r7/c3lrfpjqTZ3JdkIWELKYkMRyG0uTWqfOmxu0dWv4p1vIbWao9ZrZEghd7/Gp3yT56h5qG+dHCCGaB4fM+IXKbvbOnvlrLg9/+z63VUQqfKczDFNds/ZRFMWybO3pTxwZu+dNnjBj/UVH4hNfrf24lzfdowP/kAiVFdO0IDgyMe3Y+4Oa/fr1mZc++HJb+/oNmMLDJ84cI4ERtKWE8Z4e9W909BPTv0kwZKf8uW3xqk/7PU1vXftGO3+3RqjwnU5RVKWH8VVlcLJPg+QRDQghzvrpG9J9nhn5Qsfa0g0BwO188MEHVqvVNfa5Qj4+PidPnvzrr7+SkpLcGawqCgoK1q9fHx4eXnZpZTaby19pMQzjGvujVqsJIQqFIiwsbOnSpXIVoFesWHHt2rXbDTNnWVatVq9YsWLo0KHbt2/fs2ePTqer8JEURUVGRi5ZsuS1115r1KhRTUa+wc6dO3ft2lWWymw2syxb/u8Qx3Fmszk8PNzX19ff399oNC5btmzWrFluSwjgBSiKCgoKquAXTnsFG6H6iDm/TV9xVfHQlA0Te0VQhBBVUo8X1/lZm7+yaerqQf3H3ec9t/ZJjmPHj7y4M/UM79+9U5fPHmkZ+PDjor1Et2sVU3aaUVyjRE0jQkjSfc+G/9Zy6+mpp+tva+vndZ/zZFbhm726CkYsy/r4+KA/cT/x+q/Tl19RdH1/w3/6/N2ZJI9a529t/tLGqSuf6v+ml9wnnEfIKEIGEDKk/NaARtmLvmw5a2bIzz+LhAQQYrlxsLNESBEhAV6zdBoV3OSBrjcOtaBjHunVcdKe3WcuFpH7Knr71YgK3+l+fn7VNfcgTdMqlaqCvZQUVsvz/w+kvGOLx7/43tozjpjury+eM2lQs0AvOZugPIFVZCS0EWhWd/kA5yyN7fjUPr+IKZv+/HX3vl8UQa3b9P2jp33sB9v0SoW3vfxUQKMu/RoRQoY+/2zjp1qOnzP1v09vGxHlzguwCvuTqnyhVR1/9biH3v/1oWp4HgCoeXv37r3z9QdN0yUlJatWrfKgAvTRo0fPnz/foEED14+iKJaUlNx0mAzDFBUVuQrQhJCgoKAtW7ZkZmbKMoHy/v37K/4c+A+VSnXkyJGzZ88eOHAgMDDwDl28QqFQKpUHDhxwZwF6//79AQEBrlR2u72wsNDH54bb7lyDrYqKilwzWQcFBR08eFAURU9f4hIA6gI+9epZB9OsXSt1uY8yga3btOM2brqUUiDdF+odH3HE4nW//DbsryK1rsXGvs17NNAYOvRXZl2N+msnJUkOS9ZaQ6kmMfHBoLKjpTT1Y5rR2RdzCgSCAjTA3fGpV87amWYdkm7sTNq2U/y06WJKgdTYOzqTHEIyCfmRkB/Lby26NLhTe4aQA4S0JySekBOEFBAS9s/vBUIyCGnk/oUN3IgKDApmicTzguQ1hfZaQ0hfN+bxYSv06h7vbpz9Vn/dbQdXgUeTWGVqwwdUJXkaw1FadE37wCS07LayZbeyxzjO/2wQ6MSIUO/4Ss+RtnftYZPmwQEP/rtWLaPp3q0Zc+Di+TSBuLUAXe2q7zXiCzMuX84o5G+eeIUOa9C2vnf8cQXwAlar9a53TFAUlZaW5p481SI7O7v8jCI8z5eWlt5aEi0/9xnHcRRFZWVlub8A7XA4LBbLrVOglOe6VTYzM/OmQ6uQQqHIzMys1ox3kZ2dXda8Tqezwttwyje4j49PaWlpXl5eaGioO3MCAFQC5ecXQInWvAKRRJZd5UuF+VaRKPz8fbzkmla8cHjvyL9KmnbqvqVnNJfY/FqLh6NO/RGiP/v37y1pb228el+v8N0dAv5tBLuzUKKUHOslbQBQw/7uTKwFYrmSgVSUbxWIws/PWzoTEkrIfwhxVYYkH5/8Hp3+PLTncB47XHTEERJDCCGkAyE/ErKPkMf/+VdXCMklZIiXrEBI+DPfDpjwa8iwuUuf+XeZMEGfetVJR2k1GJhb3fgLi14YuTKz6bi1Wz58ONw7ziG4hUARIahpsCU9Jvvy35uk/N37L10NSHg2KfyfmfSFM+dSs+mwYY2CvORESN3w1qtr75vZbvfouHJXoQWFEqVU+np6X1I9r5Ht7DdP3hce17Rt+w636PKfPxzVshMAqAb3ePvVTdXbWs610mDZj7ersN+6XZb5y1w3rdx19VhJkhQKhUKhuMdHVl/AuyufiqKo2yUsa3DXMkpuDgkAUDlco47JEdKFjavWZfF/bxLzdy/5aR8f0K1LCy9ZOozPnn8oxx7dfFmPGKl5l+xmD2oObfi3+kwIFx31kK905M9LR8su48XSbUdTLxJlV22wdwwyAqhp3H2dkiOkCxtWrMss15ksXrePD+zWtZWXdCaE1CPkA0I+JGSKRjN83bp3u3Z4LE+kRMcoQqYREksIIaQ/IUpCviDENTZBIuRLQgghT8sVurqxCQkhxlOr5y7amvvPVbEz479zV/8laZ7s3xITlVYz2775C4/aW7+9fBqqz17LHBZmoyimKEVdVn0mhBDp/P7No77astz09wTyzpw/P9iV69Og3QiNl5wKXFKXh1T8kRXLjpb8s0kwbft2/UUpvGtXj5+4qTryi+nL3nprvbFet9fHPX1/1M235DGaduhxAWqNmJiYu46WlSSpefPm7slTLRITE+12e9kMDyzL+vv7OxyO8tV2URTLV9VLS0ubNm2akJDg/rQMw2g0mj///PMOM3HzPO90OrVabUJCgs1mu/MTlpaWarXa6o55J4mJiaWlpa7/VygUvr6+kiTdVN8v3+A2my0uLi4gIMCdIQEAKsm31eSJfba/s2XowLQ1vTq0UNkuH9294bQlpMvbs/p4yU19gtl0uFhS+JreO2SQjq0NyPk/WnBVmimVpsnspBDWL/79B8N37Djb+5u8Z+6rF0VKz6Rc25jliG324GStp3/8AXAX39aTJ/fb/uYutoBwAAAgAElEQVQvQx9PXdOnYwuV7fKRXRtOmUMeGj+rr5d0JmWKOnc2fvpp6Lp1EfPmUbesLZhAyDuEfEhIP0L6EnKCkJWEvERIGxmS1ozAblMmPrRjwn8H9Ux98rEOiYz59J5tm887mo/+9j9tMAKjmgkpRw7niIrAg5+8dvXG4hOlemDM7Oea4K+UR5NoOiO2RZE9XylJlN1KSLk7aKngoQPaf/HpgTc+/PZQx8SIkuzfTlw6S+rPHdG+gZfUnwkV2vf9t9vveH9B74cvPNOndZSUc2b3po0n82MHLpr8kMdPNVMd703nyYPH7HHPf7dxfjKqCwC13KBBgw4fPnyH2XidTqdKpRo5cqSbg1VF69atO3fufPnyZdcMDxRFBQYG5uTklC9AC4KgUqnKfrRard27dy+/xZ169uz5+++/BwcH326wtsVi6devn1arTU5OnjlzptPpvN1g7aKiosaNGz/0kFsn4u/Zs+f06dMdDodCoeA4TqlUFhQUlE8oiqKvr29gYKDrR4vF0rNnT3cmBACoAjqq+8QD3zf+6JtNG7et3Wrj1PGNn3trytTn2mm85UMtn19oEElRjnH9b8Ybf0OF0wmfJYUQwjTr1GO/6vT0I/qfjmbmiUxkvfCXezefcn9ElJeVzQBqEB3VY/KB5U0++nrjxi1rtto4tabJc++8N3V4B6/pTFzMQ4deHzs2etq04C1bbveY9whRE7KAkPGExBAyg5B3vGpiZKbhkC8ORS/76OsN235YvNbhG9O4wzvzX584sHGwFx1kLcEb9QZeKrq4Y/nFm35Dh7MDP3uuSYX/CjwCz/nqE9pQhOjOX6UruslWdV/vPyaFTV1/eOvu/XlMUFLz7hsHdemn9qYuVdHs9R/2R8+Z/vWmn77dk8crIxu0ffnTsVNGdvTs6Z8JIdVTgLbn59toXfMmXnMbEYAXGzdu3FdffZWamupaHe4moijyPP/0009HRES4P1ulsSz76quvDhkyxM/Pz3Vc9erVKygocDgcLMuSf6rqZev+5efnazSaV199Va7AgwcPXr9+/fnz5yts5+LiYovFMnbsWEJI27ZtR44cuXr16vj4+Fu/M+B5Pjs7e8yYMWWLK7pHUlLSiy++uHLlSleq8PBwq9Vath6uJElOp1OtVrsa32QytWrVavjw4e5MCADVjop6aWfhS3KncBs6vNWAeV8MmCd3jhrifGDI/rf7BRvOR53eTW430RPFNWveZm1z7xmheAd17PSWWR1rbTo8aeC8rwZ6a2ciKRSZU6cWdeqU+PzzynPnXBvfJeTdWx5JE/IaIa+5OZ9b+SQ8/PK3D78sdwzv59PrS3PRl3KncB+qXt+d+/tW5QGewqYM0ie2DSg0RaefpQLa7Py+wisQOrxBh68ndnB3OHei/JsNmrJ20BS5c1S/6iihK+s3ipfOHzqWf5d5SgFAfizL/vzzz2q12mazuWbmLeN0Ou12e8eOHRctWiRXvErr37//1KlT9Xp9Xl6eJEkcx8XExHAc53Q6HQ6HUqmMjY2lKEoUxZycnLCwsEmTJt13331ypQ0MDJw9e7ZOp8vIyCi/NKIkSWaz2Wg0zp8/v3Pnzq6NH374Ybdu3fR6fdmsFy6FhYVpaWnDhw8fPXq0W9MTQgiZPn169+7dXan8/Pw0Go3D4eB5XhRFh8MRFhamVqt5ns/MzIyPj//000+x/CAAQC1hSWhh6PBY1KndUad23bb6DABwN0JIyLWvv7Zrtbqnny6rPgMAVEJ+cFRq/Y6huddijKcp6ZZ5fMArVEcBmms34at3NL+OGfSfdWfMDlzGAtRyTZo0OXToULt27Ww2W2lpqd1ud/2Pn5/fSy+9tG/fPtfAVY8zfvz4JUuWaDSaK1euGI3GvLw8lmVFUaQoimVZk8lkMBiuXLnStm3buXPn9u/fX960zZo1+/777/v165eSknLt2rWMjAyj0Xj58uXGjRv/9NNP5adACQoKWrJkydixY/39/VNTU9PT09PT069evVqvXr1Zs2Z9/vnn97iwZPVSqVRLliwZN26cv79/SkpKSUlJUFCQKIpOp1OpVFIUpdfrr179f/buO7Cpqm0A+L03u03SNGmaNulMyih7lgIiyBIRBUFcgAoKDl6GgOBAHKCAigx9X7ZgZSmCCBUZKgjIkF3AltKmbdKZ1aTZyR3fH3nffjVt05KkTcfz+wuSm3Oec3Iz+uTc5+SNHj16+/btffu2iwV0AADQwlEoWtZrhKbLwORz+wUqyBYBAPzn6Ngxf98+ulabNGMGXacLdTgAgFZMG60oTegZr7ou1uSHOhbQhIKRZnKd+uLDU67wqlOrJvdYTecKRVxGjUJH7Me25mwZx6r/4QCAZpecnHzhwoVLly7t3bv37t274eHhvXr1eumll2JjY0MdWkAmT548bty48+fP5+XlWa3WmJiYtLQ0q9V69epVo9HI5/N79OjRt2/fkGRsa0tOTt66deuCBQsuX76s0+m4XG5qauqAAQOYTO+9Srhc7vvvvz9r1qzz58+r1WoGg5GYmDhkyJDqoiIhER4evmzZslmzZv3555/FxcV0Ol0mk4WFhRUWFlosFqFQ2L9//y5dutRX5xoAAEBzIpgc1YBxBIOtOL2XYasKdTgAgFbM/OCDxatXi779Nvo//wl1LACAVozEaMUJvRwcvjz3HMthCXU4oGkFIwGNsgWSmKTImKQ+dd3L7Chs/aWyAWiTBgwYkJaWptfrGQxGaFOZQcThcEaMGDFixIiaN/bs2TNU8TQoNTU1NTW1MUfGxsZOmjSpqeO5XzExMS0wKgAAADU5+CLVoCc4leWJ53/ECDzU4QAAWi0U1U6frp05M+6dd/inToU6GgBAK+ZmsFXy/jTcrcg9RyPcDT8AtHLBSEAzBi367sdFQWgIAAAAAAAAEExmSXJx2qPCgizJ7bMIAtXyAAB+oliskg8+sPXqpZg2jZWXF+pwAACtmC08UpXUj19VEVt8C4UdKdqHVlnp1W8URVkslpZ5PThFUQiCkCRpscB1B/eNoiiYukAQBAGz5weKomDq/ON5x4PZ8w9JkjB1/vGceDiON93sOZ1ODIMrv0ALok/pU5E6KO7acX7JvVDHAgBoxfDo6KL161GXSz5lCt1gCHU4AIBWzBQpK4nvLinNEekKQx0LaD7BS0BTlpzM7Rm/XFNqiIFLdsyOvHDSmjqyp5gRtA6Cg8FgtNgEtNPpRFGUwWhpc9YKUBSF4zhMnX8cDgeceP7x7LkHU+cHeMcLBEEQBEHA1PmBJElPgrjpZq+FlJgHAEEQCqOV9B5ljU5MPrufY6wIdTgAgFbMkZpatGED99w56SefoG64Uh4A4CcKQTTSVIMwPrHgSrgZ9i9tX4KUgMYLdr84euaePDuFIGgk+0XSpdww8dljSdM2H9k6JcV7P62QQVGUxWK12AS0Z3U2iwU7Nt43kiQdDgdMnR886wExDIPZ8wNBEE6nE6bODyRJInDi+QvHcbfbDVPnB4IgrFZrk554dDrdc3oDEFo4m1uU/jhKUYrfv6U7baEOBwDQipnGjCn54APxli3ir78OdSwAgFaMpNHVCb1cbJ783p8spzXU4YDmFpSrREnlppde3VfZe8F315U7JrIRBEE4D7+39fUuZbteefHLu0Qw+gAAAAAAAAA0yBEhzh/2LMtmSj63H7LPAAD/oajm9ddLly5NmD8fss8AgEC4WGH5HQZTKCa/exayz+1TMBLQxJ1d289RQz/c/elTvaRcz6WnqKDn1A0HPh2F/ZWx9zZstQ0AAAAAAEDTq4rrqBz6jFB5I+6vn1ECvoUDAPxEhoWp1q0zjh0rnzaNe/FiqMMBALRi1nChssMDXLMuUfkXjYQvJ+1UMBLQeP7dfKTDsKHxXo1h0kGDU5DCvEJYAg0AAAAAAEDTQrUd+5f0eTj+8lFx7uVQBwMAaMXcEknBzp0km6149llWQUGowwEAtGIGUUKRIk1S+ndsyZ2WWA8XNJdg1IBGIwR8xKDREQjyz5133BVlWorL48IpBgAAAAAAQJOhaPSSvg/bImPkp/ewqvShDgcA0IrZevdWrV3LP3UqdsUKlIDVZAAAP1EIWi7rYoyUJeb/FW41hDocEGLBWAHN7DPqIUHJntXb7jlr3my/vXHVvjL+A8P7NNVW8wAAAAAAALR3bjZX+eAzbg5PfgqyzwCAgFROmlS4ZUv05s3SDz+E7DMAwG8EjVGUMsDKFaXknoPsM0CCswIaiRj33kejjs+eOzD996eT7+JO3tGvVhw/vTvjaC596JplEyJhBTQAAAAAAABNwCaMVaWP55fnx17/DaXIUIcDAGitKAzTzJtnmDgx8fXXwy9DGR8AgP9crPAieRrLbpIrL2Mk/JQFECRICWiE3vHVH07xls57b+umQ1aSQjYuukjjyYfP3bHmo2ldYf0zAAAAAAAAwWeK71zSe5Tkzp+i/GuhjgUA0IqR4eHq1avdUqnimWeYJSWhDgcA0IpZ+GJ1Yh+hXiUpy0EoKtThgJYiOAloBEHCu05Z++tzK7X5OUqNncaPVXRKioTUM/ATSZLl5eU2my0qKkogEDR/AG63u6ysDMdxiUQSHh4eSFMul6usrIwgiJiYmLCwsPoOoyhKq9UajUaRSCQSiQLp8b5UVFT89ddfYWFhgwYN8hFesGi12srKSoFAEB0djSBIVVVVVlYWSZLdunUTCoVN169OpzMYDAKBQCwWo2iIL8rQ6XR37txhMBg9evTgcrkIglRWVup0Oi6XK5FIMOy+KyN5zSoAAID2AdWkDtQreiVc+ImrVYU6GABAK+ZKSCj68ktmSYn8+ecxiyXU4QAAWjGDKKFc1kWqviWohJ+ywD8ELQGNIAiCoGxxSi9xSlDbBO2LXq/fvn378ePHL168iCBIampqp06dpkyZ8sgjjzRP3rCwsHDr1q1nzpy5du0agiBdu3bt06fPjBkz0tLS7rcppVK5bdu2M2fOXL9+3dNUv379ZsyY0a9fv5qHWSyWjIyMI0eOnDlzBkGQ1NTUxMTEp59+euLEiXR6cF+h/7Bp06Z169YVFxdbrVYEQSIiInr06LFmzZr+/fsHvS+Xy7Vv376DBw8WFxdnZ2enpqbSaLSKigqDwWA2mxEE4XK5CoVi2bJlEydODG6/+/fv/+GHH9RqtadfiUQyfvz4qVOnNkO2vba9e/euXLlSqVR65pzH48XExMTFxVVVVWVnZyMIMnjw4LFjx06fPj0iIqLB1pxO53fffXfgwIGSkhLP6GJjYydMmPDcc89xOJwmHwwAAIDQIemM4v6POnlC+em9LEtlqMMBALRiloED1Z9/LjhyJPbTTxESyvgAAPxEYVhpXHcLT5ycd4FjM4U6HNDiBCu9RRpzz/x+4W65BfdeXk9PGfPywwpakPoBbVpWVtbChQuvX78uFAo7dOiAYZjT6Tx37tzhw4dfe+215cuXs1isJg3gxIkTH3zwQX5+vlAo7NixI4qiVqs1MzNz165dn3zyyZw5cxqfBP/ll1+WL1+uVCojIyOrmzp8+HBGRsbq1atnz57tOaywsHDevHlnz54ViUSeIbtcruvXr//6668nT55cs2YNn88P+jBxHB8/fvzRo0dpNBqDweBwOBRF2e32P//8c+TIkcuXL587d24Qu9PpdPPnz8/MzBSJRFwut1OnTiqVSqfTURSFYRibzfaM+vbt25MmTZo1a9bmzZuD0q/BYHjjjTcOHTokEol4PF6nTp3cbvfdu3eXLFly4sSJ9evXy2SyoHTUSNOmTdu1axeNRqPT6WFhYRRFWa3We/fu5efnR0VFderUiSTJwsLC5cuXnzhxYu3atZ06dfLRWu1Zdbvd2dnZZ8+ePXHixLp162JjY5ttaAAAAJqTKzyiaOAEhs0sP7Wb5nY2/AAAAKiH4ckny998U/rxx4LDh0MdCwCgFSPoTFVSXwqjKXLP0uHLCahLUBLQRN7XTz702k/Frrpqu7An738REtCgYWq1ev78+ffu3UtKSqq+kcViicXiiIiIrVu3MpnMFStWNF0Aly9fXrZsmU6ni4+Pr76Rw+FwOJyIiIilS5fyeLzp06c3pqmLFy9++OGHOp0uLi7Oqyk+n//WW2/xeLznn3/eaDTOnTv38uXLycnJ1altJpMpFAr5fP6PP/6IYdjGjRv9qMng29SpU3/55RdP5hdBEE8iGMMwOp1ut9uXLl0qlUqffPLJoPTlcrneeOON48ePJycn02g0BEHKy8u1Wi2KohiGURTldrtZLBadTqfT6TiOb9myRSQSffLJJwH263a7FyxYcPToUblc7ukXQRAMwwQCAZ/PP3fu3Jw5czIyMjwVMJrB/Pnzd+3axWQyq1e14zjumXmKojQaDZvNFovFfD6fx+PdvHlzzpw5u3btqq+khsvlmj9//okTJ+RyefXpUT2606dPz5s3b+fOnSFZ5Q0AAKBJ2aJkqgGPRxTnxNw8jSJQVxEA4CeKRitfssQ0cmTyyy9zbt0KdTgAgFbMweGrkvtzrJUy1Q0M9kMG9QhGYst9ecuqI6WCoW99+/vlrNvern0xmhmETkCbt3bt2jt37kgkktp3MZnMuLi4devWXbp0qYl6Jwhi5cqVpaWldZac5nA4sbGxW7duLS0tbbApHMdXrVpVVlZWZ1NhYWFSqXTTpk0VFRVbtmz5888/pVJp7YXVdDo9Li5u7969R44c8W9E9Tlz5kxmZiaDwagzr81gMGw226JFi3AcD0p333333ZEjR+Li4jxZYBzHKyoqUBT1DBlFUZIkq/ui0+kMBmPjxo1qtTrAfg8cOPDjjz9W91sThmEymez06dNff/11gL00Um5u7o4dOxgMRnX2mSRJt9tdPQkoipaWlpIk6flvbGzs9evXN2zYUF+D+/bty8zMjIuLq/0kekZ38uTJjIyMJhsQAACA0KhM7lE4aJLk9pnYm6cg+wwA8BshEBRu2WLt3VsxZQpknwEAgTDzows6DBIY1PFF1yD7DHwIRgKaLC8px3rN+WrF1If6de/qLTWOH+Idv0AroNFozp49KxaL6zuAxWJFREQcOHCgiQK4fPnyyZMno6Ki6juAx+Pl5uY2Jh186dKl3377zcdGgjwe7+7duz/++GNmZqaPPfHodLpQKAz6kL/44gu73e6jujSTySwqKjp06FBQujt48KBIJKrOAmu1WhzHvYZMEET1vxkMhslk+uKLL4LbrxcURaOiog4dOlSz66azZs0as9nMYPz/vqxek4CiKI7jWq22+haxWHzy5Mmqqqo6G/SMrr6l8RiGRUVFHTx4kIQqfgAA0FZQCFrR7cHyLg8knj8YWXQn1OEAAFoxR0pK/r59dKNRPm0ao6ws1OEAAFoxbbRCndhbVng9ujw31LGAli4YCWhafFI8Dasn0QNAY9y4cePevXtsNtvHMVwu17ObX1O4fv16WFiY72IXjQygkU2dPn362rVr4eHhvg/Lzs52OBwNdtp4t2/fri8t6+EpjnH8+PHA+9LpdGq1uuYYLbW21UZRlCAIivr/ZVwYhgW41N1kMimVygbn9tKlS/n5+YF01EhXrlzxOh9Ikqz9w4NnP0aPsLCw7OzsrKys2q1ptdri4mLfxUO4XO6ff/6pUqkCiBoAAEBLQTDYRQ88aZYkKU7tCtcVhzocAEArZn7ggYKMjIjjx+MXLcKC+lcGAKBdoTBacWLvyqhE+b3z/KqKUIcDWoFgJKDpvV6aO6zwq7e3ZVuD0Bpol4xGo++sKIIgdDrdZDLVzFQGkclkakwAlZUNbzRvMpl8rC+ubkqv12MY5ntXQzqd/vfff5tMwdxA1mpt1OtUp9MF3pfRaMzOzq45GwRB1Dnkmk8riqIBDrl2v7V5yl4bjcZAOmoks9ncYCFvTyK+5i00Gq3O8Dyj83260mg0FEWbZ3QAAACalIsbqRz2LEri8jPfMW11XxkDAACNoZ86Vf3ZZ7JlyyRr1yJN81cVAKA9wBlsZcpAF5Mjzz3HdpgbfgAAQdqEkCaf8cWSXf1f75Py7/R+HaLY/0i0MAcu3LkgnVHfYwFAEASJiIhosBgCjuM8Hs93xtZvfD6/MQFEREQEpSmCIIRCIUmSFEX5GBGO46mpqXw+v8FOGy8sLEyv1zd4mFAoDLwvT+QEQVSnX33UxKj+N0VRAQ6Zz+enpqa6XC4fWVqSJEmSrLNOd9BxudwGq2FQFOUVLUEQdZ5vnhtrzmptnkXlwT1zAAAAND+LJEmd9qiw4JbkzlnIFgEA/EYxmSXLllnT05Nfeonz99+hDgcA0Io5wiKKkvtxqzTS4jsoFH0GjRaUBLT9/HtPLf3TSiGugqyLZV4pEXbENDghQUN69OjRoUMHh8PBYrHqO8Zqtfbs2bOJAujZs6fNZiNJ0kdSz2q19urVq5FN+c4sWyyWIUOGlJSU6HQ6H7UUrFZrjx49OBxOg502XpcuXQoLC2vWI/ZCURRJkiNGjAi8r+jo6BEjRty5cycyMtJzS3h4eFVVlVe62bNct/oWkiT79u0bSL+RkZEJCQk3btzwkUa3Wq1paWnJycmBdNRIvXv3vnHjRs1bMAyrvRi85plgt9s7d+7crVu32q2JxeLhw4dnZ2f7yJ5brdaBAwcmJSUFGjoAAIDQMST1KO8xTHr9pECdHepYAACtGE4h6i1bKDpd8fTT9EasRAEAgPqYBNKS+B7iintiTXNUswRtSTBKcLgu7N6VjfWc93OR2azXelNve7zejCIA/xUbGztgwICam7B5cblcRqPxiSeeaKIA0tLSHnroIR9Lg61Wq0KhGDduXINNpaenP/jggz6aslgsHTp0eOKJJx555BGdTldfURGCIAwGQ9CHPHfuXA6Hg+N4fQe4XK64uLinnnoqKN1NmDBBr9dXr/8Vi8U0Gs1ryDVX/rrdbj6f/8YbbwTer8FgqG/dMUVROp1u3LhxPhLxQfTGG29wudyac+41CRRF0en0mntgarXaYcOGVSfua0JRdMKECTqdzvfoHn/88QbrfgAAAGiZKAQpodia1IHJZ7+H7DMAIBAOCst3sxgVFUkvvQTZZwBAIDQMfkl89/iia5B9Bn4IxgpoZ3mpntZ30fyH4yHTDPy3cOHCrKysoqIisVjsdReO48XFxa+99tqQIUOaqHcGg7FkyZKHH36YxWLVLlzgcDhKSkrmzZuXkJDQYFNMJnPx4sVjx45lMpl1NlVaWrpw4UKZTPbqq6+eO3cuKysrJibGazEsQRDFxcUTJ04MegJ61KhRI0aMOHLkiKcIste9brebw+GsXLmywTLWjfTss88eO3bsjz/+kMlkGIYxGIzo6OiysjIEQVAUpSgKw7DqvnAcd7vd06dPVygUAfb79NNPHzt27Ndff42Li/MaJkVRpaWlgwcPfvnllwPspZG6dev29NNPb9++HUVRT7adRqPR6XTPImiKoiiKiomJqZ6HioqKbt26zZ8/v74Gn3vuuePHj1fPas27PKMbOnTojBkzmnRQAICQYbTLr1uJXUIdQfMhSFJVoSNIUmEvYnTvE+pwml37PMNDpX3Odsd+oY6g+VRVVRUXF4slYvEb85A35oU6HNB2hfFCHUEo9BoW6giaD0mSxWUVDqdTESdldWlH38r+q31+XAZbUDYhjBRFUBp1iSsIbYH2Kzk5ec2aNXK5vKioyGKxeFZ3ut1ug8GgVCqnTJny4YcfNmkAgwcP3r17t0gkKikpsdvtngWqTqdTo9EUFRW9/fbbs2bNamRTDz74YEZGhlAoLC0t9WqqsLBw6dKlntSnSCRav359z549CwsLzWazZ8g4jhuNxoKCgkceeWTNmjXBSgTXtH///iFDhjgcDpfL5emUoigcxx0OB5vNfvvtt6dOnRqsvjgczvr164cOHVpQUGAymQiCkEqlIpHIU+gDwzAmk4kgCEmSTqfT5XI988wza9euDbxfFou1bt264cOHFxQUGI1Gz+pjgiCqqqoKCgr69++/bt26xlT0DpbNmzePHz/e6XQ6nU7PnDMYDBRFSZJEUTQqKkoikZAkabFYCgsLO3fuvG7dOqlUWl9rnll98MEHq2e15ujS09PXr1/vo7QLAACAFsvhcueXVtBpNHmshEG6Qx0OAKAV02q1JSUl8fHxtdf3AABA47lxvEBdQlKkIjGexWSGOhzQWgUjAc0Z9dYnj9q2vj7/+xwzlHsGAejfv/+ePXtmz54tFovv3r2bk5OTl5fXs2fPHTt2rF+/PiwsrKkDGD9+/M6dO5955hkej5eTk5OTk8NisYYNG3bkyJG33377vgoaTJw4cceOHZMnT+ZyuZ6m2Gz2Qw89dPTo0cWLF1evd+7YsePu3bvfeustmUzmGfK9e/c6duy4bt26bdu2BWUnwNqYTOYff/zxySefeNbP2u12u93OZDL79Olz5MiRd955J7jdxcbG7ty5c+XKlcnJybm5uTk5OXa7vVu3brGxsSwWy26322w2Go2mUCi+/vrrvXv3Bqvf6OjoHTt2rF69OiUl5d69ezk5Obm5ufHx8cuWLdu1a5dcLg9WR42BYdiPP/64adMmuVxOo9FsNpvdbudwOAkJCX379rXZbDk5OXfv3o2Ojl6wYMGePXt69Ojhu8HY2Nhvvvmm5qzm5uYmJCR8+OGHGRkZjVmqDwAAoKUx2+wFZRoBNzw+WoRhTbLrMgCgPaAoqri4uLKyUi6X83jtcmkqACBIbHZHfpGKw2YlyqQ1i2cCcL/Q+urP3gfX70tHLd6bdb3ASNG5IhH3nws22Y9tzdkyrmUsVx89evTx48d9bA0XQhRF6fV6Op3uY2Ox9sPpdKrVarPZLJFIfKwDrUaSZFVVVRCnzmKxqNVqt9stk8lEIlFQmoqLi/ORUMZxXKVSmUwmkUgUHx/fbGdpdnb2xYsX+Xz+0KFDa9YgbgokSapUqsrKSoFAkJiYiGFYSUnJlStXCGw2sKAAACAASURBVILo27dvYmJi0/WrVqsNBkNERERSUlIQKyMTBGE2m+/3xCsoKLh69SqLxerXr19sbCyCIMXFxVqtls/nx8fHM+/zJ+Xas3pfDw8VkiQNBkOdZWpAg3Act1qtzbmEv80gCKKysrJJT7xvv/2WJMkXXngh8KZGjRp18uTJwNtpI6ymUEfQ5PRVlgqDMU4s4of/b/PhyydCGlGIDJsc6ghaikceeeTIkSOBXwx36NChkpKS2bNnByUq0PK53W6VSoVhWHx8/P+fP25nSIMCzaWuQgHHjx+/devWokWLAm/+qaee2rx5c50b1bRH7eBlVWmqKtNoY8RRQkH7/tMDSnD8z/PPP79q1arGpOlqC8bV/ShbEBPfQxhf94I9Zkdhg/kQ0nDzwM59p28UmbmJvYY/M31Sz0iv7BtV+cuylzfe/P8LEWmySau/eqEjrRGPBa0Pi8VKSUkJYQBcLjc1NbU5m6LT6c28Jtejc+fOYrGYwWA0QzILw7CkpKSkpKTqW2QymUwma4Z+ExMTmy7Bfb+Sk5OTk5Nr3hIXFxcXF+dfa7VnFQAAQOtCUVSJzmB1OJNjozksuLIVAOA/m82mUqn4fH5sbGzLXHcFAGgVKIrS6A0GozFRJg0P4zT8AAAaEowENGPQou9+DODXNKLo4Ccf/0AMnT73GZH2zK4dH6+irfnkifh/LO0nNeUatONjCyZ2/e+3cpQjk2KNeywAAAAAAAAtEU6QRRVaFEEVUgkdrmwFAATAZDKVlJRIJJIAr+AEALRzJEmqy8rdblyRmMBkMEIdDmgjgr+/2X1zZWVmFsRNWvfqmHgagnSLMuYtOvLznUdf7VFzAYhbU1HJ75A+ZFB32n0/FgAAAAAAgBbH4XIXVWi5HLZUFAlrFQEAgdBoNHq9PiEhAXaiBgAEwuV2FxWXMpkMeUJcaynwCFqF4J1MlCXnyPp3Xn/hmSenrr/sxvPO/HJT25ituwn1nWxLTJ++Uk9mmZbQt3d0VfbfZf/YzpDUVmio6Nho0l6p0Znd1P08FgAAAAAAgBbGZLUpSyuEPK4sSgjZZwCA3zw7gphMJrlcDtlnAEAgLFZbfpGaGx6WKJNC9hkEV5BWQOMFu18cPXNPnp1CEDSS/SLpUm6Y+OyxpGmbj2ydkuJzOTKp0+gokbi6UDQmFAspnUZLIon/f7KT2jItrv195YwdBSYCofOSBj8357WxKYyGHmu3293uf6TBg7DpYtOoDqzFRtiSeSYNps4PcOIFAk48v8GJFwg48fzWDCceRVHw1IDG0BqrdCZzfLSIB3UVAQABcLlcRUVFDAZDLpfToIwPACAABqOpXKuTSqIFfF6oYwFtUFAS0KRy00uv7qvsveC7f8+2Le+6AEEQzsPvbX1d9a+Nr7zYo98fCzv5+CQkXE4c5XA4/1v3gXI4bNTldNX8640y6yrdHK7isXkfDpEhFTczN3257ZNt4g0zG3rsqlWrfv755+p2+Hy+Xq9vyWtMcBzX6/WhjqK1gqnzm9vthtnzG0yd31wuF8ye32Dq/NakJ57NZqPTW0B9M9CCkSRVrNM7nG65NJoFdRUBAAGALQcBAEFBUVS5Vmcym5Pj4zhsVqjDAW1TMP5GIu7s2n6OGrp296dPJbl/8OSaUUHPqRsO2PK6/itj7+15H/Ssvx8ak0WjTHYHhbBRBEEQym53UAzeP1ZNo5Gjl+0b/b//xac9+6+JN2Z/98fNFx9s4LFSqTQ1NbX6v2VlZXQ6vcV+NuM4jqIo/HDtH4IgYOr8Ayee3yiKIkkSps4/OI5jGAYXdvkBTjy/URRFEESTvuNhGNZiv2aAlsCNEyqNjoZhCpmEBm+AAIAAVFZWlpWVxcbGRkZGhjoWAEArRhCkqrSUIEhFYgIDFlKAJhOMcwvPv5uPdJg4NN7rWzQmHTQ4Bfk8r5BAfCSgMZE4Ci3QV5KIgIYgCEIa9UZU1FXk6ys5FiWTstyVZpewgce+8sorr7zySvXjRo8eLRAIWuZfhhRF6fV6Go0mEAhCHUvrQ5JkVVUVTJ0fPCcenU6PiIgIdSytD0EQZrMZTjw/kCRpMBjodDqfzw91LK0PjuNWqxVes34gCKKyspLBYDTdicfhcEgStqIAdbM5nCqNnh/OiRW20K+jAIBWgaIojUZjMBgSExPDw8NDHQ4AoBVzulyqkjI2i5Uoi4a1QaBJBeP0QiMEfMSg0RHed7gryrQUl8f1+QWbltA1Nbzsxk2tp24GWX4zq5zXpaus5tok24WvXnt93TlT9eaDJflFrsj4eEFiw48FAAAAAAAgtIwWa2G5VizgSUWRkH0GAPiNIIiioiKz2axQKCD7DAAIhNliVaqK+TxuvDQGss+gqQXjDGP2GfWQoGTP6m33nDVvtt/euGpfGf+B4X18V7dj9hg7NqFw/5d7/spX513Y9dVBtWLc2G5MBMHzf9359XeXKkiE0z29m/vs1s++PZ2Ve+/OhUPrPz+k7Trx0VR6vY8FAAAAAAAg9CiKqqg0lemNiTFiEezqAwAIgMvlUiqVKIrK5XImE/7sBQD4T19pVJeVy2KiJVGiUMcC2oWglHeJGPfeR6OOz547MP33p5Pv4k7e0a9WHD+9O+NoLn3ommUTIhtY5EGXP/n2Yvfmb75666AjTNZr3JJXnkikIQiCl1zOPFxADHxygITbb9byxYJvvt+18nAVTRjXsd/M5VNHSDEEwep5LAAAAAAAACFGUpRao3PjhEIqYTKgriIAwH8Wi0WtVguFQolEEupYAACtGEVRpRUai9WWHC/jsNmhDge0F8H5Hkzv+OoPp3hL5723ddMhK0khGxddpPHkw+fuWPPRtK6N2N2bJu43dWm/qV63sh98+4cH//cfRsyAKUsGTGnsYwEAAAAAAAglF44XleuYDHpybDRsOQgACITBYCgvL5dKpbD7CAAgEJ4tBymKUiQm0OmwfhM0n6AtxAjvOmXtr8+t1ObnKDV2Gj9W0SkpshGpZwCCrbCw8MqVK3q9nsfjpaam9uzZ836LGTkcjkuXLhUUFLjdbplMlp6eLhQKG3xUXl7etWvXKisr+Xx+9+7du3TpgmGY3W6/dOlSYWGhp6mBAwcGvku1xWK5dOlSUVERRVHx8fHp6el+76al0+kuXLhw79698PDwLl26pKWlsVismge43e6rV6/m5eXZbLbo6OgBAwbExsYGGH8L4XK5rly5kp+fb7fbJRJJenq6j7UkSqXyypUrlZWVPB6vW7du3bp1oyjq+vXrOTk5Wq2WyWRiGIZhWPW9Lb9+llKpvHr1qsFg4PF4Xbt27d69e8uPGQAAWherw6nW6CPCw2JFkC0CAPiPoqjS0lKz2ZycnMzhcEIdDgCgFXM4nUXFpWEcjiwGthwEzS24VwKibHFKL3FKUNsEoLFUKtXq1at37tzJYrEYDAZBEA6HY/To0YsWLRo0aFBjWqAoas+ePdu2bbt69SqLxUJR1OVyderU6Yknnpg7d25YWFidj8rLy1u1atW+fftYLBadTvf0++ijj3bt2vX333+/du1adVOdO3eeOHHinDlz/PvuiOP4tm3bdu3adevWLU+m2Ol0du3a9bnnnnvllVcYjPv4ycdsNq9duzYzMzM3N5fBYFAU5XQ609LSXn311cmTJ3uOOXr06Jdffnnu3Dk2m41hmMvlSklJGTVq1KJFixqTkW/JDh8+/O9///v8+fM1h/bwww8vXLjQ6xcCpVK5atWq3bt3s9ns6ie3f//+BEFcu3aNwWA4HA6n04lhGJPJZLPZLpdr7NixS5Ys6du3b6hG51thYeHq1aszMjJqvkzGjBmzePHitLS0UEcHAABthKHKUm4wSqOEAm7dXx4AAKAxCIJQqVQEQSgUivv6tg8AAF6qLJbisgqxMFIsat1/zoNWKngJaMqSk7k945drSg0xcMmO2ZEXTlpTR/YUw4ckaB537959++23//77b4VCUb0jB0EQV69eXbBgwZtvvjlp0iTfLZAk+f77769fv14ikXTo0KF6h/qqqqpPP/00Kytr06ZNtdcaX7lyZcGCBffu3av5pZAgiF9++eXAgQNeTZlMplWrVt28eXPTpk083v1tQ+R2u994441du3Z52qy+3WAwLF26NCsr68svv/Rav1wfg8Ewa9asU6dOSSSSlJQUHMdRFMUwrKioaMaMGbm5ue+8885//vOft956SywWd+zYsTp+u92+devWrKysLVu2SKXS+4q/5Vi/fv3SpUtrD23Tpk2eocXExHhuvHHjxrx583Jzc1NSUqqfXJ1O98cffzCZzKioKJPJRBAEm81GEMTtdjMYjISEhAsXLsyePXvZsmVjx44NyQB9uHXr1ty5c7Ozs71eJn/99dfcuXPffvvt8ePHhzZCAABo7SiKKjeYTFZbYow4nN2oz2UAAKiTw+FQqVQcDicxMRHWKgIAAqHVG7SGynhpDC88PNSxgHYqSB9jeMHuab37jJ+/cmPGdwePXq8gXVc3TOyd3OOF3Xmu4PQAgA9ms/ndd9/Nzc2Ni4uruR80jUYTi8UGg+Gzzz67ceOG70Z27ty5fv36pKSkiIiI6rwkgiDh4eFJSUknTpxYtmyZ10N0Ot3ixYuLiopkMlnNJQmVlZU2m41Go5lMJqfT6dXUsWPHPvjgg/sd47p163bt2pWUlOSVueZyuUlJSfv37//ss88a0w5FUW+99dYff/yRmJhYc003iqICgSApKWn16tXvvvvukiVLEhIShEJhzalgs9kJCQlXrlxZtGgRQRD3O4SW4Oeff166dGmdQ0tMTLx06dKiRYtIkkQQxGAwLFq0qKCgoOaTa7Va1Wq1J9FfXl7udDoZDAaKoiiKMplMu91eWloqFot1Ot3y5ctzcnJCMsb6mEymhQsX5uXl1X6ZREdHGwyGlStX3r59O4QRAgBAa0eQZFGFzupwKKQSyD4DAAJhNpsLCgoEAkF8fDxknwEAfqMoqrisvNJUpUiMh+wzCKGgfJKRyk0vvbqvsveC764rd0xkIwiCcB5+b+vrXcp2vfLil3dbZZoKtCp79uy5evVqfTV8+Xx+cXHxhg0bfLRQVVW1c+fOmJiYmom5ahiGyWSybdu2XblypebtX3/9dVZWllgsrnkjQRB6vZ5Op9PpdJfLpdVqaze1efPm69evN3Z4CFJcXPzDDz9IpVI6vY6rFuh0ulQqPXz4sFKpbLCps2fP7t27VyaT1flFlsViRUdHb9myJSoqqs46ISiKxsbGZmZm/vzzz42Pv4XAcfyrr74Si8X1Dc0zjceOHUMQ5Jtvvrl+/Xp0dHTNYyoqKuh0OoZhFEURBEFRVM17GQyGxWKprKwUCARFRUX//ve/m3Q49ysjI8P3y0StVn/55ZfNHBUAALQZTrdbWarBUFQeK2HArj4AgADo9Xq1Wi2Tyby+iwIAwH1x47hSVezGcXlCPKuuXAcAzSYYCWjizq7t56ihH+7+9KleUq7n6zYq6Dl1w4FPR2F/Zey9jQehEwB8OH78uEAgqLmg1YtQKMzKyiorK6vvgDNnzmRlZfnYzY/BYPB4vOPHj1ffQpLkyZMna1dDNpvNdrudRqMhCEKj0axWq9diYSaTyeVyazbVoF9//TUvL6++ItQIgnA4nIKCgpMnTzbY1PHjx/l8fp2JbA8Gg2EwGOpMxHvQaDSBQHBf8bcQ165dO3funI+tw2k0WkRExLFjxyiKOnHihNeT63Q6TSaT55klCAJFUZIkvXLQNBqtqqoKQRChUHjp0qXKysqmGYo/jh8/7nsPTKFQeO3aNa+fTAAAADSGxe5Qlmr44ZwESRSG1fuFBAAAfKMoqri4WKfTJScn+73TOAAAIAhiszvyi1QcNispTkaHn8ZBqAUjAY3n381HOgwbGu/VGCYdNDgFKcwrhCXQoCm5XK7i4mLf2/oxmczc3Ny8vLz6DsjPz/dU8vWBw+HUbMFgMFRWVtbu17MlneffGIbZ7XaXy7sSjVdTDcrPz29w38JGttlgU55oa8fsR18tTX5+PovF8n0NY1hYWF5eXlVVlVar9Zoop9PpqbZBURRFUXUmoDEM8xRdYbPZf//9d0FBQVMMxA9Wq7W8vNz3U89isXJycvLz85stKgAAaBv0VRaVRhcrEkgiI0IdCwCgFcNxXKlUulwuhULh36blAADgYTKbC4tLRAKBVBLtY60eAM0mGAloNELARwwaXa08s7uiTEtxeVw41UFTcjgcCII0+JZanRmsU82ssY8WPH1VPyQ7O7t2v14ZSQRBPDWFfTTVID/C89GU77kiSdKTWvXdl4/JbLEaM40oijqdTs+T63VwzWfWMz+eZLTXwz3paeT+n+Um5Xm+GnMWtcZnFgAAQoWiqBKdQWeqSo6JFnChriIAwH8Oh8OzJiY5OdnH1YoAANAgjd5QWqFNkMaKRd5XbAMQKsFIQDP7jHpIULJn9bZ7/0hb2G9vXLWvjP/A8D6M+h4JQBDweLywsDC32+3jGJIkcRyPiYmp7wCJROJ7zS+CIC6Xq2YLUVFR3bp1q90vnU6vTkp6/lFzf8I6m2qQH+H5aMr3XDEYDIqiasfs1Vd9pYRbsujo6MZMo0QiiYyM7Nmzp9fB1c8siqKeTK5nHXTNY0iSpNPpKIriOE4QxH09y01KIBCwWCzfwycIokXFDAAALRxBkoXlWqcbV0glHBbUVQQA+M9kMimVSqFQKJPJYK0iAMBvJEmqSsqMpip5Qhw3vN4angA0v6BsQhgx7r2PRtFOzB2Y/uSCPdm4M/foVyvmPNZn8KLf0QffWzYhEj5AQVNCUTQ9Pd1TeLc+VVVV6enpqamp9R0wcOBAh8PhIz1HUVRVVdXAgQOrb2GxWH379jWZTF5Hcrnc6soMBEHw+XyvesoURZnN5kGDBvkel1d4tWtJ10QQhMViqRlefQYNGuR7rjz5U99LZU0m033F30Kkp6d37NjRZrP5OKaqqmrQoEEMBqNfv35eT25YWFhYWJjnWfDsQ0ij0bwmiiAILpfraeehhx5KTk5ugnH4A8OwAQMGNPgyeeCBBzp06NBsUQEAQOvlcLnzSyvoNFqSREynQV1FAID/tFptaWlpfHy8197mAABwX1xut1JVTFKkIhG2HAQtTlAS0Ai946s/nMqY08t0bNOh227bhY2Llm38wz1g7o7TP83rCuufQZObNm2a2Wy2Wq113ovjuFarnTZtGq3+vw87duw4ffr0ioqK+g7Q6XQDBgwYN25czRuff/55o9HoVWaBzWaLRCK3201RFEEQIpGodlMDBw4cO3ZswwP7n/T09Mcee8xHeBqN5uGHHx46dGiDTU2YMKFXr156vb7OeymK0mq1gwcPNhgM9VXhMBqNnTp1euaZZxoZfMshFArHjRtXUVFRu0yKh9Fo7Ny589NPP40gyAsvvGAymex2e/W9KIoKhUIcxxEEodFongR0zYeTJMlisYRCodvt1ul0L7zwQotawOIZUX35dxzHdTrd888/32CZDgAAAGabvaBMI+CGx0eLYMtBAIDfSJJUqVSVlZVyuZzH44U6HABAK2azO5QqdRiHnSiT+kh9ABAqwUg0EDajwUCmPLf213xdee71i3+ev3xLqdXnnVj7fHcefCUHzaBr164rVqwoKSmxWCxed7lcLpVK9cwzz0yZMsV3I++++26vXr1KSkq8Eq8URel0utjY2I8++igs7B/XsKSnpy9btkytVnsl9WJjY9lstsPhEIlEAoHAqympVPrRRx81uOdhTRiGLV++PCUlpby83Ct5SlFURUVFcnLy8uXLG/Mxw+fz33//fa1WazAYvO4iCKKkpCQtLW3Xrl3Dhw9Xq9WeZGtNRqOxvLx8yZIlrbEEB4Ig8+fPHzp0qI+hvfPOO561J3379v3oo4/UanXNHzaioqIEAoHT6cRxnMvlEgRRfbYQBOFyuTyPValU06dPnzRpUnMNq1F69uy5cuXK4uLi2i8Tp9OpUqmmTp3qSb4DAACw5f/80UtjU1MSOKKYqG4jJi374bb1v5+/WmOVWqOXRQmjBfzQBhkk7vN71jxzoMD7cxFBbMWXP/r4/dQnX+SMnhr13DuTtvx52173L7gAAD+43e6CggKSJBUKBYvFCnU4TcFx/tNnn/nyRu23lzatfY4aNKc6zrFKU1VhcYkkKqrtbjkIr6xWLxgJaHvmrMTYcZtVJIKyxSm9Bgwa2K9bUiQsfAbN6sUXX1y3bp1AIPAsIjCbzSaTqbS0VKlUvvzyy2vXrm1wK4+YmJitW7cOGTIkLy+voqKiqqrKbDbrdLqCggKFQvHFF18MGDCg9qMWLVq0YsUKLperVqs9/RqNRo1GQ5Jkamqqw+HQaDTVTSmVyg4dOqxbt65///73O0CFQrF58+bevXvn5+drtVpPm1qtNj8/v3v37hs3buzcuXMjmxo6dGhmZmZCQoJSqdTpdBaLpaqqqqKiIj8/f+TIkVu3bk1ISNi8efOECRPy8/PLy8tNJpPZbNbr9YWFhbGxsfv27Xv88cfvN/4Wgs/nb9myZdy4cV5DKygokEql33//fc2V6fPnz1+9ejWPx6t+ck0mE51OxzAMwzAejxcZGUlRlGfTQhRFxWKxw+EoKCiYM2fOp59+2gKXEv/rX//6/PPPIyIiql8mRqOxtLS0oKDg1Vdf/fzzz+GncgAAQBDEfW/7pBHTPjhUKBr2/KK5L46WlGaunTVkwoYbDqpYa6i0WBWyGH44J9RhBgdlvPrVgStnVBav657c6hOT5nz+wR8aUZ8Ri54aMVpoyNy3YciSwzd9bSQBAGgsm82Wn5/P4XASExPb6hcwSnv0q6+OnLlb6Wtz8zanfY4aNCevc4yiqAqdvlyrTZRJIyPaxk/jdYBXVhsQjN11wwaMGMRZeuGyaU4ilHsGoYKi6IwZM0aOHPnDDz9cuXJFq9VGRESkpqY+9thjaWlpjWwkISFh7969R48ePXnyZEFBAY7jUql0yJAhkyZNqu+aOAzD5syZ88gjjxw8ePDatWt6vV4gEHTv3n38+PFdu3b9+eeff/vtN6VSSRCETCZ78MEHJ06c6KkR7IfU1NQDBw4cOnTo9OnThYWFnoCHDh36xBNP3Nd6agRBhg0b9tNPP+3fv//8+fOFhYUsFqtz586jRo0aM2aMJ20qFAq3bNny7LPPHjt2LDc31263SySS9PT0yZMnt/bidFFRUdu3b3/uueeOHTuWl5fnGdqgQYMmT57sVS8Fw7DXXnvt4YcfPnDgwNWrV/V6fURERLdu3R5//HGHw5GZmZmdnV1eXu5wOFAU5XK5Eomka9eu48eP7927d6hG5xuKorNmzRo9evSBAweuXLmi0+kiIiK6dOkyfvz4vn37hjo6AABoGSjTTx9/fMKYMH3Pia1jozEEQcg3f1386NjNny/cNnLLxCh5bHSbKPpM2k3aOzm3du3e952B9L6sibL+tPO7E+bo6R+t2DooAkMQhHry16/eH/vjwaW/DT08RgBf+QEIhGcFgEQiqV2sr00g7LqiO1dO7Vr9/nfltd5e2qz2OWrQnOo4xwiCUJeV4zihSExgMtrkMlB4ZbUdwUhAY4kvf/1t9qR3X/iUv/a1EQp+G/hGDlqrhISEBQsWBNICjUZ77LHHHnvssft6VEpKyuLFi2vfPn78+PHjxwcSjxcmk/nUU0899dRTgTcVERHx8ssvv/TSS3q9nsFgREREeB2Aoujw4cOHDx8eeF8tDYqiI0eOHDlyZGMOlsvlb775Zu3bBw0aRBCE2WyuWWWlVUhKSlq4cGGoowAAgJYKv33mkonWffbCh6P/eyULJho0+4Ve29+5fOmOdPZkepu4spUynnriqc3H/7ucudaIiKIzt600xbiF6RH/nQSUN/zpUYMO7zx7Lc85pt/9/e4NAPgfiqI0Go3BYEhMTAwPDw91OE2C0mQ8oXjtuNPzvxZ3RWATaZ+jBs2p9jnmcrvLikuZTIY8Ia4FXn0bFPDKakuCkYB2/7Fixhc3MceNd8Z0eJcdERXJZdQ4LdjjNt3e+GibLGkFAAAAAADaGLcViUzp/kBvxf/WVJistmKjm4ciJMKi2kT2GUEQlNd//YYEI4VQpr/mvne42OtuwonwY7v3lCtqfKlHWSwOiuBuHK5+BcA/JEmq1WqXyyWXy9to0WcEQRBU+Nj6U92MJELpDs2dvNb77aWNap+jBs3J6xxTux3KIrVEECGJapMXUvwXvLLakmAkoBE6m8vlMjs9MLZTHXcykwTwKwUAAAAAwP2gKMrhcNS+/X5rLoH7FjZ6w/nR1f/TGKv0JhPt8umrOLNXWo+2M/s0fqfOfARBKH0hv3ZSndV7w1avclJU8dlLF3B6ry7JbWcSWow6X+xe+077jSRJHMfh/STkXC5XUVERk8mUy+Vttejzf9GjOvWLQhCEKrvBbz+pgJYx6jpf6W63u3rj9AB59r+p3Qu8mTSHGucYB0UImyEmWhzNr7tSaNvRMl5Z7VOd7yckSfr9/SQYCWjG4CUHjiwJQkMAAAAAAABBEISiKIvFUvt2+Buv2ZAUVazVO5xW2s3/TH3/tDXxhaXTktrr3z7uwvN7ntp4wxozcumY6PY6CU2ozhd7sBLQBEG43W54Pwktq9WqVqsjIiJiY2NDHQtoy+p8pTscDoIggtI+SZJWq5VO984jwZtJs6EoqlRndiEIjRslaPPZZxBSdb6fkCTp9w9aQVkB7TRpjI7aX5BQlMZgccK44aw2/QMvAAAAAECwoSjaVsuDtgpunFBpdKTm4o/rVn5y8K4r6YlN369sn3vvubS31m/aueJUsUs6cNPHL4zhtcdJaGp1vtjRINV7odFoDAYD3k9CyGAwlJeXx8bGRkZGhjoW0MbV+UpnsVjBWnSPYVhYWBi8n4QKQZCq0lLc4Q5DEZTGDHU4oI2r85WOYZjfBceDkYB2HpmZOHl/HUuzEQRBUJTBbFbIwgAAIABJREFUjenQZ9iEGYsWTOkjglQ0AAAAAECDUBTlcDihjqKdsjmdqvIC5Y+r3/70p1su2Yg5W9a+9WS3dph4payXD+94eevZW+6oEU/NWfv84G5h7W8SmkWdL/ZgJaAxDKPT6fB+EhIURZWXlxuNxja85SBoUep8pTOZzGDtUIeiKJvNhveTkHA4naqSMg6bnSCLhA9j0AzqfKVjGOb395OglOBIm7PpA8d7KzIrhN0fGjW4axwfs5RnXzj+602893PTBkWYim6dO/bpi4cy/z55ftVg+NwFAAAAAAAtVKXZWqb9+/LK117bpxaPXHRozRuPy9vlX9qk7ofPP37+mEbcf+KhuRMel7XZDdMAaCIEQajVahzHU1JSGAxGqMMBALRiZou1uLxCFCmIFgmpMsg/g1YpGAloLIZb+NNv9oc+vfDDwj7/v4uJJWv95DHrNQvOZqyRIbrTS0aP/feq/auOvBiEHgEAAAAAAAgqiqI0xipDlclxaOmc78q7zvvu54+GtdeCx0T2DxtmHDN0ffqtn2d1j4Y/dQG4T06nU6VSsVgsuVwerMWnAID2SV9prNDp42IlfC431LEA4L9gfBa6//r2mzvRU96b2+cfe2hze7y+7Dnsh4823cQRLGrooleH4FcuBKE7AAAAAAAAgoqkKJVGb7bZFaJ7WzdfcfZZkPFBu80+I4jr7w0/5Do7Tch4GbLPANw3i8WiVCr5fH5CQgJknwEAfqMoqrisXGeoTI6XQfYZtHbBWAFNVuorqTBueK2PVjSMG06qi4oJpDcdDeOGoVZrELoLgGdD+WDVUwsuzz7XJEnWudEk8I2iKJi6QBAEAbPnB4qiYOr843nHg9nzD0mSMHX+8Zx4OI433ew5nU7INbRGLhwvKtcxGXS5VEL9/c1FDcnkXVj1r9f/+Vyi/MH/WjMtNShbeLdwRPHdi5UUMyxn1ef/8Z6EHuPWPBLfHiYBAP94thyUSqUCgSDUsQAAWjEcJ4pKSlAUVSQm0Omwnxpo9YJSA7pbnx60Pfu3n3qj9yjR/+d2qcoz27/PpnV/sQsDQUjNscxLhPyVIHQXGAaD0WIT0E6nE0VRKBDmB4qicByHqfOPw+GAE88/JEm63W6YOj/AO14gCIIgCAKmzg8kSXoSxE03e8HaZR40J4vdodboBdzwWJEAQRCnukiFU5ackxk5Xgdi0fSJn01LDUWMzQ3XaFQEZSm6nlHkdQ8aTRv02SPxIYkKgBaOoqjS0lKLxZKcnAy7tAEAAuFwOouKS7nhYVJJdMtMYQFwv4JSAzpp+kf/2v7IF+P75Tw/48khXaRcxFKWfe7A1xm/a7ot3vJyUuHuWc++mXHF9uCXU4PQXQBQFGWxWC3z1Vu9OpvFgj1e7htJkg6HA6bOD571gBiGwez5gSAIp9MJU+cHkiQROPH8heO42+2GqfMDQRBWq7VJTzw6ne45vUFrYaiylBuM0iihgBvmuYU15j96839CG1VzQkWjfj0xyutGVvrr+t9fD0k8ALRSBEGoVCqKohQKBZ0OFwkgCIKgsTN/Nc8MdRTNrX2OGgSXyWwuKdeIhZFikbD2ve3zHGufo25jgvLRiPKHrv71eMyCeat3vP/7ZspzGy0ideLqY/9Z8ACP/Cv7mjbxqc8+++JVRTC6AwAAAAAAICAURZUbTCarLTk2msNihjocAEAr5nA4VCoVh8ORyWRQiAkAEAit3qCrNMZLY3jh4aGOBYBgCtZvs1j0kIW7rs3ZkHfjek6JiWBHJfXo210Wjrm0d+4S/VZcUa4IUkfAT5cuXTp+/HhBQYHNZpNKpQMHDhw3blxYWFio4wqxwsLCI0eOZGVlVVVVCQSC3r17P/7441KpNOgdkST566+/nj592rMyIj4+Pj093Waz/fXXX2VlZWFhYXK5fMyYMf379w9Kdzab7fDhwxcvXmyKxquRJPn777+fOnVKpVIRBBEfHz906NDRo0e3t0UfBoPh8OHDf/31l16v53K5qampjz76aGpqu7hGGwAAWimCJFUVOoIkFVIJA+oqAgACYDabi4uLRSJRdHR0qGMBALRiJEkWl1U4nE55QhyLCT+Ng7YmuHkipjAlbUQKgiCE8d4fP3z84d59B38vGL6n8vsn4ULh0DGZTO++++7OnTt5PB6Hw0FR1O1279ixY8CAAcuXL09LSwt1gKFBkuRXX321e/dupVLJ5XJpNBqO4wcOHMjIyHjllVdeeOGFIPalUqkWL1589OhRPp/vue77xIkTa9asQVE0KioqLCyMJMljx46tXr165syZH374IZ/PD6S78+fPv//++5cvX+bz+UwmM7iNVysuLl68eHFmZiaPx2Oz2QiCnDlzZtOmTSNGjFi9enWHDh2C0kvL98svv2zcuPH27ds8Ho/BYBAEkZmZ+cEHHyxevPitt95iwvcGAABoeRwut0qj4zCZiRIxhrXEymwAgNZCq9Vqtdq4uLhgfccGALRPbhxXlZRhGCpPiIctB0GbFNwENGVTX8r8fu++vft/uVbmoBAU40gHdpfBRUihY7VaZ86c+fvvvysUipp7LonF4pycnHnz5q1duzY9PT2EEYbKihUr1qxZI5PJEhMTq2+MiorS6/Vz5syxWCyzZ88OSkclJSUvvfTS7du3FQqFZ3Mqi8Vit9sxDPMU/o6KivKkKd1u97fffltRUbF9+3a/9y05e/bsm2++WV5erlAoapY7D0rj1crKymbMmJGVlVU9KI/o6OhLly69/PLLX3/9tULR9kvu7N+/f+bMmTExMXK5vPpGkUjkcDjWrl2r0+nWrVsHl2ECAECLYrbZi7UGIZ8riYwIdSwAgFaMoqiSkhKbzaZQKGBjBgBAIGx2h6q0lM/lxkaLW+amZQAELjiZEZfmZubGt6c+qIhJHvT0og0/XtOyO46c8cHXv+aUFZ17b2BTbTUPGrZ27drffvstISGhZvYZQRAURcVicVlZ2XvvvWexWEIVXqicOHHis88+S0hIqF2EhMfjxcXFLVmy5Nq1a0Hp67333rt165ZMJvMkagmCKC0tdbvddDqdwWA4HI6SkhLPkQwGIyEh4dixY19++aV/fZlMpmXLllVUVERFRXl9bgXeeE0ffPDBzZs34+LiamafEQTBMCw2NvbevXvvvPNOm9+Gq7Cw8IsvvoiJiREIBF53sdnshISEb775Zu/evSGJDQAAQJ30VRa1Ri8TCyH7DAAIBI7jSqXS5XLJ5XLIPgMAAmEymwuLS8RCoVQSDdln0IYFlIAmjLm/71w+c0xXaVzvx15ftfucGkt+YHRfCY31xJYbJ7e/P314hwi4ciCEtFrt4cOHJRJJfWswRSLRlStXDh482MyBhdzOnTuFQmF9XxbDwsIEAsH27dsD7+jq1avff/99TExM9S2VlZU2m626SjKdTjcajdW/AWAYJpFIDh48aDQa/ehu//79N2/eFIlEdd4bYOPVsrKydu/eXXNQXiQSyS+//PLHH38E0kvLl5GRUVRUxOPx6ryXwWCIxeJvvvmmzSfiAQCgVaAoqlir15mqkmOj+WGBXgkEAGjPHA5Hfn4+m81OTk5ub3ufAACCiKKoCp2+tEKTKJOKIr1XNQHQxvifgP5qcr/42M4jpi/bdiIf6zT6pWVbfr5eXHHv1JeTEzEEgZ9tWoILFy7k5ub62GkQRdGIiIhz5841Z1QhV1FR8dNPP0VE+Fr6FBERcfXqVbvdHmBf586dCw8Pr/nF1GKx1Fw1jKIojUaruQg9PDw8Ozv74sWL/nXne1yBNF6zl7CwMK819TXRaDQul9vmz6tz5875LvbH5/PPnz9/+/btZgsJAABAnXCCKCzXutyEQirhsKA6PwDAfyaTSalUCoVCmUwGaxUBAH4jSVJVUlZltsgT4sPhp3HQDvj/g+2ZzKtlLl63KR+tWfbC8I6R/2uICE5cIBjKysoavCKMyWSWlpY2TzwtRFlZGYqivneHYzKZt27d0mg0NStE+6G0tNTrKXC73V4L0j3bQta8hcVi+feklJaWNrjrnd+N1+wFziuHw2EwGHzPA4ZhDAajtLS0R48ezRYYAAAALw6Xu6hCG85my6IiIVsEAAiERqPR6/UJCQlcLjfUsQAAWjGX211UXMpg0OUJ3mUtAWir/F8BLRIyUdJ8e8+SqU9Om7Ny95kCM1xn3tIwGAyKonwfQ1GUj6WsbZJnPbLvmfHcG/jM1H4KUBSt3bXX38MURfl3NV8jn/EALxVsTC9IMGavJaPT6XU+lV7a4esLAABalCqbXVlaIeRx48RCyD4DAPxGkqRKpTIajXK5HLLPAIBAWG12pUrNDQ9LlEkh+wzaD/8T0BsLS25m/uetZweEF/yy+Z2pw1JikgY+vWjDoWsVziDGBwKRlJTkcDh858gcDkdycnKzhdQSJCQkdO3a1en0daI6HI5+/fpFR0cH2FdSUpJXHQ8mk+n1jJAkWXPZMkVRDodDLpf70V1ycrLD4fBxQCCNV6s9qNrsdntSUlIgvbRwdDo9Pj7e92zjOO52u9vb6wsAAFoOrbGqRGuIj44SC3xVTAIAAN/cbndBQQFJkgqFArYcBAAEwmA0FZWUSqKiYqPF8NM4aFcC2ISQEdX90ddW7j6jLFee3bPqtbEdnNf3r5n35LNrb7rxG9+t3/9XqaPhRZKgKaWnp/fp06eqqqq+AwiCMJlMI0eObM6oQo7P56elpRkMBh/HGAyGYcOGBb6pyIgRI+Ryec00JZ/PJ4j/r1RDURRJkjVLCZtMprS0tP79+/vR3ciRI00mk49d7wJpvNrw4cMVCoWPHLTL5bJarW3+vBo5cmRlZaWPAwwGw6OPPhpguh8AAIAfKIoq1hoqzVa5NJoXxg51OACAVsxms+Xn53M4nMTERFirCADwG0VRZRpthU6XKJNGRsBP46DdCSAB/T9oeOLgZ5f8+8iN4pJbRze9M3WonE/l/bDkqfREaZeHZ67YdUULeegQCQsLmzFjRkVFhcvlqn0vRVFlZWXjxo0bM2ZM88cWWq+99lpCQkJ9qfnKysqOHTvOnDkz8I6Sk5MfffTR0tLS6qRzREQEn8+vLvrscrmio6PZ7P/+bex0OjUazSuvvOLf2opx48aNHj26rKysznsDbLxafHz8hAkTag6qJpIkS0tLX3311TZf+HjKlCl9+vTRarV13muz2QwGw5w5c5o5KgAAAG6cUJZp3Dgul0azoA4SACAAlZWVhYWF0dHRUqkU1ioCAPxGEERRSanVZk9JSoQtB0H7FIQEdDWGqOsjr3z87em8soI/9336f+3de3xT9f348ZNrm17StGnaJr2EJoCAgsD4MtGhDifzh+IF8YLipk6EoU7ndc4pzqlz84bCvs7p5g2dIiJDne7rvAGOh7qpsOFlUtpcekuatmmaNE1yzvn9kdmhUChJ09Okr+dfknzOOe8cz/n0nPd5n8/n8oVT9Y2vP3rzsl+/s5/kJ0bI0qVLL7/88qampq8lW2OxmMfjmTFjxt133/21OfHGgilTplx//fUtLS0dHR171wuLotje3l5RUXHbbbfV1NQMy7auv/76U089tampKRKJCIKgUqlqamoMBkN/f39/f39JSYnVak22DAaDLpfr6quvPuuss1Lbllarveeee6ZOnerxeL721CH9le/tmmuuWbRoUVNTUzgc3vvzvr4+l8t1wgkn3HLLLelvZZQrKSn51a9+VVdX19LSkkgkBj6XZbmzs9Ptdt93331z585VMEIAGIMi0f6GlnZDnn5clUVLrSKAVMmy3N7e3tbWZrfby8rKlA4HQBaLxeN73F61Su2oq9Gl/Zo1kKUyceirCmrnnHPdnHOuu7/z0zde2NA6bsylN0cRtVp9++23jx8//vHHH9+5c2d+fr5arY7FYtFodNmyZTfeeGP6wxxnqUWLFlkslrvvvvutt94qKCjQaDSJRCISiSxYsODGG2+cMWPGcG3IYDD89re/nTx58saNG//9738ni51VKpXZbO7u7hYEoa2tTZKkvr6+6dOn33LLLUuXLk2nvMJutz/55JN33HHHY489lp+fr9frh3HlA/Ly8h566KFJkya98MILn3/+eX5+vkqlikaj48ePv/LKK6+55prCwsL0tzL6TZ8+/cEHH1yzZs0LL7xgMBh0Op0oin19fUcdddTatWsXLFigdIAAMLYEw5Fmf2dlWYnZWKx0LACymCRJHo8nHo87nc69J2sBgEPVG454WtvKTCWV5WalYwGUlNFnL9qyyd9ddnMmt4AhUKvVF1988eLFi7du3frFF1/EYrGqqqqjjz56/PjxSoemsLlz5x511FHvv//+zp07u7q6ysvLp0+fPmvWrGEvCc/Pz7/hhhsuvPDCrVu3ulwuQRBqa2vnzp0bCoW2b9/e3t6el5c3YcKEb33rW3sPBp2yqqqqNWvWXHHFFZlY+QC9Xn/dddd9//vf37ZtW1NTkyRJyR9ls9mGcSujX/LpzjXXXPPBBx/4/f7i4uLJkycfffTRA8OqAABGhq+7JxAM1VWWFxnogQGkLhaLuVwuvV7vcDjG4KuiAIZRZ3ewzd9hq7SYhvVmHMhGFP+PFUaj8eSTT1Y6ilFHp9Mdc8wxxxxzzAhsq7KycvHixXt/YrVaJ06cmKHNTZw4MXMrH1BRUbFo0aJMb2WUU6lU06ZNy/kxrwFg1JJk2esP9McY9BlAunp7ez0ej8lkGhglDwBSIMtyS7uvNxypr602UJwEkIAGAABA9orFE652v06rddgqNNQqAkhDZ2dnW1ubzWYzmUxKxwIgi4mi5G5pkWXZaa/TapmRAhAEEtAAAADIUpH+mLu9o6SwoKqsZFgmOQAwNsmy3NbWFgwG6+vrDQaD0uEAyGLR/n53c6shP7+6qoJhfIABJKABAACQfbpC4dZAl9VcWlo8Jma+BZAhoii63W5RFJ1Op45hfACkIdQb9ra1m0tNFeYypWMBRhcS0AAAAMgmsiz7uns6e3rtVZbC/DylwwGQxfr7+91ud35+vt1up1YRQDr8gU5/Z1eNtdJYVKR0LMCoQwIaAAAAWUOUJI8vkBBFp61Sr+NSFkDqQqGQ1+stKyurrKxUOhYAWUyW5ea29khf1FFXk5/Ho3FgP7hqBwAAQHaIJRKutg69TuuwVaoZ9BlAGgKBQHt7e01NjdFoVDoWAFksIYoub4tKJTjqaplyEBjM6EhAS507Xnj82bc/doWK7NPnnXvRmUeWfv2OQu5renPd45u2fdrapzePO/LEJReePqNcK8hdr95yyUM74gPtNNVn/mrt9ydyzgMAAOSU3r6oxxcoMxZVlpYoHQuALCbLcktLS29vL1MOAkhTtL/f5W0pKiywVVYwHzJwAKMhAS26Nt55xwbxuIt+dK7Zv2XdY3fcpbn3zjNq984hy8G//WbV2n/VnX7BdbOsctObTz91+6qe2+69+HCdr82nmrjw6kWH65MtVYZqG0N3AQAA5JTOnt62zm5beampiCkHAaQuOeWgLMtOp1OrHQ23wwCyVTAUam7zWcpKLUw5CBzMKPiLG9v58suNNWeuXnFSrUYQjijv3n3tS6/sOnnFNP1AE7lr+1/eSxz1o+u/N7dYJQiHT6qKNF656fV/Lj18qq+9yzjhqLlHT6XmGQAAIPfIstzS0RmK9NVbKwx5+oMvAACDiEajLperoKCgurqaKQcBpMMX6Ozo7Kq1VhXzaBwYAuUT0KJn16e9VUd9w5bMIGvqvjGj4oWPPmmVptkHrgjkUDzPPut/JhX9530GjcVaqY31RRKSv90nV0ypkPq6AmFtqblYxxsPAAAAuSJZqyjG+p0VpTq1LMT7lY5oBI2bonQEQE7p6enxer0Wi8VisSgdy4jTMSsaMGwkSfJ6vdFo1Ol05jHlIDA0yiegpQ5fh2y2lH2ZbVaXWcrkDp9fEv6bgFbbF950z38XEX1b3twpjD/nMIPU0upP+N/85cWPNQZFQVs87pjzrvjhgvEFpKEBAACyXDQadbvdBoPBbipgykEA6fD7/X6/v7a2tri4WOlYAGSxeDzudrs1Go3T6dRoeBUfGCrlE9BirD+hMhgMX95UqAyGfFWsPybvv3l/2/sv/PbhjQ2Opbd9t0oI7eyKG4qcC6/8+dxqoX3Hy79d8+idj1oevGL2f2qlV61a9corrwwsbDQaOzo6RvPA8IlEoqOjQ+koskMsFgsEAmq1uqysTKfTCYIwlF3X29vb3d1dUFBQVpbKIE3BYDAUChUVFZlMpn2/DYVCwWCwsLCwtLQ0hZWnpq+vLxAIGAyG0tLSlF8kjMfjHHgpY9elLBaLsfdSxq5LWUYPvHA4zIiiwyUUCnm9XrPZXFFRIXT7lA4HQLaSZbm5uTkSiVCrCCBNkUjE7XYbjUar1TqaM0vAKKT8PZJGn6eRg31RWchXCYIgyH19UVlXvJ8B/uLtH6z/7e82/UuYevoN9579PxU6Qcibf8uz87/8vnb2kssXfXzZc+/sWDb7mORkxjabbfLkyQNraG1t1Wq1o7abSCQSKpWKZ2gH9fnnnz/55JMffPDBrl27BEGYNm3anDlzli5d6nA4BltEkqTXXnvtxRdf3L1797///e+JEydWVlaedNJJ55xzzlBmvo7H45s3b37ppZdcLldy8ZqamlNOOeWMM87Q6/WJROLll1/evHlzY2Nj8lur1XryyScvXrw4o9e4W7duXb9+/SeffPLZZ59NnDixtLR03rx5559//qGmvznwUibLsiRJ7LrUJBIJtVrN8Isp4MBLmSzLoihmtMdTq9Wj9jIjuwQCgfb29pqaGqPRqHQsALJYslZRrVY7HA4eEAJIR1dXV2tra1VVVWrVbMAYp/zfYLXZUq5qDHRJgkkjCIIgdQe6VebDzV/NSciRz9b/4vYN/oln3rB20azKQeafUZdX2/LiXaGoLCQrqpcvX758+fKB7+fPn28ymUbnnaEsy4FAQKPR7Le0FgPWrVu3YsUKo9FoMpkmTJggCEJXV9czzzyzbdu2m2++eeHChfsuEg6Hr7/++qeeeqqsrKy4uHjixImSJO3evfvnP//5li1bVq9eXVdXd4AtdnZ2XnvttZs2bTKbzYWFhRMnThRFcdeuXVu3bt2yZcttt9121113rV+/vqysrKioKPnt559//re//e2dd95ZvXq1zWYb9p2QSCRuu+22+++/v7S01Gg0Jn+R1+u9//77t2zZcs8990ybNm2Iq0oeeFqttqSkZNjjzHmiKIZCIc7ZFEiS1NnZqdVqSS2lIJFIhMNhztkUiKLY1dWl0+kyd+AZDAZJkjK08jEiWasYDofr6+uH8pAYAAZDrSKAYSHLss/n6+zstNvthYVMOQikQvnSM03d4ZMLWz/e4U+OuSG17djZVjzl8Oqv1CZF//nUfc/3HHPjPTefu3f2ObJ97Q9Xrt4W/HK4DrG5wRUrra0t5uoiR/3pT39asWJFTU2NzWYrKCjQarVarbaoqKimpiYQCCxZsmTLli1fW0SSpJ/85CfPPvusw+EoLy/Py8vTaDQ6nc5kMjkcju3bt19++eXBYHCwLcZisauuuurPf/6zw+EoKytLLq7X68vKyhwOx+uvv/7d735348aN9fX1ZrN54NvS0lKHw/HOO+9cccUV4XB42PfDr3/96wcffHDcuHEVFRX5+fnJX2Q0Guvr6z/99NOrrrrK7XYP+0YBAMi0RCKxZ8+eWCzmdDrJPgNIRzAYbGpqslgsNpuN7DOAlEmS5Ha7Q6GQ0+kk+wykTPkEtKCftmBBXdPza555v8Gze/u6tRs9zlMWHKEXhETDXx//w3PvtUtC/JN3tnVYp0wQd//j7wM+3NOVP/WoI+JbH7n7qbd3/vuLXds3PXDPJv/hi06erHxdNzIgGAzef//9VVVVRUVF+35rNBrLy8vvuuuu/v7+vT9/7bXXnnjiidra2n3fuVOpVDab7d1333344YcH2+j69es3b95cU1Oz7/vaarW6qKhoz549hYWF+65crVZXV1e/9dZbf/jDHw7hRw7Bzp0777zzzpqamv2O71FZWblr16577713eDcKAECmRaPRhoaG/Pz8+vp63pQHkA6fz9fS0lJXV2c2m5WOBUAWi8ViDQ0NgiDU19fr9YO8iw9gCEbDxb3WsfjG6+MPP7H2JxujBdXTT7lh+Rl2jSAIieYPXt7cKM5ZPFvd3BJOuP7y4C/+8t+lVPlzf/L0dXMu/cX1pifWr/vl5h5NWc3EWct+sfQE2yjIqiMDXnvttR07djidzsEamM3mbdu2bdmy5cQTTxz4cMOGDaWlpYPdx6pUKovF8tJLL1155ZX7zedu2LDBbDYPNlpoMBjUaDQ9PT0VFRX7fqtWq8vLy1988cWVK1cO43ijGzZsKC4uzs/PH6xBRUXFu+++29LSkonRPwAAyIRgMNjc3GyxWCwWi9KxAMhiyYHpotGow+FgykEA6QiHwx6Pp6SkxGq1Kh0LkPVGQwJaEDSWWUt/Nmvp1z7NP/bGDccm/3PhLzfuZ2hfQRAEoeqb59/wzfMzGR1GiQ8//HC/tc8DVCpVYWHhRx99NJCAjsfj//rXvw68VHKRTz75ZMaMGV/7yufzvf766+PHj9/vgqIoRqNRrVYbCoVisdh+H4cWFRW99957u3fvPuywww702w7FRx99dOBflJeXt3v37o8//pgENAAgK/j9/o6Ojtra2uLiYqVjAZDFYrGYy+XS6XROp5PZegGko7Ozs62tzWazMeUPMCxGRwIaGILu7u6DvpCr1Wo7OzsH/tnT07Nr167BMshJKpVKo9F0dXXtd4vJde53wWQCOllYIYriftuo1Wq1Wr3flaesq6vroPtBp9PtvR8AABidqFUEMFyYchDAsJBlua2tLRgMMh8yMIwYrQJZw2g0DpbnHSCKotFoHPhncXHxlClTDrqUJEklJSX7fp6swxpscY1GMzAOxmAaDG1bAAAgAElEQVQVFrIsy7K8d0jpG8p+SCQSw7tRAACGXTweb2xslCTJ6XSSfQaQjq6urqampsrKSqYcBJAOURSbmprC4TDzIQPDiwQ0ssbUqVPD4fABGsiyHA6Hp02bNvCJXq8/7LDDent7D7BUOByeOnXqpEmT9v2qqqrquOOOG2xxjUaj1+sTiURhYeFg0xGEw+GZM2ceuAT7UB10P8Tj8Vgstvd+AABgtIlEIg0NDQaDwW6386Y8gJTJstze3t7W1ma320tLS5UOB0AW6+/v37Nnj1ardTgcOp1O6XCAnEICGlnjpJNOmjRpUigUGqxBd3f3rFmzjj/++L0/PO2007q6ug5QMtzR0fGd73ynsLBw369UKtVpp50WCARkWd7vsiaTKZFI7Ld6WhAEWZY7OjoWLFgwvLPlnnbaacFgMBaLDdbA7/cvWbJk3Lhxw7hRAACGUXd3d1NTk8VioVYRQDpEUXS5XKFQyOl07vd6HgCGqLe3d8+ePUajsba2Vq0mVwYMM04qZI2KiopLL720tbW1r69v32/D4XB7e/uPf/zjr03Qd8YZZ5x++uler1eSpH2Xamtrmz59+uWXXz7YRi+44IJ58+Y1Nzfvm4OWZbmvr89qtfb39++78uS4UbNnz7700kuH+guH5uijj165cqXX600kEvt+GwgE6uvrr7vuuuHdKAAAwyJZq9ja2mq3281ms9LhAMhisVhsz549KpXK4XAMb8EHgLEmEAi43e7q6urKykqlYwFyEwloZJPvfe97t956q8vl8vl8AyXA0Wi0ra2tubl5zZo1p5xyytcW0Wq199133/z58/fs2dPd3Z0shZZlube3t6mpacqUKatXr66oqBhsiwUFBQ888MDRRx/d2NjY09OTTDRLkhQKhZqammbPnv3iiy8ef/zxjY2NwWDwa98eeeSRq1evLisrG/b9cOutt5533nmNjY2dnZ3JNLQsy5FIxOPx1NbW3nXXXYcddtiwbxQAgDRJkuR2u6lVBJC+3t7ehoYGo9Fot9upVQSQMlmWm5ubOzo66uvrmUgJyByt0gEAh0ClUl199dWzZs169NFHP/nkk88++0wQhClTphx11FEXXHDBcccdt9+lzGbz73//+3Xr1q1fv/7dd99Vq9WSJM2cOfOCCy5Yvnx5eXn5gTdaU1PzxBNPPPbYY5s2bXrvvfeSi8+ePXv58uWXXHKJ0Wh8/PHHH3/88Y0bN27fvj357axZs37wgx8sW7YsQ+PQJdPixx577Lp169544w21Wi3L8rRp00499dSVK1fW1dVlYqMAAKQjFou5XC69Xl9fX8+gzwDS0dnZ2dbWZrPZTCaT0rEAyGKiKLrdblmWnU6nVkt+DMggTjBkn2OPPfbYY4/1+XzNzc0qlaqurs5kMvX09Bxgkfz8/EsuueTiiy9uamrq6OgoLi52Op1Df1OvuLj4Rz/60WWXXbZnz56uri6TyeRwOAb+PhUUFKxcuXLFihWNjY2BQKCkpKS+vj7TrwFqNJqzzz777LPPdrvdPp8vPz/f4XAUFBRkdKMAAKQmHA57PJ6SkhKr1ap0LACymCzLra2tPT099fX1BoNB6XAAZLFoNOpyuQoKCqqrq3mRAsg0EtDIVhUVFQNDZ+x3fOd9qdVqh8PhcDhS26JGo5kwYcIBVu50Op1OZ2orT1ldXR0lzwCA0YxaRQDDIlmrKIqi0+nU6XRKhwMgi/X09Hi9XovFYrFYlI4FGBNIQAMAACAjklPyBoNBu93OoM8A0hGNRt1ut8FgYNBnAGny+/1+v7+2tra4uFjpWICxggQ0AAAAhp8oih6PJ5FIUKsIIE2hUMjr9ZrN5gNMHg4AB5WccjASiTidzry8PKXDAcYQEtAAAAAYZv39/W63Oy8vz+FwUKsIIB2BQKC9vb2mpsZoNCodC4AsFo/H3W53cmROphwERhinHAAAAIZTb2+vx+MpKyurrKxUOhYAWSxZqxgOh5lyEECaIpGI2+02Go1Wq1WlUikdDjDmkIAGAADAsEnWKjLlIIA0JRIJl8ulUqmcTie1igDSEQwGm5ubmXIQUBB/yAEAADAMZFluaWnp7e2lVhFAmqLRqMvlKioqstls1CoCSIfP5wsEAnV1dUVFRUrHAoxdJKABAACQLlEU3W63LMvUKgJIE7WKAIaFJElerzcajTocDqYcBJTF7QEAAADSEo1G3W63wWCorq5mykEA6fD7/R0dHbW1tcXFxUrHAiCLxWIxt9ut1WqdTqdGo1E6HGCsIwENAACA1IVCIa/XazabKyoqlI4FQBajVhHAcGHKQWC0oUQFAAAAKfL7/R6Pp7q6Oreyz3HvW2svOvVbtrq6POth9uOWXvHYhwFJ6aAyTQp+8NyvFp7yndLDj7KecMH5v9nW1K90SBhL4vF4Y2OjJElOp5PsM4B0dHV1NTU1VVZWMog8MHpQAQ0AAIBDJstyc3NzJBLJuWyRHPjrT7993lPusplnLr1sQl7HP17Z+L/XLHq3ZeO2m2YWKB1cpshdr9164RlPt1TNPPa8pdborr8+e+/KLZ/f/d7q79qoV0HmUasIYFjIsuzz+To7O+12e2FhodLhAPgvEtBA6vr7+99//32PxyPLstVq/eY3v8kfOQDAWJBIJFwul0qlcjgcuTbloNj0+N3P7ild8Pibj1xg0wiCIFx39nXzzrj34bWbVv7+vNKcTI3JwS0PLH/GO2nZI2/fMLNEJQjyxQuvPXvxn9auueQ7v5zGuJnIrO7u7paWlsrKSrPZrHQsALKYJEkejycejzudTr1er3Q4AL4it24YgJEiSdK6desee+yxf/zjH3q9XqVS9ff3T5s2bcmSJcuWLeOvHQAgh0WjUZfLVVRUlJtvtoY/3LozXnzKWWfavky8Fkw//QTb/b/7YpdLFEpz8eJZ7v7Tule9xnn3rpxRkvz/qSpbeNVtv5naVJEfFwQS0MgUahUBDJdYLOZyufR6vcPhYD5kYBTKxWtoIMMkSbrxxhsfeuihysrKCRMmDNx7+/3+m2666eOPP16zZk1+fr6yQQIAkAnBYLC5udlisVgsFqVjyQzt1Evvve/cCTP3+kMuhnr7ZHWVpTRHb2jj/3zrH3366cd8u/i/jxM0tUcvv/BoBYNCzkvWKsZiMaYcBJCm3t5ej8dTVlZWWVmpdCwA9m9sJaBlWQ6Hw6OzVEeWZUEQJEkKh8NKx5J9ZFkeyV33yCOPPPTQQ3a7XafTybKc/H8nCEJhYaHdbt+wYYPFYrnppptGJphhIYoiB14KRvjAyyXJs4YDLzWSJLHrUjMCB14sFhudlxnDxefzBQKBurq6oqIipWPJmIKJC86bKAiCIEjRUHdnR/M/3/jdtc932hbefnZtbiagJb9nT69QUWtseP6XS//wf++6+0pqJ8359uKbrzh5amEuH89QULJWUafTORwOjYYqewCp6+zsbGtrs9lsJpNJ6VgADGpsJaAFQdBqtaPzzjB5V6xSqXJtIMURIctyPB4fmV0XCASeffZZq9W633E2tFptdXX1Aw88sGTJkokTJ45APMOCAy81kiQJgsCuSwE9XjpEUUwkEuy6FCTP2YweeMP4yqcsy6FQaN/Pi4uLh2sTh0SSJK/XG41Gx1Ctothw/2nf/ulHcUFQlx51/Z9Xn5qr0/HJ4VBIFoKv3zH/j/Hx876z/Hhd64dvvvC7n77+kf/tJy86cmz831bWfk/2gRKHNImiGIvFRlV/Eg6HPR5PSUlJVVXV6Lw1A7LUfs/0aDQqiuKwrF+SpN7e3n2vo5TqTGRZbm1t7enpqa+vNxgMisQA5Kr99ieiKCZvqVIwtm5fVSpVXl7e6LzKkWW5t7c3GaHSsWQfSZKi0ejI7Lpt27Z9/vnnTqdzsAb5+fmFhYVvvfXW1KlTRyCeNCXvbdRqNQdeCkRR7O/vZ9elIPlHiwMvNYlEIh6Ps+tSkKx9zuiBp9VqU74m+xpZlvv7+/f9XJF7vHg87na7NRqN0+kcQ7WKauuiWx8e52lr+PDVR5+++5Rz1X9+7srZuThKrZwQE7LU4zdc+vBzv5lXrhEEQfrhBbecf8ozD//spYWbF5ePxkvn3LLfk324EtDJ92ZGT3+SrFW0Wq2lpaUjv3Ugt+33TI/H48N4cRKLxfbdiiKdiSiKbrdbFEWn06nT6UY+ACC3DXZxkvL1ydhKQAPp2717d0FBwYHbFBQUfPHFFyMTDwAgJ6nV6lHyJmkkEnG73Uaj0Wq1js6n+JmiKjrs2JMPEwTh/AvPm3zOkTesvvn5s1+90Jp7ZdCq/HyDSqWfvfTm48v/83hBbTpxxblz1v96y5aPIotPzMWs++iy35N9uN6o0Gq1eXl5o6E/kWW5ra2tu7ubKQeBDNnvmV5QUDBc735pNBqj0Tga+pNoNOp2uw0Gg91uZ8pBIBP2e6ZrNJqUi1FIQAOHJhqNHvT2W6VS9fX1jUw8AIBcNRoGWunq6mptbR1TtYqxxq3r3/Pbv3X63JqBG1qNfd68IzR/++zTRlHIwQS0xlJp06q+sFrL9/pt6gpbtU54vycUkQUGgs60jJ7sKpVKrVYr3p+IoujxeBKJxPjx46lVBDJkv2e6RqMZxufHWq1W8f4kFAp5vV6z2VxRUaFsJEAO2++Znk5nknuX0EBmVVRUxOPxA7eJx+NMvwsAyGqyLLe3t7e1tdnt9rGTfRYEQdjz4tWX/eiml5v3fl1ZDvWEZJWhwJCbmdiCSbPGq8ONjZ69frPY4m6KqUqqKo25+ZsxomKx2J49e9RqtcPhIPsMIB2BQMDj8VRXV5N9BrILCWjg0MyZMyccDicSicEaJKeNmjNnzkhGBQDAMJIkye12h0Ihp9M51t6U18049jij+N5TT74f+fIj0f/qoxs/kyuOP3aS8kXpmaBxnLnwcPWOZ1a90vKfZ+yi709rn/1ALl/4XeYgRLp6e3sbGhqMRmNdXR1vygNImSzLXq+3o6Ojvr7eaDQqHQ6AQ5ObV9FA5sycOXPRokWvv/56dXX1fhv4/f65c+fOnz9/hAMDAGBYxGIxl8ul1+sdDscYzBapyhasuvqbr9+69v/N+/TcBTOtsu+f77y06eNgzaK1Nx1nUDq6DFFPOv/aH29edtePz/ns1ZPm16sb3/3Lxp3ButN/9fPjipSODdktOeWgzWYbDYPGAsheiUTC5XKpVCqn06n4GCAAUsB5CxwalUp16623ulyuhoaGysrKvUfAkWU5EAhUV1ffdttter1ewSABAEhNb2+vx+MxmUxWq1XpWJSiP+Lyp7fZVt/28EsbH93SHTdUTZx16a8u/9lFc3Jw+OcBhTN+8eSj1ff95qH/23z/G3LpuCMvunn5rd+blcs/GRkmy3JLS0tvb299fb3BkKsPbwCMhGg06nK5ioqKbDbb2JoPGcghJKCBQ+ZwOB5++OHrrrtu69atJSUlyUvq/v7+YDA4c+bMO+64Y+bMmUrHCADAIaNW8T9UhUecedP6M29SOo4RpSmbftntj1x2u9JxICeIouh2u2VZplYRQJqCwWBzc7PFYrFYLErHAiB1XA0AqZg0adKGDRs2btz4xhtvJC+vrVbr8ccff9ZZZxUXFysdHQAAh0aW5ba2tmAwSK0igDRFo1G3220wGKqrq8fgMD4AhpHf7+/o6KitreUuG8h2JKCBFOXl5S1ZsmTJkiVKBwIAQFqStYqiKDqdTp1Op3Q4ALJYKBTyer1ms7miokLpWABkMUmSvF5vNBp1OBx5eUyIC2Q9EtAAAABj10Ctot1up1YRQDr8fr/f76+pqTEajUrHAiCLxeNxt9utVqsdDgfD+AC5gTMZAABgjErWKpaVlVVWViodC4AsJstyc3NzJBJxOBz5+flKhwMgi0UiEbfbbTQarVYrUw4COYMENAAAwFgUCATa29upVQSQpkQi4XK5VCoVtYoA0pSccrCystJsNisdC4DhxPUBAADA2JKsVQyHw0w5CCBN0WjU5XIVFRXZbDZqFQGkTJZln8/X2dlpt9sLCwuVDgfAMCMBDQAAMIYkEgmPxyPLstPppFYRQDqStYoWi8VisSgdC4AsJkmSx+OJxWJMOQjkKu46AAAAxopkrWJhYaHNZmPKQQDp8Pl8gUCgrq6uqKhI6VgAZLFYLOZyuXQ6ncPh0Gg0SocDICNIQAMAAIwJPT09Xq+XWkUAaZIkyev1RqNRahUBpCkcDns8npKSkqqqKobxAXIYCWgAAIDc5/f7Ozo6amtri4uLlY4FQBaLx+Nut1uj0TidTmoVAaSjs7Ozra3NarWWlpYqHQuAzCIBDQAAkMuSUw5GIhFqFQGkKRKJuN1uo9FotVqpVQSQMqYcBMYaEtAAAAA5K1mrqFarHQ4HUw4CSEdXV1dra2tVVVVZWZnSsQDIYqIoejyeRCIxfvx4nU6ndDgARgL3IQAAALmJWkUAw4JaRQDDJTnlYF5ensPhYD5kYOwgAQ0AAJCDgsFgc3NzZWWl2WxWOhYAWUySJI/HE4/HnU6nXq9XOhwAWay3t9fj8ZSVlVVWViodC4ARRQIaAAAg1/h8vkAgUFdXV1RUpHQsALJYslZRr9dTqwggTckpB202m8lkUjoWACNtdCSgpc4dLzz+7Nsfu0JF9unzzr3ozCNL93lLdLA2Q1kWAABgbJAkyev19vf3M+UggDQlaxVNJpPValU6FgBZTJbllpaW3t7e+vp6g8GgdDgAFDAaHmKLro133rHBU7PwRzdcsdDmWn/HXZs84hDbDGVZAACAMSEWizU0NEiSRPYZQJo6OzvdbrfVaiX7DCAdoig2NTX19/c7nU6yz8CYNQoqoGM7X365sebM1StOqtUIwhHl3buvfemVXSevmKY/eJtJuw6+LAAAwBjAlIMAhoUsy21tbcFgkFpFAGmKRqNut9tgMFRXVzOMDzCWKX/+i55dn/ZWzfyGTSMIgiBo6r4xo6Ln009apSG0iQ9hWQAAgJzX1dXV1NRUWVlps9nIPgNIWbJWMRwOU6sIIE2hUKixsdFkMtXW1pJ9BsY45SugpQ5fh2y2lH3ZGanLLGVyh88vCXb1wdokhrAsAABADpNl2efzdXZ22u32wsJCpcMBkMX6+/vdbnd+fr7dbidbBCAdfr/f7/fX1NQYjUalYwGgPOUT0GKsP6EyGAxfluqoDIZ8Vaw/Jg+hTeJgy65ateqVV14ZWI/RaOzo6BjNZUGJRKKjo0PpKLIVuy5l8XicvZcydl3KYrEYey9l7LqUZfTAC4fDWu2IXlyJoujxeBKJhNPp1OsZggxA6kKhkNfrLSsrq6ysVDoWAFlMluXm5uZIJOJwOPLz85UOB8CooHwCWqPP08jBvqgs5KsEQRDkvr6orCvWD6XNQZe12WyTJ08e+Gdra6tWqx21CehEIqFSqTQajdKBZCVRFNl1qeHAS5ksy5IksetSk0gk1Go11VUp4MBLmSzLoihmtMdTq9UjeZkRi8VcLpder3c4HJxNANIRCATa29upVQSQpkQi4XK5VCqVw+EY4afyAEYz5bsDtdlSrmoMdEmCSSMIgiB1B7pV5sPN6iG00R5s2eXLly9fvnxgPfPnzzeZTKMzAS3LciAQ0Gg0JpNJ6ViyjyRJPT097LoUJA88rVZbUlKidCzZRxTFUCjEgZcCSZI6Ozu1Wi13uSlIJBLhcJhzNgWiKHZ1del0uswdeAaDQZJGaCqK3t5ej8dDrSKANMmy3NLS0tvby5SDANIUjUZdLldRUREzUgD4GuWLZTR1h08ubP14hz85bobUtmNnW/GUw6s1Q2ijH8KyAAAAOaazs9PtdlutVrLPANKRnHKwv7+fKQcBpCkYDO7Zs6esrKy6uprsM4CvUT4BLeinLVhQ1/T8mmfeb/Ds3r5u7UaP85QFR+gFIdHw18f/8Nx77dLgbQZdFgAAIAclx1X0+Xz19fW8gQEgHdFodPfu3Vqtdty4cbwpDyAdPp+vubm5trbWYrEoHQuA0Wg0XGdoHYtvvD7+8BNrf7IxWlA9/ZQblp9h1wiCkGj+4OXNjeKcxd+sHLTNYJ8DAADkGlEU3W63KIpOp1On0ykdDoAs1tPT4/V6LRYL2SIA6ZAkyev1RqNRp9OZl5endDgARqnRkIAWBI1l1tKfzVr6tU/zj71xw7EHaTP45wAAADkkGo263W6DwWC320d+ysGenp5YLFZWVqbMbIemCgU2KghdXV2iKJaXlyuydaV+dSAQUKlUZWVlimxdEQNTYoydtwr8fr/f76+trS0uLh7hTSeH48/Lyxv5TSsoHo8Hg0GDwVBYWKh0LCMnGo329vYWFhaOqdFdIpFIJBIpLi4eI6nYeDzudrs1Go3T6Rz5KbJ7e3uj0ajJZBpT73AofEmmkO7u7kQiodglmUJy7JJsDJ2lAAAAWSoUCnm9XrPZXFGhTFISQG5IDuMTiUSoVQSQpkgk4na7jUaj1Wpl0GcAB0YCGgAAYFQLBALt7e01NTVGo1HpWABksWStolqtdjgcY6pgEMCw6+rqam1traqqypnyTAAZxWUHAADAKJWsVQyHw/X19WPqFWYAw45aRQDDQpZln8/X2dlpt9vH1KgyANJBAhoAAGA0SiQSLpdLpVI5nU5qFQGkIxgMNjc3V1ZWms1mpWMBkMUkSXK73fF43Ol06vV6pcMBkDXG0JjlAAAA2UKW5YaGhvz8/Pr6erLPANIRiURaWlrq6urIPgNIhyzLTU1NgiDU19eTfQZwSMbW/UxRUdEJJ5ygdBSDkiRJEIQxNZPpMJJlmXcJUyNJkkqlYu+lhgMvNbIsy7Is0OOligMvZSPwp3bZsmXDsh6tVrtixYrR8z86ec6OnnhGBr967MjhX51IJF555ZVXX31V6UD+K4f39gHwq8eI0fmTzzjjjGFZj06nu+aaa0bPBfzo3NuZxq8eO0bnr065B1Alfw8UF41Gv/Wtb02ZMuXJJ59UOhaMIcFg8IQTTpgxY8YjjzyidCwYQ9rb208++eQ5c+asWbNG6VgwhrhcrjPPPPPb3/723XffrXQsAAAAADBWjJYnVwAAAAAAAACAHEMCGgAAAAAAAACQESSgAQAAAAAAAAAZMbYmIRzNNBrNokWLqqqqlA4EY4ter1+0aFFNTY3SgWBsMRgMixYtqq+vVzoQjC3FxcWLFi2aOHGi0oEAAAAAwBjCJIQAAAAAAAAAgIxgCA4AAAAAAAAAQEaQgAYAAAAAAAAAZARjQCtH6tzxwuPPvv2xK1Rknz7v3IvOPLJU9dUWctert1zy0I74wAea6jN/tfb7EzUjHClyxMEPuaG1AQ4JfR0UJLe9dMvt/nMfuPjw/R1O9HgAAAAAkHkkoJUiujbeeccG8biLfnSu2b9l3WN33KW5984zar9ygyz52nyqiQuvXnS4PvmBylBto2gdqRnKITeUNsAhoa+DcuRo81tPbfpXZLa036/p8QAAAABgJJCAVkhs58svN9acuXrFSbUaQTiivHv3tS+9suvkFdP0ezWK+9q7jBOOmnv0VG6Hka6hHHJDOiyBQ0FfB2XI/jfvW/XY9uaemCyU778JPR4AAAAAjAhKzJQhenZ92ls18xu2ZLZFU/eNGRU9n37S+pUiLcnf7pMrrBVSX5evIxSXFYkUOWIoh9yQDkvgUNDXQSEq08xzrll1172rFk8c5FE7PR4AAAAAjAwqoJUhdfg6ZLOl7MsHAOoyS5nc4fNLgv2/zwQkf6s/4X/zlxc/1hgUBW3xuGPOu+KHC8YXMEAlDt1QDrkhHZbAoaCvg1J0phqnSZC7vjAMciDR4wEAAADAyOAmSxlirD+hMhgGbotVBkO+KtYf27vyTw51dMUNRc6FP3/8+eefWvuTBUUfP3rnox/0Uh2IFAzlkBtKG+CQ0Ndh1KLHAwAAAICRQQX0CIm/d9/SO9/ukwVBVTTvZ09cps/TyMG+qCzkqwRBEOS+vqisK/7KuJOq0vm3PDv/y3/Vzl5y+aKPL3vunR3LZh9jGOnwkfU0QzjkhtIGOCRDOajo66AIejwAAAAAGBkkoEeIbuaK3z15sSwLgkqlL9CpXZZyVWOgSxJMGkEQBKk70K0yH24+UEW6urzalhfvCkVlYbAXioHBqM0HP+SG0gY4JKkcVPR1GBH0eAAAAAAwMrjPGim6gpISk8lkMpWUFOgETd3hkwtbP97hT77qK7Xt2NlWPOXwas1eS0S2r/3hytXbgl++DSw2N7hipbW1xWRkcOiGcsgNpQ1wSOjrMGrR4wEAAADAyNDceuutSscwJmks5bH3N7z4Ybx2XGnf55sffuLvptNWnjfVpE40/PXJTR/026bUmMrUrj8//dKO/tJyQ7zj31uffnjDbvuSy846jKwMUjCEQ65IO1gbpYNH9qKvg7Kiu9966RPj8afOqkx2ZPR4AAAAADDSSEArRV06eWZ9dMcrf3z6+b/s6LUvuPzKxZMLVYIQ+9dzdz3+YckxJ8+05NtmzB4X/fTNzRs2vvru513FM869auX8Oj0pGaRkCIecerA2QMro66Coryeg6fEAAAAAYKSpZJn53gEAAAAAAAAAw48XTQEAAAAAAAAAGUECGgAAAAAAAACQESSgAQAAAAAAAAAZQQIaAAAAAAAAAJARJKABAAAAAAAAABlBAhoAAAAAAAAAkBEkoAEAAAAAAAAAGUECGgAAAAAAAACQESSgAeSUj24+Qqepvfyt+Fc/ju1+8pxxenXxzKv/zycpExkAAAAAAMDYo1U6AADItETTsz84adnzHZOv2PDqPfMrePAGAAAAAAAwQkhAA8htonfjipMufKZ14g/X/+X+kyrJPgMAAAAAAIwccjEAcpjU+soVJy19zO1c9se/PHhy1aH3eGI8fuAROw7aAAAAAAAAYAwjAQ0gV0m+/7tmwTkPN9gvfuYvvznVptnrq/7GP//yohOOqDYZ9HlFFsf/nHbNEzt65C+/fPG84rxv3voKcMMAAATHSURBVPH6putPrDcZ8nT5prpvnHbdun8OvcFBNwEAAAAAADA2MAQHgJwkBd6++ZTFD+wsOPX3rz10es3e2We5fcMPjj33j92OE8+59Mw6Q8S1fdP6+y9+v634X+sWmVXJNuLu//3ekvb4hAUX/fgwvffdzX+69/tb/+575y9XT9UPpcFQNgEAAAAAAJD7SEADyD1S17ZbT73v7h0xnRz58M0PO79vr9gr6xt664+bWoynPbHthaXJj6WrZp04/op33tgRXzTvP/llqbNNOP132//4gwn5giBIq16/+sSFa37+06eXbL7Iqjp4g6FsAgAAAAAAIPcxBAeAnCO3Prvq159Mufn19x46paz5mSuufL5173Gai05/zO1vfHrJQFJa7O+XBDkRT+zVSDtl2arvT8hP/kNd8Z1VNy409r754utd8lAaDGkTAAAAAAAAOY8KaAA5R1YVH/XTzS+vmlsq19/z0qyL1l/5o4XHPHde9X+euKnzjcaej15+5M9/2/n5niZ30xe7/tXQ0a+q/Mo6Co78xqS9OkiV8RuzJ2k27fmiSRTKDtpAO6RNAAAAAAAA5DwqoAHkHHXVeXfcPLdUJQjq2qVr7zujwrfxx5c95f5PFbTc9fZPj5k465xVz3/SV37EvHOvunfj9t+dZdx3ZOavfKJSa9QqQRKloTQY8iYAAAAAAAByGxXQAHKPWq36Mtmrrl7y4P2b/3b+hmtXPnbcn34wTiO51916/9/zFz/z8R/PqfrPM7i+jf8ryV9dReSfH32eOG3aQB8Z+vjvnyW0/+Oo1QiCeJAGQ9wEAAAAAABAzqMCGkCOU9vOeeCBc6xdr16/4pEGUZA6fR0JdZnTaf6y/4s1vfj8tr6vLZXY9cgvnt4TS/5D6nj7jjs3dRmOOW2+RXXwBkPcBAAAAAAAQM6jAhpAzlNVLV695qVtZz194/KH5r12yUknOX51/5rvnStdcqJd1f7JW889+5FsKhZ825977K/jzj9hok4QBCHflve3FXPmbF584mE677YXX9jmzZvzi19fWDfw1O4ADdSTD7aJIkbjAAAAAAAAYwIV0ADGAFXF6feuvaAm9OZNl65pnH37S09f8+2Cj/6w6vqfP/xqk/2qV3e8/+TV3zI3rPvJ3W8EkuNkqIzfXbN144ra3Zv+977fbm4wzbvy0bdeuXGm4b9rPFCD/GOGsAkAAAAAAIDcp5JlUiEAsJf+F88rX/zGuX/2PPJdfWoNAAAAAAAAIAgCFdAAAAAAAAAAgAwhAQ0AAAAAAAAAyAgmIQSAr1JXzTzpFPU0y6AP6A7aAAAAAAAAAIIgMAY0AAAAAAAAACBDKOADAAAAAAAAAGQECWgAAAAAAAAAQEaQgAYAAAAAAAAAZAQJaAAAAAAAAABARpCABgAAAAAAAABkBAloAAAAAAAAAEBGkIAGAAAAAAAAAGQECWgAAAAAAAAAQEaQgAYAAAAAAAAAZAQJaAAAAAAAAABARpCABgAAAAAAAABkBAloAAAAAAAAAEBGkIAGAAAAAAAAAGQECWgAAAAAAAAAQEaQgAYAAAAAAAAAZAQJaAAAAAAAAABARpCABgAAAAAAAABkBAloAAAAAAAAAEBGkIAGAAAAAAAAAGTE/wfAdJrpb1wdfgAAAABJRU5ErkJggg=='; $('#score-heatmaps-unpooled-pooled p.image-container')[0].style = 'background: url(&quot;' + data + '&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = data;" style="cursor: pointer">pooled</a>)</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><img data-figure-id="fig1" src="data:image/png;base64,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" width="1536"></p>
</div>
</div>
<div id="column-1" class="section level2 tabset" data-width="45">
<h2 class="tabset">Column</h2>
<div id="individual-results" class="section level3">
<h3>Individual results</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><a name='648'></a></p>
<div
id="coronis-collaborative-group-2013-caesarean-section-surgical-techniques-coronis-a-fractional-factorial-unmasked-randomised-controlled-trial"
class="section level4">
<h4>648.
<a href='https://doi.org/10.1016/S0140-6736(13)60441-9' title='Open publication'>CORONIS
Collaborative Group (2013): <i>Caesarean section surgical techniques
(CORONIS): a fractional, factorial, unmasked, randomised controlled
trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the PRECIS-2 scores I would give for the CORONIS trial based on the attached publication:

Eligibility criteria 
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pregnant women were eligible if they were to undergo delivery by lower segment caesarean section through a transverse abdominal incision, irrespective of fever in labour, gestational age, or multiple pregnancies.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Women were not eligible if there was a clear indication for a particular surgical technique or material to be used that prevented any of the allocated interventions being used, if they had more than one previous caesarean section, or if they had already been recruited into the trial.&quot;</span>

Reasoning: The eligibility criteria are quite broad, including women undergoing both elective and emergency cesarean section, at any gestational age, and with singleton or multiple pregnancies. The only notable exclusions are women with more than one previous cesarean section and those with a clear indication for a particular surgical technique. Overall, the criteria seem intended to achieve a study population that is representative of the target population for cesarean section in general.

Score: [4] Rather pragmatic

Recruitment 
Relevant quotes: No details provided on recruitment process.

Reasoning: Since no information is provided on how participants were recruited, I cannot assess this domain.

Score: [NA]

Setting
Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎CORONIS was undertaken at 19 sites in Argentina, Chile, Ghana, India, Kenya, Pakistan, and Sudan.&quot;</span>

Reasoning: The trial was conducted across multiple sites in 7 countries across 3 continents. This indicates that the setting is intended to be generalizable and applicable across diverse geographic regions and healthcare systems.

Score: [5] Very pragmatic

Organization
Relevant quotes: No details provided on organization of care delivery.

Reasoning: No information is provided on the expertise of care providers or resources available, so I cannot assess whether the organization differed from usual care.

Score: [NA] 

Flexibility: Delivery
Relevant quotes: No quotes, but the Methods section states <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All non-allocated surgical elements and all other aspects of the caesarean section procedure were undertaken at the discretion of the surgeon.&quot;</span>

Reasoning: Letting surgeons use their own discretion in how to deliver the allocated interventions suggests a very flexible approach that should mirror usual care.

Score: [5] Very pragmatic

Flexibility: Adherence
Relevant quotes: No details provided on measures to ensure adherence.

Reasoning: No information is provided on whether any measures were used to enforce or monitor adherence, so I cannot assess this domain.

Score: [NA]

Follow-up 
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data were collected at trial entry, immediately after surgery, at hospital discharge (including hospital transfer or death), and at about 6 weeks after delivery.&quot;</span>

Reasoning: Follow-up to 6 weeks post-delivery seems to represent the typical duration of follow-up after a cesarean section in usual care. No details are provided to suggest the frequency or intensity of measurement was increased beyond typical care.

Score: [4] Rather pragmatic

Primary outcome
Relevant quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

The primary outcome was the composite of death, maternal infectious morbidity, further operative procedures, or blood transfusion (>1 unit) up to the 6-week follow-up visit.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary outcome was a composite of death, maternal infectious morbidity, further operative procedures, or blood transfusion (>1 unit) up to the 6-week follow-up visit.&quot;</span>

Reasoning: The components of the primary composite outcome are clinically important events that would be meaningful to patients and providers. The 6-week time period also seems reasonable and relevant.

Score: [4] Rather pragmatic

Primary analysis
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Women were analysed in the groups into which they were allocated.&quot;</span>

Reasoning: Analyzing participants according to the group they were randomized to, regardless of adherence, represents an intention-to-treat approach that is very pragmatic.

Score: [5] Very pragmatic</pre>
<p><a name='650'></a></p>
</div>
<div
id="van-dijk-de-vries.-a-2015-lessons-learnt-from-a-cluster-randomised-trial-evaluating-the-effectiveness-of-self-management-support-sms-delivered-by-practice-nurses-in-routine-diabetes-care"
class="section level4">
<h4>650.
<a href='https://doi.org/10.1136/bmjopen-2014-007014' title='Open publication'>van
Dijk-de Vries. A, (2015): <i>Lessons learnt from a cluster-randomised
trial evaluating the effectiveness of Self-Management Support (SMS)
delivered by practice nurses in routine diabetes care</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">18 quote(s) from
publication full text</span> (mean similarity 99.3%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in "650.pdf":

Eligibility criteria:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients with a clinically established diagnosis of type 2 diabetes mellitus were sent a letter by their GPs to introduce the SMS project.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The enclosed self-administered questionnaire consisted of the screening instruments that intervention PNs would also apply for SMS in their routine practice. It included the ‘Daily Functioning Thermometer’ (DFT), which is a Visual Analogue Scale to measure how suffering under the burden of diabetes affects patients’ perceived functioning in everyday life.&quot;</span> 

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

. From all 1805 patients who participated in the screening, 357 (20%) met the detection criteria and were invited to take part in the tria' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From all 1805 patients who participated in the screening, 357 (20%) met the detection criteria and were invited to take part in the trial.&quot;</span>

Explanation: The eligibility criteria for the trial participants were based on a screening questionnaire that was not part of routine care. The screening instruments were intended to select patients with emotional distress and reduced daily functioning, but were not used in usual care. This makes the eligibility criteria more explanatory.

Score: [2]

Recruitment:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients with a clinically established diagnosis of type 2 diabetes mellitus were sent a letter by their GPs to introduce the SMS project.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The enclosed self-administered questionnaire consisted of the screening instruments that intervention PNs would also apply for SMS in their routine practice.&quot;</span>

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

. From all 1805 patients who participated in the screening, 357 (20%) met the detection criteria and were invited to take part in the tria' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From all 1805 patients who participated in the screening, 357 (20%) met the detection criteria and were invited to take part in the trial.&quot;</span>

Explanation: Patients were recruited by sending screening questionnaires to identify eligible patients. This required additional efforts beyond what would occur in routine care. Recruitment was done prior to clinic visits rather than recruiting patients who presented in clinic. This makes the recruitment more explanatory.

Score: [2] 

Setting:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study was conducted between November 2011 and February 2013 and was registered in a Dutch public trial registry [NTR2764]. The study protocol has been published elsewhere.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All the family practices of one regional organisation of GPs (a so-called ‘care group’) in the South of the Netherlands were eligible to participate in the study.&quot;</span>

Explanation: The trial was conducted in family practice settings, which matches the intended setting for the intervention's use in routine care. However, it was limited to a single regional care group, reducing generalizability. Overall this makes the setting moderately pragmatic.

Score: [3]

Organization:

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):

s in the intervention arm (n=19) were trained to integrate SMS into their routine consultations.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎PNs in the intervention arm were trained to integrate SMS into their routine consultations.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎SMS included detection of patients with emotional distress and reduced daily functioning, and supporting them when needed through problem solving and reattribution techniques.&quot;</span>

<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.5%):

the training sessions, PNs started to integrate SMS into their routine care practice.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎During the training sessions, PNs started to integrate SMS into their routine care practice.&quot;</span>

Explanation: The intervention was delivered by practice nurses as part of routine consultations, using their existing expertise and resources. No additional staffing or resources were provided. This matches the intended organization for implementation, making it pragmatic.

Score: [4]

Flexibility of experimental intervention - Delivery:

Relevant quotes: 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎PNs supported patients in the processes of defining problems and finding solutions themselves, by applying problem-solving and reattribution techniques.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Both problem solving and reattribution techniques were intended to result in action plans indicating how patients would achieve their personal goals.&quot;</span>

Explanation: The intervention involved specific techniques and structured processes for delivery, reducing flexibility compared to pure usual care. However, it allowed for some individualization in defining problems and goals. Overall this makes the delivery moderately pragmatic.

Score: [3]

Flexibility of experimental intervention - Adherence:

Relevant quotes:

No relevant quotes found.

Explanation: The paper does not provide information about measures to enforce or monitor adherence. In the absence of evidence, this domain cannot be scored.

Score: [NA] 

Follow-up:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcomes were measured at baseline and at 4-month and 12-month follow-ups.&quot;</span>

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

. In 10% of the sample, one follow-up measurement was missing. Three patients did not complete the baseline measurement and gave informed consent at the 4-month follow-up measurement. Another 23 patients completed only the baseline measuremen' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In 10% of the sample, one follow-up measurement was missing. Three patients did not complete the baseline measurement and gave informed consent at the 4-month follow-up measurement. Another 23 patients completed only the baseline measurement.&quot;</span>

Explanation: Follow-up was limited to two post-intervention assessments at 4 and 12 months. Around 10-15% of patients missed one or both follow-ups. This intensity seems moderately pragmatic compared to pure usual care.

Score: [3]

Primary outcome: 

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome measure was a dichotomised score on a Visual Analogue Scale that measured the perceived effect of diabetes on daily functioning.&quot;</span>

Explanation: The primary outcome directly measures the patient's perceived daily functioning, which is relevant and important to patients. This makes it pragmatic.

Score: [4]

Primary analysis:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Analyses were performed on an intention-to-treat basis.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Only 16 of the 117 patients in the intervention arm (14%) who were found eligible by the posted research-driven screening questionnaire were detected by their practice nurses.&quot;</span> 

Explanation: The analysis was done on an intention-to-treat basis, which is pragmatic. However, the low exposure to the actual intervention for many patients in the intervention arm reduces pragmatism. Overall this makes the analysis moderately pragmatic.

Score: [3]</pre>
<p><a name='651'></a></p>
</div>
<div
id="price.-d-2011-leukotriene-antagonists-as-first-line-or-add-on-asthma-controller-therapy"
class="section level4">
<h4>651.
<a href='https://doi.org/10.1056/NEJMoa1010846' title='Open publication'>Price.
D, (2011): <i>Leukotriene antagonists as first-line or add-on
asthma-controller therapy</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial based on the full text publication:

Eligibility criteria

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

Eligible primary care patients 12 to 80 years of age had impaired asthmarelated quality of life (Mini Asthma Quality of Life Questionnaire [MiniAQLQ] score ≤6) or inadequate asthma control (Asthma Control Questionnaire [ACQ] score ≥1).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Eligible primary care patients 12 to 80 years of age had impaired asthma-related quality of life (Mini Asthma Quality of Life Questionnaire [MiniAQLQ] score ≤6) or inadequate asthma control (Asthma Control Questionnaire [ACQ] score ≥1).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Main exclusion criteria were prior treatment within 12 weeks with an inhaled glucocorticoid or LTRA (in the first-line controller therapy trial) or LTRA or LABA (in the add-on therapy trial).&quot;</span> 

Reasoning: The trial included a broad range of primary care asthma patients based on symptom criteria, without extensive diagnostic testing. The main exclusions were prior use of the study medications. This matches usual care eligibility.

Score: [4] Rather pragmatic

Recruitment

Quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients who met the eligibility criteria completed a validated asthma-symptom diary for 2 weeks before the baseline visit for an assessment of PEF variability and to record current symptoms.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In the first-line controller therapy trial, eligible patients had asthma symptoms deemed by their physician to require initiation of asthma-controller therapy.&quot;</span>

Reasoning: Patients were recruited when they presented to their primary care physician with asthma symptoms requiring treatment. This matches usual care.

Score: [5] Very pragmatic 

Setting

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The two trials, which were conducted at 53 primary care practices in the United Kingdom, enrolled patients 12 to 80 years of age with a physician’s diagnosis of asthma.&quot;</span>

Reasoning: The trial was conducted in multiple primary care practices, the typical setting for asthma management.

Score: [5] Very pragmatic

Organisation

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Practice staffs were asked to provide each patient with a written individualized asthma-action plan. For each of the assigned treatments, choices of individual drugs and devices were made according to normal clinical practice and British asthma guidelines.&quot;</span>

Reasoning: Usual primary care staff and resources were used to deliver the interventions according to normal practice.

Score: [5] Very pragmatic

Flexibility: Delivery

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The protocol discouraged substantial treatment changes between randomization and the 2-month visit. If a patient required a disallowed asthma medication, this fact was noted, and the patient remained in the study.&quot;</span>

Reasoning: Providers had flexibility in delivering the interventions according to their normal practice, with minimal protocol restrictions.

Score: [5] Very pragmatic

Flexibility: Adherence

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients who withdrew from the study continued to receive care from their usual clinician.&quot;</span>

Reasoning: There were no special measures to enforce or monitor patient adherence. Patients could withdraw and continue usual care.

Score: [5] Very pragmatic

Follow-up

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎After the screening visit (week –2) and baseline visit (week 0), study assessments by telephone or in the clinic were scheduled at months 2, 6, 12, 18, and 24.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data collection and statistical analyses were performed by study personnel who were unaware of the treatment assignments; questionnaire-based data were collected under blinded conditions, and routine practice data (including a history of exacerbations) were extracted with the use of dedicated software.&quot;</span>

Reasoning: Follow-up visits were at most every 6 months, with some data extracted from medical records. This is reasonably close to usual care.

Score: [4] Rather pragmatic

Primary outcome

Quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome measure was the MiniAQLQ score.&quot;</span>

Reasoning: The MiniAQLQ measures asthma quality of life, a patient-centered outcome.

Score: [5] Very pragmatic

Primary analysis

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary effectiveness analysis was an intention-to-treat analysis of the MiniAQLQ score at 2 months (the primary time point) and at 2 years.&quot;</span> 

Reasoning: The primary analysis was intention-to-treat.

Score: [5] Very pragmatic</pre>
<p><a name='655'></a></p>
</div>
<div
id="galdiz-j.-b.-2020-telerehabilitation-programme-as-a-maintenance-strategy-for-copd-patients-a-12-month-randomized-clinical-trial"
class="section level4">
<h4>655.
<a href='https://doi.org/10.1016/j.arbres.2020.03.034' title='Open publication'>Galdiz,
J. B. (2020): <i>Telerehabilitation Programme as a Maintenance Strategy
for COPD Patients: A 12-Month Randomized Clinical Trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">13 quote(s) from
publication full text</span> (mean similarity 98.8%)</i></p>
<pre>
Here are the PRECIS-2 domain scores and justifications based on the provided trial publication:

1. Eligibility criteria

Relevant quotes:

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patient selection criteria were having a diagnosis of moderate-to-severe COPD (a Body mass index, Airflow obstruction, dyspnoea and Exercise capacity [BODE] index score of 3–7) according to international guidelines and having been clinically stable for the previous 4 weeks.&quot;</span>

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study was carried out in accordance with the principles of the Declaration of Helsinki and started after receiving authorization from the Spanish Agency for Medicines and Health Products and the approval of the Basque Country Ethics Committee, as well as the local Ethics Committee and Director at each institution. All patients gave written informed consent.&quot;</span>

Score: [4] Rather pragmatic

The eligibility criteria seem fairly broad, including patients with moderate to severe COPD based on BODE index score. The only major exclusion seems to be unstable COPD in the past 4 weeks. Overall, the criteria seem to target a population similar to those who would receive pulmonary rehabilitation in usual care.

2. Recruitment path

Relevant quotes: 

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Recruited patients (recruitment visit, −1) attended an initial 8-week outpatient-based PR programme conducted in each hospital rehabilitation department.&quot;</span>

- No details provided on how patients were identified and recruited initially.

Score: [NA] 

The publication does not provide information on how patients were recruited, so it's not possible to assess this domain.

3. Setting

Relevant quotes:

- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

This was a multicentre open-label pragmatic parallel-group randomized clinical trial involving 13 hospitals and was conducted between 2014 and 2017' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This was a multicentre open-label pragmatic parallel-group randomized clinical trial involving 13 hospitals and was conducted between 2014 and 2017.&quot;</span> 

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study was carried out in accordance with the principles of the Declaration of Helsinki and started after receiving authorization from the Spanish Agency for Medicines and Health Products and the approval of the Basque Country Ethics Committee, as well as the local Ethics Committee and Director at each institution.&quot;</span>

Score: [5] Very pragmatic 

The trial was conducted across 13 hospitals and various ethics committees, suggesting a setting very similar to real-world usual care.

4. Organization

Relevant quotes:

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The hospital-based outpatient programme consisted of three training sessions a week which included 30 min of weight lifting and 30 min of leg cycle ergometry along with four educational sessions which included chest physiotherapy training.&quot;</span>

- No details provided on additional resources or expertise needed beyond usual care.

Score: [NA] 

The publication does not provide enough details on the organization of the intervention to assess how different it was from usual care.

5. Flexibility - delivery

Relevant quotes:

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients in the IG were asked to continue at home with a similar training schedule to that completed in the hospital. They were provided with, for the 12-month follow-up period, a telerehabilitation kit (mobile phone, pulse oximeter, dumbbells and exercise bicycle) along with a user guide with detailed instructions on the use of the mobile device to deliver data collected to the web-based platform after completion of each scheduled session.&quot;</span>

- No other details provided on protocol flexibility.

Score: [3] Equally pragmatic/explanatory

Patients were provided prescribed equipment and instructions to follow a similar exercise regimen at home as they did in hospital. This provides some flexibility but also protocolization. Overall it seems a mix of pragmatic and explanatory elements.

6. Flexibility - adherence

Relevant quotes: 

- No details provided on measures to enforce or monitor adherence.

Score: [NA]

The publication does not provide enough information to assess the flexibility around patient adherence.

7. Follow-up

Relevant quotes:

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎After the randomization visit, follow-up appointments were arranged for both groups at 3, 9 and 12 months.&quot;</span> 

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎At each follow-up visit, the general health status of the patient was assessed, medical treatment was revised and optimized, educational reinforcement was provided, 6-minute walk test (6MWT) and spirometry tests were carried out and HRQoL measures were taken.&quot;</span>

Score: [3] Equally pragmatic/explanatory

Follow-up visits were scheduled every 3 months, which provides some intensity. However, the assessments done seem fairly routine. The frequency and intensity of follow-up seems a mix of pragmatic and explanatory elements.

8. Primary outcome

Relevant quotes:

- <span title='Moderate quote deviation. Best match in fulltext (Similarity 85.7%):

Exercise tolerance (the ability to sustain exercise) was assessed using distance covered in the 6MWT.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Exercise tolerance (the ability to sustain exercise) was assessed using distance covered in the 6-min walk test (6MWT).&quot;</span>

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Health-related quality of life (HRQoL) was measured using a generic instrument (SF-36) and the Chronic Respiratory Disease Questionnaire (CRQ).&quot;</span> 

Score: [5] Very pragmatic

The primary outcomes of exercise tolerance and quality of life are highly relevant and important to patients. They also seem to be measured in a similar way as would be done in usual practice.

9. Primary analysis

Relevant quotes:

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Missing values were not imputed. All patients were analyzed in the group to which they were randomized.&quot;</span>

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Secondly, additional analyses were conducted using linear mixed models, adjusted for baseline values and including time-group interaction terms.&quot;</span>

Score: [4] Rather pragmatic

An intention-to-treat approach was used with no imputation. Additional analyses were done, but the primary analysis seems to align with a pragmatic approach.</pre>
<p><a name='657'></a></p>
</div>
<div
id="arntzen-e.-2019-group-based-individualized-comprehensive-core-stability-intervention-improves-balance-in-persons-with-multiple-sclerosis-a-randomized-controlled-trial."
class="section level4">
<h4>657.
<a href='https://doi.org/10.1093/ptj/pzz017' title='Open publication'>Arntzen
E. (2019): <i>Group-Based Individualized Comprehensive Core Stability
Intervention Improves Balance in Persons With Multiple Sclerosis: A
Randomized Controlled Trial.</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">19 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the PRECIS-2 scores and reasoning for each domain based on the full text in "657.pdf":

Eligibility criteria

Quotes: 
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 92.7%):

Eighty persons completed baseline testing.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Eighty people completed baseline testing.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria were as follows: (1) diagnosed with MS in accordance with the McDonald criteria; (2) registered at the MS outpatient clinic; (3) living in 1 of 6 selected municipalities; (4) aged 18 years or older; (5) capable of providing signed written informed consent; and (6) EDSS score between 1 and 6.5 (1 = minor disability, 6.5 = able to walk 20 m with or without a walking aid).&quot;</span>  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were as follows: (1) pregnancy at time of examination; (2) exacerbation in the previous 2 weeks before enrollment; and (3) other acute conditions compromising balance.&quot;</span>

Reasoning: The eligibility criteria are fairly broad, including adults with all types of MS and a wide range of disability levels, which matches the intended population for the intervention. Some common exclusions like pregnancy and recent exacerbations are reasonable. Overall, the criteria seem moderately pragmatic.

Score: [3]

Recruitment

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In August 2015, 1 of the MS nurses at the Department of Neurology, Nordland Hospital Trust in Bodø, Norway, sent out invitation letters with a consent form to 160 persons with MS who were registered at the MS outpatient clinic, had EDSS scores of 0 to 7, and lived in 1 of the 6 municipalities included in the study.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To ensure maximum patient enrollment, 1 reminder letter was sent out to the nonresponders.&quot;</span>

Reasoning: Participants were recruited from an MS clinic registry, reflecting the intended population and care setting. Extra efforts like reminder letters were used to boost enrollment. Overall, recruitment seems moderately pragmatic.

Score: [3] 

Setting

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study was approved by the Regional Committees for Medical and Health Research Ethics in Norway, and the study complied with the Declaration of Helsinki.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Six neurological physical therapists conducted the intervention after being trained in GroupCoreDIST for 5 days.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants allocated to the intervention group were divided into 13 training groups by B.N. and E.C.A. according to geography.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Assessments at all time points took place at a Norwegian hospital.&quot;</span>

Reasoning: The setting was multiple sites in Norway, reflecting a typical real-world care setting for the population. Assessments were done at a hospital site. Overall, the setting seems pragmatic.

Score: [4]

Organization

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Six neurological physical therapists conducted the intervention after being trained in GroupCoreDIST for 5 days. The training included practical and theoretical training.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The physical therapists had varied experience (between 7–25 years) and certification (2 had both a master’s degree in neurological physical therapy and were clinical specialists in neurological physical therapy, 1 was a clinical specialist in neurological physical therapy, and 3 were generalists in physical therapy).&quot;</span>

Reasoning: The providers had some specialized training and expertise in neurological physical therapy, which was likely needed to properly deliver the intervention. But this level of expertise seems reasonable for this setting and population. No major additional resources were noted. Overall, organization seems moderately pragmatic.

Score: [3]

Flexibility: delivery

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The physical therapists conducted an individual clinical examination of each participant. The examinations were followed by group sessions, in which the physical therapists chose from 33 exercises, all with 5 levels of difficulty to address each individual’s impairments underlying his or her balance disturbance. The physical therapists individualized the exercises by tailoring them according to each individual’s symptoms, disability level, and general well-being, and they intensified the exercises by increasing number of repetitions, level of difficulty, and/or by adding motor-cognitive dual tasks as movement quality improved.&quot;</span> 

Reasoning: The intervention involved individualized tailoring and clinical judgment in delivery, providing flexibility similar to real-world practice. But the protocol still guided the overall standardized intervention. Delivery seems moderately pragmatic.  

Score: [3]

Flexibility: adherence

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All group members received a booklet with illustrations of the exercises in which the physical therapist prescribed unsupervised home exercises to be conducted twice per week for 30 minutes.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants in the intervention group were encouraged not to seek any physical therapy other than GroupCoreDIST during the 6 weeks of the intervention.&quot;</span>

Reasoning: Participants were encouraged to follow the prescribed exercises at home but no special measures to enforce adherence were mentioned. Adherence seems to have been handled in a reasonably pragmatic way.

Score: [4]

Follow-up

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Assessments were undertaken at baseline and at weeks 7, 18, and 30.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The participants were allowed to use a walking aid if preferred and were encouraged to use the same walking aid and shoes for all assessments.&quot;</span>

Reasoning: Follow-up visits aligned with outcome assessments at 7, 18, and 30 weeks post-intervention. This schedule seems more frequent than typical care but is reasonable for research purposes. Overall moderately pragmatic.

Score: [3]

Primary outcome

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The outcome measures were the Trunk Impairment Scale–Norwegian Version (TIS-NV), the Mini Balance Evaluation Systems Test (Mini-BESTest), and the Patient Global Impression of Change–Balance (PGIC-Balance).&quot;</span>

Reasoning: The primary outcomes of balance and trunk control are clinically meaningful to patients. The measures used are reasonably pragmatic.

Score: [4]

Primary analysis

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To examine possible differences between groups over time, we performed an intention-to-treat analysis using repeated-measures mixed models in IBM SPSS Version 24.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All participants with postintervention test assessment scores were included, although some had missing observations.&quot;</span>

Reasoning: The analysis was intention-to-treat including all participants, a pragmatic approach. 

Score: [5]</pre>
<p><a name='662'></a></p>
</div>
<div
id="bogosian-a.-2015-distress-improves-after-mindfulness-training-for-progressive-ms-a-pilot-randomised-trial"
class="section level4">
<h4>662.
<a href='https://doi.org/10.1177/1352458515576261' title='Open publication'>Bogosian
A. (2015): <i>Distress improves after mindfulness training for
progressive MS: A pilot randomised trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 domain scores for the trial described in the attached publication "662.pdf":

Eligibility criteria:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria were diagnosis of PPMS or SPMS, Internet access and some level of distress determined by a score of 3 or greater on the General Health Questionnaire (GHQ-12).&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were severe cognitive impairment, as determined by a score of 20 or smaller on the Telephone Interview for Cognitive Status-Modified (TICS-M)&quot;</span> 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Finally, people were excluded if they reported any serious psychological disorders (e.g. psychosis, substance abuse), severe hearing impairment, attending other psychological therapies or prior formal training in mindfulness.&quot;</span>

The eligibility criteria include patients with PPMS and SPMS which are the target population for the intervention. However, patients with severe cognitive impairment, serious psychological disorders, hearing impairment, or prior mindfulness training are excluded even though they may benefit from and receive the intervention in usual care. The distress screening using GHQ-12 may also exclude some patients who would receive the intervention in usual care. Overall, the criteria exclude some patients who may receive the intervention in usual care.

Score: [3]

Recruitment:

Relevant quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We recruited potential participants through adverts on the MS Society website and from National Health Service (NHS) MS centres across the UK.&quot;</span>

The participants were recruited through the MS Society website and NHS clinics. Recruiting through usual care clinics is pragmatic, but additional recruitment through website advertisements makes it slightly less pragmatic. Overall, recruitment is a mix of routine clinic recruitment and extra effort through websites.

Score: [3] 

Setting:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Recruitment took place between December 2012 and May 2013. We administered the screening questionnaires via telephone.&quot;</span>

No details provided on number or types of sites. Likely multi-center given recruitment from NHS centers across the UK, but not clearly specified.

Score: [NA]

Organization: 

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎AB, a health psychologist, facilitated the courses. AB was supervised by PC, a clinical psychologist and expert mindfulness practitioner.&quot;</span>

The intervention was delivered by a health psychologist with training in mindfulness. No mention of additional resources or expertise beyond what would be available in usual care.

Score: [5]

Flexibility of experimental intervention - delivery:

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The format and manual for the mindfulness group, including length of sessions and individual mindfulness practices, were developed in partnership with patients with MS through initial experimental case studies.&quot;</span>

The delivery of the intervention was adapted based on feedback from patients to be suitable for those with limited mobility. However, the format was still standardized based on a manual. Some flexibility but not as much as typical usual care.

Score: [3]

Flexibility of experimental intervention - adherence:

Relevant quotes:
No relevant quotes.

No mention of monitoring or enforcing adherence. Appears to be standard encouragement.

Score: [5] 

Follow-up:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants completed online questionnaires at baseline (prior to randomisation), post-intervention and three-month follow-up.&quot;</span>

Follow-up assessments at two time points. No mention of additional in-person visits beyond online questionnaires. Follow-up limited to standardized questionnaires.

Score: [4]

Primary outcome:

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The GHQ is uncontaminated by the experience of MS-related somatic symptoms and is the most treatment-responsive measure of psychological distress in MS.&quot;</span>

The primary outcome was level of distress measured by GHQ score. This measures a clinically meaningful outcome that is relevant to patients.

Score: [5]

Primary analysis:

Relevant quotes:
No relevant quotes. 

No details provided on primary analysis.

Score: [NA]</pre>
<p><a name='663'></a></p>
</div>
<div
id="callesen-j.-2020-how-do-resistance-training-and-balance-and-motor-control-training-affect-gait-performance-and-fatigue-impact-in-people-with-multiple-sclerosis-a-randomized-controlled-multi-center-study"
class="section level4">
<h4>663.
<a href='https://doi.org/10.1177/1352458519865740' title='Open publication'>Callesen
J. (2020): <i>How do resistance training and balance and motor control
training affect gait performance and fatigue impact in people with
multiple sclerosis? A randomized controlled multi-center
study</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the PRECIS-2 assessments for the 9 domains based on the attached full text:

1. Eligibility criteria

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were included from September 2016 to October 2018, after being invited via seven MS clinics (specified in “Acknowledgements” section) and targeted advertisements sent out via the Danish MS Society.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion criteria were as follows: age > 18, confirmed diagnosis of MS, Expanded Disability Status Scale (EDSS): 2.0–6.5, Six Spot Step Test (SSST) score > 8 seconds or Timed 25-Foot Walk (T25FW) > 5 seconds, relapse-free within the past 8 weeks, and no adjustment of disease-modifying medication or medication that affects gait performance and spasticity within the past 8 weeks.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were as follows: co-morbidity in terms of cognitive disorders or alcohol abuse (based on clinical judgment), pathologies that did not allow systematic PRT >1 session/week within the last 3 months.&quot;</span>

Score: [3]

The eligibility criteria seem fairly pragmatic - participants had confirmed MS diagnosis and some impairment in mobility, but no other major exclusions. However, the exclusion of those with cognitive disorders or inability to do PRT does limit generalizability somewhat. Overall, it's a mix of pragmatic and explanatory.

2. Recruitment

Relevant quotes: 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were included from September 2016 to October 2018, after being invited via seven MS clinics (specified in “Acknowledgements” section) and targeted advertisements sent out via the Danish MS Society.&quot;</span>

Score: [4] 

Recruitment was done through MS clinics and advertisements through the Danish MS Society. This seems fairly pragmatic and similar to how patients would be recruited in a real-world setting, with some additional advertisement efforts.

3. Setting

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participating staff at MS clinics: Department of neurology, Aarhus University Hospital; Department of neurology, Odense University Hospital; Department of neurology, Regional Hospital West Jutland; Department of neurology, Viborg Regional Hospital; Department of neurology, Hospital Lillebaelt; Department of neurology, Hospital South West Jutland; and Department of neurology, Hospital of Southern Jutland.&quot;</span>

Score: [4]

The study was conducted across multiple hospitals and clinics, suggesting a pragmatic and real-world setting. However, these are specialized neurology departments rather than primary care, so not fully pragmatic.

4. Organization

Relevant quotes: 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All training sessions were supervised by physiotherapists who were trained to deliver the intervention.&quot;</span>

Score: [3] 

The interventions were delivered by physiotherapists, which matches real-world implementation. However, the physiotherapists received specific training on the study interventions. This additional training makes it slightly less pragmatic.

5. Flexibility (delivery)

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The exercises were conducted in machines that targeted the specified muscle groups, but type of machines could vary between centers.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Physiotherapists with experience in providing BMCT managed the programs. The therapists were instructed to aim for a level of difficulty, where the participants experienced failure but still reached successful execution in more than 50% of the attempts/time.&quot;</span>

Score: [3]

The PRT program was defined but allowed some flexibility in equipment between centers. The BMCT program was individualized but aimed for a certain level of difficulty. Overall, moderately pragmatic flexibility.

6. Flexibility (adherence) 

Score: [NA]

No relevant quotes found regarding intervention adherence.

7. Follow-up

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

follow-up test was performed within 7 days of the last intervention session or after the last day of being on the waitlist.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A follow-up test was performed within 7 days of the last intervention session or after the last day of being on the waitlist.&quot;</span>

Score: [4] 

Follow-up was limited to a single assessment after the intervention period, which seems reasonably pragmatic.

8. Primary outcome

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary outcomes were walking speed assessed by the T25FW and complex walking assessed by the SSST.&quot;</span>

Score: [5]

The primary outcomes of walking speed and complex walking ability are highly relevant for MS patients.

9. Primary analysis

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Analyses were carried out as intention-to-treat, where all participants who completed the baseline assessment were included regardless of their adherence to the allocated intervention.&quot;</span>

Score: [5] 

The analysis was intention-to-treat, which is very pragmatic.</pre>
<p><a name='664'></a></p>
</div>
<div
id="carter-a.-2014-pragmatic-intervention-for-increasing-self-directed-exercise-behaviour-and-improving-important-health-outcomes-in-people-with-multiple-sclerosis-a-randomised-controlled-trial"
class="section level4">
<h4>664.
<a href='https://doi.org/10.1177/1352458513519354' title='Open publication'>Carter
A. (2014): <i>Pragmatic intervention for increasing self-directed
exercise behaviour and improving important health outcomes in people
with multiple sclerosis: a randomised controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 domain scores and explanations for the trial described in the paper <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: a randomised controlled trial&quot;</span> (664.pdf):

Eligibility criteria:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion criteria for the trial were clinical diagnosis of MS, as defined by the modified McDonald criteria, with an Expanded Disability Status Scale (EDSS) score of 1.0–6.5, and able to walk a 10-metre distance; aged 18–65 years; clinically stable for at least four weeks prior to entering the study; physically able to participate in exercise three times per week; able to provide written informed consent.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were comorbid conditions impairing the ability to be physically active three times per week; unwilling to be randomised; living more than 20 miles from the trial centre; already engaged in structured exercise or brisk walking ≥ 3 times per week for ≥ 30 minutes per session for at least six months.&quot;</span>

Reasoning: The eligibility criteria are reasonably broad, including patients with mild to moderate MS based on EDSS score who are able to walk at least 10 meters. The main exclusions are comorbidities impairing physical activity, living too far away, and already exercising regularly. This seems fairly similar to criteria that would be used in usual care.

Score: [4] Rather pragmatic

Recruitment:

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A total of 120 PwMS were recruited via the Sheffield MS Clinic and flyers/community adverts displayed at the local South Yorkshire MS Society branches.&quot;</span>

Reasoning: Participants were recruited through a MS clinic and local community adverts, which seems like a reasonably pragmatic approach that could be implemented in usual care. No extra incentives for participation are mentioned.

Score: [4] Rather pragmatic  

Setting:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Supervised exercise sessions involved up to three participants and lasted for approximately one hour. Studies show that aerobic exercise, resistance exercise and combined programmes bring health benefits to PwMS. Hence, the programme was designed to be pragmatic and accessible, taking into account exercise preferences and giving choices.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Where appropriate, participants also performed exercises for strength and control. The prescribed strength training was based on individual functional needs, as assessed by the trial physiotherapist (NS).&quot;</span>

Reasoning: The supervised exercise sessions took place at a university exercise research facility with supervision from an exercise physiologist and physiotherapist input. This specialized setting is more explanatory than a typical clinical setting where exercise would be prescribed. However, the program was designed to be pragmatic and tailored to individual needs.

Score: [3] Equally pragmatic and explanatory

Organization: 

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An exercise physiologist supervised the delivery of the intervention but with physiotherapist input during the early stages of the programme.&quot;</span>

Reasoning: The intervention involved supervision from an exercise physiologist and physiotherapist, which provides more resources and expertise than may be typically available in usual care. However, it does not seem that extensive additional training or experience was required.

Score: [3] Equally pragmatic and explanatory

Flexibility - Delivery:

Relevant quotes:  
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

Aerobic exercise was the core exercise modality as it is accessible (i.e. includes community-based walking exercise) and does not require equipment. Participants were asked to complete short bouts (e.g. 5 × 3 minutes, with twominute rest intervals) of low to moderate intensity aerobic exercise (e.g. stepping ergometer, cycle-ergometer, treadmill walking, rowing ergometer, arm-cranking) at 50%– 69% of predicted maximum heart rate (220–age) or 12–14 on the Borg Ratings of Perceived Exertion Scale.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Aerobic exercise was the core exercise modality as it is accessible (i.e. includes community-based walking exercise) and does not require equipment. Participants were asked to complete short bouts (e.g. 5 × 3 minutes, with two-minute rest intervals) of low to moderate intensity aerobic exercise (e.g. stepping ergometer, cycle-ergometer, treadmill walking, rowing ergometer, arm-cranking) at 50%–69% of predicted maximum heart rate (220–age) or 12–14 on the Borg Ratings of Perceived Exertion Scale.&quot;</span>

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

The homeexercise sessions were intended to mirror the supervised sessions in terms of intensity and duration of aerobic exercise, and also included tailored exercises for strength, flexibility and balance. Participants were encouraged to seek out opportunities to exercise in the local community (e.g. healthy living centres, health walks, fitness centres, swimming pools, etc.), based on their individual preferences.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The home-exercise sessions were intended to mirror the supervised sessions in terms of intensity and duration of aerobic exercise, and also included tailored exercises for strength, flexibility and balance. Participants were encouraged to seek out opportunities to exercise in the local community (e.g. healthy living centres, health walks, fitness centres, swimming pools, etc.), based on their individual preferences.&quot;</span>

Reasoning: The protocol provides guidance on the exercise intensity, duration, and modalities but leaves flexibility for individually tailored programs incorporating community-based activities. This seems reasonably similar to what would be done in usual care.

Score: [4] Rather pragmatic

Flexibility - Adherence:

Relevant quotes: No discussion of measures to enforce adherence.

Reasoning: There is no indication that measures were in place to monitor or enforce adherence. Participants seemed to have flexibility similar to what would occur in usual care.

Score: [5] Very pragmatic

Follow-up:

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcomes were assessed at baseline, and at three months (post-intervention) and nine months after randomisation.&quot;</span>

Reasoning: Outcomes were assessed at baseline, 3 months, and 9 months. There is no mention of extra visits or more extensive follow-up than would occur in usual care.

Score: [4] Rather pragmatic

Primary outcome:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was self-reported exercise behaviour at three months using the Godin Leisure Time Exercise Questionnaire (GLTEQ).&quot;</span>

Reasoning: The primary outcome was self-reported exercise behavior, which is a patient-centered outcome that would be relevant in usual care. The GLTEQ seems like a reasonable tool to assess this.

Score: [4] Rather pragmatic

Primary analysis:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All analyses were by intention to treat, whereby participants were analysed in the arm to which they were randomised irrespective of whether they complied with the intervention.&quot;</span> 

Reasoning: An intention-to-treat analysis was used, which is consistent with a pragmatic approach.

Score: [5] Very pragmatic</pre>
<p><a name='665'></a></p>
</div>
<div
id="cooper-c.-2011-computerised-cognitive-behavioural-therapy-for-the-treatment-of-depression-in-people-with-multiple-sclerosis-external-pilot-trial"
class="section level4">
<h4>665.
<a href='https://doi.org/10.1186/1745-6215-12-259' title='Open publication'>Cooper
C. (2011): <i>Computerised cognitive behavioural therapy for the
treatment of depression in people with multiple sclerosis: external
pilot trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 98.3%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 87.1%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the PRECIS-2 scores for the trial based on the full text:

Eligibility criteria

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria were: age of 18 years or above; BDI score of at least 14 on two consecutive occasions and no treatment from psychologist, psychotherapist or psychiatrist within the last three months.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were: poor English language skills or cognitive function (score of less than 24 on Mini Mental State Examination [20]); BDI score of at least 29 on two consecutive occasions; active suicidal ideas; current or life-time diagnosis of psychosis, organic mental disorder or substance dependency; Kurtzke Expanded Disability Status Scale (EDSS) score of 8.5 or above [21].&quot;</span> 

The trial had strict inclusion and exclusion criteria that excluded patients based on English proficiency, cognitive impairment, suicidal ideation, psychosis, organic mental disorders, substance dependency, and high levels of disability. This reduces the similarity of trial participants to real-world patients and limits generalizability. The exclusion of patients with severe depression (BDI ≥29) also departs from real-world practice.

Score: [2] Rather explanatory

Recruitment

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Invitations were made between October 2008 and July 2009: face-to-face by consultants in the Sheffield Teaching Hospitals NHS Foundation Trust MS clinic (n = 288); by the Sheffield MS nurses visiting patients (n = 4); and, using ink-signed personalised letters mailed out from a neuropsychologist at Sheffield (n = 40) as well as from consultant neurologists at the Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool (n = 250).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Sheffield neurologists in the MS clinic, forms were completed and returned by 63 (21.8%) candidates from which we randomised 13 in 281 days (4.5% recruitment yield), or 1.4 participants per month. From the 250 recruitment packs sent out by post from The Walton Centre, forms were completed and returned by 64 (25.6%) of recipients, from which 10 participants were randomised in 149 days (4.0% recruitment yield), or two participants per month.&quot;</span>

The trial used multiple recruitment strategies including in-clinic recruitment and mailed letters. The overall recruitment rate was low, with only 4.1% of those invited consenting to participate. The additional effort required beyond standard clinical practice reduces pragmatism.

Score: [2] Rather explanatory

Setting

Quote: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Invitations were made between October 2008 and July 2009: face-to-face by consultants in the Sheffield Teaching Hospitals NHS Foundation Trust MS clinic (n = 288); by the Sheffield MS nurses visiting patients (n = 4); and, using ink-signed personalised letters mailed out from a neuropsychologist at Sheffield (n = 40) as well as from consultant neurologists at the Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool (n = 250).&quot;</span>

The trial was conducted at two specialist NHS hospital trusts. This academic medical setting departs from the typical real-world primary care setting where depression treatment usually occurs. 

Score: [2] Rather explanatory

Organisation

Quote:
<span title='Moderate quote deviation. Best match in fulltext (Similarity 85.6%):

In the Sheffield region, Primary Care Trust (PCT) mental health care teams administered the CCBT, facilitating access and undertaking safety monitoring (PCTs were publicly funded organisations responsible for commissioning acute services for local populations). The CCBT service provided to trial participants was the routine Patients approached to take p' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎In the Sheffield region, Primary Care Trust (PCT) mental health care teams administered the CCBT, facilitating access and undertaking safety monitoring (PCTs were publicly funded organisations responsible for commissioning acute services for local populations). The CCBT service provided to trial participants was the routine service provided to all patients referred to the PCT mental health care teams.&quot;</span>

The CCBT intervention was delivered through existing PCT mental health care teams, reflecting usual care organization and resources.

Score: [4] Rather pragmatic

Flexibility: delivery

Quote: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Only one out of the five participating PCTs around the Sheffield centre formally provided any kind of community facility for accessing CCBT; PCT staff warned that clients rarely used the facility and it was closed during the course of the study. Although four out of five participating PCTs were happy to arrange alternative provision for those who did not have Internet access at home, all our participants requested home use of CCBT. In the Liverpool region, a specialist neuropsychologist, based in the acute hospital facilitated access to and provided technical advice on CCBT, but did not provide additional therapeutic input.&quot;</span>

The CCBT intervention was delivered with flexibility, allowing home access as preferred by participants. There was no strict protocol dictating delivery.

Score: [4] Rather pragmatic

Flexibility: adherence 

No relevant quotes. The paper does not mention any measures to enforce or monitor adherence. As an unguided self-administered intervention, flexibility of adherence appears high.

Score: [4] Rather pragmatic

Follow-up

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

The collection of outcome data by postal questionnaire proved to be challenging, with multiple attempts to obtain data from many participants, particularly at later outcome assessment points.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The completion of outcome data by postal questionnaire proved to be challenging, with multiple attempts to obtain data from many participants, particularly at later outcome assessment points.&quot;</span>

<span title='Moderate quote deviation. Best match in prompt (Similarity 87.1%):

Patients are contacted if they fail to keep trial appointments.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Participants were contacted if they failed to keep trial appointments.&quot;</span>

The trial used postal questionnaires for follow-up assessment, which required significant additional effort beyond usual care. Participants were contacted if they missed appointments, also indicating more intensive follow-up.

Score: [2] Rather explanatory

Primary outcome

Quote:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary clinical endpoint was the mean change in self-reported symptoms of depression as measured on the BDI. Specifically, we measured the mean change in scores between the two arms as measured at baseline, 8 and 21 weeks (13 weeks post intervention).&quot;</span>

The primary outcome was change in BDI score, a standard depression scale. This outcome is clinically meaningful and important to patients.

Score: [4] Rather pragmatic

Primary analysis

No relevant quotes. The paper states an intention-to-treat analysis was used but does not provide details.

Score: [NA] Not enough information</pre>
<p><a name='666'></a></p>
</div>
<div
id="cutter-g.-2019-higher-satisfaction-and-adherence-with-glatiramer-acetate-40-mgml-tiw-vs-20-mgml-qd-in-rrms"
class="section level4">
<h4>666.
<a href='https://doi.org/10.1016/j.msard.2019.04.036' title='Open publication'>Cutter
G. (2019): <i>Higher satisfaction and adherence with glatiramer acetate
40 mg/mL TIW vs 20 mg/mL QD in RRMS</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the PRECIS-2 scores for the clinical trial based on the attached publication:

Eligibility criteria

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Key inclusion criteria permitted the participation of men or women ≥18 years of age with confirmed and documented RRMS diagnosis (as defined by the Revised McDonald criteria)&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Key exclusion criteria were previous exposure to GA40, a progressive form of MS or neuromyelitis optica, the use of experimental or investigational drugs, participation in clinical drug studies within the 6 months before screening, recent use of immunosuppressive medications or immunoglobulins/monoclonal antibodies, or previous use of alemtuzumab, cladribine, cyclophosphamide, or mitoxantrone.&quot;</span>

The eligibility criteria are typical for an RRMS trial, excluding progressive forms of MS and severely disabled patients. The key inclusion criterion is a confirmed RRMS diagnosis. The trial excludes patients who have previously been exposed to GA40, likely to avoid bias, but does not exclude based on expected adherence or response. Overall, the criteria seem moderately pragmatic.

Score: [3]

Recruitment:

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eligible patients were randomly assigned 1:1 to receive subcutaneous injections of GA40 (n = 431) or GA20 (n = 430).&quot;</span>

No details are provided on how patients were recruited into the trial. However, since patients were randomized after being screened for eligibility, it seems that patients were recruited in a reasonably standard way, likely from MS clinics. There is no mention of extra efforts like media campaigns or incentives.

Score: [3] 

Setting:

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The CONFIDENCE study was a multinational, multicenter, randomized, parallel-group, phase 4, open-label study conducted at 88 study centers in 14 countries (Russia, Poland, Italy, France, Croatia, US [including Puerto Rico], Mexico, Spain, Austria, Turkey, Belgium, Argentina, Germany, and Finland) across different geographic regions.&quot;</span>

The trial was conducted across 88 centers in 14 countries across several continents. This diversity of settings indicates a pragmatic approach to increase generalizability of results.

Score: [4]

Organization: 

No relevant quotes.

There are no details provided on resources, staffing, or intervention delivery. It seems the trial did not make significant changes to normal care delivery.

Score: [3]

Flexibility (delivery):

No relevant quotes.

No details are provided on how the interventions were delivered. However, since this was a trial comparing two approved dosage regimens of an existing therapy, it is likely the flexibility in delivery mirrored real-world practice.

Score: [4]

Flexibility (adherence):

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Adherence to treatment when the dosing schedule differs is complicated, because missing one dose has potentially differential impacts on treatment.&quot;</span>

Adherence was measured through self-reported questionnaires. No measures were taken to enforce adherence. This pragmatic approach mirrors real-world practice.

Score: [4]

Follow-up:

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Five scheduled visits at study sites occurred at screening (within 2 weeks prior to baseline), baseline (Month 0), and Months 1, 3, and 6 (end of the core phase).&quot;</span> 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

Patients also participated in self-reported, daily athome MSQ assessments on Days 1 through 7 after the baseline visit.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patients also participated in self-reported, daily at-home MSQ assessments on Days 1 through 7 after the baseline visit.&quot;</span>

Follow-up included 5 scheduled visits over 6 months, which is reasonably frequent but not excessive. Additional patient-reported outcomes were collected daily for the first week. Follow-up intensity seems slightly greater than normal care but still moderately pragmatic.

Score: [3]

Primary outcome:

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary endpoint was patient overall satisfaction with the medication as measured by the single-item MSQ 7-point scale (1 = extremely dissatisfied to 7 = extremely satisfied)&quot;</span>

The primary outcome is patient satisfaction measured by the MSQ scale. This outcome is clinically meaningful and patient-centered.

Score: [5] 

Primary analysis:

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The intention-to-treat (ITT) analysis set included all randomly assigned participants and were analyzed according to the treatment group to which they were randomly assigned, regardless of which treatment they actually received.&quot;</span>

An intention-to-treat analysis was used including all randomized patients. This pragmatic approach is appropriate for a superiority trial.

Score: [5]</pre>
<p><a name='668'></a></p>
</div>
<div
id="dodd-k.-j.-2011-progressive-resistance-training-did-not-improve-walking-but-can-improve-muscle-performance-quality-of-life-and-fatigue-in-adults-with-multiple-sclerosis-a-randomized-controlled-trial"
class="section level4">
<h4>668.
<a href='https://doi.org/10.1177/1352458511409084' title='Open publication'>Dodd
K. J. (2011): <i>Progressive resistance training did not improve walking
but can improve muscle performance, quality of life and fatigue in
adults with multiple sclerosis: a randomized controlled
trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial based on the full text:

Eligibility criteria 

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Volunteers were excluded if they had an acute exacerbation of MS within 2 months of starting the program, had benign or progressive/relapsing types of MS, had a serious unstable medical condition, had any concurrent condition, for example stroke, or had participated in a PRT program in the 6 months before training started.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited through a statewide organization providing education and support to people with MS, and a large specialist MS outpatient clinic. To be included, people had to be aged 18 years or more, have a confirmed diagnosis of relapsing–remitting MS, have an Ambulation Index score of 2, 3 or 4 (mild to moderate walking disabilities), and have received medical clearance to participate.&quot;</span>

Reasoning: The eligibility criteria mostly match those who would receive this intervention in usual care, including adults with confirmed relapsing-remitting MS and mild to moderate walking disability. However, some exclusion criteria like recent acute exacerbation and participation in PRT in past 6 months make it slightly less pragmatic. Overall, it seems reasonably close to usual care eligibility.

Score: [4] Rather pragmatic

Recruitment

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Recruitment information flyers were sent by mail to all potential participants registered on the mailing lists of both organizations. If interested, volunteers were asked to contact one of the researchers (KD) by telephone, during which volunteers were screened to ensure they satisfied the inclusion criteria.&quot;</span>

Reasoning: Recruitment was done through organizations providing education and support to people with MS, by sending flyers to their mailing lists. This seems reasonably close to how patients would be recruited or made aware of the intervention in a real-world setting. No major additional efforts like media campaigns or incentives were mentioned.

Score: [4] Rather pragmatic  

Setting

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The experimental group completed a 10-week (two times per week), PRT program in one of four community gymnasiums in metropolitan and regional areas.&quot;</span>

Reasoning: The setting of community gymnasiums seems very typical of where patients would receive this intervention in usual care. Multiple sites were used which further enhances pragmatism.

Score: [5] Very pragmatic

Organization

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each program was attended by a group of up to 12 participants, and they were supervised by up to three experienced trainers (physiotherapists and registered personal sports trainers). Each trainer directly supervised a sub-group of three or four participants.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The training also took the form of small group-based training; this is important because it made exercising a more social activity, and it was more cost effective and time efficient than individual training.&quot;</span> 

Reasoning: The intervention utilized trainers with expertise typical of a real-world setting - physiotherapists and personal trainers. Resources were not substantially greater than usual care. Overall organization seems very similar to real-world implementation.

Score: [5] Very pragmatic

Flexibility of experimental intervention - delivery

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎While these were the core exercises, they could be individualized. For example, if any exercise caused discomfort, the starting position was modified or the exercise was replaced.&quot;</span>

Reasoning: There was flexibility in delivery of the exercises based on individual needs and tolerances. No major protocol constraints were mentioned. This matches real-world flexibility.

Score: [5] Very pragmatic

Flexibility of experimental intervention - adherence

Relevant quotes:

No relevant quotes found.

Reasoning: There is no mention of any special measures to enforce or monitor adherence. It seems to match usual encouragement.

Score: [5] Very pragmatic

Follow-up

Relevant quotes:  

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcome measurements were taken three times: at baseline, after 10 weeks to determine the immediate effects of the intervention, and after a further 12 weeks (week 22) to determine if any benefits from the program had been sustained.&quot;</span>

Reasoning: Follow-up at 10 weeks and 22 weeks seems reasonably typical to assess sustainability of outcomes. No mentions of more extensive unscheduled visits or data collection. 

Score: [4] Rather pragmatic

Primary outcome

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Changes in walking endurance were measured with the 2-minute walk test (2MWT).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Changes in maximal walking speed were measured by recording the time taken to walk the middle 10 m of a level 14-m walkway using a stopwatch.&quot;</span>

Reasoning: The primary outcomes of walking endurance and speed are highly relevant for MS patients and measure skills needed in daily life. They do not require special expertise to assess.

Score: [5] Very pragmatic

Primary analysis

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Intention-to-treat analysis was applied, with all participants who were allocated and commenced their program included in analysis. Where data were missing, the carry forward technique was used.&quot;</span>

Reasoning: An intention-to-treat analysis was used including all randomized participants. This is very typical of real-world implementation.

Score: [5] Very pragmatic</pre>
<p><a name='669'></a></p>
</div>
<div
id="feys-p.-2019-effects-of-an-individual-12-week-community-located-start-to-run-program-on-physical-capacity-walking-fatigue-cognitive-function-brain-volumes-and-structures-in-persons-with-multiple-sclerosis"
class="section level4">
<h4>669.
<a href='https://doi.org/10.1177/1352458517740211' title='Open publication'>Feys
P. (2019): <i>Effects of an individual 12-week community-located
“start-to-run” program on physical capacity, walking, fatigue, cognitive
function, brain volumes, and structures in persons with multiple
sclerosis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">15 quote(s) from
publication full text</span> (mean similarity 98.4%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial described in the paper <span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

Effects of an individual 12-week communitylocated “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Effects of an individual 12-week community-located “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis&quot;</span>:

Eligibility criteria:
Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Adults with MS were recruited through announcements at REVAL rehabilitation research institute (UHasselt), Flemish MS rehabilitation centers and MS Society, and Move-to-Sport. Adults diagnosed with MS were included based on the ability to walk 5 km without rest or use of assistive device.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Interested pwMS attended an information session and jointly walked 5 km for verification of their ability.&quot;</span>  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were reports to have run 5 km in the preceding 6 months or a relapse occurring in the preceding 3 months.&quot;</span>

Reasoning: The eligibility criteria are fairly broad, including adults with MS who are able to walk 5km without assistance. The main exclusions are related to recent running activity and relapses, to avoid carryover effects. Overall, the criteria seem reasonably similar to MS patients who might undertake such a running program in usual care.

Score: [4]

Recruitment:
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Adults with MS were recruited through announcements at REVAL rehabilitation research institute (UHasselt), Flemish MS rehabilitation centers and MS Society, and Move-to-Sport.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Interested pwMS attended an information session and jointly walked 5 km for verification of their ability.&quot;</span>

Reasoning: Recruitment was done through rehabilitation centers, MS societies, and word of mouth. While this involves some effort beyond usual care, it seems reasonably similar to how patients might learn about and enroll in a community running program in real life. No excessive advertising or incentives noted.

Score: [4] 

Setting:
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were asked to weekly upload data to allow remote supervision of the training adherence by the research assistant. If a participant had been inactive, a phone call was made for enquiry. Besides, two group training sessions were organized (weeks 4 and 8) at a 400-m outdoor running track at KULeuven.&quot;</span>

Reasoning: The setting was a community-based running program with occasional supervised sessions at a university track. This pragmatic setting matches real-world conditions where the training would be applied after the trial.

Score: [5]

Organization: 
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants in the training group adhered well to the remotely supervised program while showing low adverse event rates.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎pwMS received training instructions by email. They were asked to train three times weekly according to a personalized training intensity schedule that was based on their baseline aerobic capacity.&quot;</span>  

Reasoning: The intervention utilized remote supervision by email and activity trackers. No special staffing or resources beyond what would be available in usual care are described.

Score: [5]

Flexibility: delivery
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An illustration of a training protocol is provided in supplementary material S1.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎During the first weeks, training consisted of longer walking bouts, interspersed with short 1′ running bouts. The relative amount of running gradually increased until participants were able to run 5 km without interruption at 12 weeks.&quot;</span>

Reasoning: The running program followed a standardized gradual progression protocol. While not highly flexible, some tailoring to each participant's baseline fitness was allowed. Overall, moderately pragmatic.

Score: [3]

Flexibility: adherence
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants who completed the training program showed high adherence. The EXP group completed 607 of 648 prescribed sessions (94%).&quot;</span> 

Reasoning: No special efforts to enforce adherence are described. Participants received encouragement but were free to follow program at own pace.

Score: [5] 

Follow-up:
Quotes:
<span title='Moderate quote deviation. Best match in fulltext (Similarity 77%):

atients were tested at two time points (0 and 12 weeks).' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Evaluation was performed at two time points (0 and 12 weeks).&quot;</span>

Reasoning: Follow-up matches expected duration of the 12-week program, with pre/post analysis. Does not exceed standard care.

Score: [5]

Primary outcome:
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome measures were physical fitness, walking capacity and perceived ability, functional mobility, and quality of life.&quot;</span>

Reasoning: The outcomes of fitness, walking ability, mobility, and quality of life are highly relevant for MS patients undertaking a running program.

Score: [5]

Primary analysis:
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Intention-to-treat analysis was performed.&quot;</span>

Reasoning: An intention-to-treat analysis was used, implying all randomized participants were included. This pragmatic approach mirrors real-world conditions.  

Score: [5]</pre>
<p><a name='670'></a></p>
</div>
<div
id="finch-p.-2014-effects-of-an-individual-12-week-community-located-start-to-run-program-on-physical-capacity-walking-fatigue-cognitive-function-brain-volumes-and-structures-in-persons-with-multiple-sclerosis"
class="section level4">
<h4>670.
<a href='https://doi.org/10.1016/j.jbmt.2013.04.001' title='Open publication'>Finch
P. (2014): <i>Effects of an individual 12-week community-located
“start-to-run” program on physical capacity, walking, fatigue, cognitive
function, brain volumes, and structures in persons with multiple
sclerosis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">14 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 domain scores and explanations for the trial in the attached paper "670.pdf":

Eligibility:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion criterion for the study was a diagnosis of multiple sclerosis, and therefore the spectrum of clinical presentations was broad, as would be expected in this client population.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Of the fifteen study participants, all had previously received a diagnosis of multiple sclerosis. The time since diagnosis ranged from three to forty-one years (with a mean of 19 years) at the time of the study. Nine participants were categorized as Relapse eRemitting, four as Secondary Progressive and two as Primary Progressive.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎With respect to the ambulatory status of the participants, six walked unassisted, five used a cane, and four used a walker. All participants had prior experience of massage treatment at the clinic.&quot;</span>

Reasoning: The inclusion criterion of a diagnosis of MS is very broad and appears to match usual care eligibility. The participants represented a range of MS types and disability levels, reflecting a heterogeneous MS population typically seen in practice. The broad eligibility criteria yield a pragmatic trial design aimed at determining effectiveness under usual conditions.

Score: [5]

Recruitment:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Clients attending the clinic were interviewed, and their case histories recorded. The research project was explained, and written informed consent was obtained.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An appropriate history and physical examination was performed, and a treatment plan determined, this being reflective of the therapist’s assessment and the mutually set goals for the treatment series.&quot;</span> 

Reasoning: Participants were recruited when they attended the clinic for usual care, which matches how they would receive this intervention under normal circumstances. No additional effort was made to recruit beyond those presenting for care.

Score: [5] 

Setting:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were clients seen in the multiple sclerosis clinics at Sutherland-Chan School, in which the study was conducted.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Clients were provided with information about the clinic by the local chapter of the Multiple Sclerosis Society, and self selected on that basis.&quot;</span>

Reasoning: The setting was a multiple sclerosis specialty clinic, which appears to be the typical setting where these patients receive massage therapy. Conducting the trial in this real-world clinical setting matches the intended application.

Score: [5]

Organisation:

Relevant quotes: 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The teacher also monitored treatment delivery, which involved the application of a variety of techniques appropriate to the client’s needs. These included effleurage, petrissage, stroking, frictions, vibrations, tapotment, rocking and shaking, details of which have been reviewed by Yates (2004). These techniques all involve the manipulation of soft tissues to which was added joint mobilization, myofascial techniques, rehabilitative exercise and hydrotherapy in order to reflect the broad therapeutic armamentarium of the massage therapist.&quot;</span>

Reasoning: The massage therapy was delivered by supervised student therapists using typical resources and a variety of techniques tailored to each participant's needs. This matches how massage therapy is organized and provided in real-world practice.

Score: [5]

Flexibility (delivery): 

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Massage therapy is aligned with the wellness paradigm of health and health care (Alexander, 2006; Yates, 2004), which speaks to a holistic client centered approach to treatment. Accordingly, if the current research was to conform to the requirements of model fit/ecological validity (Menard, 2003; Mason et al., 2002), it was incumbent on the therapists to construct individualized treatment plans recognizing the importance of the client’s physical, psychological and emotional needs. The heterogeneity of the client/participant population precluded an overly prescriptive approach to treatment, and it is worth noting that this heterogeneity is also a component of the normal clinical reality of therapists involved with multiple sclerosis clients.&quot;</span>

Reasoning: The massage therapy was individualized for each participant based on presenting symptoms and tailored goals. No protocol was prescribed, allowing flexibility to match real-world practice.

Score: [5]

Flexibility (adherence):

Relevant quotes: None relevant.

Reasoning: The paper does not mention any strategies to enforce or monitor adherence. In the absence of information, it appears there was no difference from usual care.

Score: [5] 

Follow-up:

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

For both treatment and control groups, self-efficacy scores were obtained before the first treatment, midtreatment series, after the last treatment in the series, four weeks after the final treatment and again eight weeks after the final treatment had been received.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For both treatment and control groups, self-efficacy scores were obtained before the first treatment, mid-treatment series, after the last treatment in the series, four weeks after the final treatment and again eight weeks after the final treatment had been received.&quot;</span>

Reasoning: Follow-up was limited to 5 assessment time points to measure the primary outcome. This does not seem more extensive than usual care.

Score: [5]

Primary outcome:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The outcome measures for the current research were the scores yielded by the Multiple Sclerosis Self Efficacy (MSSE) survey.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The nature of the MSSE survey is such that the clients’ self-efficacy rating is captured through a series of eighteen questions to which they respond on a scale ranging from ten to one hundred. The instrument focuses on the clients’ perception of their ability to function, and the degree of control they have within the context of their disease state.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In the context presented above, the use of MSSE scores as the outcome measure in the current research reflects the notion that massage therapy has the potential to improve client well-being and adjustment to living with multiple sclerosis, through improving perceptions of function and control.&quot;</span>

Reasoning: The primary outcome was self-efficacy measured by the MSSE survey, which assessses patients' perceived ability to function and degree of control. This outcome is relevant and meaningful to the participants.

Score: [5]

Primary analysis:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The data were analyzed on an intention to treat basis, with a focus on the differences between mean MSSE values of the control and intervention groups.&quot;</span>

Reasoning: An intention-to-treat analysis was used including all participants as randomized. This pragmatic approach to analysis matches the intended purpose.

Score: [5]</pre>
<p><a name='671'></a></p>
</div>
<div
id="freeman-j.-2019-assessment-of-a-home-based-standing-frame-programme-in-people-with-progressive-multiple-sclerosis-sums-a-pragmatic-multi-centre-randomised-controlled-trial-and-cost-effectiveness-analysis"
class="section level4">
<h4>671.
<a href='https://doi.org/10.1016/S1474-4422(19)30190-5' title='Open publication'>Freeman
J. (2019): <i>Assessment of a home-based standing frame programme in
people with progressive multiple sclerosis (SUMS): a pragmatic,
multi-centre, randomised, controlled trial and cost-effectiveness
analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">17 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 domain scores and justifications based on the provided trial text:

Eligibility criteria:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Individuals were invited consecutively until the allocated number of standing frames (dependent on commissioning costs) at each health care organisation had been reached.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Key inclusion criteria were age older than 18 years, a diagnosis of progressive multiple sclerosis (primary or secondary) according to McDonald’s criteria, and a score of 6·5–8·0 on the Expanded Disability Status Scale (EDSS).&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Key exclusion criteria were being within 3 months of ceasing a multiple sclerosis disease modifying drug, receiving steroid treatment within the preceding month, or participating in another clinical trial.&quot;</span>

Reasoning: The eligibility criteria are fairly broad, including adults with primary or secondary progressive multiple sclerosis at EDSS scores indicating significant mobility impairment. The only notable exclusions are related to recent changes in medications or participation in another trial, which seem reasonable. Overall, the criteria appear to target a patient population that is representative of those who would receive this intervention in usual care.

Score: [4]

Recruitment:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited through eight health care organisations, including the UK National Health Service (NHS) Trusts, social enterprises, and third sector multiple sclerosis therapy centres, in two regions (Devon–Cornwall and East Anglia) of the UK.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Individuals were invited consecutively until the allocated number of standing frames (dependent on commissioning costs) at each health care organisation had been reached.&quot;</span>

Reasoning: Participants were recruited consecutively from multiple centers and healthcare organizations where they would normally receive care for MS. No additional recruitment efforts beyond engaging patients at their regular clinics are mentioned. This approach seems very similar to how patients would be recruited in routine practice.  

Score: [5] 

Setting:

Relevant quotes: 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited through eight health care organisations, including the UK National Health Service (NHS) Trusts, social enterprises, and third sector multiple sclerosis therapy centres, in two regions (Devon–Cornwall and East Anglia) of the UK.&quot;</span>

Reasoning: The trial was conducted at 8 healthcare organizations across 2 regions in the UK. This multicenter design should provide a diverse sample of settings that is generalizable to the intended real-world usage. The settings seem very similar to where patients would receive usual care.

Score: [5]

Organization:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The intervention consisted of two home-based physiotherapy sessions (60 min each) to set up the standing frame programme, supported by six follow-up telephone calls (15 min per call).&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The use of standing frames is a recognised core skill for UK trained neurological physiotherapists. To standardise and optimise implementation of the intervention, we provided educational materials and assessed fidelity to them.&quot;</span>

Reasoning: The intervention is delivered by NHS physiotherapists in home visits, using their existing expertise. Some educational materials are provided, but no additional training, staffing, or resources beyond what is already available in usual care are mentioned. The organization seems very similar to typical care.

Score: [5] 

Flexibility (delivery):

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In line with previous research, participants were asked to stand in the frame for 30 min three times per week over 20 weeks, and to record the frequency and duration of each stand in a daily diary.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This allowed for a graduated introduction to standing.&quot;</span>

Reasoning: Participants are given recommendations on standing duration and frequency, but the delivery seems flexible within those general guidelines. There is no strict protocol dictating exactly how the standing intervention must be implemented. This level of flexibility matches usual practice.

Score: [4]

Flexibility (adherence): 

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were asked to stand in the frame for 30 min three times per week over 20 weeks, and to record the frequency and duration of each stand in a daily diary.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This allowed for a graduated introduction to standing.&quot;</span>

Reasoning: Participants record their standing sessions in a diary, but no additional measures to enforce or improve adherence are mentioned. The flexibility to adhere to the standing intervention mirrors usual care where patients are encouraged but not coerced. 

Score: [5]

Follow-up:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Validated outcome measures included clinician rated assessments and self-reported questionnaires. The primary outcome was motor function as measured by the Amended Motor Club Assessment (AMCA) score at the primary endpoint of 36 weeks post-randomisation.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcome assessors (research therapists) were masked to treatment allocation, and all assessments were done independently and away from the participant’s home.&quot;</span>

Reasoning: Follow-up includes masked outcome assessments at baseline, 20 weeks, and 36 weeks. This limited follow-up schedule to obtain study outcomes does not seem much different from typical clinical follow-up.

Score: [4] 

Primary outcome:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was motor function as measured by the Amended Motor Club Assessment (AMCA) score at the primary endpoint of 36 weeks post-randomisation.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The AMCA score (range 0–76) is the sum of two subscores. The functional activity subscore (16 items, each scored 0–3) comprises key functional activities of the trunk and lower limbs, such as rolling in bed, sit-to stand, and sitting and standing balance. The lower limb movement subscore (14 items, each scored 0–2) rates motor impairment by grading hip and knee flexion and knee flexion and dorsiflexion in lying, sitting, and standing positions.&quot;</span>

Reasoning: The AMCA scale measures motor function and key activities relevant to patients. It seems like an appropriate and pragmatic choice of primary outcome.

Score: [5]

Primary analysis:

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):

The primary analysis population was defined as all participants who completed baseline and 36 week assess ments. The primary analysis of the primary outcome, AMCA score at 36 weeks, followed a modified intention to treat approach, regardless of compliance to the inter vention, but did exclude patients who were deemed ineligible after randomisation, those who withdrew from the trial and were unwilling for their previously collected data to be used, or those who did not provide baseline and week 36 measurements (ie, there was no imputation of missing baseline or week 36 scores for the primary analysis), and used an analysis of covariance (ANCOVA) approach.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary analysis population was defined as all participants who completed baseline and 36 week assessments. The primary analysis of the primary outcome, AMCA score at 36 weeks, followed a modified intention to treat approach, regardless of compliance to the intervention, but did exclude patients who were deemed ineligible after randomisation, those who withdrew from the trial and were unwilling for their previously collected data to be used, or those who did not provide baseline and week 36 measurements (i.e., there was no imputation of missing baseline or week 36 scores for the primary analysis), and used an analysis of covariance (ANCOVA) approach.&quot;</span>

Reasoning: The primary analysis is essentially an intention-to-treat approach, with minimal exclusions. This data handling mirrors real-world practice and is very pragmatic.

Score: [5]</pre>
<p><a name='673'></a></p>
</div>
<div
id="garrett-m.-2013-exercise-in-the-community-for-people-with-minimal-gait-impairment-due-to-ms-an-assessor-blind-randomized-controlled-trial"
class="section level4">
<h4>673.
<a href='https://doi.org/10.1177/1352458512461966' title='Open publication'>Garrett
M. (2013): <i>Exercise in the community for people with minimal gait
impairment due to MS: an assessor-blind randomized controlled
trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial based on the publication full text:

Eligibility criteria 
Quotes: 
1) <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eligible participants were over 18 years of age and had a diagnosis of MS that was confirmed by a consultant physician or neurologist.&quot;</span>
2) <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Persons with MS were excluded if they had a previous relapse or began steroid therapy in the 12 weeks prior to participating in the first assessment, were pregnant, or had a comorbidity that severely impacted their ability to safely participate in exercise.&quot;</span>

Reasoning: The eligibility criteria are reasonably broad, including adults with confirmed MS diagnosis. Some exclusions are made for safety reasons like recent relapse, pregnancy, and comorbidities impacting exercise safety. Overall, the criteria seem moderately pragmatic.

Score: [3]

Recruitment
Quotes:
1) <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were referred to the project by themselves, their care-giver, MSI, chartered physiotherapists, neurologists, general practitioners or clinical nurse specialists.&quot;</span> 
2) <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Once consent for eight people of a strand in a specific geographical area was obtained, the regional office of MSI contacted the national coordinator (AL) who allocated that block of participants to the control or an intervention.&quot;</span>

Reasoning: Participants were recruited through usual care referrals from physicians and self-referrals. The recruitment seems moderately pragmatic overall, leveraging usual care routes but with some extra coordination for grouping and randomization.

Score: [3] 

Setting
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This was a multi-centre, block randomised, assessor blind, controlled study. The methods of the trial were previously described in detail. This paper presents the results of the study participants, who used at the most unilateral support to walk outdoors&quot;</span>

Reasoning: The trial was conducted across multiple centers, suggesting a pragmatic setting close to usual care.

Score: [4]

Organization
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All interventions took place in groups of eight, for an hour per week, for 10 weeks. They were delivered in community centres such as local gyms, hotels and health centres.&quot;</span>

Reasoning: The interventions were delivered in community settings using existing resources, suggesting a pragmatic organization.

Score: [4] 

Flexibility: delivery
Quotes:
1) <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The PT-led exercise provided was pre-defined. It consisted of a circuit-style class of exercises that were either resisted by body weight or by the addition of free weights.&quot;</span>
2) <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The yoga intervention was also not predefined, and detailed descriptions of the classes were gathered by nine of the instructors.&quot;</span>

Reasoning: The PT-led intervention was protocolized while the yoga intervention was flexible. Overall, the delivery seems moderately pragmatic.

Score: [3]

Flexibility: adherence
No relevant quotes.

Reasoning: The text does not mention any measures to enforce adherence. I will assume a pragmatic approach was taken since nothing is specified.

Score: [4] 

Follow-up
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcome was assessed at week 24 for the intervention groups only, as it was felt that withholding a potentially beneficial treatment for longer than 12 weeks, from the controls, could be considered unethical. As all groups were not treated similarly between weeks 12 and 24, and due to the high attrition rates at weeks 12 and 24, the results of our follow-up phase will be presented in a separate paper.&quot;</span>

Reasoning: Follow-up was limited to 12 weeks even for the control group to avoid withholding treatment. This seems reasonably pragmatic.

Score: [4]

Primary outcome
Quotes: 
1) <span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

The primary outcome measure was the physical component of the Multiple Sclerosis Impact Scale29, version 2 (MSIS-29v2), a patient-reported outcome measure that assesses the physical impact of MS.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary outcome measure was the physical component of the Multiple Sclerosis Impact Scale-29, version 2 (MSIS-29v2), a patient-reported outcome measure that assesses the physical impact of MS.&quot;</span>
2) <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎It consists of 20 questions and it is scored from 0–100, with the higher scores indicating a greater impact of MS.&quot;</span>

Reasoning: The primary outcome is a patient-reported measure of MS physical impact, which seems highly pragmatic and relevant to participants.

Score: [5]

Primary analysis
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All participants were analysed in the groups to which they were randomised.&quot;</span> 

Reasoning: An intention-to-treat analysis was used, suggesting a pragmatic approach.

Score: [5]</pre>
<p><a name='674'></a></p>
</div>
<div
id="giovannoni-g.-2016-alemtuzumab-improves-preexisting-disability-in-active-relapsing-remitting-ms-patients"
class="section level4">
<h4>674.
<a href='https://doi.org/10.1212/WNL.0000000000003319' title='Open publication'>Giovannoni
G. (2016): <i>Alemtuzumab improves preexisting disability in active
relapsing-remitting MS patients</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 99.2%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 98.5%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in the paper <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients&quot;</span>:

Eligibility criteria

Quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy and safety of alemtuzumab 12 mg with subcutaneous interferon-b-1a (SC IFN-b-1a) 44 mg in patients with RRMS.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis II (CARE-MS II), a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy and safety of alemtuzumab 12 mg with subcutaneous interferon-β-1a (SC IFN-β-1a) 44 mg in patients with RRMS.&quot;</span>
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

CARE-MS II was a 2-year, randomized, rater-blinded, active comparator-controlled, head-to-head, trial of alemtuzumab (Lemtrada; Sanofi Genzyme, Cambridge, MA; 12 mg/day on 5 consecutive days at month 0 and on 3 consecutive days at month 12) vs SC IFN-b-1a (Rebif; EMD Serono, Rockland, MA; 44 mg 3 times weekly) in patients with RRMS with inadequate response to prior DMTs ($1 relapse during IFN-b or glatiramer acetate [GA] treatment [received for $6 months])' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎CARE-MS II was a 2-year, randomized, rater-blinded, active comparator-controlled, head-to-head, trial of alemtuzumab (Lemtrada; Sanofi Genzyme, Cambridge, MA; 12 mg/day on 5 consecutive days at month 0 and on 3 consecutive days at month 12) vs SC IFN-β-1a (Rebif; EMD Serono, Rockland, MA; 44 mg 3 times weekly) in patients with RRMS with inadequate response to prior DMTs (≥1 relapse during IFN-β or glatiramer acetate [GA] treatment [received for ≥6 months]).&quot;</span>

Explanation: The eligibility criteria include patients with RRMS who have had at least 1 relapse during prior treatment with IFN-β or GA for at least 6 months. This reflects a patient population that would be reasonably expected to receive alemtuzumab or SC IFN-β-1a in usual clinical practice. Some patients are excluded that may have been eligible in usual care, such as those with non-RRMS forms of MS. Overall, the criteria seem moderately pragmatic.

Score: [3]

Recruitment

Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

In total, 202 and 426 CARE-MS II patients were randomized to SC IFN-b-1a 44 mg and alemtuzumab 12 mg, respectively' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In total, 202 and 426 CARE-MS II patients were randomized to SC IFN-β-1a 44 mg and alemtuzumab 12 mg, respectively.&quot;</span>

Explanation: The paper does not provide details on how patients were recruited, other than saying they were randomized. Without more information, it is difficult to assess the pragmatism of recruitment.

Score: [NA] 

Setting

Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

CARE-MS II was a 2-year, randomized, rater-blinded, active comparator-controlled, head-to-head, trial of alemtuzumab (Lemtrada; Sanofi Genzyme, Cambridge, MA; 12 mg/day on 5 consecutive days at month 0 and on 3 consecutive days at month 12) vs SC IFN-b-1a (Rebif; EMD Serono, Rockland, MA; 44 mg 3 times weekly) in patients with RRMS with inadequate response to prior DMTs ($1 relapse during IFN-b or glatiramer acetate [GA] treatment [received for $6 months])' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎CARE-MS II was a 2-year, randomized, rater-blinded, active comparator-controlled, head-to-head, trial of alemtuzumab (Lemtrada; Sanofi Genzyme, Cambridge, MA; 12 mg/day on 5 consecutive days at month 0 and on 3 consecutive days at month 12) vs SC IFN-β-1a (Rebif; EMD Serono, Rockland, MA; 44 mg 3 times weekly) in patients with RRMS with inadequate response to prior DMTs (≥1 relapse during IFN-β or glatiramer acetate [GA] treatment [received for ≥6 months]).&quot;</span>

Explanation: The setting is not described in detail, but it seems to be a typical clinical trial setting across multiple centers/countries. It is unclear how similar the settings are to real-world clinical settings. Without more details, the pragmatism is difficult to judge.

Score: [NA]

Organization

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Blinded raters performed EDSS assessments at baseline, every 3 months, and when relapse was suspected.&quot;</span>
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Raters administered the MSFC 16 3 times before baseline to attenuate practice effects, then every 6 months' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Raters administered the MSFC 3 times before baseline to attenuate practice effects, then every 6 months.&quot;</span>

Explanation: The paper mentions that blinded raters performed assessments like EDSS and MSFC. It does not provide much detail on the expertise of staff or resources available. It seems reasonably similar to a real-world clinic in terms of staffing for assessments.

Score: [3]

Flexibility: Delivery

Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

Differences in study drug administration and unique adverse event profiles precluded effective double-blinding' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Differences in study drug administration and unique adverse event profiles precluded effective double-blinding.&quot;</span> 

Explanation: The paper mentions differences in drug administration between the two arms, but does not provide specifics. Without more details, it is hard to judge the flexibility of delivery.

Score: [NA]

Flexibility: Adherence 

No relevant quotes

Explanation: The paper does not mention any strategies to enforce or monitor adherence. However, it also provides no details to suggest flexibility in adherence.

Score: [NA]

Follow-up

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Blinded raters performed EDSS assessments at baseline, every 3 months, and when relapse was suspected.&quot;</span>  
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Raters administered the MSFC 16 3 times before baseline to attenuate practice effects, then every 6 months' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Raters administered the MSFC 3 times before baseline to attenuate practice effects, then every 6 months.&quot;</span>

Explanation: Patients were followed regularly with assessments every 3 months for EDSS and every 6 months for MSFC. This seems moderately frequent but not excessive compared to real-world practice.

Score: [3]

Primary outcome

Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

EDSS-based and non-EDSSbased methods. The results of these prespecified outcomes and post hoc analyses from CARE-MS II more fully characterize the effects of alemtuzumab on disability in patients with RRMS than those published previousl' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎EDSS-based and non-EDSS-based methods. The results of these prespecified outcomes and post hoc analyses from CARE-MS II more fully characterize the effects of alemtuzumab on disability in patients with RRMS than those published previously&quot;</span>

Explanation: The primary outcomes include EDSS and MSFC which measure disability and are clinically meaningful to patients.

Score: [5] 

Primary analysis

Quote: <span title='Minor quote deviation. Best match in prompt (Similarity 98.5%):

e intention-to-treat analysis has recently also become the norm for superiority trials taking a more explanatory design approach, especially when regulatory approval for an intervention is being sought' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎An intention-to-treat analysis has recently also become the norm for superiority trials taking a more explanatory design approach, especially when regulatory approval for an intervention is being sought.&quot;</span>

Explanation: The paper mentions that intention-to-treat analysis has become standard, even for explanatory trials. No other analysis details are provided.

Score: [NA]</pre>
<p><a name='675'></a></p>
</div>
<div
id="grossman-p.-2010-ms-quality-of-life-depression-and-fatigue-improve-after-mindfulness-training-a-randomized-trial"
class="section level4">
<h4>675.
<a href='https://doi.org/10.1212/WNL.0b013e3181f4d80d' title='Open publication'>Grossman
P. (2010): <i>MS quality of life, depression, and fatigue improve after
mindfulness training: a randomized trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 99.8%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial described in the paper <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

MS quality of life, depression, and fatigue improve after mindfulness training A randomized trial' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial&quot;</span>:

Eligibility criteria:

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Neurologists verified all patients for the following inclusion criteria: 1) diagnosis of relapsing-remitting (but no more than 2 exacerbations within the last year) or secondary progressive MS and 2) an Expanded Disability Status Scale (EDSS) score of ≤6 (no to moderately severe disability), with ≤1 step increase within the last year. Excluded were patients with reported or medically recorded diagnoses of current serious psychological disorders other than depression and anxiety syndromes, evidence of dementia as indicated by testing below the fifth percentile in at least 3 of 6 dimensions of neuropsychological functioning (i.e., attention and concentration, processing speed, executive function, verbal memory, and verbal processing), other currently life-threatening or severely disabling physical disorders, current MS exacerbation, symptomatic MS medication altered in the last 3 months, other disorders of the CNS, pregnancy, or inability to speak or read German.&quot;</span>

Reasoning: The eligibility criteria seem moderately pragmatic. Patients had to have a diagnosis of relapsing-remitting or secondary progressive MS, with some limitations on disability level and recent exacerbations. Some patients were excluded for serious psychological disorders, dementia, other physical disorders, and inability to speak German. Overall, the criteria exclude some patients who may receive the intervention in usual care, but still target a reasonably broad patient population.

Score: [3]

Recruitment:

Quotes: No relevant quotes.

Reasoning: The paper does not provide any details on how patients were recruited. 

Score: [NA] 

Setting:

Quotes: No relevant quotes.

Reasoning: The paper does not provide any details on the setting of the trial.

Score: [NA]

Organization:

Quotes: No relevant quotes.

Reasoning: The paper does not provide any details on the organization of care delivery in the trial.

Score: [NA]  

Flexibility of experimental intervention - Delivery:

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎MBI closely followed the program of mindfulness-based stress reduction and included 1) a personal intake interview to define realistic goals of participants and establish personal rapport; 2) 8 weekly 2.5-hour classes in mindfulness practices (10–15 participants/group; exercises did not exceed patients’ level of functioning); 3) one Saturday, 7-hour session at week 6; 4) homework assignments (approximately 40 minutes/day), emphasized as essential to success of the program; 5) a postintervention interview to evaluate personal experiences, goal attainment, and future maintenance of acquired skills. Each class covered specific exercises and topics within the context of mindfulness training, i.e., practices during lying, sitting, and dynamic yoga postures, as well as during everyday life, e.g., stressful situations and social interactions. Mindfulness exercises included observation of sensory, affective, and cognitive domains of perceptible experience. The all-day retreat integrated familiar exercises and presented new ones. In all, 6 MBI courses for the experimental arm of the study were individually conducted by 2 experienced, certified teachers, each with ≥9 years teaching experience.&quot;</span>

Reasoning: The delivery of the mindfulness intervention seems moderately flexible, following a structured program with specific components and exercises. But there was some flexibility in tailoring to patients' functioning level and goals.

Score: [3]

Flexibility of experimental intervention - Adherence:

Quotes: No relevant quotes.

Reasoning: The paper does not provide any details on measures to enforce adherence.

Score: [NA]

Follow-up:

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Reported outcome measurements occurred within 2 weeks before and after intervention and 6 months postintervention.&quot;</span>

Reasoning: Patients were followed up at 2 time points - post-intervention and 6 months. This seems moderately pragmatic.

Score: [3]

Primary outcome:

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary outcomes included disease-specific and disease-aspecific HRQOL, depression, and fatigue.&quot;</span>

Reasoning: The primary outcomes of HRQOL, depression, and fatigue are meaningful and relevant to patients.

Score: [5] 

Primary analysis:

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Intention-to-treat analyses are reported. Data of missing study patients were imputed by linear multiple regression that adjusted for age, gender, and disease progression (entry EDSS score; STATISTICA 6.0).&quot;</span>

Reasoning: An intention-to-treat analysis was used, which is pragmatic. 

Score: [5]</pre>
<p><a name='677'></a></p>
</div>
<div
id="hermens-h.-2008-clinical-assessment-of-the-hellodoc-tele-rehabilitation-service"
class="section level4">
<h4>677. <a href='https://doi.org/' title='Open publication'>Hermens H.
(2008): <i>Clinical assessment of the HELLODOC tele-rehabilitation
service</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 96.3%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the 9 domains based on the full text in "677.pdf":

Eligibility criteria

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were eligible for recruiting if they met the following criteria: (1) age > 18 years; (2) established diagnosis of the specific pathological condition MS, stroke or TBI; (3) nine hole peg test (NHPG) performed in more than 25 seconds; (4) ability to move at least one peg in 180 seconds during the NHPG; (5) sufficient autonomous functioning; (6) internet connection or telephone line and reachable internet provider; (7) clinical status stable; (8) discharged from hospital or rehabilitation setting – person lives at home.&quot;</span>

- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎exclusions were: a) disturbed upper limb function not related to MS, TBI or stroke; B) serious cognitive and/or behavioral problems; c) serious emotional problems; D) major visual problems; (e) communication problems; F) medical complications; G) other problems possibly contra-indicating autonomous exercise at home.&quot;</span>

Explanation: The eligibility criteria are fairly broad, including adults over 18 with the conditions of interest who have some minimum level of upper limb function. The exclusions seem reasonable for safety and the ability to participate in the home-based intervention. Overall, the criteria seem intended to include typical patients who would receive this intervention in usual care.

Score: [4] Rather pragmatic

Recruitment:

Quotes: No relevant quotes. The paper does not describe the recruitment methods.

Explanation: The recruitment path cannot be assessed since no details are provided on how participants were recruited. 

Score: [NA]

Setting: 

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were recruited from Unità Organica di riabilitazione Intensiva Neuromotoria (UOrIN, Italy), Foundation Institute Guttmann (FPING, Spain) and from National Multiple Sclerosis centre (NMSc, Belgium).&quot;</span>

Explanation: The settings are specialized rehabilitation centers and an MS center, which may not reflect the full range of usual care settings. However, for the specialized populations in this trial, these settings seem reasonably representative.

Score: [3] Equally pragmatic and explanatory 

Organization:

Quotes: No relevant quotes. The paper does not describe the organization of care delivery.

Explanation: The paper does not provide information about staffing, resources, or expertise required to deliver the intervention.

Score: [NA]

Flexibility: delivery

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The actual intervention with the H-CAD system at home consisted of one month, whereby the patients had an average of one training session a day lasting 30 minutes for at least 5 days a week. The following exercises are part of the H-CAD system: key, light bulb, book, jar, writing, checkers and keyboard tasks.&quot;</span>

Explanation: The delivery seems reasonably flexible in that patients could do the sessions at home and exercises were selected from a menu of options. However, the trial required a fairly standardized schedule of 30 minutes/day, 5 days/week.

Score: [3] Equally pragmatic and explanatory

Flexibility: adherence

Quotes: No relevant quotes. The paper does not describe measures to enforce adherence.

Explanation: The paper does not provide information about efforts to monitor or enforce adherence.

Score: [NA] 

Follow-up:

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All measurements were performed at the centre where the patient had been treated.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The second measurement (t1) was performed after the month of usual care (for intervention as well as control group). The third measurement (t2) was performed after the month of H-CAD intervention for the intervention group and 2 months after baseline for the control group. A month after t2 a follow up measurement was performed (t3) for the intervention group. The control group received their last measurement (t3) 4 months after baseline.&quot;</span>

Explanation: Follow-up measurements were done at discrete time points that appear more frequent than in usual care. This required patients to return to the treatment centers.

Score: [2] Rather explanatory

Primary outcome:

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The outcome measures used in the present study are in line with the international classification of functioning, disability, and health (IcF) model.&quot;</span>
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 70.2%):

the overall satisfaction of both patients and therapists was high.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The overall satisfaction of both patients and therapists concerning the H-CAD system was high.&quot;</span>

Explanation: The primary outcomes of ARAT and 9HPT assess arm/hand function, which seems highly relevant for the patients. 

Score: [5] Very pragmatic

Primary analysis:

Quotes: No relevant quotes. The paper does not provide details about the primary analysis.

Explanation: The analysis approach cannot be assessed since the paper does not describe how missing data or deviations from protocol were handled.

Score: [NA]</pre>
<p><a name='678'></a></p>
</div>
<div
id="higginson-i.-j.-2009-is-short-term-palliative-care-cost-effective-in-multiple-sclerosis-a-randomized-phase-ii-trial"
class="section level4">
<h4>678.
<a href='https://doi.org/10.1016/j.jpainsymman.2009.07.002' title='Open publication'>Higginson
I. J. (2009): <i>Is short-term palliative care cost-effective in
multiple sclerosis? A randomized phase II trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">17 quote(s) from
publication full text</span> (mean similarity 98.3%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Is Short-Term Palliative Care Cost-Effective in Multiple Sclerosis? A Randomized Phase II Trial&quot;</span>:

Eligibility criteria

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients in South East London who were severely affected by MS were referred by clinicians to the trial.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria were patients in South East London, living with MS and deemed (by clinicians) to have one or more of unresolved symptoms, psychosocial concerns, end-of-life issues, progressive illness, or complex needs (i.e., palliative care needs).&quot;</span>  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria included if the referring staff or the screening deemed patients had very urgent needs or were deteriorating rapidly when immediate referral to the service was offered.&quot;</span>

Explanation: The eligibility criteria target patients with MS who have palliative care needs, reflecting the intended population for the intervention in usual care. However, patients with very urgent needs were excluded, making the trial slightly less pragmatic. Overall, the criteria seem moderately pragmatic.

Score: [3]

Recruitment  
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were randomized to receive either the PCT immediately (fast track) or usual best practice alone (control) for 12 weeks, after which they were offered the service.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Subjects were 69 people with MS, 52 of whom took part in the trial.&quot;</span>

Explanation: Patients were referred by their regular clinicians rather than recruited through advertising or other special efforts. However, the study started with 69 patients referred and only 52 participated, suggesting some patients declined to enroll. Overall, recruitment seems moderately pragmatic without special efforts but with some self-selection by patients.

Score: [3]

Setting
Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients in South East London who were severely affected by MS were referred by clinicians to the trial.&quot;</span>
- <span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):

Inclusion criteria were patients in South East London, living with MS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria were patients in South East London, living with MS...&quot;</span>

Explanation: The trial was conducted in a specific geographic region rather than a specialized center. This matches the intended setting for delivering the intervention in usual care.

Score: [4] 

Organization
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In addition to continuing to receive usual services (see below), patients in the fast-track group received care from a PCT.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This comprised one part-time consultant in palliative medicine, one part-time clinical nurse specialist, one administrator, and one psychosocial worker, and was based in a large teaching hospital.&quot;</span>

Explanation: The palliative care team delivering the intervention was a specialized team, likely requiring more resources and expertise than available in usual care. This makes the organization more explanatory.

Score: [2]

Flexibility: delivery
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients had one to three contacts (visits and/or phone calls) from the PCT, although a small number (around 12%) were referred for longer-term ‘‘community’’ palliative care.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The PCT undertook assessments, suggested ways to improve physical, emotional, social, and other problems, provided specialist welfare benefits advice and bereavement support, and liaised with and acted as a catalyst for local services, both primary and specialist teams.&quot;</span> 

Explanation: The palliative care was delivered in a standardized way following initial assessment. The number and type of contacts were protocolized. This reduces flexibility compared to usual care.

Score: [2]

Flexibility: adherence
Quotes: None relevant

Explanation: The trial does not mention any measures to enforce or monitor adherence. There is no indication adherence was actively managed.

Score: [4] 

Follow-up
Quotes:
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.6%):

Data were collected at baseline, 6, 12, 18, and 26 weeks on use of services, patient symptoms, other outcomes, and caregiver burden.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Data were collected at baseline, 6, 12, 18 (only control groupdafter they received PCT), and 26 weeks on use of services, patient symptoms, other outcomes, and caregiver burden.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted face-to-face interviews with patients and gave self-complete questionnaires to caregivers.&quot;</span>

Explanation: Follow-up was more frequent than usual care, with interviews every 6 weeks for 6 months. This was to assess outcomes but makes follow-up more intensive.

Score: [2]

Primary outcome
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎At 12 weeks, caregiver burden was 4.47 points lower (95% confidence interval [CI]: 1.05e7.89) in the fast track compared to the control group.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There was a trend toward a reduction in pain in the fast-track group and an increase in the control group (with an effect size of 0.6 and a total sample size required to detect this is 56).&quot;</span>

Explanation: The primary outcomes of caregiver burden and pain are patient-centered and relevant for palliative care. They could be assessed in usual care.

Score: [4]

Primary analysis
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We planned an intention-to-treat analysis, irrespective of whether patients were assessed as having palliative care needs or the nature of contact with the PCT.&quot;</span>

Explanation: An intention-to-treat analysis was used including all randomized patients. This pragmatic approach includes all data in the analysis.

Score: [5]</pre>
<p><a name='679'></a></p>
</div>
<div
id="jongen-p.-j.-2019-effect-of-an-intensive-3-day-social-cognitive-treatment-can-do-treatment-on-control-self-efficacy-in-patients-with-relapsing-remitting-multiple-sclerosis-and-low-disability-a-single-centre-randomized-controlled-trial"
class="section level4">
<h4>679.
<a href='https://doi.org/10.1371/journal.pone.0223482' title='Open publication'>Jongen
P. J. (2019): <i>Effect of an intensive 3-day social cognitive treatment
(can do treatment) on control self-efficacy in patients with relapsing
remitting multiple sclerosis and low disability: A single-centre
randomized controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 99.7%)</i></p>
<pre>
Here are the PRECIS-2 assessments for the trial described in "679.pdf":

Eligibility criteria

1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eligibility criteria for patients: diagnosis RRMS since at least one year, EDSS score ≤4.0, no symptoms suggestive of a relapse, no relapse in the preceding four weeks, willing and capable of participating in the investigations, and having access to the internet for performing the web-based assessments.&quot;</span>

2. The eligibility criteria are fairly broad, including RRMS patients with EDSS scores up to 4.0. The main exclusions are active relapse in the past 4 weeks and inability to complete online assessments. Overall, the criteria seem reasonably similar to patients who would receive this intervention in usual care.

Score: [4]

Recruitment

1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited from all over the Netherlands by the patient organisation NMSF, Rotterdam, the Netherlands. Interested patients were contacted by a registered nurse experienced in MS (MH) by phone to check diagnosis and eligibility criteria.&quot;</span> 

2. Patients were recruited nationwide by a patient organization, contacting them by phone to confirm eligibility. This seems like a reasonably pragmatic approach that could be feasible in routine practice.

Score: [4] 

Setting

1. <span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):

CDT was given during three consecutive days in Zorghotel Spelderholt, Beekbergen, the Netherlands, a facility especially equipped for the accommodation of people with impaired health.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎CDTs were given during three consecutive days in Zorghotel Spelderholt, Beekbergen, the Netherlands, a facility especially equipped for the accommodation of people with impaired health.&quot;</span>

2. The intervention was delivered at a specialized facility for people with impaired health. This is more explanatory than a typical outpatient setting.

Score: [2]

Organization

1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The multidisciplinary team included a psychiatrist, psychiatric nurse, neurologist, registered nurse specialized in MS, physiotherapist, dance therapist, and a person with MS.&quot;</span>

2. The intervention required a specialized multidisciplinary team including medical specialists, nurses, therapists and a patient expert. This level of resources and expertise exceeds what would be available in usual care.

Score: [2]

Flexibility (delivery)

1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Components are large group sessions, small group sessions, consultations (carrousel), a theatre evening, and start of the day with a joint activity (optional)&quot;</span> 

2. The delivery protocol seems reasonably fixed, with pre-defined components delivered in a structured program. This reduces flexibility compared to usual care.

Score: [3]

Flexibility (adherence)

1. No mention of specific measures to enforce adherence.

2. Adherence does not seem to be directly enforced or monitored. This matches usual care.

Score: [5] 

Follow-up

1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Assessments were at baseline and at one, three and six months follow-up via online questionnaires&quot;</span>

2. Follow-up is limited to online questionnaires at 1, 3 and 6 months. This does not exceed typical follow-up frequency.

Score: [4]

Primary outcome

1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary endpoint was control self-efficacy (Multiple Sclerosis Self-Efficacy Scale Control [MSSES-C]) at six months.&quot;</span>

2. The primary outcome is a patient-centered measure of confidence in managing symptoms and illness demands. This is pragmatic.

Score: [5]

Primary analysis

1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Intention-to-treat ANCOVA analyses were performed with follow-up values as dependent, and condition, baseline values, disease duration and gender as independent variables.&quot;</span>

2. An intention-to-treat analysis was used including all participants as randomized. This is very pragmatic.

Score: [5]</pre>
<p><a name='680'></a></p>
</div>
<div
id="kiropoulos-l.-a.-2016-a-pilot-randomized-controlled-trial-of-a-tailored-cognitive-behavioural-therapy-based-intervention-for-depressive-symptoms-in-those-newly-diagnosed-with-multiple-sclerosis"
class="section level4">
<h4>680.
<a href='https://doi.org/10.1186/s12888-016-1152-7' title='Open publication'>Kiropoulos
L. A. (2016): <i>A pilot randomized controlled trial of a tailored
cognitive behavioural therapy based intervention for depressive symptoms
in those newly diagnosed with multiple sclerosis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 99.4%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 99.6%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in "680.pdf":

Eligibility criteria

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria: 1) having a definite diagnosis of MS from a neurologist; 2) being within 5 years of receiving a diagnosis of MS; 3) scoring at least 10 on the Beck Depression Inventory-II (BDI-II)&quot;</span> 
- <span title='Minor quote deviation. Best match in prompt (Similarity 99.6%):

Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Exclusion criteria: Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.&quot;</span>

The inclusion criteria are quite broad, including anyone with a definite MS diagnosis and depressive symptoms. The exclusions seem to be mainly for safety reasons. Overall, the eligibility seems reasonably similar to patients who would receive this intervention in usual care.

Score: [3]

Recruitment

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited through neurologists working in a large MS outpatient clinic at the hospital, advertisements on MS related websites and local press releases.&quot;</span>

Recruitment was done through a specialty MS clinic but also more broadly through websites and press releases. This seems like a mix of clinical and more active recruitment methods.

Score: [3] 

Setting

Quote:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study took place at a large teaching and research hospital in Melbourne, Australia. Participants were recruited through neurologists working in a large MS outpatient clinic at the hospital&quot;</span>

The setting is a specialty MS clinic at a single hospital. This seems reasonably similar but still more limited than some usual care settings.

Score: [3]

Organization

Quote:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A senior clinical psychologist and a provisional clinical psychologist (supervised by the clinical psychologist) provided the intervention.&quot;</span>

No details are provided about additional resources or training to deliver the intervention. It seems to rely on available staff.

Score: [4] 

Flexibility: delivery

Quote: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The CBT intervention consisted of 8 individual modules which focused on CBT based principles and strategies.&quot;</span>

The intervention is described as consisting of CBT modules and strategies, but no details are provided on how rigidly it was protocolized. It seems reasonably flexible.

Score: [4]

Flexibility: adherence 

No relevant quotes. The text does not mention any specific efforts to enforce adherence.

Score: [4] 

Follow-up

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All participants completed questionnaires at pre- and post-treatment and at 20 weeks follow up.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Follow up assessments ended April, 2015.&quot;</span> 

Follow-up is limited to questionnaires at post-treatment and 20 weeks, which does not seem overly intensive.

Score: [4]

Primary outcome

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was level of depressive symptoms at post and 3 month follow up which was measured with the Beck Depression Inventory-II (BDI-II)&quot;</span>

The primary outcome of depressive symptoms measured by BDI-II is clinically meaningful.

Score: [5] 

Primary analysis

Quote: 
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.8%):

ariables. To examine group differences at post and 20 week follow up assessment, individual analyses of covariance (ANCOVAs) were performed with baseline treatment outcome scores used as the' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎To examine group differences at post and 20 week follow up assessment, individual analyses of covariance (ANCOVAs) were performed with baseline treatment outcome scores used as the covariate.&quot;</span>

Using ANCOVA with baseline scores as a covariate seems like a reasonable analysis approach, but no details are provided to assess handling of missing data.

Score: [NA]</pre>
<p><a name='681'></a></p>
</div>
<div
id="learmonth-y.-c.-2012-the-effects-of-a-12-week-leisure-centre-based-group-exercise-intervention-for-people-moderately-affected-with-multiple-sclerosis-a-randomized-controlled-pilot-study"
class="section level4">
<h4>681.
<a href='https://doi.org/10.1177/0269215511423946' title='Open publication'>Learmonth
Y. C. (2012): <i>The effects of a 12-week leisure centre-based, group
exercise intervention for people moderately affected with multiple
sclerosis: a randomized controlled pilot study</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">13 quote(s) from
publication full text</span> (mean similarity 97.2%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial described in "681.pdf":

Eligibility criteria 
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants had a confirmed diagnosis of multiple sclerosis, an Extended Disability Status Scale score of 5 (ambulatory without aid or rest for about 200 m) to 6.5 (constant bilateral assistance required to walk about 20 m without resting), stable rehabilitation and drug therapy for 30 days before entry into the study, cognitive scores of over 24 on the Mini-Mental State Examination and access to the intervention sites using their own or public transport.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Potential participants were excluded if they had experienced exacerbation of their multiple sclerosis symptoms three months prior to the study, or had any medical condition which may preclude them from taking part in the exercise intervention.&quot;</span>

The eligibility criteria are reasonably inclusive, allowing a range of disability levels and only excluding those with very recent exacerbations or other medical conditions that would prevent exercise. The confirmed MS diagnosis and cognitive screening are pragmatic given the nature of the intervention. Overall, the criteria seem intended to get a representative sample of the target population.

Score: [4] 

Recruitment
Quotes: 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.7%):

were sent invitation letters and participant information sheets.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Potential participants (n 1⁄4 159) were sent invitation letters and participant information sheets.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Thus 36 people were invited for screening.&quot;</span>

Recruitment was done by contacting potential participants from a clinical register and inviting them to participate. There was no mention of advertising or other special efforts beyond invitation letters. This seems like a reasonably pragmatic approach.

Score: [4]

Setting
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The intervention took place at two different geographical locations (Site A and Site B).&quot;</span>

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

From those living near Site A a list of potential participants (n ¼ 16) was created and, to maximise class occupancy, 10 potential participants were allocated to Site A’s intervention group. A computer program (Microsoft Excel 2003) was set up to randomly assign the 10 people to the exercise group and 6 to the control group. A similar system was used for Site B (which had a class capacity of 12), for which a list of potential participants (n ¼ 20) was created.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From those living near Site A a list of potential participants (n 1⁄4 16) was created and, to maximise class occupancy, 10 potential participants were allocated to Site A’s intervention group. A similar system was used for Site B (which had a class capacity of 12), for which a list of potential participants (n 1⁄4 20) was created.&quot;</span>

The classes took place in two community leisure centers, which seems like a very pragmatic setting for an exercise intervention intended for community implementation.

Score: [5] 

Organization
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each group was led by two instructors (one physiotherapist and one fitness instructor).&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The same physiotherapist was present at both sites; however fitness instructors were different between sites.&quot;</span>

The classes were led by a physiotherapist and fitness instructor, which seems like a reasonably pragmatic level of expertise for delivering an exercise intervention in the community. There is no mention of additional resources or training beyond what would be typical.

Score: [4]

Flexibility: delivery
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Through discussion with the instructors, participants chose which level of each exercise they deemed appropriate and also when and how each exercise should be progressed.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants worked at a self-regulated pace for each exercise.&quot;</span>

The delivery of the exercises seems very flexible, with participants able to choose intensity levels and progression. This was self-paced and individualized.

Score: [5] 

Flexibility: adherence 
Quotes:
No relevant quotes found.

The paper does not mention any specific strategies to enforce or monitor adherence. Attendance was tracked but there is no indication that participants were excluded or penalized for non-adherence. 

Score: [4]

Follow-up
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcome measures were carried out within the local hospital’s rehabilitation unit. They were taken at baseline, after 8 and 12 weeks of the intervention period (i.e. either the exercise class or usual care).&quot;</span>

Follow-up assessments were done at baseline, 8 weeks, and 12 weeks. The assessments required scheduled visits but were not overly frequent.

Score: [4]

Primary outcome
Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

The Timed 25Foot Walk Test measures walking speed over a short distance and has shown good reliability and validity in the multiple sclerosis population as an individual component of the Multiple Sclerosis Functional Composite disability assessment.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Timed 25-Foot Walk Test measures walking speed over a short distance and has shown good reliability and validity in the multiple sclerosis population as an individual component of the Multiple Sclerosis Functional Composite disability assessment.&quot;</span>

The primary outcome was walking speed, which is a meaningful functional measure for MS patients. It does not seem to require special expertise or adjudication.

Score: [4]

Primary analysis
Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All outcome measures were analysed on the basis of intention to treat, with all variables summarized and comparisons made between groups and over time.&quot;</span>

The analysis was based on intention-to-treat, which is a pragmatic approach.

Score: [5]</pre>
<p><a name='682'></a></p>
</div>
<div
id="mayo-n.-e.-2020-participation-in-and-outcomes-from-a-12-month-tailored-exercise-programme-for-people-with-multiple-sclerosis-mstep-a-randomized-trial"
class="section level4">
<h4>682.
<a href='https://doi.org/10.1177/0269215520923089' title='Open publication'>Mayo
N. E. (2020): <i>Participation in and outcomes from a 12-month tailored
exercise programme for people with multiple sclerosis (MSTEP�): a
randomized trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
2
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 96.9%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial based on the full text publication:

Eligibility criteria

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

inclusion criteria were (1) ambulatory (can walk 100 m, be capable of walking 100 metres without a walking aid corresponding to a classification of ⩽5.5 on the Expanded Disability Status Scale (EDSS), 10 even if they do use an aid for daily activities; and (2) self-reported to be sedentary or irregularly active at time of study entry (i.e. do not exercise 30 minutes or more twice per week of moderate to vigorous activity).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria were (1) ambulatory (can walk 100 m, be capable of walking 100 metres without a walking aid corresponding to a classification of ≤5.5 on the Expanded Disability Status Scale (EDSS),10 even if they do use an aid for daily activities); and (2) self-reported to be sedentary or irregularly active at time of study entry (i.e. do not exercise 30 minutes or more twice per week of moderate to vigorous activity).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Excluded were people who were (1) unable to speak and read English or French; (2) unable to respond to simple questions on orientation and memory; (3) have an additional illness that restricts their function; and/or (4) experienced a relapse during the past 30 days as this may affect physical activity/exercise participation.&quot;</span>

Reasoning: The inclusion criteria targeted ambulatory individuals with relapsing-remitting MS who were sedentary. The exclusion criteria were minimal and would not exclude individuals who would normally receive the intervention in usual care. Overall, the eligibility criteria were broadly inclusive to match usual care.

Score: [4] 

Recruitment

Relevant quotes:  

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎People were recruited from four multiple sclerosis clinics in three Canadian cities and from posting on media sites.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎During the clinic visit, the treating neurologist introduced the study to their patients and referred them to the research assistant who further explained the study and assessed eligibility. Those contacting the research team directly were assessed for eligibility over the phone and sent information on the study electronically.&quot;</span>

Reasoning: Participants were recruited through usual clinic visits and referrals from treating neurologists. Additional recruitment was done through media advertising to supplement clinic recruitment. Overall, recruitment included routine clinical encounters but required some extra effort beyond typical care.

Score: [3]

Setting

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The trial received ethical approval from the Montreal Neurological Hospital Research Ethics Board (NEU-12-005) and the Health Research Ethics Board, University of Manitoba (H2014:226)&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎People were recruited from four multiple sclerosis clinics in three Canadian cities and from posting on media sites.&quot;</span>

Reasoning: The trial was conducted across multiple hospitals and clinics in Canada. This matches the typical real-world settings where people with MS receive care.

Score: [5]

Organization

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants in both groups received two private training sessions with the physical therapist or exercise therapist. For the MSTEP© group, the sessions were used to assess individual needs and design an individualized programme. For the Guideline group, the sessions were used to instruct on the guidelines and learn how to apply principles of safe and effective exercise. All were provided with a portfolio of exercise instructions.&quot;</span>

Reasoning: Both groups received some additional training and resources beyond what would be typical in usual care. However, the training was limited to 2 sessions and focused on instructing participants on the exercise regimen. No major changes were made to expertise of providers or care delivery resources. 

Score: [4] 

Flexibility: delivery

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All had their exercise regimens reviewed during the intervention year at the evaluations which were scheduled at 3, 6, and 12 months.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The MSTEP© programme is to promote regular bouts of activity most days per week, encouraging a balance between rest and activity, and taking into consideration the physical and emotional status and capacity of the person.&quot;</span> 

Reasoning: The MSTEP program was individualized and flexible based on the needs and capacities of each participant. Participants met with providers periodically to review their programs, but there was no strict protocol dictating exercise schedule or delivery. Flexibility appears very similar to usual care.

Score: [5]

Flexibility: adherence 

Relevant quotes:

No relevant quotes.

Reasoning: There is no mention of specific measures to enforce or monitor adherence. The paper notes the high dropout rate, suggesting adherence was not enforced. This matches the flexibility expected in usual care.

Score: [5] 

Follow-up

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All had their exercise regimens reviewed during the intervention year at the evaluations which were scheduled at 3, 6, and 12 months.&quot;</span>

Reasoning: Follow-up visits occurred at 3, 6 and 12 months to review the exercise regimens. This frequency of follow-up is more than would occur in usual care.

Score: [3]

Primary outcome

Relevant quotes:  

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was exercise capacity as measured by peak oxygen consumption (VO2peak) using a modified Bruce protocol on the cycle ergometer.&quot;</span>

Reasoning: VO2peak is a direct measure of exercise capacity and is clinically relevant to participants with MS who experience fatigue and deconditioning. This matches the importance of outcomes in usual care.

Score: [5]

Primary analysis

Relevant quotes:

<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.8%):

The intention was to follow participants for the first year of the intervention when the exercise programme was designed and adjusted as needed exercise-induced fatigue predicted retention. There were no' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The intention was to follow participants for the first year of the intervention when the exercise programme was designed and adjusted as needed and have a further follow-up after the second year. As there were substantial losses to follow-up, only results after one year are presented.&quot;</span>

Reasoning: The study used an intention-to-treat analysis for all randomized participants. This matches the analysis approach expected in usual care.

Score: [5]</pre>
<p><a name='684'></a></p>
</div>
<div
id="miller-l.-2011-evaluation-of-a-home-based-physiotherapy-programme-for-those-with-moderate-to-severe-multiple-sclerosis-a-randomized-controlled-pilot-study"
class="section level4">
<h4>684.
<a href='https://doi.org/10.1177/0269215511398376' title='Open publication'>Miller
L. (2011): <i>Evaluation of a home-based physiotherapy programme for
those with moderate to severe multiple sclerosis: a randomized
controlled pilot study</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 99.8%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial described in the attached paper "684.pdf":

Eligibility criteria:

Relevant quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Subjects had a definite diagnosis of primary or secondary progressive MS, and an EDSS of between 6.5 (constant bilateral assistance required to walk about 20 metres without resting) to 8 (essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed much of the day, retains many selfcare functions and generally has effective use of' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Subjects had a definite diagnosis of primary or secondary progressive MS, and an EDSS of between 6.5 (constant bilateral assistance required to walk about 20 metres without resting) to 8 (essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed much of the day, retains many self-care functions and generally has effective use of arms).&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎People with MS who were medically stable were selected where cognitive function was adequate, as assessed by a Mini Mental State Examination score of 23 or over and had at least three identifiable physiotherapy goals were included.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Potential subjects were excluded if they had rapidly progressing disease, were already involved in a physiotherapy programme, had additional neurological conditions or other medical conditions which would preclude them taking part in the study.&quot;</span>

The eligibility criteria target patients with moderate to severe MS who would be candidates for physiotherapy in usual care. The exclusion criteria remove patients with rapidly progressing disease who would not be suitable. The additional requirement of at least 3 physiotherapy goals ensures selected patients will benefit from the intervention. Overall, the criteria seem very similar to usual care.

Score: [4]

Recruitment:

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎People moderately to severely affected by MS were recruited from the MS Service, NHS Ayrshire and Arran.&quot;</span>

Patients were recruited from an MS service, which is likely the normal source for this population in usual care. No additional recruitment methods were mentioned.

Score: [4] 

Setting:

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Subjects assigned to Group 1 received physiotherapy, twice weekly for eight weeks, by an experienced domiciliary physiotherapist within their home.&quot;</span>

The setting was patients' own homes, which matches usual care for moderate to severe MS patients.

Score: [5]

Organization:

Relevant quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each session lasted up to 60 minutes, and a task-specific programme included upper and lower limb strengthening using theraband, mobile pedals, and weights. Repetition of tasks such as sit to stand, gait, balance (using gym balls and sit fits) and stretching activities were used depending on the subjects previously identified goals.&quot;</span>

The intervention was delivered by physiotherapists using resources that would be standard in usual care. No additional training or expertise was mentioned.

Score: [5] 

Flexibility (delivery):

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each subject therefore received core treatments aimed to maximize strength, flexibility and function.&quot;</span>

A tailored program was designed for each patient based on goals. This matches the flexibility expected in usual physiotherapy care.

Score: [5]

Flexibility (adherence): 

No discussion of measures to enforce adherence.

Score: [5] 

Follow-up:

Relevant quotes:  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Subjects in both groups were assessed at the beginning and at the end of the eight-week intervention period (i.e. either physiotherapy or control) and then again eight weeks later.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To improve the reliability of the data, all assessments were undertaken at the Douglas Grant Rehabilitation Centre, Irvine, and the assessor remained blind to the subjects’ treatment group allocation.&quot;</span>

Follow-up matches the intervention period with an additional assessment 8 weeks later. Assessments were done at a center rather than home. Frequency is reasonable but location differs from purely usual care.

Score: [4] 

Primary outcome:

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The MS impact scale (MSIS 29), which is a measure of the physical and psychological impact of MS, was the primary outcome measure for the study.&quot;</span> 

The MSIS measures outcomes directly relevant to patients.

Score: [5]

Primary analysis:

Relevant quote: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Where there were problems with missing data due to dropouts/non-completion, the simple repeated measures ANOVA was replaced with a general linear model where missing data are estimated within the model.&quot;</span>

An intention-to-treat approach was used with statistical methods to account for missing data.

Score: [5]</pre>
<p><a name='685'></a></p>
</div>
<div
id="ohara-l.-2002-evaluation-of-the-effectiveness-of-professionally-guided-self-care-for-people-with-multiple-sclerosis-living-in-the-community-a-randomized-controlled-trial"
class="section level4">
<h4>685.
<a href='https://doi.org/10.1191/0269215502cr478oa' title='Open publication'>O’Hara
L. (2002): <i>Evaluation of the effectiveness of professionally guided
self-care for people with multiple sclerosis living in the community: a
randomized controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">13 quote(s) from
publication full text</span> (mean similarity 98.4%)</i></p>
<pre>
Here are the PRECIS-2 domain scores and justifications for the trial described in "685.pdf":

Eligibility criteria

Quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

The only selection criterion was that the diagnosis of MS was con rmed by the general practitioner.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The only selection criterion was that the diagnosis of MS was confirmed by the general practitioner.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There were no exclusion criteria.&quot;</span>

Reasoning: The trial had very broad eligibility criteria, including anyone with a confirmed diagnosis of MS. There were no exclusions based on age, comorbidities, disease severity, ability to adhere to treatment, or any other factors. This reflects a very pragmatic approach, allowing the results to be widely generalizable.

Score: [5] 

Recruitment 
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were volunteers with MS who were recruited through voluntary organizations, were community based and lived in West London and in counties contiguous with Greater London.&quot;</span>

Reasoning: Participants were recruited through MS voluntary organizations rather than clinic visits or medical records. This requires some extra effort compared to recruiting during routine care. However, it seems reasonably feasible that this recruitment approach could occur in usual care.

Score: [4]

Setting
Quote: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎It was a community-based research study, which was approved by the appropriate local research ethics committees, and was conducted at the Centre for Research in Rehabilitation at Brunel University’s Osterley Campus in West London from June 1996 until February 1999.&quot;</span>

Reasoning: The setting was a university research center rather than a community clinic or other real-world care setting. This reduces the pragmatism of the trial.

Score: [2] 

Organization
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The intervention comprised discussion of self-care based on client priorities, using an information booklet about self-care.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Sessions were conducted either at participants’ homes or in local therapy centres.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The discussions lasted between 1 and 2 hours and were conducted on two occasions, over a one month period.&quot;</span>

Reasoning: The intervention required trained staff to deliver it, which is more resources than usual care. However, it was reasonably brief and delivered in homes/community centers. Overall, it requires some additional resources compared to usual care.

Score: [3]

Flexibility: Delivery
Quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

As  ndings from the Delphi study highlighted the need for  exibility and responsiveness to individuals the format of the discussion focused on individuals’ interests and concerns rather than on covering all the information contained in the booklet.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎As findings from the Delphi study highlighted the need for flexibility and responsiveness to individuals the format of the discussion focused on individuals’ interests and concerns rather than on covering all the information contained in the booklet.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Individuals were assigned to group or one to one sessions by the health professional in consultation with each person, and based on their needs and wishes.&quot;</span>

Reasoning: The delivery allowed flexibility in format based on individual needs and interests. There was no strict protocol. This matches usual care.

Score: [5] 

Flexibility: Adherence
Quotes: None relevant

Reasoning: Adherence does not seem applicable for this informational intervention. There is no medication or regimen for patients to adhere to.

Score: [NA]

Follow-up
Quotes:  
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 85.7%):

assessments were conducted six months after baseline.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Follow-up assessments were conducted six months after baseline.&quot;</span>
- <span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

The blind code was broken after the  nal follow-up assessments had occurred.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The blind code was broken after the final follow-up assessments had occurred.&quot;</span>

Reasoning: Participants were followed up at 6 months, with no other contacts in between. This matches reasonably well with follow-up in usual long-term MS care.

Score: [4]

Primary outcome
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Total scores on a postal version of the Barthel Index, a scale measuring mobility, the SF-36, and one measure developed for the study; the Standard Day Dependency Record (SDDR), were the main outcome measures.&quot;</span>

Reasoning: The outcomes measured mobility, quality of life, and independence in daily activities. These are highly patient-centered and relevant for MS.

Score: [5]

Primary analysis
Quote:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Missing values on scales were replaced with group means for each outcome measure. It was not possible to perform an ‘intention to treat’ analysis as those individuals who declined the intervention also withdrew from follow-up and therefore did not complete any follow-up assessments.&quot;</span>

Reasoning: An intention-to-treat analysis was not done since some patients withdrew after declining intervention. However, missing data was accounted for reasonably. This seems moderately pragmatic. 

Score: [3]</pre>
<p><a name='686'></a></p>
</div>
<div
id="papeix-c.-2015-evaluation-of-an-integrated-multidisciplinary-approach-in-multiple-sclerosis-care-a-prospective-randomized-controlled-study"
class="section level4">
<h4>686.
<a href='https://doi.org/10.1177/2055217315608864' title='Open publication'>Papeix
C. (2015): <i>Evaluation of an integrated multidisciplinary approach in
multiple sclerosis care: A prospective, randomized, controlled
study</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 99%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial described in the attached full text "686.pdf":

Eligibility criteria

Relevant quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

2012. Inclusion criteria were: having MS (MacDonald criteria); being able to complete a questionnaire; and being in need for a multidisciplinary approach, defined by the requirement, in addition to the neurology specialist, of at least two different medical (rehabilitation specialist, neurourology specialist, psychiatrist) or allied health professionals (physiotherapist, occupational therapist, social worker, psychologist, and neuropsycholo' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria were: having MS (MacDonald criteria); being able to complete a questionnaire; and being in need for a multi-disciplinary approach, defined by the requirement, in addition to the neurology specialist, of at least two different medical (rehabilitation specialist, neuro-urology specialist, psychiatrist) or allied health professionals (physiotherapist, occupational therapist, social worker, psychologist, and neuropsychologist).&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients who were not living independently in the community were excluded.&quot;</span>

The inclusion criteria are quite broad, including any MS patients in need of multidisciplinary care. The only exclusion criterion is for patients not living independently in the community. This is pragmatic as it matches usual care where interventions would likely not be provided for institutionalized patients.

Score: [4]

Recruitment

Relevant quotes: 
- No details provided on how patients were recruited.

There are no details provided on how patients were recruited into the trial. 

Score: [NA] 

Setting

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This is a prospective, randomized, controlled, monocentric clinical trial in MS patients.&quot;</span>
- <span title='Minor quote deviation. Best match in fulltext (Similarity 96%):

ents MS patients from the outpatient clinic of the Neurology Department of Pitie´-Salpeˆtrie`re Hospital were prospectively enrolled in the study between March 2010 and July' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MS patients from the outpatient clinic of the Neurology Department of Pitie ́-Salpeˆtrie`re Hospital were prospectively enrolled in the study between March 2010 and July 2012.&quot;</span>

The trial was conducted at a single hospital center. This reduces generalizability of the results to other settings.

Score: [2]

Organisation

Relevant quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):

re 1). For patients in the IMD group, the multidisciplinary integrated outpatient clinic was planned at our MS clinic within a maximum three-month period after inclusion. These patients received a half-day (four to six hours) individually tailored assessment by the multidisciplinary' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For patients in the IMD group, the multidisciplinary integrated outpatient clinic was planned at our MS clinic within a max-imum three-month period after inclusion. These patients received a half-day (four to six hours) indi-vidually tailored assessment by the multidisciplinary group.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In the control group, interventions with the different health professionals were planned after the inclusion visit, with an explanatory letter given to the patient or directly sent to the professionals.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In most cases the same health professionals were in charge of the two groups.&quot;</span>

The organization of care delivery appears similar between the two arms - the same health professionals took care of patients in both groups. The only difference is the integrated format for the intervention arm.

Score: [4] 

Flexibility: delivery

Relevant quotes: 
- No details provided on flexibility in delivering the intervention.

There are no details provided on flexibility in how the intervention was delivered.

Score: [NA]

Flexibility: adherence

Relevant quotes:
- No details provided on measures for adherence.

There are no details provided on measures to ensure adherence to the intervention. 

Score: [NA]

Follow-up

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary and secondary outcomes were assessed at inclusion, and after six (M6) and 12 (M12) months.&quot;</span>

Patients were followed up at 6 and 12 months to assess outcomes. This does not seem much different from usual follow-up care.

Score: [4]

Primary outcome

Relevant quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was the impact of the strategy on quality of life (QoL) measured using the MSIS-29 scale at inclusion and after six months.&quot;</span>

The primary outcome is quality of life measured by MSIS-29 scale. This is a patient-centered outcome that is clinically meaningful.

Score: [5]

Primary analysis

Relevant quotes:
- No details provided on primary analysis.

There are no details provided on the primary analysis.

Score: [NA]</pre>
<p><a name='687'></a></p>
</div>
<div
id="paul-l.-2014-web-based-physiotherapy-for-people-moderately-affected-with-multiple-sclerosis-quantitative-and-qualitative-data-from-a-randomized-controlled-pilot-study"
class="section level4">
<h4>687.
<a href='https://doi.org/10.1177/0269215514527995' title='Open publication'>Paul
L. (2014): <i>Web-based physiotherapy for people moderately affected
with Multiple Sclerosis; quantitative and qualitative data from a
randomized, controlled pilot study</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 scores for the clinical trial described in the attached paper "687.pdf":

Eligibility criteria 

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To be included in the study participants were required to have a confirmed diagnosis of MS, an Expanded Disability Status Score of between 5 and 6.5, stable drug therapy for 30 days, no relapses in the previous three months, no significant co-morbidities such as coexisting cardiac or pulmonary condition and have access to the internet via personal or tablet computer.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Letters were sent to 138 patients from the Multiple Sclerosis Service database, thought to be suitable for the study, inviting them to participate. Of those 37 people expressed an interest in taking part. Seven people were excluded as they did not meet the inclusion and exclusion criteria (Figure 1).&quot;</span>

The eligibility criteria are moderately pragmatic. The inclusion criteria target a specific population of MS patients with moderate disability based on the EDSS score. The exclusion criteria rule out patients with co-morbidities, recent relapses, and medication changes, which improves internal validity but reduces generalizability. However, the criteria overall are not highly restrictive and the participant population likely resembles the target population in usual care settings.

Score: [3]

Recruitment

Relevant quotes: 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Letters were sent to 138 patients from the Multiple Sclerosis Service database, thought to be suitable for the study, inviting them to participate.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Of those 37 people expressed an interest in taking part.&quot;</span>

The recruitment method involved screening a disease-specific database and mailing invitation letters, which requires some extra effort beyond usual care. However, patients were not recruited through advertising or other non-standard routes. Overall, the recruitment is moderately pragmatic.

Score: [3] 

Setting

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited from the Multiple Sclerosis Service, at the Douglas Grant Rehabilitation Centre, Irvine, Scotland.&quot;</span>

The setting is a single specialized rehabilitation center, which may not reflect the full range of usual care settings. This reduces the generalizability of the results.

Score: [2] 

Organization

Relevant quotes:

No relevant quotes found. The paper does not mention additional staffing, training, resources, or other changes to care delivery for the intervention.

The organization appears similar to usual care, but details are not provided.

Score: [NA]

Flexibility (delivery)

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Individualised therapeutic exercise programmes were developed for participants in Group 1, with exercises selected based on their baseline assessment and personal goals.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were advised to undertake the exercise programme a minimum of twice a week and to complete their online exercise diary which was seen remotely by the physiotherapist.&quot;</span>

The delivery allows for individualized programs tailored to each participant's goals and baseline assessment. Participants had flexibility in how often they performed the exercises. The physiotherapist monitored progress through the online diaries but there is no mention of strict protocols or measures to improve compliance. The flexibility seems moderately pragmatic.

Score: [3]

Flexibility (adherence) 

Relevant quotes: 

No relevant quotes found. The paper does not mention any measures to enforce or monitor adherence.

There appears to be full flexibility for participants to adhere as they want, which is very pragmatic. However, details are limited.

Score: [NA] 

Follow-up

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcome measures were recorded at baseline and at the end of the intervention period (week 13).&quot;</span>

The follow-up consists only of outcome assessments at baseline and study end, with no additional contacts or data collection. This is very pragmatic.

Score: [5]

Primary outcome

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome measure, the timed 25 foot walk, has good reliability and validity in the MS population. The time taken to walk 25ft was recorded with a stop watch and a mean of two ‘walks’ recorded.&quot;</span>

The primary outcome is gait speed measured by the 25 foot walk test. This is a clinically meaningful outcome that directly evaluates walking ability, which is relevant to MS patients. The assessment does not require specialized expertise. Overall, this is a pragmatic choice of primary outcome.

Score: [4] 

Primary analysis

Relevant quotes:

No relevant quotes found. The paper does not provide details on the primary analysis method.

There is insufficient information to assess the primary analysis.

Score: [NA]

In summary, this pilot RCT of web-based physiotherapy for MS patients has moderately pragmatic design choices for eligibility criteria, recruitment, setting, delivery flexibility, and primary outcome. Follow-up is very pragmatic with outcome assessments only at baseline and study end. Details are lacking for organization, adherence flexibility, and primary analysis. Based on the available information, the trial overall seems to have a moderately pragmatic approach.</pre>
<p><a name='688'></a></p>
</div>
<div
id="pozzilli-c.-2002-home-based-management-in-multiple-sclerosis-results-of-a-randomised-controlled-trial"
class="section level4">
<h4>688.
<a href='https://doi.org/10.1136/jnnp.73.3.250' title='Open publication'>Pozzilli
C. (2002): <i>Home based management in multiple sclerosis: results of a
randomised controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 99%)</i></p>
<pre>
Here are the PRECIS-2 scores for the clinical trial described in the attached paper "688.pdf":

Eligibility criteria

Quotes: 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.5%):

To be eligible, all patients screened for study participation had to be affected by clinically definite multiple sclerosis 17 and live in the' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎To be eligible, all patients screened for study participation had to be affected by clinically definite multiple sclerosis and live in the Rome service area.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eligible patients were assessed for suitability by the coordinator of the home based care team (LP).&quot;</span> 

Reasoning: The eligibility criteria require patients to have clinically definite multiple sclerosis, which is reasonable for this trial. Patients also had to live in the Rome service area, which may limit generalizability somewhat but is likely similar to eligibility criteria in usual care. The coordinator further assessed patients for suitability, which introduces some selectivity beyond typical eligibility. Overall, the criteria seem moderately pragmatic.

Score: [3] 

Recruitment

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were recruited from the multiple sclerosis centre of the neurological department of La Sapienza University, or from other institutional centres for multiple sclerosis in Rome.&quot;</span>

Reasoning: Patients were recruited through multiple sclerosis clinics, which is a pragmatic approach similar to how patients would present for treatment in usual care. No additional recruitment efforts beyond standard clinic visits are mentioned.

Score: [5]

Setting

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study was conducted in Rome&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were recruited from the multiple sclerosis centre of the neurological department of La Sapienza University, or from other institutional centres for multiple sclerosis in Rome.&quot;</span>

Reasoning: The study was conducted at multiple sclerosis clinics in Rome. This matches the setting where patients would receive care in usual practice.

Score: [5]

Organisation

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The home based care multidisciplinary team included two neurologists, a urologist, a rehabilitation physician, a psychologist, a physical therapist, a nurse, a social worker, and a coordinator.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The multidisciplinary team collaborated with the patient, physician, and caregiver in designing individualised clinical care and in coordinating home services as appropriate for the individual patient.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The type of care was more than is normally available in the community through National Health Service care.&quot;</span>

Reasoning: The home-based intervention used a specialized, multidisciplinary team and provided individualized and coordinated care. This level of care delivery exceeds typical organization in usual practice.

Score: [2]

Flexibility: delivery

Quotes:
No relevant quotes found.

Reasoning: The paper does not provide details on the flexibility in how the home-based intervention was delivered. It appears reasonably flexible but this is unclear.

Score: [NA] 

Flexibility: adherence 

Quotes: 
No relevant quotes found.

Reasoning: The paper does not discuss any measures to enforce or monitor adherence. However, no details are provided on this domain.

Score: [NA]

Follow-up

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎At the end of a one year follow up period, all patients underwent the same comprehensive interview as at baseline.&quot;</span>

Reasoning: Patients were followed for 1 year, which exceeds typical follow-up in usual care. However, follow-up assessments were done only at baseline and 1 year, with no additional visits in between. This seems moderately pragmatic.

Score: [3]

Primary outcome

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Functional outcomes were calculated as the mean change of scores from baseline to the final follow up at 12 months.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We assessed quality of life by means of SF-36.&quot;</span>

Reasoning: The primary outcomes were functional status and quality of life. These outcomes are clinically meaningful for patients.

Score: [5]

Primary analysis

Quotes: 
No relevant quotes found.

Reasoning: The paper does not provide details on the primary analysis methods.

Score: [NA]</pre>
<p><a name='689'></a></p>
</div>
<div
id="renfrew-l.-m.-2019-the-clinical--and-cost-effectiveness-of-functional-electrical-stimulation-and-ankle-foot-orthoses-for-foot-drop-in-multiple-sclerosis-a-multicentre-randomized-trial"
class="section level4">
<h4>689.
<a href='https://doi.org/10.1177/0269215519842254' title='Open publication'>Renfrew
L. M. (2019): <i>The clinical- and cost-effectiveness of functional
electrical stimulation and ankle-foot orthoses for foot drop in Multiple
Sclerosis: a multicentre randomized trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">14 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in "689.pdf":

Eligibility criteria

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Potential participants known to Multiple Sclerosis healthcare practitioners working across seven outpatient centres in Scotland – Ayrshire & Arran, Greater Glasgow & Clyde, Dumfries and Galloway, Lanarkshire, Lothian, Fife and Tayside – were informed of the study and issued with a participant information sheet.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants required to have a clinical diagnosis of Multiple Sclerosis, persistent foot drop (lasting a minimum of three months) observed during a 5-minute walk test, stable disease (no change in the Extended Disability Status Score12 or relapse in previous three months), 5° of passive dorsiflexion and tolerance of functional electrical stimulation.&quot;</span>  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were excluded if they had previously used functional electrical stimulation or an ankle-foot orthosis for foot drop, moderate to severe cognitive impairment (scored < 26, Montreal Cognitive Assessment),13 foot drop due to other disorders, other conditions significantly affecting gait, contraindications to functional electrical stimulation, marked proximal weakness, plantar flexor spasticity, stance phase instability or severe lower limb/trunk ataxia affecting gait.&quot;</span>

The eligibility criteria are relatively broad, including adults with MS and persistent foot drop. The main exclusions are previous use of assistive devices for foot drop and conditions that would significantly impact the effects of the interventions. Overall, the criteria seem moderately pragmatic.

Score: [3]

Recruitment

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Potential participants known to Multiple Sclerosis healthcare practitioners working across seven outpatient centres in Scotland – Ayrshire & Arran, Greater Glasgow & Clyde, Dumfries and Galloway, Lanarkshire, Lothian, Fife and Tayside – were informed of the study and issued with a participant information sheet. Potential participants contacted the researchers if they were interested in participating.&quot;</span>

Recruitment was done through healthcare practitioners at MS clinics informing potential participants. Patients then had to contact the researchers directly if interested. This seems moderately pragmatic as patients were identified through usual care clinics, but some extra effort was required for them to contact the researchers.

Score: [3]  

Setting

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Potential participants known to Multiple Sclerosis healthcare practitioners working across seven outpatient centres in Scotland – Ayrshire & Arran, Greater Glasgow & Clyde, Dumfries and Galloway, Lanarkshire, Lothian, Fife and Tayside – were informed of the study and issued with a participant information sheet.&quot;</span>

The study was conducted across 7 MS outpatient clinics in Scotland. This multicenter design across usual care settings is pragmatic.

Score: [4]

Organization

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants randomized to the usual care group were fitted with a custom-made, solid, ankle-foot orthosis by an orthotist, within four weeks of their initial assessment.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants randomized to the functional electrical stimulation group were assessed and fitted with an Odstock Dropped Foot Stimulator Pace (OML, Salisbury) device by a physiotherapist experienced in functional electrical stimulation (A.L.).&quot;</span>

The AFOs were provided by orthotists and FES devices were fitted by physiotherapists, which reflects usual expertise. No mention of extra resources or training. Seems moderately pragmatic.

Score: [3] 

Flexibility: Delivery

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The angle of the tibia was inclined forward, approximately 10° to vertical, and each orthosis was ‘tuned’ by the addition or removal of small heel wedges.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Wired heel switches and a stimulation frequency of 40 Hz were applied. Electrode position, pulse width, waveform and ramping parameters were adjusted for each participant in order to achieve a comfortable and efficient muscle contraction. The current amplitude ranged from 7 to 72 mA (mean = 40 mA).&quot;</span>

The AFOs were customized and tuned for each participant. The FES devices were also customized by adjusting parameters to optimize response. There was flexibility in delivery for both interventions.

Score: [4]

Flexibility: Adherence 

No relevant quotes. There is no mention of measures to enforce adherence. Seems pragmatic but insufficient information.

Score: [NA] 

Follow-up

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcome measures were administered by two unblinded assessors (Rebecca Hunter and A.L.) at baseline (0), 3, 6 and 12 months&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Against a background of financial constraints, there is a need for evidence of the cost benefits of interventions. Our study indicates that although the upfront costs of functional electrical stimulation are greater than usual care (ankle-foot orthoses), it may be considered as a potentially cost-effective treatment option for foot drop and offers a value for money alternative in Multiple Sclerosis.&quot;</span>

Follow-up assessments were done at baseline, 3, 6, and 12 months. This frequency seems moderately pragmatic. Cost data was also collected which may be more intensive than usual care.

Score: [3]

Primary outcome

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary aim of our study was to compare the clinical- and cost-effectiveness of ankle-foot orthoses and functional electrical stimulation over 12 months in people with Multiple Sclerosis presenting with foot drop.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was walking speed as measured by the 5-minute self-selected walk test.&quot;</span>

The primary outcome of walking speed is highly relevant and meaningful to patients with MS and foot drop.

Score: [5] 

Primary analysis

Quote:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A Restricted Maximum Likelihood approach to fitting mixed models was employed to allow intention to treat assumptions to cope with missing data.&quot;</span>

An intention-to-treat approach was used which is pragmatic.

Score: [4]</pre>
<p><a name='690'></a></p>
</div>
<div
id="solari-a.-2018-randomized-controlled-trial-of-a-home-based-palliative-approach-for-people-with-severe-multiple-sclerosis"
class="section level4">
<h4>690.
<a href='https://doi.org/10.1177/1352458517704078' title='Open publication'>Solari
A. (2018): <i>Randomized controlled trial of a home-based palliative
approach for people with severe multiple sclerosis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the PRECIS-2 domain scores and justifications based on the provided full text:

Eligibility criteria

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were non-institutionalized adults (age ≥ 18 years) with severe MS and their primary carers.&quot;</span>

<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):

Other patient inclusion criteria were primary or secondary progressive MS, 1,13 Expanded Disability Status Scale (EDSS) score ⩾ 8.0, 14 complex symptoms, 15 and ⩾2 unmet care needs.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Other patient inclusion criteria were primary or secondary progressive MS, [1,13] Expanded Disability Status Scale (EDSS) score ≥ 8.0, [14] complex symptoms, [15] and ≥2 unmet care needs.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All patient-carer dyads gave written informed consent before study enrollment.&quot;</span>

Score: [4] Rather pragmatic

The eligibility criteria target the intended population for the intervention (severe MS patients and their caregivers) using criteria commonly used in MS research like EDSS score and type of MS. While restrictive, the criteria seem aligned with identifying patients who would need and receive this intervention in usual care. The inclusion of caregivers also matches usual care. The consent requirement is standard.

Recruitment

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Dyads were randomly assigned (2:1) to receive HPA or UC. Allocation to treatment groups was done using a third-party, web-based computerized randomization procedure with stratified minimization for EDSS score (8.0–8.5, 9.0–9.5), presence of severe cognitive compromise (clinical judgment), and center&quot;</span>

Score: [3] Equally pragmatic and explanatory 

The recruitment through minimization randomization is more explanatory, since it tries to balance groups on selected factors. However, recruitment is from patients already engaged with the participating clinical centers, which is more pragmatic. Overall, recruitment has explanatory and pragmatic elements.

Setting

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In this randomized, examiner-blind, controlled study, we recruited patients from three Italian centers.&quot;</span> 

Score: [3] Equally pragmatic and explanatory

Conducting the trial across 3 centers makes it more pragmatic and enhances generalizability. However, limiting to only 3 centers in Italy without further description makes it unclear how well the settings match real-world care settings. The setting has both pragmatic and explanatory elements.

Organization

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Based on the principles of PC, each center had a HPA team consisting of a physician (neurologist or physiatrist), a nurse (case manager and team leader), a psychologist, and a social worker.&quot;</span>

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

. The nurse (team leader) performed 152 visits (33%), followed by the psychologist (25%), the physician (25%), and the social worker (17%' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The nurse (team leader) performed 152 visits (33%), followed by the psychologist (25%), the physician (25%), and the social worker (17%).&quot;</span>

Score: [2] Rather explanatory 

The HPA team brings additional expertise and resources beyond usual care for MS patients. The involvement of multiple specialists for home visits is not reflective of typical care. The organization is skewed toward being more explanatory.

Flexibility: Delivery

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎After a comprehensive assessment of the dyad needs based on direct observation and on visit 1 information (available via the eCRF), the HPA team defined the contents of the intervention, involving the dyad and the patient caring physician (the intervention was not intended to replace existing services).&quot;</span>

Score: [3] Equally pragmatic and explanatory

The delivery allows for some flexibility in tailoring to each dyad's needs, which is more pragmatic. However, it is protocolized with comprehensive assessment and eCRF documentation. The delivery has explanatory and pragmatic aspects.

Flexibility: Adherence

Relevant quotes:

No relevant quotes.

Score: [NA] 

The text does not provide enough information to assess flexibility of adherence.

Follow-up

Relevant quotes:  

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All team activities were recorded in the PeNSAMI patient study record, which was kept at the patient’s home and available to all HPs/caregivers.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Dyads assigned to UC received the three examiner visits (visits 1–3) and the monthly telephone interviews, but not the HPA team visits (except visit 0).&quot;</span>

Score: [2] Rather explanatory

The HPA team visits and detailed documentation in study records constitute more intensive follow-up than usual care. The additional examiner visits and monthly calls for the UC group also make follow-up more explanatory.

Primary Outcome

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

The pre-specified primary endpoints were changes in patient quality of life (SEIQoL-DW) and symptom burden (PC Outcome Scale-Symptoms-MS, POSS-MS).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The pre-specified primary endpoints were changes in patient quality of life (SEIQoL-DW) and symptom burden (PC Outcome Scale-Symptoms-MS, POS-S-MS).&quot;</span>

Score: [4] Rather pragmatic 

The quality of life and symptom measures seem patient-centered and relevant for evaluating a palliative care intervention. The outcomes are meaningful for patients.

Primary Analysis

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All randomly assigned patients were included in the main intention-to-treat analysis, provided that at least one contact with the team occurred (HPA group).&quot;</span>

Score: [5] Very pragmatic

The analysis used an intention-to-treat approach including all randomized patients with at least one contact. This data analysis matches usual care and is very pragmatic.</pre>
<p><a name='691'></a></p>
</div>
<div
id="thomas-s.-2013-a-pragmatic-parallel-arm-multi-centre-randomised-controlled-trial-to-assess-the-effectiveness-and-cost-effectiveness-of-a-group-based-fatigue-management-programme-facets-for-people-with-multiple-sclerosis"
class="section level4">
<h4>691.
<a href='https://doi.org/10.1136/jnnp-2012-303816' title='Open publication'>Thomas
S. (2013): <i>A pragmatic parallel arm multi-centre randomised
controlled trial to assess the effectiveness and cost-effectiveness of a
group-based fatigue management programme (FACETS) for people with
multiple sclerosis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 99.8%)</i></p>
<pre>
Here are the PRECIS-2 domain scores and reasoning based on the full text in "691.pdf":

Eligibility criteria

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The main inclusion criteria were: (1) clinically definite MS diagnosis, (2) fatigue impacting on daily life (Fatigue Severity Scale total score >4) and (3) ambulatory.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The main exclusion criteria were: (1) having taken part in a fatigue programme in the last year, (2) cognitive impairments, (3) a relapse in the previous 3 months or (4) having started treatment with disease modifying or antidepressant drugs within the previous 3 months.&quot;</span> 

Reasoning: The eligibility criteria are fairly broad, including people with clinically definite MS diagnosis and significant fatigue impacting daily life. The main exclusions are to avoid contamination from recent participation in other fatigue programs or medication changes, and to avoid issues with assessing outcomes in those with cognitive impairments or recent relapses. Overall, the criteria seem aimed at a typical MS population with fatigue, rather than highly selective subgroups.

Score: [4]

Recruitment

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited in three UK centres (Poole, Bristol, Southampton/Portsmouth) from primary or secondary care, or via MS Society newsletters/websites.&quot;</span>

Reasoning: Participants were recruited through routine clinical settings and established MS information channels. No additional targeted efforts like advertising or incentives are mentioned. This matches usual recruitment for MS interventions.

Score: [4] 

Setting

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited in three UK centres (Poole, Bristol, Southampton/Portsmouth) from primary or secondary care, or via MS Society newsletters/websites.&quot;</span>

Reasoning: The trial was conducted across 3 centers in the UK, including both primary and secondary care settings. This represents real-world variety in settings where MS fatigue interventions would be delivered.

Score: [5]

Organisation

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

The intervention consists of six sessions (∼90 min duration) held weekly and facilitated in groups of 6–12 by two health professionals with experience of working with people with MS and group-work (such as occupational therapists, nurses or physiotherapists).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The FACETS intervention consists of six sessions (∼90 min duration) held weekly and facilitated in groups of 6–12 by two health professionals with experience of working with people with MS and group-work (such as occupational therapists, nurses or physiotherapists).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Facilitators were all qualified to a senior/advanced level (in the UK minimum of a Band 7 on the NHS Agenda for Change (AfC) grading structure).&quot;</span>

Reasoning: The intervention was delivered by existing healthcare professionals as part of their standard roles. The staffing and resource level seems typical for delivery of a group intervention in the NHS. No extra training, equipment, or resources were provided.

Score: [5] 

Flexibility: delivery

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The facilitator manual provides guidance on preparation and delivery, detailed session content, notes and suggested timings, and a checklist of facilitator objectives as well as signposts to additional resources. Sessions are delivered via PowerPoint; hence can be easily replicated. A companion participant handbook, along with existing information booklets, reinforces programme content.&quot;</span>

Reasoning: The intervention is manualized with PowerPoint slides, handouts, and guidance for facilitators. This reduces flexibility in delivery compared to usual care. However, no measures to monitor or enforce compliance are mentioned.

Score: [3]

Flexibility: adherence 

Quotes:
No discussion of measures to enforce adherence by participants.

Reasoning: There is no mention of monitoring or enforcing adherence by participants. Flexibility seems to match usual care.

Score: [5] 

Follow-up

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Individuals who had attended a fatigue management programme in the past year were excluded from the trial as were those who had received a fatigue intervention from a health professional in the past 3 months (see protocol).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Outcomes were measured 1 week (baseline) before the start of FACETS and 1 month (follow-up 1) and 4 months (follow-up 2) after the final session.&quot;</span> 

Reasoning: Follow-up is at 1 and 4 months post-intervention, with no unscheduled visits. This frequency seems reasonable and not excessive compared to usual care.

Score: [4]

Primary outcome  

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎These were: (1) fatigue severity (Global Fatigue Severity (GFS) subscale of the Fatigue Assessment Instrument (FAI)), (2) disease-specific quality of life (QOL) (total score on the Multiple Sclerosis Impact Scale, V.1 (MSIS-29, V.1)) and (3) self-efficacy for managing fatigue (Multiple Sclerosis-Fatigue Self-Efficacy scale—adapted from the Control subscale of the MS Self-Efficacy scale).&quot;</span>

Reasoning: The primary outcomes are patient-centered and clinically meaningful measures of fatigue, QOL, and self-efficacy. They do not appear to require special expertise to assess.

Score: [5]

Primary analysis

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The main analysis was intention-to-treat but we also conducted a ‘per protocol’ analysis (excluding participants who attended fewer than four FACETS sessions).&quot;</span>

Reasoning: The primary analysis was intention-to-treat, including all randomized participants. This matches a pragmatic approach.

Score: [5]</pre>
<p><a name='692'></a></p>
</div>
<div
id="torkhani-e.-2021-improving-health-of-people-with-multiple-sclerosis-from-a-multicenter-randomized-controlled-study-in-parallel-groups-preliminary-results-on-the-efficacy-of-a-mindfulness-intervention-and-intention-implementation-associated-with-a-physical-activity-program"
class="section level4">
<h4>692.
<a href='https://doi.org/10.3389/fpsyg.2021.767784' title='Open publication'>Torkhani
E. (2021): <i>Improving Health of People With Multiple Sclerosis From a
Multicenter Randomized Controlled Study in Parallel Groups: Preliminary
Results on the Efficacy of a Mindfulness Intervention and Intention
Implementation Associated With a Physical Activity Program</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 93.4%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial based on the publication:

Eligibility criteria:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria for the study included (1) a diagnosis of MS, (2) not currently engaged in rehabilitation, therapy or PA program and able to undertake PA without risk-factors (3) aged between 18 and 65 (4) able to give informed consent and to understand French.&quot;</span>

Reasoning: The eligibility criteria are fairly inclusive, allowing adult MS patients with a range of disease severity and types to participate as long as they are not currently in a rehabilitation or PA program. Patients only needed to be able to undertake PA without risk factors, which is consistent with how PA would be recommended in clinical practice. The criteria do not appear to specifically select for patients expected to respond well to the intervention. The only major exclusion is due to language. 

Score: [4]

Recruitment:

Relevant quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):

Individuals participated in either a combination of PA and daily Mindfulness or a combination of PA and Implementation Intention.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Individuals participating in either a combination of PA and daily Mindfulness or a combination of PA and Implementation Intention.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited from two hospitals in the Parisian region, in France receiving outpatient services for MS at a regional medical center.&quot;</span>

Reasoning: Participants were recruited directly from hospitals providing usual care for MS patients. No additional recruitment effort beyond approaching eligible patients at outpatient clinics is described. This matches how patients would be recruited for PA in routine practice.

Score: [5] 

Setting:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This clinical and multicentric trial took place from July 2017 to January 2020, in two hospitals in the Parisian Region, France (Hospitals – CHI Poissy St Germain-en-Laye and R. Poincaré, Garches).&quot;</span>

Reasoning: The trial took place across two hospitals providing standard MS care. The setting aligns with where the intervention would be delivered in routine practice.

Score: [5]

Organization:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Practicing sessions were conducted under the supervision of a physical and sports activity trainer specializing in sports training.&quot;</span>

Reasoning: The PA program was delivered by a specialized trainer. No additional staffing or resources beyond having trained supervision are described. This matches typical organization of PA for MS patients.

Score: [4] 

Flexibility (delivery):

Relevant quotes: 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.4%):

Implementation Intention group (II) (n = 11) was asked to establish a concrete if-then plan (the ‘if ’ component 1 https://www.tailorbuilder.com/en/about.html followed by the ‘then’ component) once a week and share them through the TB application. These combinations were intended to decrease fatigue and improve mobility among people with MS.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Implementation Intention Participants were asked to develop a concrete if-then plan (the “if” component followed by the “then” component) once a week and share them through the TB application. These combinations were intended to decrease fatigue and improve mobility among people with MS.&quot;</span>

Reasoning: The implementation intention intervention allowed flexibility in the specific plans made week-to-week. The mindfulness intervention was also flexible in delivery through recorded sessions. Overall, the interventions could be individualized.

Score: [4]

Flexibility (adherence): 

Relevant quotes:
No relevant quotes.

Reasoning: Adherence was not discussed. As an exercise intervention, this domain may not be as applicable.

Score: [NA]

Follow-up:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All measurements were carried out at two phases of the study T1 (baseline) and T2 (eight weeks after randomization).&quot;</span>

Reasoning: Follow-up matched the duration of the 8-week intervention with measures at baseline and end. This minimal follow-up is consistent with routine practice.

Score: [5] 

Primary outcome:

Relevant quotes:
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 54.9%):

mobility, fatigue, quality of life and the impact of the disease on the patient’s life were measured by 6 min Walking Test (6MWT) (Guyatt et al., 1985) Modified Fatigue Impact Scale (MFIS) (Téllez et al., 2005),' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Mobility, fatigue, and the impact of the disease on the patient’s life were measured by 6 min Walking Test (6MWT) (Guyatt et al., 1985) Modified Fatigue Impact Scale (MFIS) (Téllez et al., 2005), Health-related quality of life measured with EuroQoL (EQ5D-3L) (Goodwin et al., 2019) and Multiple Sclerosis Impact Scale (MSIS-29) (Hobart, 2001), respectively.&quot;</span>

Reasoning: The primary outcomes of mobility, fatigue, and quality of life are clinically meaningful to patients. The measures used are commonly applied in MS research.

Score: [5]

Primary analysis:

Relevant quotes: 
No relevant quotes. 

Reasoning: The analysis methods are not described in detail. With the small sample size, the use of non-parametric tests is appropriate. There is no indication participants were excluded. 

Score: [4]</pre>
<p><a name='693'></a></p>
</div>
<div
id="velikonja-o.-2010-influence-of-sports-climbing-and-yoga-on-spasticity-cognitive-function-mood-and-fatigue-in-patients-with-multiple-sclerosis"
class="section level4">
<h4>693.
<a href='https://doi.org/10.1016/j.clineuro.2010.03.006' title='Open publication'>Velikonja
O. (2010): <i>Influence of sports climbing and yoga on spasticity,
cognitive function, mood and fatigue in patients with multiple
sclerosis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 96.2%)</i></p>
<pre>
Here are the PRECIS-2 scores for the clinical trial described in the paper <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis&quot;</span> (693.pdf):

Eligibility criteria:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):

usion. Twenty patients with relapsing–remitting MS, primary progressive MS or secondary progressive MS, aged 26–50 years, with an EDSS not more than 6 and EDSS pyramidal functions score (EDSSpyr) more than 2 were included in the prospective' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Twenty patients with relapsing–remitting MS, primary progressive MS or secondary progressive MS, aged 26–50 years, with an EDSS not more than 6 and EDSS pyramidal functions score (EDSSpyr) more than 2 were included in the prospective study.&quot;</span>

Score: [3] The eligibility criteria are moderately pragmatic - patients had to have a diagnosis of MS and a certain level of disability, which would likely be the case in usual care. However, the age range is restricted and patients with very high disability (EDSS>6) are excluded, making it less pragmatic.

Recruitment:
No relevant quotes. The paper does not describe the recruitment process.

Score: [NA] 

Setting: 
No relevant quotes. The paper does not describe the setting(s) where the trial took place.

Score: [NA]

Organisation:
No relevant quotes. The paper does not describe the organisation of care delivery.

Score: [NA]

Flexibility (delivery):
<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.9%):

sessions. SC took place in the Training, Occupation and Care Centre under the supervision of two SC instructors with a Slovenian Sports Climbing Committee L' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Sports climbing (SC) took place in the Training, Occupation and Care Centre under the supervision of two SC instructors with a Slovenian Sports Climbing Committee License.&quot;</span>

Score: [4] The SC intervention was delivered in a specialised climbing facility with trained instructors. This represents moderately pragmatic flexibility in delivery.

Flexibility (adherence):  
No relevant quotes. The paper does not describe measures to ensure adherence.

Score: [NA]

Follow-up:
<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.9%):

ssment Examinations were performed by the members of Multiple Sclerosis Center at the Division of Neurology, University Medical Center Lju' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Examinations were performed by the members of Multiple Sclerosis Center at the Division of Neurology, University Medical Center Ljubljana.&quot;</span> 

Score: [2] Follow-up was done by specialists at a University Medical Center, suggesting a more intensive follow-up than would occur in usual care.

Primary outcome:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A physiotherapist assessed spasticity with Modified Ashworth Scale (MAS) [16].&quot;</span>

Score: [3] The Modified Ashworth Scale is a reasonably pragmatic outcome measure that would likely be used in assessing spasticity in usual care.

Primary analysis:
No relevant quotes. The paper does not provide details on the primary analysis.

Score: [NA]</pre>
<p><a name='694'></a></p>
</div>
<div
id="vermöhlen-v.-2018-hippotherapy-for-patients-with-multiple-sclerosis-a-multicenter-randomized-controlled-trial-ms-hippo"
class="section level4">
<h4>694.
<a href='https://doi.org/10.1177/1352458517721354' title='Open publication'>Vermöhlen
V. (2018): <i>Hippotherapy for patients with multiple sclerosis: A
multicenter randomized controlled trial (MS-HIPPO)</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in "694.pdf":

Eligibility criteria

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎MS patients older than 18 years who had a confirmed MS with spasticity of the lower limbs and an Expanded Disability Status Scale (EDSS) score between 4 and 6.5 were eligible for inclusion.&quot;</span>

The eligibility criteria are reasonably broad, including adult MS patients with confirmed diagnosis and spasticity in the lower limbs. The EDSS score requirement excludes those with very mild or very severe disability. This seems moderately pragmatic for a trial intending to assess impact on symptoms like balance and spasticity.

Score: [3]

Recruitment

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eligible patients were randomized to one of the two groups using sealed opaque envelopes on the basis of a computer-generated randomization list.&quot;</span>

No details are provided on how patients were identified or approached for recruitment. This suggests typical clinic recruitment.

Score: [4] 

Setting

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study was conducted at five sites in Germany, all of which have hippotherapy experience as stipulated by the rules of the German Consortium for Therapeutic Riding.&quot;</span>

Conducting the trial across multiple sites suggests a pragmatic approach to ensure a varied patient population. The setting matches intended real-world usage.

Score: [4]

Organisation

Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

Patients of the intervention group received hippotherapy (as defined by the regulations for hippotherapy of the Deutsches Kuratorium für Therapeutisches Reiten e.V. (DKThR)) 8 once a week for 12 weeks as an addon therapy to their standard care, which remained unchanged.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patients of the intervention group received hippotherapy (as defined by the regulations for hippotherapy of the Deutsches Kuratorium für Therapeutisches Reiten e.V. (DKThR)) once a week for 12 weeks as an add-on therapy to their standard care, which remained unchanged.&quot;</span>

No mention of increased staffing, training, or resources. Hippotherapy was provided according to standard regulations. This suggests a pragmatic approach.

Score: [4]

Flexibility: delivery

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Hippotherapy (as defined by the regulations for hippotherapy of the Deutsches Kuratorium für Therapeutisches Reiten e.V. (DKThR))&quot;</span>

The hippotherapy intervention followed standard regulations, suggesting reasonable flexibility typical of real-world delivery.

Score: [4]

Flexibility: adherence

No relevant quotes. No mention of measures to enforce or monitor adherence.

Score: [NA] 

Follow-up

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Examinations and questionnaires were completed prior to the first hippotherapy session (baseline), after 6–7 weeks (interim assessment) and after 12 weeks (final assessment).&quot;</span>

Follow-up schedule matches the intervention period with baseline, interim, and end assessment. This seems pragmatic.

Score: [4]

Primary outcome

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary endpoint was the change in the BBS (difference from BBS baseline to week 12).&quot;</span>

The BBS measures balance and risk of falls. This is a relevant primary outcome for MS patients.

Score: [4]

Primary analysis

Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Analyses were based on the modified intention-totreat set (modified ITT)' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Analyses were based on the modified intention-to-treat set (modified ITT).&quot;</span>

Use of intention-to-treat analysis is a pragmatic approach.

Score: [5]</pre>
<p><a name='695'></a></p>
</div>
<div
id="ward-c.-d.-2004-education-for-people-with-progressive-neurological-conditions-can-have-negative-effects-evidence-from-a-randomized-controlled-trial"
class="section level4">
<h4>695.
<a href='https://doi.org/10.1191/0269215504cr792oa' title='Open publication'>Ward
C. D. (2004): <i>Education for people with progressive neurological
conditions can have negative effects: evidence from a randomized
controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">14 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the PRECIS-2 domain scores and explanations for the trial described in "695.pdf":

1. Eligibility criteria

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants eligible for inclusion were adults aged over 15 years with one of the following possible recorded diagnoses: MS, PD and other causes of progressive parkinsonism, motor neurone disease, Huntington's disease and other degenerative disorders affecting the central nervous system, muscles or peripheral nerves.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In order to preserve a focus on primarily physical disabilities, dementing disorders such as Alzheimer's disease were not included.&quot;</span>  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants whose clinical features appeared incompatible with the recorded diagnosis were excluded, as were those with neurological complications of primarily non-neurological conditions such as diabetes mellitus, or additional causes of severe disability.&quot;</span>

The eligibility criteria are reasonably broad, including adults over 15 years old with a range of progressive neurological conditions affecting physical function. However, some common exclusions are made, such as for dementing disorders and diabetes complications, that may limit generalizability. Overall, the criteria seem moderately pragmatic.

Score: [3]

2. Recruitment

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To avoid ascertainment bias towards people already receiving specific health or social services, we used GP information as the sole method for identifying potential participants.&quot;</span>

Participants were identified solely through GP records and referrals, avoiding additional recruitment efforts that could bias the sample. This routine recruitment approach matches how patients would present in usual care.

Score: [5] 

3. Setting

Relevant quotes:  
- <span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

The study took place between August 1997 and March 2000 and was approved by the research ethics committee of Queen&#39;s Medical Centre (Nottingham,' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The study took place between August 1997 and March 2000 and was approved by the research ethics committee of Queen's Medical Centre (Nottingham, UK).&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎From July 1998 we approached the 177 GPs based within the City of Nottingham boundaries (population 282000).&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants' homes in the City of Nottingham.&quot;</span>

The trial was conducted in participants' homes in a specific city in the UK. While a single city may limit generalizability, conducting the trial in patients' actual homes matches the real-world setting.

Score: [4]

4. Organization

Relevant quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):

(EG), baseline data were reviewed by an expert panel which advised on actions most likely to promote each individual&#39;s physical, social and psychological well-being.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In the EG, baseline data were reviewed by an expert panel which advised on actions most likely to promote each individual's physical, social and psychological well-being.&quot;</span>  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An occupational therapist (OT) then visited EG participants to provide education and information and to discuss a personalized 12-month health action plan.&quot;</span>

The intervention involves an expert panel review and home visits from an OT to provide personalized education. This likely requires more resources and coordination than usual care.

Score: [2] 

5. Flexibility (delivery)

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An occupational therapist (OT) then visited EG participants to provide education and information and to discuss a personalized 12-month health action plan.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Approximately two weeks later, EG participants received a single follow-through phone call from the research OT to confirm and reinforce the educational content of the visit, after which EG patients had no subsequent contact with the OT&quot;</span>

The education delivery seems reasonably flexible, involving a personalized discussion and plan between the OT and participant. Only 1 follow-up call was made to reinforce the education.

Score: [4]

6. Flexibility (adherence)

Relevant quotes:
No discussion of measures to enforce adherence.

The trial does not appear to monitor or enforce adherence to the education intervention. This matches the flexibility seen in usual practice.

Score: [5]

7. Follow-up

Relevant quotes:  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Information on adverse events was collected by phone at two-monthly intervals between baseline and 12-month assessments, when a general enquiry was made without specific reference to falls or sores.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To inform the expert panel, an assessor carried out a broad-ranging baseline interview, which included the Braden scale for risk of skin sores,14 risk factors for falling,l and self-reported service utilization.&quot;</span>

Follow-up intensity seems moderately pragmatic - participants were contacted every 2 months by phone without extensive data collection. However, more detailed baseline and 12 month in-person assessments were performed.

Score: [3]

8. Primary outcome

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary outcome measures were reports of one or more falls or skin sores. At interview, participants were asked 'In the past 12 months, have you fallen? Have you had a skin sore?'&quot;</span>

The primary outcomes of falls and skin sores are directly relevant adverse events for patients with neurological conditions. 

Score: [5]

9. Primary analysis

Relevant quotes: 
No details provided on primary analysis methods.

The paper does not provide enough information about the primary analysis methods.

Score: [NA]</pre>
<p><a name='696'></a></p>
</div>
<div
id="weinstock-guttman-b.-2016-randomised-natalizumab-discontinuation-study-taper-protocol-may-prevent-disease-reactivation"
class="section level4">
<h4>696.
<a href='https://doi.org/10.1136/jnnp-2015-312221' title='Open publication'>Weinstock-Guttman
B. (2016): <i>Randomised natalizumab discontinuation study: taper
protocol may prevent disease reactivation</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 scores for the 9 domains based on the full text in "696.pdf":

Eligibility criteria:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria consisted of: a diagnosis of relapsing MS according to McDonald criteria, being on natalizumab therapy for 24 months or longer, aged between 18 and 65 years and an EDSS score of ≤7.0.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Candidates were excluded from the study if active disease was identified at baseline per clinical ( presence of a relapse during the previous 30 days) and/or MRI evaluation (active gadolinium (Gd)-enhancing lesions).&quot;</span>

Reasoning: The inclusion criteria are quite broad, including all patients with relapsing MS who have been on natalizumab for at least 24 months. The main exclusion criteria are having a relapse in the past 30 days or active enhancing lesions on MRI. This is quite similar to eligibility in usual care.

Score: [4]

Recruitment:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fifty patients with relapsing MS, followed at the Jacobs MS Center for Treatment and Research, Department of Neurology, University at Buffalo, Buffalo New York, USA, were enrolled in this study.&quot;</span>

Reasoning: Patients were recruited from a single specialized MS center, which is more explanatory than recruiting more broadly from multiple centers or clinics.

Score: [2] 

Setting:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fifty patients with relapsing MS, followed at the Jacobs MS Center for Treatment and Research, Department of Neurology, University at Buffalo, Buffalo New York, USA, were enrolled in this study.&quot;</span>

Reasoning: The trial was conducted at a single specialized MS center. This is more explanatory compared to a multi-center trial or centers more representative of usual care.

Score: [2]

Organisation:

Relevant quotes: 

No relevant quotes.

Reasoning: The paper does not provide information about organization of care delivery. I cannot assess whether additional resources or training were used beyond usual care.

Score: [NA] 

Flexibility (delivery):

Relevant quotes:

No relevant quotes.

Reasoning: The paper does not provide information about flexibility in delivering the intervention. I cannot assess if it matched usual care or was more standardized.

Score: [NA]

Flexibility (adherence): 

Relevant quotes:

No relevant quotes.

Reasoning: The paper does not mention any measures to enforce adherence. But this was a trial of drug discontinuation, so adherence may not be applicable.

Score: [NA]

Follow-up:

Relevant quotes:

"Clinical assessments
A physical examination and neurological assessment was administered at baseline, 3, 6 and 12 months postdiscontinuation (counted from the last natalizumab infusion), as well as during unscheduled visits due to relapses (within 3–5 days of any new symptom development)."

Reasoning: Patients were followed regularly every 3 months, more frequently than in usual care. Additional unscheduled visits were triggered by relapses.

Score: [2] 

Primary outcome:

Relevant quotes: 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Safety parameters evaluated as primary outcomes were defined as: (1) MRI parameters quantified by lesion activity analyses and changes in lesion volume (LV) and (2) clinical parameters that included the number of clinical relapses during the cessation period compared to the number of relapses before cessation in both the group as a whole as well as between the two randomised groups.&quot;</span>

Reasoning: The primary outcomes of MRI lesion activity and clinical relapses are directly relevant for patients.

Score: [5]

Primary analysis:

Relevant quotes:

No relevant quotes about primary analysis.

Reasoning: The paper does not provide information about the primary analysis. I cannot assess if it was intention-to-treat or restrictive.

Score: [NA]</pre>
<p><a name='697'></a></p>
</div>
<div
id="williams-k.-l.-2021-center-based-group-and-home-based-individual-exercise-programs-have-similar-impacts-on-gait-and-balance-in-people-with-multiple-sclerosis-a-randomized-trial"
class="section level4">
<h4>697.
<a href='https://doi.org/10.1002/pmrj.12377' title='Open publication'>Williams
K. L. (2021): <i>Center-Based Group and Home-Based Individual Exercise
Programs Have Similar Impacts on Gait and Balance in People With
Multiple Sclerosis: A Randomized Trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 97.1%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in "697.pdf":

Eligibility criteria

Quotes:
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72%):

Inclusion criteria were the following: diagnosis of MS made by a neurologist, able to walk 10 meters with or without an aid within 2 minutes, no relapse of their MS in the past 4 weeks, and no other' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Inclusion criteria: diagnosis of MS made by a neurologist, able to walk 10 meters with or without an aid within 2 minutes, no relapse of their MS in the past 4 weeks, and no other neurological or orthopedic condition that would affect their function.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eligible participants were excluded from the study if they were already engaged in a formal exercise program lasting >30 minutes twice per week, experienced an exacerbation within the past 4 weeks, had their MS immunomodulation medications altered in the previous 4 weeks or during the trial period, or declined to be randomly allocated.&quot;</span>

Explanation: The eligibility criteria are moderately pragmatic. Patients had to have a confirmed diagnosis of MS and be able to walk at least 10 meters, which are reasonable criteria for a walking exercise intervention trial. However, excluding patients who were already exercising regularly, had a recent exacerbation or medication change, or declined randomization make the criteria less pragmatic. Overall, this domain seems moderately pragmatic but leaning towards the explanatory side. Score: [3]

Recruitment 
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Community dwelling people with MS were recruited through the Multiple Sclerosis Society of New South Wales and South Australia.&quot;</span>

Explanation: Recruitment was done through a MS society, which seems moderately pragmatic as people with MS who might be interested in an exercise program are members of such societies. However, recruiting only through a society may bias the sample compared to broad recruitment from clinical settings. There is not enough information to determine if any additional effort beyond contacting society members was made. Score: [3]

Setting
Quote: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The group program was conducted at a local community center and included four to six participants per class.&quot;</span>

Explanation: The setting was a local community center, which seems pragmatic as this matches real-world settings where group exercise classes are held. No mention is made of using specialized or academic centers. Score: [4] 

Organization
Quote:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Groups were led by a physiotherapist employed by the Multiple Sclerosis Society who received training to ensure a standard approach to intervention, intensity, and progression.&quot;</span>

Explanation: A physiotherapist led the groups, which seems reasonably pragmatic, although the additional training to standardize the interventiondelivery across sites makes it slightly less so. No major changes like increased staffing or resources were mentioned. Score: [4] 

Flexibility: delivery
Quote: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Guidelines were provided to physiotherapists and participants for exercises to be adapted and progressed to suit individual functional ability via increasing repetitions, amplitude of movement, speed of movement, and modifying base of support.&quot;</span>

Explanation: There was flexibility in how the exercises were delivered and progressed, tailored to each participant's functional level. No strict protocol was described. Score: [4]

Flexibility: adherence
Quote:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In both group and home exercise sessions, participants completed eight, 6 minute exercises/stations per session plus a 5-minute warm up and cool down.&quot;</span> 

Explanation: Participants were expected to complete the full exercise program, but no specific measures to enforce adherence were mentioned. This seems moderately pragmatic. Score: [3]

Follow-up
Quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Outcome assessments were conducted at baseline, immediately postintervention and at 8-week follow-up.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Outcome assessments were conducted at baseline, immediately post-intervention and at 8-week follow-up.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Assessments were conducted by physiotherapists blinded to group allocation and trained in administering the outcome measures.&quot;</span>

Explanation: Follow-up was at two standard time points with blinded outcome assessment. No unscheduled or more frequent visits were mentioned. This seems pragmatic. Score: [4]

Primary outcome
Quote:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome measure was gait speed, measured using the 10-meter walk test.&quot;</span>

Explanation: The primary outcome of gait speed is highly relevant and meaningful to patients. It was measured in a standard way that could be applied in real-world settings. Score: [5] 

Primary analysis
Quote: 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 96.9%):

Data were analyzed according to the intention-totreat principle' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data were analyzed according to the intention-to-treat principle.&quot;</span>

Explanation: An intention-to-treat analysis was used, which is the most pragmatic approach. No exclusions were mentioned. Score: [5]</pre>
<p><a name='705'></a></p>
</div>
<div
id="petrella-r.-j.-2017-hockey-fans-in-training-a-pilot-pragmatic-randomized-controlled-trial"
class="section level4">
<h4>705.
<a href='https://doi.org/10.1249/MSS.0000000000001380' title='Open publication'>Petrella,
R. J. (2017): <i>Hockey Fans in Training: A Pilot Pragmatic Randomized
Controlled Trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">13 quote(s) from
publication full text</span> (mean similarity 95.9%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">2
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in the attached paper "705.pdf":

Eligibility criteria

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

Eligible participants were male 35–65 yr old with a BMI of Q28 kgIm j2 and met PA safety requirements (i.e., no risk indicated by the Physical Activity Readiness Questionnaire [36] or clearance from a health care provider).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Eligible participants were male 35–65 yr old with a BMI of ≥28 kg/m2 and met PA safety requirements (i.e., no risk indicated by the Physical Activity Readiness Questionnaire [36] or clearance from a health care provider).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Age and BMI restrictions reflect evidence suggesting the following: 1) overweight/obese men in their mid-30s may experience an attitudinal shift in relation to their health, increasing their receptiveness to change health behaviors, and 2) men who are obese or at risk for becoming obese are more likely to want to lose weight (16).&quot;</span>

Explanation: The trial included men aged 35-65 years with BMI ≥28 kg/m2, reflecting the target population for the intervention if implemented in real-world practice. The eligibility criteria match the intended recipients based on evidence of when men become receptive to lifestyle changes. No exclusions were made based on ability to adhere to the intervention. Overall, the eligibility criteria appear to closely match the intended real-world recipients.

Score: [4]

Recruitment

Quotes:  

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Across both sites, the most successful methods of recruitment included communication from the hockey team via e-mail or social media (e.g., Twitter) and word of mouth, where 40% and 36% of men were recruited, respectively.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The remaining men were recruited through traditional media sources (14%), posters and handouts (9%), and other methods (1%).&quot;</span>

Explanation: Participants were primarily recruited through communication from the hockey teams and word of mouth. Some traditional media methods were also used. Overall, the recruitment methods appear moderately pragmatic, leveraging the draw of hockey fandom but requiring some additional effort beyond typical care.

Score: [3] 

Setting

Quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

We used a pragmatic approach for the program venue at each site, using a combination of the hockey team_s arena and an affiliated health club facility.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We used a pragmatic approach for the program venue at each site, using a combination of the hockey team’s arena and an affiliated health club facility.&quot;</span>

Explanation: The program was delivered in the team arenas and affiliated health clubs, which matches the intended real-world setting. Using facilities affiliated with the teams helps draw participants, but does not appear to compromise the setting.

Score: [4]

Organisation

Quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Hockey FIT coaches (coach to participant ratio 2:20) from the central research team (see Gill et al. [14] for information on coach background and training).&quot;</span>

Explanation: The intervention was delivered by coaches from the research team. There is no mention of additional staffing, training, resources, or provider expertise beyond what would be used in typical practice. The organisation appears pragmatic.

Score: [4] 

Flexibility of experimental intervention - delivery

Quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Program sessions comprised the following: 1) classroom-based teaching of behavior change techniques and simple information sharing on PA and healthy eating, delivered to encourage participant interaction and mutual learning, and 2) exercise sessions where men performed aerobic, strength, and flexibility exercises, incorporating their passion for hockey off the ice.&quot;</span>

<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 51.2%):

entives were also provided as part of the program to encourage program attendance and engagement' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Details were provided in the protocol, but coaches were able to adapt delivery based on participants' needs and engagement.&quot;</span>

Explanation: The classroom sessions and exercises allowed for flexibility in delivery, tailored to the participants. Coaches could adapt components as needed. The protocol gave a framework while allowing for individualized delivery. Overall, the flexibility of delivery appears pragmatic.

Score: [4]

Flexibility of experimental intervention - adherence

Quotes:

<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A highly pragmatic design approach would allow for full flexibility in how end user recipients engage with the intervention.&quot;</span> 

<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In usual care, health professionals encourage patients to take medication or follow therapy as best they can, and such encouragement would not count against a pragmatic design; if it also happens in usual care, allowing it in the trial is a pragmatic design decision.&quot;</span>

Explanation: There is no mention of specific measures to enforce or monitor adherence. The trial appears to have allowed flexibility in adherence matching usual care encouragement. 

Score: [4] 

Follow-up

Quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Follow-up occurred at 12 wk (both groups) and 12 months (intervention group only' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Follow-up occurred at 12 wk (both groups) and 12 months (intervention group only).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Measurement at baseline and 12 wk (both groups) and 12 months (intervention group only) included clinical outcomes (e.g., weight) and self-reported physical activity, diet, and self-rated health.&quot;</span>

Explanation: Follow-up measurements were done at 12 weeks and 12 months, with self-reported outcomes. There was no mention of additional in-person visits or extensive additional data collection. The follow-up intensity seems moderately pragmatic.

Score: [3]

Primary outcome

Quotes: 

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

planned primary outcome for the definitive trial was the difference between groups in mean weight loss (kg) and percentage weight change from baseline to 12 wk.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our planned primary outcome for the definitive trial was the difference between groups in mean weight loss (kg) and percentage weight change from baseline to 12 wk.&quot;</span>

Explanation: The primary outcome was weight loss from baseline to 12 weeks, which is a highly relevant and patient-centered outcome.

Score: [5]

Primary analysis

Quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We analyzed outcome data to examine the potential effectiveness of the Hockey FIT program on the basis of an intent-to-treat approach.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The model included terms for time (0, 12 wk), group (intervention, comparator)–time, age, and site (London, Sarnia).&quot;</span> 

Explanation: The analysis was intent-to-treat including all randomized participants. This is a pragmatic approach.

Score: [5]</pre>
<p><a name='712'></a></p>
</div>
<div
id="mafetoni-r.-r.-2016-the-effects-of-acupressure-on-labor-pains-during-child-birth-randomized-clinical-trial1"
class="section level4">
<h4>712.
<a href='https://doi.org/10.1590/1518-8345.0739.2738' title='Open publication'>Mafetoni,
R. R. (2016): <i>The effects of acupressure on labor pains during child
birth: randomized clinical trial1</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 97.4%)</i></p>
<pre>
Here are the PRECIS-2 scores for the trial described in "712.pdf":

Eligibility criteria:

Relevant quotes:
<span title='Moderate quote deviation. Best match in fulltext (Similarity 87.4%):

cted 156 pregnant women in their ≥ 37 week/s, who had cervical dilations of ≥ 4 cm and with two or more contractions in 10 minutes.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Inclusion criteria - Pregnant women at their ≥ 37 week/s, who had cervical dilations of ≥ 4 cm and with two or more contractions in 10 minutes.&quot;</span>
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.3%):

excluded: serious preeclampsia, placenta previa, immediate indication of cesarean, dilations at ≥ 8 cm and those that used analgesics for less than six hours from the study admission time.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Exclusions - severe preeclampsia, placenta previa, immediate indication of cesarean, dilations at ≥ 8 cm and those that used analgesics for less than six hours from the study admission time.&quot;</span>

The inclusion criteria target pregnant women in the active phase of labor, which is the population that would receive acupressure for labor pain in usual care. The exclusions are for safety reasons or to avoid confounding from recent analgesics. Overall, the criteria seem pragmatic and similar to usual care.

Score: [4] 

Recruitment:

Relevant quote: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The pregnant women in labor were allocated through a sequential list of random numbers in blocks of six patients generated using the program Excel® and they were distributed in three groups&quot;</span>

The participants were recruited at a public maternity hospital. No extra effort beyond usual prenatal care seems to have been made to recruit participants. This matches recruitment in usual care.

Score: [5]

Setting: 

Relevant quote:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Where the study was carried out, the following was permitted: the presence of someone to accompany the pregnant lady, the use of methods other than drugs such as taking a shower, massages in the lower back region and breathing exercises as well as liberty of movement (in cases where this did not go against medical advice).&quot;</span>

The study was conducted at a single public maternity hospital. This matches the setting where acupressure would be delivered in usual care.

Score: [5]

Organisation:

Relevant quote: 
No relevant quotes.

The study does not mention providing additional staffing, training, or resources beyond what is available in the maternity ward for usual care. 

Score: [5] 

Flexibility: delivery

Relevant quote:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The researcher that was responsible for applying the acupressure went through 32 hours’ worth of training.&quot;</span>

The acupressure protocol is precisely specified and delivered by a dedicated trained researcher. This reduces flexibility compared to usual care.

Score: [2]

Flexibility: adherence

Relevant quote: 
No relevant quotes.

There is no mention of monitoring or enforcing adherence. Patients seem to have received the 20 minutes of acupressure according to the protocol with the flexibility expected in usual care.

Score: [5] 

Follow-up:

Relevant quote:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

VAS was used to evaluate the pain and for predeveloped questions. The women were able to classify their perception of the pain (Table 3).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎VAS was used to evaluate the pain and for pre-developed questions. The women were able to classify their perception of the pain (Table 3).&quot;</span>

Follow-up is limited to pain assessment immediately and 60 minutes after the 20-minute acupressure intervention. This matches follow-up in usual labor care.

Score: [5]

Primary outcome: 

Relevant quote: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎VAS was used to evaluate the pain&quot;</span>

The primary outcome is pain, measured by the VAS scale. This is clinically relevant and commonly used to assess labor pain in practice.

Score: [5]

Primary analysis:

Relevant quote:
No relevant quotes.

The analysis appears to be intention-to-treat with no mention of excluding any participants postrandomization. This matches the analysis approach used in pragmatic trials.

Score: [5]</pre>
<p><a name='713'></a></p>
</div>
<div
id="jonsdottir-h.-2015-effectiveness-of-a-partnership-based-self-management-programme-for-patients-with-mild-and-moderate-chronic-obstructive-pulmonary-disease-a-pragmatic-randomized-controlled-trial"
class="section level4">
<h4>713.
<a href='https://doi.org/10.1111/jan.12728' title='Open publication'>Jonsdottir,
H. (2015): <i>Effectiveness of a partnership-based self-management
programme for patients with mild and moderate chronic obstructive
pulmonary disease: a pragmatic randomized controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
2
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 99.4%)</i></p>
<pre>
Here are the PRECIS-2 scores and reasoning for each domain based on the full text:

Eligibility criteria

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria were patients aged 45-65 with mild and moderate COPD (grade II and III) as the primary disease.&quot;</span>
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

Excluded were individuals who had another major disease (among them individuals with asthma who had more than 200 ml or 12% increase in FEV 1 after inhalation of 200 lg albuterol in the postbronchodilator spirometry), who were non-Icelandic speaking, not capable of travelling to the treatment site and those who had participated in a structured rehabilitation programme for people with COPD 6 months prior to the screening.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Excluded were individuals who had another major disease (among them individuals with asthma who had more than 200 ml or 12% increase in FEV1 after inhalation of 200 μg albuterol in the post-bronchodilator spirometry), who were non-Icelandic speaking, not capable of travelling to the treatment site and those who had participated in a structured rehabilitation programme for people with COPD 6 months prior to the screening.&quot;</span>

Reasoning: The inclusion criteria target patients with mild to moderate COPD, which matches the intended population for the self-management program. The exclusions are reasonable and aim to isolate the effect of COPD. Overall, the criteria seem reasonably pragmatic.

Score: [4]

Recruitment

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An invitation letter signed by the patient’s physician was sent to potential participants explaining that the study was a clinical, family trial and that as a client of the physician, the person had been identified as a possible participant and that in addition, participation by a close family member was requested.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎One to two weeks later the patient was contacted by phone. In the phone call, possibilities for participation were explored. An appointment at the research centre was set up for those who accepted the invitation.&quot;</span>

Reasoning: Participants were identified from medical records and contacted by mail and phone, which requires some additional effort compared to approaching patients directly during clinic visits. However, this seems reasonable for recruiting patients spread across multiple sites. Overall, fairly pragmatic.

Score: [4] 

Setting

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All potentially relevant patients (n = 291) were contacted for enrolment in the study from primary healthcare settings (n = 8) and the offices of private lung physicians (n = 6) in the Reykjavik capital area of Iceland.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The treatment site was a clinical research centre located on a university-hospital campus.&quot;</span>

Reasoning: Participants were recruited from primary care and physician offices where they would normally receive care. The treatment was delivered at a research center, which is slightly less pragmatic but overall the setting seems reasonably matched to real world care.

Score: [4]

Organization

Relevant quotes: No relevant quotes.

Reasoning: The paper does not provide details on expertise, resources, or care delivery organization.

Score: [NA]

Flexibility: delivery

Relevant quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 95.8%):

The main approach is to work with patients and families to find out what is meaningful for them in life as regards health and jointly decide on that which is possible and relevant for each patient and family.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The partnership approach is to work with patients and families to find out what is meaningful for them in life as regards health and jointly decide on that which is possible and relevant for each patient and family.&quot;</span>

Reasoning: The partnership approach allows flexibility in delivery tailored to each patient, which matches real world practice.

Score: [5]

Flexibility: adherence

Relevant quotes: No discussion of measures to enforce adherence.

Reasoning: There is no evidence that adherence was monitored or enforced beyond standard practice.

Score: [5] 

Follow-up

Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data were collected at baseline and at month 12. Additionally, data collection was carried out in the experimental group at month 6 after the last treatment session.&quot;</span>

Reasoning: Follow-up data collection was at 6 and 12 months, which does not seem excessive compared to real world practice.

Score: [4]

Primary outcome

Relevant quotes: 
- Primary outcomes included quality of life, anxiety, depression, illness intrusiveness, physical activity, exacerbations.

Reasoning: The outcomes measured are clinically relevant for COPD patients. No use of surrogate outcomes or specialized tests. 

Score: [5]

Primary analysis

Relevant quotes:
- Does not mention details of primary analysis.

Reasoning: No details provided about the primary analysis.

Score: [NA]</pre>
<p><a name='714'></a></p>
</div>
<div
id="pinnock-h.-2003-accessibility-acceptability-and-effectiveness-in-primary-care-of-routine-telephone-review-of-asthma-pragmatic-randomised-controlled-trial"
class="section level4">
<h4>714.
<a href='https://doi.org/10.1136/bmj.326.7387.477' title='Open publication'>Pinnock,
H. (2003): <i>Accessibility, acceptability, and effectiveness in primary
care of routine telephone review of asthma: pragmatic, randomised
controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 97%)</i></p>
<pre>
Here are the PRECIS-2 domain scores for the trial in 714.pdf based on the provided information:

Eligibility criteria:

Relevant quotes: 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.4%):

From their computerised asthma registers the practices identified adults (>18 years) who had asked for a bronchodilator inhaler prescription in the previDepartment' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎From their computerised asthma registers the practices identified adults (>18 years) who had asked for a bronchodilator inhaler prescription in the previous six months but who had not had a routine asthma review in the preceding 11 months.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were excluded if the diagnosis of asthma had been made within the previous year, if they had chronic obstructive pulmonary disease, if communication difficulties made a telephone consultation impossible, or (at the general practitioner’s request) for major social or medical reasons.&quot;</span>  

The eligibility criteria seem reasonably pragmatic - patients are selected based on having asthma and being prescribed a bronchodilator inhaler, similar to what would occur in usual care. The exclusions seem reasonable and would likely also occur in usual care. Overall, the criteria seem intended to identify typical asthma patients who would receive this intervention in routine practice.

Score: [4]

Recruitment:

Relevant quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We wrote to all eligible patients inviting them to take part in the study.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients randomised to the telephone review group were sent a letter from their practice informing them that they had been allocated to receive a telephone review and that they should expect a call from the asthma nurse within a month. Nurses were told to make up to four attempts to contact the patient by phone.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients randomised to the face to face consultation arm were sent a written invitation to make an appointment to see the asthma nurse within a month.&quot;</span>

Recruitment involved mailing invitations to participate, which requires some extra effort beyond usual care. However, patients were recruited when they presented for routine asthma care rather than through advertising campaigns. Overall, recruitment seems moderately pragmatic.

Score: [3] 

Setting:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Four general practices in England.&quot;</span> 

The setting of general practices seems identical to the usual care setting where asthma management occurs. Conducting the trial across multiple practices also enhances generalizability.

Score: [5]

Organization:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All four general practices that took part in the study had nurses who were trained and experienced in providing proactive asthma care.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We gave the nurses standardised training in the study procedure.&quot;</span>

The nurses delivering the intervention had specialized asthma training, which may not reflect the expertise of all staff involved in usual asthma care. However, no other substantial organizational changes were mentioned.

Score: [4] 

Flexibility of experimental intervention - delivery:

Relevant quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Nurses were given no instructions about the content of the review except that it should reflect their normal practice and be appropriate to each patient’s clinical need.&quot;</span>

The nurses were instructed to deliver the intervention as they normally would, with no specific protocol, allowing for flexibility.

Score: [5]

Flexibility of experimental intervention - adherence:

No measures to enforce patient adherence to the intervention were mentioned. This domain seems not applicable, as this is a trial of a single consultation rather than an ongoing treatment.

Score: [NA]

Follow-up:

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Follow up questionnaires on morbidity and satisfaction with the consultation were sent to the patients at three months.&quot;</span>

Follow-up was limited to questionnaires at 3 months, which seems moderately pragmatic. No extra clinic visits or extensive monitoring was mentioned.

Score: [4]

Primary outcome:

Relevant quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary outcome measures were the proportion of participants who were reviewed within three months of randomisation and disease specific quality of life, as measured by the Juniper mini asthma quality of life questionnaire.&quot;</span>

The outcomes of review rate and quality of life are highly relevant to patients.

Score: [5]

Primary analysis:

No details provided on primary analysis.

Score: [NA]</pre>
<p><a name='715'></a></p>
</div>
<div
id="ndosi-m.-2014-the-outcome-and-cost-effectiveness-of-nurse-led-care-in-people-with-rheumatoid-arthritis-a-multicentre-randomised-controlled-trial"
class="section level4">
<h4>715.
<a href='https://doi.org/10.1136/annrheumdis-2013-203403' title='Open publication'>Ndosi,
M. (2014): <i>The outcome and cost-effectiveness of nurse-led care in
people with rheumatoid arthritis: a multicentre randomised controlled
trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 99.8%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the PRECIS-2 domain scores and reasoning based on the full text publication:

Eligibility criteria

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion criteria were: a positive diagnosis of RA (1987 American College of Rheumatology (ACR) criteria), age 18 years or older and the ability to complete questionnaires unaided. Exclusions were: unstabilised concomitant disease, awaiting surgery and already receiving care from the practitioners involved in the study.&quot;</span>

<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Patients ≥ 3 with acute respiratory tract infections. Exclusions not common cold but severe respiratory tract infections, peptic ulcer and asthma. But even asthma patients who were not sensitive to ibuprofen or aspirin eligible. Pregnant or breast feeding women are discouraged from taking ibuprofen when pregnant but can take as low a dose as possible of Paracetemol but as both being tested in the trial cannot include this group as participants. If include visually impaired increase organisation of trial (as in carers have to assist diary completion) but that would be norm and usual if prescribed ibuprofen or Paracetemol or steam treatment in usual care, so just easier for trialists to exclude. Small proportion of participants – so why exclude? Depressed and people with psychosis unreliable diary fillers, concerned with other things.&quot;</span>

Reasoning: The eligibility criteria are relatively inclusive, requiring only a diagnosis of RA based on standard ACR criteria and age 18+ along with ability to complete questionnaires. The exclusions are limited to unstable concomitant diseases, awaiting surgery, and already receiving care from the practitioners in the study. These eligibility criteria seem fairly pragmatic and similar to what would be used in usual care.

Score: [4]

Recruitment

Relevant quotes: 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎After gaining patient consent, demographics and disease activity score in 28 joints (DAS28), patients were randomly assigned using a remote secure telephone randomisation service provided by Leeds University Clinical Trials Research Unit.&quot;</span>

Reasoning: Patients were recruited during regular clinic visits after being diagnosed. No special efforts beyond usual care were mentioned. Central randomization was used but this alone does not affect recruitment pragmatism.

Score: [5] 

Setting

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):

The study was conducted in outpatient clinics of 10 rheumatology centres across the UK.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This study was conducted in outpatient clinics of 10 rheumatology centres across the UK.&quot;</span>

Reasoning: The study was conducted across 10 rheumatology clinics in the UK. This multicenter design matches usual care settings where patients would receive treatment.

Score: [5]

Organization

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Nine CNS and 10 rheumatologists delivered the interventions. The CNS had a median experience of 10 years in their current post while the rheumatologists had a median of 9 years at consultant level.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎NLC interventions usually include allocated 30-min time slots in which the CNS takes history, performs physical examination, pain control, prescribing or recommending medication and dosage changes, intra-articular or intramuscular steroid injections, provision of patient education, psychosocial support and ordering blood tests or X-rays. Referrals for ward admission, to the rheumatologist or other health professionals, were carried out as appropriate.&quot;</span> 

Reasoning: The care was provided by regular rheumatology nurses and rheumatologists with typical experience levels. The nurse-led clinics were organized similar to usual care clinics, with adequate 30 minute slots for comprehensive care. No extra staffing or resources were mentioned.

Score: [5] 

Flexibility: delivery

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The usual RLC is similar to the above except that it usually involves an allocated 15-min time slot.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Both practitioners saw patients according to the protocol and any extra visits or admissions were recorded.&quot;</span>

Reasoning: Apart from protocol-defined visit schedule, the delivery of the intervention in both arms appears to have been flexible based on providers' discretion, matching usual practice. No strict protocol, monitoring, or measures to improve compliance were described.

Score: [5]

Flexibility: adherence

Relevant quotes:

No relevant quotes.

Reasoning: Adherence does not seem to be a major factor for this non-pharmacological intervention. No special measures to enforce or monitor adherence were mentioned.

Score: [NA]

Follow-up

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Independent assessors were health professionals trained to perform joint counts and calculating the DAS28.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎When patients arrived at the clinic, the independent assessor performed ‘joint counts’ for DAS28 and then oversaw the completion of self-reported pain visual analogue scale (pain-VAS), fatigue-VAS and duration of morning stiffness. The patients were then given questionnaires in ‘freepost’ return envelopes before consultation with their allocated practitioner.&quot;</span>

Reasoning: Follow-up at discrete time points was more frequent than usual care but involved standard disease activity and patient-reported outcome measures. No additional unscheduled visits or more extensive data collection was mentioned. 

Score: [4] 

Primary outcome

Relevant quotes:  

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was DAS28 and secondary outcomes were pain severity (pain-VAS), fatigue (fatigue-VAS) and duration of morning stiffness measured at each study visit.&quot;</span>

Reasoning: The DAS28 is a standard composite measure of disease activity widely used in RA trials and practice. It is clinically meaningful to patients.

Score: [5]

Primary analysis

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Analysis followed per-protocol (PP) and intention-to-treat (ITT) approaches.&quot;</span>

Reasoning: Both PP and ITT analyses were conducted, indicating an intention to include all randomized patients in the primary analysis.

Score: [5]</pre>
<p><a name='722'></a></p>
</div>
<div
id="patel.-a.-2015-a-pragmatic-randomized-trial-of-a-polypill-based-strategy-to-improve-use-of-indicated-preventive-treatments-in-people-at-high-cardiovascular-disease-risk"
class="section level4">
<h4>722.
<a href='https://doi.org/10.1177/2047487314530382' title='Open publication'>Patel.
A. (2015): <i>A pragmatic randomized trial of a polypill-based strategy
to improve use of indicated preventive treatments in people at high
cardiovascular disease risk</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 96.5%)</i></p>
<pre>
Here are the PRECIS-2 scores for the clinical trial paper "722.pdf":

Eligibility criteria

Relevant quotes:

<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 57.9%):

established CVD or an estimated five-year CVD risk of 15%, w' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Patients ≥ 18 years of age with established CVD or an estimated five-year CVD risk of ≥15%...were eligible.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each participant had to have, in their doctor’s view, indications for all and no contraindications to any component of at least one of two polypills...&quot;</span>

The eligibility criteria seem fairly broad, including adults with either established CVD or high estimated CVD risk. The main exclusions are contraindications to the polypill components, which seems pragmatic as these patients likely wouldn't receive the polypill in usual care. However, there is some uncertainty around how patients were determined to be "high risk" beyond the CVD risk calculator. Overall, the criteria appear more pragmatic than explanatory.

Score: [4] 

Recruitment:

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

Central, computer-based randomization to polypillbased strategy or usual care was stratified by primary healthcare centre, type of indication (established CVD versus high risk), Indigenous identification and level of preventive treatment at baseline.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Central, computer-based randomization to polypill-based strategy or usual care was stratified by primary healthcare centre, type of indication (established CVD versus high risk), Indigenous identification and level of preventive treatment at baseline.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All participants were treated by their regular doctor following randomization.&quot;</span>

The patients seem to have been recruited through their regular primary care doctors, without extra recruitment efforts like media campaigns or incentives. The recruitment path matches how patients would access this intervention under usual care conditions.

Score: [5]

Setting:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted a randomized, open-label trial involving 623 participants from Australian general practices.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Rural and remote communities included to ensure that ‘real-life’ variations in healthcare delivery were captured.&quot;</span>  

The trial was conducted in a range of general practice settings across Australia, including rural and remote areas. This diversity of real-world settings matches where the intervention would be delivered under usual care.

Score: [5]

Organisation:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Prescription and dispensing of the polypill occurred in the same way as for other medications.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This mostly involved doctors providing patients with written prescriptions, and patients presenting the prescriptions to designated local pharmacies where all drugs (including the polypill) were dispensed.&quot;</span>

The polypill was prescribed and dispensed through the existing healthcare system, similar to other medications. There is no mention of extra staffing, training, or resources to deliver the intervention. The organization matches usual care.

Score: [5] 

Flexibility of experimental intervention - delivery:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Those allocated to the polypill-based strategy were prescribed one of the polypill versions at the discretion of their doctor, to be taken at a time suggested by the doctor.&quot;</span> 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The doctor could, at any time, change prescription to the alternative polypill version, add drugs on top of the polypill, or withdraw the polypill and substitute individual drugs of their choice.&quot;</span>

The doctors had flexibility in terms of which polypill version to prescribe, when patients should take it, and ability to modify/change the polypill over time. There was no strict protocol dictating delivery. This matches the flexibility expected under usual care.

Score: [5]

Flexibility of experimental intervention - adherence:

Relevant quotes: 

No discussion of measures to enforce adherence.

There is no mention of monitoring or enforcing adherence. Patients seem to have been free to take the polypill as in usual care.

Score: [5] 

Follow-up:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants attended the primary healthcare centres for trial assessments at randomization and 12 month intervals thereafter. All participants were also reviewed one month post-randomization and at intervening six month intervals, but these could be conducted by telephone.&quot;</span>

Follow-up included visits at 12 months and phone calls at 1 month and 6 months. This does not seem substantially more intensive than typical follow-up for high CVD risk patients.

Score: [4]

Primary outcome:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary outcomes were self-reported use of indicated combination treatment (antiplatelet, statin and ≥2 BP lowering therapies for ≥4 of the previous seven days) at study end; and changes in systolic BP and total cholesterol from baseline to study end.&quot;</span>

The primary outcomes are clinically meaningful to patients - medication adherence, blood pressure, and cholesterol. They do not require special tests beyond what is typical in usual care.

Score: [5] 

Primary analysis:

Relevant quotes:

No mention of exclusions from primary analysis.

In the absence of any stated exclusions, the analysis approach seems to have been a standard intention-to-treat analysis.

Score: [5]</pre>
<p><a name='725'></a></p>
</div>
<div
id="rangan-a.-2015-surgical-vs-nonsurgical-treatment-of-adults-with-displaced-fractures-of-the-proximal-humerus-the-profher-randomized-clinical-trial"
class="section level4">
<h4>725.
<a href='https://doi.org/10.1001/jama.2015.1629' title='Open publication'>Rangan,
A. (2015): <i>Surgical vs nonsurgical treatment of adults with displaced
fractures of the proximal humerus: the PROFHER randomized clinical
trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 99.4%)</i></p>
<pre>
Here are the PRECIS-2 scores for the 9 domains based on the given trial publication:

Eligibility criteria

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were eligible for inclusion if they were aged 16 years or older and presented within 3 weeks after sustaining a displaced fracture of the proximal humerus that involved the surgical neck. The degree of displacement had to be sufficient for the treating surgeon to consider surgical intervention but did not have to meet the displacement criteria of Neer for inclusion in the trial.&quot;</span>

The eligibility criteria are reasonably broad, including adults over 16 years old with displaced fractures of the surgical neck that the treating surgeon would consider for surgery. The criteria do not exclude patients based on comorbidities, adherence, or response to treatment. However, there is some selection bias in that the fracture must be severe enough that the surgeon would consider surgery.

Score: [3]

Recruitment

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients received their allocated treatment from the recruiting hospital.&quot;</span> 

<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.4%):

he 563 eligible patients, 250 (44%) consented to take part in the tria' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Of 563 eligible patients, 250 (44%) consented to take part in the trial.&quot;</span>

Patients were recruited when presenting to the orthopedic department at the hospitals participating in the trial. No additional recruitment methods beyond usual care are mentioned.

Score: [5] 

Setting

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The PROFHER collaborators recruited patients for this pragmatic, open, multicenter, parallel-group, superiority, randomized clinical trial between September 2008 and April 2011 from orthopedic departments (fracture clinics or wards) at 32 acute UK National Health Service hospitals.&quot;</span>

The trial was conducted across 32 hospitals in the UK National Health Service system, a very typical setting for this patient population.

Score: [5]

Organization

Quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Care pathways for all patients included outpatientand community-based rehabilitation, which primarily comprised 1 or more 1-on-1 sessions with a physiotherapist that focused on restoring function.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Care pathways for all patients included outpatient- and community-based rehabilitation, which primarily comprised 1 or more 1-on-1 sessions with a physiotherapist that focused on restoring function.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Consistent with the study protocol, 29 of 32 recruiting centers (91%) recommended 3 or more weeks of sling use.&quot;</span> 

The organization of care seems very similar to usual care, with outpatient rehab and sling immobilization. No additional resources or training are mentioned.

Score: [5] 

Flexibility: Delivery

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎It was emphasized that good standards of care, both surgical and nonsurgical, should be provided throughout the treatment pathway for the injury, including surgical care or management of the sling, postoperative care, and rehabilitation in both groups.&quot;</span>

No strict protocol is mentioned for the delivery of the intervention. Surgeons used techniques they were familiar with.

Score: [5]

Flexibility: Adherence

No measures to enforce or improve adherence are mentioned.

Score: [5] 

Follow-up

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Follow-up was up to 2 years (until April 2013) for all patients.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The OSS was collected by postal questionnaires at 6, 12, and 24 months. There was no trial-related clinical assessment or radiological follow-up of patients.&quot;</span>

Follow-up was limited to questionnaires sent by mail with no extra clinical visits, similar to usual care.

Score: [5]

Primary outcome  

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was the Oxford Shoulder Score (OSS), which is a shoulder-specific outcome measure validated in a UK population.&quot;</span>

The OSS is a patient-reported measure of shoulder function and pain, very relevant to participants.

Score: [5] 

Primary analysis

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Analyses followed a prespecified analysis plan, endorsed by the data monitoring and ethics committee, and were performed using Stata version 12 (StataCorp). All analyses were on an intention-to-treat basis and included all randomized patients in the groups to which they were randomized.&quot;</span>

The primary analysis was intention-to-treat including all randomized patients.

Score: [5]</pre>
<p><a name='733'></a></p>
</div>
<div
id="iliffe-s.-2015-promoting-physical-activity-in-older-people-in-general-practice-proact65-cluster-randomised-controlled-trial"
class="section level4">
<h4>733.
<a href='https://doi.org/10.3399/bjgp15X687361' title='Open publication'>Iliffe,
S. (2015): <i>Promoting physical activity in older people in general
practice: ProAct65+ cluster randomised controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">15 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial based on the publication:

Eligibility criteria

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were eligible to participate if they were: community dwelling aged ≥65 years; independently mobile (with or without a walking aid); and physically able to take part in group exercise.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were excluded if they: had experienced ≥3 falls in the previous year; had unstable clinical conditions; would be unable to follow instructions about exercise safely; or were receiving palliative care.&quot;</span>

Explanation: The eligibility criteria are fairly broad, including community-dwelling adults aged 65+ who are mobile and can participate in exercise. The exclusions are mainly for safety reasons in patients who are seriously ill, at high fall risk, or unable to follow instructions. This matches typical eligibility for exercise programs in this population.

Score: [4]

Recruitment 
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Practices were recruited with assistance from Primary Care Research Networks for London, Derby, and Nottingham.&quot;</span>  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients aged ≥65 years were identified by searches of computerised medical records and invited to participate by letter from their GP.&quot;</span>

Explanation: Participants were recruited through their regular GP practices by searching medical records and sending invitation letters. This is a fairly pragmatic recruitment approach leveraging existing primary care resources and records. More intensive advertising or incentives were not used.

Score: [4] 

Setting
Quote: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A three-arm, parallel-design cluster controlled trial was used, with allocation at the level of general practice in two centres (London and Nottingham/Derby).&quot;</span>

Explanation: The trial was conducted in multiple general practices in London and Nottingham/Derby, matching the typical primary care setting where the intervention would be implemented. No specialist centers were used.

Score: [5]

Organization 
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Volunteer peer mentors supported participants in the OEP arm, and weekly FaME classes were run in local venues by postural stability instructors trained to work with older people.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All FaME classes were fully staffed but recruitment of peer mentors was difficult...and not all participants in the OEP arm received per protocol peer mentor support.&quot;</span>

Explanation: The interventions leveraged existing local resources like venues and some additional trained instructors. Volunteer peer mentors were intended to provide support but this was not fully implemented due to recruitment difficulties. Overall the organization is fairly typical for what would be available in these settings.

Score: [4]  

Flexibility: Delivery
Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The FaME intervention took place in a group once a week and included exercises to be carried out at home, unsupervised, twice weekly.&quot;</span>  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The OEP was undertaken at home, unsupervised, and comprised exercises to be done three times per week.&quot;</span>

Explanation: The exercise interventions were prescribed but the delivery allows flexibility in how participants complete the exercises at home with minimal supervision. This matches typical flexibility in exercise recommendations.

Score: [4]

Flexibility: Adherence
Quotes: 
- No mention of specific measures to enforce adherence.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There was no evidence of difference in primary outcome between adherers and non-adherers for either analysis.&quot;</span>

Explanation: Adherence was measured but there were no specific strategies described to improve adherence, exclude or withdraw participants based on adherence. This suggests a pragmatic approach.

Score: [4] 

Follow-up
Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were followed up every 6 months after the end of the intervention period, until 24 months.&quot;</span>
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

The primary time point was chosen as 12 months postintervention to match other trials.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary time point was chosen as 12 months post-intervention to match other trials.&quot;</span>

Explanation: Follow-up was at 6 month intervals for 2 years, with the primary outcome at 12 months. This does not seem substantially different from typical follow-up that would occur.

Score: [4]

Primary Outcome
Quotes:  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome was the proportion reaching the recommended physical activity target 12 months post-intervention.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Physical activity was assessed using three validated questionnaires: Phone-FITT, the Physical Activity Scale for the Elderly (PASE), and the Community Healthy Activities Model Program for Seniors (CHAMPS).&quot;</span>

Explanation: The primary outcome of physical activity level is highly relevant for participants in exercise trials. It was measured by self-report instruments commonly used in these settings.

Score: [5] 

Primary Analysis
Quote:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

The primary analysis was carried out on 572 participants with complete data on CHAMPS score at baseline and 12months follow-up. Also carried out were two multiple imputation analyses o' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary analysis was carried out on 572 participants with complete data on CHAMPS score at baseline and 12months follow-up. Also carried out were two multiple imputation analyses...&quot;</span>

Explanation: The primary analysis was intention-to-treat including all available data. Multiple imputation was used to assess robustness for missing data. This is a pragmatic analysis approach.  

Score: [5]</pre>
<p><a name='1528'></a></p>
</div>
<div
id="humphreys-i.-2013-cost-effectiveness-of-an-adjustment-group-for-people-with-multiple-sclerosis-and-low-mood-a-randomized-trial"
class="section level4">
<h4>1528.
<a href='https://doi.org/10.1177/0269215513488608' title='Open publication'>Humphreys
I. (2013): <i>Cost-effectiveness of an adjustment group for people with
multiple sclerosis and low mood: a randomized trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">10 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 domain scores I would give for this trial along with relevant quotes and reasoning:

Eligibility criteria 
Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were included who scored >2 on the General Health Questionnaire 12, a measure of psychological distress, or >7 on the anxiety and depression subscales of the Hospital Anxiety and Depression Scale, thus confirming they had low mood.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Those who were not able to complete the outcome measures, such as people with visual problems, were visited by a researcher who was unaware of their group allocation, who completed the questionnaires with them.&quot;</span>

Reasoning: The eligibility criteria selected participants with low mood, which is appropriate for the aim of evaluating a psychological intervention. People with visual problems were still included by having questionnaires administered by a researcher. Overall, the criteria seem reasonably inclusive and similar to actual practice.

Score: [4] 

Recruitment
Relevant quotes:  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Clusters of eight participants, who could attend groups on the same day, were randomly allocated, using a web-based randomization programme prepared in advance by the Clinical Trials Unit at Nottingham University, to an intervention or control group.&quot;</span>

Reasoning: Participants were recruited in clusters based on ability to attend group sessions. This recruitment process seems specifically designed for the trial rather than reflecting usual care referral.

Score: [2]

Setting
Relevant quotes:
- Not reported

Reasoning: The setting is not clearly described.

Score: [NA] 

Organization
Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The groups were delivered by two Band 5 assistant psychologists, who were supervised by a Band 8a clinical psychologist, experienced in working with people with multiple sclerosis.&quot;</span>  

Reasoning: The intervention was delivered by psychologists, which represents additional resources compared to usual care.

Score: [2]

Flexibility: delivery
Relevant quotes:
- Not reported

Reasoning: Details on flexibility in delivery are not provided.

Score: [NA]

Flexibility: adherence  
Relevant quotes:  
- Not reported

Reasoning: Details on flexibility in adherence are not provided.

Score: [NA]

Follow-up
Relevant quotes:  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Four and eight months after random allocation, participants were sent a booklet of outcome questionnaires to complete and return by post.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎If participants failed to return outcome questionnaires they were telephoned once to remind them.&quot;</span>

Reasoning: Follow-up was limited to questionnaires sent by mail with phone reminders if not returned. This does not seem more intensive than usual care.

Score: [4]

Primary outcome
Relevant quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To ascertain costs, a questionnaire was used to assess the use of NHS services and prescribed medication in the previous three months.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The EQ-5D was included as a generic quality of life measure.&quot;</span>

Reasoning: The primary outcomes of resource utilization and quality of life seem highly relevant to both participants and health system.

Score: [5]

Primary analysis
Relevant quotes:  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The main analysis evaluated the total costs of the intervention, resource use and medication at eight months after randomization, but costs at four months follow-up were also recorded.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In the intervention group, there was an overall reduction in resource use from baseline to eight months follow-up of £30,985 (mean per patient reduction of £429).&quot;</span> 

Reasoning: The analysis appears to have included all randomized participants without exclusions.

Score: [5]</pre>
<p><a name='1529'></a></p>
</div>
<div
id="khayeri-f.-2016-effect-of-fordyce-happiness-model-on-depression-stress-anxiety-and-fatigue-in-patients-with-multiple-sclerosis"
class="section level4">
<h4>1529.
<a href='https://doi.org/10.1016/j.ctcp.2016.09.009' title='Open publication'>Khayeri
F. (2016): <i>Effect of Fordyce Happiness Model on depression, stress,
anxiety, and fatigue in patients with multiple sclerosis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the PRECIS-2 scores and rationale for the trial based on the full text:

Eligibility criteria

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion criteria were being definitely diagnosed with MS and having records in the Society and the exclusion criteria having history of other psychiatric disorders including major depressive disorder (according to the medical records and the physician's examinations) or bipolar disorder (except for cognitive disorders by which MS is characterized), substance dependency, any neurological disorders, history of taking corticosteroids or the disease recurrence within the previous six months.&quot;</span>

The eligibility criteria seem reasonably inclusive, excluding only patients with comorbid psychiatric disorders that could confound the results. However, patients had to be definitely diagnosed with MS and have records at the MS Society to participate. This may exclude some MS patients who are not engaged with the Society. Overall, the criteria seem moderately pragmatic.

Score: [3] 

Recruitment

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Because the patients were not hospitalized and regularly referred to the Association, to follow randomized assignment, we decided to run the sampling within two consecutive months until we enrolled an adequate number of participants. Accordingly, 70 numbers, equal to the number of people required in each group, were developed and the numbers 1e70 were randomly assigned to two groups: experimental and control. After eligible patients referred to the Association, a number was randomly assigned to each patient according to his/her referring time and the patients were assigned to the two groups.&quot;</span>

Patients were recruited as they presented to the MS Society clinic over 2 months. No extra effort beyond usual clinic recruitment was mentioned. This seems quite pragmatic.

Score: [4]

Setting

Relevant quotes: 
The study was conducted at the Multiple Sclerosis Society of Isfahan, Iran.

The setting is a specialty clinic for MS patients, which is likely where many patients receive their usual care. The single center design is moderately pragmatic.

Score: [3]

Organization

Relevant quotes:
No information provided on expertise of staff or resources used. The intervention itself (Fordyce Happiness Model) does not seem to require additional resources.

Score: [NA] 

Flexibility: Delivery

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The intervention consisted of: defining depression, stress, anxiety, and their symptoms, defining happiness, and explaining its necessity, reviewing the results of previous studies on happiness (the first session); the technique of increasing physical activity, the technique of being productive, and doing useful and meaningful things (the second session); the principles of planning and better organization–the technique of removing concerns, the technique of reducing expectations and wishes (the third session); the technique of enhancing creativity, the technique of living at present (the fourth session; the technique of increasing social relationships, the technique of being the real self (the fifth session). The technique of increasing intimacy as the most important source of happiness–the technique of giving priority to happiness and making it invaluable (the sixth session); the technique of expressing emotions, the technique of enhancing optimism (the seventh session); reviewing all the techniques taught, administering post-test (the eighth session).&quot;</span>

The intervention consists of training sessions that cover specific topics, suggesting low flexibility in delivery. However, no information is provided on protocol compliance monitoring. 

Score: [2] 

Flexibility: Adherence

Relevant quotes:
No mention of monitoring or enforcing patient adherence.

Score: [NA]

Follow-up

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Moreover, to investigate the efficacy of the FHM, the DASS-21 and Piper Standard Scale were administered to the experimental group in the follow-up session.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The data obtained before and after conduction of the program were analyzed by chi-square test, Mann-Whitney, covariance statistics, repeated measures ANOVA, and independent t-test in SPSS 18.&quot;</span>

Follow-up was done at the end of the 8-week intervention and 3 months later. Outcomes were assessed with questionnaires. Follow-up seems moderately pragmatic.

Score: [3]

Primary Outcome

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To investigate depression, anxiety, and stress, DASS-21, developed by Lovibond and Lovibond in 1995, was used and its validity and reliability were confirmed [17]. To measure fatigue, the Piper Standard Scale was used.&quot;</span>

The primary outcomes of depression, anxiety, stress, and fatigue are patient-important outcomes, assessed with standard instruments. The choice of outcomes is pragmatic.

Score: [4]

Primary Analysis

Relevant quotes: 
No mention of how missing data or protocol deviations were handled. Intention-to-treat analysis is not explicitly mentioned.

Score: [NA]</pre>
<p><a name='1567'></a></p>
</div>
<div
id="stuifbergen-a.k.-2018-computer-assisted-cognitive-rehabilitation-in-persons-with-multiple-sclerosis-results-of-a-multi-site-randomized-controlled-trial-with-six-month-follow-up"
class="section level4">
<h4>1567.
<a href='https://doi.org/10.1016/j.dhjo.2018.02.001' title='Open publication'>Stuifbergen
A.K. (2018): <i>Computer-assisted cognitive rehabilitation in persons
with multiple sclerosis: Results of a multi-site randomized controlled
trial with six month follow-up</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">10 quote(s) from
publication full text</span> (mean similarity 98.8%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the clinical trial described in the paper <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Computer-assisted cognitive rehabilitation in persons with multiple sclerosis: Results of a multi-site randomized controlled trial with six month follow-up&quot;</span>:

Eligibility criteria 
Relevant quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.4%):

18e60 years of age, able to understand and comply with the study protocol, visual acuity with correction sufficient to work on a computer screen, clinically definite MS for at least 6 months and exacerbation free for 90 days). The Perceived Deficits Questionnaire 19 was administered by phone, and those scoring at least 10 (indicating some problems in at least 5 areas' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎18e60 years of age, able to understand and comply with the study protocol, visual acuity with correction sufficient to work on a computer screen, clinically definite MS for at least 6 months and exacerbation free for 90 days...score ≥ 10 [on the Perceived Deficits Questionnaire], indicating some problems in at least 5 areas&quot;</span>

The eligibility criteria are moderately broad - the age range covers adults of working age, and excludes only those with very recent MS diagnoses or exacerbations. The Perceived Deficits Questionnaire screens for self-reported cognitive difficulties. Overall, the criteria aim to recruit typical MS patients with cognitive complaints, not just an ideal adherent sample.

Score: [3]

Recruitment 
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Participants were recruited via physician referral, targeted mailings to persons with MS on the mailing list of the National MS Society, contact with support groups, and notices in MS newsletters and web sites.&quot;</span>

Recruitment utilized typical methods like physician referral and contacting MS support groups. No excessive incentives or advertising campaigns were mentioned. This matches routine patient recruitment.

Score: [4] 

Setting
Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Following approval by the Institutional Review Board for the University of Texas at Austin, participants were recruited from three large metropolitan communities in Texas: Houston, San Antonio and Dallas.&quot;</span>

The trial was conducted across multiple sites in diverse metropolitan areas, indicating a pragmatic setting.

Score: [4]

Organisation
Relevant quotes:
No relevant quotes.

The paper does not mention extensive additional staffing, training, or resources beyond routine care. 

Score: [4] 

Flexibility: Delivery
Relevant quotes:
No relevant quotes. 

The computer training protocol is specified but allows flexibility in delivery. No further protocol details are provided.

Score: [4]

Flexibility: Adherence
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The facilitator prescribed exercises from a study-specific protocol addressing the most common deficits experienced by persons with MS (attention, memory, flexibility, and problem solving). The games/tasks (see Table 1) were arranged so that the most basic cognitive skills (attention) were addressed first.&quot;</span>

Adherence was encouraged but not tightly monitored or enforced. This matches routine practice. 

Score: [4]

Follow-up
Relevant quotes:
<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.1%):

Neuropsychological testing and questionnaire data were collected from all subjects at baseline, following completion of the intervention, and 3 and 6 months post-intervention.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Neuropsychological testing and questionnaire data were collected from all subjects at baseline, following completion of the 8-week MAPPS intervention, and 3 and 6 months post-intervention.&quot;</span>

Follow-up data collection was at limited time points over 6 months. No excessive visits or monitoring is mentioned.

Score: [4]

Primary outcome
Relevant quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

The primary purpose of this study was to determine the effectiveness of a novel computerassisted cognitive rehabilitation intervention MAPSS-MS (Memory, Attention, Problem Solving Skills in MS) in a multi-site trial with persons with MS.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary purpose of this study was to determine the effectiveness of a novel computer-assisted cognitive rehabilitation intervention MAPSS-MS (Memory, Attention, Problem Solving Skills in MS) in a multi-site trial with persons with MS.&quot;</span> 

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

The 70-min battery included the following widely used tests: the Controlled Oral Word Association Test (COWAT) 26 - verbal fluency and word finding; The California Verbal Learning Test, 2nd ed, (CVLT-II) 27 - verbal learning and remembering; The Brief Visuospatial Memory Test e Revised (BVMT-R) 28 nonverbal learning and memory; The Paced Auditory Serial Addition Test (PASAT) 29 - auditory information processing speed and flexibility, as well as calculation abilities; and The Symbol Digit Modalities Test (SDMT) 30 - complex scanning and visual tracking.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The 70-min battery included the following widely used tests: the Controlled Oral Word Association Test (COWAT) - verbal fluency and word finding; The California Verbal Learning Test, 2nd ed, (CVLT-II) - verbal learning and remembering; The Brief Visuospatial Memory Test e Revised (BVMT-R) - nonverbal learning and memory; The Paced Auditory Serial Addition Test (PASAT) - auditory information processing speed and flexibility, as well as calculation abilities; and The Symbol Digit Modalities Test (SDMT) - complex scanning and visual tracking.&quot;</span>

The primary outcome was cognitive performance on clinically relevant neuropsychological tests.

Score: [5] 

Primary analysis
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data analyses were conducted using SPSS, version 24.0 for Windows (SPSS Inc., Chicago, IL, USA). Neuropsychological data were scored by the testers and verified by a second staff member. Data were entered and checked for accuracy.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎For the current study, we employed intention-to-treat strategies to handle missing data using a “last observation carried forward” (LOCF) strategy in which missing data points are imputed based on the participant's existing data.&quot;</span>

An intention-to-treat analysis was used with all available data.

Score: [5]</pre>
<p><a name='1568'></a></p>
</div>
<div
id="riemenschneider-m.-2022-investigating-the-potential-disease-modifying-and-neuroprotective-efficacy-of-exercise-therapy-early-in-the-disease-course-of-multiple-sclerosis-the-early-multiple-sclerosis-exercise-study-emses"
class="section level4">
<h4>1568.
<a href='https://doi.org/10.1177/13524585221079200' title='Open publication'>Riemenschneider
M. (2022): <i>Investigating the potential disease-modifying and
neuroprotective efficacy of exercise therapy early in the disease course
of multiple sclerosis: The Early Multiple Sclerosis Exercise Study
(EMSES)</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 96.4%)</i></p>
<pre>
Here are the PRECIS-2 domain scores for the clinical trial described in the paper <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES)&quot;</span> (1568.pdf):

Eligibility criteria:

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients (n = 84) were recruited in collaboration with six Danish regional MS clinics and The Danish MS Society. Inclusion criteria were (1) 18–60 years of age, (2) ⩽2 years since clinical diagnosis with relapsing remitting MS (RRMS) and (3) no relapses or changes in medication status 8 weeks prior to inclusion.&quot;</span>

Reasoning: The eligibility criteria are fairly broad, including adult RRMS patients within 2 years of diagnosis. The only major exclusions are recent relapse and medication changes. This matches typical eligibility for early RRMS patients in usual care.

Score: [4] 

Recruitment:

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were randomized to the two study conditions by the sealed envelope principle in a 1:1 ratio stratified by line of treatment.&quot;</span> 

Reasoning: Patients were recruited through Danish MS clinics, reflecting recruitment through usual healthcare settings. No extra effort beyond normal clinic recruitment is described.

Score: [5]

Setting: 

Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

The present study is a national multicentre singleblinded parallel group randomized controlled trial (RCT) comparing two groups receiving either supervised exercise therapy (intervention group) or health education (active control group).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The present study is a national multicentre single-blinded parallel group randomized controlled trial (RCT) comparing two groups receiving either supervised exercise therapy (intervention group) or health education (active control group).&quot;</span>

Reasoning: The multicenter design across regional Danish MS clinics represents the typical real-world settings where patients receive care.

Score: [5]

Organization:

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The supervised exercise sessions were performed twice weekly for the full study period of 48 weeks, and was planned on the basis of four principles...Therefore, the exercise intervention was planned as high-intense aerobic exercise, monitored relative to the patients’ individual maximal heart rate (HRmax), and progressed within and between 4 meso cycles of 12 weeks.&quot;</span>

Reasoning: The exercise intervention required specialized equipment, training and monitoring beyond usual care. This differed from typical organization.

Score: [2]

Flexibility (delivery):

Quote: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68%):

In addition to usual care the control group of this study received four 1.5-hour health educational He' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎In addition to usual care the control group of this study received four 1.5-hour health educational sessions throughout the study periods of 48 weeks.&quot;</span> 

Reasoning: Health education sessions were provided to the control group as usual care. The intervention group received a standardized exercise protocol. This contrasts with flexibility in usual care.

Score: [2]

Flexibility (adherence): 

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients in the supervised exercise group completed 90.0 (8.6)% of the planned sessions at an average intensity of 84.4 (3.0)% HRmax.&quot;</span>

Reasoning: Adherence was measured but patients were not excluded for non-adherence. Encouragement to adhere to the protocol was similar to encouragement in usual care.

Score: [4]  

Follow-up:

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All patients were scanned using the exact same 3-Tesla MRI scanner (MAGNETOM Skyra, Siemens Medical Systems, Erlangen, Germany) at the same location, for all patients, and at all timepoints.&quot;</span>

Reasoning: Follow-up schedule matched the study timepoints with MRI scans. This intensity is greater than typical follow-up in usual care.

Score: [2]

Primary outcome:

Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The relapse rate and the global brain atrophy rate were the primary outcomes of this study.&quot;</span>

Reasoning: Relapse rate and brain atrophy are clinically meaningful outcomes to patients.  

Score: [5]

Primary analysis:

Quote: No explicit description of primary analysis method.

Reasoning: The analysis method is not described, so it cannot be determined if it was by intention-to-treat.

Score: [NA]</pre>
<p><a name='1569'></a></p>
</div>
<div
id="straudi-s.-2022-combining-a-supervised-and-home-based-task-oriented-circuit-training-improves-walking-endurance-in-patients-with-multiple-sclerosis.-the-ms_toct-randomized-controlled-trial"
class="section level4">
<h4>1569.
<a href='https://doi.org/10.1016/j.msard.2022.103721' title='Open publication'>Straudi
S. (2022): <i>Combining a supervised and home-based task-oriented
circuit training improves walking endurance in patients with multiple
sclerosis. The MS_TOCT randomized-controlled trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in the paper "1569.pdf":

Eligibility criteria 
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion criteria were: males and females; age 18 to 70; diagnosis of MS (primary or secondary progressive, relapsing-remitting), without relapses in the preceding three months and an Expanded Disability Status Scale (EDSS) score between 4 and 5.5. This criteria reflects the inclusion of PwMS with an unassisted but limited walking competency (100–500 m).&quot;</span>

The inclusion criteria target patients with MS who have moderate disability but are still ambulatory. The EDSS 4-5.5 range selects those with limited walking ability. The criteria seem reasonably aligned with patients who would receive this intervention in usual clinical care.

Score: [4] 

Recruitment  
Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients have been recruited at Ferrara University Hospital from patients who attend the Rehabilitation Outpatient Clinic for gait rehabilitation. They signed informed consent before any evaluation or treatment.&quot;</span>

Patients were recruited from a rehabilitation clinic where they were already receiving care for gait issues. This pragmatic recruitment approach mirrors how patients would access this intervention in usual care.

Score: [5]

Setting
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients have been recruited at Ferrara University Hospital from patients who attend the Rehabilitation Outpatient Clinic for gait rehabilitation.&quot;</span>

The trial was conducted at a single hospital rehabilitation clinic. While a multi-center trial would be more pragmatic, this setting aligns with usual care for gait rehabilitation in MS patients.  

Score: [4] 

Organization
Relevant quotes:
No relevant quotes. The paper does not mention any differences in staffing, training, or resources compared to usual care.

The organization of care delivery seems unchanged from what patients would receive in usual gait rehabilitation.

Score: [5] 

Flexibility: delivery
Relevant quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

TOCT includes six workstations with five levels of complexity (step, slalom, tandem exercise, goals, obstacles, long step). PwMS exercised for 5 min in each one (3 min of activities and 2 min of rest). A full description of exercise protocol is available elsewhere (Straudi et al., 2014). They were encouraged to increase their level of functioning among sessions. They underwent two laps during each session that take about 60 min (6 workstations x 5 min x 2 laps), with 10 min of rest after each lap' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎TOCT includes six workstations with five levels of complexity (step, slalom, tandem exercise, goals, obstacles, long step). PwMS exercised for 5 min in each one (3 min of activities and 2 min of rest). A full description of exercise protocol is available elsewhere. They underwent two laps during each session that take about 60 min (6 workstations x 5 min x 2 laps), with 10 min of rest after each lap.&quot;</span>

The supervised TOCT protocol is highly structured with prescribed stations, exercise duration, and rest periods. This reduces flexibility in intervention delivery.

Score: [2]

Flexibility: adherence
Relevant quotes: 
No relevant quotes. The paper does not mention any measures to enforce or monitor adherence.

There seems to be no less flexibility than in usual care for how patients adhere to the intervention.

Score: [5] 

Follow-up
Relevant quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

The blind evaluator, who did not supervise the training program, performed functional tests, questionnaires and instrumental measurements the week before treatment, the week after the end of the supervised-TOCT, after the 12-weeks home-based TOCT program' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The blind evaluator, who did not supervise the training program, performed functional tests, questionnaires and instrumental measurements the week before treatment, the week after the end of the supervised-TOCT, after the 12-weeks home-based TOCT program.&quot;</span>

Follow-up intensity mirrors what would occur in usual care, with assessment at baseline, after the supervised portion, and after the full program.

Score: [4]

Primary outcome
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary outcome measure was the 6-minute walking test (6MWT) for walking endurance.&quot;</span>

The 6MWT is a direct measure of walking ability and clinically important to patients.

Score: [5]

Primary analysis
Relevant quotes:
No relevant quotes, but the paper states <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An intention-to-treat analysis was carried out on all outcome measures&quot;</span>

The intention-to-treat approach is pragmatic and includes all randomized participants. 

Score: [5]</pre>
<p><a name='1570'></a></p>
</div>
<div
id="mazdeh-m.-2010-the-therapeutic-effect-of-avonex-rebif-and-betaferon-on-edss-and-relapse-in-multiple-sclerosis-a-comparative-study"
class="section level4">
<h4>1570. <a href='https://doi.org/' title='Open publication'>Mazdeh M.
(2010): <i>The therapeutic effect of Avonex, Rebif and Betaferon on EDSS
and relapse in multiple sclerosis: a comparative study</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 98.7%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in "1570.pdf":

Eligibility criteria

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

iteria: Age between 14 – 50 yrs, definite diagnosis of MS based on clinical manifestations and performing MRI according to McDonald’s criteria, acceptance of the 24 month protocol by the patients, not being pregnant or lactating, history of having received a kind of βinterferon under the supervision of a neurologist in a period of no more than 30 days prior to t' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Age between 14 – 50 yrs, definite diagnosis of MS based on clinical manifestations and performing MRI according to McDonald’s criteria, acceptance of the 24 month protocol by the patients, not being pregnant or lactating, history of having received a kind of β-interferon under the supervision of a neurologist in a period of no more than 30 days prior to the study.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎At the onset of treatment all of the patients had an EDSS of less than 6.&quot;</span> 

The eligibility criteria include patients with relapsing-remitting MS between ages 14-50, diagnosed based on clinical manifestations and MRI findings. Patients must accept the 24 month protocol. Some exclusions are made for safety reasons like pregnancy, but overall the criteria reflect typical MS patients who would receive interferon therapy in usual care.

Score: [4] 

Recruitment

Quotes: None relevant

The paper does not describe how patients were recruited, so there is insufficient information to assess this domain.

Score: [NA]

Setting

Quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.1%):

Methods The study was a randomized clinical trial and included all the patients with MS referring to the Farshchian Hospital, Hamadan (West Iran) during the year 2' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The study was a randomized clinical trial and included all the patients with MS referring to the Farshchian Hospital, Hamadan (West Iran) during the year 2005-2006&quot;</span>

The study was conducted at a single hospital center in Iran. The setting may not reflect the typical setting where interferon therapy is delivered and applied in other countries. 

Score: [2]

Organization

Quotes: None relevant

The paper does not describe the expertise, resources, or organization of care delivery, so there is insufficient information to assess this domain.

Score: [NA] 

Flexibility: delivery

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎30 patients received Av (30 mcg IM on a weekly basis), 30 patients received Re (44 mcg SC three times a week) and 30 patients received Be (250 mcg SC on an alternate day basis).&quot;</span>

The interferon drugs were delivered according to fixed injection schedules without flexibility. This suggests an explanatory approach.

Score: [2]

Flexibility: adherence

Quotes: None relevant

The paper does not describe any measures to enforce or improve patient adherence, so there is insufficient information to assess this domain.

Score: [NA]

Follow-up

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The patients in all three groups were evaluated at the end of months 6, 12, 18, 24 and in case of development of reactions were excluded from the study.&quot;</span>

Patients were followed closely with evaluations every 6 months, more frequent than typical follow-up care. This suggests an explanatory approach.

Score: [2] 

Primary outcome 

Quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎At the end of 24 months the patients were again evaluated for EDSS, and the number of relapses for each patient was calculated&quot;</span>

The primary outcomes of EDSS and relapse rate are clinically meaningful to patients.

Score: [4]

Primary analysis

Quotes: None relevant

The paper does not describe the primary analysis methods, so there is insufficient information to assess this domain.

Score: [NA]</pre>
<p><a name='1769'></a></p>
</div>
<div
id="millar-j.h.-1967-long-term-treatment-of-multiple-sclerosis-with-corticotrophin"
class="section level4">
<h4>1769.
<a href='https://doi.org/10.1016/s0140-6736(67)90850-1' title='Open publication'>Millar
J.H. (1967): <i>Long-term treatment of multiple sclerosis with
corticotrophin</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 99.7%)</i></p>
<pre>
Here are the PRECIS-2 scores for the clinical trial described in the attached paper "1769.pdf":

Eligibility criteria

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients with multiple sclerosis were randomly selected into treated and control groups; only patients who could walk with or without walking aids were admitted to the trial, and these cases were initially assessed and scored during an inactive phase of the disease.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients with diabetes mellitus or hypertension or who gave a history of psychiatric illness or peptic ulcer were not admitted to the treated group.&quot;</span> 

Score: [3] 

The eligibility criteria are moderately pragmatic - patients had to have a diagnosis of MS and be ambulatory, which matches the target population, but other exclusions like diabetes, hypertension, and psychiatric illness make it less pragmatic.

Recruitment

Quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

This controlled study was started in 1963 in three citiesBelfast, Leeds, and Manchester.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This controlled study was started in 1963 in three cities-Belfast, Leeds, and Manchester.&quot;</span>

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

separate trial was carried out in the three centres using the same treatment and scoring methods. Patients with multiple sclerosis were randomly selected into treated and control groups;' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A separate trial was carried out in the three centres using the same treatment and scoring methods. Patients with multiple sclerosis were randomly selected into treated and control groups;&quot;</span>

Score: [4] 

Patients were recruited from multiple centers, suggesting a pragmatic recruitment approach. However, no details are provided on how exactly patients were recruited.

Setting

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

This controlled study was started in 1963 in three citiesBelfast, Leeds, and Manchester.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This controlled study was started in 1963 in three cities-Belfast, Leeds, and Manchester.&quot;</span> 

Score: [4]

The trial was conducted across three cities, suggesting a reasonably pragmatic setting.

Organization

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The treated group were given corticotrophin (’ Acthar ’ gel) in a dosage which varied between 15 and 25 units daily, potassium chloride orally, and a low-salt diet.&quot;</span>

Score: [5] 

The intervention appears to be delivered as part of routine care without substantial additional resources, suggesting a very pragmatic approach.

Flexibility: Delivery

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The dose of corticotrophin was adjusted to produce just enough " mooning " of the face to be appreciated by the physician in charge of the trial and the dose was not increased during a relapse.&quot;</span>

Score: [2]

The corticotrophin dosage was standardized based on a specific physician assessment ("mooning" of the face), suggesting an explanatory approach.

Flexibility: Adherence

Score: [NA]

No relevant information provided in the text.

Follow-up

Quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All cases were seen at three-monthly intervals and scored on the Kurtzke (1961) scale; relapses lasting longer than twenty-four hours were also scored by a system in the three centres.&quot;</span>

Score: [3] 

Follow-up every 3 months is more frequent than usual care but not excessively burdensome.

Primary outcome

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There is no evidence to suggest that the treated group do better than the controls, either from the point of view of deterioration or reduction in number or severity of relapses.&quot;</span>

Score: [4] 

Deterioration and relapse rate/severity seem like pragmatic and clinically meaningful outcomes.

Primary analysis

Quotes:
No relevant information provided in the text.

Score: [NA]

No details provided on the primary analysis.</pre>
<p><a name='1770'></a></p>
</div>
<div
id="hoogstraten-m.c.-1990-long-term-effect-of-acth-treatment-of-relapse-in-multiple-sclerosis"
class="section level4">
<h4>1770.
<a href='https://doi.org/10.1111/j.1600-0404.1990.tb01590.x' title='Open publication'>Hoogstraten
M.C. (1990): <i>Long-term effect of ACTH treatment of relapse in
multiple sclerosis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 94.6%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial described in the publication "1770.pdf":

Domain 1 - Eligibility criteria

Quotes: 

<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.4%):

ported definite diagnosis of MS according to the Poser criteria (6), suffering from a relapse, were included.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Only patients with a clinical or laboratory supported definite diagnosis of MS according to the Poser criteria were included.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎At entry the exacerbation had been lasting less than 8 weeks and no spontaneous recovery had occurred.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients with contraindications to bed rest or ACTH-treatment, such as hypersensitivity to ACTH, acute infections, cardial insufficiency, psychosis, pregnancy, Cushing syndrome or peptic ulcer, were excluded.&quot;</span>

Explanation: The trial had strict inclusion criteria requiring a definite diagnosis of MS and being in an acute exacerbation phase. It also excluded patients with various comorbidities and contraindications. This makes the sample less representative of real-world MS patients.

Score: [2]

Domain 2 - Recruitment path

Quotes: No relevant quotes. The paper does not describe the recruitment path.

Explanation: Unable to assess due to lack of information.

Score: [NA] 

Domain 3 - Setting

Quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Three neurological departments in the Netherlands (University Hospital Groningen, Streekziekenhuis Almelo, Diaconessenhuis Meppel) participated in this study.&quot;</span>

Explanation: The trial was conducted across multiple centers and hospitals, suggesting a pragmatic approach.

Score: [4]

Domain 4 - Organization

Quotes: No relevant quotes. The paper does not describe the organization.

Explanation: Unable to assess due to lack of information.

Score: [NA]

Domain 5 - Flexibility (delivery)

Quotes: No relevant quotes. The paper does not describe flexibility of delivery.

Explanation: Unable to assess due to lack of information.

Score: [NA]

Domain 6 - Flexibility (adherence) 

Quotes: No relevant quotes. The paper does not describe flexibility of adherence.

Explanation: Unable to assess due to lack of information.

Score: [NA]

Domain 7 - Follow-up

Quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Follow-up was performed in the 6th and 12th week of treatment and 6, 9, and 12 months after the start of treatment.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Assessment included: EDSS, FS, AI, ISS, in the 6th and 12th week an overall impression by both the patient and the neurologist in a 7-point scale (from much worse via unchanged to much better), and on a 3-point scale (worse, unchanged, better) in the 6th, 9th and 12th month.&quot;</span>

Explanation: Participants were followed closely with multiple assessments over 12 months. This is more frequent than usual care.

Score: [2] 

Domain 8 - Primary outcome

Quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In some Kurtzke Functional Systems, the Ambulation Index and the Kurtzke Incapacity Scale a transient greater improvement in the ACTH-treated patients was observed.&quot;</span>

Explanation: The primary outcomes of functional systems, ambulation, and disability scales are clinically relevant but may require specialized training to assess.

Score: [3]

Domain 9 - Primary analysis

Quotes: No relevant quotes. The paper does not describe the primary analysis.

Explanation: Unable to assess due to lack of information.

Score: [NA]</pre>
<p><a name='1771'></a></p>
</div>
<div
id="langeskov-christensen-m.-2021-efficacy-of-high-intensity-aerobic-exercise-on-cognitive-performance-in-people-with-multiple-sclerosis-a-randomized-controlled-trial"
class="section level4">
<h4>1771.
<a href='https://doi.org/10.1177/1352458520973619' title='Open publication'>Langeskov-Christensen
M. (2021): <i>Efficacy of high-intensity aerobic exercise on cognitive
performance in people with multiple sclerosis: A randomized controlled
trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 99.2%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial based on the full text:

Eligibility criteria

Quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 95.8%):

For inclusion and exclusion criteria, see LangeskovChristensen et al.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For inclusion and exclusion criteria, see Langeskov-Christensen et al24&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎At inclusion, a neurologist examined participants to determine the Expanded Disability Status Scale (EDSS) score, unless a recent score (<6 months) followed by a disease stable period existed.&quot;</span>

Reasoning: The eligibility criteria seem fairly broad, including people with any MS subtype as long as they have a recent stable EDSS score. The only major exclusions seem to be significant comorbidities and inability to exercise. This matches usual care pretty closely.

Score: [4] 

Recruitment

Quotes: 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eighty-six participants were recruited from Danish MS clinics (Aarhus University Hospital, Viborg Regional Hospital, Odense University Hospital, and the MS Clinic of Southern Jutland (Kolding)).&quot;</span>

Reasoning: Participants were recruited when they attended standard clinic appointments at multiple centers. No extra efforts like advertising seem to have been used. This matches usual care.

Score: [5]

Setting

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eighty-six participants were recruited from Danish MS clinics (Aarhus University Hospital, Viborg Regional Hospital, Odense University Hospital, and the MS Clinic of Southern Jutland (Kolding)).&quot;</span>

Reasoning: The trial was conducted at standard MS clinics where patients receive usual care. No specialized or single-center settings were used.

Score: [5] 

Organization

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Supervised PAE sessions were conducted twice weekly during the 24 weeks, with one continuous and one interval exercise session performed each week.&quot;</span>

Reasoning: The intervention was delivered by study staff during supervised sessions twice per week. This provides more resources and monitoring than would occur in usual care.

Score: [2]

Flexibility: Delivery

Quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

In brief, the session volume increased from 30 to 60 minutes during the intervention while the intensity M Langeskov-Christensen, LG Hvid et al. journals.sagepub.com/home/msj 3 increased from 65% to 95% of individual maximum heart rate (HR max' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In brief, the session volume increased from 30 to 60 minutes during the intervention while the intensity increased from 65% to 95% of individual maximum heart rate (HRmax).&quot;</span> 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

For further details on exercise modality options and the progressing volume and intensity of the exercise sessions, see LangeskovChristensen et al.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For further details on exercise modality options and the progressing volume and intensity of the exercise sessions, see Langeskov-Christensen et al.23&quot;</span>

Reasoning: The exercise intervention followed a standardized protocol with set progression of duration and intensity. This leaves little flexibility in how it is delivered compared to usual care.

Score: [2]

Flexibility: Adherence

Quotes: 
- No discussion of measures to enforce adherence

Reasoning: There is no mention of monitoring or enforcing patient adherence to the exercise program. This matches the flexibility expected in usual care.

Score: [5] 

Follow-up

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎At baseline (T0), after 24 (T24) and after 48 (T48) weeks, participants performed the BRB-N, the Major Depression Inventory (MDI), and a cardiorespiratory fitness test (VO2-max test).&quot;</span>

Reasoning: Follow-up assessments were done at baseline, 24 weeks, and 48 weeks. This minimal follow-up matches usual care.

Score: [5]

Primary outcome 

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Assessments included the Brief Repeatable Battery of Neuropsychological tests (BRB-N)&quot;</span>

Reasoning: The BRB-N measures cognitive domains that are functionally relevant and important to patients.

Score: [5]

Primary analysis

Quotes:
- No discussion of exclusions from analysis

Reasoning: There is no mention of excluding any participants from the analysis. This likely means an intention-to-treat approach was used, matching usual care.

Score: [5]</pre>
<p><a name='1772'></a></p>
</div>
<div
id="calkwood-j.-2014-impact-of-a-switch-to-fingolimod-versus-staying-on-glatiramer-acetate-or-beta-interferons-on-patient--and-physician-reported-outcomes-in-relapsing-multiple-sclerosis-post-hoc-analyses-of-the-epoc-trial"
class="section level4">
<h4>1772.
<a href='https://doi.org/10.1186/s12883-014-0220-1' title='Open publication'>Calkwood
J. (2014): <i>Impact of a switch to fingolimod versus staying on
glatiramer acetate or beta interferons on patient- and
physician-reported outcomes in relapsing multiple sclerosis: post hoc
analyses of the EPOC trial</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 99.3%)</i></p>
<pre>
Here are the PRECIS-2 scores with explanations for the trial <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial&quot;</span> based on the provided briefings and full text:

Eligibility criteria:

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

a Men and women aged 18–65 years with relapsing forms of MS, as defined by the 2005 revised McDonald criteria [14], and an Expanded Disability Status Scale (EDSS) Calkwood et al. BMC Neurology 2014, 14:220 Page 2 of 11 http://www.biomedcentral.com/1471-2377/14/220 score of 0–5.5 were eligible to participate in the stud' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Men and women aged 18–65 years with relapsing forms of MS, as defined by the 2005 revised McDonald criteria [14], and an Expanded Disability Status Scale (EDSS) score of 0–5.5 were eligible to participate in the study.&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patients were required to have received a single iDMT (except natalizumab) continuously for at least 6 months prior to study initiation and to be candidates for therapy change.&quot;</span> 

<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):

. Patients were required to have been naïve to fingolimod treatmen' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patients were required to have been naïve to fingolimod treatment.&quot;</span>

Explanation: The eligibility criteria are reasonably broad, including adult patients with relapsing forms of MS up to EDSS 5.5 who have been on a single iDMT for at least 6 months. The main exclusions are safety-related such as cardiac conditions. Overall, the criteria reflect typical patients who would receive DMTs in usual care.

Score: [4] Rather pragmatic

Recruitment:

Relevant quotes: 

No details provided on how patients were recruited.

Explanation: No information is provided on how patients were recruited.

Score: [NA]

Setting: 

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎EPOC was a 6-month, randomized, open-label, multicenter, phase 4 study conducted in the USA and Canada.&quot;</span>

Explanation: The study was conducted across multiple centers in the USA and Canada. No further details are provided on the settings.

Score: [3] Equally pragmatic and explanatory 

Organization:

Relevant quotes:

No details provided on expertise or resources required to deliver the intervention.

Explanation: No information is provided on the organization of care delivery.

Score: [NA] 

Flexibility of Experimental Intervention - Delivery:

Relevant quotes: 

No details provided on flexibility in delivering fingolimod.

Explanation: No information is provided on flexibility in how fingolimod was delivered to patients.

Score: [NA]

Flexibility of Experimental Intervention - Adherence:

Relevant quotes:

No details provided on measures to enforce adherence.

Explanation: No information is provided on measures to ensure adherence to fingolimod. 

Score: [NA]

Follow-up:

Relevant quotes:

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All outcomes were evaluated after 6 months of treatment.&quot;</span>

Explanation: Patients were followed for 6 months to assess outcomes. No details are provided on frequency or intensity of follow-up.

Score: [3] Equally pragmatic and explanatory

Primary Outcome: 

Relevant quotes:

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

t The primary post hoc study endpoint was the least-squares mean (LSM) change in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction score from baseline to 6 months [15' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary endpoint was the change in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction score from baseline to 6 months [15].&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This was measured using the Global Satisfaction subscale score on the TSQM v1.4, where higher scores indicate greater satisfaction.&quot;</span>

Explanation: The primary outcome is patient satisfaction with treatment measured by the TSQM questionnaire. This outcome is directly relevant and meaningful to patients.

Score: [5] Very pragmatic

Primary Analysis:

Relevant quotes:

No details provided on handling of non-adherence or missing data.

Explanation: No information is provided on the primary analysis methods.

Score: [NA]</pre>
<p><a name='1773'></a></p>
</div>
<div
id="medina-perez-c.-2014-effects-of-a-resistance-training-program-and-subsequent-detraining-on-muscle-strength-and-muscle-power-in-multiple-sclerosis-patients"
class="section level4">
<h4>1773.
<a href='https://doi.org/10.3233/NRE-141062' title='Open publication'>Medina-Perez
C. (2014): <i>Effects of a resistance training program and subsequent
detraining on muscle strength and muscle power in multiple sclerosis
patients</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRECIS-2
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Eligibility">
D1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Recruitment">
D2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Setting"> D3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Organization">
D4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (delivery)"> D5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Flexibility (adherence)"> D6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Follow-up">
D7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary outcome">
D8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black" title="Primary analysis">
D9</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
3
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
5
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
4
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
5
</td>
<td style="text-align:left;">
4
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">14 quote(s) from
publication full text</span> (mean similarity 92.6%)</i></p>
<pre>
Here are the PRECIS-2 scores and explanations for the trial based on the full text in "1773.pdf":

Eligibility criteria

Quotes:
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66.3%):

ing to Mc-Donald criteria (McDonald, 2001); ability to walk (with or without aid) at least 20 m without rest; absence of other diseases that might have affected muscle function.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Patient inclusion criteria included a confirmed disease diagnosis by a neurologist, according to Mc-Donald criteria (McDonald, 2001); ability to walk (with or without aid) at least 20 m without rest; absence of other diseases that might have affected muscle function.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎None of the patients had previous experience with resistance training.&quot;</span>

Explanation: The inclusion criteria seem fairly broad - patients only need to be diagnosed by a neurologist and able to walk 20m without rest. The only notable exclusion is prior resistance training experience, which makes sense in assessing the effect of a resistance training intervention. Overall, the criteria seem fairly pragmatic.

Score: [4] 

Recruitment

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎After a group meeting where the details of the investigation were described to the patients, including possible risks and discomfort associated to the intervention, a formal invitation to take part in the study was offered.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All training sessions took place in MS rehabilitation centers and the patients were continuously supervised by physical therapists.&quot;</span>

Explanation: Patients were recruited through MS rehabilitation centers where they were already receiving care. No additional recruitment efforts beyond the group meeting seem to have been made. Recruiting through usual care settings is a pragmatic approach.

Score: [4]

Setting

Quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

All participants were recruited among six MS rehabilitation centers within the region of Castilla y Le´on (Spain).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All participants were recruited among six MS rehabilitation centers within the region of Castilla y León (Spain).&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All training sessions took place in MS rehabilitation centers and the patients were continuously supervised by physical therapists.&quot;</span>

Explanation: Conducting the trial in the same rehabilitation centers where patients were receiving usual care is a pragmatic choice of setting. Multiple centers were used as well.

Score: [5]

Organization

Quotes:
- <span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):

ts performed 3 sets of 8–12 reps with a load that was progressively increased from 35 to 70% of MVIC through the training period (Table 2). Recovery time between sets was 3 minutes.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Subjects performed 3 sets of 8–12 reps with a load that was progressively increased from 35 to 70% of MVIC through the training period (Table 2). Recovery time between sets was 3 minutes.&quot;</span> 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All training sessions took place in MS rehabilitation centers and the patients were continuously supervised by physical therapists.&quot;</span>

Explanation: The intervention was delivered by physical therapists during usual rehabilitation sessions, without requiring additional expertise, training, or resources. This matches usual care and is pragmatic.

Score: [5] 

Flexibility: Delivery

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Subjects were requested to push with maximal effort during the concentric phase of the movement (90–180°) and to lower the load (eccentric action; 180–90°) in a controlled manner.&quot;</span>
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.4%):

the sessions included in the resistance training program.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Table 2 shows the progressive loading scheme used during the resistance training program.&quot;</span>

Explanation: The resistance training protocol is clearly specified, including number of sets/reps, load, and concentric/eccentric timing. This reduces flexibility in delivery and is more explanatory.

Score: [2]

Flexibility: Adherence

Quotes: None relevant

Explanation: There is no mention of any measures to enforce or monitor adherence by patients. This suggests a pragmatic approach.

Score: [5] 

Follow-up

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Testing was performed on three different occasions: before (week 0) and after (week 12) the training program, and after the detraining period (week 24).&quot;</span>

Explanation: Follow-up is limited to testing at baseline, after training, and after detraining. This matches what would occur in usual care and is pragmatic.

Score: [5]

Primary Outcome

Quotes:
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 75.8%):

Dependent variables included maximal voluntary isometric contraction (MVIC), maximal torque, aver' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Dependent variables included maximal voluntary isometric contraction (MVIC), maximal torque, average power and muscle endurance.&quot;</span>

Explanation: The primary outcomes of strength, power, and endurance are clinically meaningful to patients. This is pragmatic.

Score: [5]

Primary Analysis 

Quotes:
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data were analyzed using SPSS® 17.0 (SPSS Inc., USA).&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To assess any training or detraining effect, as well as any difference between groups, MVIC, torque, average power and muscle endurance raw values were examined using two-way ANOVA with repeated measurements for group and time.&quot;</span>

Explanation: The analysis approach is not explicitly described but seems to follow intention-to-treat principles by including all participants and using repeated measures ANOVA. This is pragmatic.

Score: [4]</pre>
</div>
</div>
<div id="quote-accuracy" class="section level3">
<h3>Quote accuracy</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<ul>
<li>602 quotes for 56 / 56 (100%) publications, median 11 (IQR 8-12.25,
range 5-19)</li>
<li>487 / 602 (80.9%) perfect <span
style="border-bottom: 1px dashed black;">quotes from the publication
full text</span></li>
<li>3 / 602 (0.5%) perfect <span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">quotes from
the LLM prompt briefing</span> - were instructions quoted (ok) or
examples (unwanted beahviour)?</li>
<li>112 / 602 (18.6%) quotes with deviations from source, where the
accuracy was measured by a <a
href="https://maxbachmann.github.io/RapidFuzz/Usage/distance/Levenshtein.html#normalized-similarity">“normalized
Levenshtein similarity”</a> <span
style="border-bottom: 1px dashed black;"
title="Weights for insertion: 1, deletion: 0.5, substitution: 1.5. Penalizes &quot;positive hallucinations&quot; (insertions) more than omissions of e.g. brackets and references (deletions).">with
custom weights</span>, ranging from 0-100%
<ul>
<li><span style="background-color: #ffe9e2">83 minor</span> deviations
(95% ≤ similarity &lt; 100%); mean: 98.5%</li>
<li><span style="background-color: #ff9e81">16 moderate</span>
deviations (75% ≤ similarity &lt; 95%); mean: 88.7%</li>
<li><span style="background-color: red">13 major</span> deviations
(similarity &lt; 75%); mean: 64%</li>
</ul></li>
</ul>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-2bad2889947eefa5cc95" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-2bad2889947eefa5cc95">{"x":{"filter":"none","vertical":false,"fillContainer":false,"data":[["Stuifbergen A.K. (2018)","Stuifbergen A.K. (2018)","Stuifbergen A.K. (2018)","Stuifbergen A.K. (2018)","Riemenschneider M. (2022)","Riemenschneider M. (2022)","Straudi S. (2022)","Straudi S. (2022)","Mazdeh M. (2010)","Mazdeh M. (2010)","Millar J.H. (1967)","Millar J.H. (1967)","Millar J.H. (1967)","Hoogstraten M.C. (1990)","Langeskov-Christensen M. (2021)","Langeskov-Christensen M. (2021)","Langeskov-Christensen M. (2021)","Calkwood J. (2014)","Calkwood J. (2014)","Calkwood J. (2014)","Medina-Perez C. (2014)","Medina-Perez C. (2014)","Medina-Perez C. (2014)","Medina-Perez C. (2014)","Medina-Perez C. (2014)","CORONIS Collaborative Group (2013)","van Dijk-de Vries. A, (2015)","van Dijk-de Vries. A, (2015)","van Dijk-de Vries. A, (2015)","van Dijk-de Vries. A, (2015)","van Dijk-de Vries. A, (2015)","Price. D, (2011)","Galdiz, J. B.  (2020)","Galdiz, J. B.  (2020)","Arntzen E. (2019)","Callesen J. (2020)","Carter A. (2014)","Carter A. (2014)","Cooper C. (2011)","Cooper C. (2011)","Cooper C. (2011)","Cutter G. (2019)","Feys P. (2019)","Feys P. (2019)","Finch P. (2014)","Freeman J. (2019)","Garrett M. (2013)","Giovannoni G. (2016)","Giovannoni G. (2016)","Giovannoni G. (2016)","Giovannoni G. (2016)","Giovannoni G. (2016)","Giovannoni G. (2016)","Giovannoni G. (2016)","Giovannoni G. (2016)","Giovannoni G. (2016)","Grossman P. (2010)","Hermens H. (2008)","Higginson I. J. (2009)","Higginson I. J. (2009)","Jongen P. J. (2019)","Kiropoulos L. A. (2016)","Kiropoulos L. A. (2016)","Learmonth Y. C. (2012)","Learmonth Y. C. (2012)","Learmonth Y. C. (2012)","Mayo N. E. (2020)","Mayo N. E. (2020)","Miller L. (2011)","O'Hara L. (2002)","O'Hara L. (2002)","O'Hara L. (2002)","O'Hara L. (2002)","Papeix C. (2015)","Papeix C. (2015)","Papeix C. (2015)","Pozzilli C. (2002)","Solari A. (2018)","Solari A. (2018)","Solari A. (2018)","Thomas S. (2013)","Torkhani E. (2021)","Torkhani E. (2021)","Torkhani E. (2021)","Velikonja O. (2010)","Velikonja O. (2010)","Velikonja O. (2010)","Vermöhlen V. (2018)","Vermöhlen V. (2018)","Ward C. D. (2004)","Ward C. D. (2004)","Williams K. L. (2021)","Williams K. L. (2021)","Williams K. L. (2021)","Petrella, R. J.  (2017)","Petrella, R. J.  (2017)","Petrella, R. J.  (2017)","Petrella, R. J.  (2017)","Petrella, R. J.  (2017)","Mafetoni, R. R.  (2016)","Mafetoni, R. R.  (2016)","Mafetoni, R. R.  (2016)","Jonsdottir, H. (2015)","Jonsdottir, H. (2015)","Pinnock, H. (2003)","Ndosi, M. (2014)","Patel. A. (2015)","Patel. A. (2015)","Rangan, A. (2015)","Rangan, A. (2015)","Iliffe, S. (2015)","Iliffe, S. (2015)"],["fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext"],["<span title='Minor quote deviation. Best match in fulltext (Similarity 95.4%):\n\n18e60 years of age, able to understand and comply with the study protocol, visual acuity with correction sufficient to work on a computer screen, clinically definite MS for at least 6 months and exacerbation free for 90 days). The Perceived Deficits Questionnaire 19 was administered by phone, and those scoring at least 10 (indicating some problems in at least 5 areas' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎18e60 years of age, able to understand and comply with the study protocol, visual acuity with correction sufficient to work on a computer screen, clinically definite MS for at least 6 months and exacerbation free for 90 days...score ≥ 10 [on the Perceived Deficits Questionnaire], indicating some problems in at least 5 areas&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.1%):\n\nNeuropsychological testing and questionnaire data were collected from all subjects at baseline, following completion of the intervention, and 3 and 6 months post-intervention.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Neuropsychological testing and questionnaire data were collected from all subjects at baseline, following completion of the 8-week MAPPS intervention, and 3 and 6 months post-intervention.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nThe primary purpose of this study was to determine the effectiveness of a novel computerassisted cognitive rehabilitation intervention MAPSS-MS (Memory, Attention, Problem Solving Skills in MS) in a multi-site trial with persons with MS.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary purpose of this study was to determine the effectiveness of a novel computer-assisted cognitive rehabilitation intervention MAPSS-MS (Memory, Attention, Problem Solving Skills in MS) in a multi-site trial with persons with MS.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nThe 70-min battery included the following widely used tests: the Controlled Oral Word Association Test (COWAT) 26 - verbal fluency and word finding; The California Verbal Learning Test, 2nd ed, (CVLT-II) 27 - verbal learning and remembering; The Brief Visuospatial Memory Test e Revised (BVMT-R) 28 nonverbal learning and memory; The Paced Auditory Serial Addition Test (PASAT) 29 - auditory information processing speed and flexibility, as well as calculation abilities; and The Symbol Digit Modalities Test (SDMT) 30 - complex scanning and visual tracking.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The 70-min battery included the following widely used tests: the Controlled Oral Word Association Test (COWAT) - verbal fluency and word finding; The California Verbal Learning Test, 2nd ed, (CVLT-II) - verbal learning and remembering; The Brief Visuospatial Memory Test e Revised (BVMT-R) - nonverbal learning and memory; The Paced Auditory Serial Addition Test (PASAT) - auditory information processing speed and flexibility, as well as calculation abilities; and The Symbol Digit Modalities Test (SDMT) - complex scanning and visual tracking.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nThe present study is a national multicentre singleblinded parallel group randomized controlled trial (RCT) comparing two groups receiving either supervised exercise therapy (intervention group) or health education (active control group).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The present study is a national multicentre single-blinded parallel group randomized controlled trial (RCT) comparing two groups receiving either supervised exercise therapy (intervention group) or health education (active control group).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68%):\n\nIn addition to usual care the control group of this study received four 1.5-hour health educational He' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎In addition to usual care the control group of this study received four 1.5-hour health educational sessions throughout the study periods of 48 weeks.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nTOCT includes six workstations with five levels of complexity (step, slalom, tandem exercise, goals, obstacles, long step). PwMS exercised for 5 min in each one (3 min of activities and 2 min of rest). A full description of exercise protocol is available elsewhere (Straudi et al., 2014). They were encouraged to increase their level of functioning among sessions. They underwent two laps during each session that take about 60 min (6 workstations x 5 min x 2 laps), with 10 min of rest after each lap' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎TOCT includes six workstations with five levels of complexity (step, slalom, tandem exercise, goals, obstacles, long step). PwMS exercised for 5 min in each one (3 min of activities and 2 min of rest). A full description of exercise protocol is available elsewhere. They underwent two laps during each session that take about 60 min (6 workstations x 5 min x 2 laps), with 10 min of rest after each lap.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nThe blind evaluator, who did not supervise the training program, performed functional tests, questionnaires and instrumental measurements the week before treatment, the week after the end of the supervised-TOCT, after the 12-weeks home-based TOCT program' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The blind evaluator, who did not supervise the training program, performed functional tests, questionnaires and instrumental measurements the week before treatment, the week after the end of the supervised-TOCT, after the 12-weeks home-based TOCT program.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\niteria: Age between 14 – 50 yrs, definite diagnosis of MS based on clinical manifestations and performing MRI according to McDonald’s criteria, acceptance of the 24 month protocol by the patients, not being pregnant or lactating, history of having received a kind of βinterferon under the supervision of a neurologist in a period of no more than 30 days prior to t' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Age between 14 – 50 yrs, definite diagnosis of MS based on clinical manifestations and performing MRI according to McDonald’s criteria, acceptance of the 24 month protocol by the patients, not being pregnant or lactating, history of having received a kind of β-interferon under the supervision of a neurologist in a period of no more than 30 days prior to the study.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.1%):\n\nMethods The study was a randomized clinical trial and included all the patients with MS referring to the Farshchian Hospital, Hamadan (West Iran) during the year 2' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The study was a randomized clinical trial and included all the patients with MS referring to the Farshchian Hospital, Hamadan (West Iran) during the year 2005-2006&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nThis controlled study was started in 1963 in three citiesBelfast, Leeds, and Manchester.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This controlled study was started in 1963 in three cities-Belfast, Leeds, and Manchester.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nseparate trial was carried out in the three centres using the same treatment and scoring methods. Patients with multiple sclerosis were randomly selected into treated and control groups;' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A separate trial was carried out in the three centres using the same treatment and scoring methods. Patients with multiple sclerosis were randomly selected into treated and control groups;&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nThis controlled study was started in 1963 in three citiesBelfast, Leeds, and Manchester.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This controlled study was started in 1963 in three cities-Belfast, Leeds, and Manchester.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.4%):\n\nported definite diagnosis of MS according to the Poser criteria (6), suffering from a relapse, were included.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Only patients with a clinical or laboratory supported definite diagnosis of MS according to the Poser criteria were included.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.8%):\n\nFor inclusion and exclusion criteria, see LangeskovChristensen et al.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For inclusion and exclusion criteria, see Langeskov-Christensen et al24&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nIn brief, the session volume increased from 30 to 60 minutes during the intervention while the intensity M Langeskov-Christensen, LG Hvid et al. journals.sagepub.com/home/msj 3 increased from 65% to 95% of individual maximum heart rate (HR max' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In brief, the session volume increased from 30 to 60 minutes during the intervention while the intensity increased from 65% to 95% of individual maximum heart rate (HRmax).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nFor further details on exercise modality options and the progressing volume and intensity of the exercise sessions, see LangeskovChristensen et al.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For further details on exercise modality options and the progressing volume and intensity of the exercise sessions, see Langeskov-Christensen et al.23&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\na Men and women aged 18–65 years with relapsing forms of MS, as defined by the 2005 revised McDonald criteria [14], and an Expanded Disability Status Scale (EDSS) Calkwood et al. BMC Neurology 2014, 14:220 Page 2 of 11 http://www.biomedcentral.com/1471-2377/14/220 score of 0–5.5 were eligible to participate in the stud' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Men and women aged 18–65 years with relapsing forms of MS, as defined by the 2005 revised McDonald criteria [14], and an Expanded Disability Status Scale (EDSS) score of 0–5.5 were eligible to participate in the study.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):\n\n. Patients were required to have been naïve to fingolimod treatmen' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patients were required to have been naïve to fingolimod treatment.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nt The primary post hoc study endpoint was the least-squares mean (LSM) change in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction score from baseline to 6 months [15' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary endpoint was the change in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction score from baseline to 6 months [15].&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66.3%):\n\ning to Mc-Donald criteria (McDonald, 2001); ability to walk (with or without aid) at least 20 m without rest; absence of other diseases that might have affected muscle function.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Patient inclusion criteria included a confirmed disease diagnosis by a neurologist, according to Mc-Donald criteria (McDonald, 2001); ability to walk (with or without aid) at least 20 m without rest; absence of other diseases that might have affected muscle function.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nAll participants were recruited among six MS rehabilitation centers within the region of Castilla y Le´on (Spain).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All participants were recruited among six MS rehabilitation centers within the region of Castilla y León (Spain).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):\n\nts performed 3 sets of 8–12 reps with a load that was progressively increased from 35 to 70% of MVIC through the training period (Table 2). Recovery time between sets was 3 minutes.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Subjects performed 3 sets of 8–12 reps with a load that was progressively increased from 35 to 70% of MVIC through the training period (Table 2). Recovery time between sets was 3 minutes.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.4%):\n\nthe sessions included in the resistance training program.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Table 2 shows the progressive loading scheme used during the resistance training program.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 75.8%):\n\nDependent variables included maximal voluntary isometric contraction (MVIC), maximal torque, aver' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Dependent variables included maximal voluntary isometric contraction (MVIC), maximal torque, average power and muscle endurance.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nThe primary outcome was the composite of death, maternal infectious morbidity, further operative procedures, or blood transfusion (>1 unit) up to the 6-week follow-up visit.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary outcome was a composite of death, maternal infectious morbidity, further operative procedures, or blood transfusion (>1 unit) up to the 6-week follow-up visit.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\n. From all 1805 patients who participated in the screening, 357 (20%) met the detection criteria and were invited to take part in the tria' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From all 1805 patients who participated in the screening, 357 (20%) met the detection criteria and were invited to take part in the trial.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\n. From all 1805 patients who participated in the screening, 357 (20%) met the detection criteria and were invited to take part in the tria' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From all 1805 patients who participated in the screening, 357 (20%) met the detection criteria and were invited to take part in the trial.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):\n\ns in the intervention arm (n=19) were trained to integrate SMS into their routine consultations.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎PNs in the intervention arm were trained to integrate SMS into their routine consultations.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.5%):\n\nthe training sessions, PNs started to integrate SMS into their routine care practice.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎During the training sessions, PNs started to integrate SMS into their routine care practice.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\n. In 10% of the sample, one follow-up measurement was missing. Three patients did not complete the baseline measurement and gave informed consent at the 4-month follow-up measurement. Another 23 patients completed only the baseline measuremen' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In 10% of the sample, one follow-up measurement was missing. Three patients did not complete the baseline measurement and gave informed consent at the 4-month follow-up measurement. Another 23 patients completed only the baseline measurement.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nEligible primary care patients 12 to 80 years of age had impaired asthmarelated quality of life (Mini Asthma Quality of Life Questionnaire [MiniAQLQ] score ≤6) or inadequate asthma control (Asthma Control Questionnaire [ACQ] score ≥1).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Eligible primary care patients 12 to 80 years of age had impaired asthma-related quality of life (Mini Asthma Quality of Life Questionnaire [MiniAQLQ] score ≤6) or inadequate asthma control (Asthma Control Questionnaire [ACQ] score ≥1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nThis was a multicentre open-label pragmatic parallel-group randomized clinical trial involving 13 hospitals and was conducted between 2014 and 2017' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This was a multicentre open-label pragmatic parallel-group randomized clinical trial involving 13 hospitals and was conducted between 2014 and 2017.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 85.7%):\n\nExercise tolerance (the ability to sustain exercise) was assessed using distance covered in the 6MWT.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Exercise tolerance (the ability to sustain exercise) was assessed using distance covered in the 6-min walk test (6MWT).&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.7%):\n\nEighty persons completed baseline testing.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Eighty people completed baseline testing.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\nfollow-up test was performed within 7 days of the last intervention session or after the last day of being on the waitlist.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A follow-up test was performed within 7 days of the last intervention session or after the last day of being on the waitlist.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nAerobic exercise was the core exercise modality as it is accessible (i.e. includes community-based walking exercise) and does not require equipment. Participants were asked to complete short bouts (e.g. 5 × 3 minutes, with twominute rest intervals) of low to moderate intensity aerobic exercise (e.g. stepping ergometer, cycle-ergometer, treadmill walking, rowing ergometer, arm-cranking) at 50%– 69% of predicted maximum heart rate (220–age) or 12–14 on the Borg Ratings of Perceived Exertion Scale.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Aerobic exercise was the core exercise modality as it is accessible (i.e. includes community-based walking exercise) and does not require equipment. Participants were asked to complete short bouts (e.g. 5 × 3 minutes, with two-minute rest intervals) of low to moderate intensity aerobic exercise (e.g. stepping ergometer, cycle-ergometer, treadmill walking, rowing ergometer, arm-cranking) at 50%–69% of predicted maximum heart rate (220–age) or 12–14 on the Borg Ratings of Perceived Exertion Scale.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nThe homeexercise sessions were intended to mirror the supervised sessions in terms of intensity and duration of aerobic exercise, and also included tailored exercises for strength, flexibility and balance. Participants were encouraged to seek out opportunities to exercise in the local community (e.g. healthy living centres, health walks, fitness centres, swimming pools, etc.), based on their individual preferences.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The home-exercise sessions were intended to mirror the supervised sessions in terms of intensity and duration of aerobic exercise, and also included tailored exercises for strength, flexibility and balance. Participants were encouraged to seek out opportunities to exercise in the local community (e.g. healthy living centres, health walks, fitness centres, swimming pools, etc.), based on their individual preferences.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 85.6%):\n\nIn the Sheffield region, Primary Care Trust (PCT) mental health care teams administered the CCBT, facilitating access and undertaking safety monitoring (PCTs were publicly funded organisations responsible for commissioning acute services for local populations). The CCBT service provided to trial participants was the routine Patients approached to take p' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎In the Sheffield region, Primary Care Trust (PCT) mental health care teams administered the CCBT, facilitating access and undertaking safety monitoring (PCTs were publicly funded organisations responsible for commissioning acute services for local populations). The CCBT service provided to trial participants was the routine service provided to all patients referred to the PCT mental health care teams.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nThe collection of outcome data by postal questionnaire proved to be challenging, with multiple attempts to obtain data from many participants, particularly at later outcome assessment points.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The completion of outcome data by postal questionnaire proved to be challenging, with multiple attempts to obtain data from many participants, particularly at later outcome assessment points.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 87.1%):\n\nPatients are contacted if they fail to keep trial appointments.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Participants were contacted if they failed to keep trial appointments.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\nPatients also participated in self-reported, daily athome MSQ assessments on Days 1 through 7 after the baseline visit.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patients also participated in self-reported, daily at-home MSQ assessments on Days 1 through 7 after the baseline visit.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nEffects of an individual 12-week communitylocated “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Effects of an individual 12-week community-located “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 77%):\n\natients were tested at two time points (0 and 12 weeks).' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Evaluation was performed at two time points (0 and 12 weeks).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nFor both treatment and control groups, self-efficacy scores were obtained before the first treatment, midtreatment series, after the last treatment in the series, four weeks after the final treatment and again eight weeks after the final treatment had been received.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For both treatment and control groups, self-efficacy scores were obtained before the first treatment, mid-treatment series, after the last treatment in the series, four weeks after the final treatment and again eight weeks after the final treatment had been received.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):\n\nThe primary analysis population was defined as all participants who completed baseline and 36 week assess ments. The primary analysis of the primary outcome, AMCA score at 36 weeks, followed a modified intention to treat approach, regardless of compliance to the inter vention, but did exclude patients who were deemed ineligible after randomisation, those who withdrew from the trial and were unwilling for their previously collected data to be used, or those who did not provide baseline and week 36 measurements (ie, there was no imputation of missing baseline or week 36 scores for the primary analysis), and used an analysis of covariance (ANCOVA) approach.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary analysis population was defined as all participants who completed baseline and 36 week assessments. The primary analysis of the primary outcome, AMCA score at 36 weeks, followed a modified intention to treat approach, regardless of compliance to the intervention, but did exclude patients who were deemed ineligible after randomisation, those who withdrew from the trial and were unwilling for their previously collected data to be used, or those who did not provide baseline and week 36 measurements (i.e., there was no imputation of missing baseline or week 36 scores for the primary analysis), and used an analysis of covariance (ANCOVA) approach.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nThe primary outcome measure was the physical component of the Multiple Sclerosis Impact Scale29, version 2 (MSIS-29v2), a patient-reported outcome measure that assesses the physical impact of MS.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary outcome measure was the physical component of the Multiple Sclerosis Impact Scale-29, version 2 (MSIS-29v2), a patient-reported outcome measure that assesses the physical impact of MS.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nComparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy and safety of alemtuzumab 12 mg with subcutaneous interferon-b-1a (SC IFN-b-1a) 44 mg in patients with RRMS.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis II (CARE-MS II), a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy and safety of alemtuzumab 12 mg with subcutaneous interferon-β-1a (SC IFN-β-1a) 44 mg in patients with RRMS.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nCARE-MS II was a 2-year, randomized, rater-blinded, active comparator-controlled, head-to-head, trial of alemtuzumab (Lemtrada; Sanofi Genzyme, Cambridge, MA; 12 mg/day on 5 consecutive days at month 0 and on 3 consecutive days at month 12) vs SC IFN-b-1a (Rebif; EMD Serono, Rockland, MA; 44 mg 3 times weekly) in patients with RRMS with inadequate response to prior DMTs ($1 relapse during IFN-b or glatiramer acetate [GA] treatment [received for $6 months])' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎CARE-MS II was a 2-year, randomized, rater-blinded, active comparator-controlled, head-to-head, trial of alemtuzumab (Lemtrada; Sanofi Genzyme, Cambridge, MA; 12 mg/day on 5 consecutive days at month 0 and on 3 consecutive days at month 12) vs SC IFN-β-1a (Rebif; EMD Serono, Rockland, MA; 44 mg 3 times weekly) in patients with RRMS with inadequate response to prior DMTs (≥1 relapse during IFN-β or glatiramer acetate [GA] treatment [received for ≥6 months]).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nIn total, 202 and 426 CARE-MS II patients were randomized to SC IFN-b-1a 44 mg and alemtuzumab 12 mg, respectively' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In total, 202 and 426 CARE-MS II patients were randomized to SC IFN-β-1a 44 mg and alemtuzumab 12 mg, respectively.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nCARE-MS II was a 2-year, randomized, rater-blinded, active comparator-controlled, head-to-head, trial of alemtuzumab (Lemtrada; Sanofi Genzyme, Cambridge, MA; 12 mg/day on 5 consecutive days at month 0 and on 3 consecutive days at month 12) vs SC IFN-b-1a (Rebif; EMD Serono, Rockland, MA; 44 mg 3 times weekly) in patients with RRMS with inadequate response to prior DMTs ($1 relapse during IFN-b or glatiramer acetate [GA] treatment [received for $6 months])' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎CARE-MS II was a 2-year, randomized, rater-blinded, active comparator-controlled, head-to-head, trial of alemtuzumab (Lemtrada; Sanofi Genzyme, Cambridge, MA; 12 mg/day on 5 consecutive days at month 0 and on 3 consecutive days at month 12) vs SC IFN-β-1a (Rebif; EMD Serono, Rockland, MA; 44 mg 3 times weekly) in patients with RRMS with inadequate response to prior DMTs (≥1 relapse during IFN-β or glatiramer acetate [GA] treatment [received for ≥6 months]).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nRaters administered the MSFC 16 3 times before baseline to attenuate practice effects, then every 6 months' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Raters administered the MSFC 3 times before baseline to attenuate practice effects, then every 6 months.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nDifferences in study drug administration and unique adverse event profiles precluded effective double-blinding' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Differences in study drug administration and unique adverse event profiles precluded effective double-blinding.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nRaters administered the MSFC 16 3 times before baseline to attenuate practice effects, then every 6 months' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Raters administered the MSFC 3 times before baseline to attenuate practice effects, then every 6 months.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\nEDSS-based and non-EDSSbased methods. The results of these prespecified outcomes and post hoc analyses from CARE-MS II more fully characterize the effects of alemtuzumab on disability in patients with RRMS than those published previousl' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎EDSS-based and non-EDSS-based methods. The results of these prespecified outcomes and post hoc analyses from CARE-MS II more fully characterize the effects of alemtuzumab on disability in patients with RRMS than those published previously&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.5%):\n\ne intention-to-treat analysis has recently also become the norm for superiority trials taking a more explanatory design approach, especially when regulatory approval for an intervention is being sought' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎An intention-to-treat analysis has recently also become the norm for superiority trials taking a more explanatory design approach, especially when regulatory approval for an intervention is being sought.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nMS quality of life, depression, and fatigue improve after mindfulness training A randomized trial' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 70.2%):\n\nthe overall satisfaction of both patients and therapists was high.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The overall satisfaction of both patients and therapists concerning the H-CAD system was high.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):\n\nInclusion criteria were patients in South East London, living with MS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria were patients in South East London, living with MS...&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.6%):\n\nData were collected at baseline, 6, 12, 18, and 26 weeks on use of services, patient symptoms, other outcomes, and caregiver burden.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Data were collected at baseline, 6, 12, 18 (only control groupdafter they received PCT), and 26 weeks on use of services, patient symptoms, other outcomes, and caregiver burden.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):\n\nCDT was given during three consecutive days in Zorghotel Spelderholt, Beekbergen, the Netherlands, a facility especially equipped for the accommodation of people with impaired health.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎CDTs were given during three consecutive days in Zorghotel Spelderholt, Beekbergen, the Netherlands, a facility especially equipped for the accommodation of people with impaired health.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.6%):\n\nExclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Exclusion criteria: Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.8%):\n\nariables. To examine group differences at post and 20 week follow up assessment, individual analyses of covariance (ANCOVAs) were performed with baseline treatment outcome scores used as the' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎To examine group differences at post and 20 week follow up assessment, individual analyses of covariance (ANCOVAs) were performed with baseline treatment outcome scores used as the covariate.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.7%):\n\nwere sent invitation letters and participant information sheets.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Potential participants (n 1⁄4 159) were sent invitation letters and participant information sheets.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nFrom those living near Site A a list of potential participants (n ¼ 16) was created and, to maximise class occupancy, 10 potential participants were allocated to Site A’s intervention group. A computer program (Microsoft Excel 2003) was set up to randomly assign the 10 people to the exercise group and 6 to the control group. A similar system was used for Site B (which had a class capacity of 12), for which a list of potential participants (n ¼ 20) was created.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From those living near Site A a list of potential participants (n 1⁄4 16) was created and, to maximise class occupancy, 10 potential participants were allocated to Site A’s intervention group. A similar system was used for Site B (which had a class capacity of 12), for which a list of potential participants (n 1⁄4 20) was created.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nThe Timed 25Foot Walk Test measures walking speed over a short distance and has shown good reliability and validity in the multiple sclerosis population as an individual component of the Multiple Sclerosis Functional Composite disability assessment.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Timed 25-Foot Walk Test measures walking speed over a short distance and has shown good reliability and validity in the multiple sclerosis population as an individual component of the Multiple Sclerosis Functional Composite disability assessment.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\ninclusion criteria were (1) ambulatory (can walk 100 m, be capable of walking 100 metres without a walking aid corresponding to a classification of ⩽5.5 on the Expanded Disability Status Scale (EDSS), 10 even if they do use an aid for daily activities; and (2) self-reported to be sedentary or irregularly active at time of study entry (i.e. do not exercise 30 minutes or more twice per week of moderate to vigorous activity).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria were (1) ambulatory (can walk 100 m, be capable of walking 100 metres without a walking aid corresponding to a classification of ≤5.5 on the Expanded Disability Status Scale (EDSS),10 even if they do use an aid for daily activities); and (2) self-reported to be sedentary or irregularly active at time of study entry (i.e. do not exercise 30 minutes or more twice per week of moderate to vigorous activity).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.8%):\n\nThe intention was to follow participants for the first year of the intervention when the exercise programme was designed and adjusted as needed exercise-induced fatigue predicted retention. There were no' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The intention was to follow participants for the first year of the intervention when the exercise programme was designed and adjusted as needed and have a further follow-up after the second year. As there were substantial losses to follow-up, only results after one year are presented.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nSubjects had a definite diagnosis of primary or secondary progressive MS, and an EDSS of between 6.5 (constant bilateral assistance required to walk about 20 metres without resting) to 8 (essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed much of the day, retains many selfcare functions and generally has effective use of' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Subjects had a definite diagnosis of primary or secondary progressive MS, and an EDSS of between 6.5 (constant bilateral assistance required to walk about 20 metres without resting) to 8 (essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed much of the day, retains many self-care functions and generally has effective use of arms).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nThe only selection criterion was that the diagnosis of MS was con rmed by the general practitioner.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The only selection criterion was that the diagnosis of MS was confirmed by the general practitioner.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nAs  ndings from the Delphi study highlighted the need for  exibility and responsiveness to individuals the format of the discussion focused on individuals’ interests and concerns rather than on covering all the information contained in the booklet.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎As findings from the Delphi study highlighted the need for flexibility and responsiveness to individuals the format of the discussion focused on individuals’ interests and concerns rather than on covering all the information contained in the booklet.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 85.7%):\n\nassessments were conducted six months after baseline.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Follow-up assessments were conducted six months after baseline.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nThe blind code was broken after the  nal follow-up assessments had occurred.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The blind code was broken after the final follow-up assessments had occurred.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\n2012. Inclusion criteria were: having MS (MacDonald criteria); being able to complete a questionnaire; and being in need for a multidisciplinary approach, defined by the requirement, in addition to the neurology specialist, of at least two different medical (rehabilitation specialist, neurourology specialist, psychiatrist) or allied health professionals (physiotherapist, occupational therapist, social worker, psychologist, and neuropsycholo' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria were: having MS (MacDonald criteria); being able to complete a questionnaire; and being in need for a multi-disciplinary approach, defined by the requirement, in addition to the neurology specialist, of at least two different medical (rehabilitation specialist, neuro-urology specialist, psychiatrist) or allied health professionals (physiotherapist, occupational therapist, social worker, psychologist, and neuropsychologist).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96%):\n\nents MS patients from the outpatient clinic of the Neurology Department of Pitie´-Salpeˆtrie`re Hospital were prospectively enrolled in the study between March 2010 and July' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MS patients from the outpatient clinic of the Neurology Department of Pitie ́-Salpeˆtrie`re Hospital were prospectively enrolled in the study between March 2010 and July 2012.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):\n\nre 1). For patients in the IMD group, the multidisciplinary integrated outpatient clinic was planned at our MS clinic within a maximum three-month period after inclusion. These patients received a half-day (four to six hours) individually tailored assessment by the multidisciplinary' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For patients in the IMD group, the multidisciplinary integrated outpatient clinic was planned at our MS clinic within a max-imum three-month period after inclusion. These patients received a half-day (four to six hours) indi-vidually tailored assessment by the multidisciplinary group.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.5%):\n\nTo be eligible, all patients screened for study participation had to be affected by clinically definite multiple sclerosis 17 and live in the' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎To be eligible, all patients screened for study participation had to be affected by clinically definite multiple sclerosis and live in the Rome service area.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):\n\nOther patient inclusion criteria were primary or secondary progressive MS, 1,13 Expanded Disability Status Scale (EDSS) score ⩾ 8.0, 14 complex symptoms, 15 and ⩾2 unmet care needs.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Other patient inclusion criteria were primary or secondary progressive MS, [1,13] Expanded Disability Status Scale (EDSS) score ≥ 8.0, [14] complex symptoms, [15] and ≥2 unmet care needs.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\n. The nurse (team leader) performed 152 visits (33%), followed by the psychologist (25%), the physician (25%), and the social worker (17%' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The nurse (team leader) performed 152 visits (33%), followed by the psychologist (25%), the physician (25%), and the social worker (17%).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nThe pre-specified primary endpoints were changes in patient quality of life (SEIQoL-DW) and symptom burden (PC Outcome Scale-Symptoms-MS, POSS-MS).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The pre-specified primary endpoints were changes in patient quality of life (SEIQoL-DW) and symptom burden (PC Outcome Scale-Symptoms-MS, POS-S-MS).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nThe intervention consists of six sessions (∼90 min duration) held weekly and facilitated in groups of 6–12 by two health professionals with experience of working with people with MS and group-work (such as occupational therapists, nurses or physiotherapists).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The FACETS intervention consists of six sessions (∼90 min duration) held weekly and facilitated in groups of 6–12 by two health professionals with experience of working with people with MS and group-work (such as occupational therapists, nurses or physiotherapists).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):\n\nIndividuals participated in either a combination of PA and daily Mindfulness or a combination of PA and Implementation Intention.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Individuals participating in either a combination of PA and daily Mindfulness or a combination of PA and Implementation Intention.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.4%):\n\nImplementation Intention group (II) (n = 11) was asked to establish a concrete if-then plan (the ‘if ’ component 1 https://www.tailorbuilder.com/en/about.html followed by the ‘then’ component) once a week and share them through the TB application. These combinations were intended to decrease fatigue and improve mobility among people with MS.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Implementation Intention Participants were asked to develop a concrete if-then plan (the “if” component followed by the “then” component) once a week and share them through the TB application. These combinations were intended to decrease fatigue and improve mobility among people with MS.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 54.9%):\n\nmobility, fatigue, quality of life and the impact of the disease on the patient’s life were measured by 6 min Walking Test (6MWT) (Guyatt et al., 1985) Modified Fatigue Impact Scale (MFIS) (Téllez et al., 2005),' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Mobility, fatigue, and the impact of the disease on the patient’s life were measured by 6 min Walking Test (6MWT) (Guyatt et al., 1985) Modified Fatigue Impact Scale (MFIS) (Téllez et al., 2005), Health-related quality of life measured with EuroQoL (EQ5D-3L) (Goodwin et al., 2019) and Multiple Sclerosis Impact Scale (MSIS-29) (Hobart, 2001), respectively.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):\n\nusion. Twenty patients with relapsing–remitting MS, primary progressive MS or secondary progressive MS, aged 26–50 years, with an EDSS not more than 6 and EDSS pyramidal functions score (EDSSpyr) more than 2 were included in the prospective' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Twenty patients with relapsing–remitting MS, primary progressive MS or secondary progressive MS, aged 26–50 years, with an EDSS not more than 6 and EDSS pyramidal functions score (EDSSpyr) more than 2 were included in the prospective study.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.9%):\n\nsessions. SC took place in the Training, Occupation and Care Centre under the supervision of two SC instructors with a Slovenian Sports Climbing Committee L' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Sports climbing (SC) took place in the Training, Occupation and Care Centre under the supervision of two SC instructors with a Slovenian Sports Climbing Committee License.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.9%):\n\nssment Examinations were performed by the members of Multiple Sclerosis Center at the Division of Neurology, University Medical Center Lju' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Examinations were performed by the members of Multiple Sclerosis Center at the Division of Neurology, University Medical Center Ljubljana.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nPatients of the intervention group received hippotherapy (as defined by the regulations for hippotherapy of the Deutsches Kuratorium für Therapeutisches Reiten e.V. (DKThR)) 8 once a week for 12 weeks as an addon therapy to their standard care, which remained unchanged.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patients of the intervention group received hippotherapy (as defined by the regulations for hippotherapy of the Deutsches Kuratorium für Therapeutisches Reiten e.V. (DKThR)) once a week for 12 weeks as an add-on therapy to their standard care, which remained unchanged.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nAnalyses were based on the modified intention-totreat set (modified ITT)' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Analyses were based on the modified intention-to-treat set (modified ITT).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nThe study took place between August 1997 and March 2000 and was approved by the research ethics committee of Queen&#39;s Medical Centre (Nottingham,' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The study took place between August 1997 and March 2000 and was approved by the research ethics committee of Queen's Medical Centre (Nottingham, UK).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):\n\n(EG), baseline data were reviewed by an expert panel which advised on actions most likely to promote each individual&#39;s physical, social and psychological well-being.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In the EG, baseline data were reviewed by an expert panel which advised on actions most likely to promote each individual's physical, social and psychological well-being.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72%):\n\nInclusion criteria were the following: diagnosis of MS made by a neurologist, able to walk 10 meters with or without an aid within 2 minutes, no relapse of their MS in the past 4 weeks, and no other' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Inclusion criteria: diagnosis of MS made by a neurologist, able to walk 10 meters with or without an aid within 2 minutes, no relapse of their MS in the past 4 weeks, and no other neurological or orthopedic condition that would affect their function.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nOutcome assessments were conducted at baseline, immediately postintervention and at 8-week follow-up.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Outcome assessments were conducted at baseline, immediately post-intervention and at 8-week follow-up.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.9%):\n\nData were analyzed according to the intention-totreat principle' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data were analyzed according to the intention-to-treat principle.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nEligible participants were male 35–65 yr old with a BMI of Q28 kgIm j2 and met PA safety requirements (i.e., no risk indicated by the Physical Activity Readiness Questionnaire [36] or clearance from a health care provider).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Eligible participants were male 35–65 yr old with a BMI of ≥28 kg/m2 and met PA safety requirements (i.e., no risk indicated by the Physical Activity Readiness Questionnaire [36] or clearance from a health care provider).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nWe used a pragmatic approach for the program venue at each site, using a combination of the hockey team_s arena and an affiliated health club facility.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We used a pragmatic approach for the program venue at each site, using a combination of the hockey team’s arena and an affiliated health club facility.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 51.2%):\n\nentives were also provided as part of the program to encourage program attendance and engagement' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Details were provided in the protocol, but coaches were able to adapt delivery based on participants' needs and engagement.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nFollow-up occurred at 12 wk (both groups) and 12 months (intervention group only' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Follow-up occurred at 12 wk (both groups) and 12 months (intervention group only).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nplanned primary outcome for the definitive trial was the difference between groups in mean weight loss (kg) and percentage weight change from baseline to 12 wk.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our planned primary outcome for the definitive trial was the difference between groups in mean weight loss (kg) and percentage weight change from baseline to 12 wk.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 87.4%):\n\ncted 156 pregnant women in their ≥ 37 week/s, who had cervical dilations of ≥ 4 cm and with two or more contractions in 10 minutes.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Inclusion criteria - Pregnant women at their ≥ 37 week/s, who had cervical dilations of ≥ 4 cm and with two or more contractions in 10 minutes.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.3%):\n\nexcluded: serious preeclampsia, placenta previa, immediate indication of cesarean, dilations at ≥ 8 cm and those that used analgesics for less than six hours from the study admission time.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Exclusions - severe preeclampsia, placenta previa, immediate indication of cesarean, dilations at ≥ 8 cm and those that used analgesics for less than six hours from the study admission time.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nVAS was used to evaluate the pain and for predeveloped questions. The women were able to classify their perception of the pain (Table 3).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎VAS was used to evaluate the pain and for pre-developed questions. The women were able to classify their perception of the pain (Table 3).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nExcluded were individuals who had another major disease (among them individuals with asthma who had more than 200 ml or 12% increase in FEV 1 after inhalation of 200 lg albuterol in the postbronchodilator spirometry), who were non-Icelandic speaking, not capable of travelling to the treatment site and those who had participated in a structured rehabilitation programme for people with COPD 6 months prior to the screening.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Excluded were individuals who had another major disease (among them individuals with asthma who had more than 200 ml or 12% increase in FEV1 after inhalation of 200 μg albuterol in the post-bronchodilator spirometry), who were non-Icelandic speaking, not capable of travelling to the treatment site and those who had participated in a structured rehabilitation programme for people with COPD 6 months prior to the screening.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.8%):\n\nThe main approach is to work with patients and families to find out what is meaningful for them in life as regards health and jointly decide on that which is possible and relevant for each patient and family.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The partnership approach is to work with patients and families to find out what is meaningful for them in life as regards health and jointly decide on that which is possible and relevant for each patient and family.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.4%):\n\nFrom their computerised asthma registers the practices identified adults (>18 years) who had asked for a bronchodilator inhaler prescription in the previDepartment' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎From their computerised asthma registers the practices identified adults (>18 years) who had asked for a bronchodilator inhaler prescription in the previous six months but who had not had a routine asthma review in the preceding 11 months.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):\n\nThe study was conducted in outpatient clinics of 10 rheumatology centres across the UK.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This study was conducted in outpatient clinics of 10 rheumatology centres across the UK.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 57.9%):\n\nestablished CVD or an estimated five-year CVD risk of \u001515%, w' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Patients ≥ 18 years of age with established CVD or an estimated five-year CVD risk of ≥15%...were eligible.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nCentral, computer-based randomization to polypillbased strategy or usual care was stratified by primary healthcare centre, type of indication (established CVD versus high risk), Indigenous identification and level of preventive treatment at baseline.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Central, computer-based randomization to polypill-based strategy or usual care was stratified by primary healthcare centre, type of indication (established CVD versus high risk), Indigenous identification and level of preventive treatment at baseline.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.4%):\n\nhe 563 eligible patients, 250 (44%) consented to take part in the tria' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Of 563 eligible patients, 250 (44%) consented to take part in the trial.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nCare pathways for all patients included outpatientand community-based rehabilitation, which primarily comprised 1 or more 1-on-1 sessions with a physiotherapist that focused on restoring function.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Care pathways for all patients included outpatient- and community-based rehabilitation, which primarily comprised 1 or more 1-on-1 sessions with a physiotherapist that focused on restoring function.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nThe primary time point was chosen as 12 months postintervention to match other trials.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary time point was chosen as 12 months post-intervention to match other trials.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nThe primary analysis was carried out on 572 participants with complete data on CHAMPS score at baseline and 12months follow-up. Also carried out were two multiple imputation analyses o' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary analysis was carried out on 572 participants with complete data on CHAMPS score at baseline and 12months follow-up. Also carried out were two multiple imputation analyses...&quot;<\/span>"],[95.3846153846154,93.0851063829787,99.5798319327731,99.8165137614679,99.5798319327731,68,99.7518610421836,99.6078431372549,97.2677595628415,95.0920245398773,98.876404494382,99.468085106383,98.876404494382,62.4,95.774647887324,99.4186046511628,98,99.0825688073395,96.969696969697,98.7096774193548,66.2921348314607,99.1150442477876,96.7914438502674,58.4269662921348,75.78125,99.4152046783626,98.5507246376812,98.5507246376812,97.8021978021978,93.4782608695652,99.1735537190083,99.5762711864407,99.3243243243243,85.7142857142857,92.6829268292683,99.2,99.8,99.7613365155131,85.6435643564356,98.9528795811518,87.1428571428571,99.1666666666667,99.4949494949495,77.0491803278689,99.625468164794,99.6978851963746,99.4897959183673,97.9591836734694,99.3492407809111,98.2608695652174,99.3492407809111,99.0384615384615,99.0990990990991,99.0384615384615,99.1596638655462,98.5221674876847,98.9795918367347,70.2127659574468,97.2222222222222,74.5762711864407,97.8378378378378,99.6138996138996,94.7643979057592,65.6565656565657,98.1927710843374,99.6,99.7652582159624,62.8070175438596,98.1132075471698,98,98.4,85.7142857142857,97.4025974025974,98.2062780269058,96,96.8421052631579,88.5350318471338,96.7914438502674,98.5401459854015,99.3243243243243,97.3684210526316,97.6923076923077,94.4444444444444,54.9019607843137,97.0833333333333,88.8888888888889,94.9275362318841,99.6282527881041,97.2972972972973,97.3154362416107,96.4705882352941,72,99.0196078431373,96.9230769230769,99.0950226244344,99.3377483443709,51.219512195122,98.780487804878,98.1707317073171,87.4125874125874,95.2631578947368,99.2753623188406,99.5283018867924,95.8139534883721,67.3640167364017,97.7272727272727,57.9439252336449,99.601593625498,94.4444444444444,98.989898989899,98.8505747126437,98.9189189189189]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th>Author & Year<\/th>\n      <th>Source<\/th>\n      <th>Quote with deviation<\/th>\n      <th>Similarity<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"ft","order":[[3,"desc"]],"columnDefs":[{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 1, 3, \",\", \".\", null);\n  }"},{"visible":false,"targets":1},{"className":"dt-right","targets":3}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render"],"jsHooks":[]}</script>
</div>
<div id="formatting-accuracy" class="section level3">
<h3>Formatting accuracy</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<ul>
<li>56 / 56 (100%) usable responses with correctly formatted scores</li>
<li>0 / 56 (0%) usable responses with minor fixable score formatting
issues <br><br></li>
<li>51 / 56 (91.1%) publications yielded usable responses in the first
try</li>
<li>5 / 56 (8.9%) publications yielded usable responses after a median
of 3 retries (IQR 2-4, range 1-16), thus being ultimately successful
<ul>
<li>26 responses with failure reason
‘analyzed-and-quoted-mostly-examples-from-briefing’</li>
</ul></li>
<li>0 / 56 (0%) publications yielded no usable responses and were thus
ultimately unsuccessful. <a href="https://doi.org/"></a></li>
</ul>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-f443007d298af16046af" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-f443007d298af16046af">{"x":{"filter":"none","vertical":false,"fillContainer":false,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26"],["Callesen J. (2020)","Callesen J. (2020)","Callesen J. (2020)","Callesen J. (2020)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Freeman J. (2019)","Hermens H. (2008)","Hermens H. (2008)","Higginson I. J. (2009)","Higginson I. J. (2009)","Higginson I. J. (2009)","Velikonja O. (2010)"],["analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing","analyzed-and-quoted-mostly-examples-from-briefing"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[" Here are the PRECIS-2 scores and explanations for the 9 domains based on the full text in '663.pdf':\n\nEligibility criteria\n\nRelevant quotes:\n\n'Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nThe eligibility criteria are rather explanatory as patients had to be confirmed by a specialist (otorhinolaryngologist) even though Bell's palsy is usually diagnosed by a general practitioner. There are also many exclusion criteria that would not apply in usual care.\n\nScore: [2]\n\nRecruitment\n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe the recruitment process.\n\nScore: [NA] \n\nSetting\n\nRelevant quotes: \n\nNo relevant quotes. The paper does not describe the setting(s) of the trial.\n\nScore: [NA]\n\nOrganization\n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe the organization of the trial. \n\nScore: [NA]\n\nFlexibility: Delivery\n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe flexibility in delivery of the intervention.\n\nScore: [NA]  \n\nFlexibility: Adherence \n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe flexibility in adherence.\n\nScore: [NA]\n\nFollow-up\n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe follow-up procedures.\n\nScore: [NA]\n\nPrimary outcome\n\nRelevant quotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nThe primary outcome uses a scale and central adjudication not routinely used in primary care, making it less relevant to participants. This is more explanatory.\n\nScore: [1]\n\nPrimary analysis\n\nRelevant quotes: \n\nNo relevant quotes. The paper does not describe the primary analysis.\n\nScore: [NA]\n"," Here are the PRECIS-2 assessments for the attached study:\n\nEligibility criteria\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nThe eligibility criteria are rather explanatory, with several exclusions beyond what would be typical in usual care. Patients had to be confirmed by a specialist rather than just diagnosed by a general practitioner as is typical. Several medical comorbidities were exclusions even though they would not preclude treatment in usual practice. Overall, this design choice limits the trial's applicability.\n\nScore: [2]\n\nRecruitment\n\nRelevant quotes: \n\nNo relevant quotes provided in the full text.\n\nThe paper does not provide any details on the recruitment process. Therefore, there is insufficient information to assess this domain.\n\nScore: [NA] \n\nSetting\n\nRelevant quotes:\n\nNo relevant quotes provided in the full text.\n\nThe setting is not described, so there is insufficient information to assess pragmatism.\n\nScore: [NA]\n\nOrganisation\n\nRelevant quotes:\n\nNo relevant quotes provided in the full text.\n\nThe paper does not provide any details on resources, provider expertise, or organization of care delivery. There is insufficient information to assess this domain.\n\nScore: [NA]\n\nFlexibility: Delivery\n\nRelevant quotes:\n\nNo relevant quotes provided in the full text.\n\nThe paper does not provide any details on flexibility in intervention delivery. There is insufficient information to assess this domain.\n\nScore: [NA]\n\nFlexibility: Adherence \n\nRelevant quotes:\n\nNo relevant quotes provided in the full text.\n\nThe paper does not discuss adherence monitoring or measures. There is insufficient information to assess this domain.\n\nScore: [NA]\n\nFollow-up\n\nRelevant quotes:\n\nNo relevant quotes provided in the full text.\n\nThe paper does not provide details on follow-up intensity or procedures. There is insufficient information to assess this domain.\n\nScore: [NA]\n\nPrimary outcome\n\nRelevant quotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nThe primary outcome used a scale not routinely used in primary care and required special training, making it less applicable. Central adjudication by experts is also less pragmatic. This reduces the relevance of the outcome to patients in usual practice.\n\nScore: [2]\n\nPrimary analysis\n\nRelevant quotes:\n\nNo relevant quotes provided in the full text.\n\nThe paper does not provide details on the primary analysis. There is insufficient information to assess this domain.\n\nScore: [NA]\n"," Here are the PRECIS-2 domain scores and justifications based on the attached full text:\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The eligibility criteria exclude patients with certain medical conditions that are not routinely screened for Bell's palsy diagnosis in usual care. Confirmation by a specialist otorhinolaryngologist is also not typical in primary care. These additional exclusion criteria and confirmation make the trial more explanatory than pragmatic.\n\nScore: [2]\n\nRecruitment:\n\nRelevant quotes: NA\n\nReasoning: No information provided on recruitment methods. \n\nScore: [NA] \n\nSetting: \n\nRelevant quotes: NA\n\nReasoning: No information provided on settings where the trial took place.\n\nScore: [NA]\n\nOrganization:\n\nRelevant quotes: NA\n\nReasoning: No information provided on organization of care delivery. \n\nScore: [NA]\n\nFlexibility (delivery):\n\nRelevant quotes: NA\n\nReasoning: No information provided on flexibility in intervention delivery.\n\nScore: [NA]\n\nFlexibility (adherence): \n\nRelevant quotes: NA\n\nReasoning: No information provided on measures to ensure adherence.\n\nScore: [NA]\n\nFollow-up:\n\nRelevant quotes: NA\n\nReasoning: No information provided on follow-up procedures.\n\nScore: [NA]  \n\nPrimary outcome:\n\nRelevant quotes: \n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The House-Brackmann scale is not used routinely in primary care, requires special training, and outcomes were centrally adjudicated. This makes the choice of primary outcome more explanatory.\n\nScore: [1]\n\nPrimary analysis: \n\nRelevant quotes: NA\n\nReasoning: No information provided on primary analysis methods.\n\nScore: [NA]\n","Here are the PRECIS-2 scores and explanations for the trial described in '663.pdf':\n\nEligibility criteria\n\nQuotes:\n- 'Inclusion criteria—Patients ≥ 3 with acute respiratory tract infections.'\n- 'Exclusions not common cold but severe respiratory tract infections, peptic ulcer and asthma.'\n- 'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nThe eligibility criteria are rather explanatory as patients had to be confirmed by a specialist, even though Bell's palsy is usually diagnosed by a general practitioner. There are also several exclusion criteria that would not apply in usual care.\n\nScore: [2]\n\nRecruitment\n\nQuotes: \n- 'Patients presenting to GP or nurse in primary care with respiratory tract infections as diagnosed by health professional.'\n- 'Recruitment was inadequate using a postal questionnaire, so participants were then recruited through clinic attendances...'\n\nRecruitment started pragmatically through usual appointments but then became more explanatory by using a postal questionnaire. Overall it seems to be a mix of methods, some feasible in usual care.\n\nScore: [3] \n\nSetting\n\nQuotes:\n- 'Identical setting to usual care setting: primary care, where patients usually go for advice and treatment of the common cold in the UK.' \n- 'Multi-centre: 25 practices in UK.'\n\nThe setting is very pragmatic, identical to usual care and involving multiple centres.\n\nScore: [5]\n\nOrganisation\n\nQuote: \n- 'Information sheets given out to participants. This is not usual practice, would it be if trial had shown this helped? Need more staff for follow up of trial participants to get diary results so more extensive data collection than usual. Otherwise no difference in provider expertise and organisation of care delivery.'\n\nThe organisation is moderately pragmatic - some additional resources for follow-up but otherwise similar expertise and delivery.\n\nScore: [3]\n\nFlexibility: Delivery\n\nQuote: \n- 'Full flexibility'\n\nNo protocol or measures to improve compliance, so very pragmatic flexibility in delivery. \n\nScore: [5]\n\nFlexibility: Adherence\n\nQuotes:\n- 'Compliance measured with diary – “reasonably good” participants free to “not-comply” with advice. Little impact of advising patients to take analgesics regularly. No measures to improve compliance'\n\nNo special measures to enforce adherence, very pragmatic.\n\nScore: [5]\n\nFollow-up\n\nQuotes:\n- 'Participants Followed up one month – usual care no follow up. Patients come back to GP if problems.' \n- 'Trial more extensive data colleaction - patients telephoned day two to three to check for any problems with diary completion. If no diary after 2 weeks then mailed reminder and then phoned as necessary to document outcomes using validated questionnaire.'\n\nMore intensive follow-up than usual care to collect trial data. Moderately explanatory. \n\nScore: [2]\n\nPrimary outcome\n\nQuotes:\n- 'Very relevant to participants - Mean symptom severity on days 2-4. Symptoms 0 (no problem) to 6 (as bad as they can be 7 in abstract). Completed in diary – children with parents or participants.'\n\nSymptom severity very relevant to patients. Pragmatic choice.\n\nScore: [5]\n\nPrimary analysis\n\nQuote:\n- 'ITT no matter whether compliance.'\n\nIntention-to-treat analysis very pragmatic.\n\nScore: [5]\n","Here are the PRECIS-2 domain scores for the trial based on the provided text:\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—All patients aged ≥15 with suspected asthma were included in the study, based on a crude clinical diagnosis of asthma, as the standard respiratory testing machinery was not available in this rural setting in South Africa.' \n\n'Suggested PRECIS score—5, very pragmatic.'\n\nReasoning: The trial included all patients aged 15 and above with suspected asthma based on a crude clinical diagnosis. This matches usual care in the rural South African setting where the standard respiratory testing machinery is often not available. The inclusion criteria appear very similar to real world practice.\n\nScore: [5]\n\nRecruitment:\n\nRelevant quotes:  \n\n'Patients presenting to GP or nurse in primary care with respiratory tract infections as diagnosed by health professional. Easy to recruit to but time pressures in busy winter clinics prevented recruitment and meant non-recruitments logs poorly completed.'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: Patients were recruited as they presented to their regular GP or nurse with respiratory tract infections, as would occur in usual practice. Some issues with recruitment due to time pressures indicate that no extra effort was made beyond what would normally occur.\n\nScore: [5] \n\nSetting:\n\nRelevant quotes:\n\n'Identical setting to usual care setting - primary care where patients usually go for advice and treatment.'  \n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: The trial was conducted in primary care clinics, which is the typical setting where patients would seek treatment for respiratory tract infections in usual practice.\n\nScore: [5]\n\nOrganisation:\n\nRelevant quotes: \n\n'Information sheets given out to participants. This is not usual practice, would it be if trial had shown this helped? Need more staff for follow up of trial participants to get diary results so more extensive data collection than usual. Otherwise no difference in provider expertise and organisation of care delivery.'\n\n'Suggested PRECIS score—3'\n\nReasoning: Some additional resources were used such as information sheets and extra staff for follow-up, indicating more extensive data collection than usual care. But provider expertise and care delivery seems unchanged.\n\nScore: [3]\n\nFlexibility (delivery): \n\nRelevant quotes: \n\n'Compliance measured with diary – “reasonably good” participants free to “not-comply” with advice. Little impact of advising patients to take analgesics regularly. No measures to improve compliance'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: No protocol specified for intervention delivery and participants were free to adhere as in usual practice. No special measures were in place to improve compliance.\n\nScore: [5]\n\nFlexibility (adherence):\n\nRelevant quotes:\n\n'Participants Followed up one month – usual care no follow up. Patients come back to GP if problems.' \n\n'Trial more extensive data colleaction - patients telephoned day two to three to check for any problems with diary completion. If no diary after 2 weeks then mailed reminder and then phoned as necessary to document outcomes using validated questionnaire.'\n\n'Suggested PRECIS score—2, rather explanatory.'\n\nReasoning: Follow-up was more extensive than usual care, with phone calls and reminders to participants. This indicates adherence was monitored and encouraged more closely than typical practice.\n\nScore: [2]\n\nPrimary outcome:\n\nRelevant quotes:\n\n'Very relevant to participants - Mean symptom severity on days 2-4. Symptoms 0 (no problem) to 6 (as bad as they can be 7 in abstract). Completed in diary at end of day – children with parents or participants.'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: The primary outcome of symptom severity is very relevant to patients with respiratory tract infections. It was measured through patient diaries, similar to usual practice.\n\nScore: [5]\n\nPrimary analysis:\n\nRelevant quotes:\n\n'ITT no matter whether compliance.'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: An intention-to-treat analysis was used including all participants regardless of compliance. This matches real world practice.\n\nScore: [5]\n"," Here are the PRECIS-2 scores for the trial in the attached paper '671.pdf':\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The inclusion criteria are reasonably broad, including adult patients presenting with unilateral facial nerve weakness without identifiable cause. However, the exclusion criteria eliminate some patients who would be eligible for the intervention in routine practice, such as those with diabetes, infection, or pregnancy/breastfeeding. Additionally, requiring confirmation by a specialist rather than diagnosis by a general practitioner makes the trial population less representative of real-world practice.\n\nScore: [2]\n\nRecruitment:\n\nRelevant quotes:\n\nNo details provided on recruitment process.\n\nReasoning: The paper does not provide any information about how patients were recruited into the trial. Without this information, it is not possible to assess whether extra effort was made compared to routine practice.\n\nScore: [NA] \n\nSetting: \n\nRelevant quotes:\n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The trial was conducted in a specialist hospital setting and required confirmation by a senior otorhinolaryngologist, whereas bell's palsy is usually diagnosed and treated in primary care by a general practitioner. The specialized setting makes the trial less pragmatic.\n\nScore: [2]\n\nOrganization:\n\nRelevant quotes:\n\nNo details provided on organization of intervention delivery.\n\nReasoning: The paper does not provide information about the expertise, resources, or organizational model used to deliver the intervention. This lack of details makes it impossible to assess the pragmatism of this domain.\n\nScore: [NA]\n\nFlexibility (delivery):\n\nRelevant quotes: \n\nNo details provided on flexibility in delivering the intervention.\n\nReasoning: The paper does not discuss whether providers had flexibility in how the intervention was implemented or if it was rigidly protocolized. Without this information, the pragmatism of delivery cannot be evaluated.\n\nScore: [NA]\n\nFlexibility (adherence):\n\nRelevant quotes:\n\nNo details provided on measures to enforce adherence.\n\nReasoning: The paper does not mention if there were any measures to monitor or enforce patient adherence to the prescribed treatment. This absence of information prevents assessment of this domain's pragmatism.\n\nScore: [NA]\n\nFollow-up:\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual: Pre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. Troponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery) ECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\n\nReasoning: The trial had more extensive follow-up than usual care, including longer clinical follow-up, more extensive monitoring and data collection, and unscheduled visits triggered by the primary outcome event. This intensity of follow-up makes it more explanatory.\n\nScore: [1]\n\nPrimary outcome:\n\nRelevant quotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.' \n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.'\n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The House-Brackmann scale is not routinely used in primary care and required specialized training and central adjudication by experts. This makes the choice of outcome measure less relevant to real-world practice.\n\nScore: [1]\n\nPrimary analysis:\n\nRelevant quotes:\n\nNo details provided on analysis methods.\n\nReasoning: The paper does not provide information about the primary analysis, including handling of non-adherence and missing data. This absence of details prevents assessment of the pragmatism of the analysis.\n\nScore: [NA]\n"," Here are the PRECIS-2 scores for each domain based on the provided full text:\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The inclusion criteria are quite broad, including patients over 16 years old with unilateral facial nerve weakness presenting to primary care or emergency department. However, the exclusion criteria exclude some patients who would likely receive the intervention in usual care, like those with uncontrolled diabetes or infection. Additionally, requiring confirmation by a senior otorhinolaryngologist is more restrictive than usual care where Bell's palsy is often diagnosed by a general practitioner.\n\nScore: [2]\n\nRecruitment:\n\nRelevant quotes:\n\n'Initially extra resources were used to recruit patients at 53 primary care practices. Patients were recruited via a postal questionnaire to identify symptoms and trial eligibility, not just to invite to participate.'\n\nReasoning: Recruitment initially involved extra resources like postal questionnaires to identify eligible patients, which is more restrictive than usual care recruitment during clinic visits. This was changed during the trial to be more pragmatic by recruiting during clinic visits.\n\nScore: [2], but became more pragmatic over time, so could be scored as [3].\n\nSetting: \n\nRelevant quotes:\n\n'Single centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.'\n\nReasoning: The trial was done at a single specialized military medical center, which is likely different from the usual care setting for most patients receiving physiotherapy for shoulder impingement.\n\nScore: [2]\n\nOrganization:\n\nRelevant quotes: \n\n'Multicentre clinical trials of ARDS treatments, but there was difficulty translating results from a trial involving low tidal volume (Vt) into usual clinical practice' \n\n'Ten academic centres with 75 intensive care units'\n\n'Extra staff, and very labour intensive' \n\n'Used additional equipment beyond usual care, none of which was planned for at the trial design stage'\n\nReasoning: The trial involved multiple academic centers with extra staffing, training, equipment and resources beyond what is typical in usual care settings, making it more explanatory.\n\nScore: [1] \n\nFlexibility (delivery):\n\nRelevant quotes:\n\n'Protocol driven—Much detail given, with protocol violations recorded in self reported case form. Investigators accept this may occur due to clinical needs (such as anaesthesia).'\n\n'Co-interventions—Specific direction' \n\n'Complications—Specific directions for managing complications or side effects'\n\nReasoning: The delivery of the intervention is highly specified and protocolized, with measures to record protocol violations. Specific directions are given for co-interventions and complications. Overall, this reduces flexibility compared to usual care.\n\nScore: [2]\n\nFlexibility (adherence):\n\nRelevant quotes:\n\n'The sessions were all individual based on interaction with child and allowed for range of responses to the intervention'\n\nReasoning: The therapy sessions allow for a range of responses and interaction with the child, without specific measures to enforce adherence. This level of flexibility is likely similar to usual care.\n\nScore: [5]\n\nFollow-up:\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual: Pre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. Troponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery) ECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nReasoning: Follow-up was more extensive than usual care, with clinical follow-up for 30 days, extensive data collection, and unscheduled visits triggered by primary outcome events.\n\nScore: [1]\n\nPrimary outcome:\n\nRelevant quotes: \n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The House-Brackmann scale is not routinely used in primary care and required central adjudication by experts rather than general practitioners who would normally assess facial nerve function. This makes it more explanatory.\n\nScore: [1]\n\nPrimary analysis:\n\nRelevant quotes:\n\n'Intention-to-treat principle was applied with multiple imputation of data'\n\nReasoning: An intention-to-treat analysis was used including all randomized participants, which is a pragmatic approach.\n\nScore: [5]\n"," Here are the PRECIS-2 scores for the trial described in the attached publication (671.pdf):\n\nEligibility criteria\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The inclusion criteria are fairly broad, including adult patients presenting with unilateral facial nerve weakness. However, the exclusion criteria eliminate some patients who would be eligible in usual care, such as those with certain medical conditions. Confirmation of diagnosis by a specialist rather than a general practitioner is also not reflective of usual care. Overall, the eligibility criteria are rather explanatory.\n\nScore: [2]\n\nRecruitment\n\nRelevant quotes:\n\nNo details provided on recruitment process.\n\nReasoning: Since no information is provided on how patients were recruited, I cannot assess whether extra effort beyond usual care was made.\n\nScore: [NA] \n\nSetting\n\nRelevant quotes:\n\nSingle centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.\n\nReasoning: The trial was conducted at a single, specialized military medical center, which is likely not the typical setting where most patients would receive care for this condition. This makes the setting rather explanatory.\n\nScore: [2]\n\nOrganisation\n\nRelevant quotes:\n\nNo details provided on organization of intervention delivery.\n\nReasoning: No information is provided on the expertise, resources, or care delivery organization for the intervention. I cannot assess this domain.\n\nScore: [NA]\n\nFlexibility: delivery\n\nRelevant quotes: \n\nNo details provided on flexibility in delivering the intervention.\n\nReasoning: There is no information provided on how flexibly the intervention was delivered. I cannot assess this domain.\n\nScore: [NA]\n\nFlexibility: adherence \n\nRelevant quotes:\n\nNo details provided on measures to enforce adherence.\n\nReasoning: There is no information provided on measures to enforce patient adherence. I cannot assess this domain.\n\nScore: [NA]\n\nFollow-up\n\nRelevant quotes:\n\nClinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care. \n\nMonitoring intensity involved more extensive data collection than usual:\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. \n\nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery)\n\nECG after randomisation and at 7 and 30 days after surgery.\n\nUnscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)\n\nReasoning: Follow-up was more intensive than usual care, with clinical follow-up for a longer duration, more extensive data collection, and additional unscheduled visits triggered by cardiovascular events. This indicates the follow-up was very explanatory.\n\nScore: [1]\n\nPrimary outcome\n\nRelevant quotes:\n\nPrimary outcome—composite of 30-day cardiovascular mortality and morbidity\n\nReasoning: The primary outcome is a composite measure of cardiovascular events, which does not directly reflect outcomes of importance to patients in terms of symptoms or functioning. It is a more explanatory, surrogate outcome.\n\nScore: [2] \n\nPrimary analysis\n\nRelevant quotes:\n\nNo details provided on primary analysis.\n\nReasoning: There is no information provided about the primary analysis. I cannot assess this domain.\n\nScore: [NA]\n"," Here are the PRECIS-2 scores for the trial reported in the attached paper '671.pdf':\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.'\n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The eligibility criteria are rather restrictive, excluding pregnant women, patients with certain medical conditions, and requiring confirmation by a specialist rather than diagnosis in primary care as is typical. This makes the trial population less representative of real-world patients.\n\nScore: [2]\n\nRecruitment:\n\nRelevant quotes:\n\n'Initially extra resources were used to recruit patients at 53 primary care practices. Patients were recruited via a postal questionnaire to identify symptoms and trial eligibility, not just to invite to participate. This would push the recruitment path of this domain towards the explanatory end.' \n\n'In this trial, recruitment was inadequate using a postal questionnaire, so participants were then recruited through clinic attendances changing the recruitment towards a more pragmatic trial design, creating results which are more applicable to users of the results in a primary care setting.'\n\nReasoning: Recruitment started in an explanatory way by using questionnaires and resources not typical of primary care. But this was shifted to a more pragmatic approach recruiting through clinic visits later. Overall a mix of recruitment methods were used.\n\nScore: [3]\n\nSetting:\n\nRelevant quote:\n\n'Single centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.'\n\nReasoning: The trial was done in a single specialized center which is not the typical real-world setting.\n\nScore: [2] \n\nOrganization:\n\nRelevant quote: \n\nNo relevant quotes. The paper does not provide information about organization.\n\nReasoning: The paper does not report on organization such as provider expertise, resources, etc.\n\nScore: [NA]\n\nFlexibility (delivery): \n\nRelevant quotes:\n\nNo relevant quotes. The paper does not provide information about flexibility of delivery.\n\nReasoning: The paper does not report on flexibility of delivery of the intervention. \n\nScore: [NA]\n\nFlexibility (adherence):\n\nRelevant quotes: \n\nNo relevant quotes. The paper does not provide information about flexibility of adherence.\n\nReasoning: The paper does not report on flexibility of adherence such as measures to ensure adherence.\n\nScore: [NA]\n\nFollow-up:\n\nRelevant quote:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\nReasoning: Follow-up was more extensive than usual care, until 30 days after surgery.\n\nScore: [1]\n\nPrimary outcome:\n\nRelevant quotes:  \n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The primary outcome is a scale not used in primary care, requires specific training, and uses central adjudication rather than assessment by the typical providers. This makes it less relevant to real-world practice.\n\nScore: [1]\n\nPrimary analysis:\n\nRelevant quotes:\n\nNo relevant quotes. The paper does not provide information about the primary analysis.\n\nReasoning: The paper does not report details about the primary analysis such as intention-to-treat versus per-protocol.\n\nScore: [NA]\n"," Here are the PRECIS-2 scores for each domain based on the full text '671.pdf':\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning:\n\nThe inclusion criteria seem reasonably broad, including adult patients presenting with unilateral facial nerve weakness. However, the exclusion criteria appear more restrictive, excluding several medical conditions as well as pregnancy and breastfeeding. The requirement for a senior otorhinolaryngologist to confirm eligibility also makes this more explanatory, since Bell's palsy is usually diagnosed by a general practitioner in primary care. Overall, the eligibility criteria reduce the participants' similarity to real-world patients.\n\nScore: [2]\n\nRecruitment:\n\nRelevant quotes: \n\nNo relevant quotes found. The full text does not describe the recruitment methods.\n\nReasoning: \n\nSince no information is provided on how patients were recruited, I cannot assess this domain.\n\nScore: [NA] \n\nSetting:\n\nRelevant quotes:\n\n'Single centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.'\n\nReasoning: \n\nThe trial was conducted at a single specialized center, which is not the typical setting where most patients would receive treatment. This reduces the trial's applicability.\n\nScore: [2]\n\nOrganization:\n\nRelevant quotes:\n\nNo relevant quotes found. The full text does not describe the organization of care delivery.\n\nReasoning: \n\nSince no information is provided on the organization of care delivery, I cannot assess this domain.\n\nScore: [NA]\n\nFlexibility - Delivery:\n\nRelevant quotes:\n\nNo relevant quotes found. The full text does not describe flexibility in delivery of the intervention. \n\nReasoning:\n\nSince no information is provided on flexibility in delivery, I cannot assess this domain.\n\nScore: [NA]\n\nFlexibility - Adherence: \n\nRelevant quotes:\n\nNo relevant quotes found. The full text does not describe measures to ensure adherence.\n\nReasoning: \n\nSince no information is provided on measures for adherence, I cannot assess this domain.\n\nScore: [NA]\n\nFollow-up:\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual: \nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. \nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery)\nECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nReasoning: \n\nFollow-up was more frequent and intense than usual care, with additional data collection and unscheduled visits triggered by the primary outcome. This makes it more explanatory.\n\nScore: [1]\n\nPrimary Outcome:\n\nRelevant quotes:\n\nNo relevant quotes found. The full text does not describe the primary outcome.\n\nReasoning: \n\nSince no information is provided on the primary outcome, I cannot assess this domain.\n\nScore: [NA]\n\nPrimary Analysis:\n\nRelevant quotes:\n\nNo relevant quotes found. The full text does not describe the primary analysis.\n\nReasoning: \n\nSince no information is provided on the primary analysis, I cannot assess this domain.\n\nScore: [NA]\n"," Here are the PRECIS-2 assessments for each domain based on the full text publication:\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning:\n\nThe inclusion criteria are quite broad, including adult patients presenting with unilateral facial nerve weakness. However, the exclusion criteria are more restrictive, excluding several medical conditions and requiring confirmation by a specialist otorhinolaryngologist, whereas Bell's palsy is typically diagnosed by a general practitioner. The extra test to confirm eligibility makes the trial population less representative of patients who would receive this intervention in usual care.\n\nScore: [2]\n\nRecruitment:\n\nRelevant quotes:  \n\n'Initially extra resources were used to recruit patients at 53 primary care practices. Patients were recruited via a postal questionnaire to identify symptoms and trial eligibility, not just to invite to participate. This would push the recruitment path of this domain towards the explanatory end.'\n\n'In this trial, recruitment was inadequate using a postal questionnaire, so participants were then recruited through clinic attendances changing the recruitment towards a more pragmatic trial design, creating results which are more applicable to users of the results in a primary care setting.'\n\nReasoning: \n\nThe initial recruitment using postal questionnaires is more explanatory, since it requires additional resources not typically used in usual care. However, recruitment was later changed to be done through clinic visits, which is more pragmatic and representative of usual care. The mix of recruitment methods places this domain in the middle of the pragmatic-explanatory continuum.\n\nScore: [3]\n\nSetting:\n\nRelevant quote: \n\n'Single centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.'\n\nReasoning:\n\nThe trial was conducted in a single, specialized military medical center, which is likely not the typical setting where most patients would receive treatment for shoulder impingement. This makes the setting less generalizable and more explanatory.\n\nScore: [2] \n\nOrganization:\n\nRelevant quotes:\n\n'Identical organisation to usual care, usual clinic'\n\n'Same number of staff' \n\n'Usual experience—fully qualified ophthalmologists who have completed general and specialist training (in ophthalmology and glaucoma, respectively) and able to perform lens extraction procedures'\n\n'No additional training'\n\n'No additional resources'\n\nReasoning:\n\nThe organization of care delivery in the trial matches that of usual care - using the typical clinic setting, usual staffing, and providers with typical qualifications and experience. No extra training or resources were provided. This indicates a very pragmatic approach for this domain.\n\nScore: [5]\n\nFlexibility (delivery):\n\nRelevant quotes:\n\n'Protocol driven—Much detail given, with protocol violations recorded in self reported case form. Investigators accept this may occur due to clinical needs (such as anaesthesia).' \n\n'Co-interventions—Specific direction'\n\n'Complications—Specific directions for managing complications or side effects'\n\nReasoning: \n\nThe delivery of the intervention is specified in detail in the protocol, protocol violations are recorded, co-interventions and complications are managed in a directed way. This reduces flexibility in how the intervention is delivered compared to usual care, indicating a more explanatory approach.\n\nScore: [2]\n\nFlexibility (adherence): \n\nRelevant quote:\n\n'The sessions were all individual based on interaction with child and allowed for range of responses to the intervention'\n\nReasoning:\n\nThe intervention is tailored and allows flexibility in how the child adheres and responds to it. There are no measures to enforce or improve adherence. This indicates a very pragmatic approach.\n\nScore: [5]\n\nFollow-up:\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual: Pre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. Troponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery) ECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nReasoning:\n\nFollow-up is more extensive than usual care, with more frequent visits, more data collection, and unscheduled visits triggered by the primary outcome event. This indicates a very explanatory approach.\n\nScore: [1]\n\nPrimary outcome: \n\nRelevant quotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning:\n\nThe primary outcome requires specialized training and central adjudication by experts, and is not typically used in primary care where Bell's palsy is usually diagnosed and monitored. This makes it less relevant to patients and indicates a more explanatory approach.\n\nScore: [1]\n\nPrimary analysis:\n\nRelevant quote:  \n\n'Intention-to-treat principle was applied with multiple imputation of data'\n\nReasoning: \n\nA full intention-to-treat analysis was used with no exclusions. This indicates a very pragmatic approach.\n\nScore: [5]\n"," Here are the PRECIS-2 scores for the trial based on the provided full text article:\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The inclusion criteria are quite broad, including patients aged 16 years or older who present within 72 hours of onset. However, the exclusion criteria exclude some patients who would receive this treatment in usual care, like pregnant/breastfeeding women and those with certain medical conditions. Additionally, requiring confirmation by a specialist rather than just a GP diagnosis makes it less like usual care.\n\nScore: [2]\n\nRecruitment:\n\nRelevant quotes:\n\nNo quotes, the article does not describe the recruitment process.\n\nReasoning: Since the recruitment process is not described, there is insufficient information to assess this domain.  \n\nScore: [NA] \n\nSetting:\n\nRelevant quotes:\n\nNo quotes, the article does not describe the setting.\n\nReasoning: Since the setting is not described, there is insufficient information to assess this domain.\n\nScore: [NA]\n\nOrganization:\n\nRelevant quotes: \n\nNo quotes, the article does not describe the organization.\n\nReasoning: Since the organization is not described, there is insufficient information to assess this domain.\n\nScore: [NA]\n\nFlexibility (delivery):\n\nRelevant quotes:\n\nNo quotes, the article does not describe flexibility of delivery.\n\nReasoning: Since flexibility of delivery is not described, there is insufficient information to assess this domain.\n\nScore: [NA]\n\nFlexibility (adherence):\n\nRelevant quotes:\n\nNo quotes, the article does not describe measures for adherence.\n\nReasoning: Since measures for adherence are not described, there is insufficient information to assess this domain.\n\nScore: [NA]\n\nFollow-up:\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual:\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. \nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery)\nECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\n\nReasoning: The trial had more extensive follow-up than usual care, including longer clinical follow-up, more frequent troponin measurements, and ECGs at more timepoints. Additionally, unscheduled visits were triggered by cardiovascular events. This intensive follow-up makes it very explanatory.\n\nScore: [1]\n\nPrimary outcome:\n\nRelevant quotes: \n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The primary outcome is a scale not routinely used in primary care, requires special training, and uses central adjudication rather than assessment by GPs who usually diagnose Bell's palsy. This makes it very explanatory.\n\nScore: [1]\n\nPrimary analysis:\n\nRelevant quotes:\n\nNo quotes, the article does not describe the primary analysis.\n\nReasoning: Since the primary analysis is not described, there is insufficient information to assess this domain.\n\nScore: [NA]\n"," Here are the PRECIS-2 domain scores for the trial described in the attached publication '671.pdf':\n\nEligibility criteria\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The inclusion criteria focus on patients with a confirmed diagnosis of Bell's palsy, which is appropriate for the trial's purpose. However, the exclusion criteria rule out several groups that would likely receive the intervention in usual care, such as pregnant/breastfeeding women and those with certain comorbidities. The extra eligibility test requiring confirmation by a specialist is also not typical in usual care. These exclusions make the participants less representative of real-world populations.\n\nScore: [2]\n\nRecruitment\n\nRelevant quotes:\n\nNo relevant quotes found. The publication does not describe the recruitment methods.\n\nReasoning: Since no information is provided on how participants were recruited, I cannot assess whether extra effort beyond usual care was made.\n\nScore: [NA] \n\nSetting\n\nRelevant quotes:\n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The setting involving specialist confirmation in a hospital is more specialized than the typical primary care setting where Bell's palsy is diagnosed and treated.\n\nScore: [2]\n\nOrganization\n\nRelevant quotes: \n\nNo relevant quotes found. The publication does not describe the organization of care delivery.\n\nReasoning: No information is provided on the expertise, resources, and organization of care delivery.\n\nScore: [NA]\n\nFlexibility: delivery\n\nRelevant quotes:\n\nNo relevant quotes found. The publication does not describe flexibility in delivering the intervention.\n\nReasoning: No information is provided on how flexibly the intervention was delivered. \n\nScore: [NA]\n\nFlexibility: adherence\n\nRelevant quotes:\n\nNo relevant quotes found. The publication does not describe measures to ensure adherence.\n\nReasoning: No information is provided on measures to ensure adherence to the intervention.\n\nScore: [NA] \n\nFollow-up\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual:\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. \nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery)\nECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nReasoning: The extended follow-up period and more extensive data collection, including additional tests and unscheduled visits triggered by events, exceeds typical follow-up in usual care.\n\nScore: [1]\n\nPrimary outcome\n\nRelevant quotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.' \n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.'\n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The House-Brackmann scale is not routinely used in primary care, requires special training, and involved central adjudication by experts. This makes the outcome measure less relevant to usual care.\n\nScore: [1] \n\nPrimary analysis\n\nRelevant quotes:\n\nNo relevant quotes found. The publication does not describe the primary analysis population and methods.\n\nReasoning: No information is provided on the primary analysis methods.\n\nScore: [NA]\n"," Here are the PRECIS-2 domain scores and explanations for the trial described in the attached paper:\n\n1. Eligibility criteria\n\nQuotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.'  \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nExplanation: The trial has strict inclusion and exclusion criteria that make the sample less representative of the patients who would receive this intervention in usual care. Confirmation by a specialist otorhinolaryngologist is not typical in primary care. Overall, this makes the eligibility criteria quite explanatory. Score: [2]\n\n2. Recruitment\n\nQuote: 'Initially extra resources were used to recruit patients at 53 primary care practices. Patients were recruited via a postal questionnaire to identify symptoms and trial eligibility, not just to invite to participate. This would push the recruitment path of this domain towards the explanatory end.'\n\nExplanation: The initial postal questionnaire recruiting method required additional resources not normally used in primary care. This makes recruitment more explanatory. The recruitment path became more pragmatic later when participants were recruited directly through clinic visits, but the initial approach was more explanatory. Score: [2]\n\n3. Setting\n\nQuote: 'Single centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.'\n\nExplanation: The trial was done at a single, specialized treatment center which is different from the usual care setting where most patients receive treatment for this condition. This makes the setting rather explanatory. Score: [2]  \n\n4. Organization\n\nQuotes: \n\n'Multicentre clinical trials of ARDS treatments, but there was difficulty translating results from a trial involving low tidal volume (Vt) into usual clinical practice.'\n\n'Ten academic centres with 75 intensive care units.' \n\n'Extra staff, and very labour intensive.'\n\n'Used additional equipment beyond usual care, none of which was planned for at the trial design stage.'\n\nExplanation: The trial required substantially more resources, staff, equipment, and intensive care units than would be available in usual practice. This makes the organization very explanatory. Score: [1]\n\n5. Flexibility: Delivery\n\nQuote: 'Protocol driven—Much detail given, with protocol violations recorded in self reported case form. Investigators accept this may occur due to clinical needs (such as anaesthesia).' \n\n'Co-interventions—Specific direction.'\n\n'Complications—Specific directions for managing complications or side effects.'\n\n'Improving adherence—No measures in place.'\n\nExplanation: The protocol is highly prescriptive about intervention delivery, co-interventions, and handling of complications. This reduces flexibility compared to usual care. Score: [2]\n\n6. Flexibility: Adherence\n\nQuote: 'The sessions were all individual based on interaction with child and allowed for range of responses to the intervention.'\n\nExplanation: The intervention allows flexibility in how the child responds and adheres. There are no special measures to enforce adherence. This makes it very pragmatic. Score: [5]\n\n7. Follow-up\n\nQuotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual: Pre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. Troponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery) ECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke).'\n\nExplanation: Follow-up is more frequent and intensive than usual care, with additional data collection. Unscheduled visits are also triggered by primary outcome events. This makes follow-up very explanatory. Score: [1] \n\n8. Primary Outcome  \n\nQuotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.' \n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.'\n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nExplanation: The primary outcome measure is not routinely used in primary care and requires specialist training and central adjudication. This makes it quite explanatory. Score: [1]\n\n9. Primary Analysis\n\nQuote: 'Dietary lead in to screen and exclude non-compliers, then post-randomisation excluded non-compliers who did not take medication, so “per protocol analysis.” The trial did, however, include those who violated protocol, deviated from protocol, or withdrew (mainly due to adverse events).'\n\nExplanation: The primary analysis excludes non-compliers, making it more explanatory. However, it does include those who violated or deviated from the protocol. Overall, this approach seems rather explanatory. Score: [2]\n"," Here are the PRECIS-2 scores for each domain based on the full text:\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—All patients aged ≥15 with suspected asthma were included in the study, based on a crude clinical diagnosis of asthma, as the standard respiratory testing machinery was not available in this rural setting in South Africa.'\n\n'Suggested PRECIS score—5, very pragmatic.'\n\nReasoning: The inclusion criteria are very broad, including all patients aged 15 or older with a suspected clinical diagnosis of asthma. The criteria do not exclude patients based on adherence, responsiveness, or requiring additional tests not used in usual care. The inclusion reflects usual care in this setting.\n\nScore: [5]\n\nRecruitment:\n\nRelevant quotes: \n\n'Patients presenting to GP or nurse in primary care with respiratory tract infections as diagnosed by health professional. Easy to recruit to but time pressures in busy winter clinics prevented recruitment and meant non-recruitments logs poorly completed.'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: Patients were recruited through usual appointments at primary care clinics, the typical setting where they would seek treatment. No additional effort was made to recruit patients.\n\nScore: [5] \n\nSetting:\n\nRelevant quotes:\n\n'Identical setting to usual care setting - primary care where patients usually go for advice and treatment.' \n\n'Multi-centre: 25 practices in UK.'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: The trial was conducted in 25 primary care clinics, the identical setting to usual care for respiratory infections.\n\nScore: [5]\n\nOrganization:\n\nRelevant quotes:\n\n'Information sheets given out to participants. This is not usual practice, would it be if trial had shown this helped? Need more staff for follow up of trial participants to get diary results so more extensive data collection than usual. Otherwise no difference in provider expertise and organisation of care delivery.'\n\n'Suggested PRECIS score—3, equally pragmatic and explanatory'\n\nReasoning: Additional staff were needed for follow-up and data collection beyond usual care. But otherwise the organization was identical. The information sheets do not affect organization.\n\nScore: [3]\n\nFlexibility (delivery):\n\nRelevant quotes: \n\n'Full flexibility'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: The intervention delivery was left fully flexible, up to the providers as in usual care.\n\nScore: [5]\n\nFlexibility (adherence):\n\nRelevant quotes:\n\n'Compliance measured with diary – “reasonably good” participants free to “not-comply” with advice. Little impact of advising patients to take analgesics regularly. No measures to improve compliance'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: Participants were free to adhere as in usual care, with no special measures to enforce or monitor adherence.\n\nScore: [5]\n\nFollow-up:\n\nRelevant quotes:\n\n'Participants followed up one month – usual care no follow up. Patients come back to GP if problems.' \n\n'Trial more extensive data colleaction - patients telephoned day two to three to check for any problems with diary completion. If no diary after 2 weeks then mailed reminder and then phoned as necessary to document outcomes using validated questionnaire.'\n\n'Suggested PRECIS score—2, rather explanatory.'\n\nReasoning: Patients were followed up at 1 month when there is no follow-up in usual care. Additional contacts were made to collect trial data. This makes follow-up more intensive than usual care.\n\nScore: [2]\n\nPrimary outcome:\n\nRelevant quotes:\n\n'Very relevant to participants - Mean symptom severity on days 2-4. Symptoms 0 (no problem) to 6 (as bad as they can be 7 in abstract). Completed in diary at end of day – children with parents or participants.'\n\n'Suggested PRECIS score—5, very pragmatic' \n\nReasoning: The primary outcome of symptom severity is very relevant to patients and measured similarly as in usual care through patient self-report.\n\nScore: [5]\n\nPrimary analysis:\n\nRelevant quotes:\n\n'ITT no matter whether compliance.'\n\n'Suggested PRECIS score—5, very pragmatic'\n\nReasoning: An intention-to-treat analysis was used including all participants regardless of compliance. This is a very pragmatic approach.\n\nScore: [5]\n"," Here are the PRECIS-2 scores for the trial based on the full text publication:\n\nEligibility criteria:\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The trial has strict inclusion and exclusion criteria that make the participants less similar to those who would receive this intervention in usual care. Confirmation by a specialist otorhinolaryngologist is not typical in usual care. The exclusions for pregnancy, breastfeeding and several medical conditions reduce the pragmatism. The extra test requirement also makes it less pragmatic.\n\nScore: [2]\n\nRecruitment:\n\nRelevant quotes: \n\nNo direct quotes related to recruitment.\n\nReasoning: The paper does not provide enough details on how participants were recruited. Without this information, it is difficult to assess the pragmatism of recruitment.\n\nScore: [NA] \n\nSetting: \n\nRelevant quotes:\n\nNo direct quotes related to setting. \n\nReasoning: The paper does not specify the settings where the trial was conducted. Without knowing the settings, it is not possible to judge the pragmatism of this domain.\n\nScore: [NA]\n\nOrganization:\n\nRelevant quotes: \n\nNo direct quotes related to organization.\n\nReasoning: The paper does not provide any details on the organization, expertise and resources used to deliver the intervention. This lack of information prevents assessment of this domain.\n\nScore: [NA]\n\nFlexibility (delivery):\n\nRelevant quotes: \n\nNo direct quotes related to flexibility of delivery.\n\nReasoning: The paper does not mention how flexibly the intervention was delivered to participants. Without such details, this domain cannot be scored.\n\nScore: [NA]\n\nFlexibility (adherence): \n\nRelevant quotes:\n\nNo direct quotes related to flexibility of adherence.\n\nReasoning: The paper does not provide any information on measures to ensure participant adherence. This domain cannot be assessed without such details. \n\nScore: [NA]\n\nFollow-up:\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual:\n\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. \n\nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery)\n\nECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nReasoning: The trial has more frequent and longer follow-up than usual care. There is extensive data collection and unscheduled visits triggered by the primary outcome event. This intensive follow-up is not very pragmatic.\n\nScore: [1]\n\nPrimary outcome:\n\nRelevant quotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.' \n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.'\n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The primary outcome is graded on a scale not routinely used in primary care and requires special training. Central adjudication by a panel of experts is also not typical. These make the choice of primary outcome less pragmatic.\n\nScore: [1]\n\nPrimary analysis:\n\nRelevant quotes:\n\nNo direct quotes related to primary analysis.\n\nReasoning: The paper does not provide any details on the primary analysis and what proportion of data were included. This prevents assessment of the pragmatism of the analysis. \n\nScore: [NA]\n"," Here are the PRECIS-2 domain scores for the trial described in the publication '671.pdf':\n\nEligibility criteria:\n\nQuotes:\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The inclusion criteria seem fairly broad, including adult patients presenting with the condition of interest to primary care or emergency departments. However, there are several exclusions that limit the pragmatic nature, including pregnant/breastfeeding women, several medical comorbidities, and inability to consent. Additionally, requiring confirmation by a specialist rather than the usual GP diagnosis makes it less pragmatic. Overall, the eligibility seems intended to identify a more narrowly defined sample compared to usual care.\n\nScore: [2]\n\nRecruitment:\n\nQuotes: No relevant quotes provided.\n\nReasoning: The publication does not contain enough details about the recruitment methods to assess this domain.\n\nScore: [NA] \n\nSetting: \n\nQuote: 'Single centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.'\n\nReasoning: The trial was conducted at a single specialized center in the US. For most patients, this would not be the typical setting where they would receive care for shoulder impingement. Conducting the trial at a single specialized center reduces the pragmatic nature.\n\nScore: [2] \n\nOrganization:\n\nQuotes: No relevant quotes provided.\n\nReasoning: The publication does not contain enough details about the organization of care delivery to assess this domain.\n\nScore: [NA]\n\nFlexibility (delivery):\n\nQuotes: No relevant quotes provided.\n\nReasoning: The publication does not contain enough details about the flexibility in delivery of the intervention to assess this domain.\n\nScore: [NA] \n\nFlexibility (adherence): \n\nQuotes: No relevant quotes provided.\n\nReasoning: The publication does not contain enough details about the flexibility in adherence or measures to ensure adherence to assess this domain.\n\nScore: [NA]\n\nFollow-up:\n\nQuote: 'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.' \n\n'Monitoring intensity involved more extensive data collection than usual:\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours.\nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery) \nECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nReasoning: The follow-up period was longer than usual care. There was also more extensive data collection through ECG, troponin levels, and triggering of follow-up visits based on cardiovascular events. This intensive follow-up is less pragmatic.\n\nScore: [1]\n\nPrimary outcome:\n\nQuotes: 'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The House-Brackmann scale is not routinely used in primary care and required central adjudication by experts, making it less pragmatic. It measures recovery of facial nerve function which is relevant but involves specialized assessment.\n\nScore: [1]\n\nPrimary analysis:\n\nQuotes: No relevant quotes provided.\n\nReasoning: The publication does not contain enough details about the primary analysis to assess this domain.\n\nScore: [NA]\n"," Here are the PRECIS-2 scores for each domain based on the full text:\n\nEligibility criteria\n\nQuotes:\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.  \n\nExclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.\n\nExtra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The inclusion criteria are moderately pragmatic as patients had to present within 72 hours and be referred to a specialist, which limits generalizability somewhat. The exclusions seem reasonable. However, requiring confirmation by a specialist rather than allowing GP diagnosis makes it more explanatory.\n\nScore: [2]\n\nRecruitment\n\nQuotes:\n'Initially extra resources were used to recruit patients at 53 primary care practices. Patients were recruited via a postal questionnaire to identify symptoms and trial eligibility, not just to invite to participate. This would push the recruitment path of this domain towards the explanatory end. By using this method of recruitment, which requires administration not normally present in primary care, it is possible that responders may be healthier than those at the clinic being invited to the trial and also more highly motivated and compliant as they have come through a different route than those invited during a clinic attendance.\n\nIn this trial, recruitment was inadequate using a postal questionnaire, so participants were then recruited through clinic attendances changing the recruitment towards a more pragmatic trial design, creating results which are more applicable to users of the results in a primary care setting.'\n\nReasoning: Recruitment started out as rather explanatory by using postal questionnaires to screen and recruit, but then became more pragmatic by switching to clinic-based recruitment. Overall it's a mix of methods, some feasible in usual care.  \n\nScore: [3]\n\nSetting\n\nQuote:\n'Single centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.'\n\nReasoning: The trial was done at a single, specialized military medical center, which is not the usual care setting for most shoulder impingement patients.\n\nScore: [2]\n\nOrganisation\n\nQuotes: \n'Extra staff, and very labour intensive. Used additional equipment beyond usual care, none of which was planned for at the trial design stage.'\n\n'Ten academic centres with 75 intensive care units'\n\nReasoning: The trial required extra staffing and intensive labor. Additional equipment was used beyond what is available in usual care. It was done at specialized academic centers. All of this makes the organization more explanatory.\n\nScore: [1]  \n\nFlexibility (delivery)\n\nQuote: \n'Protocol driven—Much detail given, with protocol violations recorded in self reported case form. Investigators accept this may occur due to clinical needs (such as anaesthesia).\n\nCo-interventions—Specific direction\n\nComplications—Specific directions for managing complications or side effects\n\nImproving adherence—No measures in place'\n\nReasoning: The delivery was protocol-driven with tracking of violations, specific directions for co-interventions and complications. This reduces flexibility compared to usual care. However, no measures were in place to improve adherence. Overall, it tends toward a more explanatory design.\n\nScore: [2]\n\nFlexibility (adherence)\n\nQuote:\n'The sessions were all individual based on interaction with child and allowed for range of responses to the intervention'\n\nReasoning: Adherence was very flexible, allowing a range of responses tailored to each child's needs. This is very pragmatic.\n\nScore: [5]\n\nFollow-up\n\nQuotes:\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care. \n\nMonitoring intensity involved more extensive data collection than usual:\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours.  \n\nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery)\n\nECG after randomisation and at 7 and 30 days after surgery.'\n\nReasoning: Follow-up was more extensive than usual care, with clinical follow-up for 30 days, more frequent troponin testing, and ECGs. The data collection was also more intensive. This makes it very explanatory.\n\nScore: [1]\n\nPrimary outcome\n\nQuotes:  \n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.\n\nTest not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.\n\nCentral adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The primary outcome of facial function recovery is clinically relevant but requires specialized training and assessment not normally done in primary care. There was also central adjudication by experts. This makes it more explanatory.\n\nScore: [1]\n\nPrimary analysis\n\nQuote:\n'Intention-to-treat principle was applied with multiple imputation of data'\n\nReasoning: The analysis followed an intention-to-treat approach with multiple imputation of missing data. This is a very pragmatic analysis.\n\nScore: [5]\n"," Here are the PRECIS-2 domain scores for the trial described in the attached paper '671.pdf':\n\nEligibility criteria\n\nQuotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.'  \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The eligibility criteria are quite restrictive, excluding many patients who would receive this treatment in usual care, such as pregnant/breastfeeding women and those with certain comorbidities. The extra test requiring confirmation by a specialist is also not reflective of usual care diagnosis by a general practitioner. This makes the trial less pragmatic.\n\nScore: [2]\n\nRecruitment\n\nQuotes: No relevant quotes\n\nReasoning: The paper does not provide any details on how patients were recruited into the trial. Without this information, the recruitment path cannot be assessed.\n\nScore: [NA] \n\nSetting\n\nQuotes: No relevant quotes\n\nReasoning: The paper does not provide any details on the settings where the trial was conducted. Without this information, the trial setting cannot be assessed.\n\nScore: [NA]\n\nOrganisation\n\nQuotes: No relevant quotes\n\nReasoning: The paper does not provide any details on the expertise, resources, and organization of care delivery in the trial. Without this information, the trial organization cannot be assessed.\n\nScore: [NA]\n\nFlexibility: delivery\n\nQuotes: No relevant quotes\n\nReasoning: The paper does not provide any details on the flexibility in delivering the intervention. Without this information, the flexibility of delivery cannot be assessed.\n\nScore: [NA]\n\nFlexibility: adherence \n\nQuotes: No relevant quotes\n\nReasoning: The paper does not provide any details on measures to ensure patient adherence. Without this information, the flexibility of adherence cannot be assessed.\n\nScore: [NA]\n\nFollow-up\n\nQuotes: \n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual:\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours.\nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery)  \nECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nReasoning: The follow-up period is longer than usual care, with more frequent assessments and data collection. Unscheduled visits are also triggered by cardiovascular events related to the primary outcome. This intensive follow-up and data collection makes the trial more explanatory.\n\nScore: [1]\n\nPrimary outcome\n\nQuotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.' \n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.'\n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The primary outcome is a surrogate measure that requires specialized training and central adjudication, rather than assessment methods used in routine primary care. This makes the outcome less pragmatic.\n\nScore: [1]\n\nPrimary analysis\n\nQuotes: No relevant quotes\n\nReasoning: The paper does not provide any details on the primary analysis. Without this information, the analysis approach cannot be assessed.\n\nScore: [NA]\n","Here are the PRECIS-2 domain scores for the trial with supporting quotes and explanations:\n\nEligibility Criteria\n\nQuotes:\n\n'Inclusion criteria - Patients ≥3 with acute respiratory tract infections. Exclusions not common cold but severe respiratory tract infections, peptic ulcer and asthma. But even asthma patients who were not sensitive to ibuprofen or aspirin eligible. Pregnant or breast feeding women are discouraged from taking ibuprofen when pregnant but can take as low a dose as possible of Paracetemol but as both being tested in the trial cannot include this group as participants. If include visually impaired increase organisation of trial (as in carers have to assist diary completion) but that would be norm and usual if prescribed ibuprofen or Paracetemol or steam treatment in usual care, so just easier for trialists to exclude. Small proportion of participants – so why exclude?'\n\nReasoning: The eligibility criteria are quite broad, including patients with acute respiratory tract infections who would receive the intervention in usual care. Some common exclusions are made for safety reasons or to simplify trial procedures, but overall the criteria seem pragmatic.\n\nScore: [4]\n\nRecruitment\n\nQuotes:\n\n'Patients presenting to GP or nurse in primary care with respiratory tract infections as diagnosed by health professional. Easy to recruit to but time pressures in busy winter clinics prevented recruitment and meant non-recruitments logs poorly completed.'\n\nReasoning: Patients were recruited through usual appointments in primary care, which is a very pragmatic approach. Some non-recruitment due to time pressures indicates that recruitment conditions were similar to real-world constraints.\n\nScore: [5] \n\nSetting\n\nQuotes:\n\n'Identical setting to usual care setting: primary care, where patients usually go for advice and treatment of the common cold in the UK.'\n\n'Multi-centre: 25 practices in UK.'\n\nReasoning: The setting of primary care clinics is identical to where patients would receive treatment in usual practice. Multiple sites were used to increase generalizability.\n\nScore: [5]\n\nOrganization\n\nQuotes: \n\n'Information sheets given out to participants. This is not usual practice, would it be if trial had shown this helped? Need more staff for follow up of trial participants to get diary results so more extensive data collection than usual. Otherwise no difference in provider expertise and organisation of care delivery.'\n\nReasoning: The intervention was delivered with existing primary care staff and resources. Some additional materials and data collection were required for the trial but unlikely to affect care delivery.\n\nScore: [4]\n\nFlexibility: Delivery\n\nQuotes:\n\n'Full flexibility'\n\nReasoning: No protocol prescribed how providers should deliver the intervention, indicating full flexibility.\n\nScore: [5]\n\nFlexibility: Adherence\n\nQuotes:\n\n'Compliance measured with diary – “reasonably good” participants free to “not-comply” with advice. Little impact of advising patients to take analgesics regularly. No measures to improve compliance'\n\nReasoning: Adherence was measured but participants were free to follow the advice or not. No special measures were used to enforce adherence.\n\nScore: [5]\n\nFollow-Up\n\nQuotes:\n\n'Participants Followed up one month – usual care no follow up. Patients come back to GP if problems. Trial more extensive data colleaction - patients telephoned day two to three to check for any problems with diary completion. If no diary after 2 weeks then mailed reminder and then phoned as necessary to document outcomes using validated questionnaire.'\n\nReasoning: One month follow-up is more than usual care. Additional contacts were made to collect trial data but unlikely to affect care.\n\nScore: [3]\n\nPrimary Outcome\n\nQuotes:\n\n'Very relevant to participants - Mean symptom severity on days 2-4. Symptoms 0 (no problem) to 6 (as bad as they can be 7 in abstract). Completed in diary at end of day – children with parents or participants.'\n\nReasoning: Symptom severity is a very relevant outcome that was self-reported by patients.\n\nScore: [5]\n\nPrimary Analysis\n\nQuotes:\n\n'ITT no matter whether compliance.'\n\nReasoning: An intention-to-treat approach was used with no exclusions based on compliance.\n\nScore: [5]\n","Here are the PRECIS-2 scores for the 9 domains based on the provided full text:\n\n1. Eligibility criteria\n\nRelevant quotes:\n\n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Extra test—Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nThe trial has quite tight inclusion and exclusion criteria, including requiring a senior otorhinolaryngologist to confirm eligibility when Bell's palsy is usually diagnosed by a general practitioner. This makes the trial less pragmatic.\n\nScore: [2]\n\n2. Recruitment\n\nRelevant quote: \n\nNo relevant information provided.\n\nThe paper does not provide any information about how patients were recruited into the trial.\n\nScore: [NA] \n\n3. Setting\n\nRelevant quote:\n\n'Single centre and specialised centre (Madigan Army Medical Center, USA), unlikely to be the usual setting for most individuals receiving physiotherapy for shoulder impingement.'\n\nThe trial was conducted in a single specialized centre, which is not the usual care setting for most patients. This makes the trial more explanatory.\n\nScore: [2]\n\n4. Organization\n\nRelevant quotes: \n\nNo relevant information provided.\n\nThe paper does not provide any details on the expertise, resources, and care delivery in the trial.\n\nScore: [NA]\n\n5. Flexibility (delivery) \n\nRelevant quotes:\n\nNo relevant information provided.\n\nThe paper does not provide any details on flexibility in delivering the intervention.\n\nScore: [NA]\n\n6. Flexibility (adherence)\n\nRelevant quotes: \n\nNo relevant information provided.\n\nThe paper does not provide any details on measures to ensure adherence.\n\nScore: [NA]\n\n7. Follow-up\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual:\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. \nTroponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery)\nECG after randomisation and at 7 and 30 days after surgery.'\n\nThe trial had more frequent and longer follow-up than usual care, with more extensive data collection. This makes it more explanatory.\n\nScore: [1] \n\n8. Primary outcome\n\nRelevant quotes:\n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.' \n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.'\n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nThe primary outcome uses a scale not routinely used in primary care and requires central adjudication by experts. This makes it more explanatory.\n\nScore: [1]\n\n9. Primary analysis\n\nRelevant quotes: \n\nNo relevant information provided.\n\nThe paper does not provide details on the primary analysis.\n\nScore: [NA]\n","Here are the PRECIS-2 domain scores and reasoning based on the provided full text:\n\nEligibility criteria \n\nRelevant quotes:\n\n'Patients ≥ 3 with acute respiratory tract infections. Exclusions not common cold but severe respiratory tract infections, peptic ulcer and asthma. But even asthma patients who were not sensitive to ibuprofen or aspirin eligible. Pregnant or breast feeding women are discouraged from taking ibuprofen when pregnant but can take as low a dose as possible of Paracetemol but as both being tested in the trial cannot include this group as participants. If include visually impaired increase organisation of trial (as in carers have to assist diary completion) but that would be norm and usual if prescribed ibuprofen or Paracetemol or steam treatment in usual care, so just easier for trialists to exclude. Small proportion of participants – so why exclude? Depressed and people with psychosis unreliable diary fillers, concerned with other things.'\n\nScore: [4] Rather pragmatic\n\nThe eligibility criteria mostly match those who would receive the intervention in usual care, with some minor exclusions for practical trial reasons like visual impairment and mental health issues that could affect diary completion. Overall the criteria seem designed to maximize applicability.\n\nRecruitment\n\nRelevant quotes:\n\n'Patients presenting to GP or nurse in primary care with respiratory tract infections as diagnosed by health professional. Easy to recruit to but time pressures in busy winter clinics prevented recruitment and meant non-recruitments logs poorly completed.'\n\nScore: [5] Very pragmatic  \n\nPatients were recruited through their usual primary care appointments, matching how they would receive the intervention in real-world practice. No extra recruitment efforts were mentioned.\n\nSetting\n\nRelevant quotes: \n\n'Identical setting to usual care setting: primary care, where patients usually go for advice and treatment of the common cold in the UK. Multi-centre: 25 practices in UK.'\n\nScore: [5] Very pragmatic\n\nThe trial was conducted in real-world primary care settings across multiple centers, maximizing applicability.\n\nOrganization\n\nRelevant quotes:\n\n'Information sheets given out to participants. This is not usual practice, would it be if trial had shown this helped? Need more staff for follow up of trial participants to get diary results so more extensive data collection than usual. Otherwise no difference in provider expertise and organisation of care delivery.'\n\nScore: [3] Equally pragmatic and explanatory\n\nExtra staff were needed for follow-up, but otherwise organization matched usual care. The information sheets do not affect care delivery. Overall somewhat mixed pragmatism.\n\nFlexibility: delivery\n\nRelevant quotes: \n\nNo relevant quotes provided in the text.\n\nScore: [NA]\n\nFlexibility: adherence\n\nRelevant quotes:\n\n'Compliance measured with diary – “reasonably good” participants free to “not-comply” with advice. Little impact of advising patients to take analgesics regularly. No measures to improve compliance'\n\nScore: [5] Very pragmatic\n\nPatients were free to adhere as in usual care, with no special measures to enforce compliance. Maximally pragmatic.\n\nFollow-up\n\nRelevant quotes:\n\n'Patients Followed up one month – usual care no follow up. Patients come back to GP if problems. Trial more extensive data colleaction - patients telephoned day two to three to check for any problems with diary completion. If no diary after 2 weeks then mailed reminder and then phoned as necessary to document outcomes using validated questionnaire.'\n\nScore: [2] Rather explanatory\n\nFollow-up was more extensive than usual care to ensure diary completion, reducing pragmatism.\n\nPrimary outcome\n\nRelevant quotes: \n\n'Very relevant to participants - Mean symptom severity on days 2-4. Symptoms 0 (no problem) to 6 (as bad as they can be 7 in abstract). Completed in diary at end of day – children with parents or participants.'\n\nScore: [5] Very pragmatic \n\nThe patient-centered symptom severity outcome matches what is important to participants in real-world practice. Maximally pragmatic choice.\n\nPrimary analysis\n\nRelevant quotes:\n\n'ITT no matter whether compliance.'\n\nScore: [5] Very pragmatic\n\nAn intention-to-treat analysis was used, with no exclusions based on compliance. Maximally pragmatic.\n","Here are the PRECIS-2 scores for the trial described in the publication '678.pdf':\n\n1. Eligibility criteria\n\nRelevant quotes:\n\n'Patients ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.' \n\n'Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nThe eligibility criteria are quite restrictive, excluding many patients who would normally receive treatment for Bell's palsy in routine practice. The requirement for confirmation by a specialist otorhinolaryngologist is not typical for Bell's palsy diagnosis. This makes the trial less pragmatic.\n\nScore: [2] \n\n2. Recruitment\n\nRelevant quotes: \n\nNo relevant quotes. The paper does not describe the recruitment methods.\n\nScore: [NA]\n\n3. Setting\n\nRelevant quotes:  \n\nNo relevant quotes. The paper does not describe the settings where the trial was conducted.\n\nScore: [NA] \n\n4. Organization\n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe the expertise, resources, and organization of care delivery.\n\nScore: [NA]\n\n5. Flexibility (delivery)\n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe flexibility in intervention delivery. \n\nScore: [NA]\n\n6. Flexibility (adherence)  \n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe measures to ensure adherence.\n\nScore: [NA]\n\n7. Follow-up\n\nRelevant quotes:\n\n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual: Pre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. Troponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery) ECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nThe trial has more frequent and longer follow-up than usual care, with additional data collection. This makes it more explanatory.\n\nScore: [2]\n\n8. Primary outcome  \n\nRelevant quotes: \n\n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nThe primary outcome requires specialized training and central adjudication not routine in usual care. This makes it more explanatory.  \n\nScore: [2]\n\n9. Primary analysis\n\nRelevant quotes:\n\nNo relevant quotes. The paper does not describe the primary analysis.\n\nScore: [NA]\n"," Here are the PRECIS-2 scores and explanations for the trial described in '678.pdf':\n\n1. Eligibility criteria\n\nQuotes:\n- 'Inclusion criteria were patients aged ≥15 with suspected asthma were included in the study, based on a crude clinical diagnosis of asthma, as the standard respiratory testing machinery was not available in this rural setting in South Africa.'\n\n- 'Patients judged to not be adherent are excluded.'\n\nExplanation: The trial includes patients with a clinical diagnosis of asthma, reflecting real-world practice where testing machinery may not be available. However, patients judged to be non-adherent were excluded, which reduces pragmatism. Overall, the eligibility seems moderately pragmatic.\n\nScore: [3] \n\n2. Recruitment \n\nQuotes: None relevant\n\nExplanation: The text does not provide information on how patients were recruited.\n\nScore: [NA]\n\n3. Setting\n\nQuotes: \n- 'This pragmatic cluster randomised controlled trial took place in two rural health districts ('subdistricts') in two provinces of South Africa.'\n\nExplanation: The trial took place in the rural health care setting where the intervention would be applied in real-world practice. This indicates a pragmatic approach.\n\nScore: [5]\n\n4. Organization\n\nQuotes: None relevant\n\nExplanation: The text does not provide information on resources, expertise, or care delivery organization.\n\nScore: [NA] \n\n5. Flexibility of experimental intervention - Delivery\n\nQuotes: None relevant\n\nExplanation: The text does not provide information on flexibility in delivering the intervention.\n\nScore: [NA]\n\n6. Flexibility of experimental intervention - Adherence\n\nQuotes: None relevant\n\nExplanation: The text does not provide information on flexibility in adherence by participants.\n\nScore: [NA]\n\n7. Follow-up\n\nQuotes: None relevant\n\nExplanation: The text does not provide information on follow-up of participants. \n\nScore: [NA]\n\n8. Primary outcome\n\nQuotes:\n- 'The primary outcome was the proportion of patients classified as having asthma in each group at the end of the one year intervention period.'\n\nExplanation: The primary outcome of asthma classification is clinically relevant to patients. This indicates a pragmatic choice.\n\nScore: [5]\n\n9. Primary analysis\n\nQuotes: None relevant\n\nExplanation: The text does not provide information on the primary analysis.\n\nScore: [NA]\n","Here are the PRECIS-2 scores and reasoning for each domain based on the full text in '678.pdf':\n\nEligibility criteria\n\nQuotes:\n'Patients ≥ 3 with acute respiratory tract infections. Exclusions not common cold but severe respiratory tract infections, peptic ulcer and asthma. But even asthma patients who were not sensitive to ibuprofen or aspirin eligible. Pregnant or breast feeding women are discouraged from taking ibuprofen when pregnant but can take as low a dose as possible of Paracetemol but as both being tested in the trial cannot include this group as participants. If include visually impaired increase organisation of trial (as in carers have to assist diary completion) but that would be norm and usual if prescribed ibuprofen or Paracetemol or steam treatment in usual care, so just easier for trialists to exclude. Small proportion of participants – so why exclude? Depressed and people with psychosis unreliable diary fillers, concerned with other things.'\n\nReasoning: The eligibility criteria mostly match patients who would receive this treatment in usual care, with some typical exclusions like pregnant women. However, the exclusions of visually impaired, depressed, and psychotic patients seem overly restrictive compared to usual care. Overall quite pragmatic but some limitations.\n\nScore: [4] \n\nRecruitment\n\nQuotes: \n'Patients presenting to GP or nurse in primary care with respiratory tract infections as diagnosed by health professional. Easy to recruit to but time pressures in busy winter clinics prevented recruitment and meant non-recruitments logs poorly completed.'\n\nReasoning: Patients were recruited through normal primary care visits where they would seek treatment for respiratory infections. Very pragmatic recruitment.\n\nScore: [5]\n\nSetting\n\nQuotes:\n'Identical setting to usual care setting: primary care, where patients usually go for advice and treatment of the common cold in the UK. Multi-centre: 25 practices in UK.'\n\nReasoning: The trial was conducted in multiple primary care clinics, which is the typical setting where patients receive treatment for respiratory infections. Very pragmatic setting.\n\nScore: [5]\n\nOrganization\n\nQuotes:\n'Information sheets given out to participants. This is not usual practice, would it be if trial had shown this helped? Need more staff for follow up of trial participants to get diary results so more extensive data collection than usual. Otherwise no difference in provider expertise and organisation of care delivery.'\n\nReasoning: The organization was mostly similar to usual care, except for providing information sheets and needing extra staff for follow-up, which made data collection more extensive. Moderately pragmatic.\n\nScore: [3]\n\nFlexibility: Delivery\n\nQuotes: \nNo relevant quotes.\n\nReasoning: The text does not seem to describe flexibility in delivery of the intervention.\n\nScore: [NA] \n\nFlexibility: Adherence \n\nQuotes:\n'Compliance measured with diary – “reasonably good” participants free to “not-comply” with advice. Little impact of advising patients to take analgesics regularly. No measures to improve compliance'\n\nReasoning: Patients were free to adhere as in usual care, with no special measures to enforce adherence. Very pragmatic.\n\nScore: [5]\n\nFollow-up\n\nQuotes:\n'Participants Followed up one month – usual care no follow up. Patients come back to GP if problems. Trial more extensive data colleaction - patients telephoned day two to three to check for any problems with diary completion. If no diary after 2 weeks then mailed reminder and then phoned as necessary to document outcomes using validated questionnaire.'\n\nReasoning: Follow-up was more extensive than usual care, with phone calls and reminders to ensure diary completion. Moderately explanatory. \n\nScore: [2]\n\nPrimary outcome\n\nQuotes:\n'Very relevant to participants - Mean symptom severity on days 2-4. Symptoms 0 (no problem) to 6 (as bad as they can be 7 in abstract). Completed in diary at end of day – children with parents or participants.'\n\nReasoning: The primary outcome of symptom severity is highly relevant to patients with respiratory infections. Very pragmatic.\n\nScore: [5] \n\nPrimary analysis\n\nQuotes: \n'ITT no matter whether compliance.'\n\nReasoning: Primary analysis was intention-to-treat, very pragmatic.\n\nScore: [5]\n","Here are my assessments for the PRECIS-2 scores for the trial described in '693.pdf':\n\nEligibility criteria:\n\nQuotes: \n'Inclusion criteria—Patients with confirmed diagnosis: ≥16 years of age with unilateral facial nerve weakness of no identifiable cause who presented to primary care or an emergency department and could be referred to a collaborating otorhinolaryngologist &lt;72 hours after the onset of symptoms.'\n\n'Exclusion criteria—Pregnancy, breast feeding, uncontrolled diabetes, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, systematic infection, sarcoidosis and other rare conditions, and an inability to provide informed consent.'  \n\n'Randomised controlled trial of Bell’s palsy treatment required senior otorhinolaryngologist in hospitals to confirm a patient’s eligibility to participate. Bell’s palsy is usually diagnosed by a general practitioner in primary care.'\n\nReasoning: The inclusion criteria seem reasonably broad, including adults ≥16 years old with unilateral facial nerve weakness without identifiable cause. However, the exclusions eliminate some patients who would likely receive prednisolone or acyclovir treatment for Bell's palsy in usual care, such as pregnant/breastfeeding women and those with certain medical conditions. Requiring confirmation by a specialist ORL rather than diagnosis by a GP makes the trial more explanatory.\n\nScore: [2]\n\nRecruitment:\n\nQuotes: No relevant quotes about recruitment process.\n\nReasoning: No details provided on recruitment process.\n\nScore: [NA] \n\nSetting:  \n\nQuotes: No quotes on settings provided.\n\nReasoning: No details provided on settings of the trial.\n\nScore: [NA]\n\nOrganisation:\n\nQuotes: No relevant quotes about organization.\n\nReasoning: No details provided on organization of the trial.\n\nScore: [NA]\n\nFlexibility (delivery):\n\nQuotes: No relevant quotes about flexibility of delivery.\n\nReasoning: No details provided on flexibility of delivery. \n\nScore: [NA]\n\nFlexibility (adherence):\n\nQuotes: No relevant quotes about adherence.\n\nReasoning: No details provided on adherence or measures to enforce it.\n\nScore: [NA]\n\nFollow-up:\n\nQuotes: \n'Clinical follow-up until patient left hospital (discharge or death) or until 30 days after surgery, whichever was the longer, so more than usual care.'\n\n'Monitoring intensity involved more extensive data collection than usual:\nPre-operation—three-lead electrocardiogram (ECG) Holter monitor (Flashcard with 2×48 hour recording) set up on each patient and maintained for 72 hours. Troponin values at 1, 3, and 7 days after surgery (more usual for only 1 and 3 days after surgery) ECG after randomisation and at 7 and 30 days after surgery.'\n\n'Unscheduled follow-up visits triggered by primary outcome: a cardiovascular event (such as angina, myocardial infarction, stroke)'\n\nReasoning: Follow-up was more extensive than usual care, with more frequent visits, longer monitoring, and additional tests. Unscheduled visits were triggered by cardiovascular events. \n\nScore: [1]\n\nPrimary outcome:\n\nQuotes:  \n'Primary outcome—Recovery of facial function as rated on the House-Brackmann scale.'\n\n'Test not routinely used in primary care and requires training. It is, however, an easy clinical test widely used in secondary care for grading recovery from facial nerve paralysis caused by damage to lower motor neurons.' \n\n'Central adjudication—Photographs taken of patients were assessed and graded independently by a panel of three experts (not general practitioners, who usually assess).'\n\nReasoning: The House-Brackmann scale is not used routinely in primary care and required central adjudication by experts rather than assessment by GPs who usually diagnose Bell's palsy. This makes the outcome less relevant to usual care.\n\nScore: [1]\n\nPrimary analysis:\n\nQuotes: No relevant quotes about analysis plan.\n\nReasoning: No details provided on analysis plan.\n\nScore: [NA]\n"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Author &amp; Year<\/th>\n      <th>Reason for failed response (click to show LLM response)<\/th>\n      <th>Ultimately successful<\/th>\n      <th>LLM response<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"ft","columnDefs":[{"targets":2,"render":"function(data, type, row, meta) { return '<a onclick=\"javascript:alert(`'+row[4]+'`)\" style=\"cursor: pointer\">' + data + '<\/a>' }"},{"targets":[0,4],"visible":false},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render"],"jsHooks":[]}</script>
</div>
<div id="llm-prompt" class="section level3">
<h3>LLM prompt</h3>
<ul>
<li>Model: <a href="https://www.anthropic.com/index/claude-2">Claude
2</a></li>
<li>Temperature: Chat interface (<a
href="https://docs.anthropic.com/claude/reference/complete_post">probably
<code>1</code></a>)</li>
<li>Briefing derived from: <a
href="https://doi.org/10.1371/journal.pone.0175213">Cullis 2017</a>
Supporting information: <a
href="https://doi.org/10.1371/journal.pone.0175213.s004">S1
Dataset</a></li>
</ul>
<div id="user-prompt" class="section level4">
<h4>User prompt</h4>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<pre>
You are an expert in clinical trial design and are tasked to assess the PRECIS-2 scores of a trial based on the full text of its publication. You have the briefing in the attached "Loudon 2015.pdf" and "PRECIS Toolkit.pdf"

The full text to be assessed is attached as "ID.pdf".

For each of the 9 domains of PRECIS-2, perform the following steps:

1. Extract 1-3 relevant quotes from the full text.

2. Explain your reasoning in 1 paragraph.

3. Give a score X from 1 (very explanatory) to 5 (very pragmatic) in square brackets like this: "Score: [X]". If the full text does not contain enough information to assess a specific domain, report "Score: [NA]".

Do not provide a final summary paragraph in the end.
 
</pre>
</div>
</div>
</div>

</div>

<script>
$(document).ready(function() {
  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed table-sm');

  // initialize mathjax

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460,
    resize_reload: true
  });
  var navbar = $(".navbar").first();
  var body = $("body").first();
  var sidebar = $(".section.sidebar").first();
  function addNavbarPadding() {
    var navHeight = navbar.outerHeight();
    body.css("padding-top", (navHeight + 8) + "px");
    sidebar.css("top", navHeight + "px");
    var resizeEvent = window.document.createEvent("UIEvents");
    resizeEvent.initUIEvent("resize", true, false, window, 0);
    window.dispatchEvent(resizeEvent);
  }
  if (!window.Shiny) setTimeout(addNavbarPadding, 100);
  $(document).on("shiny:idle", function() {
    setTimeout(addNavbarPadding, 50);
  });
});
</script>

</body>
</html>
